22 - oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure .	22 - oxacalcitriol suppresses disease* secondary hyperparathyroidism *disease without inducing disease* low bone turnover *disease in dogs with disease* renal failure *disease .
BACKGROUND : Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .	BACKGROUND : Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with disease* renal failure *disease but has several drawbacks , including disease* hypercalcemia *disease and / or marked disease* suppression of bone turnover *disease , which may lead to disease* adynamic bone disease *disease .
A new vitamin D analogue , 22 - oxacalcitriol ( OCT ) , has been shown to have promising characteristics .	A new vitamin D analogue , 22 - oxacalcitriol ( OCT ) , has been shown to have promising characteristics .
This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .	This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or disease* impaired renal function *disease .
METHODS : Sixty dogs were either nephrectomized ( Nx , N = 38 ) or sham - operated ( Sham , N = 22 ) .	METHODS : Sixty dogs were either nephrectomized ( Nx , N = 38 ) or sham - operated ( Sham , N = 22 ) .
The animals received supplemental phosphate to enhance PTH secretion .	The animals received supplemental phosphate to enhance PTH secretion .
Fourteen weeks after the start of phosphate supplementation , half of the Nx and Sham dogs received doses of OCT ( three times per week ) ; the other half were given vehicle for 60 weeks .	Fourteen weeks after the start of phosphate supplementation , half of the Nx and Sham dogs received doses of OCT ( three times per week ) ; the other half were given vehicle for 60 weeks .
Thereafter , the treatment modalities for a subset of animals were crossed over for an additional eight months .	Thereafter , the treatment modalities for a subset of animals were crossed over for an additional eight months .
Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study , and bone biopsies were done at baseline , 60 weeks after OCT or vehicle treatment , and at the end of the crossover period .	Biochemical and hormonal indices of calcium and bone metabolism were measured throughout the study , and bone biopsies were done at baseline , 60 weeks after OCT or vehicle treatment , and at the end of the crossover period .
RESULTS : In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .	RESULTS : In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of disease* renal insufficiency *disease .
In long - standing secondary hyperparathyroidism , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .	In long - standing disease* secondary hyperparathyroidism *disease , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .
Serum PTH levels rose thereafter , but the rise was less pronounced compared with baseline than the rise seen in Nx control .	Serum PTH levels rose thereafter , but the rise was less pronounced compared with baseline than the rise seen in Nx control .
These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia .	These effects were accompanied by episodes of disease* hypercalcemia *disease and disease* hyperphosphatemia *disease .
In animals with normal renal function , OCT induced a transient decrease in serum PTH levels at a dose of 0 . 1 microg / kg , which was not sustained with lowering of the doses .	In animals with normal renal function , OCT induced a transient decrease in serum PTH levels at a dose of 0 . 1 microg / kg , which was not sustained with lowering of the doses .
In Nx dogs , OCT reversed abnormal bone formation , such as woven osteoid and fibrosis , but did not significantly alter the level of bone turnover .	In Nx dogs , OCT reversed abnormal bone formation , such as disease* woven osteoid *disease and disease* fibrosis *disease , but did not significantly alter the level of bone turnover .
In addition , OCT improved mineralization lag time , ( that is , the rate at which osteoid mineralizes ) in both Nx and Sham dogs .	In addition , OCT improved mineralization lag time , ( that is , the rate at which osteoid mineralizes ) in both Nx and Sham dogs .
CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .	CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of disease* hypercalcemia *disease in experimental dogs with disease* renal insufficiency *disease , it may be of use in the management of disease* secondary hyperparathyroidism *disease because it does not induce disease* low bone turnover *disease and , therefore , does not increase the risk of disease* adynamic bone disease *disease .
Hypotension , bradycardia , and asystole after high - dose intravenous methylprednisolone in a monitored patient .	disease* Hypotension *disease , disease* bradycardia *disease , and disease* asystole *disease after high - dose intravenous methylprednisolone in a monitored patient .
We report a case of hypotension , bradycardia , and asystole after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .	We report a case of disease* hypotension *disease , disease* bradycardia *disease , and disease* asystole *disease after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .
There was a history of ischemic cardiac disease 9 years earlier .	There was a history of disease* ischemic disease* cardiac disease *disease 9 years earlier .
The patient was admitted with a pulmonary - renal syndrome with hemoptysis , rapidly progressive renal failure , and hypoxemia that required mechanical ventilation in the intensive care unit .	The patient was admitted with a disease* pulmonary - renal syndrome *disease with disease* hemoptysis *disease , rapidly progressive disease* renal failure *disease , and disease* hypoxemia *disease that required mechanical ventilation in the intensive care unit .
After receiving advanced cardiopulmonary resuscitation , the patient recovered cardiac rhythm .	After receiving advanced cardiopulmonary resuscitation , the patient recovered cardiac rhythm .
The ECG showed a junctional rhythm without ventricular arrhythmia .	The ECG showed a junctional rhythm without disease* ventricular arrhythmia *disease .
This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .	This study reviews the current proposed mechanisms of disease* sudden death *disease after a high dose of intravenous methylprednisolone ( IVMP ) .
These mechanisms are not well understood because , in most cases , the patients were not monitored at the moment of the event .	These mechanisms are not well understood because , in most cases , the patients were not monitored at the moment of the event .
Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .	Rapid infusion and underlying disease* cardiac disease *disease were important risk factors in the case reported here , and the authors discount disease* ventricular arrhythmia *disease as the main mechanism .
Worsening of levodopa - induced dyskinesias by motor and mental tasks .	Worsening of levodopa - induced disease* dyskinesias *disease by motor and mental tasks .
Ten patients who had Parkinson ' s disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of apomorphine .	Ten patients who had disease* Parkinson ' s disease *disease with disabling disease* dyskinesia *disease were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose disease* dyskinesia *disease following administration of an effective single dose of apomorphine .
Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the dyskinesia score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 + / - 1 . 0 , p < 0 . 05 ) .	Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the disease* dyskinesia *disease score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 + / - 1 . 0 , p < 0 . 05 ) .
These results suggest that activation tasks such as " speaking aloud " could be used for objective assessment of dyskinesia severity .	These results suggest that activation tasks such as " speaking aloud " could be used for objective assessment of disease* dyskinesia *disease severity .
Urine N - acetyl - beta - D - glucosaminidase - - a marker of tubular damage ?	Urine N - acetyl - beta - D - glucosaminidase - - a marker of tubular damage ?
BACKGROUND : Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .	BACKGROUND : Although an indicator of disease* renal tubular dysfunction *disease , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .
METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .	METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce disease* proteinuria *disease .
Total protein , albumin , NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days .	Total protein , albumin , NAG activity and protein electrophoretic pattern were assessed in daily urine samples for 33 days .
The morphological appearance of the kidneys was examined on days three , four , six , eight and thirty three and the NAG isoenzyme patterns on days zero , four , eight and thirty three .	The morphological appearance of the kidneys was examined on days three , four , six , eight and thirty three and the NAG isoenzyme patterns on days zero , four , eight and thirty three .
RESULTS : Following intravenous PAN urine volume and urine NAG activity increased significantly by day two , but returned to normal by day four .	RESULTS : Following intravenous PAN urine volume and urine NAG activity increased significantly by day two , but returned to normal by day four .
After day four all treated animals exhibited a marked rise in urine albumin , total protein excretion and NAG activity .	After day four all treated animals exhibited a marked rise in urine albumin , total protein excretion and NAG activity .
Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards .	Electrophoresis showed a generalised increase in middle and high molecular weight urine proteins from day four onwards .
Protein droplets first appeared prominent in tubular cells on day four .	Protein droplets first appeared prominent in tubular cells on day four .
Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .	Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak disease* proteinuria *disease and the reduction in intracellular protein and NAG droplets ( day six onwards ) .
CONCLUSIONS : This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity , occurs when increased protein is presented to the tubular cells .	CONCLUSIONS : This animal model demonstrates that an increase in lysosomal turnover and hence urine NAG activity , occurs when increased protein is presented to the tubular cells .
Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage .	Urine NAG activity is thus a measure of altered function in the renal tubules and not simply an indicator of damage .
Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .	disease* Cauda equina syndrome *disease after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of disease* cauda equina syndrome *disease reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .
Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .	Six cases of disease* cauda equina syndrome *disease with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .
All were associated with spinal anaesthesia using hyperbaric 5 % lignocaine .	All were associated with spinal anaesthesia using hyperbaric 5 % lignocaine .
Five cases had single - shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block .	Five cases had single - shot spinal anaesthesia and one had a repeat spinal anaesthetic due to inadequate block .
The dose of hyperbaric 5 % lignocaine administered ranged from 60 to 120 mg .	The dose of hyperbaric 5 % lignocaine administered ranged from 60 to 120 mg .
Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5 % lignocaine .	Three of the cases were most likely caused by direct disease* neurotoxicity *disease of hyperbaric 5 % lignocaine .
In the other 3 cases , direct neurotoxicity was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .	In the other 3 cases , direct disease* neurotoxicity *disease was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .
All cases sustained permanent neurological deficits .	All cases sustained permanent disease* neurological deficits *disease .
We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2 % and at a total dose preferably not exceeding 60 mg .	We recommend that hyperbaric lignocaine should be administered in concentrations not greater than 2 % and at a total dose preferably not exceeding 60 mg .
Systemic toxicity following administration of sirolimus ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .	Systemic disease* toxicity *disease following administration of sirolimus ( formerly rapamycin ) for disease* psoriasis *disease : association of disease* capillary leak syndrome *disease with apoptosis of lesional lymphocytes .
BACKGROUND : Sirolimus ( formerly rapamycin ) is an immunosuppressive agent that interferes with T - cell activation .	BACKGROUND : Sirolimus ( formerly rapamycin ) is an immunosuppressive agent that interferes with T - cell activation .
After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .	After 2 individuals with disease* psoriasis *disease developed a disease* capillary leak syndrome *disease following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .
OBSERVATIONS : A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .	OBSERVATIONS : A keratome skin specimen from 1 patient with sirolimus - induced disease* capillary leak syndrome *disease had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with disease* psoriasis *disease ( 21 % ) .
Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .	Activated peripheral blood T cells from patients with disease* psoriasis *disease tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .
CONCLUSIONS : Severe adverse effects of sirolimus include fever , anemia , and capillary leak syndrome .	CONCLUSIONS : Severe adverse effects of sirolimus include disease* fever *disease , disease* anemia *disease , and disease* capillary leak syndrome *disease .
These symptoms may be the result of drug - induced apoptosis of lesional leukocytes , especially activated T lymphocytes , and possibly release of inflammatory mediators .	These symptoms may be the result of drug - induced apoptosis of lesional leukocytes , especially activated T lymphocytes , and possibly release of inflammatory mediators .
Because patients with severe psoriasis may develop capillary leak from various systemic therapies , clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators .	Because patients with severe disease* psoriasis *disease may develop disease* capillary leak *disease from various systemic therapies , clinical monitoring is advisable for patients with disease* inflammatory diseases *disease who are treated with immune modulators .
Effect of lithium maintenance therapy on thyroid and parathyroid function .	Effect of lithium maintenance therapy on thyroid and parathyroid function .
OBJECTIVES : To assess changes induced by lithium maintenance therapy on the incidence of thyroid , parathyroid and ion alterations .	OBJECTIVES : To assess changes induced by lithium maintenance therapy on the incidence of thyroid , parathyroid and ion alterations .
These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .	These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with disease* thyroid disease *disease ) .
DESIGN : Prospective study .	DESIGN : Prospective study .
SETTING : Affective Disorders Clinic at St .	SETTING : Affective Disorders Clinic at St .
Mary ' s Hospital , Montreal .	Mary ' s Hospital , Montreal .
PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year ' s to 32 years ' duration .	PATIENTS : One hundred and one patients ( 28 men and 73 women ) with disease* bipolar disorder *disease receiving lithium maintenance therapy ranging from 1 year ' s to 32 years ' duration .
The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital ' s out - patient clinics .	The control group consisted of 82 patients with no disease* psychiatric *disease or endocrinological diagnoses from the hospital ' s out - patient clinics .
OUTCOME MEASURES : Laboratory analyses of calcium , magnesium and thyroid - stimulating hormone levels performed before beginning lithium therapy and at biannual follow - up .	OUTCOME MEASURES : Laboratory analyses of calcium , magnesium and thyroid - stimulating hormone levels performed before beginning lithium therapy and at biannual follow - up .
RESULTS : Hypothyroidism developed in 40 patients , excluding 8 patients who were hypothyroid at baseline .	RESULTS : disease* Hypothyroidism *disease developed in 40 patients , excluding 8 patients who were disease* hypothyroid *disease at baseline .
All patients having first - degree relatives affected by thyroid illness had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .	All patients having first - degree relatives affected by disease* thyroid illness *disease had accelerated onset of disease* hypothyroidism *disease ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .
Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .	Women over 60 years of age were more often affected by disease* hypothyroidism *disease than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .
Magnesium levels in patients on lithium treatment were unchanged from baseline levels .	Magnesium levels in patients on lithium treatment were unchanged from baseline levels .
After lithium treatment , calcium levels were higher than either baseline levels or control levels .	After lithium treatment , calcium levels were higher than either baseline levels or control levels .
Thus , lithium treatment counteracted the decrease in plasma calcium levels associated with aging .	Thus , lithium treatment counteracted the decrease in plasma calcium levels associated with aging .
CONCLUSIONS : Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy .	CONCLUSIONS : Familial disease* thyroid illness *disease is a risk factor for disease* hypothyroidism *disease and disease* hypercalcemia *disease during lithium therapy .
Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .	Severe immune disease* hemolytic anemia *disease associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .
Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .	Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune disease* hemolytic anemia *disease .
We noticed that 10 of our 35 cases of cefotetan - induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .	We noticed that 10 of our 35 cases of cefotetan - induced disease* hemolytic anemias *disease were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .
Eight of these cases of severe immune hemolytic anemia are described .	Eight of these cases of severe immune disease* hemolytic anemia *disease are described .
Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage .	Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with disease* aneurysmal subarachnoid hemorrhage *disease .
Platelet function is impaired by nonsteroidal anti - inflammatory drugs ( NSAIDs ) with prominent anti - inflammatory properties .	Platelet function is impaired by nonsteroidal anti - inflammatory drugs ( NSAIDs ) with prominent anti - inflammatory properties .
Their safety in patients undergoing intracranial surgery is under debate .	Their safety in patients undergoing intracranial surgery is under debate .
Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .	Patients with disease* aneurysmal subarachnoid hemorrhage *disease ( disease* SAH *disease ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of disease* aneurysmal disease* SAH *disease .
Treatment was continued for 3 days postoperatively .	Treatment was continued for 3 days postoperatively .
Test blood samples were taken before treatment and surgery as well as on the first , third , and fifth postoperative mornings .	Test blood samples were taken before treatment and surgery as well as on the first , third , and fifth postoperative mornings .
Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .	Maximal disease* platelet aggregation *disease induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .
Aggregation was lower ( P < . 05 ) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day .	Aggregation was lower ( P < . 05 ) in the ketoprofen group than in the acetaminophen group just before surgery and on the third postoperative day .
In contrast , maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .	In contrast , maximal disease* platelet aggregation *disease increased in the acetaminophen group on the third postoperative day as compared with the pretreatment disease* platelet aggregation *disease results ( P < . 05 ) .
One patient in the ketoprofen group developed a postoperative intracranial hematoma .	One patient in the ketoprofen group developed a postoperative intracranial disease* hematoma *disease .
Coagulation ( prothrombin time [ PT ] , activated partial thromboplastin time [ APPT ] , fibrinogen concentration , and antithrombin III [ AT III ] ) was comparable between the two groups .	Coagulation ( prothrombin time [ PT ] , activated partial thromboplastin time [ APPT ] , fibrinogen concentration , and antithrombin III [ AT III ] ) was comparable between the two groups .
Ketoprofen but not acetaminophen impaired platelet function in patients with SAH .	Ketoprofen but not acetaminophen impaired platelet function in patients with disease* SAH *disease .
If ketoprofen is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for hemorrhage .	If ketoprofen is used before surgery on cerebral disease* artery aneurysms *disease , it may pose an additional risk factor for disease* hemorrhage *disease .
Nitric oxide synthase expression in the course of lead - induced hypertension .	Nitric oxide synthase expression in the course of lead - induced disease* hypertension *disease .
We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced hypertension .	We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced disease* hypertension *disease .
This study was designed to discern whether the reduction in urinary NOx in lead - induced hypertension is , in part , due to depressed NO synthase ( NOS ) expression .	This study was designed to discern whether the reduction in urinary NOx in lead - induced disease* hypertension *disease is , in part , due to depressed NO synthase ( NOS ) expression .
Male Sprague - Dawley rats were randomly assigned to a lead - treated group ( given lead acetate , 100 ppm , in drinking water and regular rat chow ) , a group given lead and vitamin E - fortified chow , or a normal control group given either regular food and water or vitamin E - fortified food for 12 weeks .	Male Sprague - Dawley rats were randomly assigned to a lead - treated group ( given lead acetate , 100 ppm , in drinking water and regular rat chow ) , a group given lead and vitamin E - fortified chow , or a normal control group given either regular food and water or vitamin E - fortified food for 12 weeks .
Tail blood pressure , urinary NOx excretion , plasma malondialdehyde ( MDA ) , and endothelial and inducible NOS ( eNOS and iNOS ) isotypes in the aorta and kidney were measured .	Tail blood pressure , urinary NOx excretion , plasma malondialdehyde ( MDA ) , and endothelial and inducible NOS ( eNOS and iNOS ) isotypes in the aorta and kidney were measured .
The lead - treated group exhibited a rise in blood pressure and plasma MDA concentration , a fall in urinary NOx excretion , and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression .	The lead - treated group exhibited a rise in blood pressure and plasma MDA concentration , a fall in urinary NOx excretion , and a paradoxical rise in vascular and renal tissue eNOS and iNOS expression .
Vitamin E supplementation ameliorated hypertension , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .	Vitamin E supplementation ameliorated disease* hypertension *disease , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .
Vitamin E supplementation had no effect on either blood pressure , plasma MDA , or NOS expression in the control group .	Vitamin E supplementation had no effect on either blood pressure , plasma MDA , or NOS expression in the control group .
The study also revealed significant inhibition of NOS enzymatic activity by lead in cell - free preparations .	The study also revealed significant inhibition of NOS enzymatic activity by lead in cell - free preparations .
In conclusion , lead - induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .	In conclusion , lead - induced disease* hypertension *disease in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .
This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with hypertension .	This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with disease* hypertension *disease .
Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura .	Glyceryl trinitrate induces attacks of disease* migraine without aura *disease in sufferers of disease* migraine with aura *disease .
Migraine with aura and migraine without aura have the same pain phase , thus indicating that migraine with aura and migraine without aura share a common pathway of nociception .	disease* Migraine with aura *disease and disease* migraine without aura *disease have the same disease* pain *disease phase , thus indicating that disease* migraine with aura *disease and disease* migraine without aura *disease share a common pathway of nociception .
In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in pain mechanisms of migraine without aura .	In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in disease* pain *disease mechanisms of disease* migraine without aura *disease .
In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .	In order to clarify whether the same is true for disease* migraine with aura *disease , in the present study we examined the disease* headache *disease response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of disease* migraine with aura *disease .
The specific aim was to elucidate whether an aura and / or an attack of migraine without aura could be induced .	The specific aim was to elucidate whether an aura and / or an attack of disease* migraine without aura *disease could be induced .
Fourteen healthy subjects served as controls .	Fourteen healthy subjects served as controls .
Aura symptoms were not elicited in any subject .	Aura symptoms were not elicited in any subject .
Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .	disease* Headache *disease was more severe in disease* migraineurs *disease than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .
In the controls , the GTN - induced headache gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .	In the controls , the GTN - induced disease* headache *disease gradually disappeared , whereas in disease* migraineurs *disease peak disease* headache *disease intensity occurred at a mean time of 240 min post - infusion .
At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society .	At this time the induced disease* headache *disease in 6 of 12 disease* migraineurs *disease fulfilled the diagnostic criteria for disease* migraine without aura *disease of the International disease* Headache *disease Society .
The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura .	The results therefore suggest that NO is involved in the disease* pain *disease mechanisms of disease* migraine with aura *disease .
Since cortical spreading depression has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .	Since cortical spreading disease* depression *disease has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading disease* depression *disease and disease* headache *disease in disease* migraine with aura *disease .
Rapid reversal of life - threatening diltiazem - induced tetany with calcium chloride .	Rapid reversal of life - threatening diltiazem - induced disease* tetany *disease with calcium chloride .
We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem .	We describe a patient who developed disease* tetany *disease with sudden disease* respiratory arrest *disease after the infusion of intravenous diltiazem .
The administration of calcium chloride rapidly resolved the patient ' s tetany with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .	The administration of calcium chloride rapidly resolved the patient ' s disease* tetany *disease with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .
The emergency physician should be aware that life - threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .	The emergency physician should be aware that life - threatening disease* tetany *disease may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .
Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD )	Predictors of disease* decreased renal function *disease in patients with disease* heart failure *disease during angiotensin - converting enzyme inhibitor therapy : results from the studies of disease* left ventricular dysfunction *disease ( SOLVD )
BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .	BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with disease* congestive heart failure *disease ( disease* CHF *disease ) , it may also cause disease* decreased renal function *disease .
Little information is available to predict which patients are at highest risk for this complication .	Little information is available to predict which patients are at highest risk for this complication .
OBJECTIVE : To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin - converting enzyme inhibitor therapy .	OBJECTIVE : To quantify specific clinical predictors of disease* reduction in renal function *disease in patients with disease* CHF *disease who are prescribed angiotensin - converting enzyme inhibitor therapy .
METHOD : We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of CHF .	METHOD : We analyzed data from the Studies of disease* Left Ventricular Dysfunction *disease ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of disease* CHF *disease .
There were 3379 patients randomly assigned to enalapril with a median follow - up of 974 days and 3379 patients randomly assigned to placebo with a mean follow - up of 967 days .	There were 3379 patients randomly assigned to enalapril with a median follow - up of 974 days and 3379 patients randomly assigned to placebo with a mean follow - up of 967 days .
Decreased renal function was defined as a rise in serum creatinine > / = 0 . 5 mg / dL ( 44 micromol / L ) from baseline .	disease* Decreased renal function *disease was defined as a rise in serum creatinine > / = 0 . 5 mg / dL ( 44 micromol / L ) from baseline .
We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .	We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of disease* hypertension *disease , disease* diabetes *disease , and use of antiplatelet , diuretic , and beta - blocker therapy .
RESULTS : Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .	RESULTS : Patients randomly assigned to enalapril had a 33 % greater likelihood of disease* decreased renal function *disease than controls ( P = . 003 ) .
By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .	By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and disease* diabetes *disease were associated with disease* decreased renal function *disease , whereas beta - blocker therapy and higher ejection fraction were renoprotective .
Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .	Older age was associated with a greater risk of developing disease* decreased renal function *disease in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .
Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .	Diuretic therapy was likewise associated with a greater risk of disease* decreased renal function *disease in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .
Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .	Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with disease* diabetes *disease .
A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 . 96 ) .	A lower risk of disease* renal impairment *disease was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 . 96 ) .
CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of decreased renal function in patients with CHF .	CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of disease* decreased renal function *disease in patients with disease* CHF *disease .
Diuretic use and advanced age increased this risk .	Diuretic use and advanced age increased this risk .
Diabetes was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the enalapril group compared with the placebo group .	disease* Diabetes *disease was associated with an increased risk of disease* renal impairment *disease in all patients with disease* CHF *disease , but this risk was reduced in the enalapril group compared with the placebo group .
beta - Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy .	beta - Blocker therapy and higher ejection fraction were renoprotective in all patients regardless of therapy .
Hypomania - like syndrome induced by olanzapine .	disease* Hypomania *disease - like syndrome induced by olanzapine .
We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed hypomania shortly after the introduction of olanzapine treatment .	We report a female patient with a diagnosis of a not otherwise specified disease* psychotic disorder *disease ( DSM - IV ) who developed disease* hypomania *disease shortly after the introduction of olanzapine treatment .
Acetazolamide - induced Gerstmann syndrome .	Acetazolamide - induced disease* Gerstmann syndrome *disease .
Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment .	Acute disease* confusion *disease induced by acetazolamide is a well known adverse drug reaction in patients with disease* renal impairment *disease .
We report a case of acetazolamide - induced Gerstmann syndrome in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .	We report a case of acetazolamide - induced disease* Gerstmann syndrome *disease in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .
Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .	Vasopressin in the treatment of milrinone - induced disease* hypotension *disease in severe disease* heart failure *disease .
The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .	The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe disease* heart failure *disease is frequently restricted because they cause vasodilation and disease* hypotension *disease .
In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .	In patients with decompensated disease* heart failure *disease with disease* hypotension *disease after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .
Treatment of tacrolimus - related adverse effects by conversion to cyclosporine in liver transplant recipients .	Treatment of tacrolimus - related adverse effects by conversion to cyclosporine in liver transplant recipients .
When tacrolimus side effects persist despite dose reduction , conversion to cyclosporine - based immunosuppression ( CyA ) is necessary .	When tacrolimus side effects persist despite dose reduction , conversion to cyclosporine - based immunosuppression ( CyA ) is necessary .
We characterized tacrolimus side effects that warranted discontinuation of the drug , and outcomes after conversion .	We characterized tacrolimus side effects that warranted discontinuation of the drug , and outcomes after conversion .
Of 388 liver recipients who received tacrolimus as primary immunosuppression , 70 required conversion to CyA .	Of 388 liver recipients who received tacrolimus as primary immunosuppression , 70 required conversion to CyA .
We recorded indication for conversion , whether conversion was early or late after transplantation , tacrolimus dose and trough blood level at conversion , and incidence of rejection after conversion .	We recorded indication for conversion , whether conversion was early or late after transplantation , tacrolimus dose and trough blood level at conversion , and incidence of rejection after conversion .
Conversion was early in 29 patients ( 41 . 4 % ) and late in 41 ( 58 . 6 % ) .	Conversion was early in 29 patients ( 41 . 4 % ) and late in 41 ( 58 . 6 % ) .
Indications for early conversion were neurotoxicity ( 20 ) , ( insulin - dependent ) diabetes mellitus ( IDDM ) ( 5 ) , nephrotoxicity ( 3 ) , gastrointestinal ( GI ) toxicity ( 6 ) , and cardiomyopathy ( 1 ) , and for late conversion were neurotoxicity ( 15 ) , IDDM ( 12 ) , nephrotoxicity ( 3 ) , GI toxicity ( 5 ) , hepatotoxicity ( 6 ) , post - transplant lmphoproliferate disease ( PTLD ) ( 2 ) , cardiomyopathy ( 1 ) , hemolytic anemia ( 1 ) , and pruritus ( 1 ) .	Indications for early conversion were disease* neurotoxicity *disease ( 20 ) , disease* ( insulin - dependent ) diabetes mellitus *disease ( disease* IDDM *disease ) ( 5 ) , disease* nephrotoxicity *disease ( 3 ) , disease* gastrointestinal ( GI ) toxicity *disease ( 6 ) , and disease* cardiomyopathy *disease ( 1 ) , and for late conversion were disease* neurotoxicity *disease ( 15 ) , disease* IDDM *disease ( 12 ) , disease* nephrotoxicity *disease ( 3 ) , disease* GI toxicity *disease ( 5 ) , disease* hepatotoxicity *disease ( 6 ) , disease* post - transplant lmphoproliferate disease *disease ( disease* PTLD *disease ) ( 2 ) , disease* cardiomyopathy *disease ( 1 ) , disease* hemolytic anemia *disease ( 1 ) , and disease* pruritus *disease ( 1 ) .
All early - conversion patients showed improvement / resolution of symptoms .	All early - conversion patients showed improvement / resolution of symptoms .
Among late - conversion patients , 37 ( 90 . 2 % ) had improvement / resolution ; in 4 ( 9 . 8 % ) , adverse effects persisted .	Among late - conversion patients , 37 ( 90 . 2 % ) had improvement / resolution ; in 4 ( 9 . 8 % ) , adverse effects persisted .
The overall rejection rate was 30 % .	The overall rejection rate was 30 % .
Sixty - two patients ( 88 . 6 % ) are alive with functioning grafts 686 + / - 362 days ( range , 154 - 1433 days ) after conversion .	Sixty - two patients ( 88 . 6 % ) are alive with functioning grafts 686 + / - 362 days ( range , 154 - 1433 days ) after conversion .
When tacrolimus side effects are unresponsive to dose reduction , conversion to CyA can be accomplished safely , with no increased risk of rejection and excellent long - term outcome .	When tacrolimus side effects are unresponsive to dose reduction , conversion to CyA can be accomplished safely , with no increased risk of rejection and excellent long - term outcome .
Ocular manifestations of juvenile rheumatoid arthritis .	Ocular manifestations of disease* juvenile rheumatoid arthritis *disease .
We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .	We followed 210 cases of disease* juvenile rheumatoid arthritis *disease closely for eleven years .
Thirty - six of the 210 patients ( 17 . 2 % ) developed iridocyclitis .	Thirty - six of the 210 patients ( 17 . 2 % ) developed disease* iridocyclitis *disease .
Iridocyclitis was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the arthritis .	disease* Iridocyclitis *disease was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the disease* arthritis *disease .
However , 30 % of the patients developed uveitis after 16 years of age .	However , 30 % of the patients developed disease* uveitis *disease after 16 years of age .
Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active uveitis on entry .	Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active disease* uveitis *disease on entry .
Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases .	Our approach was effective in detecting disease* uveitis *disease in new cases and exacerbations of disease* uveitis *disease in established cases .
Forty - four percent of patients with uveitis had one or more identifiable signs or symptoms , such as red eye , ocular pain , decreased visual acuity , or photophobia , in order of decreasing frequency .	Forty - four percent of patients with disease* uveitis *disease had one or more identifiable signs or symptoms , such as red eye , disease* ocular pain *disease , disease* decreased visual acuity *disease , or disease* photophobia *disease , in order of decreasing frequency .
Even after early detection and prompt treatment , 41 % of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .	Even after early detection and prompt treatment , 41 % of cases of disease* uveitis *disease did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .
Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of uveitis cited in earlier studies .	Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of disease* uveitis *disease cited in earlier studies .
Cataract and band keratopathy occurred in only 22 and 13 % of our group , respectively .	disease* Cataract *disease and disease* band keratopathy *disease occurred in only 22 and 13 % of our group , respectively .
We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs .	We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of disease* chorioretinopathy *disease attributable to these drugs .
Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .	Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular disease* cataracts *disease was found .
Typical keratoconjunctivitis sicca developed in three of the uveitis cases .	Typical disease* keratoconjunctivitis *disease sicca developed in three of the disease* uveitis *disease cases .
This association with uveitis and JRA was not noted previously .	This association with disease* uveitis *disease and JRA was not noted previously .
Surgical treatment of cataracts , band keratopathy , and glaucoma achieved uniformly discouraging results .	Surgical treatment of disease* cataracts *disease , disease* band keratopathy *disease , and disease* glaucoma *disease achieved uniformly discouraging results .
Cyclophosphamide - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of visceral pain .	Cyclophosphamide - induced disease* cystitis *disease in freely - moving conscious rats : behavioral approach to a new model of disease* visceral pain *disease .
PURPOSE : To develop a model of visceral pain in rats using a behavioral approach .	PURPOSE : To develop a model of disease* visceral pain *disease in rats using a behavioral approach .
Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce cystitis .	Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce disease* cystitis *disease .
MATERIALS AND METHODS : CP was administered at doses of 50 , 100 and 200 mg . / kg .	MATERIALS AND METHODS : CP was administered at doses of 50 , 100 and 200 mg . / kg .
i . p . to male rats , and their behavior observed and scored .	i . p . to male rats , and their behavior observed and scored .
The effects of morphine ( 0 . 5 to 4 mg . / kg . i . v . ) on CP - induced behavioral modifications were tested administered alone and after naloxone ( 1 mg . / kg . s . c . ) .	The effects of morphine ( 0 . 5 to 4 mg . / kg . i . v . ) on CP - induced behavioral modifications were tested administered alone and after naloxone ( 1 mg . / kg . s . c . ) .
In addition , 90 minutes after CP injection , that is , at the time of administration of morphine , the bladder was removed in some rats for histological examination .	In addition , 90 minutes after CP injection , that is , at the time of administration of morphine , the bladder was removed in some rats for histological examination .
Finally , to show that the bladder is essential for the CP - induced behavioral modifications , female rats also received CP at doses of 200 mg . / kg .	Finally , to show that the bladder is essential for the CP - induced behavioral modifications , female rats also received CP at doses of 200 mg . / kg .
i . p . and of 20 mg . by the intravesical route , and acrolein at doses of 0 . 5 mg . by the intravesical route and of 5 mg . / kg .	i . p . and of 20 mg . by the intravesical route , and acrolein at doses of 0 . 5 mg . by the intravesical route and of 5 mg . / kg .
i . v . RESULTS : CP dose - relatedly induced marked behavioral modifications in male rats : breathing rate decrease , closing of the eyes and occurrence of specific postures .	i . v . RESULTS : CP dose - relatedly induced marked behavioral modifications in male rats : breathing rate decrease , closing of the eyes and occurrence of specific postures .
Morphine dose - dependently reversed these behavioral disorders .	Morphine dose - dependently reversed these disease* behavioral disorders *disease .
A dose of 0 . 5 mg . / kg . produced a reduction of almost 50 % of the behavioral score induced by CP 200 mg . / kg .	A dose of 0 . 5 mg . / kg . produced a reduction of almost 50 % of the behavioral score induced by CP 200 mg . / kg .
This effect was completely prevented by pretreatment with naloxone .	This effect was completely prevented by pretreatment with naloxone .
At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .	At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer disease* edema *disease , were observed .
In female rats , CP 200 mg . / kg .	In female rats , CP 200 mg . / kg .
i . p . produced the same marked behavioral modifications as those observed in male rats .	i . p . produced the same marked behavioral modifications as those observed in male rats .
Administered at the dose of 20 mg . intravesically , CP did not produce any behavioral effects , whereas acrolein at 0 . 5 mg . intravesically induced behavioral modifications identical to those under CP 200 mg . / kg .	Administered at the dose of 20 mg . intravesically , CP did not produce any behavioral effects , whereas acrolein at 0 . 5 mg . intravesically induced behavioral modifications identical to those under CP 200 mg . / kg .
i . p . , with the same maximal levels .	i . p . , with the same maximal levels .
Conversely , acrolein 5 mg . / kg .	Conversely , acrolein 5 mg . / kg .
i . v . did not produce any behavioral effects at all .	i . v . did not produce any behavioral effects at all .
CONCLUSIONS : Overall , these results indicate that this experimental model of CP - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .	CONCLUSIONS : Overall , these results indicate that this experimental model of CP - induced disease* cystitis *disease may be an interesting new behavioral model of inflammatory disease* visceral pain *disease , allowing a better understanding of these disease* painful syndromes *disease and thus a better therapeutic approach to them .
Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .	Prednisolone - induced disease* muscle dysfunction *disease is caused more by disease* atrophy *disease than by altered acetylcholine receptor expression .
Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood .	Large doses of glucocorticoids can alter muscle physiology and susceptibility to neuromuscular blocking drugs by mechanisms not clearly understood .
We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology , and their relationship to changes in muscle size and acetylcholine receptor ( AChR ) expression .	We investigated the effects of moderate and large doses of prednisolone on muscle function and pharmacology , and their relationship to changes in muscle size and acetylcholine receptor ( AChR ) expression .
With institutional approval , 35 Sprague - Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg / kg prednisolone ( P10 group ) , 100 mg / kg prednisolone ( P100 group ) , or an equal volume of saline ( S group ) for 7 days .	With institutional approval , 35 Sprague - Dawley rats were randomly allocated to receive daily subcutaneous doses of 10 mg / kg prednisolone ( P10 group ) , 100 mg / kg prednisolone ( P100 group ) , or an equal volume of saline ( S group ) for 7 days .
A fourth group of rats was pair fed ( food restricted ) with the P100 rats for 7 days ( FR group ) .	A fourth group of rats was pair fed ( food restricted ) with the P100 rats for 7 days ( FR group ) .
On Day 8 , the nerve - evoked peak twitch tensions , tetanic tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .	On Day 8 , the nerve - evoked peak twitch tensions , disease* tetanic *disease tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .
Rate of body weight gain was depressed in the P100 , FR , and P10 groups compared with the S group .	Rate of body weight gain was depressed in the P100 , FR , and P10 groups compared with the S group .
Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups .	Tibialis muscle mass was smaller in the P100 group than in the P10 or S groups .
The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .	The evoked peak twitch and disease* tetanic *disease tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .
The 50 % effective dose of d - tubocurarine ( microg / kg ) in the tibialis muscle was smaller in the P10 ( 33 . 6 + / - 5 . 4 ) than in the S ( 61 . 9 + / - 5 . 0 ) or the P100 ( 71 . 3 + / - 9 . 6 ) groups .	The 50 % effective dose of d - tubocurarine ( microg / kg ) in the tibialis muscle was smaller in the P10 ( 33 . 6 + / - 5 . 4 ) than in the S ( 61 . 9 + / - 5 . 0 ) or the P100 ( 71 . 3 + / - 9 . 6 ) groups .
AChR expression was less in the P10 group than in the S group .	AChR expression was less in the P10 group than in the S group .
The evoked tensions correlated with muscle mass ( r ( 2 ) = 0 . 32 , P < 0 . 001 ) , however , not with expression of AChR .	The evoked tensions correlated with muscle mass ( r ( 2 ) = 0 . 32 , P < 0 . 001 ) , however , not with expression of AChR .
The 50 % effective dose of d - tubocurarine did not correlate with muscle mass or AChR expression .	The 50 % effective dose of d - tubocurarine did not correlate with muscle mass or AChR expression .
Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .	Our results suggest that the disease* neuromuscular dysfunction *disease after prednisolone is dose - dependent , and derives primarily from disease* muscle atrophy *disease and derives less so from changes in AChR expression .
IMPLICATIONS : The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear .	IMPLICATIONS : The mechanisms by which chronic glucocorticoid therapy alters neuromuscular physiology and pharmacology are unclear .
We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .	We suggest that the observed effects are dose - dependent and derive primarily from disease* muscle atrophy *disease and derive less from changes in acetylcholine receptor expression .
Apomorphine : an underutilized therapy for Parkinson ' s disease .	Apomorphine : an underutilized therapy for disease* Parkinson ' s disease *disease .
Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson ' s disease .	Apomorphine was the first dopaminergic drug ever used to treat symptoms of disease* Parkinson ' s disease *disease .
While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating Parkinson ' s disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .	While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating disease* Parkinson ' s disease *disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .
A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off - periods even in patients with complex on - off motor swings .	A number of small scale clinical trials have unequivocally shown that intermittent subcutaneous apomorphine injections produce antiparkinsonian benefit close if not identical to that seen with levodopa and that apomorphine rescue injections can reliably revert off - periods even in patients with complex on - off motor swings .
Continuous subcutaneous apomorphine infusions can reduce daily off - time by more than 50 % in this group of patients , which appears to be a stronger effect than that generally seen with add - on therapy with oral dopamine agonists or COMT inhibitors .	Continuous subcutaneous apomorphine infusions can reduce daily off - time by more than 50 % in this group of patients , which appears to be a stronger effect than that generally seen with add - on therapy with oral dopamine agonists or COMT inhibitors .
Extended follow - up studies of up to 8 years have demonstrated long - term persistence of apomorphine efficacy .	Extended follow - up studies of up to 8 years have demonstrated long - term persistence of apomorphine efficacy .
In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced dyskinesias .	In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced disease* dyskinesias *disease .
The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .	The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and disease* psychiatric *disease complications play a lesser role .
Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson ' s disease , this approach seems to deserve more widespread clinical use .	Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating disease* Parkinson ' s disease *disease , this approach seems to deserve more widespread clinical use .
Probing peripheral and central cholinergic system responses .	Probing peripheral and central cholinergic system responses .
OBJECTIVE : The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer ' s disease , yet correlations between central and peripheral responses have not been properly studied .	OBJECTIVE : The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as disease* Alzheimer ' s disease *disease , yet correlations between central and peripheral responses have not been properly studied .
This study assessed the effect of normal aging on ( 1 ) the tropicamide - induced increase in pupil diameter , and ( 2 ) the reversal of this effect with pilocarpine .	This study assessed the effect of normal aging on ( 1 ) the tropicamide - induced increase in pupil diameter , and ( 2 ) the reversal of this effect with pilocarpine .
Scopolamine was used as a positive control to detect age - dependent changes in central cholinergic functioning in the elderly .	Scopolamine was used as a positive control to detect age - dependent changes in central cholinergic functioning in the elderly .
DESIGN : Randomized double - blind controlled trial .	DESIGN : Randomized double - blind controlled trial .
PARTICIPANTS : Ten healthy elderly ( mean age 70 ) and 9 young ( mean age 33 ) volunteers .	PARTICIPANTS : Ten healthy elderly ( mean age 70 ) and 9 young ( mean age 33 ) volunteers .
INTERVENTIONS : Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours .	INTERVENTIONS : Pupil diameter was monitored using a computerized infrared pupillometer over 4 hours .
The study involved 4 sessions .	The study involved 4 sessions .
In 1 session , tropicamide ( 20 microL , 0 . 01 % ) was administered to one eye and placebo to the other .	In 1 session , tropicamide ( 20 microL , 0 . 01 % ) was administered to one eye and placebo to the other .
In another session , tropicamide ( 20 microL , 0 . 01 % ) was administered to both eyes , followed 23 minutes later by the application of pilocarpine ( 20 microL , 0 . 1 % ) to one eye and placebo to the other .	In another session , tropicamide ( 20 microL , 0 . 01 % ) was administered to both eyes , followed 23 minutes later by the application of pilocarpine ( 20 microL , 0 . 1 % ) to one eye and placebo to the other .
All eye drops were given in a randomized order .	All eye drops were given in a randomized order .
In 2 separate sessions , a single dose of scopolamine ( 0 . 5 mg , intravenously ) or placebo was administered , and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours .	In 2 separate sessions , a single dose of scopolamine ( 0 . 5 mg , intravenously ) or placebo was administered , and the effects on word recall were measured using the Buschke Selective Reminding Test over 2 hours .
OUTCOME MEASURES : Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced impairment in word recall .	OUTCOME MEASURES : Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced disease* impairment in word recall *disease .
RESULTS : There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point ( p > 0 . 05 ) .	RESULTS : There was no significant difference between elderly and young volunteers in pupillary response to tropicamide at any time point ( p > 0 . 05 ) .
The elderly group had a significantly greater pilocarpine - induced net decrease in pupil size 85 , 125 , 165 and 215 minutes after administration , compared with the young group ( p < 0 . 05 ) .	The elderly group had a significantly greater pilocarpine - induced net decrease in pupil size 85 , 125 , 165 and 215 minutes after administration , compared with the young group ( p < 0 . 05 ) .
Compared with the young group , the elderly group had greater scopolamine - induced impairment in word recall 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .	Compared with the young group , the elderly group had greater scopolamine - induced disease* impairment in word recall *disease 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .
CONCLUSION : There is an age - related pupillary response to pilocarpine that is not found with tropicamide .	CONCLUSION : There is an age - related pupillary response to pilocarpine that is not found with tropicamide .
Thus , pilocarpine may be useful to assess variations in central cholinergic function in elderly patients .	Thus , pilocarpine may be useful to assess variations in central cholinergic function in elderly patients .
Pain responses in methadone - maintained opioid abusers .	disease* Pain *disease responses in methadone - maintained opioid abusers .
Providing pain management for known opioid abusers is a challenging clinical task , in part because little is known about their pain experience and analgesic requirements .	Providing disease* pain *disease management for known opioid abusers is a challenging clinical task , in part because little is known about their disease* pain *disease experience and analgesic requirements .
This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .	This study was designed to describe disease* pain *disease tolerance and analgesic response in a sample of disease* opioid addicts *disease stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .
By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) pain was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .	By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) disease* pain *disease was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .
Results showed that MM individuals were significantly less tolerant of CP pain than control subjects , replicating previous work .	Results showed that MM individuals were significantly less tolerant of CP disease* pain *disease than control subjects , replicating previous work .
Analgesic effects were significant neither for medication nor group .	Analgesic effects were significant neither for medication nor group .
These data indicate that MM opioid abusers represent a pain - intolerant subset of clinical patients .	These data indicate that MM opioid abusers represent a disease* pain - intolerant *disease subset of clinical patients .
Their complaints of pain should be evaluated seriously and managed aggressively .	Their complaints of disease* pain *disease should be evaluated seriously and managed aggressively .
High - dose methylprednisolone may do more harm for spinal cord injury .	High - dose methylprednisolone may do more harm for disease* spinal cord injury *disease .
Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute spinal cord injury .	Because of the National Acute disease* Spinal Cord Injury *disease Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute disease* spinal cord injury *disease .
In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .	In the NASCIS , there was no mention regarding the possibility of acute corticosteroid disease* myopathy *disease that high - dose methylprednisolone may cause .
The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2 - day period for any clinical condition .	The dosage of methylprednisolone recommended by the NASCIS 3 is the highest dose of steroids ever being used during a 2 - day period for any clinical condition .
We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .	We hypothesize that it may cause some disease* damage to the muscle *disease of disease* spinal cord injury *disease patients .
Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .	Further , steroid disease* myopathy *disease recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid disease* myopathy *disease , instead of any protection that methylprednisolone offers to the disease* spinal cord injury *disease .
To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .	To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid disease* myopathy *disease .
Conversion to rapamycin immunosuppression in renal transplant recipients : report of an initial experience .	Conversion to rapamycin immunosuppression in renal transplant recipients : report of an initial experience .
BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .	BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) disease* toxicity *disease .
METHODS : Twenty renal transplant recipients were switched to fixed dose rapamycin ( RAPA ) ( 5 mg / day ) 0 to 204 months posttransplant .	METHODS : Twenty renal transplant recipients were switched to fixed dose rapamycin ( RAPA ) ( 5 mg / day ) 0 to 204 months posttransplant .
Drug monitoring was not initially used to adjust doses .	Drug monitoring was not initially used to adjust doses .
The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .	The indications for switch were chronic CsA or Tac disease* nephrotoxicity *disease ( 12 ) , acute CsA or Tac disease* toxicity *disease ( 3 ) , severe disease* facial dysmorphism *disease ( 2 ) , disease* posttransplant lymphoproliferative disorder *disease ( disease* PTLD *disease ) in remission ( 2 ) , and disease* hepatotoxicity *disease in 1 .
Follow - up is 7 to 24 months .	Follow - up is 7 to 24 months .
RESULTS : In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .	RESULTS : In the 12 patients switched because of chronic disease* nephrotoxicity *disease there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .
Facial dysmorphism improved in two patients .	disease* Facial dysmorphism *disease improved in two patients .
No relapse of PTLD was observed .	No relapse of disease* PTLD *disease was observed .
Five patients developed pneumonia ( two Pneumocystis carinii pneumonia , one infectious mononucleosis with polyclonal PTLD lung infiltrate ) and two had bronchiolitis obliterans .	Five patients developed disease* pneumonia *disease ( two disease* Pneumocystis carinii pneumonia *disease , one disease* infectious mononucleosis *disease with polyclonal disease* PTLD *disease lung infiltrate ) and two had disease* bronchiolitis obliterans *disease .
There were no deaths .	There were no deaths .
RAPA was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral aphtous ulcers in one .	RAPA was discontinued in four patients , because of disease* pneumonia *disease in two , disease* PTLD *disease in one , and oral disease* aphtous ulcers *disease in one .
RAPA levels were high ( > 15 ng / ml ) in 7 of 13 ( 54 % ) patients .	RAPA levels were high ( > 15 ng / ml ) in 7 of 13 ( 54 % ) patients .
CONCLUSIONS : RAPA conversion provides adequate immunosuppression to enable CsA withdrawal .	CONCLUSIONS : RAPA conversion provides adequate immunosuppression to enable CsA withdrawal .
However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given .	However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and disease* Pneumocystis carinii pneumonia *disease prophylaxis should be given .
Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .	Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed disease* visual field constriction *disease .
PURPOSE : Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .	PURPOSE : Symptomatic disease* visual field constriction *disease thought to be associated with vigabatrin has been reported .
The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .	The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed disease* visual field loss *disease , three of whom were reported previously .
Six of the patients were no longer receiving vigabatrin .	Six of the patients were no longer receiving vigabatrin .
METHODS : The central and peripheral fields were examined with the Humphrey Visual Field Analyzer .	METHODS : The central and peripheral fields were examined with the Humphrey Visual Field Analyzer .
Full visual electrophysiology , including flash electroretinography ( ERG ) , pattern electroretinography , multifocal ERG using the VERIS system , electro - oculography , and flash and pattern visual evoked potentials , was undertaken .	Full visual electrophysiology , including flash electroretinography ( ERG ) , pattern electroretinography , multifocal ERG using the VERIS system , electro - oculography , and flash and pattern visual evoked potentials , was undertaken .
RESULTS : Seven patients showed marked visual field constriction with some sparing of the temporal visual field .	RESULTS : Seven patients showed marked disease* visual field constriction *disease with some sparing of the temporal visual field .
The eighth exhibited concentric constriction .	The eighth exhibited concentric constriction .
Most electrophysiological responses were usually just within normal limits ; two patients had subnormal Arden electro - oculography indices ; and one patient showed an abnormally delayed photopic b wave .	Most electrophysiological responses were usually just within normal limits ; two patients had subnormal Arden electro - oculography indices ; and one patient showed an abnormally delayed photopic b wave .
However , five patients showed delayed 30 - Hz flicker b waves , and seven patients showed delayed oscillatory potentials .	However , five patients showed delayed 30 - Hz flicker b waves , and seven patients showed delayed oscillatory potentials .
Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level .	Multifocal ERG showed abnormalities that sometimes correlated with the visual field appearance and confirmed that the deficit occurs at the retinal level .
CONCLUSION : Marked visual field constriction appears to be associated with vigabatrin therapy .	CONCLUSION : Marked disease* visual field constriction *disease appears to be associated with vigabatrin therapy .
The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .	The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn .
Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography .	disease* Myocardial ischemia *disease due to disease* coronary artery spasm *disease during dobutamine stress echocardiography .
Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for myocardial ischemia .	Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for disease* myocardial ischemia *disease .
Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed coronary artery stenosis .	Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed disease* coronary artery stenosis *disease .
The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine .	The aim of the present study is to examine whether disease* myocardial ischemia *disease due to disease* coronary spasm *disease is induced by dobutamine .
We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis .	We performed DSE on 51 patients with disease* coronary spastic angina *disease but without significant fixed disease* coronary artery stenosis *disease .
All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( variant angina ) .	All patients had disease* anginal *disease attacks at rest with ST elevation on the electrocardiogram ( disease* variant angina *disease ) .
Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed coronary artery stenosis was documented on angiograms in all patients .	Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed disease* coronary artery stenosis *disease was documented on angiograms in all patients .
DSE was performed with intravenous dobutamine infusion with an incremental doses of 5 , 10 , 20 , 30 , and 40 microg / kg / min every 5 minutes .	DSE was performed with intravenous dobutamine infusion with an incremental doses of 5 , 10 , 20 , 30 , and 40 microg / kg / min every 5 minutes .
Of the 51 patients , 7 patients showed asynergy with ST elevation .	Of the 51 patients , 7 patients showed asynergy with ST elevation .
All 7 patients ( 13 . 7 % ) had chest pain during asynergy , and both chest pain and electrocardiographic changes were preceded by asynergy .	All 7 patients ( 13 . 7 % ) had disease* chest pain *disease during asynergy , and both disease* chest pain *disease and electrocardiographic changes were preceded by asynergy .
These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina .	These findings indicate that dobutamine can provoke disease* coronary spasm *disease in some patients with disease* coronary spastic angina *disease .
When DSE is performed to evaluate coronary artery disease , not only fixed coronary stenosis , but also coronary spasm should be considered as a genesis of asynergy .	When DSE is performed to evaluate disease* coronary artery disease *disease , not only fixed disease* coronary stenosis *disease , but also disease* coronary spasm *disease should be considered as a genesis of asynergy .
Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced myocardial ischemia .	Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced disease* myocardial ischemia *disease .
STUDY OBJECTIVE : To determine the effect of metoprolol on dobutamine stress testing with technetium - 99m sestamibi single - photon emission computed tomography imaging and ST - segment monitoring , and to assess the impact of intravenous glucagon on metoprolol ' s effects .	STUDY OBJECTIVE : To determine the effect of metoprolol on dobutamine stress testing with technetium - 99m sestamibi single - photon emission computed tomography imaging and ST - segment monitoring , and to assess the impact of intravenous glucagon on metoprolol ' s effects .
DESIGN : Randomized , double - blind , placebo - controlled trial .	DESIGN : Randomized , double - blind , placebo - controlled trial .
SETTING : Community hospital .	SETTING : Community hospital .
PATIENTS : Twenty - two patients with known reversible perfusion defects .	PATIENTS : Twenty - two patients with known reversible perfusion defects .
INTERVENTION : Patients underwent dobutamine stress tests per standard protocol .	INTERVENTION : Patients underwent dobutamine stress tests per standard protocol .
Before dobutamine was begun , no therapy was given during the first visit , and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg .	Before dobutamine was begun , no therapy was given during the first visit , and patients were randomized on subsequent visits to receive metoprolol or metoprolol plus glucagon 1 mg .
Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats / minute or a total intravenous dose of 20 mg .	Metoprolol was dosed to achieve a resting predobutamine heart rate below 65 beats / minute or a total intravenous dose of 20 mg .
MEASUREMENTS AND MAIN RESULTS : Metoprolol reduced maximum heart rate 31 % , summed stress scores 29 % , and summed difference scores 43 % versus control .	MEASUREMENTS AND MAIN RESULTS : Metoprolol reduced maximum heart rate 31 % , summed stress scores 29 % , and summed difference scores 43 % versus control .
Metoprolol plus glucagon also reduced the maximum heart rate 29 % versus control .	Metoprolol plus glucagon also reduced the maximum heart rate 29 % versus control .
Summed stress and summed difference scores were not significantly reduced , although they were 18 % and 30 % lower , respectively , than control .	Summed stress and summed difference scores were not significantly reduced , although they were 18 % and 30 % lower , respectively , than control .
No significant differences were found in any parameter between metoprolol and metoprolol - glucagon .	No significant differences were found in any parameter between metoprolol and metoprolol - glucagon .
CONCLUSION : During dobutamine stress testing , metoprolol attenuates or eliminates evidence of myocardial ischemia .	CONCLUSION : During dobutamine stress testing , metoprolol attenuates or eliminates evidence of disease* myocardial ischemia *disease .
Glucagon 1 mg , although somewhat effective , does not correct this effect to the extent that it can be administered clinically .	Glucagon 1 mg , although somewhat effective , does not correct this effect to the extent that it can be administered clinically .
Evidence of functional somatotopy in GPi from results of pallidotomy .	Evidence of functional somatotopy in GPi from results of pallidotomy .
The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and levodopa - induced dyskinesias ( LID ) .	The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on disease* parkinsonian *disease ' off ' signs and levodopa - induced disease* dyskinesias *disease ( disease* LID *disease ) .
We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in LID .	We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in disease* LID *disease .
We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in parkinsonian ' off ' signs .	We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in disease* LID *disease in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in disease* parkinsonian *disease ' off ' signs .
The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian ' off ' signs .	The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either disease* dyskinesias *disease or disease* parkinsonian *disease ' off ' signs .
The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .	The differential predictive value of levodopa responsiveness for the outcome of disease* parkinsonian *disease ' off ' signs and disease* LID *disease and the different correlations of ventral lesion volume with disease* dyskinesias *disease and disease* parkinsonian *disease ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of disease* parkinsonian *disease ' off ' signs and disease* dyskinesias *disease .
Whereas cells in a wider area of the GPi may be implicated in parkinsonism , the ventral GPi seems to be crucial for the manifestation of LID .	Whereas cells in a wider area of the GPi may be implicated in disease* parkinsonism *disease , the ventral GPi seems to be crucial for the manifestation of disease* LID *disease .
We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias , especially along the dorsoventral trajectory used in pallidotomy .	We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate disease* parkinsonism *disease and disease* dyskinesias *disease , especially along the dorsoventral trajectory used in pallidotomy .
The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms , and hence could be variable .	The outcome of pallidotomy in which the lesion involves the ventral and dorsal GPi could be the net effect of alteration in the activity of pathways which mediate different symptoms , and hence could be variable .
Screening for stimulant use in adult emergency department seizure patients .	Screening for stimulant use in adult emergency department disease* seizure *disease patients .
OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .	OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department disease* seizure *disease patients .
METHODS : This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .	METHODS : This prospective study evaluated consecutive eligible disease* seizure *disease patients who had a plasma sample collected as part of their clinical evaluation .
Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .	Plasma was tested for amphetamine and the cocaine metabolite benzoylecgonine using enzyme - mediated immunoassay methodology .
Plasma samples with benzoylecgonine greater than 150 ng / mL or an amphetamine greater than 500 ng / mL were defined as positive .	Plasma samples with benzoylecgonine greater than 150 ng / mL or an amphetamine greater than 500 ng / mL were defined as positive .
Patient demographics , history of underlying drug or alcohol - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .	Patient demographics , history of underlying drug or alcohol - related disease* seizure *disease disorder , estimated time from disease* seizure *disease to sample collection , history or suspicion of disease* cocaine or amphetamine abuse *disease , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .
RESULTS : Fourteen of 248 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples ( 0 % , 95 % CI 0 - 1 . 2 % ) were positive for amphetamine .	RESULTS : Fourteen of 248 ( 5 . 6 % , 95 % CI 2 . 7 % - 8 . 5 % ) plasma samples were positive by immunoassay testing for benzoylecgonine and no samples ( 0 % , 95 % CI 0 - 1 . 2 % ) were positive for amphetamine .
Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse ( p < 0 . 0005 ) .	Positive test results were more common in patient visits where there was a history or suspicion of disease* cocaine or amphetamine abuse *disease ( p < 0 . 0005 ) .
CONCLUSIONS : During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .	CONCLUSIONS : During this study period , routine plasma screening for cocaine and amphetamines in adult disease* seizure *disease patients had a low yield .
As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population .	As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of disease* drug abuse *disease in this population .
Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone .	Contribution of sodium valproate to the disease* syndrome of inappropriate secretion of antidiuretic hormone *disease .
We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) .	We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the disease* syndrome of inappropriate secretion of antidiuretic hormone *disease ( disease* SIADH *disease ) .
He had been taking VPA for treatment of idiopathic generalized tonic - clonic convulsions since he was 56 years old .	He had been taking VPA for treatment of idiopathic generalized disease* tonic - clonic convulsions *disease since he was 56 years old .
After substituting VPA with zonisamide , the serum sodium level returned to normal .	After substituting VPA with zonisamide , the serum sodium level returned to normal .
We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of VPA .	We consider this episode of disease* SIADH *disease to be the result of a combination of factors including a disease* weakness of the central nervous system *disease and the long - term administration of VPA .
Association of nitric oxide production and apoptosis in a model of experimental nephropathy .	Association of nitric oxide production and apoptosis in a model of experimental disease* nephropathy *disease .
BACKGROUND : In recent studies increased amounts of nitric oxide ( NO ) and apoptosis have been implicated in various pathological conditions in the kidney .	BACKGROUND : In recent studies increased amounts of nitric oxide ( NO ) and apoptosis have been implicated in various pathological conditions in the kidney .
We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin ( ADR ) .	We have studied the role of NO and its association with apoptosis in an experimental model of disease* nephrotic syndrome *disease induced by a single injection of adriamycin ( ADR ) .
METHODS : The alteration in the NO pathway was assessed by measuring nitrite levels in serum / urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney ( IPRK ) system .	METHODS : The alteration in the NO pathway was assessed by measuring nitrite levels in serum / urine and by evaluating the changes in vascular reactivity of the isolated perfused rat kidney ( IPRK ) system .
Rats were stratified into control groups and ADR - induced nephropathy groups .	Rats were stratified into control groups and ADR - induced disease* nephropathy *disease groups .
These two groups were then divided into : group 1 , animals receiving saline ; and group 2 , animals receiving aminoguanidine ( AG ) which is a specific inhibitor of inducible - NO synthase .	These two groups were then divided into : group 1 , animals receiving saline ; and group 2 , animals receiving aminoguanidine ( AG ) which is a specific inhibitor of inducible - NO synthase .
On day 21 , rats were sacrificed after obtaining material for biochemical analysis .	On day 21 , rats were sacrificed after obtaining material for biochemical analysis .
RESULTS : Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation .	RESULTS : Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of disease* mesangial proliferation *disease and mild disease* tubulointerstitial inflammation *disease .
They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .	They also had significantly higher levels of disease* proteinuria *disease compared with control and treatment groups ( P < 0 . 05 ) .
Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .	Urine nitrite levels were significantly increased in the ADR - disease* nephropathy *disease group ( P < 0 . 05 ) .
In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .	In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - disease* nephropathy *disease group .
Apoptosis was not detected in controls .	Apoptosis was not detected in controls .
However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .	However , in the ADR - disease* nephropathy *disease group , numerous apoptotic cells were identified in the tubulointerstitial areas .
Double staining revealed numerous interstitial apoptotic cells to stain for ED1 , a marker for monocytes / macrophages .	Double staining revealed numerous interstitial apoptotic cells to stain for ED1 , a marker for monocytes / macrophages .
Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels .	Treatment with AG prevented the impairment of renal vascular bed responses and reduced both urine nitrite levels and apoptosis to control levels .
CONCLUSION : We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced nephrosis .	CONCLUSION : We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced disease* nephrosis *disease .
Dual effects of melatonin on barbiturate - induced narcosis in rats .	Dual effects of melatonin on barbiturate - induced disease* narcosis *disease in rats .
Melatonin affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced narcosis .	Melatonin affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced disease* narcosis *disease .
Sodium thiopenthal was administered intraperitoneally into male rats pre - treated with melatonin ( 0 . 05 , 0 . 5 , 5 and 50 mg / kg ) .	Sodium thiopenthal was administered intraperitoneally into male rats pre - treated with melatonin ( 0 . 05 , 0 . 5 , 5 and 50 mg / kg ) .
Melatonin pre - treatment affected in a dual manner barbiturate narcosis , however , no dose - effect correlation was found .	Melatonin pre - treatment affected in a dual manner barbiturate disease* narcosis *disease , however , no dose - effect correlation was found .
In particular , low doses reduced the latency to and prolonged the duration of barbiturate narcosis .	In particular , low doses reduced the latency to and prolonged the duration of barbiturate disease* narcosis *disease .
In contrast , the highest dose of melatonin ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis , and a reduction in mortality rate .	In contrast , the highest dose of melatonin ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of disease* narcosis *disease , and a reduction in mortality rate .
Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced narcosis .	Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced disease* narcosis *disease .
Thus , the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action .	Thus , the dual action of melatonin on pharmacological disease* narcosis *disease seems to be specific for the barbiturate mechanism of action .
Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .	Reduced disease* cardiotoxicity *disease and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic disease* breast cancer *disease .
PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .	PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin disease* cardiotoxicity *disease while providing comparable antitumor efficacy in first - line treatment of metastatic disease* breast cancer *disease ( disease* MBC *disease ) .
PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .	PATIENTS AND METHODS : Two hundred ninety - seven patients with disease* MBC *disease and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable disease* toxicity *disease .
Cardiotoxicity was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or congestive heart failure ( CHF ) .	disease* Cardiotoxicity *disease was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or disease* congestive heart failure *disease ( disease* CHF *disease ) .
Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .	Antitumor efficacy was assessed by objective disease* tumor *disease response rates ( World Health Organization criteria ) , time to progression , and survival .
RESULTS : Six percent of MC patients versus 21 % ( including five cases of CHF ) of AC patients developed cardiotoxicity ( P = . 0002 ) .	RESULTS : Six percent of MC patients versus 21 % ( including five cases of disease* CHF *disease ) of AC patients developed disease* cardiotoxicity *disease ( P = . 0002 ) .
Median cumulative doxorubicin dose at onset was more than 2 , 220 mg / m ( 2 ) for MC versus 480 mg / m ( 2 ) for AC ( P = . 0001 , hazard ratio , 5 . 04 ) .	Median cumulative doxorubicin dose at onset was more than 2 , 220 mg / m ( 2 ) for MC versus 480 mg / m ( 2 ) for AC ( P = . 0001 , hazard ratio , 5 . 04 ) .
MC patients also experienced less grade 4 neutropenia .	MC patients also experienced less grade 4 disease* neutropenia *disease .
Antitumor efficacy of MC versus AC was comparable : objective response rates , 43 % versus 43 % ; median time to progression , 5 . 1 % versus 5 . 5 months ; median time to treatment failure , 4 . 6 versus 4 . 4 months ; and median survival , 19 versus 16 months .	Antitumor efficacy of MC versus AC was comparable : objective response rates , 43 % versus 43 % ; median time to progression , 5 . 1 % versus 5 . 5 months ; median time to treatment failure , 4 . 6 versus 4 . 4 months ; and median survival , 19 versus 16 months .
CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .	CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing disease* cardiotoxicity *disease and grade 4 disease* neutropenia *disease and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for disease* MBC *disease .
The role of nitrergic system in lidocaine - induced convulsion in the mouse .	The role of nitrergic system in lidocaine - induced disease* convulsion *disease in the mouse .
The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .	The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced disease* convulsions *disease .
In the first experiment , four groups of mice received physiological saline ( 0 . 9 % ) , L - arginine ( 300 mg / kg , i . p . ) , L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) , respectively .	In the first experiment , four groups of mice received physiological saline ( 0 . 9 % ) , L - arginine ( 300 mg / kg , i . p . ) , L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) , respectively .
Thirty minutes after these injections , all mice received lidocaine ( 50 mg / kg , i . p . ) .	Thirty minutes after these injections , all mice received lidocaine ( 50 mg / kg , i . p . ) .
In the second experiment , four groups of mice received similar treatment in the first experiment , and 30 min after these injections , all mice received a higher dose of lidocaine ( 80 mg / kg ) .	In the second experiment , four groups of mice received similar treatment in the first experiment , and 30 min after these injections , all mice received a higher dose of lidocaine ( 80 mg / kg ) .
L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .	L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced disease* convulsions *disease .
In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .	In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced disease* convulsions *disease significantly .
These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .	These results may suggest that NO is a proconvulsant mediator in lidocaine - induced disease* convulsions *disease .
Erythropoietin restores the anemia - induced reduction in cyclophosphamide cytotoxicity in rat tumors .	Erythropoietin restores the disease* anemia *disease - induced reduction in cyclophosphamide disease* cytotoxicity *disease in rat disease* tumors *disease .
The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors .	The aim of this study was to examine the impact of disease* anemia *disease prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the disease* cytotoxicity *disease of cyclophosphamide in solid experimental disease* tumors *disease .
Anemia was induced using a single dose of carboplatin ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .	disease* Anemia *disease was induced using a single dose of carboplatin ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .
In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c . three times / week starting 7 days before carboplatin application .	In a second group , the development of disease* anemia *disease was prevented by rHuEPO ( 1000 IU / kg ) administered s . c . three times / week starting 7 days before carboplatin application .
Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c . onto the hind food dorsum .	Four days after carboplatin treatment , disease* tumors *disease ( DS - disease* sarcoma *disease of the rat ) were implanted s . c . onto the hind food dorsum .
Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .	Neither carboplatin nor rHuEPO treatment influenced disease* tumor *disease growth rate per se .
When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .	When disease* tumors *disease were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the disease* tumors *disease was observed .
In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .	In the disease* anemia *disease group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .
In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .	In the group where disease* anemia *disease was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .
These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .	These results suggest that chemotherapy - induced disease* anemia *disease reduces disease* cytotoxicity *disease of cyclophosphamide in disease* tumors *disease , whereas correction of disease* anemia *disease by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to disease* tumor *disease tissue .
Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy .	Fatal disease* haemorrhagic myocarditis *disease secondary to cyclophosphamide therapy .
Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy .	disease* Haemorrhagic myocarditis *disease is a rare but important complication of cyclophosphamide therapy .
Echocardiographic identification of the disorder can be made .	Echocardiographic identification of the disorder can be made .
We believe that the ultrasound features of this disorder have not been previously reported .	We believe that the ultrasound features of this disorder have not been previously reported .
Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs .	Effects of verapamil on disease* atrial fibrillation *disease and its electrophysiological determinants in dogs .
BACKGROUND : Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type Ca ( 2 + ) current .	BACKGROUND : disease* Atrial tachycardia *disease - induced remodeling promotes the occurrence and maintenance of disease* atrial fibrillation *disease ( disease* AF *disease ) and decreases L - type Ca ( 2 + ) current .
There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote AF , consistent with an AF promoting effect of Ca ( 2 + ) channel inhibition .	There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote disease* AF *disease , consistent with an disease* AF *disease promoting effect of Ca ( 2 + ) channel inhibition .
METHODS : To evaluate the potential mechanisms of AF promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .	METHODS : To evaluate the potential mechanisms of disease* AF *disease promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .
Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments .	Diltiazem was used as a comparison drug and autonomic blockade with atropine and nadolol was applied in some experiments .
Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF .	Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during disease* AF *disease .
RESULTS : Verapamil caused AF promotion in six dogs , increasing mean duration of AF induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs . control ) at a loading dose of 0 . 1 mg / kg and 228 + / - 101 s ( P < 0 . 0005 vs . control ) at a dose of 0 . 2 mg / kg .	RESULTS : Verapamil caused disease* AF *disease promotion in six dogs , increasing mean duration of disease* AF *disease induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs . control ) at a loading dose of 0 . 1 mg / kg and 228 + / - 101 s ( P < 0 . 0005 vs . control ) at a dose of 0 . 2 mg / kg .
Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil .	Underlying electrophysiological mechanisms were studied in detail in five additional dogs under control conditions and in the presence of the higher dose of verapamil .
In these experiments , verapamil shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of AF ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .	In these experiments , verapamil shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of disease* AF *disease ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .
Diltiazem did not affect ERP , AF cycle length or AF duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .	Diltiazem did not affect ERP , disease* AF *disease cycle length or disease* AF *disease duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .
In the presence of autonomic blockade , verapamil failed to promote AF and increased , rather than decreasing , refractoriness .	In the presence of autonomic blockade , verapamil failed to promote disease* AF *disease and increased , rather than decreasing , refractoriness .
Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade .	Neither verapamil nor diltiazem affected atrial conduction in the presence of autonomic blockade .
Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .	Epicardial mapping suggested that verapamil promoted disease* AF *disease by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .
CONCLUSIONS : Verapamil promotes AF in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .	CONCLUSIONS : Verapamil promotes disease* AF *disease in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .
Calcitonin gene - related peptide levels during nitric oxide - induced headache in patients with chronic tension - type headache .	Calcitonin gene - related peptide levels during nitric oxide - induced disease* headache *disease in patients with chronic disease* tension - type headache *disease .
It has been proposed that nitric oxide ( NO ) induced headache in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .	It has been proposed that nitric oxide ( NO ) induced disease* headache *disease in disease* primary headaches *disease may be associated with release of calcitonin gene - related peptide ( CGRP ) .
In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .	In the present study we aimed to investigate plasma levels of CGRP during disease* headache *disease induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic disease* tension - type headache *disease and 16 healthy controls .
The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two headache - free days .	The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two disease* headache *disease - free days .
Blood samples were collected at baseline , 10 , 20 and 60 min after start of infusion .	Blood samples were collected at baseline , 10 , 20 and 60 min after start of infusion .
Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls .	Both patients and controls developed significantly stronger immediate disease* headache *disease on the GTN day than on the placebo day and the disease* headache *disease was significantly more pronounced in patients than in controls .
There was no difference between the area under the CGRP curve ( AUCCGRP ) on GTN vs . placebo day in either patients ( P = 0 . 65 ) or controls ( P = 0 . 48 ) .	There was no difference between the area under the CGRP curve ( AUCCGRP ) on GTN vs . placebo day in either patients ( P = 0 . 65 ) or controls ( P = 0 . 48 ) .
The AUCCGRP recorded on the GTN day did not differ between patients and controls ( P = 0 . 36 ) .	The AUCCGRP recorded on the GTN day did not differ between patients and controls ( P = 0 . 36 ) .
Both in patients and controls , CGRP levels changed significantly over time , on both the GTN and placebo days ( P < 0 . 05 ) .	Both in patients and controls , CGRP levels changed significantly over time , on both the GTN and placebo days ( P < 0 . 05 ) .
The present study indicates that NO - induced immediate headache is not associated with release of CGRP .	The present study indicates that NO - induced immediate disease* headache *disease is not associated with release of CGRP .
Fluconazole - induced torsade de pointes .	Fluconazole - induced disease* torsade de pointes *disease .
OBJECTIVE : To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss fluconazole ' s role in causing TDP .	OBJECTIVE : To present a case of fluconazole - associated disease* torsade de pointes *disease ( disease* TDP *disease ) and discuss fluconazole ' s role in causing disease* TDP *disease .
CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .	CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed disease* TDP *disease eight days after commencing oral fluconazole The patient had no other risk factors for disease* TDP *disease , including disease* coronary artery disease *disease , disease* cardiomyopathy *disease , disease* congestive heart failure *disease , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and disease* TDP *disease .
The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .	The disease* TDP *disease resolved when fluconazole was discontinued ; however , the patient continued to have disease* premature ventricular contractions *disease and nonsustained disease* ventricular tachycardia *disease ( disease* NSVT *disease ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of disease* TDP *disease .
The possible mechanism is depression of rapidly activating delayed rectifier potassium currents .	The possible mechanism is disease* depression *disease of rapidly activating delayed rectifier potassium currents .
In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .	In our patient , there was no other etiology identified that could explain disease* QT prolongation *disease or disease* TDP *disease The complete disappearance of disease* NSVT *disease and disease* premature ventricular contractions *disease followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .
CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause prolongation of the QT interval , leading to TDP .	CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause disease* prolongation of the QT interval *disease , leading to disease* TDP *disease .
Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias .	Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for disease* ventricular arrhythmias *disease .
Cutaneous leucocytoclastic vasculitis associated with oxacillin .	disease* Cutaneous leucocytoclastic vasculitis *disease associated with oxacillin .
A 67 - year - old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .	A 67 - year - old man who was treated with oxacillin for one week because of disease* Staphylococcus aureus bacteremia *disease , developed disease* renal failure *disease and diffuse , symmetric , palpable disease* purpuric lesions *disease on his feet .
Necrotic blisters were noted on his fingers .	disease* Necrotic blisters *disease were noted on his fingers .
Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis .	Skin biopsies showed findings diagnostic of disease* leucocytoclastic vasculitis *disease .
Oxacillin was discontinued and patient was treated with corticosteroids .	Oxacillin was discontinued and patient was treated with corticosteroids .
The rash disappeared after three weeks and renal function returned to normal .	The disease* rash *disease disappeared after three weeks and renal function returned to normal .
Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain , arthralgia , and renal involvement .	disease* Leucocytoclastic vasculitis *disease presents as palpable disease* purpura *disease of the lower extremities often accompanied by disease* abdominal pain *disease , disease* arthralgia *disease , and disease* renal involvement *disease .
Etiologic factors or associated disorders include infections , medications , collagen vascular disease and neoplasia .	Etiologic factors or associated disorders include disease* infections *disease , medications , disease* collagen vascular disease *disease and disease* neoplasia *disease .
However , in half of the cases no etiologic factor is identified .	However , in half of the cases no etiologic factor is identified .
Usually it is a self - limited disorder , but corticosteroid therapy may be needed in life - threatening cases since early treatment with corticosteroids in severe cases can prevent complications .	Usually it is a self - limited disorder , but corticosteroid therapy may be needed in life - threatening cases since early treatment with corticosteroids in severe cases can prevent complications .
Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis .	Oxacillin should be included among the drugs that can cause disease* leucocytoclastic vasculitis *disease .
The renal pathology in a case of lithium - induced diabetes insipidus .	The renal pathology in a case of lithium - induced disease* diabetes insipidus *disease .
A case of lithium - induced diabetes insipidus is reported .	A case of lithium - induced disease* diabetes insipidus *disease is reported .
At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron .	At necropsy microscopy shoed unique and extensive damage to cells lining the distal nephron .
It is suggested that these changes represent a specific toxic effect of lithium , reported here for the first time in man .	It is suggested that these changes represent a specific toxic effect of lithium , reported here for the first time in man .
Cholestatic jaundice associated with the use of metformin .	disease* Cholestatic jaundice *disease associated with the use of metformin .
We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride .	We report a patient who developed disease* cholestatic jaundice *disease shortly after initiation of treatment with metformin hydrochloride .
Ultrasound of the liver and abdominal CT were normal .	Ultrasound of the liver and abdominal CT were normal .
An ERCP showed normal biliary anatomy .	An ERCP showed normal biliary anatomy .
A percutaneous liver biopsy was obtained showing marked cholestasis , with portal edema , ductular proliferation , and acute inflammation .	A percutaneous liver biopsy was obtained showing marked disease* cholestasis *disease , with portal disease* edema *disease , ductular proliferation , and acute disease* inflammation *disease .
Metformin hydrochloride was discontinued , and the patient ' s jaundice resolved slowly over a period of several months .	Metformin hydrochloride was discontinued , and the patient ' s disease* jaundice *disease resolved slowly over a period of several months .
Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .	Given the onset of his disease* jaundice *disease 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated disease* hepatotoxicity *disease , the first such case reported .
Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .	Systemic disease* toxicity *disease and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .
We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .	We compared the systemic disease* toxicity *disease of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .
We also compared the ability to resuscitate rats after lethal doses of these local anesthetics .	We also compared the ability to resuscitate rats after lethal doses of these local anesthetics .
Bupivacaine , levobupivacaine , or ropivacaine was infused at a rate of 2 mg .	Bupivacaine , levobupivacaine , or ropivacaine was infused at a rate of 2 mg .
kg ( - 1 ) .	kg ( - 1 ) .
min ( - 1 ) while electrocardiogram , electroencephalogram , and arterial pressure were continuously monitored .	min ( - 1 ) while electrocardiogram , electroencephalogram , and arterial pressure were continuously monitored .
When asystole was recorded , drug infusion was stopped and a resuscitation sequence was begun .	When disease* asystole *disease was recorded , drug infusion was stopped and a resuscitation sequence was begun .
Epinephrine 0 . 01 mg / kg was administered at 1 - min intervals while external cardiac compressions were applied .	Epinephrine 0 . 01 mg / kg was administered at 1 - min intervals while external cardiac compressions were applied .
Resuscitation was considered successful when a systolic arterial pressure > or = 100 mm Hg was achieved within 5 min .	Resuscitation was considered successful when a systolic arterial pressure > or = 100 mm Hg was achieved within 5 min .
The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .	The cumulative doses of levobupivacaine and ropivacaine that produced disease* seizures *disease were similar and were larger than those of bupivacaine .
The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .	The cumulative doses of levobupivacaine that produced disease* dysrhythmias *disease and disease* asystole *disease were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .
The number of successful resuscitations did not differ among groups .	The number of successful resuscitations did not differ among groups .
However , a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups .	However , a smaller dose of epinephrine was required in the Ropivacaine group than in the other groups .
We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .	We conclude that the systemic disease* toxicity *disease of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced disease* cardiac arrest *disease appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .
Amphotericin B - induced seizures in a patient with AIDS .	Amphotericin B - induced disease* seizures *disease in a patient with disease* AIDS *disease .
OBJECTIVE : To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .	OBJECTIVE : To report a case of multiple episodes of disease* seizure *disease activity in an disease* AIDS *disease patent following amphotericin B infusion .
CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .	CASE SUMMARY : A 46 - year - old African - American man experienced recurrent disease* grand mal seizures *disease during intravenous infusion of amphotericin B , then petit mal disease* seizures *disease as the infusion was stopped and the drug concentrations decreased with time .
The patients concurrent medications included didanosine , hydroxyzine , promethazine , hydrocortisone , and prochlorperazine .	The patients concurrent medications included didanosine , hydroxyzine , promethazine , hydrocortisone , and prochlorperazine .
Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .	Despite administration of phenytoin and lorazepam , the disease* seizures *disease persisted and occurred only during amphotercin B administration .
DISCUSSION : AIDS and cryptococcal meningitis , both of which the patient had , can potentially cause seizures .	DISCUSSION : disease* AIDS *disease and disease* cryptococcal meningitis *disease , both of which the patient had , can potentially cause disease* seizures *disease .
The patient had a history of alcohol abuse ; alcohol intake as well as withdrawal can also cause seizures .	The patient had a history of disease* alcohol abuse *disease ; alcohol intake as well as withdrawal can also cause disease* seizures *disease .
Didanosine also has a potential for inducing seizures .	Didanosine also has a potential for inducing disease* seizures *disease .
However , these other potential causes of seizure were ruled out .	However , these other potential causes of disease* seizure *disease were ruled out .
The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .	The time course of events suggested that amphotericin B was the cause of the disease* seizures *disease in this disease* AIDS *disease patient .
CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .	CONCLUSIONS : Amphotericin B seems to be the probable cause of the disease* seizures *disease .
To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .	To date , only three cases of disease* seizures *disease associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .
Sirolimus and mycophenolate mofetil for calcineurin - free immunosuppression in renal transplant recipients .	Sirolimus and mycophenolate mofetil for calcineurin - free immunosuppression in renal transplant recipients .
Calcineurin inhibitors , such as cyclosporine and tacrolimus , have been available for almost 20 years .	Calcineurin inhibitors , such as cyclosporine and tacrolimus , have been available for almost 20 years .
Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic nephrotoxicity .	Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic disease* nephrotoxicity *disease .
Acute nephrotoxicity , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic nephrotoxicity may eventually result in graft loss .	Acute disease* nephrotoxicity *disease , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic disease* nephrotoxicity *disease may eventually result in graft loss .
Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases .	Acute and chronic disease* nephrotoxicity *disease is becoming more common as the use of marginal kidneys for transplantation increases .
Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no nephrotoxicity .	Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no disease* nephrotoxicity *disease .
The use of these drugs in combination with other agents has led to the development of new paradigms of immunosuppressive therapy .	The use of these drugs in combination with other agents has led to the development of new paradigms of immunosuppressive therapy .
This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients .	This paper reviews the results of clinical trials that have investigated these new approaches to immunosuppression in renal transplant recipients .
Tolerability of nimesulide and paracetamol in patients with NSAID - induced urticaria / angioedema .	Tolerability of nimesulide and paracetamol in patients with NSAID - induced disease* urticaria *disease / disease* angioedema *disease .
Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous , respiratory and anaphylactoid reactions induced by nonsteroidal anti - inflammatory drugs ( NSAIDs ) .	Previous studies evaluated the tolerance of nimesulide and paracetamol in subjects with cutaneous , respiratory and anaphylactoid reactions induced by nonsteroidal anti - inflammatory drugs ( NSAIDs ) .
In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / angioedema .	In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced disease* urticaria *disease / disease* angioedema *disease .
Furthermore , we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide .	Furthermore , we evaluated whether some factors have the potential to increase the risk of reaction to paracetamol and nimesulide .
A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / angioedema .	A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced disease* urticaria *disease / disease* angioedema *disease .
A total of 75 / 829 ( 9 . 4 % ) patients experienced reactions to nimesulide or paracetamol .	A total of 75 / 829 ( 9 . 4 % ) patients experienced reactions to nimesulide or paracetamol .
Of the 715 patients tested with nimesulide 62 ( 8 . 6 % ) showed a positive test , while of 114 subjects submitted to the challenge with paracetamol , 13 ( 9 . 6 % ) did not tolerate this drug .	Of the 715 patients tested with nimesulide 62 ( 8 . 6 % ) showed a positive test , while of 114 subjects submitted to the challenge with paracetamol , 13 ( 9 . 6 % ) did not tolerate this drug .
Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of NSAID - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .	Furthermore , 18 . 28 % of patients with a history of chronic disease* urticaria *disease and 11 . 8 % of subjects with an history of NSAID - induced disease* urticaria *disease / disease* angioedema *disease or disease* angioedema *disease alone ( with or without chronic disease* urticaria *disease ) resulted to be intolerant to alternative drugs .
Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / angioedema caused by NSAIDs .	Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced disease* urticaria *disease / disease* angioedema *disease caused by NSAIDs .
However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of NSAID - induced angioedema .	However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic disease* urticaria *disease and , above all , by a history of NSAID - induced disease* angioedema *disease .
Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .	Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for disease* glaucoma *disease .
PURPOSE : Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .	PURPOSE : Topical beta - blocker treatment is routine therapy in the management of patients with disease* glaucoma *disease .
Therapy results in systemic absorption , however , the degree of reduction of resting and peak heart rate has not been quantified .	Therapy results in systemic absorption , however , the degree of reduction of resting and peak heart rate has not been quantified .
DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .	DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for disease* glaucoma *disease to quantify the reduction in mean heart rate .
METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .	METHODS : Forty - three Caucasian patients with primary disease* open - angle glaucoma *disease or disease* ocular hypertension *disease with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .
On the 13th day of each period , heart rate was recorded continuously during a typical , ambulant 24 - hour period .	On the 13th day of each period , heart rate was recorded continuously during a typical , ambulant 24 - hour period .
RESULTS : Both timolol solution and timolol gellan reduced the mean 24 - hour heart rate compared with placebo ( P < or = . 001 ) , and this reduction was most pronounced during the daytime ( - 7 . 5 % change in mean heart rate , - 5 . 7 beats / min ) .	RESULTS : Both timolol solution and timolol gellan reduced the mean 24 - hour heart rate compared with placebo ( P < or = . 001 ) , and this reduction was most pronounced during the daytime ( - 7 . 5 % change in mean heart rate , - 5 . 7 beats / min ) .
Timolol gellan showed a numerically but not significantly smaller reduction in 24 - hour heart rate , compared with timolol solution .	Timolol gellan showed a numerically but not significantly smaller reduction in 24 - hour heart rate , compared with timolol solution .
During the night , the mean 12 - hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution ; the difference between solution and gellan treatments was statistically significant ( P = . 01 ) .	During the night , the mean 12 - hour heart rate on placebo and timolol gellan were both significantly less than on timolol solution ; the difference between solution and gellan treatments was statistically significant ( P = . 01 ) .
CONCLUSIONS : Both timolol solution and timolol gellan decrease the mean 24 - hour heart rate compared with placebo .	CONCLUSIONS : Both timolol solution and timolol gellan decrease the mean 24 - hour heart rate compared with placebo .
This response was most pronounced during the active daytime period .	This response was most pronounced during the active daytime period .
These data quantify the modest bradycardia associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for glaucoma .	These data quantify the modest disease* bradycardia *disease associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for disease* glaucoma *disease .
Although exercise performance was not assessed in this trial , reductions of this magnitude should not have substantial clinical consequences .	Although exercise performance was not assessed in this trial , reductions of this magnitude should not have substantial clinical consequences .
Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .	Management strategies for ribavirin - induced disease* hemolytic anemia *disease in the treatment of disease* hepatitis C *disease : clinical and economic implications .
OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( CHC ) .	OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of disease* chronic hepatitis C *disease ( disease* CHC *disease ) .
Combination therapy is associated with a clinically important adverse effect : ribavirin - induced hemolytic anemia ( RIHA ) .	Combination therapy is associated with a clinically important adverse effect : ribavirin - induced disease* hemolytic anemia *disease ( disease* RIHA *disease ) .
The objective of this study was to evaluate the direct health - care costs and management of RIHA during treatment of CHC in a clinical trial setting .	The objective of this study was to evaluate the direct health - care costs and management of disease* RIHA *disease during treatment of disease* CHC *disease in a clinical trial setting .
METHODS : A systematic literature review was conducted to synthesize information on the incidence and management of RIHA .	METHODS : A systematic literature review was conducted to synthesize information on the incidence and management of disease* RIHA *disease .
Decision - analytic techniques were used to estimate the cost of treating RIHA .	Decision - analytic techniques were used to estimate the cost of treating disease* RIHA *disease .
Uncertainty was evaluated using sensitivity analyses .	Uncertainty was evaluated using sensitivity analyses .
RESULTS : RIHA , defined as a reduction in hemoglobin to less than 100 g / L , occurs in approximately 7 % to 9 % of patients treated with combination therapy .	RESULTS : disease* RIHA *disease , defined as a reduction in hemoglobin to less than 100 g / L , occurs in approximately 7 % to 9 % of patients treated with combination therapy .
The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage .	The standard of care for management of disease* RIHA *disease is reduction or discontinuation of the ribavirin dosage .
We estimated the direct cost of treating clinically significant RIHA to be 170 per patient receiving combination therapy per 48 - week treatment course ( range 68 - 692 ) .	We estimated the direct cost of treating clinically significant disease* RIHA *disease to be 170 per patient receiving combination therapy per 48 - week treatment course ( range 68 - 692 ) .
The results of the one - way sensitivity analyses ranged from 57 to 317 .	The results of the one - way sensitivity analyses ranged from 57 to 317 .
In comparison , the cost of 48 weeks of combination therapy is 16 , 459 .	In comparison , the cost of 48 weeks of combination therapy is 16 , 459 .
CONCLUSIONS : The direct cost of treating clinically significant RIHA is 1 % ( 170 / 16 , 459 ) of drug treatment costs .	CONCLUSIONS : The direct cost of treating clinically significant disease* RIHA *disease is 1 % ( 170 / 16 , 459 ) of drug treatment costs .
Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real - world population .	Questions remain about the optimal dose of ribavirin and the incidence of disease* RIHA *disease in a real - world population .
Despite these uncertainties , this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect .	Despite these uncertainties , this initial evaluation of the direct cost of treating disease* RIHA *disease provides an estimate of the cost and management implications of this clinically important adverse effect .
Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans .	Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans .
BACKGROUND : Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .	BACKGROUND : Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of disease* acute and chronic pain *disease in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in disease* hypersensitivity *disease states but not with acute noxious stimulation .
The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .	The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical disease* hypersensitivity *disease .
METHODS : Following Food and Drug Administration and institutional review board approval and written informed consent , 65 volunteers were studied in two trials : an open - label , dose - escalating trial with intrathecal adenosine doses of 0 . 25 - 2 . 0 mg and a double - blind , placebo - controlled trial of adenosine , 2 mg .	METHODS : Following Food and Drug Administration and institutional review board approval and written informed consent , 65 volunteers were studied in two trials : an open - label , dose - escalating trial with intrathecal adenosine doses of 0 . 25 - 2 . 0 mg and a double - blind , placebo - controlled trial of adenosine , 2 mg .
Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined .	Cerebrospinal fluid was obtained for pharmacokinetic analysis , and disease* pain *disease ratings in response to acute heat stimuli and areas of disease* mechanical hyperalgesia *disease and disease* allodynia *disease after intradermal capsaicin injection were determined .
RESULTS : Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .	RESULTS : Adenosine produced no effect on disease* pain *disease report to acute noxious thermal or chemical stimulation but reduced disease* mechanical hyperalgesia *disease and disease* allodynia *disease from intradermal capsaicin injection for at least 24 h .
In contrast , residence time of adenosine in cerebrospinal fluid was short ( < 4 h ) .	In contrast , residence time of adenosine in cerebrospinal fluid was short ( < 4 h ) .
CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .	CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of disease* hypersensitivity *disease , presumed to reflect central sensitization in humans after peripheral capsaicin injection .
The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid .	The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic disease* neuropathic pain *disease and is not due to prolonged residence of adenosine in cerebrospinal fluid .
Delayed - onset heparin - induced thrombocytopenia .	Delayed - onset heparin - induced disease* thrombocytopenia *disease .
BACKGROUND : Heparin - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .	BACKGROUND : Heparin - induced disease* thrombocytopenia *disease presents 5 to 12 days after heparin exposure , with or without disease* arterial or venous thromboemboli *disease .
Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .	Delayed recognition and treatment of heparin - induced disease* thrombocytopenia *disease contribute to poor patient outcomes .
OBJECTIVE : To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .	OBJECTIVE : To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced disease* thrombocytopenia *disease are delayed .
DESIGN : Retrospective case series .	DESIGN : Retrospective case series .
SETTING : Three large urban hospitals ( with active cardiovascular surgery programs ) .	SETTING : Three large urban hospitals ( with active cardiovascular surgery programs ) .
PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications .	PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced disease* thrombocytopenia *disease became apparent on delayed presentation with disease* thromboembolic *disease complications .
MEASUREMENTS : Platelet counts , onset of objectively determined thromboembolism , results of heparin - induced platelet factor 4 antibody tests , and outcomes .	MEASUREMENTS : Platelet counts , onset of objectively determined disease* thromboembolism *disease , results of heparin - induced platelet factor 4 antibody tests , and outcomes .
RESULTS : Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .	RESULTS : Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no disease* thrombocytopenia *disease recognized - - only to return to the hospital ( median , day 14 ) with disease* thromboembolic *disease complications .
Thromboemboli were venous ( 12 patients , 7 with pulmonary emboli ) or arterial ( 4 patients ) or both .	disease* Thromboemboli *disease were venous ( 12 patients , 7 with disease* pulmonary emboli *disease ) or arterial ( 4 patients ) or both .
Platelet counts were mildly decreased in all but 2 patients on second presentation .	Platelet counts were mildly decreased in all but 2 patients on second presentation .
On readmission , 11 patients received therapeutic heparin , which worsened the patients ' clinical condition and , in all 11 cases , decreased the platelet count ( mean at readmission , 143 x 10 ( 9 ) cells / L ; mean nadir after heparin re - exposure , 39 x 10 ( 9 ) cells / L ) .	On readmission , 11 patients received therapeutic heparin , which worsened the patients ' clinical condition and , in all 11 cases , decreased the platelet count ( mean at readmission , 143 x 10 ( 9 ) cells / L ; mean nadir after heparin re - exposure , 39 x 10 ( 9 ) cells / L ) .
Results of serologic tests for heparin - induced antibodies were positive in all patients .	Results of serologic tests for heparin - induced antibodies were positive in all patients .
Subsequent treatments included alternative anticoagulants ( 11 patients ) , thrombolytic drugs ( 3 patients ) , inferior vena cava filters ( 3 patients ) and , eventually , warfarin ( 11 patients ) .	Subsequent treatments included alternative anticoagulants ( 11 patients ) , thrombolytic drugs ( 3 patients ) , inferior vena cava filters ( 3 patients ) and , eventually , warfarin ( 11 patients ) .
Three patients died .	Three patients died .
CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .	CONCLUSIONS : Delayed - onset heparin - induced disease* thrombocytopenia *disease is increasingly being recognized .
To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .	To avoid disastrous outcomes , physicians must consider heparin - induced disease* thrombocytopenia *disease whenever a recently hospitalized patient returns with disease* thromboembolism *disease ; therapy with alternative anticoagulants , not heparin , should be initiated .
Treatment of risperidone - induced hyperprolactinemia with a dopamine agonist in children .	Treatment of risperidone - induced disease* hyperprolactinemia *disease with a dopamine agonist in children .
BACKGROUND : Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children .	BACKGROUND : Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with disease* hyperprolactinemia *disease in adults and children .
Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature .	Chronically elevated prolactin levels in children with disease* prolactinomas *disease may be associated with arrested growth and development resulting in either disease* delayed puberty *disease or short stature .
These possibilities stress the importance of developing a safe and effective approach to drug - induced hyperprolactinemia in youth .	These possibilities stress the importance of developing a safe and effective approach to drug - induced disease* hyperprolactinemia *disease in youth .
We report the successful treatment of risperidone - induced hyperprolactinemia with cabergoline in youth .	We report the successful treatment of risperidone - induced disease* hyperprolactinemia *disease with cabergoline in youth .
METHODS : We undertook a retrospective case review of four children with risperidone - induced hyperprolactinemia treated with cabergoline .	METHODS : We undertook a retrospective case review of four children with risperidone - induced disease* hyperprolactinemia *disease treated with cabergoline .
RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .	RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of disease* Mental Disorders *disease ( fourth edition ) disease* bipolar disorder *disease or disease* psychoses *disease , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .
When serum prolactin levels normalized in all four subjects ( mean 11 . 2 + / - 10 . 9 ng / mL ) , the cabergoline dose was reduced to 1 mg / week in three of four subjects .	When serum prolactin levels normalized in all four subjects ( mean 11 . 2 + / - 10 . 9 ng / mL ) , the cabergoline dose was reduced to 1 mg / week in three of four subjects .
The mean duration of therapy with cabergoline was 523 . 5 + / - 129 . 7 days , and the mean duration of therapy with risperidone was 788 . 5 + / - 162 . 5 days .	The mean duration of therapy with cabergoline was 523 . 5 + / - 129 . 7 days , and the mean duration of therapy with risperidone was 788 . 5 + / - 162 . 5 days .
Cabergoline was well tolerated without adverse effects .	Cabergoline was well tolerated without adverse effects .
CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced hyperprolactinemia in youth ; however , further research is needed .	CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced disease* hyperprolactinemia *disease in youth ; however , further research is needed .
Acute cholestatic hepatitis after exposure to isoflurane .	Acute disease* cholestatic hepatitis *disease after exposure to isoflurane .
OBJECTIVE : To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane .	OBJECTIVE : To report a case of acute disease* cholestatic hepatitis *disease following exposure to the inhalational anesthetic isoflurane .
CASE SUMMARY : A 70 - year - old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia .	CASE SUMMARY : A 70 - year - old healthy woman from Iraq developed acute disease* cholestatic hepatitis *disease 3 weeks following repair of the right rotator cuff under general anesthesia .
There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .	There was no evidence for viral , autoimmune , or metabolic causes of disease* hepatitis *disease .
No other medications were involved except for dipyrone for analgesia .	No other medications were involved except for dipyrone for disease* analgesia *disease .
The alanine aminotransferase was elevated to a peak concentration of 1533 U / L and the serum bilirubin reached a peak of 17 . 0 mg / dL .	The alanine aminotransferase was elevated to a peak concentration of 1533 U / L and the serum bilirubin reached a peak of 17 . 0 mg / dL .
There was slow improvement over 4 months .	There was slow improvement over 4 months .
Accidental reexposure by the patient to dipyrone was uneventful .	Accidental reexposure by the patient to dipyrone was uneventful .
DISCUSSION : The clinical and histologic picture of this case resembles halothane hepatitis , which has a significant mortality rate .	DISCUSSION : The clinical and histologic picture of this case resembles disease* halothane hepatitis *disease , which has a significant mortality rate .
CONCLUSIONS : Isoflurane , a common anesthetic agent , can cause severe cholestatic hepatitis .	CONCLUSIONS : Isoflurane , a common anesthetic agent , can cause severe disease* cholestatic hepatitis *disease .
Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block .	disease* Torsade de pointes *disease induced by metoclopramide in an elderly woman with preexisting complete disease* left bundle branch block *disease .
There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes .	There is a growing list of drugs implicated in acquired disease* long QT syndrome *disease and disease* torsade de pointes *disease .
However , the torsadogenic potential of metoclopramide , a commonly used antiemetic and prokinetic drug , has not been reported in the literature , despite its chemical similarity to procainamide .	However , the torsadogenic potential of metoclopramide , a commonly used antiemetic and prokinetic drug , has not been reported in the literature , despite its chemical similarity to procainamide .
We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide .	We report on a 92 - year - old woman with preexisting complete disease* left bundle branch block *disease who developed disease* torsade de pointes *disease after intravenous and oral administration of metoclopramide .
This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously .	This patient also developed disease* torsade de pointes *disease when cisapride and erythromycin were given simultaneously .
These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs .	These two episodes were suppressed successfully after discontinuing the offending drugs and administering class IB drugs .
This is the first documentation that metoclopramide provokes torsade de pointes clinically .	This is the first documentation that metoclopramide provokes disease* torsade de pointes *disease clinically .
Metoclopramide should be used cautiously in patients with a risk of torsade de pointes .	Metoclopramide should be used cautiously in patients with a risk of disease* torsade de pointes *disease .
Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs .	Dopamine D2 receptor signaling controls neuronal cell death induced by muscarinic and glutamatergic drugs .
Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of epileptic seizures arising in the limbic system .	Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of disease* epileptic seizures *disease arising in the limbic system .
Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level .	disease* Excitotoxicity *disease leading to neuronal cell death in the affected areas is a major consequence of disease* seizures *disease at the cellular level .
In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .	In this respect , little is known about the role of DA receptors in the occurrence of disease* epilepsy *disease - induced neuronal cell death .
Here we analyze the occurrence of seizures and neurotoxicity in D2R - / - mice treated with the cholinergic agonist pilocarpine .	Here we analyze the occurrence of disease* seizures *disease and disease* neurotoxicity *disease in D2R - / - mice treated with the cholinergic agonist pilocarpine .
We compared these results with those previously obtained with kainic acid ( KA ) , a potent glutamate agonist .	We compared these results with those previously obtained with kainic acid ( KA ) , a potent glutamate agonist .
Importantly , D2R - / - mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity .	Importantly , D2R - / - mice develop disease* seizures *disease at doses of both drugs that are not epileptogenic for WT littermates and show greater disease* neurotoxicity *disease .
However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .	However , pilocarpine - induced disease* seizures *disease result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .
Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .	Thus , the absence of D2R lowers the threshold for disease* seizures *disease induced by both glutamate and acetylcholine .
Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .	Moreover , the dopaminergic control of disease* epilepsy *disease - induced disease* neurodegeneration *disease seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .
Steroid structure and pharmacological properties determine the anti - amnesic effects of pregnenolone sulphate in the passive avoidance task in rats .	Steroid structure and pharmacological properties determine the anti - disease* amnesic *disease effects of pregnenolone sulphate in the passive avoidance task in rats .
Pregnenolone sulphate ( PREGS ) has generated interest as one of the most potent memory - enhancing neurosteroids to be examined in rodent learning studies , with particular importance in the ageing process .	Pregnenolone sulphate ( PREGS ) has generated interest as one of the most potent memory - enhancing neurosteroids to be examined in rodent learning studies , with particular importance in the ageing process .
The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems .	The mechanism by which this endogenous steroid enhances memory formation is hypothesized to involve actions on glutamatergic and GABAergic systems .
This hypothesis stems from findings that PREGS is a potent positive modulator of N - methyl - d - aspartate receptors ( NMDARs ) and a negative modulator of gamma - aminobutyric acid ( A ) receptors ( GABA ( A ) Rs ) .	This hypothesis stems from findings that PREGS is a potent positive modulator of N - methyl - d - aspartate receptors ( NMDARs ) and a negative modulator of gamma - aminobutyric acid ( A ) receptors ( GABA ( A ) Rs ) .
Moreover , PREGS is able to reverse the amnesic - like effects of NMDAR and GABA ( A ) R ligands .	Moreover , PREGS is able to reverse the disease* amnesic *disease - like effects of NMDAR and GABA ( A ) R ligands .
To investigate this hypothesis , the present study in rats examined the memory - altering abilities of structural analogs of PREGS , which differ in their modulation of NMDAR and / or GABA ( A ) R function .	To investigate this hypothesis , the present study in rats examined the memory - altering abilities of structural analogs of PREGS , which differ in their modulation of NMDAR and / or GABA ( A ) R function .
The analogs tested were : 11 - ketopregnenolone sulphate ( an agent that is inactive at GABA ( A ) Rs and NMDARs ) , epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate , an inhibitor of both GABA ( A ) Rs and NMDARs ) , and a newly synthesized ( - ) PREGS enantiomer ( which is identical to PREGS in effects on GABA ( A ) Rs and NMDARs ) .	The analogs tested were : 11 - ketopregnenolone sulphate ( an agent that is inactive at GABA ( A ) Rs and NMDARs ) , epipregnanolone ( [ 3beta - hydroxy - 5beta - pregnan - 20 - one ] sulphate , an inhibitor of both GABA ( A ) Rs and NMDARs ) , and a newly synthesized ( - ) PREGS enantiomer ( which is identical to PREGS in effects on GABA ( A ) Rs and NMDARs ) .
The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced amnesia .	The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced disease* amnesia *disease .
Both PREGS and its ( - ) enantiomer blocked the effects of scopolamine .	Both PREGS and its ( - ) enantiomer blocked the effects of scopolamine .
The results show that , unlike PREGS , 11 - ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine , suggesting that altering the modulation of NMDA receptors diminishes the memory - enhancing effects of PREGS .	The results show that , unlike PREGS , 11 - ketopregnenolone sulphate and epipregnanolone sulphate failed to block the effect of scopolamine , suggesting that altering the modulation of NMDA receptors diminishes the memory - enhancing effects of PREGS .
Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced amnesia .	Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced disease* amnesia *disease .
These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids .	These results identify a novel neuropharmacological site for the modulation of memory processes by neuroactive steroids .
Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .	Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced disease* heart failure *disease .
Activation of the nuclear enzyme poly ( ADP - ribose ) polymerase ( PARP ) by oxidant - mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress .	Activation of the nuclear enzyme poly ( ADP - ribose ) polymerase ( PARP ) by oxidant - mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress .
Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .	Increased oxidative stress is a major factor implicated in the disease* cardiotoxicity *disease of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .
Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced cardiotoxicity .	Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced disease* cardiotoxicity *disease .
Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .	Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of disease* cardiac dysfunction *disease induced by DOX .
PARP - 1 + / + and PARP - 1 - / - mice received a single injection of DOX ( 25 mg / kg i . p ) .	PARP - 1 + / + and PARP - 1 - / - mice received a single injection of DOX ( 25 mg / kg i . p ) .
Five days after DOX administration , left ventricular performance was significantly depressed in PARP - 1 + / + mice , but only to a smaller extent in PARP - 1 - / - ones .	Five days after DOX administration , left ventricular performance was significantly depressed in PARP - 1 + / + mice , but only to a smaller extent in PARP - 1 - / - ones .
Similar experiments were conducted in BALB / c mice treated with PJ34 or vehicle .	Similar experiments were conducted in BALB / c mice treated with PJ34 or vehicle .
Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .	Treatment with a PJ34 significantly improved disease* cardiac dysfunction *disease and increased the survival of the animals .
In addition PJ34 significantly reduced the DOX - induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart .	In addition PJ34 significantly reduced the DOX - induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart .
Thus , PARP activation contributes to the cardiotoxicity of DOX .	Thus , PARP activation contributes to the disease* cardiotoxicity *disease of DOX .
PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment .	PARP inhibitors may exert protective effects against the development of severe disease* cardiac complications *disease associated with the DOX treatment .
Spironolactone : is it a novel drug for the prevention of amphotericin B - related hypokalemia in cancer patients ?	Spironolactone : is it a novel drug for the prevention of amphotericin B - related disease* hypokalemia *disease in disease* cancer *disease patients ?
OBJECTIVE : Nephrotoxicity is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .	OBJECTIVE : disease* Nephrotoxicity *disease is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .
Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB .	Selective distal tubular epithelial disease* toxicity *disease seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB .
Potassium depletion also potentiates the tubular toxicity of AmB .	Potassium depletion also potentiates the tubular disease* toxicity *disease of AmB .
This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment .	This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent disease* hypokalemia *disease in disease* neutropenic *disease patients on AmB treatment .
METHODS : In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .	METHODS : In this study 26 patients with various disease* hematological disorders *disease were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected disease* fungal infection *disease .
RESULTS : Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone ( P = 0 . 0027 ) .	RESULTS : Patients receiving concomitant AmB and spironolactone had significantly higher plasma potassium levels than those receiving AmB alone ( P = 0 . 0027 ) .
Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range ( P = 0 . 022 ) .	Those patients receiving AmB and spironolactone required significantly less potassium supplementation to maintain their plasma potassium within the normal range ( P = 0 . 022 ) .
Moreover , urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone ( P = 0 . 040 ) .	Moreover , urinary potassium losses were significantly less in patients receiving AmB and spironolactone than those receiving AmB alone ( P = 0 . 040 ) .
CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment .	CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent disease* hypokalemia *disease by reducing urinary potassium loss in disease* neutropenic *disease patients on AmB treatment .
Erectile dysfunction occurs following substantia nigra lesions in the rat .	disease* Erectile dysfunction *disease occurs following substantia nigra lesions in the rat .
Erectile function was assessed 6 weeks following uni - and bilateral injections of 6 - hydroxydopamine in the substantia nigra nucleus of the brain .	Erectile function was assessed 6 weeks following uni - and bilateral injections of 6 - hydroxydopamine in the substantia nigra nucleus of the brain .
Behavioral apomorphine - induced penile erections were reduced ( 5 / 8 ) and increased ( 3 / 8 ) in uni - and bilateral lesioned animals .	Behavioral apomorphine - induced penile erections were reduced ( 5 / 8 ) and increased ( 3 / 8 ) in uni - and bilateral lesioned animals .
Intracavernous pressures , following electrical stimulation of the cavernous nerve , decreased in lesioned animals .	Intracavernous pressures , following electrical stimulation of the cavernous nerve , decreased in lesioned animals .
Lesions of the substantia nigra were confirmed by histology .	Lesions of the substantia nigra were confirmed by histology .
Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats .	Concentration of dopamine and its metabolites were decreased in the striatum of substantia nigra lesioned rats .
Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson ' s disease .	Lesions of the substantia nigra are therefore associated with disease* erectile dysfunction *disease in rats and may serve as a model to study disease* erectile dysfunction *disease in disease* Parkinson ' s disease *disease .
Nicotine potentiation of morphine - induced catalepsy in mice .	Nicotine potentiation of morphine - induced disease* catalepsy *disease in mice .
In the present study , effects of nicotine on catalepsy induced by morphine in mice have been investigated .	In the present study , effects of nicotine on disease* catalepsy *disease induced by morphine in mice have been investigated .
Morphine but not nicotine induced a dose - dependent catalepsy .	Morphine but not nicotine induced a dose - dependent disease* catalepsy *disease .
The response of morphine was potentiated by nicotine .	The response of morphine was potentiated by nicotine .
Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine .	Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced disease* catalepsy *disease induced by a combination of morphine with nicotine .
Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased catalepsy induced by morphine plus nicotine .	Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased disease* catalepsy *disease induced by morphine plus nicotine .
Intraperitoneal administration of atropine , but not intraperitoneal or intracerebroventricular injection of hexamethonium , decreased the effect of a single dose of morphine .	Intraperitoneal administration of atropine , but not intraperitoneal or intracerebroventricular injection of hexamethonium , decreased the effect of a single dose of morphine .
It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .	It was concluded that morphine disease* catalepsy *disease can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .
Force overflow and levodopa - induced dyskinesias in Parkinson ' s disease .	Force overflow and levodopa - induced disease* dyskinesias *disease in disease* Parkinson ' s disease *disease .
We assessed force coordination of the hand in Parkinson ' s disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced dyskinesias ( LID ) .	We assessed force coordination of the hand in disease* Parkinson ' s disease *disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced disease* dyskinesias *disease ( disease* LID *disease ) .
We studied two groups of Parkinson ' s disease patients with ( Parkinson ' s disease + LID , n = 23 ) and without levodopa - induced dyskinesias ( Parkinson ' s disease - LID , n = 10 ) , and age - matched healthy controls .	We studied two groups of disease* Parkinson ' s disease *disease patients with ( disease* Parkinson ' s disease *disease + disease* LID *disease , n = 23 ) and without levodopa - induced disease* dyskinesias *disease ( disease* Parkinson ' s disease *disease - disease* LID *disease , n = 10 ) , and age - matched healthy controls .
The motor score of the Unified Parkinson ' s Disease Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF levodopa .	The motor score of the Unified disease* Parkinson ' s Disease *disease Rating Scale , a disease* dyskinesia *disease score and force in a grip - lift paradigm were assessed ON and OFF levodopa .
A pathological increase of forces was seen in ON - state in Parkinson ' s disease + LID only .	A pathological increase of forces was seen in ON - state in disease* Parkinson ' s disease *disease + disease* LID *disease only .
In Parkinson ' s disease + LID , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .	In disease* Parkinson ' s disease *disease + disease* LID *disease , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .
An overshooting of peak grip force by 51 % ( P < 0 . 05 ) and of static grip force by 45 % ( P < 0 . 01 ) was observed in the ON - compared with the OFF - drug condition .	An overshooting of peak grip force by 51 % ( P < 0 . 05 ) and of static grip force by 45 % ( P < 0 . 01 ) was observed in the ON - compared with the OFF - drug condition .
In contrast , no excessive force was found in Parkinson ' s disease - LID .	In contrast , no excessive force was found in disease* Parkinson ' s disease *disease - disease* LID *disease .
Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in Parkinson ' s disease + LID than in Parkinson ' s disease - LID , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .	Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in disease* Parkinson ' s disease *disease + disease* LID *disease than in disease* Parkinson ' s disease *disease - disease* LID *disease , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .
Severity of peak - dose dyskinesias was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .	Severity of peak - dose disease* dyskinesias *disease was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .
No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication .	No correlation was observed between forces and the motor score as well as with the daily dose of dopaminergic medication .
Force excess was only observed in patients with LID and motor fluctuations .	Force excess was only observed in patients with disease* LID *disease and motor fluctuations .
A close relationship was seen between the overshooting of forces and dyskinesias in the ON - drug condition .	A close relationship was seen between the overshooting of forces and disease* dyskinesias *disease in the ON - drug condition .
We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations .	We postulate that both disease* LID *disease and grip force excess share common pathophysiological mechanisms related to motor fluctuations .
Behavioral effects of MK - 801 on reserpine - treated mice .	Behavioral effects of MK - 801 on reserpine - treated mice .
The effects of dizocilpine ( MK - 801 ) , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , were studied on dopamine - related behaviors induced by reserpine treatments .	The effects of dizocilpine ( MK - 801 ) , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , were studied on dopamine - related behaviors induced by reserpine treatments .
This study focuses on behavioral syndromes that may used as models for Parkinson ' s disease , or tardive dyskinesia , and its response after glutamatergic blockage .	This study focuses on behavioral syndromes that may used as models for disease* Parkinson ' s disease *disease , or disease* tardive dyskinesia *disease , and its response after glutamatergic blockage .
Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .	Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in disease* orofacial dyskinesia *disease , tongue protrusion and vacuous chewing in mice , which are signs indicative of disease* tardive dyskinesia *disease .
Reserpine also produced tremor and catalepsy , which are signs suggestive of Parkinson ' s disease .	Reserpine also produced disease* tremor *disease and disease* catalepsy *disease , which are signs suggestive of disease* Parkinson ' s disease *disease .
MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and catalepsy induced by reserpine .	MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and disease* catalepsy *disease induced by reserpine .
However , MK - 801 injection produced a significant increase of tremor in reserpine - treated mice .	However , MK - 801 injection produced a significant increase of disease* tremor *disease in reserpine - treated mice .
Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce oral dyskinesia in mice .	Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce disease* oral dyskinesia *disease in mice .
On the other hand , reserpine induced increases in tremor and catalepsy compared to control mice .	On the other hand , reserpine induced increases in disease* tremor *disease and disease* catalepsy *disease compared to control mice .
MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and tremor induced by reserpine .	MK - 801 ( 0 . 1 mg / kg ) administration attenuated the disease* catalepsy *disease and disease* tremor *disease induced by reserpine .
Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .	Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in disease* tremor *disease and disease* catalepsy *disease , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .
These results show that reserpine produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .	These results show that reserpine produces different and disease* abnormal movements *disease , which are related to dose and schedule employed and can be considered as disease* parkinsonian *disease - like and disease* tardive dsykinesia *disease signs .
The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and tremor according to the employed model .	The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , disease* catalepsy *disease and disease* tremor *disease according to the employed model .
Risperidone - associated , benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse .	Risperidone - associated , benign transient disease* visual disturbances *disease in disease* schizophrenic *disease patients with a past history of LSD abuse .
Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .	Two disease* schizophrenic *disease patients , who had a prior history of LSD abuse and who had previously developed disease* EPS *disease with classic antipsychotics , were successfully treated with risperidone .
They both reported short episodes of transient visual disturbances , which appeared immediately after starting treatment with risperidone .	They both reported short episodes of transient disease* visual disturbances *disease , which appeared immediately after starting treatment with risperidone .
This imagery resembled visual disturbances previously experienced as " flashbacks " related to prior LSD consumption .	This imagery resembled disease* visual disturbances *disease previously experienced as " flashbacks " related to prior LSD consumption .
Risperidone administration was continued and the visual disturbances gradually wore off .	Risperidone administration was continued and the disease* visual disturbances *disease gradually wore off .
During a six - month follow - up period , there was no recurrence of visual disturbances .	During a six - month follow - up period , there was no recurrence of disease* visual disturbances *disease .
This phenomenon may be interpreted as a benign , short - term and self - limiting side effect which does not contraindicate the use of risperidone or interfere with treatment .	This phenomenon may be interpreted as a benign , short - term and self - limiting side effect which does not contraindicate the use of risperidone or interfere with treatment .
Conclusions based on two case reports should be taken with appropriate caution .	Conclusions based on two case reports should be taken with appropriate caution .
Topiramate - induced nephrolithiasis .	Topiramate - induced disease* nephrolithiasis *disease .
Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating refractory seizures .	Topiramate is a recently developed antiepileptic medication that is becoming more widely prescribed because of its efficacy in treating disease* refractory seizures *disease .
Urologists should be aware that this medication can cause metabolic acidosis in patients secondary to inhibition of carbonic anhydrase .	Urologists should be aware that this medication can cause disease* metabolic acidosis *disease in patients secondary to inhibition of carbonic anhydrase .
In addition , a distal tubular acidification defect may result , thus impairing the normal compensatory drop in urine pH .	In addition , a distal tubular acidification defect may result , thus impairing the normal compensatory drop in urine pH .
These factors can lead to the development of calcium phosphate nephrolithiasis .	These factors can lead to the development of calcium phosphate disease* nephrolithiasis *disease .
We report the first two cases of topiramate - induced nephrolithiasis in the urologic literature .	We report the first two cases of topiramate - induced disease* nephrolithiasis *disease in the urologic literature .
Ketamine in war / tropical surgery ( a final tribute to the racemic mixture ) .	Ketamine in war / tropical surgery ( a final tribute to the racemic mixture ) .
A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients , aged from 6 weeks to 70 years , undergoing limb and abdominal surgery including caesarian sections and interventions in neonates .	A technique of continuous intravenous anaesthesia with ketamine was used successfully during the Somalia civil war in 1994 and in north Uganda in 1999 for 64 operations in 62 patients , aged from 6 weeks to 70 years , undergoing limb and abdominal surgery including caesarian sections and interventions in neonates .
Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air / oxygen only .	Operations lasting up to 2h could be performed in the absence of sophisticated equipment such as pulse oximeters or ventilators in patients on spontaneous ventilation breathing air / oxygen only .
After premedication with diazepam , glycopyrrolate and local anaesthesia , and induction with standard doses of ketamine , a maintenance dose of 10 - 20 microg / kg / min of ketamine proved safe and effective .	After premedication with diazepam , glycopyrrolate and local anaesthesia , and induction with standard doses of ketamine , a maintenance dose of 10 - 20 microg / kg / min of ketamine proved safe and effective .
Emphasis was placed on bedside clinical monitoring , relying heavily on the heart rate .	Emphasis was placed on bedside clinical monitoring , relying heavily on the heart rate .
Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative hallucinations .	Diazepam , unless contraindicated or risky , remains the only necessary complementary drug to ketamine as it buffers its cardiovascular response and decreases the duration and intensity of operative and postoperative disease* hallucinations *disease .
Local anaesthetic blocks were useful in decreasing the requirement for postoperative analgesia .	Local anaesthetic blocks were useful in decreasing the requirement for postoperative disease* analgesia *disease .
An antisialogue was usually unnecessary in operations lasting up to 2 h , glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects , especially in a hot climate .	An antisialogue was usually unnecessary in operations lasting up to 2 h , glycopyrrolate being the best choice for its lowest psychotropic and chronotropic effects , especially in a hot climate .
Experience in war / tropical settings suggests this technique could be useful in civilian contexts such as outdoor life - saving emergency surgery or in mass casualties where , e . g . amputation and rapid extrication were required .	Experience in war / tropical settings suggests this technique could be useful in civilian contexts such as outdoor life - saving emergency surgery or in mass casualties where , e . g . amputation and rapid extrication were required .
Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children .	Intravenous ribavirin treatment for severe disease* adenovirus disease *disease in immunocompromised children .
BACKGROUND : Adenovirus is an important cause of morbidity and mortality in the immunocompromised host .	BACKGROUND : Adenovirus is an important cause of morbidity and mortality in the immunocompromised host .
The incidence of severe adenovirus disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .	The incidence of severe disease* adenovirus disease *disease in pediatrics is increasing in association with growing numbers of immunocompromised children , where case fatality rates as high as 50 % to 80 % have been reported .
There are no approved antiviral agents with proven efficacy for the treatment of severe adenovirus disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .	There are no approved antiviral agents with proven efficacy for the treatment of severe disease* adenovirus disease *disease , nor are there any prospective randomized , controlled trials of potentially useful anti - adenovirus therapies .
Apparent clinical success in the treatment of severe adenovirus disease is limited to a few case reports and small series .	Apparent clinical success in the treatment of severe disease* adenovirus disease *disease is limited to a few case reports and small series .
Experience is greatest with intravenous ribavirin and cidofovir .	Experience is greatest with intravenous ribavirin and cidofovir .
Ribavirin , a guanosine analogue , has broad antiviral activity against both RNA and DNA viruses , including documented activity against adenovirus in vitro .	Ribavirin , a guanosine analogue , has broad antiviral activity against both RNA and DNA viruses , including documented activity against adenovirus in vitro .
Ribavirin is licensed in aerosol form for the treatment of respiratory syncytial virus infection , and orally in combination with interferon to treat hepatitis C .	Ribavirin is licensed in aerosol form for the treatment of disease* respiratory syncytial virus infection *disease , and orally in combination with interferon to treat disease* hepatitis C *disease .
Intravenous ribavirin is the treatment of choice for infection with hemorrhagic fever viruses .	Intravenous ribavirin is the treatment of choice for disease* infection with hemorrhagic fever viruses *disease .
The most common adverse effect of intravenous ribavirin is reversible mild anemia .	The most common adverse effect of intravenous ribavirin is reversible mild disease* anemia *disease .
The use of cidofovir in severe adenovirus infection has been limited by adverse effects , the most significant of which is nephrotoxicity .	The use of cidofovir in severe disease* adenovirus infection *disease has been limited by adverse effects , the most significant of which is disease* nephrotoxicity *disease .
OBJECTIVE : We report our experience with intravenous ribavirin therapy for severe adenovirus disease in a series of immunocompromised children and review the literature .	OBJECTIVE : We report our experience with intravenous ribavirin therapy for severe disease* adenovirus disease *disease in a series of immunocompromised children and review the literature .
DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe adenovirus disease .	DESIGN / METHODS : We retrospectively reviewed the medical records of 5 children treated with intravenous ribavirin for documented severe disease* adenovirus disease *disease .
Two patients developed adenovirus hemorrhagic cystitis after cardiac and bone marrow transplants , respectively .	Two patients developed adenovirus disease* hemorrhagic cystitis *disease after cardiac and bone marrow transplants , respectively .
The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease .	The bone marrow transplant patient also received intravenous cidofovir for progressive disseminated disease .
An additional 3 children developed adenovirus pneumonia ; 2 were neonates , 1 of whom had partial DiGeorge syndrome .	An additional 3 children developed disease* adenovirus pneumonia *disease ; 2 were neonates , 1 of whom had partial disease* DiGeorge syndrome *disease .
The remaining infant had recently undergone a cardiac transplant .	The remaining infant had recently undergone a cardiac transplant .
Intravenous ribavirin was administered on a compassionate - use protocol .	Intravenous ribavirin was administered on a compassionate - use protocol .
RESULTS : Complete clinical recovery followed later by viral clearance was observed in 2 children : the cardiac transplant recipient with adenovirus hemorrhagic cystitis and the immunocompetent neonate with adenovirus pneumonia .	RESULTS : Complete clinical recovery followed later by viral clearance was observed in 2 children : the cardiac transplant recipient with adenovirus disease* hemorrhagic cystitis *disease and the immunocompetent neonate with disease* adenovirus pneumonia *disease .
The remaining 3 children died of adenovirus disease .	The remaining 3 children died of disease* adenovirus disease *disease .
Intravenous ribavirin therapy was well tolerated .	Intravenous ribavirin therapy was well tolerated .
Use of cidofovir in 1 child was associated with progressive renal failure and neutropenia .	Use of cidofovir in 1 child was associated with disease* progressive renal failure *disease and disease* neutropenia *disease .
DISCUSSION : Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe adenovirus disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with immunodeficiency .	DISCUSSION : Our series of patients is representative of the spectrum of immunocompromised children at greatest risk for severe disease* adenovirus disease *disease , namely solid - organ and bone marrow transplant recipients , neonates , and children with disease* immunodeficiency *disease .
Although intravenous ribavirin was not effective for all children with severe adenovirus disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the infection .	Although intravenous ribavirin was not effective for all children with severe disease* adenovirus disease *disease in this series or in the literature , therapy is unlikely to be of benefit if begun late in the course of the disease* infection *disease .
Early identification , eg by polymerase chain reaction of those patients at risk of disseminated adenovirus disease may permit earlier antiviral treatment and better evaluation of therapeutic response .	Early identification , eg by polymerase chain reaction of those patients at risk of disseminated disease* adenovirus disease *disease may permit earlier antiviral treatment and better evaluation of therapeutic response .
CONCLUSIONS : Two of 5 children with severe adenovirus disease treated with intravenous ribavirin recovered .	CONCLUSIONS : Two of 5 children with severe disease* adenovirus disease *disease treated with intravenous ribavirin recovered .
The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of adenovirus infection possible .	The availability of newer rapid diagnostic techniques , such as polymerase chain reaction , may make earlier , more effective treatment of disease* adenovirus infection *disease possible .
Given the seriousness and increasing prevalence of adenovirus disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .	Given the seriousness and increasing prevalence of disease* adenovirus disease *disease in certain hosts , especially children , a large , multicenter clinical trial of potentially useful anti - adenoviral therapies , such as intravenous ribavirin , is clearly required to demonstrate the most effective and least toxic therapy .
Delayed asystolic cardiac arrest after diltiazem overdose ; resuscitation with high dose intravenous calcium .	Delayed disease* asystolic disease* cardiac arrest *disease after diltiazem disease* overdose *disease ; resuscitation with high dose intravenous calcium .
A 51 year old man took a mixed overdose including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and alcohol .	A 51 year old man took a mixed disease* overdose *disease including 1 . 8 - 3 . 6 g of diltiazem , paracetamol , aspirin , isosorbide nitrate , and alcohol .
He initially presented to hospital after six hours with mild hypotension and was treated with activated charcoal and intravenous fluids .	He initially presented to hospital after six hours with mild disease* hypotension *disease and was treated with activated charcoal and intravenous fluids .
Eighteen hours after the overdose he had two generalised tonic - clonic seizures .	Eighteen hours after the disease* overdose *disease he had two generalised disease* tonic - clonic seizures *disease .
The patient remained unresponsive with junctional bradycardia , unrecordable blood pressure , and then became asystolic .	The patient remained unresponsive with junctional disease* bradycardia *disease , unrecordable blood pressure , and then became disease* asystolic *disease .
He was resuscitated with high dose ( 13 . 5 g ) intravenous calcium and adrenaline ( epinephrine ) .	He was resuscitated with high dose ( 13 . 5 g ) intravenous calcium and adrenaline ( epinephrine ) .
He required inotropic support and temporary pacing over the next 48 hours .	He required inotropic support and temporary pacing over the next 48 hours .
This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem overdose , particularly with the onset of asystole .	This case suggests there is a role for aggressive high dose intravenous calcium therapy in severe diltiazem disease* overdose *disease , particularly with the onset of disease* asystole *disease .
It should be considered early in cases of cardiac arrest after diltiazem overdose .	It should be considered early in cases of disease* cardiac arrest *disease after diltiazem disease* overdose *disease .
The case also highlights the problems with delayed toxicity when whole bowel irrigation is not administered .	The case also highlights the problems with delayed disease* toxicity *disease when whole bowel irrigation is not administered .
Low - molecular - weight heparin for the treatment of patients with mechanical heart valves .	Low - molecular - weight heparin for the treatment of patients with mechanical heart valves .
BACKGROUND : The interruption of oral anticoagulant ( OAC ) administration is sometimes indicated in patients with mechanical heart valves , mainly before noncardiac surgery , non - surgical interventions , and pregnancy .	BACKGROUND : The interruption of oral anticoagulant ( OAC ) administration is sometimes indicated in patients with mechanical heart valves , mainly before noncardiac surgery , non - surgical interventions , and pregnancy .
Unfractionated heparin ( UH ) is currently the substitute for selected patients .	Unfractionated heparin ( UH ) is currently the substitute for selected patients .
Low - molecular - weight heparin ( LMWH ) offers theoretical advantages over UH , but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves .	Low - molecular - weight heparin ( LMWH ) offers theoretical advantages over UH , but is not currently considered in clinical guidelines as an alternative to UH in patients with prosthetic valves .
HYPOTHESIS : The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice .	HYPOTHESIS : The aim of the present study was to review the data accumulated so far on the use of LMWH in this patient population and to discuss its applicability in common practice .
METHODS : For this paper , the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed .	METHODS : For this paper , the current medical literature on LMWH in patients with mechanical heart valves was extensively reviewed .
RESULTS : There were eight series and six case reports .	RESULTS : There were eight series and six case reports .
None of the studies was randomized , and only one was prospective .	None of the studies was randomized , and only one was prospective .
Data to establish the thromboembolic risk were incomplete .	Data to establish the disease* thromboembolic *disease risk were incomplete .
After excluding case reports , the following groups were constructed : ( a ) short - term administration , after valve insertion ( n = 212 ) ; ( b ) short - term , perioperative ( noncardiac ) / periprocedural ( n = 114 ) ; ( c ) long - term , due to intolerance to OAC ( n = 16 ) ; ( d ) long - term , in pregnancy ( n = 10 ) .	After excluding case reports , the following groups were constructed : ( a ) short - term administration , after valve insertion ( n = 212 ) ; ( b ) short - term , perioperative ( noncardiac ) / periprocedural ( n = 114 ) ; ( c ) long - term , due to intolerance to OAC ( n = 16 ) ; ( d ) long - term , in pregnancy ( n = 10 ) .
The incidence rate of thromboembolism was 0 . 9 % for all the studies and 0 . 5 , 0 , 20 , and 0 % in groups a , b , c , and d , respectively ; for hemorrhage , the overall rate was 3 . 4 % ( 3 . 8 , 2 . 6 , 10 , and 0 % for the respective groups ) .	The incidence rate of disease* thromboembolism *disease was 0 . 9 % for all the studies and 0 . 5 , 0 , 20 , and 0 % in groups a , b , c , and d , respectively ; for disease* hemorrhage *disease , the overall rate was 3 . 4 % ( 3 . 8 , 2 . 6 , 10 , and 0 % for the respective groups ) .
CONCLUSIONS : In patients with mechanical heart valves , short - term LMWH therapy compares favorably with UH .	CONCLUSIONS : In patients with mechanical heart valves , short - term LMWH therapy compares favorably with UH .
Data on mid - and long - term LMWH administration in these patients are sparse .	Data on mid - and long - term LMWH administration in these patients are sparse .
Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves .	Further randomized studies are needed to confirm the safety and precise indications for the use of LMWH in patients with mechanical heart valves .
Cardiac arrest after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of cardiac arrest .	disease* Cardiac arrest *disease after intravenous metoclopramide - a case of five repeated injections of metoclopramide causing five episodes of disease* cardiac arrest *disease .
We describe a patient where intravenous injection of metoclopramide was immediately followed by asystole repeatedly .	We describe a patient where intravenous injection of metoclopramide was immediately followed by disease* asystole *disease repeatedly .
The patient received metoclopramide 10 mg i . v . five times during 48 h .	The patient received metoclopramide 10 mg i . v . five times during 48 h .
After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of metoclopramide was immediately ( within s ) followed by asystole .	After interviewing the attending nurses and reviewing the written documentation , it is clear that every administration of metoclopramide was immediately ( within s ) followed by disease* asystole *disease .
The asystole lasted 15 - 30 s on four occasions , on one occasion it lasted 2 min .	The disease* asystole *disease lasted 15 - 30 s on four occasions , on one occasion it lasted 2 min .
The patient received atropine 0 . 5 - 1 mg and chest compressions , before sinus rhythm again took over .	The patient received atropine 0 . 5 - 1 mg and chest compressions , before sinus rhythm again took over .
We interpret this as episodes of cardiac arrest caused by metoclopramide .	We interpret this as episodes of disease* cardiac arrest *disease caused by metoclopramide .
The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction .	The rapid injection via the central venous route and the concomitant tapering of dopamine infusion might have contributed in precipitating the adverse drug reaction .
Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) in arteritis induced in rats by fenoldopam and theophylline , vasodilators .	Immunohistochemical study on inducible type of nitric oxide ( iNOS ) , basic fibroblast growth factor ( bFGF ) and disease* tumor *disease growth factor - beta1 ( TGF - beta1 ) in disease* arteritis *disease induced in rats by fenoldopam and theophylline , vasodilators .
Arteritis induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and tumor growth factor - beta1 ( TGF - beta1 ) .	disease* Arteritis *disease induced in rats by vasodilators , fenoldopam and theophylline , was examined immunohistochemically for expressions of inducible type of nitric oxide synthase ( iNOS ) , basic fibroblast growth factor ( bFGF ) and disease* tumor *disease growth factor - beta1 ( TGF - beta1 ) .
Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline .	Rats were administered fenoldopam for 24 hours by intravenous infusion with or without following repeated daily oral administrations of theophylline .
Irrespective of theophylline administration , iNOS antigens were remarkably abundant in ED - 1 - positive cells on day 5 and 8 post - fenoldopam - infusion ( DPI ) ; bFGF antigens were remarkably abundant in ED - 1 - positive cells on 1 and 3 DPI ; TGF - beta1 antigens were observed in ED - 1 - positive cells on and after 5 DPI .	Irrespective of theophylline administration , iNOS antigens were remarkably abundant in ED - 1 - positive cells on day 5 and 8 post - fenoldopam - infusion ( DPI ) ; bFGF antigens were remarkably abundant in ED - 1 - positive cells on 1 and 3 DPI ; TGF - beta1 antigens were observed in ED - 1 - positive cells on and after 5 DPI .
These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen , and bFGF may have a suppressive effect on iNOS expression in these rat arteritis models .	These results suggest that the peak expression of iNOS antigen was followed by that of bFGF antigen , and bFGF may have a suppressive effect on iNOS expression in these rat disease* arteritis *disease models .
On the other hand , TGF - beta1 was not considered to have a suppressive effect on iNOS expression in these models .	On the other hand , TGF - beta1 was not considered to have a suppressive effect on iNOS expression in these models .
The striatum as a target for anti - rigor effects of an antagonist of mGluR1 , but not an agonist of group II metabotropic glutamate receptors .	The striatum as a target for anti - rigor effects of an antagonist of mGluR1 , but not an agonist of group II metabotropic glutamate receptors .
The aim of the present study was to find out whether the metabotropic receptor 1 ( mGluR1 ) and group II mGluRs , localized in the striatum , are involved in antiparkinsonian - like effects in rats .	The aim of the present study was to find out whether the metabotropic receptor 1 ( mGluR1 ) and group II mGluRs , localized in the striatum , are involved in antiparkinsonian - like effects in rats .
Haloperidol ( 1 mg / kg ip ) induced parkinsonian - like muscle rigidity , measured as an increased resistance of a rat ' s hind foot to passive flexion and extension at the ankle joint .	Haloperidol ( 1 mg / kg ip ) induced disease* parkinsonian *disease - like disease* muscle rigidity *disease , measured as an increased resistance of a rat ' s hind foot to passive flexion and extension at the ankle joint .
( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid ( AIDA ; 0 . 5 - 15 microg / 0 . 5 microl ) , a potent and selective mGluR1 antagonist , or ( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate ( 2R , 4R - APDC ; 7 . 5 - 15 microg / 0 . 5 microl ) , a selective group II agonist , was injected bilaterally into the striatum of haloperidol - treated animals .	( RS ) - 1 - aminoindan - 1 , 5 - dicarboxylic acid ( AIDA ; 0 . 5 - 15 microg / 0 . 5 microl ) , a potent and selective mGluR1 antagonist , or ( 2R , 4R ) - 4 - aminopyrrolidine - 2 , 4 - dicarboxylate ( 2R , 4R - APDC ; 7 . 5 - 15 microg / 0 . 5 microl ) , a selective group II agonist , was injected bilaterally into the striatum of haloperidol - treated animals .
AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced muscle rigidity .	AIDA in doses of 7 . 5 - 15 microg / 0 . 5 microl diminished the haloperidol - induced disease* muscle rigidity *disease .
In contrast , 2R , 4R - APDC injections were ineffective .	In contrast , 2R , 4R - APDC injections were ineffective .
The present results may suggest that the blockade of striatal mGluR1 , but not the stimulation of group II mGluRs , may ameliorate parkinsonian muscle rigidity .	The present results may suggest that the blockade of striatal mGluR1 , but not the stimulation of group II mGluRs , may ameliorate disease* parkinsonian disease* muscle rigidity *disease .
A phase II study of thalidomide in advanced metastatic renal cell carcinoma .	A phase II study of thalidomide in advanced metastatic disease* renal cell carcinoma *disease .
OBJECTIVES : To evaluate the toxicity and activity of thalidomide in patients with advanced metastatic renal cell cancer and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .	OBJECTIVES : To evaluate the disease* toxicity *disease and activity of thalidomide in patients with advanced metastatic disease* renal cell cancer *disease and to measure changes of one angiogenic factor , vascular endothelial growth factor ( VEGF ) 165 , with therapy .
PATIENTS AND METHODS : 29 patients were enrolled on a study of thalidomide using an intra - patient dose escalation schedule .	PATIENTS AND METHODS : 29 patients were enrolled on a study of thalidomide using an intra - patient dose escalation schedule .
Patients began thalidomide at 400 mg / d and escalated as tolerated to 1200 mg / d by day 54 .	Patients began thalidomide at 400 mg / d and escalated as tolerated to 1200 mg / d by day 54 .
Fifty - nine per cent of patients had had previous therapy with IL - 2 and 52 % were performance status 2 or 3 .	Fifty - nine per cent of patients had had previous therapy with IL - 2 and 52 % were performance status 2 or 3 .
Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients .	Systemic plasma VEGF165 levels were measured by dual monoclonal ELISA in 8 patients .
RESULTS : 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary metastases ( 4 % ) , one minor response , and 2 patients stable for over 6 months .	RESULTS : 24 patients were evaluable for response with one partial response of 11 months duration of a patient with hepatic and pulmonary disease* metastases *disease ( 4 % ) , one minor response , and 2 patients stable for over 6 months .
Somnolence and constipation were prominent toxicities and most patients could not tolerate the 1200 mg / day dose level .	disease* Somnolence *disease and disease* constipation *disease were prominent disease* toxicities *disease and most patients could not tolerate the 1200 mg / day dose level .
Systemic plasma VEGF165 levels did not change with therapy .	Systemic plasma VEGF165 levels did not change with therapy .
CONCLUSION : These results are consistent with a low level of activity of thalidomide in renal cell carcinoma .	CONCLUSION : These results are consistent with a low level of activity of thalidomide in disease* renal cell carcinoma *disease .
Administration of doses over 800 mg / day was difficult to achieve in this patient population , however lower doses were practical .	Administration of doses over 800 mg / day was difficult to achieve in this patient population , however lower doses were practical .
The dose - response relationship , if any , of thalidomide for renal cell carcinoma is unclear .	The dose - response relationship , if any , of thalidomide for disease* renal cell carcinoma *disease is unclear .
Can lidocaine reduce succinylcholine induced postoperative myalgia ?	Can lidocaine reduce succinylcholine induced disease* postoperative myalgia *disease ?
This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced myalgia in patients undergoing general anesthesia for gynecological surgery .	This study was undertaken to determine the effect of lidocaine pretreatment on reduction of succinylcholine - induced disease* myalgia *disease in patients undergoing general anesthesia for gynecological surgery .
One hundred and thirty - five patients were assigned to one of three groups in a prospective , double blind , randomized manner .	One hundred and thirty - five patients were assigned to one of three groups in a prospective , double blind , randomized manner .
Group PS , the control group , received normal saline and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group LS , lidocaine 1 . 5 mg x kg ( - 1 ) and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group PR , normal saline and rocuronium 0 . 6 mg x kg ( - 1 ) .	Group PS , the control group , received normal saline and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group LS , lidocaine 1 . 5 mg x kg ( - 1 ) and succinylcholine 1 . 5 mg x kg ( - 1 ) ; Group PR , normal saline and rocuronium 0 . 6 mg x kg ( - 1 ) .
Morphine 0 . 1 mg x kg ( - 1 ) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor , ECG and pulse oximetry .	Morphine 0 . 1 mg x kg ( - 1 ) iv was given for premedication and all patients were monitored with a noninvasive blood pressure monitor , ECG and pulse oximetry .
Anesthesia was induced with 5 mg . kg ( - 1 ) thiopental iv . followed by succinylcholine ( Group PS , LS ) or rocuronium ( Group PR ) for tracheal intubation .	Anesthesia was induced with 5 mg . kg ( - 1 ) thiopental iv . followed by succinylcholine ( Group PS , LS ) or rocuronium ( Group PR ) for tracheal intubation .
Following administration of these agents , the presence , and degree of fasciculation were assessed visually on a four point scale by one investigator who was blinded to the drug administered .	Following administration of these agents , the presence , and degree of disease* fasciculation *disease were assessed visually on a four point scale by one investigator who was blinded to the drug administered .
The blood pressure and heart rate of each patient were monitored on nine occasions .	The blood pressure and heart rate of each patient were monitored on nine occasions .
Twenty - four hours later , any myalgia experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .	Twenty - four hours later , any disease* myalgia *disease experienced was assessed according to a structured questionaire and graded by a four point scale by one investigator blinded to the intraoperative management .
The results indicate that muscle fasciculation was not found in Group PR while the patients in Group LS had a lower incidence of muscle fasciculation than those in Group PS ( p < 0 . 001 ) .	The results indicate that disease* muscle fasciculation *disease was not found in Group PR while the patients in Group LS had a lower incidence of disease* muscle fasciculation *disease than those in Group PS ( p < 0 . 001 ) .
At 24 h , the incidence of myalgia was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .	At 24 h , the incidence of disease* myalgia *disease was higher in Group PS than in Group LS and PR ( p < 0 . 05 ) .
A correlation was not found between the incidence of myalgia and the occurrence of muscle fasciculation .	A correlation was not found between the incidence of disease* myalgia *disease and the occurrence of disease* muscle fasciculation *disease .
The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups .	The changes in systolic and diastolic blood pressure and heart rate were not significant among the three groups .
In conclusion , where succinylcholine is used , lidocaine is proven to be the useful pretreatment agent for the reduction of postoperative myalgia .	In conclusion , where succinylcholine is used , lidocaine is proven to be the useful pretreatment agent for the reduction of disease* postoperative myalgia *disease .
Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to seizures in mice lacking sodium channel beta 2 - subunits .	Reduced sodium channel density , altered voltage dependence of inactivation , and increased susceptibility to disease* seizures *disease in mice lacking sodium channel beta 2 - subunits .
Sodium channel beta - subunits modulate channel gating , assembly , and cell surface expression in heterologous cell systems .	Sodium channel beta - subunits modulate channel gating , assembly , and cell surface expression in heterologous cell systems .
We generated beta2 ( - / - ) mice to investigate the role of beta2 in control of sodium channel density , localization , and function in neurons in vivo .	We generated beta2 ( - / - ) mice to investigate the role of beta2 in control of sodium channel density , localization , and function in neurons in vivo .
Measurements of [ ( 3 ) H ] saxitoxin ( STX ) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2 ( - / - ) neurons .	Measurements of [ ( 3 ) H ] saxitoxin ( STX ) binding showed a significant reduction in the level of plasma membrane sodium channels in beta2 ( - / - ) neurons .
The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons .	The loss of beta2 resulted in negative shifts in the voltage dependence of inactivation as well as significant decreases in sodium current density in acutely dissociated hippocampal neurons .
The integral of the compound action potential in optic nerve was significantly reduced , and the threshold for action potential generation was increased , indicating a reduction in the level of functional plasma membrane sodium channels .	The integral of the compound action potential in optic nerve was significantly reduced , and the threshold for action potential generation was increased , indicating a reduction in the level of functional plasma membrane sodium channels .
In contrast , the conduction velocity , the number and size of axons in the optic nerve , and the specific localization of Na ( v ) 1 . 6 channels in the nodes of Ranvier were unchanged .	In contrast , the conduction velocity , the number and size of axons in the optic nerve , and the specific localization of Na ( v ) 1 . 6 channels in the nodes of Ranvier were unchanged .
beta2 ( - / - ) mice displayed increased susceptibility to seizures , as indicated by reduced latency and threshold for pilocarpine - induced seizures , but seemed normal in other neurological tests .	beta2 ( - / - ) mice displayed increased susceptibility to disease* seizures *disease , as indicated by reduced latency and threshold for pilocarpine - induced disease* seizures *disease , but seemed normal in other neurological tests .
Our observations show that beta2 - subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability .	Our observations show that beta2 - subunits play an important role in the regulation of sodium channel density and function in neurons in vivo and are required for normal action potential generation and control of excitability .
Acute liver failure with concurrent bupropion and carbimazole therapy .	disease* Acute liver failure *disease with concurrent bupropion and carbimazole therapy .
OBJECTIVE : To report a case of fatal liver failure possibly associated with concurrent use of bupropion and carbimazole .	OBJECTIVE : To report a case of fatal disease* liver failure *disease possibly associated with concurrent use of bupropion and carbimazole .
CASE SUMMARY : A 41 - year - old Chinese man with a history of hyperthyroidism had been treated with carbimazole and propranolol for the past 5 years .	CASE SUMMARY : A 41 - year - old Chinese man with a history of disease* hyperthyroidism *disease had been treated with carbimazole and propranolol for the past 5 years .
He received a 10 - day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation .	He received a 10 - day course of bupropion as an aid for smoking cessation 10 weeks prior to presentation .
He developed acute liver failure with rapid deterioration of renal function .	He developed disease* acute liver failure *disease with rapid deterioration of renal function .
Liver biopsy showed evidence of nonspecific drug - induced acute liver injury .	Liver biopsy showed evidence of nonspecific disease* drug - induced acute liver injury *disease .
His condition was further complicated by sepsis and coagulopathy .	His condition was further complicated by disease* sepsis *disease and disease* coagulopathy *disease .
Death resulted 19 days after the onset of symptoms .	Death resulted 19 days after the onset of symptoms .
The likelihood that bupropion induced hepatotoxicity in our patient was possible , based on the Naranjo probability scale .	The likelihood that bupropion induced disease* hepatotoxicity *disease in our patient was possible , based on the Naranjo probability scale .
DISCUSSION : Although there is increasing evidence of hepatotoxicity induced by bupropion , this is the first case of fatality that could have resulted from acute liver failure in a patient receiving bupropion while on concomitant treatment with carbimazole .	DISCUSSION : Although there is increasing evidence of disease* hepatotoxicity *disease induced by bupropion , this is the first case of fatality that could have resulted from disease* acute liver failure *disease in a patient receiving bupropion while on concomitant treatment with carbimazole .
CONCLUSIONS : Clinicians should be aware of the possibility of acute liver insult induced by bupropion given concurrently with other hepatotoxic drugs .	CONCLUSIONS : Clinicians should be aware of the possibility of disease* acute liver insult *disease induced by bupropion given concurrently with other disease* hepatotoxic *disease drugs .
Pyeloureteral filling defects associated with systemic anticoagulation : a case report .	Pyeloureteral filling defects associated with systemic anticoagulation : a case report .
The etiology of pyeloureteritis cystica has long been attributed to chronic infection and inflammation .	The etiology of disease* pyeloureteritis cystica *disease has long been attributed to chronic disease* infection *disease and disease* inflammation *disease .
A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography .	A case is presented that is unique in that the acute onset and the rapid resolution of pyeloureteral filling defects in this patient were documented by radiography .
There is no evidence of antecedent or concurrent infection in this patient .	There is no evidence of antecedent or concurrent disease* infection *disease in this patient .
The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic thrombophlebitis and cleared rapidly subsequent to its discontinuation .	The disease occurred subsequent to the initiation of heparin therapy for suspected pelvic disease* thrombophlebitis *disease and cleared rapidly subsequent to its discontinuation .
The rate of resolution of the radiographic findings may be helpful in distinguishing between true pyeloureteritis cystica and submucosal hemorrhage .	The rate of resolution of the radiographic findings may be helpful in distinguishing between true disease* pyeloureteritis cystica *disease and disease* submucosal hemorrhage *disease .
Nephrotoxic effects in high - risk patients undergoing angiography .	disease* Nephrotoxic *disease effects in high - risk patients undergoing angiography .
BACKGROUND : The use of iodinated contrast medium can result in nephropathy .	BACKGROUND : The use of iodinated contrast medium can result in disease* nephropathy *disease .
Whether iso - osmolar contrast medium is less nephrotoxic than low - osmolar contrast medium in high - risk patients is uncertain .	Whether iso - osmolar contrast medium is less disease* nephrotoxic *disease than low - osmolar contrast medium in high - risk patients is uncertain .
METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the nephrotoxic effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .	METHODS : We conducted a randomized , double - blind , prospective , multicenter study comparing the disease* nephrotoxic *disease effects of an iso - osmolar , dimeric , nonionic contrast medium , iodixanol , with those of a low - osmolar , nonionic , monomeric contrast medium , iohexol .
The study involved 129 patients with diabetes with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .	The study involved 129 patients with disease* diabetes *disease with serum creatinine concentrations of 1 . 5 to 3 . 5 mg per deciliter who underwent coronary or aortofemoral angiography .
The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography .	The primary end point was the peak increase from base line in the creatinine concentration during the three days after angiography .
Other end points were an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , an increase of 1 . 0 mg per deciliter or more , and a change in the creatinine concentration from day 0 to day 7 .	Other end points were an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , an increase of 1 . 0 mg per deciliter or more , and a change in the creatinine concentration from day 0 to day 7 .
RESULTS : The creatinine concentration increased significantly less in patients who received iodixanol .	RESULTS : The creatinine concentration increased significantly less in patients who received iodixanol .
From day 0 to day 3 , the mean peak increase in creatinine was 0 . 13 mg per deciliter in the iodixanol group and 0 . 55 mg per deciliter in the iohexol group ( P = 0 . 001 ; the increase with iodixanol minus the increase with iohexol , - 0 . 42 mg per deciliter [ 95 percent confidence interval , - 0 . 73 to - 0 . 22 ] ) .	From day 0 to day 3 , the mean peak increase in creatinine was 0 . 13 mg per deciliter in the iodixanol group and 0 . 55 mg per deciliter in the iohexol group ( P = 0 . 001 ; the increase with iodixanol minus the increase with iohexol , - 0 . 42 mg per deciliter [ 95 percent confidence interval , - 0 . 73 to - 0 . 22 ] ) .
Two of the 64 patients in the iodixanol group ( 3 percent ) had an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , as compared with 17 of the 65 patients in the iohexol group ( 26 percent ) ( P = 0 . 002 ; odds ratio for such an increase in the iodixanol group , 0 . 09 [ 95 percent confidence interval , 0 . 02 to 0 . 41 ] ) .	Two of the 64 patients in the iodixanol group ( 3 percent ) had an increase in the creatinine concentration of 0 . 5 mg per deciliter or more , as compared with 17 of the 65 patients in the iohexol group ( 26 percent ) ( P = 0 . 002 ; odds ratio for such an increase in the iodixanol group , 0 . 09 [ 95 percent confidence interval , 0 . 02 to 0 . 41 ] ) .
No patient receiving iodixanol had an increase of 1 . 0 mg per deciliter or more , but 10 patients in the iohexol group ( 15 percent ) did .	No patient receiving iodixanol had an increase of 1 . 0 mg per deciliter or more , but 10 patients in the iohexol group ( 15 percent ) did .
The mean change in the creatinine concentration from day 0 to day 7 was 0 . 07 mg per deciliter in the iodixanol group and 0 . 24 mg per deciliter in the iohexol group ( P = 0 . 003 ; value in the iodixanol group minus the value in the iohexol group , - 0 . 17 mg per deciliter [ 95 percent confidence interval , - 0 . 34 to - 0 . 07 ] ) .	The mean change in the creatinine concentration from day 0 to day 7 was 0 . 07 mg per deciliter in the iodixanol group and 0 . 24 mg per deciliter in the iohexol group ( P = 0 . 003 ; value in the iodixanol group minus the value in the iohexol group , - 0 . 17 mg per deciliter [ 95 percent confidence interval , - 0 . 34 to - 0 . 07 ] ) .
CONCLUSIONS : Nephropathy induced by contrast medium may be less likely to develop in high - risk patients when iodixanol is used rather than a low - osmolar , nonionic contrast medium .	CONCLUSIONS : disease* Nephropathy *disease induced by contrast medium may be less likely to develop in high - risk patients when iodixanol is used rather than a low - osmolar , nonionic contrast medium .
Protective effect of edaravone against streptomycin - induced vestibulotoxicity in the guinea pig .	Protective effect of edaravone against streptomycin - induced disease* vestibulotoxicity *disease in the guinea pig .
This study investigated alleviation of streptomycin - induced vestibulotoxicity by edaravone in guinea pigs .	This study investigated alleviation of streptomycin - induced disease* vestibulotoxicity *disease by edaravone in guinea pigs .
Edaravone , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat cerebral infarction .	Edaravone , a free radical scavenger , has potent free radical quenching action and is used in clinical practice to treat disease* cerebral infarction *disease .
Streptomycin was administered to the inner ear by osmotic pump for 24 h , and edaravone ( n = 8 ) or saline ( n = 6 ) was intraperitoneally injected once a day for 7 days .	Streptomycin was administered to the inner ear by osmotic pump for 24 h , and edaravone ( n = 8 ) or saline ( n = 6 ) was intraperitoneally injected once a day for 7 days .
We observed horizontal vestibulo - ocular reflex as a marker of postoperative vestibular function .	We observed horizontal vestibulo - ocular reflex as a marker of postoperative vestibular function .
Animals injected with saline showed statistically smaller gains than those injected with edaravone .	Animals injected with saline showed statistically smaller gains than those injected with edaravone .
These results suggest that edaravone suppresses streptomycin - induced vestibulotoxicity .	These results suggest that edaravone suppresses streptomycin - induced disease* vestibulotoxicity *disease .
Levodopa - induced oromandibular dystonia in progressive supranuclear palsy .	Levodopa - induced oromandibular disease* dystonia *disease in disease* progressive supranuclear palsy *disease .
Levodopa - induced dyskinesias have been reported in Parkinson ' s disease and multiple system atrophy .	Levodopa - induced disease* dyskinesias *disease have been reported in disease* Parkinson ' s disease *disease and disease* multiple system atrophy *disease .
Cranial dystonias are rare in patients with progressive supranuclear palsy ( PSP ) .	Cranial disease* dystonias *disease are rare in patients with disease* progressive supranuclear palsy *disease ( disease* PSP *disease ) .
In this report we describe an unusual case of reversible levodopa - induced Oromandibular dystonia ( OMD ) in a PSP patient to highlight the importance of recognizing this drug related complication in the management of PSP , and discuss the possible underlying pathophysiology .	In this report we describe an unusual case of reversible levodopa - induced disease* Oromandibular dystonia *disease ( disease* OMD *disease ) in a disease* PSP *disease patient to highlight the importance of recognizing this drug related complication in the management of disease* PSP *disease , and discuss the possible underlying pathophysiology .
Case report : Dexatrim ( Phenylpropanolamine ) as a cause of myocardial infarction .	Case report : Dexatrim ( Phenylpropanolamine ) as a cause of disease* myocardial infarction *disease .
Phenylpropanolamine ( PPA ) is a sympathetic amine used in over - the - counter cold remedies and weight - control preparations worldwide .	Phenylpropanolamine ( PPA ) is a sympathetic amine used in over - the - counter cold remedies and weight - control preparations worldwide .
Its use has been associated with hypertensive episodes and hemorrhagic strokes in younger women .	Its use has been associated with disease* hypertensive *disease episodes and disease* hemorrhagic strokes *disease in younger women .
Several reports have linked the abuse of PPA with myocardial injury , especially when overdose is involved .	Several reports have linked the abuse of PPA with disease* myocardial injury *disease , especially when disease* overdose *disease is involved .
We report here the first case of Dexatrim ( PPA ) - induced myocardial injury in a young woman who was using it at recommended doses for weight control .	We report here the first case of Dexatrim ( PPA ) - induced disease* myocardial injury *disease in a young woman who was using it at recommended doses for weight control .
In addition , we review the 7 other cases of PPA related myocardial injury that have been reported so far .	In addition , we review the 7 other cases of PPA related disease* myocardial injury *disease that have been reported so far .
Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA , even at doses generally considered to be safe .	Physicians and patients should be alert to the potential cardiac risk associated with the use of PPA , even at doses generally considered to be safe .
Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus .	Differential diagnosis of high serum creatine kinase levels in disease* systemic lupus erythematosus *disease .
We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced myopathy .	We report the clinical and bioptic findings for a 57 - year - old woman with severe chloroquine - induced disease* myopathy *disease .
Since 1989 , she had been suffering from systemic lupus erythematosus ( SLE ) with renal involvement and undergone periods of treatment with azathioprine and cyclophosphamide .	Since 1989 , she had been suffering from disease* systemic lupus erythematosus *disease ( disease* SLE *disease ) with disease* renal involvement *disease and undergone periods of treatment with azathioprine and cyclophosphamide .
Additional therapy with chloroquine ( CQ ) was started because of arthralgia .	Additional therapy with chloroquine ( CQ ) was started because of disease* arthralgia *disease .
At the same time , slightly increased creatine kinase ( CK ) levels were noted .	At the same time , slightly increased creatine kinase ( CK ) levels were noted .
Myositis was suspected , and the patient was treated with steroids .	disease* Myositis *disease was suspected , and the patient was treated with steroids .
The CK increase persisted , however , and she developed progressive muscular weakness and muscular atrophy .	The CK increase persisted , however , and she developed progressive disease* muscular weakness *disease and disease* muscular atrophy *disease .
Routine controls revealed markedly elevated CK levels of 1 , 700 U / l .	Routine controls revealed markedly elevated CK levels of 1 , 700 U / l .
The neurological and electrophysiological findings were not typical of myositis .	The neurological and electrophysiological findings were not typical of disease* myositis *disease .
Thus , muscle biopsy of the deltoid muscle was performed in order to exclude polymyositis or toxic myopathy .	Thus , muscle biopsy of the deltoid muscle was performed in order to exclude disease* polymyositis *disease or toxic disease* myopathy *disease .
As it revealed chloroquine - induced myopathy , medication was stopped .	As it revealed chloroquine - induced disease* myopathy *disease , medication was stopped .
Discriminating between primary SLE - induced affection of the musculoskeletal system and drug - induced side effects is important for appropriate treatment of SLE patients .	Discriminating between primary disease* SLE *disease - induced disease* affection of the musculoskeletal system *disease and drug - induced side effects is important for appropriate treatment of disease* SLE *disease patients .
Seizure associated with sleep deprivation and sustained - release bupropion .	disease* Seizure *disease associated with disease* sleep deprivation *disease and sustained - release bupropion .
This case report describes a generalized seizure associated with sustained - release bupropion use and sleep deprivation .	This case report describes a generalized disease* seizure *disease associated with sustained - release bupropion use and disease* sleep deprivation *disease .
The subject , a 31 - year - old female smoker , was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained - release bupropion as an active control .	The subject , a 31 - year - old female smoker , was participating in a clinical trial evaluating an investigational medication for smoking cessation that used sustained - release bupropion as an active control .
After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic seizure after staying up nearly all night packing and moving to a new residence .	After 5 weeks of bupropion use , the subject experienced a generalized tonic clonic disease* seizure *disease after staying up nearly all night packing and moving to a new residence .
The patient had no other risk factors for seizures .	The patient had no other risk factors for disease* seizures *disease .
We suggest that sleep deprivation may add to the risk of bupropion - associated seizures .	We suggest that disease* sleep deprivation *disease may add to the risk of bupropion - associated disease* seizures *disease .
Postoperative myalgia after succinylcholine : no evidence for an inflammatory origin .	disease* Postoperative myalgia *disease after succinylcholine : no evidence for an inflammatory origin .
A common side effect associated with succinylcholine is postoperative myalgia .	A common side effect associated with succinylcholine is disease* postoperative myalgia *disease .
The pathogenesis of this myalgia is still unclear ; inflammation has been suggested but without convincing evidence .	The pathogenesis of this disease* myalgia *disease is still unclear ; disease* inflammation *disease has been suggested but without convincing evidence .
We designed the present study to investigate whether an inflammatory reaction contributes to this myalgia .	We designed the present study to investigate whether an inflammatory reaction contributes to this disease* myalgia *disease .
The incidence and severity of succinylcholine - associated myalgia was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .	The incidence and severity of succinylcholine - associated disease* myalgia *disease was determined in 64 patients pretreated with saline or dexamethasone before succinylcholine ( n = 32 for each ) .
Incidence and severity of myalgia did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of myalgia compared with 18 patients in the saline group , and severe myalgia was reported by five patients and three patients , respectively ( not significant ) .	Incidence and severity of disease* myalgia *disease did not differ significantly between the two groups : 15 patients in the dexamethasone group complained of disease* myalgia *disease compared with 18 patients in the saline group , and severe disease* myalgia *disease was reported by five patients and three patients , respectively ( not significant ) .
At 48 h after surgery , 12 patients in both groups still suffered from myalgia ( not significant ) .	At 48 h after surgery , 12 patients in both groups still suffered from disease* myalgia *disease ( not significant ) .
In addition , interleukin - 6 ( IL - 6 ) as an early marker of inflammation was assessed in a subgroup of 10 patients pretreated with saline .	In addition , interleukin - 6 ( IL - 6 ) as an early marker of disease* inflammation *disease was assessed in a subgroup of 10 patients pretreated with saline .
We found an increase of IL - 6 for only three patients , but only one patient reported myalgia ; no relationship between myalgia and the increase of IL - 6 was found .	We found an increase of IL - 6 for only three patients , but only one patient reported disease* myalgia *disease ; no relationship between disease* myalgia *disease and the increase of IL - 6 was found .
In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated myalgia .	In conclusion , there is no evidence for an inflammatory origin of succinylcholine - associated disease* myalgia *disease .
IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced postoperative myalgia .	IMPLICATIONS : Administration of dexamethasone before succinylcholine was not effective in decreasing the incidence or the severity of succinylcholine - induced disease* postoperative myalgia *disease .
Furthermore , there was no significant relationship between postoperative myalgia and time course of interleukin - 6 concentrations , a marker of inflammation .	Furthermore , there was no significant relationship between disease* postoperative myalgia *disease and time course of interleukin - 6 concentrations , a marker of disease* inflammation *disease .
Pretreatment with dexamethasone is not justified to prevent postoperative myalgia after succinylcholine .	Pretreatment with dexamethasone is not justified to prevent disease* postoperative myalgia *disease after succinylcholine .
Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced neurotoxicity .	Effect of lindane on hepatic and brain cytochrome P450s and influence of P450 modulation in lindane induced disease* neurotoxicity *disease .
Oral administration of lindane ( 2 . 5 , 5 , 10 and 15 mg / kg , body weight ) for 5 days was found to produce a dose - dependent increase in the activity of P450 dependent 7 - ethoxyresorufin - O - deethylase ( EROD ) , 7 - pentoxyresorufin - O - dealkylase ( PROD ) and N - nitrosodimethylamine demethylase ( NDMA - d ) in rat brain and liver .	Oral administration of lindane ( 2 . 5 , 5 , 10 and 15 mg / kg , body weight ) for 5 days was found to produce a dose - dependent increase in the activity of P450 dependent 7 - ethoxyresorufin - O - deethylase ( EROD ) , 7 - pentoxyresorufin - O - dealkylase ( PROD ) and N - nitrosodimethylamine demethylase ( NDMA - d ) in rat brain and liver .
A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose ( 2 . 5 mg / kg ) of lindane was increased from 5 days to 15 or 21 days .	A significant increase in the hepatic and brain P450 monooxygenases was also observed when the duration of exposure of low dose ( 2 . 5 mg / kg ) of lindane was increased from 5 days to 15 or 21 days .
As observed with different doses , the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain .	As observed with different doses , the magnitude of induction in the activity of P450 monooxygenases was several fold higher in liver microsomes when compared with the brain .
Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1 / 1A2 , 2B1 / 2B2 and 2E1 isoenzymes .	Western blotting studies have indicated that the increase in the P450 enzymes could be due to the increase in the expression of P450 1A1 / 1A2 , 2B1 / 2B2 and 2E1 isoenzymes .
In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD , EROD and NDMA - d are due to the increase in the levels of P450 2B1 / 2B2 , 1A1 / 1A2 and 2E1 isoenzymes , respectively .	In vitro studies using organic inhibitors specific for individual P450 isoenzymes and antibody inhibition experiments have further demonstrated that the increase in the activity of PROD , EROD and NDMA - d are due to the increase in the levels of P450 2B1 / 2B2 , 1A1 / 1A2 and 2E1 isoenzymes , respectively .
Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced convulsions , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced convulsions .	Induction studies have further shown that while pretreatment of 3 - methylcholanthrene ( MC ) , an inducer of P4501A1 / 1A2 , did not produce any significant effect in the incidence of lindane induced disease* convulsions *disease , pretreatment with phenobarbital ( PB ) , an inducer of P450 2B1 / 2B2 or ethanol , an inducer of P450 2E1 catalysed reactions , significantly increased the incidence of lindane induced disease* convulsions *disease .
Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of convulsions was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral toxicity .	Similarly , when the P450 - mediated metabolism of lindane was blocked by cobalt chloride incidence of disease* convulsions *disease was increased in animals treated with lindane indicating that lindane per se or its metabolites formed by PB or ethanol inducible P450 isoenzymes are involved in its neurobehavioral disease* toxicity *disease .
Absolute and attributable risk of venous thromboembolism in women on combined cyproterone acetate and ethinylestradiol .	Absolute and attributable risk of disease* venous thromboembolism *disease in women on combined cyproterone acetate and ethinylestradiol .
OBJECTIVE : To achieve absolute risk estimates of venous thromboembolism ( VTE ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .	OBJECTIVE : To achieve absolute risk estimates of disease* venous thromboembolism *disease ( disease* VTE *disease ) among women on cyproterone acetate plus ethinylestradiol ( CPA / EE ) , and among women on combined oral contraceptives ( COCs ) .
METHODS : From the Danish National Register of Patients ( NRP ) , 1996 to 1998 , the records of 1 . 1 million Danish women , ages 15 to 44 years , were searched for evidence of VTE .	METHODS : From the Danish National Register of Patients ( NRP ) , 1996 to 1998 , the records of 1 . 1 million Danish women , ages 15 to 44 years , were searched for evidence of disease* VTE *disease .
COC use was ascertained through mailed questionnaires .	COC use was ascertained through mailed questionnaires .
Sales statistics of COCs and CPA / EE were provided through Danish Drug Statistics .	Sales statistics of COCs and CPA / EE were provided through Danish Drug Statistics .
RESULTS : During the time frame of the study , 330 women were found to have had VTE while on COCs .	RESULTS : During the time frame of the study , 330 women were found to have had disease* VTE *disease while on COCs .
Of these women , 67 were on levonorgestrel - containing COCs .	Of these women , 67 were on levonorgestrel - containing COCs .
Eleven were on CPA / EE .	Eleven were on CPA / EE .
The corresponding absolute risk of VTE was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .	The corresponding absolute risk of disease* VTE *disease was 3 . 4 ( range , 3 . 1 - 3 . 8 ) per 10 000 women years among the women on COCs , 4 . 2 ( range , 3 . 2 - 5 . 2 ) per 10 000 women years among women on levonorgestrel - containing COCs , and 3 . 1 ( range , 1 . 3 - 4 . 9 ) per 10 000 women years among the women on CPA / EE .
CONCLUSION : Our results suggest the absolute risk of VTE among Danish women on COCs is similar to that among women taking CPA / EE .	CONCLUSION : Our results suggest the absolute risk of disease* VTE *disease among Danish women on COCs is similar to that among women taking CPA / EE .
Comparison of developmental toxicology of aspirin ( acetylsalicylic acid ) in rats using selected dosing paradigms .	Comparison of developmental toxicology of aspirin ( acetylsalicylic acid ) in rats using selected dosing paradigms .
BACKGROUND : Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of developmental anomalies occurs in rats given NSAIDs on specific days during organogenesis .	BACKGROUND : Analysis of the literature for nonsteroidal anti - inflammatory drugs ( NSAIDs ) suggests that a low incidence of disease* developmental anomalies *disease occurs in rats given NSAIDs on specific days during organogenesis .
Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces developmental anomalies when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ . Teratology 4 : 15 - 24 , 1971 ) .	Aspirin ( acetylsalicylic acid [ ASA ] ) , an irreversible cyclooxygenase 1 and 2 inhibitor , induces disease* developmental anomalies *disease when administered to Wistar rats on gestational day ( GD ) 9 , 10 , or 11 ( Kimmel CA , Wilson JG , Schumacher HJ . Teratology 4 : 15 - 24 , 1971 ) .
There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17 .	There are no published ASA studies using the multiple dosing paradigm of GDs 6 to 17 .
Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal gastrointestinal toxicity confounds the detection of low incidence malformations with ASA when a multiple dosing paradigm is used .	Objectives of the current study were to compare results between Sprague - Dawley ( SD ) and Wistar strains when ASA is administered on GD 9 , 10 , or 11 ; to compare the malformation patterns following single and multiple dosings during organogenesis in SD rats ; and to test the hypothesis that maternal disease* gastrointestinal toxicity *disease confounds the detection of low incidence disease* malformations *disease with ASA when a multiple dosing paradigm is used .
METHODS : ASA was administered as a single dose on GD 9 ( 0 , 250 , 500 , or 625 mg / kg ) , 10 ( 0 , 500 , 625 , or 750 mg / kg ) , or 11 ( 0 , 500 , 750 , or 1000 mg / kg ) and from GD 6 to GD 17 ( 0 , 50 , 125 , or 250 mg / kg a day ) in the multiple dose study to SD rats .	METHODS : ASA was administered as a single dose on GD 9 ( 0 , 250 , 500 , or 625 mg / kg ) , 10 ( 0 , 500 , 625 , or 750 mg / kg ) , or 11 ( 0 , 500 , 750 , or 1000 mg / kg ) and from GD 6 to GD 17 ( 0 , 50 , 125 , or 250 mg / kg a day ) in the multiple dose study to SD rats .
Animals were killed on GD 21 , and fetuses were examined viscerally .	Animals were killed on GD 21 , and fetuses were examined viscerally .
RESULTS : The literature evaluation suggested that NSAIDs induce ventricular septal defects ( VSDs ) and midline defects ( MDs ) in rats and diaphragmatic hernia ( DH ) , MDs , and VSDs in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these malformations , even though ASA induces several other low - incidence malformations .	RESULTS : The literature evaluation suggested that NSAIDs induce disease* ventricular septal defects *disease ( disease* VSDs *disease ) and disease* midline defects *disease ( disease* MDs *disease ) in rats and disease* diaphragmatic hernia *disease ( disease* DH *disease ) , disease* MDs *disease , and disease* VSDs *disease in rabbits ( Cook JC et al . , 2003 ) ; hence , the present study focused on these disease* malformations *disease , even though ASA induces several other low - incidence disease* malformations *disease .
In single dose studies , DH , MD , and VSD were induced on GDs 9 and 10 .	In single dose studies , disease* DH *disease , disease* MD *disease , and disease* VSD *disease were induced on GDs 9 and 10 .
VSD also was noted following treatment on GD 11 .	disease* VSD *disease also was noted following treatment on GD 11 .
In contrast , DH and MD were noted in the multiple dose study design only in the high - dose group , and VSD was noted across all dose groups .	In contrast , disease* DH *disease and disease* MD *disease were noted in the multiple dose study design only in the high - dose group , and disease* VSD *disease was noted across all dose groups .
CONCLUSIONS : High concordance in major developmental anomalies between Wistar and SD rats were noted with the exception of VSD in the SD rats and hydrocephalus in the Wistar rats .	CONCLUSIONS : High concordance in major disease* developmental anomalies *disease between Wistar and SD rats were noted with the exception of disease* VSD *disease in the SD rats and disease* hydrocephalus *disease in the Wistar rats .
Variations and malformations were similar when ASA was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .	Variations and disease* malformations *disease were similar when ASA was administered as a single dose or during the period of organogenesis ( GDs 6 to 17 ) .
It was also evident that , by titrating the dose to achieve a maximum tolerated dose , malformations that normally occur at low incidence , as reported from previous single dose studies , could also be induced with ASA given at multiple doses .	It was also evident that , by titrating the dose to achieve a maximum tolerated dose , disease* malformations *disease that normally occur at low incidence , as reported from previous single dose studies , could also be induced with ASA given at multiple doses .
Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids : report of a double - blind multicenter study .	Reversal of central benzodiazepine effects by flumazenil after intravenous conscious sedation with diazepam and opioids : report of a double - blind multicenter study .
The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II .	The Flumazenil in Intravenous Conscious Sedation with Diazepam Multicenter Study Group II .
The efficacy and safety of a new benzodiazepine antagonist , flumazenil , were assessed in a double - blind multicenter study .	The efficacy and safety of a new benzodiazepine antagonist , flumazenil , were assessed in a double - blind multicenter study .
Flumazenil ( mean dose , 0 . 76 mg ) or placebo ( mean dose , 8 . 9 ml ) was administered intravenously to 130 and 67 patients , respectively , who had been given diazepam in conjunction with an opioid ( fentanyl , meperidine , or morphine ) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures .	Flumazenil ( mean dose , 0 . 76 mg ) or placebo ( mean dose , 8 . 9 ml ) was administered intravenously to 130 and 67 patients , respectively , who had been given diazepam in conjunction with an opioid ( fentanyl , meperidine , or morphine ) for the induction and maintenance of intravenous conscious sedation for diagnostic or therapeutic surgical procedures .
The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo .	The group assessable for efficacy comprised 122 patients treated with flumazenil and 64 patients given placebo .
After 5 minutes , 80 / 115 ( 70 % ) flumazenil - treated patients , compared with 21 / 63 ( 33 % ) placebo - treated patients , were completely awake and alert , as indicated by a score of 5 on the Observer ' s Assessment of Alertness / Sedation Scale .	After 5 minutes , 80 / 115 ( 70 % ) flumazenil - treated patients , compared with 21 / 63 ( 33 % ) placebo - treated patients , were completely awake and alert , as indicated by a score of 5 on the Observer ' s Assessment of Alertness / Sedation Scale .
Ninety - five percent of patients in each group who attained a score of 5 at the 5 - minute assessment showed no loss of alertness throughout the 180 - minute assessment period .	Ninety - five percent of patients in each group who attained a score of 5 at the 5 - minute assessment showed no loss of alertness throughout the 180 - minute assessment period .
Flumazenil - treated patients also performed significantly better on the Finger - to - Nose Test and the recall of pictures shown at the 5 - minute assessment .	Flumazenil - treated patients also performed significantly better on the Finger - to - Nose Test and the recall of pictures shown at the 5 - minute assessment .
Flumazenil was well tolerated , with no serious adverse effects reported .	Flumazenil was well tolerated , with no serious adverse effects reported .
Thirty - nine ( 30 % ) of flumazenil - treated patients , compared with 17 ( 25 % ) of placebo - treated patients had one or more drug - related adverse experiences .	Thirty - nine ( 30 % ) of flumazenil - treated patients , compared with 17 ( 25 % ) of placebo - treated patients had one or more drug - related adverse experiences .
The most common adverse effects were nausea and vomiting in the flumazenil group and nausea and injection - site pain in the placebo group .	The most common adverse effects were disease* nausea *disease and disease* vomiting *disease in the flumazenil group and disease* nausea *disease and injection - site disease* pain *disease in the placebo group .
Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids .	Flumazenil was found to promptly reverse sedation induced by diazepam in the presence of opioids .
Methylphenidate - induced obsessive - compulsive symptoms in an elderly man .	Methylphenidate - induced disease* obsessive - compulsive symptoms *disease in an elderly man .
An 82 - year - old man with treatment - resistant depression and early Alzheimer ' s disease was started on methylphenidate .	An 82 - year - old man with disease* treatment - resistant depression *disease and early disease* Alzheimer ' s disease *disease was started on methylphenidate .
Significant obsessive - compulsive behavior ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine .	Significant disease* obsessive - compulsive behavior *disease ensued but diminished over several weeks when methylphenidate was replaced by fluvoxamine .
The patient had no prior psychiatric history , but he had a sister with obsessive - compulsive disorder .	The patient had no prior disease* psychiatric *disease history , but he had a sister with disease* obsessive - compulsive disorder *disease .
It appears that methylphenidate precipitated the patient ' s pathological behavior .	It appears that methylphenidate precipitated the patient ' s pathological behavior .
Ciprofloxacin - induced acute interstitial nephritis and autoimmune hemolytic anemia .	Ciprofloxacin - induced acute disease* interstitial nephritis *disease and disease* autoimmune hemolytic anemia *disease .
Ciprofloxacin has been associated with several side effects including interstitial nephritis and hemolytic anemia .	Ciprofloxacin has been associated with several side effects including disease* interstitial nephritis *disease and disease* hemolytic anemia *disease .
The combination of both side effects is extremely rare .	The combination of both side effects is extremely rare .
In this report , we describe a case of ciprofloxacin - induced interstitial nephritis and autoimmune hemolytic anemia .	In this report , we describe a case of ciprofloxacin - induced disease* interstitial nephritis *disease and disease* autoimmune hemolytic anemia *disease .
Hemolytic anemia improved after stopping the drug and initiation of steroid therapy .	disease* Hemolytic anemia *disease improved after stopping the drug and initiation of steroid therapy .
Unfortunately , acute interstitial nephritis was irreversible and the patient developed end - stage renal disease .	Unfortunately , acute disease* interstitial nephritis *disease was irreversible and the patient developed disease* end - stage renal disease *disease .
Potential deleterious effect of furosemide in radiocontrast nephropathy .	Potential deleterious effect of furosemide in radiocontrast disease* nephropathy *disease .
The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast nephropathy .	The purpose of the study was to determine the efficacy of furosemide in addition to intravenous fluids in the prevention of radiocontrast disease* nephropathy *disease .
18 patients , referred to a radiocontrast study , considered at risk because of preexisting renal insufficiency , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .	18 patients , referred to a radiocontrast study , considered at risk because of preexisting disease* renal insufficiency *disease , were enrolled in a prospective , randomized , controlled trial , performed at the secondary care center of a 1 , 100 - bed private university hospital .
In addition to fluids , the treatment group received furosemide ( mean dose 110 mg ) intravenously 30 min prior to the injection of contrast material .	In addition to fluids , the treatment group received furosemide ( mean dose 110 mg ) intravenously 30 min prior to the injection of contrast material .
The control group received fluids ( mean 3 liters ) .	The control group received fluids ( mean 3 liters ) .
Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .	Radiological studies were mostly angiographies performed with both ionic and non - ionic contrast material , at an average dose of 245 ml .
Renal function significantly deteriorated in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .	disease* Renal function significantly deteriorated *disease in the group pretreated with furosemide ( p < 0 . 005 by ANOVA ) , with a rise in serum creatinine from 145 + / - 13 to 182 + / - 16 mumol / l at 24 h , while no change occurred in the control group ( from 141 + / - 6 to 142 + / - 7 mumol / l ) .
Renal failure was associated with weight loss in the furosemide - treated group .	disease* Renal failure *disease was associated with disease* weight loss *disease in the furosemide - treated group .
Furosemide may be deleterious in the prevention of radiocontrast nephropathy .	Furosemide may be deleterious in the prevention of radiocontrast disease* nephropathy *disease .
Progestational agents and blood coagulation .	Progestational agents and disease* blood coagulation *disease .
VII .	VII .
Thromboembolic and other complications of oral contraceptive therapy in relationship to pretreatment levels of blood coagulation factors : summary report of a ten - year study .	disease* Thromboembolic *disease and other complications of oral contraceptive therapy in relationship to pretreatment levels of disease* blood coagulation *disease factors : summary report of a ten - year study .
During a ten - year period , 348 women were studied for a total of 5 , 877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters .	During a ten - year period , 348 women were studied for a total of 5 , 877 patient months in four separate studies relating oral contraceptives to changes in hematologic parameters .
Significant increases in certain factors of the blood coagulation and fibrinolysin systems ( factors I , II , VII , VIII , IX , and X and plasminogen ) were observed in the treated groups .	Significant increases in certain factors of the disease* blood coagulation *disease and fibrinolysin systems ( factors I , II , VII , VIII , IX , and X and plasminogen ) were observed in the treated groups .
Severe complications developed in four patients .	Severe complications developed in four patients .
All four had an abnormal blood coagulation profile , suggesting " hypercoagulability " before initiation of therapy .	All four had an abnormal disease* blood coagulation *disease profile , suggesting " disease* hypercoagulability *disease " before initiation of therapy .
Some of these findings represented the most extreme abnormalities seen in the entire group of patients ; some increased further during therapy .	Some of these findings represented the most extreme abnormalities seen in the entire group of patients ; some increased further during therapy .
One of these patients developed a myocardial infarction before receiving any medication , shortly after the base - line values were obtained .	One of these patients developed a disease* myocardial infarction *disease before receiving any medication , shortly after the base - line values were obtained .
One patient developed retinopathy 19 months after she began therapy , and another developed thrombophlebitis after 27 months of therapy .	One patient developed disease* retinopathy *disease 19 months after she began therapy , and another developed disease* thrombophlebitis *disease after 27 months of therapy .
The fourth patient developed thrombophlebitis 14 days after initiation of contraceptive therapy .	The fourth patient developed disease* thrombophlebitis *disease 14 days after initiation of contraceptive therapy .
All four patients were of the A or AB blood group .	All four patients were of the A or AB blood group .
Previous studies suggested the possiblility of increased propensity for thromboembolic episodes in patients possessing the A antigen .	Previous studies suggested the possiblility of increased propensity for disease* thromboembolic episodes *disease in patients possessing the A antigen .
It appears from these data that hematologic work - ups may be useful in women who are about to start long - term oral contraceptive therapy .	It appears from these data that hematologic work - ups may be useful in women who are about to start long - term oral contraceptive therapy .
Orthostatic hypotension occurs following alpha 2 - adrenoceptor blockade in chronic prazosin - pretreated conscious spontaneously hypertensive rats .	disease* Orthostatic hypotension *disease occurs following alpha 2 - adrenoceptor blockade in chronic prazosin - pretreated conscious spontaneously disease* hypertensive *disease rats .
1 .	1 .
Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously hypertensive rats ( SHR ) .	Studies were performed to evaluate whether chronic prazosin treatment alters the alpha 2 - adrenoceptor function for orthostatic control of arterial blood pressure in conscious spontaneously disease* hypertensive *disease rats ( SHR ) .
2 .	2 .
Conscious SHR ( male 300 - 350 g ) were subjected to 90 degrees head - up tilts for 60 s following acute administration of prazosin ( 0 . 1 mg kg - 1 i . p . ) or rauwolscine ( 3 mg kg - 1 i . v . ) .	Conscious SHR ( male 300 - 350 g ) were subjected to 90 degrees head - up tilts for 60 s following acute administration of prazosin ( 0 . 1 mg kg - 1 i . p . ) or rauwolscine ( 3 mg kg - 1 i . v . ) .
Orthostatic hypotension was determined by the average decrease ( % ) in mean arterial pressure ( MAP femoral ) over the 60 - s tilt period .	disease* Orthostatic hypotension *disease was determined by the average decrease ( % ) in mean arterial pressure ( MAP femoral ) over the 60 - s tilt period .
The basal MAP of conscious SHR was reduced to a similar extent by prazosin ( - 23 % ( - ) - 26 % MAP ) and rauwolscine ( - 16 % ( - ) - 33 % MAP ) .	The basal MAP of conscious SHR was reduced to a similar extent by prazosin ( - 23 % ( - ) - 26 % MAP ) and rauwolscine ( - 16 % ( - ) - 33 % MAP ) .
However , the head - up tilt induced orthostatic hypotension in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .	However , the head - up tilt induced disease* orthostatic hypotension *disease in the SHR treated with prazosin ( - 16 % MAP , n = 6 ) , but not in the SHR treated with rauwolscine ( less than + 2 % MAP , n = 6 ) .
3 .	3 .
Conscious SHR were treated for 4 days with prazosin at 2 mg kg - 1 day - 1 i . p . for chronic alpha 1 - adrenoceptor blockade .	Conscious SHR were treated for 4 days with prazosin at 2 mg kg - 1 day - 1 i . p . for chronic alpha 1 - adrenoceptor blockade .
MAP in conscious SHR after chronic prazosin treatment was 14 % lower than in the untreated SHR ( n = 8 ) .	MAP in conscious SHR after chronic prazosin treatment was 14 % lower than in the untreated SHR ( n = 8 ) .
Head - up tilts in these rats did not produce orthostatic hypotension when performed either prior to or after acute dosing of prazosin ( 0 . 1 mg kg - 1 i . p . ) .	Head - up tilts in these rats did not produce disease* orthostatic hypotension *disease when performed either prior to or after acute dosing of prazosin ( 0 . 1 mg kg - 1 i . p . ) .
Conversely , administration of rauwolscine ( 3 mg kg - 1 i . v . ) in chronic prazosin treated SHR decreased the basal MAP by 12 - 31 % ( n = 4 ) , and subsequent tilts induced further drops of MAP by 19 - 23 % in these rats .	Conversely , administration of rauwolscine ( 3 mg kg - 1 i . v . ) in chronic prazosin treated SHR decreased the basal MAP by 12 - 31 % ( n = 4 ) , and subsequent tilts induced further drops of MAP by 19 - 23 % in these rats .
4 .	4 .
The pressor responses and bradycardia to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .	The pressor responses and disease* bradycardia *disease to the alpha 1 - agonist cirazoline ( 0 . 6 and 2 micrograms kg - 1 i . v . ) , the alpha 2 - agonist Abbott - 53693 ( 1 and 3 micrograms kg - 1 i . v . ) , and noradrenaline ( 0 . 1 and 1 . 0 micrograms kg - 1 i . v . ) were determined in conscious SHR with and without chronic prazosin pretreatment .
Both the pressor and bradycardia effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .	Both the pressor and disease* bradycardia *disease effects of cirazoline were abolished in chronic prazosin treated SHR ( n = 4 ) as compared to the untreated SHR ( n = 4 ) .
On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying bradycardia was greater in SHR with chronic prazosin treatment than without such treatment .	On the other hand , the pressor effects of Abbott - 53693 were similar in both groups of SHR , but the accompanying disease* bradycardia *disease was greater in SHR with chronic prazosin treatment than without such treatment .
Furthermore , the bradycardia that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )	Furthermore , the disease* bradycardia *disease that accompanied the noradrenaline - induced pressor effect in SHR was similar with and without chronic prazosin treatment despite a 47 - 71 % reduction of the pressor effect in chronic alpha 1 - receptor blocked SHR . ( ABSTRACT TRUNCATED AT 400 WORDS )
Hemolytic - uremic syndrome associated with ingestion of quinine .	disease* Hemolytic - uremic syndrome *disease associated with ingestion of quinine .
Hemolytic - uremic syndrome following quinine ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .	disease* Hemolytic - uremic syndrome *disease following quinine ingestion is a newly described phenomenon , with just two previous descriptions of 4 cases in the literature .
We describe a 5th case .	We describe a 5th case .
The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine .	The reaction may be mediated by the presence of antibodies reactive against platelets in the presence of quinine .
Treatment has included use of plasma exchange , prednisone , aspirin , and dipyridamole .	Treatment has included use of plasma exchange , prednisone , aspirin , and dipyridamole .
The patients have all regained some degree of renal function .	The patients have all regained some degree of renal function .
However , it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement .	However , it is unclear whether pharmacological treatment or spontaneous resolution is responsible for the improvement .
Quinine - associated hemolytic - uremic syndrome probably occurs more often than is recognized .	Quinine - associated disease* hemolytic - uremic syndrome *disease probably occurs more often than is recognized .
It is important to recognize this reaction when it occurs and to avoid further quinine exposure , since the reaction seems to be recurrent .	It is important to recognize this reaction when it occurs and to avoid further quinine exposure , since the reaction seems to be recurrent .
Amnestic syndrome associated with propranolol toxicity : a case report .	disease* Amnestic syndrome *disease associated with propranolol disease* toxicity *disease : a case report .
An elderly woman developed an Alzheimer - like subacute dementia as a result of propranolol toxicity .	An elderly woman developed an disease* Alzheimer *disease - like subacute disease* dementia *disease as a result of propranolol disease* toxicity *disease .
Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities .	Analysis of the manifestations showed that severe impairment of memory accounted for virtually all of the abnormalities .
There is evidence that cerebral reactions to drug toxicity can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .	There is evidence that cerebral reactions to drug disease* toxicity *disease can exhibit patterns that suggest highly selective involvement of functional subdivisions of the brain .
Cefotetan - induced immune hemolytic anemia .	Cefotetan - induced immune disease* hemolytic anemia *disease .
Immune hemolytic anemia due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .	Immune disease* hemolytic anemia *disease due to a drug - adsorption mechanism has been described primarily in patients receiving penicillins and first - generation cephalosporins .
We describe a patient who developed anemia while receiving intravenous cefotetan .	We describe a patient who developed disease* anemia *disease while receiving intravenous cefotetan .
Cefotetan - dependent antibodies were detected in the patient ' s serum and in an eluate prepared from his red blood cells .	Cefotetan - dependent antibodies were detected in the patient ' s serum and in an eluate prepared from his red blood cells .
The eluate also reacted weakly with red blood cells in the absence of cefotetan , suggesting the concomitant formation of warm - reactive autoantibodies .	The eluate also reacted weakly with red blood cells in the absence of cefotetan , suggesting the concomitant formation of warm - reactive autoantibodies .
These observations , in conjunction with clinical and laboratory evidence of extravascular hemolysis , are consistent with drug - induced hemolytic anemia , possibly involving both drug - adsorption and autoantibody formation mechanisms .	These observations , in conjunction with clinical and laboratory evidence of extravascular disease* hemolysis *disease , are consistent with drug - induced disease* hemolytic anemia *disease , possibly involving both drug - adsorption and autoantibody formation mechanisms .
This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins .	This case emphasizes the need for increased awareness of hemolytic reactions to all cephalosporins .
Use of dexamethasone with mesna for the prevention of ifosfamide - induced hemorrhagic cystitis .	Use of dexamethasone with mesna for the prevention of ifosfamide - induced disease* hemorrhagic cystitis *disease .
AIM : Hemorrhagic cystitis ( HC ) is a limiting side - effect of chemotherapy with ifosfamide ( IFS ) .	AIM : disease* Hemorrhagic cystitis *disease ( disease* HC *disease ) is a limiting side - effect of chemotherapy with ifosfamide ( IFS ) .
In the study presented here , we investigated the use of dexamethasone in combination with mesna for the prevention of IFS - induced HC .	In the study presented here , we investigated the use of dexamethasone in combination with mesna for the prevention of IFS - induced disease* HC *disease .
METHODS : Male Wistar rats ( 150 - 200 g ; 6 rats per group ) were treated with saline or mesna 5 min ( i . p . ) before and 2 and 6 h after ( v . o . ) administration of IFS .	METHODS : Male Wistar rats ( 150 - 200 g ; 6 rats per group ) were treated with saline or mesna 5 min ( i . p . ) before and 2 and 6 h after ( v . o . ) administration of IFS .
One , two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna .	One , two or three doses of mesna were replaced with dexamethasone alone or with dexamethasone plus mesna .
Cystitis was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis .	disease* Cystitis *disease was evaluated 24 h after its induction by the changes in bladder wet weight and by macroscopic and microscopic analysis .
RESULTS : The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84 . 79 % and 89 . 13 % , respectively .	RESULTS : The replacement of the last dose or the last two doses of mesna with dexamethasone reduced the increase in bladder wet weight induced by IFS by 84 . 79 % and 89 . 13 % , respectively .
In addition , it almost abolished the macroscopic and microscopic alterations induced by IFS .	In addition , it almost abolished the macroscopic and microscopic alterations induced by IFS .
Moreover , the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically .	Moreover , the addition of dexamethasone to the last two doses of mesna was more efficient than three doses of mesna alone when evaluated microscopically .
CONCLUSION : Dexamethasone in combination with mesna was efficient in blocking IFS - induced HC .	CONCLUSION : Dexamethasone in combination with mesna was efficient in blocking IFS - induced disease* HC *disease .
However , the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent HC .	However , the replacement of last two doses of mesna with saline or all of the mesna doses with dexamethasone did not prevent disease* HC *disease .
All - trans - retinoic acid - induced erythema nodosum in patients with acute promyelocytic leukemia .	All - trans - retinoic acid - induced disease* erythema nodosum *disease in patients with disease* acute promyelocytic leukemia *disease .
Erythema nodosum associated with all - trans - retinoic acid ( ATRA ) for acute promyelocytic leukemia ( APL ) is very rare .	disease* Erythema nodosum *disease associated with all - trans - retinoic acid ( ATRA ) for disease* acute promyelocytic leukemia *disease ( disease* APL *disease ) is very rare .
We describe four patients with classic APL who developed erythema nodosum during ATRA therapy .	We describe four patients with classic disease* APL *disease who developed disease* erythema nodosum *disease during ATRA therapy .
Fever and subsequent multiple painful erythematous nodules over extremities developed on D11 , D16 , D17 , and D19 , respectively , after ATRA therapy .	disease* Fever *disease and subsequent multiple disease* painful disease* erythematous nodules *disease over extremities developed on D11 , D16 , D17 , and D19 , respectively , after ATRA therapy .
The skin biopsy taken from each patient was consistent with erythema nodosum .	The skin biopsy taken from each patient was consistent with disease* erythema nodosum *disease .
All patients received short course of steroids .	All patients received short course of steroids .
Fever subsided rapidly and the skin lesions regressed completely .	disease* Fever *disease subsided rapidly and the skin lesions regressed completely .
All patients achieved complete remission without withdrawal of ATRA .	All patients achieved complete remission without withdrawal of ATRA .
ATRA seemed to be the most possible etiology of erythema nodosum in our patients .	ATRA seemed to be the most possible etiology of disease* erythema nodosum *disease in our patients .
Short - term use of steroid is very effective in ATRA - induced erythema nodosum .	Short - term use of steroid is very effective in ATRA - induced disease* erythema nodosum *disease .
Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala - kindled rats .	Effect of some convulsants on the protective activity of loreclezole and its combinations with valproate or clonazepam in amygdala - kindled rats .
Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both seizure and afterdischarge durations .	Loreclezole ( 5 mg / kg ) exerted a significant protective action in amygdala - kindled rats , reducing both disease* seizure *disease and afterdischarge durations .
The combinations of loreclezole ( 2 . 5 mg / kg ) with valproate , clonazepam , or carbamazepine ( applied at their subprotective doses ) also exhibited antiseizure effect in this test .	The combinations of loreclezole ( 2 . 5 mg / kg ) with valproate , clonazepam , or carbamazepine ( applied at their subprotective doses ) also exhibited antiseizure effect in this test .
However , only two first combinations occurred to be of pharmacodynamic nature .	However , only two first combinations occurred to be of pharmacodynamic nature .
Among several chemoconvulsants , bicuculline , N - methyl - D - aspartic acid and BAY k - 8644 ( the opener of L - type calcium channels ) reversed the protective activity of loreclezole alone and its combination with valproate .	Among several chemoconvulsants , bicuculline , N - methyl - D - aspartic acid and BAY k - 8644 ( the opener of L - type calcium channels ) reversed the protective activity of loreclezole alone and its combination with valproate .
On the other hand , bicuculline , aminophylline and BAY k - 8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam .	On the other hand , bicuculline , aminophylline and BAY k - 8644 inhibited the anticonvulsive action of loreclezole combined with clonazepam .
The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L - type of calcium channels .	The results support the hypothesis that the protective activity of loreclezole and its combinations with other antiepileptics may involve potentiation of GABAergic neurotransmission and blockade of L - type of calcium channels .
Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis .	Mitochondrial DNA and its respiratory chain products are defective in doxorubicin disease* nephrosis *disease .
BACKGROUND : Doxorubicin induces a self - perpetuating nephropathy characterized by early glomerular and late - onset tubular lesions in rats .	BACKGROUND : Doxorubicin induces a self - perpetuating disease* nephropathy *disease characterized by early disease* glomerular and late - onset tubular lesions *disease in rats .
We investigated the potential role of mitochondrial injury in the onset of these lesions .	We investigated the potential role of disease* mitochondrial injury *disease in the onset of these lesions .
METHODS : Rats were treated with intravenous doxorubicin ( 1 mg kg ( - 1 ) week ( - 1 ) ) for 7 weeks and were sacrificed either 1 week ( ' short - term ' ) or 30 weeks ( ' long - term ' ) following the last dose .	METHODS : Rats were treated with intravenous doxorubicin ( 1 mg kg ( - 1 ) week ( - 1 ) ) for 7 weeks and were sacrificed either 1 week ( ' short - term ' ) or 30 weeks ( ' long - term ' ) following the last dose .
Additional rats received a single dose either 6 days or 2 h prior to euthanasia .	Additional rats received a single dose either 6 days or 2 h prior to euthanasia .
All rats were killed at 48 weeks of age .	All rats were killed at 48 weeks of age .
Glomerular and tubular injury was monitored and correlated to the activity or expression of respiratory chain components .	disease* Glomerular and tubular injury *disease was monitored and correlated to the activity or expression of respiratory chain components .
Finally , we quantified both nuclear and mitochondrial DNA ( mtDNA ) as well as superoxide production and the 4834 base pair ' common ' mtDNA deletion .	Finally , we quantified both nuclear and mitochondrial DNA ( mtDNA ) as well as superoxide production and the 4834 base pair ' common ' mtDNA deletion .
RESULTS : The ' long - term ' group had significant glomerular and tubular lesions , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased citrate synthase activity .	RESULTS : The ' long - term ' group had significant disease* glomerular and tubular lesions *disease , depressed activities of mtDNA - encoded NADH dehydrogenase and cytochrome - c oxidase ( COX ) and increased citrate synthase activity .
In addition , expression of the mtDNA - encoded COX subunit I was reduced and mtDNA levels were decreased .	In addition , expression of the mtDNA - encoded COX subunit I was reduced and mtDNA levels were decreased .
In ' short - term ' rats , there were fewer tubular lesions , but similar numbers of glomerular lesions activity .	In ' short - term ' rats , there were fewer disease* tubular lesions *disease , but similar numbers of disease* glomerular lesions *disease activity .
Among all animals , glomerular and tubular injury were inversely correlated with mtDNA levels , mtDNA - encoded respiratory chain activities and with the expression of the mtDNA - encoded respiratory chain subunit COX - I .	Among all animals , disease* glomerular and tubular injury *disease were inversely correlated with mtDNA levels , mtDNA - encoded respiratory chain activities and with the expression of the mtDNA - encoded respiratory chain subunit COX - I .
Injury was positively correlated with superoxide production and the activities of nucleus - encoded mitochondrial or cytoplasmic enzymes .	Injury was positively correlated with superoxide production and the activities of nucleus - encoded mitochondrial or cytoplasmic enzymes .
Kidneys from the ' long - term ' group showed more mtDNA deletions than in ' short - term ' animals and these were not observed in the other groups .	Kidneys from the ' long - term ' group showed more mtDNA deletions than in ' short - term ' animals and these were not observed in the other groups .
CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced renal lesions .	CONCLUSIONS : These results suggest an important role for quantitative and qualitative mtDNA alterations through the reduction of mtDNA - encoded respiratory chain function and induction of superoxide in doxorubicin - induced disease* renal lesions *disease .
A randomized , placebo - controlled , crossover study of ephedrine for SSRI - induced female sexual dysfunction .	A randomized , placebo - controlled , crossover study of ephedrine for SSRI - induced female disease* sexual dysfunction *disease .
The objective of this study was to determine whether ephedrine , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced sexual dysfunction .	The objective of this study was to determine whether ephedrine , an alpha - and beta - adrenergic agonist previously shown to enhance genital blood flow in women , has beneficial effects in reversing antidepressant - induced disease* sexual dysfunction *disease .
Nineteen sexually dysfunctional women receiving either fluoxetine , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .	Nineteen disease* sexually dysfunctional *disease women receiving either fluoxetine , sertraline , or paroxetine participated in an eight - week , double - blind , placebo - controlled , cross - over study of the effects of ephedrine ( 50 mg ) on self - report measures of sexual desire , arousal , orgasm , and sexual satisfaction .
Although there were significant improvements relative to baseline in sexual desire and orgasm intensity / pleasure on 50 mg ephedrine 1 - hr prior to sexual activity , significant improvements in these measures , as well as in sexual arousal and orgasmic ability also were noted with placebo .	Although there were significant improvements relative to baseline in sexual desire and orgasm intensity / pleasure on 50 mg ephedrine 1 - hr prior to sexual activity , significant improvements in these measures , as well as in sexual arousal and orgasmic ability also were noted with placebo .
These findings highlight the importance of conducting placebo - controlled trials for this condition .	These findings highlight the importance of conducting placebo - controlled trials for this condition .
Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition ?	Does hormone therapy for the treatment of disease* breast cancer *disease have a disease* detrimental effect on memory and cognition *disease ?
A pilot study .	A pilot study .
This pilot study examines whether hormone therapy for breast cancer affects cognition .	This pilot study examines whether hormone therapy for disease* breast cancer *disease affects cognition .
Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without breast cancer ( n = 35 ) completed a battery of neuropsychological measures .	Patients participating in a randomised trial of anastrozole , tamoxifen alone or combined ( ATAC ) ( n = 94 ) and a group of women without disease* breast cancer *disease ( n = 35 ) completed a battery of neuropsychological measures .
Compared with the control group , the patients were impaired on a processing speed task ( p = 0 . 032 ) and on a measure of immediate verbal memory ( p = 0 . 026 ) after controlling for the use of hormone replacement therapy in both groups .	Compared with the control group , the patients were impaired on a processing speed task ( p = 0 . 032 ) and on a measure of immediate verbal memory ( p = 0 . 026 ) after controlling for the use of hormone replacement therapy in both groups .
Patient group performance was not significantly related to length of treatment or measures of psychological morbidity .	Patient group performance was not significantly related to length of treatment or measures of psychological morbidity .
The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of breast cancer .	The results showed specific impairments in processing speed and verbal memory in women receiving hormonal therapy for the treatment of disease* breast cancer *disease .
Verbal memory may be especially sensitive to changes in oestrogen levels , a finding commonly reported in studies of hormone replacement therapy in healthy women .	Verbal memory may be especially sensitive to changes in oestrogen levels , a finding commonly reported in studies of hormone replacement therapy in healthy women .
In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly .	In view of the increased use of hormone therapies in an adjuvant and preventative setting their impact on cognitive functioning should be investigated more thoroughly .
Expression of p300 protects cardiac myocytes from apoptosis in vivo .	Expression of p300 protects cardiac myocytes from apoptosis in vivo .
Doxorubicin is an anti - tumor agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .	Doxorubicin is an anti - disease* tumor *disease agent that represses cardiac - specific gene expression and induces myocardial cell apoptosis .
Doxorubicin depletes cardiac p300 , a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes .	Doxorubicin depletes cardiac p300 , a transcriptional coactivator that is required for the maintenance of the differentiated phenotype of cardiac myocytes .
However , the role of p300 in protection against doxorubicin - induced apoptosis is unknown .	However , the role of p300 in protection against doxorubicin - induced apoptosis is unknown .
Transgenic mice overexpressing p300 in the heart and wild - type mice were subjected to doxorubicin treatment .	Transgenic mice overexpressing p300 in the heart and wild - type mice were subjected to doxorubicin treatment .
Compared with wild - type mice , transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha - sarcomeric actin .	Compared with wild - type mice , transgenic mice exhibited higher survival rate as well as more preserved left ventricular function and cardiac expression of alpha - sarcomeric actin .
Doxorubicin induced myocardial cell apoptosis in wild - type mice but not in transgenic mice .	Doxorubicin induced myocardial cell apoptosis in wild - type mice but not in transgenic mice .
Expression of p300 increased the cardiac level of bcl - 2 and mdm - 2 , but not that of p53 or other members of the bcl - 2 family .	Expression of p300 increased the cardiac level of bcl - 2 and mdm - 2 , but not that of p53 or other members of the bcl - 2 family .
These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute heart failure in adult mice in vivo .	These findings demonstrate that overexpression of p300 protects cardiac myocytes from doxorubicin - induced apoptosis and reduces the extent of acute disease* heart failure *disease in adult mice in vivo .
Methimazole - induced cholestatic jaundice .	Methimazole - induced disease* cholestatic jaundice *disease .
Methimazole is a widely used and generally well - tolerated antithyroid agent .	Methimazole is a widely used and generally well - tolerated antithyroid agent .
A 43 - year - old woman had severe jaundice and itching 1 month after receiving methimazole ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of hyperthyroidism .	A 43 - year - old woman had severe disease* jaundice *disease and disease* itching *disease 1 month after receiving methimazole ( 10 mg tid ) and propranolol ( 20 mg tid ) for treatment of disease* hyperthyroidism *disease .
The patient continued treatment for another 4 days after the appearance of jaundice until she finished both medications .	The patient continued treatment for another 4 days after the appearance of disease* jaundice *disease until she finished both medications .
When seen at the emergency department 2 weeks later , she still had severe icterus , pruritus , and hyperbilirubinemia , formed mainly of the conjugated fraction .	When seen at the emergency department 2 weeks later , she still had severe disease* icterus *disease , disease* pruritus *disease , and disease* hyperbilirubinemia *disease , formed mainly of the conjugated fraction .
Methimazole - induced cholestasis was diagnosed , and propranolol therapy was resumed .	Methimazole - induced disease* cholestasis *disease was diagnosed , and propranolol therapy was resumed .
Over the following 9 days , the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole .	Over the following 9 days , the symptoms improved and plasma bilirubin levels were normal after 12 weeks without methimazole .
In rare cases within the first few weeks of therapy , this drug can cause severe and reversible cholestatic jaundice .	In rare cases within the first few weeks of therapy , this drug can cause severe and reversible disease* cholestatic jaundice *disease .
Physicians and patients should be aware of this adverse effect so that , upon occurrence , they can discontinue methimazole therapy and avoid unnecessary invasive procedures .	Physicians and patients should be aware of this adverse effect so that , upon occurrence , they can discontinue methimazole therapy and avoid unnecessary invasive procedures .
Atrial fibrillation following chemotherapy for stage IIIE diffuse large B - cell gastric lymphoma in a patient with myotonic dystrophy ( Steinert ' s disease ) .	disease* Atrial fibrillation *disease following chemotherapy for stage IIIE diffuse large B - cell disease* gastric lymphoma *disease in a patient with disease* myotonic dystrophy *disease ( disease* Steinert ' s disease *disease ) .
The authors describe the unusual association between diffuse B - cell gastric lymphoma and myotonic dystrophy , the most common form of adult muscular dystrophy , and sudden atrial fibrillation following one cycle of doxorubicin - based chemotherapy in the same patient .	The authors describe the unusual association between diffuse B - cell disease* gastric lymphoma *disease and disease* myotonic dystrophy *disease , the most common form of adult disease* muscular dystrophy *disease , and sudden disease* atrial fibrillation *disease following one cycle of doxorubicin - based chemotherapy in the same patient .
Atrial fibrillation or other cardiac arrhythmias are unusual complications in patients treated with chemotherapy .	disease* Atrial fibrillation *disease or other disease* cardiac arrhythmias *disease are unusual complications in patients treated with chemotherapy .
The cardiac toxicity intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the arrhythmia in the predisposed myocardium of this patient .	The disease* cardiac toxicity *disease intrinsically associated with the aggressive chemotherapy employed could function as a triggering factor for the disease* arrhythmia *disease in the predisposed myocardium of this patient .
Hypersensitivity immune reaction as a mechanism for dilevalol - associated hepatitis .	disease* Hypersensitivity *disease immune reaction as a mechanism for dilevalol - associated disease* hepatitis *disease .
OBJECTIVE : To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced liver injury .	OBJECTIVE : To assess lymphocyte reactivity to dilevalol and to serum containing putative ex vivo dilevalol antigens or metabolites in a case of dilevalol - induced disease* liver injury *disease .
PATIENT : A 58 - year - old woman with a clinical diagnosis of dilevalol - induced liver injury .	PATIENT : A 58 - year - old woman with a clinical diagnosis of dilevalol - induced disease* liver injury *disease .
METHODS : Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake .	METHODS : Peripheral blood mononuclear cells collected from the patient were cultured in the presence of a solution of dilevalol and also with sera collected from a volunteer before and after dilevalol intake .
A similar protocol was performed with lymphocytes from a healthy subject .	A similar protocol was performed with lymphocytes from a healthy subject .
RESULTS : No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions .	RESULTS : No lymphocyte proliferation was observed either in the patient or in the healthy volunteer in the presence of dilevalol solutions .
A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake .	A significant proliferative response to serum collected after dilevalol intake was observed in the case of the patient compared with the proliferative response to the serum collected before the drug intake .
No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions .	No reactivity was found when lymphocytes from the healthy subject were tested under similar conditions .
CONCLUSIONS : The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced liver injury .	CONCLUSIONS : The methodology used allowed the detection of lymphocyte sensitization to sera containing ex vivo - prepared dilevalol antigens , suggesting the involvement of an immunologic mechanism in dilevalol - induced disease* liver injury *disease .
Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside - induced nephrotic syndrome in rats .	Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside - induced disease* nephrotic syndrome *disease in rats .
Nephrotic syndrome is often accompanied by sodium retention and generalized edema .	disease* Nephrotic syndrome *disease is often accompanied by sodium retention and generalized disease* edema *disease .
However , the molecular basis for the decreased renal sodium excretion remains undefined .	However , the molecular basis for the decreased renal sodium excretion remains undefined .
We hypothesized that epithelial Na channel ( ENaC ) subunit dysregulation may be responsible for the increased sodium retention .	We hypothesized that epithelial Na channel ( ENaC ) subunit dysregulation may be responsible for the increased sodium retention .
An experimental group of rats was treated with puromycin aminonucleoside ( PAN ; 180 mg / kg iv ) , whereas the control group received only vehicle .	An experimental group of rats was treated with puromycin aminonucleoside ( PAN ; 180 mg / kg iv ) , whereas the control group received only vehicle .
After 7 days , PAN treatment induced significant proteinuria , hypoalbuminemia , decreased urinary sodium excretion , and extensive ascites .	After 7 days , PAN treatment induced significant disease* proteinuria *disease , disease* hypoalbuminemia *disease , decreased urinary sodium excretion , and extensive disease* ascites *disease .
The protein abundance of alpha - ENaC and beta - ENaC was increased in the inner stripe of the outer medulla ( ISOM ) and in the inner medulla ( IM ) but was not altered in the cortex .	The protein abundance of alpha - ENaC and beta - ENaC was increased in the inner stripe of the outer medulla ( ISOM ) and in the inner medulla ( IM ) but was not altered in the cortex .
gamma - ENaC abundance was increased in the cortex , ISOM , and IM .	gamma - ENaC abundance was increased in the cortex , ISOM , and IM .
Immunoperoxidase brightfield - and laser - scanning confocal fluorescence microscopy demonstrated increased targeting of alpha - ENaC , beta - ENaC , and gamma - ENaC subunits to the apical plasma membrane in the distal convoluted tubule ( DCT2 ) , connecting tubule , and cortical and medullary collecting duct segments .	Immunoperoxidase brightfield - and laser - scanning confocal fluorescence microscopy demonstrated increased targeting of alpha - ENaC , beta - ENaC , and gamma - ENaC subunits to the apical plasma membrane in the distal convoluted tubule ( DCT2 ) , connecting tubule , and cortical and medullary collecting duct segments .
Immunoelectron microscopy further revealed an increased labeling of alpha - ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN - treated rats , indicating enhanced apical targeting of alpha - ENaC subunits .	Immunoelectron microscopy further revealed an increased labeling of alpha - ENaC in the apical plasma membrane of cortical collecting duct principal cells of PAN - treated rats , indicating enhanced apical targeting of alpha - ENaC subunits .
In contrast , the protein abundances of Na ( + ) / H ( + ) exchanger type 3 ( NHE3 ) , Na ( + ) - K ( + ) - 2Cl ( - ) cotransporter ( BSC - 1 ) , and thiazide - sensitive Na ( + ) - Cl ( - ) cotransporter ( TSC ) were decreased .	In contrast , the protein abundances of Na ( + ) / H ( + ) exchanger type 3 ( NHE3 ) , Na ( + ) - K ( + ) - 2Cl ( - ) cotransporter ( BSC - 1 ) , and thiazide - sensitive Na ( + ) - Cl ( - ) cotransporter ( TSC ) were decreased .
Moreover , the abundance of the alpha ( 1 ) - subunit of the Na - K - ATPase was decreased in the cortex and ISOM , but it remained unchanged in the IM .	Moreover , the abundance of the alpha ( 1 ) - subunit of the Na - K - ATPase was decreased in the cortex and ISOM , but it remained unchanged in the IM .
In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with PAN - induced nephrotic syndrome .	In conclusion , the increased or sustained expression of ENaC subunits combined with increased apical targeting in the DCT2 , connecting tubule , and collecting duct are likely to play a role in the sodium retention associated with PAN - induced disease* nephrotic syndrome *disease .
The decreased abundance of NHE3 , BSC - 1 , TSC , and Na - K - ATPase may play a compensatory role to promote sodium excretion .	The decreased abundance of NHE3 , BSC - 1 , TSC , and Na - K - ATPase may play a compensatory role to promote sodium excretion .
Pallidal stimulation : an alternative to pallidotomy ?	Pallidal stimulation : an alternative to pallidotomy ?
A resurgence of interest in the surgical treatment of Parkinson ' s disease ( PD ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .	A resurgence of interest in the surgical treatment of disease* Parkinson ' s disease *disease ( disease* PD *disease ) came with the rediscovery of posteroventral pallidotomy by Laitinen in 1985 .
Laitinen ' s procedure improved most symptoms in drug - resistant PD , which engendered wide interest in the neurosurgical community .	Laitinen ' s procedure improved most symptoms in drug - resistant disease* PD *disease , which engendered wide interest in the neurosurgical community .
Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .	Another lesioning procedure , ventrolateral thalamotomy , has become a powerful alternative to stimulate the nucleus ventralis intermedius , producing high long - term success rates and low morbidity rates .
Pallidal stimulation has not met with the same success .	Pallidal stimulation has not met with the same success .
According to the literature pallidotomy improves the " on " symptoms of PD , such as dyskinesias , as well as the " off " symptoms , such as rigidity , bradykinesia , and on - off fluctuations .	According to the literature pallidotomy improves the " on " symptoms of disease* PD *disease , such as disease* dyskinesias *disease , as well as the " off " symptoms , such as disease* rigidity *disease , disease* bradykinesia *disease , and on - off fluctuations .
Pallidal stimulation improves bradykinesia and rigidity to a minor extent ; however , its strength seems to be in improving levodopa - induced dyskinesias .	Pallidal stimulation improves disease* bradykinesia *disease and disease* rigidity *disease to a minor extent ; however , its strength seems to be in improving levodopa - induced disease* dyskinesias *disease .
Stimulation often produces an improvement in the hyper - or dyskinetic upper limbs , but increases the " freezing " phenomenon in the lower limbs at the same time .	Stimulation often produces an improvement in the disease* hyper - or dyskinetic *disease upper limbs , but increases the " freezing " phenomenon in the lower limbs at the same time .
Considering the small increase in the patient ' s independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .	Considering the small increase in the patient ' s independence , the high costs of bilateral implants , and the difficulty most patients experience in handling the devices , the question arises as to whether bilateral pallidal stimulation is a real alternative to pallidotomy .
Effects of the cyclooxygenase - 2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis .	Effects of the cyclooxygenase - 2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular disease* thrombotic *disease events in patients with disease* arthritis *disease .
There have been concerns that the risk of cardiovascular thrombotic events may be higher with cyclooxygenase ( COX ) - 2 - specific inhibitors than nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) .	There have been concerns that the risk of cardiovascular disease* thrombotic *disease events may be higher with cyclooxygenase ( COX ) - 2 - specific inhibitors than nonselective nonsteroidal antiinflammatory drugs ( NSAIDs ) .
We evaluated cardiovascular event data for valdecoxib , a new COX - 2 - specific inhibitor in approximately 8000 patients with osteoarthritis and rheumatoid arthritis treated with this agent in randomized clinical trials .	We evaluated cardiovascular event data for valdecoxib , a new COX - 2 - specific inhibitor in approximately 8000 patients with disease* osteoarthritis *disease and disease* rheumatoid arthritis *disease treated with this agent in randomized clinical trials .
The incidence of cardiovascular thrombotic events ( cardiac , cerebrovascular and peripheral vascular , or arterial thrombotic ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized osteoarthritis and rheumatoid arthritis trials that were 6 - 52 weeks in duration .	The incidence of cardiovascular disease* thrombotic *disease events ( cardiac , cerebrovascular and peripheral vascular , or arterial disease* thrombotic *disease ) was determined by analyzing pooled valdecoxib ( 10 - 80 mg daily ) , nonselective NSAID ( diclofenac 75 mg bid , ibuprofen 800 mg tid , or naproxen 500 mg bid ) and placebo data from 10 randomized disease* osteoarthritis *disease and disease* rheumatoid arthritis *disease trials that were 6 - 52 weeks in duration .
The incidence rates of events were determined in all patients ( n = 7934 ) and in users of low - dose ( < or = 325 mg daily ) aspirin ( n = 1051 ) and nonusers of aspirin ( n = 6883 ) .	The incidence rates of events were determined in all patients ( n = 7934 ) and in users of low - dose ( < or = 325 mg daily ) aspirin ( n = 1051 ) and nonusers of aspirin ( n = 6883 ) .
Crude and exposure - adjusted incidences of thrombotic events were similar for valdecoxib , NSAIDs , and placebo .	Crude and exposure - adjusted incidences of disease* thrombotic *disease events were similar for valdecoxib , NSAIDs , and placebo .
The risk of serious thrombotic events was also similar for each valdecoxib dose .	The risk of serious disease* thrombotic *disease events was also similar for each valdecoxib dose .
Thrombotic risk was consistently higher for users of aspirin users than nonusers of aspirin ( placebo , 1 . 4 % vs . 0 % ; valdecoxib , 1 . 7 % vs . 0 . 2 % ; NSAIDs , 1 . 9 % vs . 0 . 5 % ) .	disease* Thrombotic *disease risk was consistently higher for users of aspirin users than nonusers of aspirin ( placebo , 1 . 4 % vs . 0 % ; valdecoxib , 1 . 7 % vs . 0 . 2 % ; NSAIDs , 1 . 9 % vs . 0 . 5 % ) .
The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses .	The rates of events in users of aspirin were similar for all 3 treatment groups and across valdecoxib doses .
Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials .	Short - and intermediate - term treatment with therapeutic ( 10 or 20 mg daily ) and supratherapeutic ( 40 or 80 mg daily ) valdecoxib doses was not associated with an increased incidence of disease* thrombotic *disease events relative to nonselective NSAIDs or placebo in disease* osteoarthritis *disease and disease* rheumatoid arthritis *disease patients in controlled clinical trials .
Hypersensitivity myocarditis complicating hypertrophic cardiomyopathy heart .	disease* Hypersensitivity disease* myocarditis *disease complicating disease* hypertrophic cardiomyopathy *disease heart .
The present report describes a case of eosinophilic myocarditis complicating hypertrophic cardiomyopathy .	The present report describes a case of disease* eosinophilic myocarditis *disease complicating disease* hypertrophic cardiomyopathy *disease .
The 47 - year - old female patient , known to have hypertrophic cardiomyopathy , was admitted with biventricular failure and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation .	The 47 - year - old female patient , known to have disease* hypertrophic cardiomyopathy *disease , was admitted with disease* biventricular failure *disease and managed aggressively with dobutamine infusion and other drugs while being assessed for heart transplantation .
On transthoracic echocardiogram , she had moderate left ventricular dysfunction with regional variability and moderate mitral regurgitation .	On transthoracic echocardiogram , she had moderate disease* left ventricular dysfunction *disease with regional variability and moderate disease* mitral regurgitation *disease .
The recipient ' s heart showed the features of apical hypertrophic cardiomyopathy and myocarditis with abundant eosinophils .	The recipient ' s heart showed the features of apical disease* hypertrophic cardiomyopathy *disease and disease* myocarditis *disease with abundant eosinophils .
Myocarditis is rare and eosinophilic myocarditis is rarer .	disease* Myocarditis *disease is rare and disease* eosinophilic myocarditis *disease is rarer .
It is likely that the hypersensitivity ( eosinophilic ) myocarditis was related to dobutamine infusion therapy .	It is likely that the disease* hypersensitivity *disease ( disease* eosinophilic *disease ) disease* myocarditis *disease was related to dobutamine infusion therapy .
Eosinophilic myocarditis has been reported with an incidence of 2 . 4 % to 7 . 2 % in explanted hearts and may be related to multidrug therapy .	disease* Eosinophilic myocarditis *disease has been reported with an incidence of 2 . 4 % to 7 . 2 % in explanted hearts and may be related to multidrug therapy .
Time trends in warfarin - associated hemorrhage .	Time trends in warfarin - associated disease* hemorrhage *disease .
The annual incidence of warfarin - related bleeding at Brigham and Women ' s Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .	The annual incidence of warfarin - related disease* bleeding *disease at Brigham and Women ' s Hospital increased from 0 . 97 / 1 , 000 patient admissions in the first time period ( January 1995 to October 1998 ) to 1 . 19 / 1 , 000 patient admissions in the second time period ( November 1998 to August 2002 ) of this study .
The proportion of patients with major and intracranial bleeding increased from 20 . 2 % and 1 . 9 % , respectively , in the first time period , to 33 . 3 % and 7 . 8 % , respectively , in the second .	The proportion of patients with major and disease* intracranial bleeding *disease increased from 20 . 2 % and 1 . 9 % , respectively , in the first time period , to 33 . 3 % and 7 . 8 % , respectively , in the second .
Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers .	Yohimbine treatment of disease* sexual side effects *disease induced by serotonin reuptake blockers .
BACKGROUND : Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of male impotence .	BACKGROUND : Preclinical and clinical studies suggest that yohimbine facilitates sexual behavior and may be helpful in the treatment of disease* male impotence *disease .
A single case report suggests that yohimbine may be used to treat the sexual side effects of clomipramine .	A single case report suggests that yohimbine may be used to treat the disease* sexual side effects *disease of clomipramine .
This study evaluated yohimbine as a treatment for the sexual side effects caused by serotonin reuptake blockers .	This study evaluated yohimbine as a treatment for the disease* sexual side effects *disease caused by serotonin reuptake blockers .
METHOD : Six patients with either obsessive compulsive disorder , trichotillomania , anxiety , or affective disorders who suffered sexual side effects after treatment with serotonin reuptake blockers were given yohimbine on a p . r . n . basis in an open clinical trial .	METHOD : Six patients with either disease* obsessive compulsive disorder *disease , disease* trichotillomania *disease , disease* anxiety *disease , or disease* affective disorders *disease who suffered disease* sexual side effects *disease after treatment with serotonin reuptake blockers were given yohimbine on a p . r . n . basis in an open clinical trial .
Various doses of yohimbine were used to determine the ideal dose for each patient .	Various doses of yohimbine were used to determine the ideal dose for each patient .
RESULTS : Five of the six patients experienced improved sexual functioning after taking yohimbine .	RESULTS : Five of the six patients experienced improved sexual functioning after taking yohimbine .
One patient who failed to comply with yohimbine treatment had no therapeutic effects .	One patient who failed to comply with yohimbine treatment had no therapeutic effects .
Side effects of yohimbine included excessive sweating , increased anxiety , and a wound - up feeling in some patients .	Side effects of yohimbine included excessive sweating , increased disease* anxiety *disease , and a wound - up feeling in some patients .
CONCLUSION : The results of this study indicate that yohimbine may be an effective treatment for the sexual side effects caused by serotonin reuptake blockers .	CONCLUSION : The results of this study indicate that yohimbine may be an effective treatment for the disease* sexual side effects *disease caused by serotonin reuptake blockers .
Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication .	Future controlled studies are needed to further investigate the effectiveness and safety of yohimbine for this indication .
Hemorrhagic cystitis complicating bone marrow transplantation .	disease* Hemorrhagic cystitis *disease complicating bone marrow transplantation .
Hemorrhagic cystitis is a potentially serious complication of high - dose cyclophosphamide therapy administered before bone marrow transplantation .	disease* Hemorrhagic cystitis *disease is a potentially serious complication of high - dose cyclophosphamide therapy administered before bone marrow transplantation .
As standard practice at our institution , patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation .	As standard practice at our institution , patients who are scheduled to receive a bone marrow transplant are treated prophylactically with forced hydration and bladder irrigation .
In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of cyclophosphamide that causes hemorrhagic cystitis .	In an attempt to obviate the inconvenience of bladder irrigation , we conducted a feasibility trial of uroprophylaxis with mesna , which neutralizes the hepatic metabolite of cyclophosphamide that causes disease* hemorrhagic cystitis *disease .
Of 97 patients who received standard prophylaxis , 4 had symptomatic hemorrhagic cystitis .	Of 97 patients who received standard prophylaxis , 4 had symptomatic disease* hemorrhagic cystitis *disease .
In contrast , two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe hemorrhagic cystitis for at least 2 weeks .	In contrast , two of four consecutive patients who received mesna uroprophylaxis before allogeneic bone marrow transplantation had severe disease* hemorrhagic cystitis *disease for at least 2 weeks .
Because of this suboptimal result , we resumed the use of bladder irrigation and forced hydration to minimize the risk of hemorrhagic cystitis .	Because of this suboptimal result , we resumed the use of bladder irrigation and forced hydration to minimize the risk of disease* hemorrhagic cystitis *disease .
Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases , with special reference to systemic sclerosis and multiple sclerosis .	Consensus statement concerning disease* cardiotoxicity *disease occurring during haematopoietic stem cell transplantation in the treatment of disease* autoimmune diseases *disease , with special reference to disease* systemic sclerosis *disease and disease* multiple sclerosis *disease .
Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe autoimmune diseases .	Autologous haematopoietic stem cell transplantation is now a feasible and effective treatment for selected patients with severe disease* autoimmune diseases *disease .
Worldwide , over 650 patients have been transplanted in the context of phase I and II clinical trials .	Worldwide , over 650 patients have been transplanted in the context of phase I and II clinical trials .
The results are encouraging enough to begin randomised phase III trials .	The results are encouraging enough to begin randomised phase III trials .
However , as predicted , significant transplant - related morbidity and mortality have been observed .	However , as predicted , significant transplant - related morbidity and mortality have been observed .
This is primarily due to complications related to either the stage of the disease at transplant or due to infections .	This is primarily due to complications related to either the stage of the disease at transplant or due to disease* infections *disease .
The number of deaths related to cardiac toxicity is low .	The number of deaths related to disease* cardiac toxicity *disease is low .
However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying heart damage , for example , systemic sclerosis patients .	However , caution is required when cyclophosphamide or anthracyclines such as mitoxantrone are used in patients with a possible underlying disease* heart damage *disease , for example , disease* systemic sclerosis *disease patients .
In November 2002 , a meeting was held in Florence , bringing together a number of experts in various fields , including rheumatology , cardiology , neurology , pharmacology and transplantation medicine .	In November 2002 , a meeting was held in Florence , bringing together a number of experts in various fields , including rheumatology , cardiology , neurology , pharmacology and transplantation medicine .
The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation autoimmune disease database , and to propose a safe approach to such patients .	The object of the meeting was to analyse existing data , both published or available , in the European Group for Blood and Marrow Transplantation disease* autoimmune disease *disease database , and to propose a safe approach to such patients .
A full cardiological assessment before and during the transplant emerged as the major recommendation .	A full cardiological assessment before and during the transplant emerged as the major recommendation .
Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes ?	Does supplemental vitamin C increase disease* cardiovascular disease *disease risk in women with disease* diabetes *disease ?
BACKGROUND : Vitamin C acts as a potent antioxidant ; however , it can also be a prooxidant and glycate protein under certain circumstances in vitro .	BACKGROUND : Vitamin C acts as a potent antioxidant ; however , it can also be a prooxidant and glycate protein under certain circumstances in vitro .
These observations led us to hypothesize that a high intake of vitamin C in diabetic persons might promote atherosclerosis .	These observations led us to hypothesize that a high intake of vitamin C in disease* diabetic *disease persons might promote disease* atherosclerosis *disease .
OBJECTIVE : The objective was to examine the relation between vitamin C intake and mortality from cardiovascular disease .	OBJECTIVE : The objective was to examine the relation between vitamin C intake and mortality from disease* cardiovascular disease *disease .
DESIGN : We studied the relation between vitamin C intake and mortality from total cardiovascular disease ( n = 281 ) , coronary artery disease ( n = 175 ) , and stroke ( n = 57 ) in 1923 postmenopausal women who reported being diabetic at baseline .	DESIGN : We studied the relation between vitamin C intake and mortality from total disease* cardiovascular disease *disease ( n = 281 ) , disease* coronary artery disease *disease ( n = 175 ) , and disease* stroke *disease ( n = 57 ) in 1923 postmenopausal women who reported being disease* diabetic *disease at baseline .
Diet was assessed with a food - frequency questionnaire at baseline , and subjects initially free of coronary artery disease were prospectively followed for 15 y .	Diet was assessed with a food - frequency questionnaire at baseline , and subjects initially free of disease* coronary artery disease *disease were prospectively followed for 15 y .
RESULTS : After adjustment for cardiovascular disease risk factors , type of diabetes medication used , duration of diabetes , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total cardiovascular disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .	RESULTS : After adjustment for disease* cardiovascular disease *disease risk factors , type of disease* diabetes *disease medication used , duration of disease* diabetes *disease , and intakes of folate , vitamin E , and beta - carotene , the adjusted relative risks of total disease* cardiovascular disease *disease mortality were 1 . 0 , 0 . 97 , 1 . 11 , 1 . 47 , and 1 . 84 ( P for trend < 0 . 01 ) across quintiles of total vitamin C intake from food and supplements .
Adjusted relative risks of coronary artery disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of stroke were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .	Adjusted relative risks of disease* coronary artery disease *disease were 1 . 0 , 0 . 81 , 0 . 99 , 1 . 26 , and 1 . 91 ( P for trend = 0 . 01 ) and of disease* stroke *disease were 1 . 0 , 0 . 52 , 1 . 23 , 2 . 22 , and 2 . 57 ( P for trend < 0 . 01 ) .
When dietary and supplemental vitamin C were analyzed separately , only supplemental vitamin C showed a positive association with mortality endpoints .	When dietary and supplemental vitamin C were analyzed separately , only supplemental vitamin C showed a positive association with mortality endpoints .
Vitamin C intake was unrelated to mortality from cardiovascular disease in the nondiabetic subjects at baseline .	Vitamin C intake was unrelated to mortality from disease* cardiovascular disease *disease in the nondiabetic subjects at baseline .
CONCLUSION : A high vitamin C intake from supplements is associated with an increased risk of cardiovascular disease mortality in postmenopausal women with diabetes .	CONCLUSION : A high vitamin C intake from supplements is associated with an increased risk of disease* cardiovascular disease *disease mortality in postmenopausal women with disease* diabetes *disease .
Optical coherence tomography can measure axonal loss in patients with ethambutol - induced optic neuropathy .	Optical coherence tomography can measure axonal loss in patients with ethambutol - induced disease* optic neuropathy *disease .
PURPOSE : To map and identify the pattern , in vivo , of axonal degeneration in ethambutol - induced optic neuropathy using optical coherence tomography ( OCT ) .	PURPOSE : To map and identify the pattern , in vivo , of disease* axonal degeneration *disease in ethambutol - induced disease* optic neuropathy *disease using optical coherence tomography ( OCT ) .
Ethambutol is an antimycobacterial agent often used to treat tuberculosis .	Ethambutol is an antimycobacterial agent often used to treat disease* tuberculosis *disease .
A serious complication of ethambutol is an optic neuropathy that impairs visual acuity , contrast sensitivity , and color vision .	A serious complication of ethambutol is an disease* optic neuropathy *disease that impairs visual acuity , contrast sensitivity , and color vision .
However , early on , when the toxic optic neuropathy is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .	However , early on , when the toxic disease* optic neuropathy *disease is mild and partly reversible , the funduscopic findings are often subtle and easy to miss .
METHODS : Three subjects with a history of ethambutol ( EMB ) - induced optic neuropathy of short - , intermediate - , and long - term visual deficits were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .	METHODS : Three subjects with a history of ethambutol ( EMB ) - induced disease* optic neuropathy *disease of short - , intermediate - , and long - term disease* visual deficits *disease were administered a full neuro - ophthalmologic examination including visual acuity , color vision , contrast sensitivity , and fundus examination .
In addition , OCT ( OCT 3000 , Humphrey - Zeiss , Dublin , CA ) was performed on both eyes of each subject using the retinal nerve fiber layer ( RNFL ) analysis protocol .	In addition , OCT ( OCT 3000 , Humphrey - Zeiss , Dublin , CA ) was performed on both eyes of each subject using the retinal nerve fiber layer ( RNFL ) analysis protocol .
OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL .	OCT interpolates data from 100 points around the optic nerve to effectively map out the RNFL .
RESULTS : The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT , n = 661 .	RESULTS : The results were compared to the calculated average RNFL of normal eyes accumulated from four prior studies using OCT , n = 661 .
In all subjects with history of EMB - induced optic neuropathy , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate visual deficits , 68 % loss ; patient C , with chronic visual deficits , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .	In all subjects with history of EMB - induced disease* optic neuropathy *disease , there was a mean loss of 72 % nerve fiber layer thickness in the temporal quadrant ( patient A , with eventual recovery of visual acuity and fields , 58 % loss ; patient B , with intermediate disease* visual deficits *disease , 68 % loss ; patient C , with chronic disease* visual deficits *disease , 90 % loss ) , with an average mean optic nerve thickness of 26 + / - 16 microm .
There was a combined mean loss of 46 % of fibers from the superior , inferior , and nasal quadrants in the ( six ) eyes of all three subjects ( mean average thickness of 55 + / - 29 microm ) .	There was a combined mean loss of 46 % of fibers from the superior , inferior , and nasal quadrants in the ( six ) eyes of all three subjects ( mean average thickness of 55 + / - 29 microm ) .
In both sets ( four ) of eyes of the subjects with persistent visual deficits ( patients B and C ) , there was an average loss of 79 % of nerve fiber thickness in the temporal quadrant .	In both sets ( four ) of eyes of the subjects with persistent disease* visual deficits *disease ( patients B and C ) , there was an average loss of 79 % of nerve fiber thickness in the temporal quadrant .
CONCLUSIONS : The OCT results in these patients with EMB - induced optic neuropathy show considerable loss especially of the temporal fibers .	CONCLUSIONS : The OCT results in these patients with EMB - induced disease* optic neuropathy *disease show considerable loss especially of the temporal fibers .
This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary optic neuropathies .	This is consistent with prior histopathological studies that show predominant loss of parvo - cellular axons ( or small - caliber axons ) within the papillo - macular bundle in toxic or hereditary disease* optic neuropathies *disease .
OCT can be a valuable tool in the quantitative analysis of optic neuropathies .	OCT can be a valuable tool in the quantitative analysis of disease* optic neuropathies *disease .
Additionally , in terms of management of EMB - induced optic neuropathy , it is important to properly manage ethambutol dosing in patients with renal impairment and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .	Additionally , in terms of management of EMB - induced disease* optic neuropathy *disease , it is important to properly manage ethambutol dosing in patients with disease* renal impairment *disease and to achieve proper transition to a maintenance dose once an appropriate loading dose has been reached .
Hypoxia in renal disease with proteinuria and / or glomerular hypertension .	disease* Hypoxia *disease in disease* renal disease *disease with disease* proteinuria *disease and / or glomerular disease* hypertension *disease .
Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .	Despite the increasing need to identify and quantify tissue oxygenation at the cellular level , relatively few methods have been available .
In this study , we developed a new hypoxia - responsive reporter vector using a hypoxia - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel hypoxia - sensing transgenic rat .	In this study , we developed a new disease* hypoxia *disease - responsive reporter vector using a disease* hypoxia *disease - responsive element of the 5 ' vascular endothelial growth factor untranslated region and generated a novel disease* hypoxia *disease - sensing transgenic rat .
We then applied this animal model to the detection of tubulointerstitial hypoxia in the diseased kidney .	We then applied this animal model to the detection of tubulointerstitial disease* hypoxia *disease in the disease* diseased kidney *disease .
With this model , we were able to identify diffuse cortical hypoxia in the puromycin aminonucleoside - induced nephrotic syndrome and focal and segmental hypoxia in the remnant kidney model .	With this model , we were able to identify diffuse cortical disease* hypoxia *disease in the puromycin aminonucleoside - induced disease* nephrotic syndrome *disease and focal and segmental disease* hypoxia *disease in the remnant kidney model .
Expression of the hypoxia - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .	Expression of the disease* hypoxia *disease - responsive transgene increased throughout the observation period , reaching 2 . 2 - fold at 2 weeks in the puromycin aminonucleoside model and 2 . 6 - fold at 4 weeks in the remnant kidney model , whereas that of vascular endothelial growth factor showed a mild decrease , reflecting distinct behaviors of the two genes .
The degree of hypoxia showed a positive correlation with microscopic tubulointerstitial injury in both models .	The degree of disease* hypoxia *disease showed a positive correlation with microscopic disease* tubulointerstitial injury *disease in both models .
Finally , we identified the localization of proliferating cell nuclear antigen - positive , ED - 1 - positive , and terminal dUTP nick - end labeled - positive cells in the hypoxic cortical area in the remnant kidney model .	Finally , we identified the localization of proliferating cell nuclear antigen - positive , ED - 1 - positive , and terminal dUTP nick - end labeled - positive cells in the disease* hypoxic *disease cortical area in the remnant kidney model .
We propose here a possible pathological tie between chronic tubulointerstitial hypoxia and progressive glomerular diseases .	We propose here a possible pathological tie between chronic tubulointerstitial disease* hypoxia *disease and progressive disease* glomerular diseases *disease .
Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C .	Adequate timing of ribavirin reduction in patients with disease* hemolysis *disease during combination therapy of interferon and ribavirin for disease* chronic hepatitis C *disease .
BACKGROUND : Hemolytic anemia is one of the major adverse events of the combination therapy of interferon and ribavirin .	BACKGROUND : disease* Hemolytic anemia *disease is one of the major adverse events of the combination therapy of interferon and ribavirin .
Because of ribavirin - related hemolytic anemia , dose reduction is a common event in this therapy .	Because of ribavirin - related disease* hemolytic anemia *disease , dose reduction is a common event in this therapy .
In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with hemolysis during combination therapy .	In this clinical retrospective cohort study we have examined the suitable timing of ribavirin reduction in patients with disease* hemolysis *disease during combination therapy .
METHODS : Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed anemia with hemoglobin level < 10 g / dl or anemia - related signs during therapy .	METHODS : Thirty - seven of 160 patients who had HCV - genotype 1b , had high virus load , and received 24 - week combination therapy developed disease* anemia *disease with hemoglobin level < 10 g / dl or disease* anemia *disease - related signs during therapy .
After that , these 37 patients were reduced one tablet of ribavirin ( 200 mg ) per day .	After that , these 37 patients were reduced one tablet of ribavirin ( 200 mg ) per day .
After reduction of ribavirin , 27 of 37 patients could continue combination therapy for a total of 24 weeks ( group A ) .	After reduction of ribavirin , 27 of 37 patients could continue combination therapy for a total of 24 weeks ( group A ) .
However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or anemia - related severe side effects occurred ( group B ) .	However , 10 of 37 patients with reduction of ribavirin could not continue combination therapy because their < 8 . 5 g / dl hemoglobin values decreased to or disease* anemia *disease - related severe side effects occurred ( group B ) .
We assessed the final efficacy and safety after reduction of ribavirin in groups A and B .	We assessed the final efficacy and safety after reduction of ribavirin in groups A and B .
RESULTS : A sustained virological response ( SVR ) was 29 . 6 % ( 8 / 27 ) in group A and 10 % ( 1 / 10 ) in group B , respectively .	RESULTS : A sustained virological response ( SVR ) was 29 . 6 % ( 8 / 27 ) in group A and 10 % ( 1 / 10 ) in group B , respectively .
A 34 . 4 % ( 12 / 27 ) of SVR + biological response in group A was higher than 10 % ( 1 / 10 ) in group B ( P = 0 . 051 ) , with slight significance .	A 34 . 4 % ( 12 / 27 ) of SVR + biological response in group A was higher than 10 % ( 1 / 10 ) in group B ( P = 0 . 051 ) , with slight significance .
With respect to hemoglobin level at the time of ribavirin reduction , a rate of continuation of therapy in patients with > or = 10 g / dl hemoglobin was higher than that in patients with < 10 g / dl ( P = 0 . 036 ) .	With respect to hemoglobin level at the time of ribavirin reduction , a rate of continuation of therapy in patients with > or = 10 g / dl hemoglobin was higher than that in patients with < 10 g / dl ( P = 0 . 036 ) .
CONCLUSIONS : Reduction of ribavirin at hemoglobin level > or = 10 g / dl is suitable in terms of efficacy and side effects .	CONCLUSIONS : Reduction of ribavirin at hemoglobin level > or = 10 g / dl is suitable in terms of efficacy and side effects .
Aging process of epithelial cells of the rat prostate lateral lobe in experimental hyperprolactinemia induced by haloperidol .	Aging process of epithelial cells of the rat prostate lateral lobe in experimental disease* hyperprolactinemia *disease induced by haloperidol .
The aim of the study was to examine the influence of hyperprolactinemia , induced by haloperidol ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .	The aim of the study was to examine the influence of disease* hyperprolactinemia *disease , induced by haloperidol ( HAL ) on age related morphology and function changes of epithelial cells in rat prostate lateral lobe .
The study was performed on sexually mature male rats .	The study was performed on sexually mature male rats .
Serum concentrations of prolactin ( PRL ) and testosterone ( T ) were measured .	Serum concentrations of prolactin ( PRL ) and testosterone ( T ) were measured .
Tissue sections were evaluated with light and electron microscopy .	Tissue sections were evaluated with light and electron microscopy .
Immunohistochemical reactions for Anti - Proliferating Cell Nuclear Antigen ( PCNA ) were performed .	Immunohistochemical reactions for Anti - Proliferating Cell Nuclear Antigen ( PCNA ) were performed .
In rats of the experimental group , the mean concentration of : PRL was more than twice higher , whereas T concentration was almost twice lower than that in the control group .	In rats of the experimental group , the mean concentration of : PRL was more than twice higher , whereas T concentration was almost twice lower than that in the control group .
Light microscopy visualized the following : hypertrophy and epithelium hyperplasia of the glandular ducts , associated with increased PCNA expression .	Light microscopy visualized the following : disease* hypertrophy *disease and epithelium disease* hyperplasia *disease of the glandular ducts , associated with increased PCNA expression .
Electron microscopy revealed changes in columnar epithelial cells , concerning organelles , engaged in protein synthesis and secretion .	Electron microscopy revealed changes in columnar epithelial cells , concerning organelles , engaged in protein synthesis and secretion .
Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of coronary stenosis : correlation with thallium - 201 single - photon emission tomography .	Relation of perfusion defects observed with myocardial contrast echocardiography to the severity of disease* coronary stenosis *disease : correlation with thallium - 201 single - photon emission tomography .
It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to coronary occlusion and to critical coronary stenoses in the presence of hyperemic stimulation .	It has been previously shown that myocardial contrast echocardiography is a valuable technique for delineating regions of myocardial underperfusion secondary to disease* coronary occlusion *disease and to critical disease* coronary stenoses *disease in the presence of disease* hyperemic *disease stimulation .
The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of coronary stenosis .	The aim of this study was to determine whether myocardial contrast echocardiography performed with a stable solution of sonicated albumin could detect regions of myocardial underperfusion resulting from various degrees of disease* coronary stenosis *disease .
The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual - perfusion technique and with thallium - 201 single - photon emission tomography ( SPECT ) .	The perfusion defect produced in 16 open chest dogs was compared with the anatomic area at risk measured by the postmortem dual - perfusion technique and with thallium - 201 single - photon emission tomography ( SPECT ) .
During a transient ( 20 - s ) coronary occlusion , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced .	During a transient ( 20 - s ) disease* coronary occlusion *disease , a perfusion defect was observed with contrast echocardiography in 14 of the 15 dogs in which the occlusion was produced .
The perfusion defect correlated significantly with the anatomic area at risk ( r = 0 . 74 ; p less than 0 . 002 ) .	The perfusion defect correlated significantly with the anatomic area at risk ( r = 0 . 74 ; p less than 0 . 002 ) .
During dipyridamole - induced hyperemia , 12 of the 16 dogs with a partial coronary stenosis had a visible area of hypoperfusion by contrast echocardiography .	During dipyridamole - induced disease* hyperemia *disease , 12 of the 16 dogs with a partial disease* coronary stenosis *disease had a visible area of hypoperfusion by contrast echocardiography .
The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in dipyridamole - induced hyperemia .	The four dogs without a perfusion defect had a stenosis that resulted in a mild ( 0 % to 50 % ) reduction in dipyridamole - induced disease* hyperemia *disease .
The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk ( r = 0 . 61 ; p = 0 . 02 ) .	The size of the perfusion defect during stenosis correlated significantly with the anatomic area at risk ( r = 0 . 61 ; p = 0 . 02 ) .
Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced hyperemia ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .	Thallium - 201 SPECT demonstrated a perfusion defect in all 14 dogs analyzed during dipyridamole - induced disease* hyperemia *disease ; the size of the perfusion defect correlated with the anatomic area at risk ( r = 0 . 58 ; p less than 0 . 03 ) and with the perfusion defect by contrast echocardiography ( r = 0 . 58 ; p less than 0 . 03 ) .
Thus , myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of coronary stenosis .	Thus , myocardial contrast echocardiography can be used to visualize and quantitate the amount of jeopardized myocardium during moderate to severe degrees of disease* coronary stenosis *disease .
The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium - 201 SPECT .	The results obtained show a correlation with the anatomic area at risk similar to that obtained with thallium - 201 SPECT .
The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of spinal cord ischemia .	The activation of spinal N - methyl - D - aspartate receptors may contribute to degeneration of spinal motor neurons induced by neuraxial morphine after a noninjurious interval of disease* spinal cord ischemia *disease .
We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of aortic occlusion in rats .	We investigated the relationship between the degeneration of spinal motor neurons and activation of N - methyl - d - aspartate ( NMDA ) receptors after neuraxial morphine following a noninjurious interval of disease* aortic occlusion *disease in rats .
Spinal cord ischemia was induced by aortic occlusion for 6 min with a balloon catheter .	disease* Spinal cord ischemia *disease was induced by disease* aortic occlusion *disease for 6 min with a balloon catheter .
In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .	In a microdialysis study , 10 muL of saline ( group C ; n = 8 ) or 30 mug of morphine ( group M ; n = 8 ) was injected intrathecally ( IT ) 0 . 5 h after reflow , and 30 mug of morphine ( group SM ; n = 8 ) or 10 muL of saline ( group SC ; n = 8 ) was injected IT 0 . 5 h after sham operation .
Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .	Microdialysis samples were collected preischemia , before IT injection , and at 2 , 4 , 8 , 24 , and 48 h of reperfusion ( after IT injection ) .
Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced spastic paraparesis .	Second , we investigated the effect of IT MK - 801 ( 30 mug ) on the histopathologic changes in the spinal cord after morphine - induced disease* spastic paraparesis *disease .
After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .	After IT morphine , the cerebrospinal fluid ( CSF ) glutamate concentration was increased in group M relative to both baseline and group C ( P < 0 . 05 ) .
This increase persisted for 8 hrs .	This increase persisted for 8 hrs .
IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced spastic paraparesis compared with the saline group .	IT MK - 801 significantly reduced the number of dark - stained alpha - motoneurons after morphine - induced disease* spastic paraparesis *disease compared with the saline group .
These data indicate that IT morphine induces spastic paraparesis with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .	These data indicate that IT morphine induces disease* spastic paraparesis *disease with a concomitant increase in CSF glutamate , which is involved in NMDA receptor activation .
We suggest that opioids may be neurotoxic in the setting of spinal cord ischemia via NMDA receptor activation .	We suggest that opioids may be disease* neurotoxic *disease in the setting of disease* spinal cord ischemia *disease via NMDA receptor activation .
Acute low back pain during intravenous administration of amiodarone : a report of two cases .	Acute disease* low back pain *disease during intravenous administration of amiodarone : a report of two cases .
Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent - onset atrial fibrillation ( AF ) and maintenance of sinus rhythm .	Amiodarone represents an effective antiarrhythmic drug for cardioversion of recent - onset disease* atrial fibrillation *disease ( disease* AF *disease ) and maintenance of sinus rhythm .
We briefly describe two patients suffering from recent - onset atrial fibrillation , who experienced an acute devastating low back pain a few minutes after initiation of intravenous amiodarone loading .	We briefly describe two patients suffering from recent - onset disease* atrial fibrillation *disease , who experienced an acute devastating disease* low back pain *disease a few minutes after initiation of intravenous amiodarone loading .
Notably , this side effect has not been ever reported in the medical literature .	Notably , this side effect has not been ever reported in the medical literature .
Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution .	Clinicians should be aware of this reaction since prompt termination of parenteral administration leads to complete resolution .
Quantitative drug levels in stimulant psychosis : relationship to symptom severity , catecholamines and hyperkinesia .	Quantitative drug levels in stimulant disease* psychosis *disease : relationship to symptom severity , catecholamines and disease* hyperkinesia *disease .
To examine the relationship between quantitative stimulant drug levels , catecholamines , and psychotic symptoms , nineteen patients in a psychiatric emergency service with a diagnosis of amphetamine - or cocaine - induced psychosis were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .	To examine the relationship between quantitative stimulant drug levels , catecholamines , and disease* psychotic symptoms *disease , nineteen patients in a disease* psychiatric *disease emergency service with a diagnosis of amphetamine - or cocaine - induced disease* psychosis *disease were interviewed , and plasma and urine were collected for quantitative assays of stimulant drug and catecholamine metabolite levels .
Methamphetamine or amphetamine levels were related to several psychopathology scores and the global hyperkinesia rating .	Methamphetamine or amphetamine levels were related to several psychopathology scores and the global disease* hyperkinesia *disease rating .
HVA levels were related to global hyperkinesia but not to psychopathology ratings .	HVA levels were related to global disease* hyperkinesia *disease but not to psychopathology ratings .
Although many other factors such as sensitization may play a role , intensity of stimulant - induced psychotic symptoms and stereotypies appears to be at least in part dose - related .	Although many other factors such as sensitization may play a role , intensity of stimulant - induced disease* psychotic symptoms *disease and disease* stereotypies *disease appears to be at least in part dose - related .
Pheochromocytoma unmasked by amisulpride and tiapride .	disease* Pheochromocytoma *disease unmasked by amisulpride and tiapride .
OBJECTIVE : To describe the unmasking of pheochromocytoma in a patient treated with amisulpride and tiapride .	OBJECTIVE : To describe the unmasking of disease* pheochromocytoma *disease in a patient treated with amisulpride and tiapride .
CASE SUMMARY : A 42 - year - old white man developed acute hypertension with severe headache and vomiting 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .	CASE SUMMARY : A 42 - year - old white man developed acute disease* hypertension *disease with severe disease* headache *disease and disease* vomiting *disease 2 hours after the first doses of amisulpride 100 mg and tiapride 100 mg .
Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .	Both drugs were immediately discontinued , and the patient recovered after subsequent nicardipine and verapamil treatment .
Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of pheochromocytoma .	Abdominal ultrasound showed an adrenal mass , and postoperative histologic examination confirmed the diagnosis of disease* pheochromocytoma *disease .
DISCUSSION : Drug - induced symptoms of pheochromocytoma are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .	DISCUSSION : Drug - induced symptoms of disease* pheochromocytoma *disease are often associated with the use of substituted benzamide drugs , but the underlying mechanism is unknown .
In our case , use of the Naranjo probability scale indicated a possible relationship between the hypertensive crisis and amisulpride and tiapride therapy .	In our case , use of the Naranjo probability scale indicated a possible relationship between the disease* hypertensive *disease crisis and amisulpride and tiapride therapy .
CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced hypertensive crisis in a patient with pheochromocytoma .	CONCLUSIONS : As of March 24 , 2005 , this is the first reported case of amisulpride - and tiapride - induced disease* hypertensive *disease crisis in a patient with disease* pheochromocytoma *disease .
Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .	Physicians and other healthcare professionals should be aware of this potential adverse effect of tiapride and amisulpride .
Minor neurological dysfunction , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .	Minor disease* neurological dysfunction *disease , cognitive development , and somatic development at the age of 3 to 7 years after dexamethasone treatment in very - low birth - weight infants .
The objective of this study was to assess minor neurological dysfunction , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .	The objective of this study was to assess minor disease* neurological dysfunction *disease , cognitive development , and somatic development after dexamethasone therapy in very - low - birthweight infants .
Thirty - three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment .	Thirty - three children after dexamethasone treatment were matched to 33 children without dexamethasone treatment .
Data were assessed at the age of 3 - 7 years .	Data were assessed at the age of 3 - 7 years .
Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2 . 35 mg / kg / day .	Dexamethasone was started between the 7th and the 28th day of life over 7 days with a total dose of 2 . 35 mg / kg / day .
Exclusion criteria were asphyxia , malformations , major surgical interventions , small for gestational age , intraventricular haemorrhage grades III and IV , periventricular leukomalacia , and severe psychomotor retardation .	Exclusion criteria were disease* asphyxia *disease , disease* malformations *disease , major surgical interventions , small for gestational age , intraventricular disease* haemorrhage *disease grades III and IV , disease* periventricular leukomalacia *disease , and severe disease* psychomotor retardation *disease .
Each child was examined by a neuropediatrician for minor neurological dysfunctions and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw - a - Man Test .	Each child was examined by a neuropediatrician for minor disease* neurological dysfunctions *disease and tested by a psychologist for cognitive development with a Kaufman Assessment Battery for Children and a Draw - a - Man Test .
There were no differences in demographic data , growth , and socio - economic status between the two groups .	There were no differences in demographic data , growth , and socio - economic status between the two groups .
Fine motor skills and gross motor function were significantly better in the control group ( p < 0 . 01 ) .	Fine motor skills and gross motor function were significantly better in the control group ( p < 0 . 01 ) .
In the Draw - a - Man Test , the control group showed better results ( p < 0 . 001 ) .	In the Draw - a - Man Test , the control group showed better results ( p < 0 . 001 ) .
There were no differences in development of speech , social development , and the Kaufman Assessment Battery for Children .	There were no differences in development of speech , social development , and the Kaufman Assessment Battery for Children .
After dexamethasone treatment , children showed a higher rate of minor neurological dysfunctions .	After dexamethasone treatment , children showed a higher rate of minor disease* neurological dysfunctions *disease .
Neurological development was affected even without neurological diagnosis .	Neurological development was affected even without neurological diagnosis .
Further long - term follow - up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development .	Further long - term follow - up studies will be necessary to fully evaluate the impact of dexamethasone on neurological and cognitive development .
Valproic acid I : time course of lipid peroxidation biomarkers , liver toxicity , and valproic acid metabolite levels in rats .	Valproic acid I : time course of lipid peroxidation biomarkers , disease* liver toxicity *disease , and valproic acid metabolite levels in rats .
A single dose of valproic acid ( VPA ) , which is a widely used antiepileptic drug , is associated with oxidative stress in rats , as recently demonstrated by elevated levels of 15 - F ( 2t ) - isoprostane ( 15 - F ( 2t ) - IsoP ) .	A single dose of valproic acid ( VPA ) , which is a widely used antiepileptic drug , is associated with oxidative stress in rats , as recently demonstrated by elevated levels of 15 - F ( 2t ) - isoprostane ( 15 - F ( 2t ) - IsoP ) .
To determine whether there was a temporal relationship between VPA - associated oxidative stress and hepatotoxicity , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .	To determine whether there was a temporal relationship between VPA - associated oxidative stress and disease* hepatotoxicity *disease , adult male Sprague - Dawley rats were treated ip with VPA ( 500 mg / kg ) or 0 . 9 % saline ( vehicle ) once daily for 2 , 4 , 7 , 10 , or 14 days .
Oxidative stress was assessed by determining plasma and liver levels of 15 - F ( 2t ) - IsoP , lipid hydroperoxides ( LPO ) , and thiobarbituric acid reactive substances ( TBARs ) .	Oxidative stress was assessed by determining plasma and liver levels of 15 - F ( 2t ) - IsoP , lipid hydroperoxides ( LPO ) , and thiobarbituric acid reactive substances ( TBARs ) .
Plasma and liver 15 - F ( 2t ) - IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control .	Plasma and liver 15 - F ( 2t ) - IsoP were elevated and reached a plateau after day 2 of VPA treatment compared to control .
Liver LPO levels were not elevated until day 7 of treatment ( 1 . 8 - fold versus control , p < 0 . 05 ) .	Liver LPO levels were not elevated until day 7 of treatment ( 1 . 8 - fold versus control , p < 0 . 05 ) .
Liver and plasma TBARs were not increased until 14 days ( 2 - fold vs . control , p < 0 . 05 ) .	Liver and plasma TBARs were not increased until 14 days ( 2 - fold vs . control , p < 0 . 05 ) .
Liver toxicity was evaluated based on serum levels of alpha - glutathione S - transferase ( alpha - GST ) and by histology .	disease* Liver toxicity *disease was evaluated based on serum levels of alpha - glutathione S - transferase ( alpha - GST ) and by histology .
Serum alpha - GST levels were significantly elevated by day 4 , which corresponded to hepatotoxicity as shown by the increasing incidence of inflammation of the liver capsule , necrosis , and steatosis throughout the study .	Serum alpha - GST levels were significantly elevated by day 4 , which corresponded to disease* hepatotoxicity *disease as shown by the increasing incidence of disease* inflammation *disease of the liver capsule , disease* necrosis *disease , and disease* steatosis *disease throughout the study .
The liver levels of beta - oxidation metabolites of VPA were decreased by day 14 , while the levels of 4 - ene - VPA and ( E ) - 2 , 4 - diene - VPA were not elevated throughout the study .	The liver levels of beta - oxidation metabolites of VPA were decreased by day 14 , while the levels of 4 - ene - VPA and ( E ) - 2 , 4 - diene - VPA were not elevated throughout the study .
Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of necrosis , steatosis , and elevated levels of serum alpha - GST .	Overall , these findings indicate that VPA treatment results in oxidative stress , as measured by levels of 15 - F ( 2t ) - IsoP , which precedes the onset of disease* necrosis *disease , disease* steatosis *disease , and elevated levels of serum alpha - GST .
Assessment of perinatal hepatitis B and rubella prevention in New Hampshire delivery hospitals .	Assessment of perinatal disease* hepatitis B *disease and disease* rubella *disease prevention in New Hampshire delivery hospitals .
OBJECTIVE : To evaluate current performance on recommended perinatal hepatitis B and rubella prevention practices in New Hampshire .	OBJECTIVE : To evaluate current performance on recommended perinatal disease* hepatitis B *disease and disease* rubella *disease prevention practices in New Hampshire .
METHODS : Data were extracted from 2021 paired mother - infant records for the year 2000 birth cohort in New Hampshire ' s 25 delivery hospitals .	METHODS : Data were extracted from 2021 paired mother - infant records for the year 2000 birth cohort in New Hampshire ' s 25 delivery hospitals .
Assessment was done on the following : prenatal screening for hepatitis B and rubella , administration of the hepatitis B vaccine birth dose to all infants , administration of hepatitis B immune globulin to infants who were born to hepatitis B surface antigen - positive mothers , rubella immunity , and administration of in - hospital postpartum rubella vaccine to rubella nonimmune women .	Assessment was done on the following : prenatal screening for disease* hepatitis B *disease and disease* rubella *disease , administration of the disease* hepatitis B *disease vaccine birth dose to all infants , administration of disease* hepatitis B *disease immune globulin to infants who were born to hepatitis B surface antigen - positive mothers , disease* rubella *disease immunity , and administration of in - hospital postpartum disease* rubella *disease vaccine to disease* rubella *disease nonimmune women .
RESULTS : Prenatal screening rates for hepatitis B ( 98 . 8 % ) and rubella ( 99 . 4 % ) were high .	RESULTS : Prenatal screening rates for disease* hepatitis B *disease ( 98 . 8 % ) and disease* rubella *disease ( 99 . 4 % ) were high .
Hepatitis B vaccine birth dose was administered to 76 . 2 % of all infants .	disease* Hepatitis B *disease vaccine birth dose was administered to 76 . 2 % of all infants .
All infants who were born to hepatitis B surface antigen - positive mothers also received hepatitis B immune globulin .	All infants who were born to hepatitis B surface antigen - positive mothers also received disease* hepatitis B *disease immune globulin .
Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of hepatitis B vaccination .	Multivariate logistic regression showed that the month of delivery and infant birth weight were independent predictors of disease* hepatitis B *disease vaccination .
The proportion of infants who were vaccinated in January and February 2000 ( 48 . 5 % and 67 . 5 % , respectively ) was less than any other months , whereas the proportion who were vaccinated in December 2000 ( 88 . 2 % ) was the highest .	The proportion of infants who were vaccinated in January and February 2000 ( 48 . 5 % and 67 . 5 % , respectively ) was less than any other months , whereas the proportion who were vaccinated in December 2000 ( 88 . 2 % ) was the highest .
Women who were born between 1971 and 1975 had the highest rate of rubella nonimmunity ( 9 . 5 % ) .	Women who were born between 1971 and 1975 had the highest rate of disease* rubella *disease nonimmunity ( 9 . 5 % ) .
In - hospital postpartum rubella vaccine administration was documented for 75 . 6 % of nonimmune women .	In - hospital postpartum disease* rubella *disease vaccine administration was documented for 75 . 6 % of nonimmune women .
CONCLUSION : This study documents good compliance in New Hampshire ' s birthing hospitals with national guidelines for perinatal hepatitis B and rubella prevention and highlights potential areas for improvement .	CONCLUSION : This study documents good compliance in New Hampshire ' s birthing hospitals with national guidelines for perinatal disease* hepatitis B *disease and disease* rubella *disease prevention and highlights potential areas for improvement .
Succinylcholine - induced masseter muscle rigidity during bronchoscopic removal of a tracheal foreign body .	Succinylcholine - induced disease* masseter muscle rigidity *disease during bronchoscopic removal of a tracheal foreign body .
Masseter muscle rigidity during general anesthesia is considered an early warning sign of a possible episode of malignant hyperthermia .	disease* Masseter muscle rigidity *disease during general anesthesia is considered an early warning sign of a possible episode of disease* malignant hyperthermia *disease .
The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of masseter muscle rigidity .	The decision whether to continue or discontinue the procedure depends on the urgency of the surgery and severity of disease* masseter muscle rigidity *disease .
Here , we describe a case of severe masseter muscle rigidity ( jaw of steel ) after succinylcholine ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .	Here , we describe a case of severe disease* masseter muscle rigidity *disease ( disease* jaw of steel *disease ) after succinylcholine ( Sch ) administration during general anesthetic management for rigid bronchoscopic removal of a tracheal foreign body .
Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat malignant hyperthermia .	Anesthesia was continued uneventfully with propofol infusion while all facilities were available to detect and treat disease* malignant hyperthermia *disease .
Dexrazoxane protects against myelosuppression from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .	Dexrazoxane protects against disease* myelosuppression *disease from the DNA cleavage - enhancing drugs etoposide and daunorubicin but not doxorubicin .
PURPOSE : The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , myelosuppression and cardiac toxicity limit their use .	PURPOSE : The anthracyclines daunorubicin and doxorubicin and the epipodophyllotoxin etoposide are potent DNA cleavage - enhancing drugs that are widely used in clinical oncology ; however , disease* myelosuppression *disease and disease* cardiac toxicity *disease limit their use .
Dexrazoxane ( ICRF - 187 ) is recommended for protection against anthracycline - induced cardiotoxicity .	Dexrazoxane ( ICRF - 187 ) is recommended for protection against anthracycline - induced disease* cardiotoxicity *disease .
EXPERIMENTAL DESIGN : Because of their widespread use , the hematologic toxicity following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .	EXPERIMENTAL DESIGN : Because of their widespread use , the disease* hematologic toxicity *disease following coadministration of dexrazoxane and these three structurally different DNA cleavage enhancers was investigated : Sensitivity of human and murine blood progenitor cells to etoposide , daunorubicin , and doxorubicin + / - dexrazoxane was determined in granulocyte - macrophage colony forming assays .
Likewise , in vivo , B6D2F1 mice were treated with etoposide , daunorubicin , and doxorubicin , with or without dexrazoxane over a wide range of doses : posttreatment , a full hematologic evaluation was done .	Likewise , in vivo , B6D2F1 mice were treated with etoposide , daunorubicin , and doxorubicin , with or without dexrazoxane over a wide range of doses : posttreatment , a full hematologic evaluation was done .
RESULTS : Nontoxic doses of dexrazoxane reduced myelosuppression and weight loss from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced myelosuppression , weight loss , nor the in vitro cytotoxicity from doxorubicin .	RESULTS : Nontoxic doses of dexrazoxane reduced disease* myelosuppression *disease and disease* weight loss *disease from daunorubicin and etoposide in mice and antagonized their antiproliferative effects in the colony assay ; however , dexrazoxane neither reduced disease* myelosuppression *disease , disease* weight loss *disease , nor the in vitro disease* cytotoxicity *disease from doxorubicin .
CONCLUSION : Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .	CONCLUSION : Although our findings support the observation that dexrazoxane reduces neither hematologic activity nor antitumor activity from doxorubicin clinically , the potent antagonism of daunorubicin activity raises concern ; a possible interference with anticancer efficacy certainly would call for renewed attention .
Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane .	Our data also suggest that significant etoposide dose escalation is perhaps possible by the use of dexrazoxane .
Clinical trials in patients with brain metastases combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating hematologic toxicity .	Clinical trials in patients with brain disease* metastases *disease combining dexrazoxane and high doses of etoposide is ongoing with the aim of improving efficacy without aggravating disease* hematologic toxicity *disease .
If successful , this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy .	If successful , this represents an exciting mechanism for pharmacologic regulation of side effects from cytotoxic chemotherapy .
Assessment of the onset and persistence of amnesia during procedural sedation with propofol .	Assessment of the onset and persistence of disease* amnesia *disease during procedural sedation with propofol .
OBJECTIVES : To assess patients ' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol , and correlate their recall with their level of awareness as measured by bispectral index ( BIS ) monitoring .	OBJECTIVES : To assess patients ' ability to repeat and recall words presented to them while undergoing procedural sedation with propofol , and correlate their recall with their level of awareness as measured by bispectral index ( BIS ) monitoring .
METHODS : This was a prospective , single - intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28 , 2002 , and October 31 , 2003 .	METHODS : This was a prospective , single - intervention study of consenting adult patients undergoing procedural sedation with propofol between December 28 , 2002 , and October 31 , 2003 .
BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status .	BIS monitoring was initiated starting 3 minutes before the procedure and continuing until the patient had regained baseline mental status .
At 1 - minute intervals during the procedural sedation , until the patient regained baseline mental status at the end of the procedure , a word from a standardized list was read aloud , and the patient was asked to immediately repeat the word to the investigator .	At 1 - minute intervals during the procedural sedation , until the patient regained baseline mental status at the end of the procedure , a word from a standardized list was read aloud , and the patient was asked to immediately repeat the word to the investigator .
The BIS score at the time the word was read and the patient ' s ability to repeat the word were recorded .	The BIS score at the time the word was read and the patient ' s ability to repeat the word were recorded .
After the procedure , the patient was asked to state all of the words from the list that he or she could recall , and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed .	After the procedure , the patient was asked to state all of the words from the list that he or she could recall , and to identify the last word recalled from prior to the start of the procedure and the first word recalled from after the procedure was completed .
RESULTS : Seventy - five consenting patients were enrolled ; one patient was excluded from data analysis for a protocol violation .	RESULTS : Seventy - five consenting patients were enrolled ; one patient was excluded from data analysis for a protocol violation .
No serious adverse events were noted during the procedural sedations .	No serious adverse events were noted during the procedural sedations .
The mean ( + / - standard deviation ) time of data collection was 16 . 4 minutes ( + / - 7 . 1 ; range 5 to 34 minutes ) .	The mean ( + / - standard deviation ) time of data collection was 16 . 4 minutes ( + / - 7 . 1 ; range 5 to 34 minutes ) .
The mean initial ( preprocedure ) BIS score was 97 . 1 ( + / - 2 . 3 ; range 92 to 99 ) .	The mean initial ( preprocedure ) BIS score was 97 . 1 ( + / - 2 . 3 ; range 92 to 99 ) .
The mean lowest BIS score occurring during these procedural sedations was 66 . 9 ( + / - 14 . 4 ; range 33 to 91 ) .	The mean lowest BIS score occurring during these procedural sedations was 66 . 9 ( + / - 14 . 4 ; range 33 to 91 ) .
The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77 . 1 ( 95 % CI = 74 . 3 to 80 . 0 ) .	The mean lowest BIS score corresponding to the ability of the patient to immediately repeat words read from the list was 77 . 1 ( 95 % CI = 74 . 3 to 80 . 0 ) .
The mean highest BIS score corresponding to the inability to repeat words was 81 . 5 ( 95 % CI = 78 . 1 to 84 . 8 ) .	The mean highest BIS score corresponding to the disease* inability to repeat words *disease was 81 . 5 ( 95 % CI = 78 . 1 to 84 . 8 ) .
The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96 . 7 ( + / - 2 . 4 ; range 84 to 98 ) .	The mean BIS score corresponding to the last word recalled from prior to the initiation of the sedation was 96 . 7 ( + / - 2 . 4 ; range 84 to 98 ) .
The mean BIS score corresponding to the first word recalled after the procedure was completed was 91 . 2 ( 95 % CI = 88 . 1 to 94 . 3 ) .	The mean BIS score corresponding to the first word recalled after the procedure was completed was 91 . 2 ( 95 % CI = 88 . 1 to 94 . 3 ) .
All patients recalled at least one word that had been read to them during the protocol .	All patients recalled at least one word that had been read to them during the protocol .
The mean lowest BIS score for any recalled word was 91 . 5 ( + / - 11 . 1 ; range 79 to 98 ) , and no words were recalled when the corresponding BIS score was less than 90 .	The mean lowest BIS score for any recalled word was 91 . 5 ( + / - 11 . 1 ; range 79 to 98 ) , and no words were recalled when the corresponding BIS score was less than 90 .
CONCLUSIONS : There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words .	CONCLUSIONS : There is a range of BIS scores during which sedated patients are able to repeat words read to them but are not able to subsequently recall these words .
Furthermore , patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation , suggestive of retrograde amnesia .	Furthermore , patients had no recall of words repeated prior to procedural sedation in BIS ranges associated with recall after procedural sedation , suggestive of disease* retrograde amnesia *disease .
Amiodarone pulmonary toxicity .	Amiodarone disease* pulmonary toxicity *disease .
Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being pneumonitis .	Amiodarone is an effective antiarrhythmic agent whose utility is limited by many side - effects , the most problematic being disease* pneumonitis *disease .
The pulmonary toxicity of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated hypersensitivity pneumonitis .	The disease* pulmonary toxicity *disease of amiodarone is thought to result from direct injury related to the intracellular accumulation of phospholipid and T cell - mediated disease* hypersensitivity pneumonitis *disease .
The clinical and radiographic features of amiodarone - induced pulmonary toxicity are characteristic but nonspecific .	The clinical and radiographic features of amiodarone - induced disease* pulmonary toxicity *disease are characteristic but nonspecific .
The diagnosis depends on exclusion of other entities , such as heart failure , infection , and malignancy .	The diagnosis depends on exclusion of other entities , such as disease* heart failure *disease , disease* infection *disease , and disease* malignancy *disease .
While withdrawal of amiodarone leads to clinical improvement in majority of cases , this is not always possible or advisable .	While withdrawal of amiodarone leads to clinical improvement in majority of cases , this is not always possible or advisable .
Dose reduction or concomitant steroid therapy may have a role in selected patients .	Dose reduction or concomitant steroid therapy may have a role in selected patients .
Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain .	Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of disease* pain *disease .
Amino acids 5 and 7 , two potent and selective competitive GluR5 KA receptor antagonists , exhibited high GluR5 receptor affinity over other glutamate receptors .	Amino acids 5 and 7 , two potent and selective competitive GluR5 KA receptor antagonists , exhibited high GluR5 receptor affinity over other glutamate receptors .
Their ester prodrugs 6 and 8 were orally active in three models of pain : reversal of formalin - induced paw licking , carrageenan - induced thermal hyperalgesia , and capsaicin - induced mechanical hyperalgesia .	Their ester prodrugs 6 and 8 were orally active in three models of disease* pain *disease : reversal of formalin - induced paw licking , carrageenan - induced disease* thermal hyperalgesia *disease , and capsaicin - induced disease* mechanical hyperalgesia *disease .
Possible azithromycin - associated hiccups .	Possible azithromycin - associated disease* hiccups *disease .
OBJECTIVE : To report a case of persistent hiccups associated by azithromycin therapy .	OBJECTIVE : To report a case of persistent disease* hiccups *disease associated by azithromycin therapy .
CASE SUMMARY : A 76 - year - old man presented with persistent hiccups after beginning azithromycin for the treatment of pharyngitis .	CASE SUMMARY : A 76 - year - old man presented with persistent disease* hiccups *disease after beginning azithromycin for the treatment of disease* pharyngitis *disease .
Hiccups were persistent and exhausting .	disease* Hiccups *disease were persistent and exhausting .
Discontinuation of azithromycin and therapy with baclofen finally resolved hiccups .	Discontinuation of azithromycin and therapy with baclofen finally resolved disease* hiccups *disease .
No organic cause of hiccups was identified despite extensive investigation .	No organic cause of disease* hiccups *disease was identified despite extensive investigation .
DISCUSSION : Pharmacotherapeutic agents have been uncommonly associated with hiccups .	DISCUSSION : Pharmacotherapeutic agents have been uncommonly associated with disease* hiccups *disease .
Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of hiccups .	Corticosteroids ( dexamethasone and methylprednisolone ) , benzodiazepines ( midazolam ) and general anaesthesia have been the specific agents mentioned most frequently in the literature as being associated with the development of disease* hiccups *disease .
Few cases of drug - induced hiccups have been reported related to macrolide antimicrobials .	Few cases of drug - induced disease* hiccups *disease have been reported related to macrolide antimicrobials .
Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other macrolides and the absence of any alternative explanation for hiccups .	Using the Naranjo adverse effect reaction probability scale this event could be classified as possible ( score 5 points ) , mostly because of the close temporal sequence , previous reports on this reaction with other macrolides and the absence of any alternative explanation for disease* hiccups *disease .
Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of hiccups in our patient .	Our hypothesis is that a vagal mechanism mediated by azithromycin could be the pathogenesis of disease* hiccups *disease in our patient .
CONCLUSIONS : Diagnosis of drug - induced hiccups is difficult and often achieved only by a process of elimination .	CONCLUSIONS : Diagnosis of drug - induced disease* hiccups *disease is difficult and often achieved only by a process of elimination .
However , macrolide antimicrobials have been reported to be associated with hiccups and vagal mechanism could explain the development of this side - effect .	However , macrolide antimicrobials have been reported to be associated with disease* hiccups *disease and vagal mechanism could explain the development of this side - effect .
Calcium carbonate toxicity : the updated milk - alkali syndrome ; report of 3 cases and review of the literature .	Calcium carbonate disease* toxicity *disease : the updated disease* milk - alkali syndrome *disease ; report of 3 cases and review of the literature .
OBJECTIVE : To describe 3 patients with calcium carbonate - induced hypercalcemia and gain insights into the cause and management of the milk - alkali syndrome .	OBJECTIVE : To describe 3 patients with calcium carbonate - induced disease* hypercalcemia *disease and gain insights into the cause and management of the disease* milk - alkali syndrome *disease .
METHODS : We report the clinical and laboratory data in 3 patients who presented with severe hypercalcemia ( corrected serum calcium > or = 14 mg / dL ) and review the pertinent literature on milk - alkali syndrome .	METHODS : We report the clinical and laboratory data in 3 patients who presented with severe disease* hypercalcemia *disease ( corrected serum calcium > or = 14 mg / dL ) and review the pertinent literature on disease* milk - alkali syndrome *disease .
RESULTS : The 3 patients had acute renal insufficiency , relative metabolic alkalosis , and low parathyroid hormone ( PTH ) , PTH - related peptide , and 1 , 25 - dihydroxyvitamin D concentrations .	RESULTS : The 3 patients had disease* acute renal insufficiency *disease , relative disease* metabolic alkalosis *disease , and low parathyroid hormone ( PTH ) , PTH - related peptide , and 1 , 25 - dihydroxyvitamin D concentrations .
No malignant lesion was found .	No malignant lesion was found .
Treatment included aggressive hydration and varied amounts of furosemide .	Treatment included aggressive hydration and varied amounts of furosemide .
The 2 patients with the higher serum calcium concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe hypocalcemia .	The 2 patients with the higher serum calcium concentrations received pamidronate intravenously ( 60 and 30 mg , respectively ) , which caused severe disease* hypocalcemia *disease .
Of the 3 patients , 2 were ingesting acceptable doses of elemental calcium ( 1 g and 2 g daily , respectively ) in the form of calcium carbonate .	Of the 3 patients , 2 were ingesting acceptable doses of elemental calcium ( 1 g and 2 g daily , respectively ) in the form of calcium carbonate .
In addition to our highlighted cases , we review the history , classification , pathophysiologic features , and treatment of milk - alkali syndrome and summarize the cases reported from early 1995 to November 2003 .	In addition to our highlighted cases , we review the history , classification , pathophysiologic features , and treatment of disease* milk - alkali syndrome *disease and summarize the cases reported from early 1995 to November 2003 .
CONCLUSION : Milk - alkali syndrome may be a common cause of unexplained hypercalcemia and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons .	CONCLUSION : disease* Milk - alkali syndrome *disease may be a common cause of unexplained disease* hypercalcemia *disease and can be precipitated by small amounts of orally ingested calcium carbonate in susceptible persons .
Treatment with hydration , furosemide , and discontinuation of the calcium and vitamin D source is adequate .	Treatment with hydration , furosemide , and discontinuation of the calcium and vitamin D source is adequate .
Pamidronate treatment is associated with considerable risk for hypocalcemia , even in cases of initially severe hypercalcemia .	Pamidronate treatment is associated with considerable risk for disease* hypocalcemia *disease , even in cases of initially severe disease* hypercalcemia *disease .
Warfarin - induced leukocytoclastic vasculitis .	Warfarin - induced disease* leukocytoclastic vasculitis *disease .
Skin reactions associated with oral coumarin - derived anticoagulants are an uncommon occurrence .	Skin reactions associated with oral coumarin - derived anticoagulants are an uncommon occurrence .
Leukocytoclastic vasculitis ( LV ) is primarily a cutaneous small vessel vasculitis , though systemic involvement may be encountered .	disease* Leukocytoclastic vasculitis *disease ( disease* LV *disease ) is primarily a disease* cutaneous small vessel vasculitis *disease , though systemic involvement may be encountered .
We report 4 patients with late - onset LV probably due to warfarin .	We report 4 patients with late - onset disease* LV *disease probably due to warfarin .
All 4 patients presented with skin eruptions that developed after receiving warfarin for several years .	All 4 patients presented with disease* skin eruptions *disease that developed after receiving warfarin for several years .
The results of skin lesion biopsies were available in 3 patients , confirming LV Cutaneous lesions resolved in all patients after warfarin was discontinued .	The results of disease* skin lesion *disease biopsies were available in 3 patients , confirming disease* LV Cutaneous lesions *disease resolved in all patients after warfarin was discontinued .
In 2 of the 4 patients , rechallenge with warfarin led to recurrence of the lesions .	In 2 of the 4 patients , rechallenge with warfarin led to recurrence of the lesions .
LV may be a late - onset adverse reaction associated with warfarin therapy .	disease* LV *disease may be a late - onset adverse reaction associated with warfarin therapy .
Cocaine - induced brainstem seizures and behavior .	Cocaine - induced brainstem disease* seizures *disease and behavior .
A variety of abnormal sensory / motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical ( electrode implants ) and DC electrical current stimulations and by acute and chronic administration of cocaine .	A variety of abnormal sensory / motor behaviors associated with electrical discharges recorded from the bilateral brainstem were induced in adult WKY rats by mechanical ( electrode implants ) and DC electrical current stimulations and by acute and chronic administration of cocaine .
The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations .	The electrode implant implicated one side or the other of the reticular system of the brainstem but subjects were not incapacitated by the stimulations .
Cocaine ( 40 mg / kg ) was injected subcutaneously for an acute experiment and subsequent 20 mg / kg doses twice daily for 3 days in a chronic study .	Cocaine ( 40 mg / kg ) was injected subcutaneously for an acute experiment and subsequent 20 mg / kg doses twice daily for 3 days in a chronic study .
Cocaine generated more abnormal behaviors in the brainstem perturbation group , especially the electrically perturbated subjects .	Cocaine generated more abnormal behaviors in the brainstem perturbation group , especially the electrically perturbated subjects .
The abnormal behaviors were yawning , retrocollis , hyperactivity , hypersensitivity , " beating drum " behavior , squealing , head bobbing , circling , sniffing , abnormal posturing , and facial twitching .	The abnormal behaviors were yawning , retrocollis , disease* hyperactivity *disease , disease* hypersensitivity *disease , " beating drum " behavior , squealing , head bobbing , circling , sniffing , abnormal posturing , and facial twitching .
Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states .	Shifts in the power frequency spectra of the discharge patterns were noted between quiet and pacing behavioral states .
Hypersensitivity to various auditory , tactile , and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation .	disease* Hypersensitivity *disease to various auditory , tactile , and visual stimulation was present and shifts in the brainstem ambient power spectral frequency occurred in response to tactile stimulation .
These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation .	These findings suggest that the brainstem generates and propagates pathological discharges that can be elicited by mechanical and DC electrical perturbation .
Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates .	Cocaine was found to activate the discharge system and thus induce abnormal behaviors that are generated at the discharge site and at distant sites to which the discharge propagates .
Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated .	Cognitive functions may also be involved since dopaminergic and serotonergic cellular elements at the brainstem level are also implicated .
rTMS of supplementary motor area modulates therapy - induced dyskinesias in Parkinson disease .	rTMS of supplementary motor area modulates therapy - induced disease* dyskinesias *disease in disease* Parkinson disease *disease .
The neural mechanisms and circuitry involved in levodopa - induced dyskinesia are unclear .	The neural mechanisms and circuitry involved in levodopa - induced disease* dyskinesia *disease are unclear .
Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced Parkinson disease , the authors investigated whether modulation of SMA excitability may result in a modification of a dyskinetic state induced by continuous apomorphine infusion .	Using repetitive transcranial magnetic stimulation ( rTMS ) over the supplementary motor area ( SMA ) in a group of patients with advanced disease* Parkinson disease *disease , the authors investigated whether modulation of SMA excitability may result in a modification of a disease* dyskinetic *disease state induced by continuous apomorphine infusion .
rTMS at 1 Hz was observed to markedly reduce drug - induced dyskinesias , whereas 5 - Hz rTMS induced a slight but not significant increase .	rTMS at 1 Hz was observed to markedly reduce disease* drug - induced dyskinesias *disease , whereas 5 - Hz rTMS induced a slight but not significant increase .
Intracavitary chemotherapy ( paclitaxel / carboplatin liquid crystalline cubic phases ) for recurrent glioblastoma - - clinical observations .	Intracavitary chemotherapy ( paclitaxel / carboplatin liquid crystalline cubic phases ) for recurrent disease* glioblastoma *disease - - clinical observations .
Human malignant brain tumors have a poor prognosis in spite of surgery and radiation therapy .	Human malignant disease* brain tumors *disease have a poor prognosis in spite of surgery and radiation therapy .
Cubic phases consist of curved biocontinuous lipid bilayers , separating two congruent networks of water channels .	Cubic phases consist of curved biocontinuous lipid bilayers , separating two congruent networks of water channels .
Used as a host for cytotoxic drugs , the gel - like matrix can easily be applied to the walls of a surgical resection cavity .	Used as a host for cytotoxic drugs , the gel - like matrix can easily be applied to the walls of a surgical resection cavity .
For human glioblastoma recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .	For human disease* glioblastoma *disease recurrences , the feasibility , safety , and short - term effects of a surgical intracavitary application of paclitaxel and carboplatin encapsulated by liquid crystalline cubic phases are examined in a pilot study .
A total of 12 patients with a recurrence of a glioblastoma multiforme underwent re - resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages .	A total of 12 patients with a recurrence of a disease* glioblastoma *disease multiforme underwent re - resection and received an intracavitary application of paclitaxel and carboplatin cubic phases in different dosages .
Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe brain edema , while the remaining patients received only a total of 15 mg paclitaxel .	Six of the patients received more than 15 mg paclitaxel and suffered from moderate to severe disease* brain edema *disease , while the remaining patients received only a total of 15 mg paclitaxel .
In the latter group , brain edema was markedly reduced and dealt medically .	In the latter group , disease* brain edema *disease was markedly reduced and dealt medically .
Intracavitary chemotherapy in recurrent glioblastoma using cubic phases is feasible and safe , yet the clinical benefit remains to be examined in a clinical phase II study .	Intracavitary chemotherapy in recurrent disease* glioblastoma *disease using cubic phases is feasible and safe , yet the clinical benefit remains to be examined in a clinical phase II study .
Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies .	Lamotrigine associated with exacerbation or de novo disease* myoclonus *disease in disease* idiopathic generalized epilepsies *disease .
Five patients with idiopathic generalized epilepsies ( IGE ) treated with lamotrigine ( LTG ) experienced exacerbation or de novo appearance of myoclonic jerks ( MJ ) .	Five patients with disease* idiopathic generalized epilepsies *disease ( disease* IGE *disease ) treated with lamotrigine ( LTG ) experienced exacerbation or de novo appearance of disease* myoclonic jerks *disease ( disease* MJ *disease ) .
In three patients , LTG exacerbated MJ in a dose - dependent manner with early aggravation during titration .	In three patients , LTG exacerbated disease* MJ *disease in a dose - dependent manner with early aggravation during titration .
MJ disappeared when LTG dose was decreased by 25 to 50 % .	disease* MJ *disease disappeared when LTG dose was decreased by 25 to 50 % .
In two patients , LTG exacerbated MJ in a delayed but more severe manner , with myoclonic status that only ceased after LTG withdrawal .	In two patients , LTG exacerbated disease* MJ *disease in a delayed but more severe manner , with disease* myoclonic status *disease that only ceased after LTG withdrawal .
Absence of acute cerebral vasoconstriction after cocaine - associated subarachnoid hemorrhage .	Absence of acute cerebral vasoconstriction after cocaine - associated disease* subarachnoid hemorrhage *disease .
INTRODUCTION : Cocaine use has been associated with neurovascular complications , including arterial vasoconstriction and vasculitis .	INTRODUCTION : Cocaine use has been associated with disease* neurovascular complications *disease , including arterial vasoconstriction and disease* vasculitis *disease .
However , there are few studies of angiographic effects of cocaine on human cerebral arteries .	However , there are few studies of angiographic effects of cocaine on human cerebral arteries .
Information on these effects could be obtained from angiograms of patients with cocaine - associated subarachnoid hemorrhage ( SAH ) who underwent angiography shortly after cocaine use .	Information on these effects could be obtained from angiograms of patients with cocaine - associated disease* subarachnoid hemorrhage *disease ( disease* SAH *disease ) who underwent angiography shortly after cocaine use .
METHODS : We screened patients with SAH retrospectively and identified those with positive urine toxicology for cocaine or its metabolites .	METHODS : We screened patients with disease* SAH *disease retrospectively and identified those with positive urine toxicology for cocaine or its metabolites .
Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with SAH who were matched for factors known to influence arterial diameter .	Quantitative arterial diameter measurements from angiograms of these patients were compared to measurements from control patients with disease* SAH *disease who were matched for factors known to influence arterial diameter .
Qualitative comparisons of small artery changes also were made .	Qualitative comparisons of small artery changes also were made .
RESULTS : Thirteen patients with positive cocaine toxicology were compared to 26 controls .	RESULTS : Thirteen patients with positive cocaine toxicology were compared to 26 controls .
There were no significant differences between groups in the mean diameters of the intradural internal carotid , sphenoidal segment of the middle cerebral , precommunicating segment of the anterior cerebral , or basilar arteries ( p greater than 0 . 05 for all comparisons , unpaired t - tests ) .	There were no significant differences between groups in the mean diameters of the intradural internal carotid , sphenoidal segment of the middle cerebral , precommunicating segment of the anterior cerebral , or basilar arteries ( p greater than 0 . 05 for all comparisons , unpaired t - tests ) .
There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery ( p greater than 0 . 05 , unpaired t - tests ) .	There also were no significant differences between groups when expressing diameters as the sum of the precommunicating segment of the anterior cerebral + sphenoidal segment of the middle cerebral + supraclinoid internal carotid artery + basilar artery divided by the diameter of the petrous internal carotid artery ( p greater than 0 . 05 , unpaired t - tests ) .
Qualitative assessments showed two arterial irregularities in the distal vasculature in each group .	Qualitative assessments showed two arterial irregularities in the distal vasculature in each group .
CONCLUSION : No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or vasculitis could be found in patients who underwent angiography after aneurysmal SAH associated with cocaine use .	CONCLUSION : No quantitative evidence for narrowing of large cerebral arteries or qualitative angiographic evidence for distal narrowing or disease* vasculitis *disease could be found in patients who underwent angiography after disease* aneurysmal disease* SAH *disease associated with cocaine use .
Methamphetamine causes alterations in the MAP kinase - related pathways in the brains of mice that display increased aggressiveness .	Methamphetamine causes alterations in the MAP kinase - related pathways in the brains of mice that display increased disease* aggressiveness *disease .
Aggressive behaviors have been reported in patients who suffer from some psychiatric disorders , and are common in methamphetamine ( METH ) abusers .	disease* Aggressive behaviors *disease have been reported in patients who suffer from some disease* psychiatric disorders *disease , and are common in methamphetamine ( METH ) abusers .
Herein , we report that multiple ( but not single ) injections of METH significantly increased aggressiveness in male CD - 1 mice .	Herein , we report that multiple ( but not single ) injections of METH significantly increased disease* aggressiveness *disease in male CD - 1 mice .
This increase in aggressiveness was not secondary to METH - induced hyperactivity .	This increase in disease* aggressiveness *disease was not secondary to METH - induced disease* hyperactivity *disease .
Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase - related pathways after multiple and single METH injections .	Analysis of protein expression using antibody microarrays and Western blotting revealed differential changes in MAP kinase - related pathways after multiple and single METH injections .
There were statistically significant ( p < 0 . 05 ) decreases in MEK1 , Erk2p , GSK3alpha , 14 - 3 - 3e , and MEK7 in the striata of mice after multiple injections of METH .	There were statistically significant ( p < 0 . 05 ) decreases in MEK1 , Erk2p , GSK3alpha , 14 - 3 - 3e , and MEK7 in the striata of mice after multiple injections of METH .
MEK1 was significantly decreased also after a single injection of METH , but to a much lesser degree than after multiple injections of METH .	MEK1 was significantly decreased also after a single injection of METH , but to a much lesser degree than after multiple injections of METH .
In the frontal cortex , there was a statistically significant decrease in GSK3alpha after multiple ( but not single ) injections of METH .	In the frontal cortex , there was a statistically significant decrease in GSK3alpha after multiple ( but not single ) injections of METH .
These findings suggest that alterations in MAP kinase - related pathways in the prefronto - striatal circuitries might be involved in the manifestation of aggressive behaviors in mice .	These findings suggest that alterations in MAP kinase - related pathways in the prefronto - striatal circuitries might be involved in the manifestation of disease* aggressive behaviors *disease in mice .
Amisulpride related tic - like symptoms in an adolescent schizophrenic .	Amisulpride related disease* tic - like symptoms *disease in an adolescent disease* schizophrenic *disease .
Tic disorders can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .	disease* Tic disorders *disease can be effectively treated by atypical antipsychotics such as risperidone , olanzapine and ziprasidone .
However , there are two case reports that show tic - like symptoms , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .	However , there are two case reports that show disease* tic - like symptoms *disease , including motor and phonic variants , occurring during treatment with quetiapine or clozapine .
We present a 15 - year - old girl schizophrenic who developed frequent involuntary eye - blinking movements after 5 months of amisulpride treatment ( 1000 mg per day ) .	We present a 15 - year - old girl disease* schizophrenic *disease who developed frequent disease* involuntary eye - blinking movements *disease after 5 months of amisulpride treatment ( 1000 mg per day ) .
The tic - like symptoms resolved completely after we reduced the dose of amisulpride down to 800 mg per day .	The disease* tic - like symptoms *disease resolved completely after we reduced the dose of amisulpride down to 800 mg per day .
However , her psychosis recurred after the dose reduction .	However , her disease* psychosis *disease recurred after the dose reduction .
We then placed her on an additional 100 mg per day of quetiapine .	We then placed her on an additional 100 mg per day of quetiapine .
She has been in complete remission under the combined medications for more than one year and maintains a fair role function .	She has been in complete remission under the combined medications for more than one year and maintains a fair role function .
No more tic - like symptoms or other side effects have been reported .	No more disease* tic - like symptoms *disease or other side effects have been reported .
Together with previously reported cases , our patient suggests that tic - like symptoms might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .	Together with previously reported cases , our patient suggests that disease* tic - like symptoms *disease might occur in certain vulnerable individuals during treatment with atypical antipsychotics such as quetiapine , clozapine , or amisulpride .
Chloroquine related complete heart block with blindness : case report .	Chloroquine related complete disease* heart block *disease with disease* blindness *disease : case report .
A 27 - year old African woman with history of regular chloroquine ingestion presented with progressive deterioration of vision , easy fatiguability , dyspnoea , dizziness progressing to syncopal attacks .	A 27 - year old African woman with history of regular chloroquine ingestion presented with progressive disease* deterioration of vision *disease , easy disease* fatiguability *disease , disease* dyspnoea *disease , disease* dizziness *disease progressing to disease* syncopal attacks *disease .
Ophthalmological assessment revealed features of chloroquine retinopathy , cardiac assessment revealed features of heart failure and a complete heart block with right bundle branch block pattern .	Ophthalmological assessment revealed features of chloroquine disease* retinopathy *disease , cardiac assessment revealed features of disease* heart failure *disease and a complete disease* heart block *disease with disease* right bundle branch block *disease pattern .
The heart block was treated by pacemaker insertion and the heart failure resolved spontaneously following chloroquine discontinuation .	The disease* heart block *disease was treated by pacemaker insertion and the disease* heart failure *disease resolved spontaneously following chloroquine discontinuation .
She however remains blind .	She however remains disease* blind *disease .
Effects of suprofen on the isolated perfused rat kidney .	Effects of suprofen on the isolated perfused rat kidney .
Although suprofen has been associated with the development of acute renal failure in greater than 100 subjects , the mechanism of damage remains unclear .	Although suprofen has been associated with the development of disease* acute renal failure *disease in greater than 100 subjects , the mechanism of damage remains unclear .
The direct nephrotoxic effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .	The direct disease* nephrotoxic *disease effects of a single dose of 15 mg of suprofen were compared in the recirculating isolated rat kidney perfused with cell - free buffer with or without the addition of 5 mg / dL of uric acid .
There were no significant differences in renal sodium excretion , oxygen consumption , or urinary flow rates in kidneys perfused with suprofen compared with the drug - free control groups .	There were no significant differences in renal sodium excretion , oxygen consumption , or urinary flow rates in kidneys perfused with suprofen compared with the drug - free control groups .
In contrast , a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid ; no changes were found with suprofen in the absence of uric acid .	In contrast , a significant decline in glomerular filtration rate was found after the introduction of suprofen to the kidney perfused with uric acid ; no changes were found with suprofen in the absence of uric acid .
A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen , compared with drug - free controls .	A significant decrease in the baseline excretion rate of uric acid was found in rats given suprofen , compared with drug - free controls .
However , the fractional excretion of uric acid was unchanged between the groups over the experimental period .	However , the fractional excretion of uric acid was unchanged between the groups over the experimental period .
In summary , suprofen causes acute declines in renal function , most likely by directly altering the intrarenal distribution of uric acid .	In summary , suprofen causes disease* acute declines in renal function *disease , most likely by directly altering the intrarenal distribution of uric acid .
Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine - induced amnesia in adult male rats .	Microinjection of ritanserin into the CA1 region of hippocampus improves scopolamine - induced disease* amnesia *disease in adult male rats .
The effect of ritanserin ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced amnesia in Morris water maze ( MWM ) was investigated .	The effect of ritanserin ( 5 - HT2 antagonist ) on scopolamine ( muscarinic cholinergic antagonist ) - induced disease* amnesia *disease in Morris water maze ( MWM ) was investigated .
Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus .	Rats were divided into eight groups and bilaterally cannulated into CA1 region of the hippocampus .
One week later , they received repeatedly vehicles ( saline , DMSO , saline + DMSO ) , scopolamine ( 2 microg / 0 . 5 microl saline / side ; 30 min before training ) , ritanserin ( 2 , 4 and 8 microg / 0 . 5 microl DMSO / side ; 20 min before training ) and scopolamine ( 2 microg / 0 . 5 microl ; 30 min before ritanserin injection ) + ritanserin ( 4 microg / 0 . 5 microl DMSO ) through cannulae each day .	One week later , they received repeatedly vehicles ( saline , DMSO , saline + DMSO ) , scopolamine ( 2 microg / 0 . 5 microl saline / side ; 30 min before training ) , ritanserin ( 2 , 4 and 8 microg / 0 . 5 microl DMSO / side ; 20 min before training ) and scopolamine ( 2 microg / 0 . 5 microl ; 30 min before ritanserin injection ) + ritanserin ( 4 microg / 0 . 5 microl DMSO ) through cannulae each day .
Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .	Animals were tested for four consecutive days ( 4 trial / day ) in MWM during which the position of hidden platform was unchanged .
In the fifth day , the platform was elevated above the water surface in another position to evaluate the function of motor , motivational and visual systems .	In the fifth day , the platform was elevated above the water surface in another position to evaluate the function of motor , motivational and visual systems .
The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine - treated group as compared to saline group .	The results showed a significant increase in escape latencies and traveled distances to find platform in scopolamine - treated group as compared to saline group .
Ritanserin - treated rats ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to DMSO - treated group .	Ritanserin - treated rats ( 4 microg / 0 . 5 microl / side ) showed a significant decrease in the mentioned parameters as compared to DMSO - treated group .
However , scopolamine and ritanserin co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine - treated rats .	However , scopolamine and ritanserin co - administration resulted in a significant decrease in escape latencies and traveled distances as compared to the scopolamine - treated rats .
Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine - induced amnesia .	Our findings show that microinjection of ritanserin into the CA1 region of the hippocampus improves the scopolamine - induced disease* amnesia *disease .
PTU - associated vasculitis in a girl with Turner Syndrome and Graves ' disease .	PTU - associated disease* vasculitis *disease in a girl with disease* Turner Syndrome *disease and disease* Graves ' disease *disease .
Palpable purpura is a concerning clinical finding in pediatric patients and can have many causes , including infectious and autoimmune processes .	Palpable disease* purpura *disease is a concerning clinical finding in pediatric patients and can have many causes , including infectious and autoimmune processes .
A rare cause , drug - induced vasculitis , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .	A rare cause , drug - induced disease* vasculitis *disease , may result from the production of antineutrophil cytoplasmic antibodies ( ANCAs ) in response to a medication .
We report a girl with Turner syndrome and Graves ' disease who presented with palpable purpuric lesions .	We report a girl with disease* Turner syndrome *disease and disease* Graves ' disease *disease who presented with palpable disease* purpuric lesions *disease .
The diagnosis of propylthiouracil ( PTU ) - associated vasculitis was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .	The diagnosis of propylthiouracil ( PTU ) - associated disease* vasculitis *disease was made by observation of consistent clinical features , the detection of elevated ANA and ANCA in the blood , and the observed clinical resolution of symptoms following withdrawal of PTU .
Subsequent treatment of persistent hyperthyroidism with radioablation did not result in an exacerbation of the vasculitis , a complication described in prior case reports .	Subsequent treatment of persistent disease* hyperthyroidism *disease with radioablation did not result in an exacerbation of the disease* vasculitis *disease , a complication described in prior case reports .
Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced amnesia .	Daidzein activates choline acetyltransferase from MC - IXC cells and improves drug - induced disease* amnesia *disease .
The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of Alzheimer ' s disease ( AD ) .	The choline acetyltransferase ( ChAT ) activator , which enhances cholinergic transmission via an augmentation of the enzymatic production of acetylcholine ( ACh ) , is an important factor in the treatment of disease* Alzheimer ' s disease *disease ( disease* AD *disease ) .
Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .	Methanolic extracts from Pueraria thunbergiana exhibited an activation effect ( 46 % ) on ChAT in vitro .
Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4 ' , 7 - dihydroxy - isoflavone ) .	Via the sequential isolation of Pueraria thunbergiana , the active component was ultimately identified as daidzein ( 4 ' , 7 - dihydroxy - isoflavone ) .
In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced impairments of learning and memory , we conducted a series of in vivo tests .	In order to investigate the effects of daidzein from Pueraria thunbergiana on scopolamine - induced disease* impairments of learning and memory *disease , we conducted a series of in vivo tests .
Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced amnesia , according to the results of a Y - maze test .	Administration of daidzein ( 4 . 5 mg / kg body weight ) to mice was shown significantly to reverse scopolamine - induced disease* amnesia *disease , according to the results of a Y - maze test .
Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .	Injections of scopolamine into mice resulted in impaired performance on Y - maze tests ( a 37 % decreases in alternation behavior ) .
By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .	By way of contrast , mice treated with daidzein prior to the scopolamine injections were noticeably protected from this performance impairment ( an approximately 12 % - 21 % decrease in alternation behavior ) .
These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced amnesia .	These results indicate that daidzein might play a role in acetylcholine biosynthesis as a ChAT activator , and that it also ameliorates scopolamine - induced disease* amnesia *disease .
Urinary symptoms and quality of life changes in Thai women with overactive bladder after tolterodine treatment .	Urinary symptoms and quality of life changes in Thai women with disease* overactive bladder *disease after tolterodine treatment .
OBJECTIVES : To study the urinary symptoms and quality of life changes in Thai women with overactive bladder ( OAB ) after tolterodine treatment .	OBJECTIVES : To study the urinary symptoms and quality of life changes in Thai women with disease* overactive bladder *disease ( disease* OAB *disease ) after tolterodine treatment .
MATERIAL AND METHOD : Thirty women ( aged 30 - 77 years ) diagnosed as having OAB at the Gynecology Clinic , King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study .	MATERIAL AND METHOD : Thirty women ( aged 30 - 77 years ) diagnosed as having disease* OAB *disease at the Gynecology Clinic , King Chulalongkorn Memorial Hospital from January to April 2004 were included in the present study .
Tolterodine 2 mg , twice daily was given .	Tolterodine 2 mg , twice daily was given .
After 8 weeks treatment , changes in micturition diary variables and tolerability were determined .	After 8 weeks treatment , changes in micturition diary variables and tolerability were determined .
Short form 36 ( SF36 ) questionaires ( Thai version ) were given before and after 8 weeks of treatment .	Short form 36 ( SF36 ) questionaires ( Thai version ) were given before and after 8 weeks of treatment .
RESULTS : At 8 weeks , all micturition per day decreased from 16 .	RESULTS : At 8 weeks , all micturition per day decreased from 16 .
7 + / - 5 .	7 + / - 5 .
3 to 6 .	3 to 6 .
7 + / - 2 . 4 times per day .	7 + / - 2 . 4 times per day .
The number of nocturia episodes decreased from 5 . 4 + / - 4 . 2 to 1 . 1 + / - 1 . 0 times per night .	The number of disease* nocturia *disease episodes decreased from 5 . 4 + / - 4 . 2 to 1 . 1 + / - 1 . 0 times per night .
The most common side effect was dry month in 5 cases ( 16 . 7 % ) with 2 cases reporting a moderate degree and 1 case with severe degree .	The most common side effect was disease* dry month *disease in 5 cases ( 16 . 7 % ) with 2 cases reporting a moderate degree and 1 case with severe degree .
Only one case ( 3 . 3 % ) withdrew from the present study due to a severe dry mouth .	Only one case ( 3 . 3 % ) withdrew from the present study due to a severe disease* dry mouth *disease .
The SF - 36 scores changed significantly in the domains of physical functioning , role function emotional , social function and mental heath .	The SF - 36 scores changed significantly in the domains of physical functioning , role function emotional , social function and mental heath .
CONCLUSION : Tolterodine was well tolerated and its effects improved the quality of life in Thai women with OAB .	CONCLUSION : Tolterodine was well tolerated and its effects improved the quality of life in Thai women with disease* OAB *disease .
Remifentanil pretreatment reduces myoclonus after etomidate .	Remifentanil pretreatment reduces disease* myoclonus *disease after etomidate .
STUDY OBJECTIVE : The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of myoclonus after anesthesia induction with etomidate .	STUDY OBJECTIVE : The aim of the study was to compare the effect of pretreatment with remifentanil 1 microg / kg and the effect of gender on the incidence of disease* myoclonus *disease after anesthesia induction with etomidate .
DESIGN : This was a randomized , double - blind study .	DESIGN : This was a randomized , double - blind study .
SETTING : The study was conducted at a university hospital .	SETTING : The study was conducted at a university hospital .
PATIENTS : Sixty patients were pretreated in a randomized double - blinded fashion with remifentanil 1 microg / kg or placebo .	PATIENTS : Sixty patients were pretreated in a randomized double - blinded fashion with remifentanil 1 microg / kg or placebo .
Two minutes after remifentanil or placebo injection , etomidate 0 . 3 mg / kg was given .	Two minutes after remifentanil or placebo injection , etomidate 0 . 3 mg / kg was given .
MEASUREMENTS : Myoclonus was recorded with a scale of 0 to 3 .	MEASUREMENTS : disease* Myoclonus *disease was recorded with a scale of 0 to 3 .
The grade of sedation ( none , mild , moderate , severe ) , nausea , pruritus , and apnea were recorded after injection of both drugs .	The grade of sedation ( none , mild , moderate , severe ) , disease* nausea *disease , disease* pruritus *disease , and disease* apnea *disease were recorded after injection of both drugs .
MAIN RESULTS : The incidence of myoclonus was significantly lower in the remifentanil group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .	MAIN RESULTS : The incidence of disease* myoclonus *disease was significantly lower in the remifentanil group ( 6 . 7 % ) than in the placebo group ( 70 % ) ( P < 0 . 001 ) .
None of the patients experienced sedation , apnea , nausea , or pruritus after injection of both drugs .	None of the patients experienced sedation , disease* apnea *disease , disease* nausea *disease , or disease* pruritus *disease after injection of both drugs .
In the placebo group , male patients were associated with significantly increased incidence of myoclonus after etomidate administration .	In the placebo group , male patients were associated with significantly increased incidence of disease* myoclonus *disease after etomidate administration .
CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced myoclonus after etomidate induction without side effects such as sedation , apnea , nausea , or pruritus .	CONCLUSION : Pretreatment with remifentanil 1 microg / kg reduced disease* myoclonus *disease after etomidate induction without side effects such as sedation , disease* apnea *disease , disease* nausea *disease , or disease* pruritus *disease .
Men experience increased incidence of myoclonus than women after etomidate administration .	Men experience increased incidence of disease* myoclonus *disease than women after etomidate administration .
Memory function and serotonin transporter promoter gene polymorphism in ecstasy ( MDMA ) users .	Memory function and serotonin transporter promoter gene polymorphism in ecstasy ( MDMA ) users .
Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT neurotoxic lesions on functions in which 5 - HT is involved , such as cognitive function .	Although 3 , 4 - methylenedioxymethamphetamine ( MDMA or ecstasy ) has been shown to damage brain serotonin ( 5 - HT ) neurons in animals and possibly humans , little is known about the long - term consequences of MDMA - induced 5 - HT disease* neurotoxic lesions *disease on functions in which 5 - HT is involved , such as cognitive function .
Because 5 - HT transporters play a key element in the regulation of synaptic 5 - HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5 - HT transporter promoter gene region ( 5 - HTTLPR ) when studying the effects of MDMA as well as cognitive functioning .	Because 5 - HT transporters play a key element in the regulation of synaptic 5 - HT transmission it may be important to control for the potential covariance effect of a polymorphism in the 5 - HT transporter promoter gene region ( 5 - HTTLPR ) when studying the effects of MDMA as well as cognitive functioning .
The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function , as well as the effects of long - term abstention from MDMA , in subjects genotyped for 5 - HTTLPR .	The aim of the study was to investigate the effects of moderate and heavy MDMA use on cognitive function , as well as the effects of long - term abstention from MDMA , in subjects genotyped for 5 - HTTLPR .
A second aim of the study was to determine whether these effects differ for females and males .	A second aim of the study was to determine whether these effects differ for females and males .
Fifteen moderate MDMA users ( < 55 lifetime tablets ) , 22 heavy MDMA + users ( > 55 lifetime tablets ) , 16 ex - MDMA + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .	Fifteen moderate MDMA users ( < 55 lifetime tablets ) , 22 heavy MDMA + users ( > 55 lifetime tablets ) , 16 ex - MDMA + users ( last tablet > 1 year ago ) and 13 controls were compared on a battery of neuropsychological tests .
DNA from peripheral nuclear blood cells was genotyped for 5 - HTTLPR using standard polymerase chain reaction methods . A significant group effect was observed only on memory function tasks ( p = 0 . 04 ) but not on reaction times ( p = 0 . 61 ) or attention / executive functioning ( p = 0 . 59 ) .	DNA from peripheral nuclear blood cells was genotyped for 5 - HTTLPR using standard polymerase chain reaction methods . A significant group effect was observed only on memory function tasks ( p = 0 . 04 ) but not on reaction times ( p = 0 . 61 ) or attention / executive functioning ( p = 0 . 59 ) .
Heavy and ex - MDMA + users performed significantly poorer on memory tasks than controls .	Heavy and ex - MDMA + users performed significantly poorer on memory tasks than controls .
In contrast , no evidence of memory impairment was observed in moderate MDMA users .	In contrast , no evidence of disease* memory impairment *disease was observed in moderate MDMA users .
No significant effect of 5 - HTTLPR or gender was observed .	No significant effect of 5 - HTTLPR or gender was observed .
While the use of MDMA in quantities that may be considered " moderate " is not associated with impaired memory functioning , heavy use of MDMA use may lead to long lasting memory impairments .	While the use of MDMA in quantities that may be considered " moderate " is not associated with disease* impaired memory functioning *disease , heavy use of MDMA use may lead to long lasting disease* memory impairments *disease .
No effect of 5 - HTTLPR or gender on memory function or MDMA use was observed .	No effect of 5 - HTTLPR or gender on memory function or MDMA use was observed .
Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol - induced myocardial infarction in rats .	Role of mangiferin on biochemical alterations and antioxidant status in isoproterenol - induced disease* myocardial infarction *disease in rats .
The current study dealt with the protective role of mangiferin , a polyphenol from Mangifera indica Linn .	The current study dealt with the protective role of mangiferin , a polyphenol from Mangifera indica Linn .
( Anacardiaceae ) , on isoproterenol ( ISPH ) - induced myocardial infarction ( MI ) in rats through its antioxidative mechanism .	( Anacardiaceae ) , on isoproterenol ( ISPH ) - induced disease* myocardial infarction *disease ( disease* MI *disease ) in rats through its antioxidative mechanism .
Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused myocardial damage in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .	Subcutaneous injection of ISPH ( 200 mg / kg body weight in 1 ml saline ) to rats for 2 consecutive days caused disease* myocardial damage *disease in rat heart , which was determined by the increased activity of serum lactate dehydrogenase ( LDH ) and creatine phosphokinase isoenzymes ( CK - MB ) , increased uric acid level and reduced plasma iron binding capacity .
The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the ischemic myocardium .	The protective role of mangiferin was analyzed by triphenyl tetrazolium chloride ( TTC ) test used for macroscopic enzyme mapping assay of the disease* ischemic myocardium *disease .
The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in MI rats .	The heart tissue antioxidant enzymes such as superoxide dismutase , catalase , glutathione peroxidase , glutathione transferase and glutathione reductase activities , non - enzymic antioxidants such as cerruloplasmin , Vitamin C , Vitamin E and glutathione levels were altered in disease* MI *disease rats .
Upon pretreatment with mangiferin ( 100 mg / kg body weight suspended in 2 ml of dimethyl sulphoxide ) given intraperitoneally for 28 days to MI rats protected the above - mentioned parameters to fall from the normal levels .	Upon pretreatment with mangiferin ( 100 mg / kg body weight suspended in 2 ml of dimethyl sulphoxide ) given intraperitoneally for 28 days to disease* MI *disease rats protected the above - mentioned parameters to fall from the normal levels .
Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH - induced MI rats .	Activities of heart tissue enzymic antioxidants and serum non - enzymic antioxidants levels rose significantly upon mangiferin administration as compared to ISPH - induced disease* MI *disease rats .
From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH - induced MI due to its antioxidant potential , which regulated the tissues defense system against cardiac damage .	From the present study it is concluded that mangiferin exerts a beneficial effect against ISPH - induced disease* MI *disease due to its antioxidant potential , which regulated the tissues defense system against disease* cardiac damage *disease .
Cardiovascular risk with cyclooxygenase inhibitors : general problem with substance specific differences ?	Cardiovascular risk with cyclooxygenase inhibitors : general problem with substance specific differences ?
Randomised clinical trials and observational studies have shown an increased risk of myocardial infarction , stroke , hypertension and heart failure during treatment with cyclooxygenase inhibitors .	Randomised clinical trials and observational studies have shown an increased risk of disease* myocardial infarction *disease , disease* stroke *disease , disease* hypertension *disease and disease* heart failure *disease during treatment with cyclooxygenase inhibitors .
Adverse cardiovascular effects occurred mainly , but not exclusively , in patients with concomitant risk factors .	Adverse cardiovascular effects occurred mainly , but not exclusively , in patients with concomitant risk factors .
Cyclooxygenase inhibitors cause complex changes in renal , vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention .	Cyclooxygenase inhibitors cause complex changes in renal , vascular and cardiac prostanoid profiles thereby increasing vascular resistance and fluid retention .
The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time .	The incidence of cardiovascular adverse events tends to increase with the daily dose and total exposure time .
A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance - specific differences , which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin - independent effects .	A comparison of individual selective and unselective cyclooxygenase inhibitors suggests substance - specific differences , which may depend on differences in pharmacokinetic parameters or inhibitory potency and may be contributed by prostaglandin - independent effects .
Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious cardiovascular toxicity .	Diagnostic markers such as N - terminal pro brain natriuretic peptide ( NT - proBNP ) or high - sensitive C - reactive protein might help in the early identification of patients at risk , thus avoiding the occurrence of serious disease* cardiovascular toxicity *disease .
Pilocarpine seizures cause age - dependent impairment in auditory location discrimination .	Pilocarpine disease* seizures *disease cause age - dependent disease* impairment in auditory location discrimination *disease .
Children who have status epilepticus have continuous or rapidly repeating seizures that may be life - threatening and may cause life - long changes in brain and behavior .	Children who have disease* status epilepticus *disease have continuous or rapidly repeating disease* seizures *disease that may be life - threatening and may cause life - long changes in brain and behavior .
The extent to which status epilepticus causes deficits in auditory discrimination is unknown .	The extent to which disease* status epilepticus *disease causes disease* deficits in auditory discrimination *disease is unknown .
A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of status epilepticus .	A naturalistic auditory location discrimination method was used to evaluate this question using an animal model of disease* status epilepticus *disease .
Male Sprague - Dawley rats were injected with saline on postnatal day ( P ) 20 , or a convulsant dose of pilocarpine on P20 or P45 .	Male Sprague - Dawley rats were injected with saline on postnatal day ( P ) 20 , or a convulsant dose of pilocarpine on P20 or P45 .
Pilocarpine on either day induced status epilepticus ; status epilepticus at P45 resulted in CA3 cell loss and spontaneous seizures , whereas P20 rats had no cell loss or spontaneous seizures .	Pilocarpine on either day induced disease* status epilepticus *disease ; disease* status epilepticus *disease at P45 resulted in CA3 cell loss and spontaneous disease* seizures *disease , whereas P20 rats had no cell loss or spontaneous disease* seizures *disease .
Mature rats were trained with sound - source location and sound - silence discriminations .	Mature rats were trained with sound - source location and sound - silence discriminations .
Control ( saline P20 ) rats acquired both discriminations immediately .	Control ( saline P20 ) rats acquired both discriminations immediately .
In status epilepticus ( P20 ) rats , acquisition of the sound - source location discrimination was moderately impaired .	In disease* status epilepticus *disease ( P20 ) rats , acquisition of the sound - source location discrimination was moderately impaired .
Status epilepticus ( P45 ) rats failed to acquire either sound - source location or sound - silence discriminations .	disease* Status epilepticus *disease ( P45 ) rats failed to acquire either sound - source location or sound - silence discriminations .
Status epilepticus in rat causes an age - dependent , long - term impairment in auditory discrimination .	disease* Status epilepticus *disease in rat causes an age - dependent , long - term disease* impairment in auditory discrimination *disease .
This impairment may explain one cause of impaired auditory location discrimination in humans .	This impairment may explain one cause of disease* impaired auditory location discrimination *disease in humans .
Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder .	Nerve growth factor and prostaglandins in the urine of female patients with disease* overactive bladder *disease .
PURPOSE : NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine .	PURPOSE : NGF and PGs in the bladder can be affected by pathological changes in the bladder and these changes can be detected in urine .
We investigated changes in urinary NGF and PGs in women with OAB .	We investigated changes in urinary NGF and PGs in women with disease* OAB *disease .
MATERIALS AND METHODS : The study groups included 65 women with OAB and 20 without bladder symptoms who served as controls .	MATERIALS AND METHODS : The study groups included 65 women with disease* OAB *disease and 20 without bladder symptoms who served as controls .
Evaluation included patient history , urinalysis , a voiding diary and urodynamic studies .	Evaluation included patient history , urinalysis , a voiding diary and urodynamic studies .
Urine samples were collected .	Urine samples were collected .
NGF , PGE2 , PGF2alpha and PGI2 were measured using enzyme - linked immunosorbent assay and compared between the groups .	NGF , PGE2 , PGF2alpha and PGI2 were measured using enzyme - linked immunosorbent assay and compared between the groups .
In addition , correlations between urinary NGF and PG , and urodynamic parameters in patients with OAB were examined .	In addition , correlations between urinary NGF and PG , and urodynamic parameters in patients with disease* OAB *disease were examined .
RESULTS : Urinary NGF , PGE2 and PGF2alpha were significantly increased in patients with OAB compared with controls ( p < 0 . 05 ) .	RESULTS : Urinary NGF , PGE2 and PGF2alpha were significantly increased in patients with disease* OAB *disease compared with controls ( p < 0 . 05 ) .
However , urinary PGI2 was not different between controls and patients with OAB .	However , urinary PGI2 was not different between controls and patients with disease* OAB *disease .
In patients with OAB urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity ( p < 0 . 05 ) .	In patients with disease* OAB *disease urinary PGE2 positively correlated with volume at first desire to void and maximum cystometric capacity ( p < 0 . 05 ) .
Urinary NGF , PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with OAB .	Urinary NGF , PGF2alpha and PGI2 did not correlate with urodynamic parameters in patients with disease* OAB *disease .
CONCLUSIONS : NGF and PGs have important roles in the development of OAB symptoms in female patients .	CONCLUSIONS : NGF and PGs have important roles in the development of disease* OAB *disease symptoms in female patients .
Urinary levels of these factors may be used as markers to evaluate OAB symptoms .	Urinary levels of these factors may be used as markers to evaluate disease* OAB *disease symptoms .
Definition and management of anemia in patients infected with hepatitis C virus .	Definition and management of disease* anemia *disease in patients disease* infected with hepatitis C virus *disease .
Chronic infection with hepatitis C virus ( HCV ) can progress to cirrhosis , hepatocellular carcinoma , and end - stage liver disease .	disease* Chronic infection with hepatitis C virus *disease ( HCV ) can progress to disease* cirrhosis *disease , disease* hepatocellular carcinoma *disease , and disease* end - stage liver disease *disease .
The current best treatment for HCV infection is combination therapy with pegylated interferon and ribavirin .	The current best treatment for disease* HCV infection *disease is combination therapy with pegylated interferon and ribavirin .
Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting hemolytic anemia .	Although this regimen produces sustained virologic responses ( SVRs ) in approximately 50 % of patients , it can be associated with a potentially dose - limiting disease* hemolytic anemia *disease .
Hemoglobin concentrations decrease mainly as a result of ribavirin - induced hemolysis , and this anemia can be problematic in patients with HCV infection , especially those who have comorbid renal or cardiovascular disorders .	Hemoglobin concentrations decrease mainly as a result of ribavirin - induced disease* hemolysis *disease , and this disease* anemia *disease can be problematic in patients with disease* HCV infection *disease , especially those who have comorbid disease* renal or cardiovascular disorders *disease .
In general , anemia can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .	In general , disease* anemia *disease can increase the risk of morbidity and mortality , and may have negative effects on cerebral function and quality of life .
Although ribavirin - associated anemia can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .	Although ribavirin - associated disease* anemia *disease can be reversed by dose reduction or discontinuation , this approach compromises outcomes by significantly decreasing SVR rates .
Recombinant human erythropoietin has been used to manage ribavirin - associated anemia but has other potential disadvantages .	Recombinant human erythropoietin has been used to manage ribavirin - associated disease* anemia *disease but has other potential disadvantages .
Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of hemolytic anemia in patients with chronic hepatitis C .	Viramidine , a liver - targeting prodrug of ribavirin , has the potential to maintain the virologic efficacy of ribavirin while decreasing the risk of disease* hemolytic anemia *disease in patients with disease* chronic hepatitis C *disease .
Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures .	Impact of alcohol exposure after pregnancy recognition on ultrasonographic fetal growth measures .
BACKGROUND : More than 3 decades after Jones and Smith ( 1973 ) reported on the devastation caused by alcohol exposure on fetal development , the rates of heavy drinking during pregnancy remain relatively unchanged .	BACKGROUND : More than 3 decades after Jones and Smith ( 1973 ) reported on the devastation caused by alcohol exposure on fetal development , the rates of heavy drinking during pregnancy remain relatively unchanged .
Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes .	Early identification of fetal alcohol exposure and maternal abstinence led to better infant outcomes .
This study examined the utility of biometry for detecting alcohol - related fetal growth impairment .	This study examined the utility of biometry for detecting alcohol - related fetal disease* growth impairment *disease .
METHODS : We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study .	METHODS : We obtained fetal ultrasound measures from routine ultrasound examinations for 167 pregnant hazardous drinkers who were enrolled in a brief alcohol intervention study .
The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies .	The fetal measures for women who quit after learning of their pregnancies were compared with measures for women who continued some drinking throughout the course of their pregnancies .
Because intensity of alcohol consumption is associated with poorer fetal outcomes , separate analyses were conducted for the heavy ( average of > or = 5 drinks per drinking day ) alcohol consumers .	Because intensity of alcohol consumption is associated with poorer fetal outcomes , separate analyses were conducted for the heavy ( average of > or = 5 drinks per drinking day ) alcohol consumers .
Fetal measures from the heavy - exposed fetuses were also compared with measures from a nondrinking group that was representative of normal , uncomplicated pregnancies from our clinics .	Fetal measures from the heavy - exposed fetuses were also compared with measures from a nondrinking group that was representative of normal , uncomplicated pregnancies from our clinics .
Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and drug abuse .	Analyses of covariance were used to determine whether there were differences between groups after controlling for influences of gestational age and disease* drug abuse *disease .
RESULTS : Nearly half of the pregnant drinkers abstained after learning of their pregnancies .	RESULTS : Nearly half of the pregnant drinkers abstained after learning of their pregnancies .
When women reportedly quit drinking early in their pregnancies , fetal growth measures were not significantly different from a non - alcohol - exposed group , regardless of prior drinking patterns .	When women reportedly quit drinking early in their pregnancies , fetal growth measures were not significantly different from a non - alcohol - exposed group , regardless of prior drinking patterns .
Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in reduced cerebellar growth as well as decreased cranial to body growth in comparison with women who either quit drinking or who were nondrinkers .	Any alcohol consumption postpregnancy recognition among the heavy drinkers resulted in disease* reduced cerebellar growth *disease as well as disease* decreased cranial to body growth *disease in comparison with women who either quit drinking or who were nondrinkers .
Amphetamine abuse was predictive of larger cranial to body growth ratios .	Amphetamine abuse was predictive of larger cranial to body growth ratios .
CONCLUSIONS : Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies .	CONCLUSIONS : Alterations in fetal biometric measurements were observed among the heavy drinkers only when they continued drinking after becoming aware of their pregnancies .
Although the reliance on self - reported drinking is a limitation in this study , these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects .	Although the reliance on self - reported drinking is a limitation in this study , these findings support the benefits of early abstinence and the potential for ultrasound examinations in the detection of fetal alcohol effects .
Ethambutol - associated optic neuropathy .	Ethambutol - associated disease* optic neuropathy *disease .
INTRODUCTION : Ethambutol is used in the treatment of tuberculosis , which is still prevalent in Southeast Asia , and can be associated with permanent visual loss .	INTRODUCTION : Ethambutol is used in the treatment of disease* tuberculosis *disease , which is still prevalent in Southeast Asia , and can be associated with permanent disease* visual loss *disease .
We report 3 cases which presented with bitemporal hemianopia .	We report 3 cases which presented with disease* bitemporal hemianopia *disease .
CLINICAL PICTURE : Three patients with ethambutol - associated toxic optic neuropathy are described .	CLINICAL PICTURE : Three patients with ethambutol - associated toxic disease* optic neuropathy *disease are described .
All 3 patients had loss of central visual acuity , colour vision ( Ishihara ) and visual field .	All 3 patients had disease* loss of central visual acuity , colour vision ( Ishihara ) and visual field *disease .
The visual field loss had a bitemporal flavour , suggesting involvement of the optic chiasm .	The disease* visual field loss *disease had a bitemporal flavour , suggesting involvement of the optic chiasm .
TREATMENT : Despite stopping ethambutol on diagnosis , visual function continued to deteriorate for a few months .	TREATMENT : Despite stopping ethambutol on diagnosis , visual function continued to deteriorate for a few months .
Subsequent improvement was mild in 2 cases .	Subsequent improvement was mild in 2 cases .
In the third case , visual acuity and colour vision normalised but the optic discs were pale .	In the third case , visual acuity and colour vision normalised but the optic discs were pale .
OUTCOME : All 3 patients had some permanent loss of visual function .	OUTCOME : All 3 patients had some permanent disease* loss of visual function *disease .
CONCLUSIONS : Ethambutol usage is associated with permanent visual loss and should be avoided if possible or used with caution and proper ophthalmological follow - up .	CONCLUSIONS : Ethambutol usage is associated with permanent disease* visual loss *disease and should be avoided if possible or used with caution and proper ophthalmological follow - up .
The author postulates that in cases of ethambutol associated chiasmopathy , ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm .	The author postulates that in cases of ethambutol associated chiasmopathy , ethambutol may initially affect the optic nerves and subsequently progress to involve the optic chiasm .
Possible neuroleptic malignant syndrome related to concomitant treatment with paroxetine and alprazolam .	Possible disease* neuroleptic malignant syndrome *disease related to concomitant treatment with paroxetine and alprazolam .
A 74 - year - old man with depressive symptoms was admitted to a psychiatric hospital due to insomnia , loss of appetite , exhaustion , and agitation .	A 74 - year - old man with disease* depressive symptoms *disease was admitted to a disease* psychiatric *disease hospital due to disease* insomnia *disease , disease* loss of appetite *disease , exhaustion , and disease* agitation *disease .
Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1 . 2 mg alprazolam .	Medical treatment was initiated at a daily dose of 20 mg paroxetine and 1 . 2 mg alprazolam .
On the 10th day of paroxetine and alprazolam treatment , the patient exhibited marked psychomotor retardation , disorientation , and severe muscle rigidity with tremors .	On the 10th day of paroxetine and alprazolam treatment , the patient exhibited marked disease* psychomotor retardation *disease , disorientation , and severe disease* muscle rigidity *disease with disease* tremors *disease .
The patient had a fever ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70 mg mm Hg ) , and severe extrapyramidal symptoms .	The patient had a disease* fever *disease ( 38 . 2 degrees C ) , fluctuating blood pressure ( between 165 / 90 and 130 / 70 mg mm Hg ) , and severe disease* extrapyramidal symptoms *disease .
Laboratory tests showed an elevation of creatine phosphokinase ( 2218 IU / L ) , aspartate aminotransferase ( 134 IU / L ) , alanine aminotransferase ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .	Laboratory tests showed an elevation of creatine phosphokinase ( 2218 IU / L ) , aspartate aminotransferase ( 134 IU / L ) , alanine aminotransferase ( 78 IU / L ) , and BUN ( 27 . 9 mg / ml ) levels .
The patient received bromocriptine and diazepam to treat his symptoms .	The patient received bromocriptine and diazepam to treat his symptoms .
7 days later , the fever disappeared and the patient ' s serum CPK levels were normalized ( 175 IU / L ) .	7 days later , the disease* fever *disease disappeared and the patient ' s serum CPK levels were normalized ( 175 IU / L ) .
This patient presented with symptoms of neuroleptic malignant syndrome ( NMS ) , thus demonstrating that NMS - like symptoms can occur after combined paroxetine and alprazolam treatment .	This patient presented with symptoms of disease* neuroleptic malignant syndrome *disease ( disease* NMS *disease ) , thus demonstrating that disease* NMS *disease - like symptoms can occur after combined paroxetine and alprazolam treatment .
The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case , indicating a probable relationship between the patient ' s NMS - like adverse symptoms and the combined treatment used in this case .	The adverse drug reaction score obtained by the Naranjo algorithm was 6 in our case , indicating a probable relationship between the patient ' s disease* NMS *disease - like adverse symptoms and the combined treatment used in this case .
The involvement of physiologic and environmental aspects specific to this patient was suspected .	The involvement of physiologic and environmental aspects specific to this patient was suspected .
Several risk factors for NMS should be noted in elderly depressive patients whose symptoms often include dehydration , agitation , malnutrition , and exhaustion .	Several risk factors for disease* NMS *disease should be noted in elderly disease* depressive *disease patients whose symptoms often include disease* dehydration *disease , disease* agitation *disease , disease* malnutrition *disease , and exhaustion .
Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from depression .	Careful therapeutic intervention is necessary in cases involving elderly patients who suffer from disease* depression *disease .
Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced convulsions and the counteraction by co - administration with local anesthetics .	Down - regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local - anesthetics - induced disease* convulsions *disease and the counteraction by co - administration with local anesthetics .
Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to seizures induce by cocaine and local anesthetics were studied in mice .	Alterations of norepinephrine transporter ( NET ) function by chronic inhibition of NET in relation to sensitization to disease* seizures *disease induce by cocaine and local anesthetics were studied in mice .
Daily administration of desipramine , an inhibitor of the NET , for 5 days decreased [ ( 3 ) H ] norepinephrine uptake in the P2 fractions of hippocampus but not cortex , striatum or amygdalae .	Daily administration of desipramine , an inhibitor of the NET , for 5 days decreased [ ( 3 ) H ] norepinephrine uptake in the P2 fractions of hippocampus but not cortex , striatum or amygdalae .
Co - administration of lidocaine , bupivacaine or tricaine with desipramine reversed this effect .	Co - administration of lidocaine , bupivacaine or tricaine with desipramine reversed this effect .
Daily treatment of cocaine increased [ ( 3 ) H ] norepinephrine uptake into the hippocampus .	Daily treatment of cocaine increased [ ( 3 ) H ] norepinephrine uptake into the hippocampus .
Daily administration of desipramine increased the incidence of appearance of lidocaine - induced convulsions and decreased that of cocaine - induced convulsions .	Daily administration of desipramine increased the incidence of appearance of lidocaine - induced disease* convulsions *disease and decreased that of cocaine - induced disease* convulsions *disease .
Co - administration of lidocaine with desipramine reversed the changes of convulsive activity of lidocaine and cocaine induced by repeated administration of desipramine .	Co - administration of lidocaine with desipramine reversed the changes of disease* convulsive *disease activity of lidocaine and cocaine induced by repeated administration of desipramine .
These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine convulsions .	These results suggest that down - regulation of hippocampal NET induced by chronic administration of desipramine may be relevant to desipramine - induced sensitization of lidocaine disease* convulsions *disease .
Inhibition of Na ( + ) channels by local anesthetics may regulate desipramine - induced down - regulation of NET function .	Inhibition of Na ( + ) channels by local anesthetics may regulate desipramine - induced down - regulation of NET function .
Repeated administration of cocaine induces up - regulation of hippocampal NET function .	Repeated administration of cocaine induces up - regulation of hippocampal NET function .
Desipramine - induced sensitization of lidocaine seizures may have a mechanism distinct from kindling resulting from repeated administration of cocaine .	Desipramine - induced sensitization of lidocaine disease* seizures *disease may have a mechanism distinct from kindling resulting from repeated administration of cocaine .
Atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .	Atorvastatin prevented and reversed dexamethasone - induced disease* hypertension *disease in the rat .
To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced hypertension , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .	To assess the antioxidant effects of atorvastatin ( atorva ) on dexamethasone ( dex ) - induced disease* hypertension *disease , 60 male Sprague - Dawley rats were treated with atorva 30 mg / kg / day or tap water for 15 days .
Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / - 392 . 8 U / ml dex , P < 0 . 001 ) .	Dex increased systolic blood pressure ( SBP ) from 109 + / - 1 . 8 to 135 + / - 0 . 6 mmHg and plasma superoxide ( 5711 + / - 284 . 9 saline , 7931 + / - 392 . 8 U / ml dex , P < 0 . 001 ) .
In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .	In this prevention study , SBP in the atorva + dex group was increased from 115 + / - 0 . 4 to 124 + / - 1 . 5 mmHg , but this was significantly lower than in the dex - only group ( P ' < 0 . 05 ) .
Atorva reversed dex - induced hypertension ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / - 441 . 2 atorva + dex , P < 0 . 0001 ) .	Atorva reversed dex - induced disease* hypertension *disease ( 129 + / - 0 . 6 mmHg , vs . 135 + / - 0 . 6 mmHg P ' < 0 . 05 ) and decreased plasma superoxide ( 7931 + / - 392 . 8 dex , 1187 + / - 441 . 2 atorva + dex , P < 0 . 0001 ) .
Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .	Plasma nitrate / nitrite ( NOx ) was decreased in dex - treated rats compared to saline - treated rats ( 11 . 2 + / - 1 . 08 microm , 15 . 3 + / - 1 . 17 microm , respectively , P < 0 . 05 ) .
Atorva affected neither plasma NOx nor thymus weight .	Atorva affected neither plasma NOx nor thymus weight .
Thus , atorvastatin prevented and reversed dexamethasone - induced hypertension in the rat .	Thus , atorvastatin prevented and reversed dexamethasone - induced disease* hypertension *disease in the rat .
Peripheral neuropathy caused by high - dose cytosine arabinoside treatment in a patient with acute myeloid leukemia .	disease* Peripheral neuropathy *disease caused by high - dose cytosine arabinoside treatment in a patient with disease* acute myeloid leukemia *disease .
The central nervous system toxicity of high - dose cytosine arabinoside is well recognized , but the toxicity of cytosine arabinoside in the peripheral nervous system has been infrequently reported .	The central nervous system disease* toxicity *disease of high - dose cytosine arabinoside is well recognized , but the disease* toxicity *disease of cytosine arabinoside in the peripheral nervous system has been infrequently reported .
A 49 - year - old Japanese man was diagnosed with acute myeloid leukemia .	A 49 - year - old Japanese man was diagnosed with disease* acute myeloid leukemia *disease .
After he achieved complete remission , he received high - dose cytosine arabinoside treatment ( 2 g / m2 twice a day for 5 days ; total , 20 g / m2 ) as consolidation therapy .	After he achieved complete remission , he received high - dose cytosine arabinoside treatment ( 2 g / m2 twice a day for 5 days ; total , 20 g / m2 ) as consolidation therapy .
The first course of high - dose cytosine arabinoside resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of numbness in his right foot .	The first course of high - dose cytosine arabinoside resulted in no unusual symptoms , but on day 21 of the second course of treatment , the patient complained of disease* numbness *disease in his right foot .
Electromyogram and nerve - conduction studies showed peripheral neuropathy in both peroneal nerves .	Electromyogram and nerve - conduction studies showed disease* peripheral neuropathy *disease in both peroneal nerves .
This neuropathy was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of graft - versus - host disease , and the symptoms subsequently responded to methylprednisolone .	This disease* neuropathy *disease was gradually resolving ; however , after the patient received allogeneic bone marrow transplantation , the symptoms worsened , with the development of disease* graft - versus - host disease *disease , and the symptoms subsequently responded to methylprednisolone .
Although the mechanisms of peripheral neuropathy are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .	Although the mechanisms of disease* peripheral neuropathy *disease are still unclear , high - dose cytosine arabinoside is a therapy that is potentially toxic to the peripheral nervous system , and auto / alloimmunity may play an important role in these mechanisms .
Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced neurotoxicity .	Effect of alpha - tocopherol and deferoxamine on methamphetamine - induced disease* neurotoxicity *disease .
Methamphetamine ( MA ) - induced dopaminergic neurotoxicity is believed to be associated with the increased formation of free radicals .	Methamphetamine ( MA ) - induced dopaminergic disease* neurotoxicity *disease is believed to be associated with the increased formation of free radicals .
This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced neurotoxicity .	This study examined the effect of alpha - tocopherol ( alpha - TC ) , a scavenger of reactive oxygen species , and deferoxamine ( DFO ) , an iron chelator , on the MA - induced disease* neurotoxicity *disease .
Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .	Male rats were treated with MA ( 10 mg / kg , every 2 h for four injections ) .
The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .	The rat received either alpha - TC ( 20 mg / kg ) intraperitoneally for 3 days and 30 min prior to MA administration or DFO ( 50 mg / kg ) subcutaneously 30 min before MA administration .
The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .	The concentrations of dopamine ( DA ) , serotonin and their metabolites decreased significantly after MA administration , which was inhibited by the alpha - TC and DFO pretreatment .
alpha - TC and DFO attenuated the MA - induced hyperthermia as well as the alterations in the locomotor activity .	alpha - TC and DFO attenuated the MA - induced disease* hyperthermia *disease as well as the alterations in the locomotor activity .
The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .	The level of lipid peroxidation was higher and the reduced glutathione concentration was lower in the MA - treated rats .
These changes were significantly attenuated by alpha - TC and DFO .	These changes were significantly attenuated by alpha - TC and DFO .
This suggests that alpha - TC and DFO ameliorate the MA - induced neuronal damage by decreasing the level of oxidative stress .	This suggests that alpha - TC and DFO ameliorate the MA - induced disease* neuronal damage *disease by decreasing the level of oxidative stress .
Blockade of both D - 1 and D - 2 dopamine receptors may induce catalepsy in mice .	Blockade of both D - 1 and D - 2 dopamine receptors may induce disease* catalepsy *disease in mice .
1 .	1 .
The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined .	The disease* catalepsy *disease induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in disease* catalepsy *disease was determined .
2 .	2 .
Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced catalepsy .	Dopamine antagonist fluphenazine , D - 1 antagonist SCH 23390 or D - 2 antagonist sulpiride induced disease* catalepsy *disease .
The effect of fluphenazine and sulpiride was dose - dependent .	The effect of fluphenazine and sulpiride was dose - dependent .
Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation .	Combination of SCH 23390 with sulpiride did not induce disease* catalepsy *disease potentiation .
3 .	3 .
D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the catalepsy induced by fluphenazine , SCH 23390 or sulpiride .	D - 1 agonist SKF 38393 or D - 2 agonist quinpirole decreased the disease* catalepsy *disease induced by fluphenazine , SCH 23390 or sulpiride .
4 .	4 .
Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists .	Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on disease* catalepsy *disease induced by dopamine antagonists .
5 .	5 .
The data may indicate that although D - 2 receptor blockade is involved in catalepsy , the D - 1 receptor may plan a role .	The data may indicate that although D - 2 receptor blockade is involved in disease* catalepsy *disease , the D - 1 receptor may plan a role .
Sustained clinical improvement of a patient with decompensated hepatitis B virus - related cirrhosis after treatment with lamivudine monotherapy .	Sustained clinical improvement of a patient with decompensated disease* hepatitis B *disease virus - related disease* cirrhosis *disease after treatment with lamivudine monotherapy .
Hepatitis B virus ( HBV ) infection , which causes liver cirrhosis and hepatocellular carcinoma , remains a major health problem in Asian countries .	disease* Hepatitis B virus ( HBV ) infection *disease , which causes disease* liver cirrhosis *disease and disease* hepatocellular carcinoma *disease , remains a major health problem in Asian countries .
Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers , although the standard medical therapies have not been established up to now .	Recent development of vaccine for prevention is reported to be successful in reducing the size of chronically infected carriers , although the standard medical therapies have not been established up to now .
In this report , we encountered a patient with decompensated HBV - related cirrhosis who exhibited the dramatic improvements after antiviral therapy .	In this report , we encountered a patient with decompensated HBV - related disease* cirrhosis *disease who exhibited the dramatic improvements after antiviral therapy .
The patient was a 50 - year - old woman .	The patient was a 50 - year - old woman .
Previous conventional medical treatments were not effective for this patient , thus this patient had been referred to our hospital .	Previous conventional medical treatments were not effective for this patient , thus this patient had been referred to our hospital .
However , the administration of lamivudine , a reverse transcriptase inhibitor , for 23 months dramatically improved her liver severity .	However , the administration of lamivudine , a reverse transcriptase inhibitor , for 23 months dramatically improved her liver severity .
During this period , no drug resistant mutant HBV emerged , and the serum HBV - DNA level was continuously suppressed .	During this period , no drug resistant mutant HBV emerged , and the serum HBV - DNA level was continuously suppressed .
These virological responses were also maintained even after the antiviral therapy was discontinued .	These virological responses were also maintained even after the antiviral therapy was discontinued .
Moreover , both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient .	Moreover , both hepatitis B surface antigen and e antigen were observed to have disappeared in this patient .
The administration of lamivudine to patients with HBV - related cirrhosis , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .	The administration of lamivudine to patients with HBV - related disease* cirrhosis *disease , like our present case , should be considered as an initial medical therapeutic option , especially in countries where liver transplantation is not reliably available .
Antiarrhythmic effects of optical isomers of cibenzoline on canine ventricular arrhythmias .	Antiarrhythmic effects of optical isomers of cibenzoline on canine disease* ventricular arrhythmias *disease .
Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine ventricular arrhythmia models .	Antiarrhythmic effects of ( + ) - cibenzoline and ( - ) - cibenzoline were examined using two canine disease* ventricular arrhythmia *disease models .
Digitalis arrhythmia , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in pentobarbital - anesthetized dogs .	Digitalis disease* arrhythmia *disease , which is suppressed by Na channel blockers , was induced by intermittent intravenous ( i . v . ) injection of ouabain in pentobarbital - anesthetized dogs .
Adrenaline arrhythmia , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .	disease* Adrenaline arrhythmia *disease , which is suppressed by Ca channel blockers , was induced by adrenaline infusion in halothane - anesthetized dogs .
Ten and 5 mg / kg i . v . ( + ) - cibenzoline suppressed digitalis - and adrenaline - induced arrhythmias , respectively .	Ten and 5 mg / kg i . v . ( + ) - cibenzoline suppressed digitalis - and adrenaline - induced disease* arrhythmias *disease , respectively .
The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and adrenaline - induced arrhythmias were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .	The minimum effective plasma concentrations of ( + ) - cibenzoline for digitalis - and adrenaline - induced disease* arrhythmias *disease were 1 . 4 + / - 0 . 4 and 2 . 0 + / - 0 . 6 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
A lower dose of 1 mg / kg i . v . of ( - ) - cibenzoline suppressed the digitalis - induced arrhythmia , whereas 5 mg / kg i . v . was needed to suppress adrenaline - induced arrhythmias .	A lower dose of 1 mg / kg i . v . of ( - ) - cibenzoline suppressed the digitalis - induced disease* arrhythmia *disease , whereas 5 mg / kg i . v . was needed to suppress adrenaline - induced disease* arrhythmias *disease .
The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced arrhythmia were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .	The minimum effective plasma concentrations of ( - ) - cibenzoline for digitalis - and adrenaline - induced disease* arrhythmia *disease were 0 . 06 + / - 0 . 04 and 0 . 7 + / - 0 . 1 micrograms / ml , respectively ( mean + / - SD , n = 6 ) .
The stronger antiarrhythmic effect of ( - ) - cibenzoline indicates that ( - ) - isomer may have an effect nearly 5 - 20 times stronger in suppressing Na channels , but effects of both drugs on Ca channels may be almost equipotent .	The stronger antiarrhythmic effect of ( - ) - cibenzoline indicates that ( - ) - isomer may have an effect nearly 5 - 20 times stronger in suppressing Na channels , but effects of both drugs on Ca channels may be almost equipotent .
Passage of mannitol into the brain around gliomas : a potential cause of rebound phenomenon .	Passage of mannitol into the brain around disease* gliomas *disease : a potential cause of rebound phenomenon .
A study on 21 patients .	A study on 21 patients .
AIM : Widespread use of mannitol to reduce brain edema and lower elevated ICP in brain tumor patients continues to be afflicted by the so - called rebound phenomenon .	AIM : Widespread use of mannitol to reduce disease* brain edema *disease and lower disease* elevated ICP *disease in disease* brain tumor *disease patients continues to be afflicted by the so - called rebound phenomenon .
Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .	Leakage of mannitol into the brain parenchyma through an altered BBB and secondary reversal of osmotic gradient is considered the major cause of rebound .
This has only been demonstrated experimentally in animals .	This has only been demonstrated experimentally in animals .
As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 brain tumor patients .	As a contribution to this issue we decided to research the possible passage of mannitol into the brain after administration to 21 disease* brain tumor *disease patients .
METHODS : Mannitol ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had malignant glioma , seven brain metastases and four meningioma ) about 30 minutes before craniotomy .	METHODS : Mannitol ( 18 % solution ; 1 g / kg ) was administered as a bolus to patients ( ten had disease* malignant glioma *disease , seven brain disease* metastases *disease and four disease* meningioma *disease ) about 30 minutes before craniotomy .
During resection , a sample of the surrounding edematous white matter was taken at the same time as a 10 ml venous blood sample .	During resection , a sample of the surrounding disease* edematous *disease white matter was taken at the same time as a 10 ml venous blood sample .
Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al .	Mannitol concentrations were measured in plasma and white matter by a modified version of the enzyme assay of Blonquist et al .
RESULTS : In most glioma patients , mannitol concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .	RESULTS : In most disease* glioma *disease patients , mannitol concentrations in white matter were 2 to 6 times higher than in plasma ( mean 3 . 5 times ) .
In meningioma and metastases patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .	In disease* meningioma *disease and disease* metastases *disease patients plasma concentrations of mannitol were higher than white matter concentrations except in three cases with infiltration by neoplastic cells .
CONCLUSIONS : The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near gliomas , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral edema and promoting rebound of ICP .	CONCLUSIONS : The results of our study show that even after a single bolus , mannitol may leak through the altered BBB near disease* gliomas *disease , reversing the initial plasma - to - blood osmotic gradient , aggravating peritumoral disease* edema *disease and promoting rebound of ICP .
Placebo - level incidence of extrapyramidal symptoms ( EPS ) with quetiapine in controlled studies of patients with bipolar mania .	Placebo - level incidence of disease* extrapyramidal symptoms *disease ( disease* EPS *disease ) with quetiapine in controlled studies of patients with disease* bipolar mania *disease .
OBJECTIVES : To evaluate extrapyramidal symptoms ( EPS ) , including akathisia , with quetiapine in patients with bipolar mania .	OBJECTIVES : To evaluate disease* extrapyramidal symptoms *disease ( disease* EPS *disease ) , including disease* akathisia *disease , with quetiapine in patients with disease* bipolar mania *disease .
METHODS : Data were analyzed from four similarly designed , randomized , double - blind , 3 - to 12 - week studies .	METHODS : Data were analyzed from four similarly designed , randomized , double - blind , 3 - to 12 - week studies .
Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .	Two studies evaluated quetiapine monotherapy ( up to 800 mg / day ) ( n = 209 ) versus placebo ( n = 198 ) , with lithium or haloperidol monotherapy as respective active controls .
Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .	Two studies evaluated quetiapine ( up to 800 mg / day ) in combination with a mood stabilizer ( lithium or divalproex , QTP + Li / DVP ) ( n = 196 ) compared to placebo and mood stabilizer ( PBO + Li / DVP ) ( n = 203 ) .
Extrapyramidal symptoms were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .	disease* Extrapyramidal symptoms *disease were evaluated using the Simpson - Angus Scale ( SAS ) , the Barnes Akathisia Rating Scale ( BARS ) , adverse event reports and anticholinergic drug usage .
RESULTS : The incidence of EPS - related adverse events , including akathisia , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .	RESULTS : The incidence of disease* EPS *disease - related adverse events , including disease* akathisia *disease , was no different with quetiapine monotherapy ( 12 . 9 % ) than with placebo ( 13 . 1 % ) .
Similarly , EPS - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .	Similarly , disease* EPS *disease - related adverse events with QTP + Li / DVP ( 21 . 4 % ) were no different than with PBO + Li / DVP ( 19 . 2 % ) .
Adverse events related to EPS occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to EPS .	Adverse events related to disease* EPS *disease occurred in 59 . 6 % of patients treated with haloperidol ( n = 99 ) monotherapy , whereas 26 . 5 % of patients treated with lithium ( n = 98 ) monotherapy experienced adverse events related to disease* EPS *disease .
The incidence of akathisia was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .	The incidence of disease* akathisia *disease was low and similar with quetiapine monotherapy ( 3 . 3 % ) and placebo ( 6 . 1 % ) , and with QTP + Li / DVP ( 3 . 6 % ) and PBO + Li / DVP ( 4 . 9 % ) .
Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of tremor ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar tremor , which is a known adverse effect of lithium , may have contributed to the elevated rate of tremor in patients receiving lithium therapy .	Lithium was associated with a significantly higher incidence ( p < 0 . 05 ) of disease* tremor *disease ( 18 . 4 % ) than quetiapine ( 5 . 6 % ) ; cerebellar disease* tremor *disease , which is a known adverse effect of lithium , may have contributed to the elevated rate of disease* tremor *disease in patients receiving lithium therapy .
Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of akathisia ( 33 . 3 % versus 5 . 9 % ) , tremor ( 30 . 3 % versus 7 . 8 % ) , and extrapyramidal syndrome ( 35 . 4 % versus 5 . 9 % ) than quetiapine .	Haloperidol induced a significantly higher incidence ( p < 0 . 001 ) of disease* akathisia *disease ( 33 . 3 % versus 5 . 9 % ) , disease* tremor *disease ( 30 . 3 % versus 7 . 8 % ) , and disease* extrapyramidal syndrome *disease ( 35 . 4 % versus 5 . 9 % ) than quetiapine .
No significant differences were observed between quetiapine and placebo on SAS and BARS scores .	No significant differences were observed between quetiapine and placebo on SAS and BARS scores .
Anticholinergic use was low and similar with quetiapine or placebo .	Anticholinergic use was low and similar with quetiapine or placebo .
CONCLUSIONS : In bipolar mania , the incidence of EPS , including akathisia , with quetiapine therapy is similar to that with placebo .	CONCLUSIONS : In disease* bipolar mania *disease , the incidence of disease* EPS *disease , including disease* akathisia *disease , with quetiapine therapy is similar to that with placebo .
Is phenytoin administration safe in a hypothermic child ?	Is phenytoin administration safe in a disease* hypothermic *disease child ?
A male neonate with a Chiari malformation and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele .	A male neonate with a disease* Chiari malformation *disease and a leaking myelomeningocoele underwent ventriculoperitoneal shunt insertion followed by repair of myelomeningocoele .
During anaesthesia and surgery , he inadvertently became moderately hypothermic .	During anaesthesia and surgery , he inadvertently became moderately disease* hypothermic *disease .
Intravenous phenytoin was administered during the later part of the surgery for seizure prophylaxis .	Intravenous phenytoin was administered during the later part of the surgery for disease* seizure *disease prophylaxis .
Following phenytoin administration , the patient developed acute severe bradycardia , refractory to atropine and adrenaline .	Following phenytoin administration , the patient developed acute severe disease* bradycardia *disease , refractory to atropine and adrenaline .
The cardiac depressant actions of phenytoin and hypothermia can be additive .	The cardiac depressant actions of phenytoin and disease* hypothermia *disease can be additive .
Administration of phenytoin in the presence of hypothermia may lead to an adverse cardiac event in children .	Administration of phenytoin in the presence of disease* hypothermia *disease may lead to an adverse cardiac event in children .
As phenytoin is a commonly used drug , clinicians need to be aware of this interaction .	As phenytoin is a commonly used drug , clinicians need to be aware of this interaction .
Valproate - induced chorea and encephalopathy in atypical nonketotic hyperglycinemia .	Valproate - induced disease* chorea *disease and disease* encephalopathy *disease in atypical disease* nonketotic hyperglycinemia *disease .
Nonketotic hyperglycinemia is a disorder of amino acid metabolism in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments .	disease* Nonketotic hyperglycinemia *disease is a disease* disorder of amino acid metabolism *disease in which a defect in the glycine cleavage system leads to an accumulation of glycine in the brain and other body compartments .
In the classical form it presents as neonatal apnea , intractable seizures , and hypotonia , followed by significant psychomotor retardation .	In the classical form it presents as neonatal disease* apnea *disease , intractable disease* seizures *disease , and disease* hypotonia *disease , followed by significant disease* psychomotor retardation *disease .
An important subset of children with nonketotic hyperglycinemia are atypical variants who present in a heterogeneous manner .	An important subset of children with disease* nonketotic hyperglycinemia *disease are atypical variants who present in a heterogeneous manner .
This report describes a patient with mild language delay and mental retardation , who was found to have nonketotic hyperglycinemia following her presentation with acute encephalopathy and chorea shortly after initiation of valproate therapy .	This report describes a patient with mild disease* language delay *disease and disease* mental retardation *disease , who was found to have disease* nonketotic hyperglycinemia *disease following her presentation with acute disease* encephalopathy *disease and disease* chorea *disease shortly after initiation of valproate therapy .
Delayed institution of hypertension during focal cerebral ischemia : effect on brain edema .	Delayed institution of disease* hypertension *disease during focal disease* cerebral ischemia *disease : effect on disease* brain edema *disease .
The effect of induced hypertension instituted after a 2 - h delay following middle cerebral artery occlusion ( MCAO ) on brain edema formation and histochemical injury was studied .	The effect of induced disease* hypertension *disease instituted after a 2 - h delay following disease* middle cerebral artery occlusion *disease ( disease* MCAO *disease ) on disease* brain edema *disease formation and histochemical injury was studied .
Under isoflurane anesthesia , the MCA of 14 spontaneously hypertensive rats was occluded .	Under isoflurane anesthesia , the MCA of 14 spontaneously disease* hypertensive *disease rats was occluded .
In the control group ( n = 7 ) , the mean arterial pressure ( MAP ) was not manipulated .	In the control group ( n = 7 ) , the mean arterial pressure ( MAP ) was not manipulated .
In the hypertensive group ( n = 7 ) , the MAP was elevated by 25 - 30 mm Hg beginning 2 h after MCAO .	In the disease* hypertensive *disease group ( n = 7 ) , the MAP was elevated by 25 - 30 mm Hg beginning 2 h after disease* MCAO *disease .
Four hours after MCAO , the rats were killed and the brains harvested .	Four hours after disease* MCAO *disease , the rats were killed and the brains harvested .
The brains were sectioned along coronal planes spanning the distribution of ischemia produced by MCAO .	The brains were sectioned along coronal planes spanning the distribution of disease* ischemia *disease produced by disease* MCAO *disease .
Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the ischemic territory ) .	Specific gravity ( SG ) was determined in the subcortex and in two sites in the cortex ( core and periphery of the disease* ischemic *disease territory ) .
The extent of neuronal injury was determined by 2 , 3 , 5 - triphenyltetrazolium staining .	The extent of disease* neuronal injury *disease was determined by 2 , 3 , 5 - triphenyltetrazolium staining .
In the ischemic core , there was no difference in SG in the subcortex and cortex in the two groups .	In the disease* ischemic *disease core , there was no difference in SG in the subcortex and cortex in the two groups .
In the periphery of the ischemic territory , SG in the cortex was greater ( less edema accumulation ) in the hypertensive group ( 1 . 041 + / - 0 . 001 vs 1 . 039 + / - 0 . 001 , P less than 0 . 05 ) .	In the periphery of the disease* ischemic *disease territory , SG in the cortex was greater ( less disease* edema *disease accumulation ) in the disease* hypertensive *disease group ( 1 . 041 + / - 0 . 001 vs 1 . 039 + / - 0 . 001 , P less than 0 . 05 ) .
The area of histochemical injury ( as a percent of the cross - sectional area of the hemisphere ) was less in the hypertensive group ( 33 + / - 3 % vs 21 + / - 2 % , P less than 0 . 05 ) .	The area of histochemical injury ( as a percent of the cross - sectional area of the hemisphere ) was less in the disease* hypertensive *disease group ( 33 + / - 3 % vs 21 + / - 2 % , P less than 0 . 05 ) .
The data indicate that phenylephrine - induced hypertension instituted 2 h after MCAO does not aggravate edema in the ischemic core , that it improves edema in the periphery of the ischemic territory , and that it reduces the area of histochemical neuronal dysfunction .	The data indicate that phenylephrine - induced disease* hypertension *disease instituted 2 h after disease* MCAO *disease does not aggravate disease* edema *disease in the disease* ischemic *disease core , that it improves disease* edema *disease in the periphery of the disease* ischemic *disease territory , and that it reduces the area of histochemical disease* neuronal dysfunction *disease .
Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin .	Behavioral effects of pubertal anabolic androgenic steroid exposure in male rats with low serotonin .
The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid ( AAS ) exposure and brain serotonin ( 5 - hydroxytryptamine , 5 - HT ) depletion on behavior of pubertal male rats .	The goal of this study was to assess the interactive effects of chronic anabolic androgenic steroid ( AAS ) exposure and brain serotonin ( 5 - hydroxytryptamine , 5 - HT ) depletion on behavior of pubertal male rats .
Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine ( PCPA 100 mg / kg , every other day ) ; controls received saline .	Serotonin was depleted beginning on postnatal day 26 with parachlorophenylalanine ( PCPA 100 mg / kg , every other day ) ; controls received saline .
At puberty ( P40 ) , half the PCPA - treated rats and half the saline - treated rats began treatment with testosterone ( T , 5 mg / kg , 5 days / week ) .	At puberty ( P40 ) , half the PCPA - treated rats and half the saline - treated rats began treatment with testosterone ( T , 5 mg / kg , 5 days / week ) .
Behavioral measures included locomotion , irritability , copulation , partner preference , and aggression .	Behavioral measures included locomotion , disease* irritability *disease , copulation , partner preference , and disease* aggression *disease .
Animals were tested for aggression in their home cage , both with and without physical provocation ( mild tail pinch ) .	Animals were tested for disease* aggression *disease in their home cage , both with and without physical provocation ( mild tail pinch ) .
Brain levels of 5 - HT and its metabolite , 5 - hydroxyindoleacetic acid ( 5 - HIAA ) , were determined using HPLC .	Brain levels of 5 - HT and its metabolite , 5 - hydroxyindoleacetic acid ( 5 - HIAA ) , were determined using HPLC .
PCPA significantly and substantially depleted 5 - HT and 5 - HIAA in all brain regions examined .	PCPA significantly and substantially depleted 5 - HT and 5 - HIAA in all brain regions examined .
Chronic T treatment significantly decreased 5 - HT and 5 - HIAA in certain brain areas , but to a much lesser extent than PCPA .	Chronic T treatment significantly decreased 5 - HT and 5 - HIAA in certain brain areas , but to a much lesser extent than PCPA .
Chronic exposure to PCPA alone significantly decreased locomotor activity and increased irritability but had no effect on sexual behavior , partner preference , or aggression .	Chronic exposure to PCPA alone significantly decreased locomotor activity and increased disease* irritability *disease but had no effect on sexual behavior , partner preference , or disease* aggression *disease .
T alone had no effect on locomotion , irritability , or sexual behavior but increased partner preference and aggression .	T alone had no effect on locomotion , disease* irritability *disease , or sexual behavior but increased partner preference and disease* aggression *disease .
The most striking effect of combining T + PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .	The most striking effect of combining T + PCPA was a significant increase in attack frequency as well as a significant decrease in the latency to attack , particularly following physical provocation .
Based on these data , it can be speculated that pubertal AAS users with low central 5 - HT may be especially prone to exhibit aggressive behavior .	Based on these data , it can be speculated that pubertal AAS users with low central 5 - HT may be especially prone to exhibit disease* aggressive behavior *disease .
Effects of UMB24 and ( + / - ) - SM 21 , putative sigma2 - preferring antagonists , on behavioral toxic and stimulant effects of cocaine in mice .	Effects of UMB24 and ( + / - ) - SM 21 , putative sigma2 - preferring antagonists , on behavioral toxic and stimulant effects of cocaine in mice .
Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the convulsive , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .	Earlier studies have demonstrated that antagonism of sigma1 receptors attenuates the disease* convulsive *disease , lethal , locomotor stimulatory and rewarding actions of cocaine in mice .
In contrast , the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable .	In contrast , the contribution of sigma2 receptors is unclear because experimental tools to selectively target this subtype are unavailable .
To begin addressing this need , we characterized UMB24 ( 1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine ) and ( + / - ) - SM 21 ( 3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate ) in receptor binding and behavioral studies .	To begin addressing this need , we characterized UMB24 ( 1 - ( 2 - phenethyl ) - 4 - ( 2 - pyridyl ) - piperazine ) and ( + / - ) - SM 21 ( 3alpha - tropanyl - 2 - ( 4 - chorophenoxy ) butyrate ) in receptor binding and behavioral studies .
Receptor binding studies confirmed that UMB24 and ( + / - ) - SM 21 display preferential affinity for sigma2 over sigma1 receptors .	Receptor binding studies confirmed that UMB24 and ( + / - ) - SM 21 display preferential affinity for sigma2 over sigma1 receptors .
In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced convulsions and locomotor activity , but not lethality .	In behavioral studies , pretreatment of Swiss Webster mice with UMB24 or ( + / - ) - SM 21 significantly attenuated cocaine - induced disease* convulsions *disease and locomotor activity , but not lethality .
When administered alone , ( + / - ) - SM 21 produced no significant effects compared to control injections of saline , but UMB24 had locomotor depressant actions .	When administered alone , ( + / - ) - SM 21 produced no significant effects compared to control injections of saline , but UMB24 had locomotor depressant actions .
Together , the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine , and further development of more selective , high affinity ligands are warranted .	Together , the data suggest that sigma2 receptor antagonists have the potential to attenuate some of the behavioral effects of cocaine , and further development of more selective , high affinity ligands are warranted .
Cardiac arrest in a child with cerebral palsy undergoing sevoflurane induction of anesthesia after preoperative clonidine .	disease* Cardiac arrest *disease in a child with disease* cerebral palsy *disease undergoing sevoflurane induction of anesthesia after preoperative clonidine .
Clonidine is a frequently administered alpha2 - adrenergic agonist which can decrease heart rate and blood pressure .	Clonidine is a frequently administered alpha2 - adrenergic agonist which can decrease heart rate and blood pressure .
We present a case of a 5 - year - old child with cerebral palsy and seizure disorder , receiving clonidine for restlessness , who presented for placement of a baclofen pump .	We present a case of a 5 - year - old child with disease* cerebral palsy *disease and disease* seizure disorder *disease , receiving clonidine for disease* restlessness *disease , who presented for placement of a baclofen pump .
Without the knowledge of the medical personnel , the patient ' s mother administered three doses of clonidine during the evening before and morning of surgery to reduce anxiety .	Without the knowledge of the medical personnel , the patient ' s mother administered three doses of clonidine during the evening before and morning of surgery to reduce disease* anxiety *disease .
During induction of anesthesia , the patient developed bradycardia and hypotension requiring cardiac resuscitation .	During induction of anesthesia , the patient developed disease* bradycardia *disease and disease* hypotension *disease requiring cardiac resuscitation .
There are no previous reports of clonidine - associated cardiac arrest in a child undergoing induction of anesthesia .	There are no previous reports of clonidine - associated disease* cardiac arrest *disease in a child undergoing induction of anesthesia .
Angiotensin - converting enzyme ( ACE ) inhibitor - associated angioedema of the stomach and small intestine : a case report .	Angiotensin - converting enzyme ( ACE ) inhibitor - associated disease* angioedema *disease of the stomach and small intestine : a case report .
This is a case report on a 45 - year old African - American female with newly diagnosed hypertension , who was started on a combination pill of amlodipine / benazapril 10 / 5 mg .	This is a case report on a 45 - year old African - American female with newly diagnosed disease* hypertension *disease , who was started on a combination pill of amlodipine / benazapril 10 / 5 mg .
The very next day , she presented at the emergency room ( ER ) with abdominal pain , nausea and vomiting .	The very next day , she presented at the emergency room ( ER ) with disease* abdominal pain *disease , disease* nausea *disease and disease* vomiting *disease .
Physical exam , complete metabolic panel , and hemogram were in the normal range .	Physical exam , complete metabolic panel , and hemogram were in the normal range .
She was discharged from the ER after a few hours of treatment with fluid and analgesics .	She was discharged from the ER after a few hours of treatment with fluid and analgesics .
However , she returned to the ER the next day with the same complaints .	However , she returned to the ER the next day with the same complaints .
This time the physical exam was significant for a distended abdomen with dullness to percussion .	This time the physical exam was significant for a distended abdomen with dullness to percussion .
CT scan of the abdomen revealed markedly thickened antrum of the stomach , duodenum and jejunum , along with fluid in the abdominal and pelvic cavity .	CT scan of the abdomen revealed markedly thickened antrum of the stomach , duodenum and jejunum , along with fluid in the abdominal and pelvic cavity .
Angiotensin - converting enzyme inhibitor ( ACEI ) - induced angioedema was suspected , and anti - hypertensive medications were discontinued .	Angiotensin - converting enzyme inhibitor ( ACEI ) - induced disease* angioedema *disease was suspected , and anti - disease* hypertensive *disease medications were discontinued .
Her symptoms improved within the next 24 hours , and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of ascites .	Her symptoms improved within the next 24 hours , and repeat CT after 72 hours revealed marked improvement in stomach and small bowel thickening and resolution of disease* ascites *disease .
The recognition of angiotensin - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) intestinal angioedema constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .	The recognition of angiotensin - converting enzyme ( ACE ) and angiotensin receptor blocker ( ARB ) disease* intestinal angioedema *disease constitutes a challenge to primary care physicians , internists , emergency room personal and surgeons .
Carbamazepine - induced cardiac dysfunction .	Carbamazepine - induced disease* cardiac dysfunction *disease .
Characterization of two distinct clinical syndromes .	Characterization of two distinct clinical syndromes .
A patient with sinus bradycardia and atrioventricular block , induced by carbamazepine , prompted an extensive literature review of all previously reported cases .	A patient with sinus disease* bradycardia *disease and disease* atrioventricular block *disease , induced by carbamazepine , prompted an extensive literature review of all previously reported cases .
From the analysis of these cases , two distinct forms of carbamazepine - associated cardiac dysfunction emerged .	From the analysis of these cases , two distinct forms of carbamazepine - associated disease* cardiac dysfunction *disease emerged .
One patient group developed sinus tachycardias in the setting of a massive carbamazepine overdose .	One patient group developed disease* sinus tachycardias *disease in the setting of a massive carbamazepine disease* overdose *disease .
The second group consisted almost exclusively of elderly women who developed potentially life - threatening bradyarrhythmias or atrioventricular conduction delay , associated with either therapeutic or modestly elevated carbamazepine serum levels .	The second group consisted almost exclusively of elderly women who developed potentially life - threatening disease* bradyarrhythmias *disease or disease* atrioventricular conduction delay *disease , associated with either therapeutic or modestly elevated carbamazepine serum levels .
Because carbamazepine is widely used in the treatment of many neurologic and psychiatric conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .	Because carbamazepine is widely used in the treatment of many neurologic and disease* psychiatric *disease conditions , the recognition of the latter syndrome has important implications for the use of this drug in elderly patients .
Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced cardiomyopathy with iodine - 125 - metaiodobenzylguanidine .	Detection of abnormal cardiac adrenergic neuron activity in adriamycin - induced disease* cardiomyopathy *disease with iodine - 125 - metaiodobenzylguanidine .
Radiolabeled metaiodobenzylguanidine ( MIBG ) , an analog of norepinephrine ( NE ) , serves as an index of adrenergic neuron integrity and function .	Radiolabeled metaiodobenzylguanidine ( MIBG ) , an analog of norepinephrine ( NE ) , serves as an index of adrenergic neuron integrity and function .
Using a rat model of adriamycin - induced cardiomyopathy , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin cardiomyopathy .	Using a rat model of adriamycin - induced disease* cardiomyopathy *disease , we tested the hypothesis that abnormal cardiac adrenergic neuron activity may appear and be exacerbated dose - dependently in adriamycin disease* cardiomyopathy *disease .
The degree of vacuolar degeneration of myocardial cells was analyzed in relation to the duration of adriamycin treatment ( 2 mg / kg , once a week ) .	The degree of disease* vacuolar degeneration of myocardial cells *disease was analyzed in relation to the duration of adriamycin treatment ( 2 mg / kg , once a week ) .
There were no abnormalities or only isolated degeneration in the 1 - or 2 - wk treatment groups , isolated or scattered degeneration in half of the 3 - wk group , frequent scattered degeneration in the 4 - wk group , scattered or focal degeneration in the 5 - wk group , and extensive degeneration in the 8 - wk group .	There were no abnormalities or only isolated degeneration in the 1 - or 2 - wk treatment groups , isolated or scattered degeneration in half of the 3 - wk group , frequent scattered degeneration in the 4 - wk group , scattered or focal degeneration in the 5 - wk group , and extensive degeneration in the 8 - wk group .
Myocardial accumulation of [ 125I ] MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less .	Myocardial accumulation of [ 125I ] MIBG 4 hr after intravenous injection did not differ between the controls and the groups treated 3 wk or less .
However , the 4 - wk group had a slightly lower accumulation in the right ventricular wall ( 82 % of the control ) and significantly lower accumulation in the left ventricular wall ( about 66 % of the control : p less than 0 . 05 ) .	However , the 4 - wk group had a slightly lower accumulation in the right ventricular wall ( 82 % of the control ) and significantly lower accumulation in the left ventricular wall ( about 66 % of the control : p less than 0 . 05 ) .
In the 5 - wk group , MIBG accumulation in the right and left ventricular wall was 35 % and 27 % of that in controls , respectively ( p less than 0 . 001 ) .	In the 5 - wk group , MIBG accumulation in the right and left ventricular wall was 35 % and 27 % of that in controls , respectively ( p less than 0 . 001 ) .
In the 8 - wk group , MIBG accumulation in the right and left ventricular wall was 18 % and 14 % of that in controls , respectively ( p less than 0 . 001 ) .	In the 8 - wk group , MIBG accumulation in the right and left ventricular wall was 18 % and 14 % of that in controls , respectively ( p less than 0 . 001 ) .
Thus , MIBG accumulation in the myocardium decreased in an adriamycin dose - dependent manner .	Thus , MIBG accumulation in the myocardium decreased in an adriamycin dose - dependent manner .
The appearance of impaired cardiac adrenergic neuron activity in the presence of slight myocardial impairment ( scattered or focal vacuolar degeneration ) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin - induced cardiomyopathy .	The appearance of impaired cardiac adrenergic neuron activity in the presence of slight disease* myocardial impairment *disease ( scattered or focal disease* vacuolar degeneration *disease ) indicates that MIBG scintigraphy may be a useful method for detection of adriamycin - induced disease* cardiomyopathy *disease .
Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen .	disease* Syncope *disease and disease* QT prolongation *disease among patients treated with methadone for heroin dependence in the city of Copenhagen .
BACKGROUND : Methadone is prescribed to heroin addicts to decrease illicit opioid use .	BACKGROUND : Methadone is prescribed to heroin addicts to decrease illicit opioid use .
Prolongation of the QT interval in the ECG of patients with torsade de pointes ( TdP ) has been reported in methadone users .	Prolongation of the QT interval in the ECG of patients with disease* torsade de pointes *disease ( disease* TdP *disease ) has been reported in methadone users .
As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of syncope to illicit drug use and thereby underestimate the incidence of TdP in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .	As heroin addicts sometimes faint while using illicit drugs , doctors might attribute too many episodes of disease* syncope *disease to illicit drug use and thereby underestimate the incidence of disease* TdP *disease in this special population , and the high mortality in this population may , in part , be caused by the proarrhythmic effect of methadone .
METHODS : In this cross - sectional study interview , ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis .	METHODS : In this cross - sectional study interview , ECGs and blood samples were collected in a population of adult heroin addicts treated with methadone or buprenorphine on a daily basis .
Of the patients at the Drug Addiction Service in the municipal of Copenhagen , 450 ( approximately 52 % ) were included .	Of the patients at the Drug Addiction Service in the municipal of Copenhagen , 450 ( approximately 52 % ) were included .
The QT interval was estimated from 12 lead ECGs .	The QT interval was estimated from 12 lead ECGs .
All participants were interviewed about any experience of syncope .	All participants were interviewed about any experience of disease* syncope *disease .
The association between opioid dose and QT , and methadone dose and reporting of syncope was assessed using multivariate linear regression and logistic regression , respectively .	The association between opioid dose and QT , and methadone dose and reporting of disease* syncope *disease was assessed using multivariate linear regression and logistic regression , respectively .
RESULTS : Methadone dose was associated with longer QT interval of 0 . 140 ms / mg ( p = 0 . 002 ) .	RESULTS : Methadone dose was associated with longer QT interval of 0 . 140 ms / mg ( p = 0 . 002 ) .
No association between buprenorphine and QTc was found .	No association between buprenorphine and QTc was found .
Among the subjects treated with methadone , 28 % men and 32 % women had prolonged QTc interval .	Among the subjects treated with methadone , 28 % men and 32 % women had disease* prolonged QTc interval *disease .
None of the subjects treated with buprenorphine had QTc interval > 0 . 440 s ( ( 1 / 2 ) ) .	None of the subjects treated with buprenorphine had QTc interval > 0 . 440 s ( ( 1 / 2 ) ) .
A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for syncope .	A 50 mg higher methadone dose was associated with a 1 . 2 ( 95 % CI 1 . 1 to 1 . 4 ) times higher odds for disease* syncope *disease .
CONCLUSIONS : Methadone is associated with QT prolongation and higher reporting of syncope in a population of heroin addicts .	CONCLUSIONS : Methadone is associated with disease* QT prolongation *disease and higher reporting of disease* syncope *disease in a population of heroin addicts .
Neuroleptic malignant syndrome induced by ziprasidone on the second day of treatment .	disease* Neuroleptic malignant syndrome *disease induced by ziprasidone on the second day of treatment .
Neuroleptic malignant syndrome ( NMS ) is the rarest and most serious of the neuroleptic - induced movement disorders .	disease* Neuroleptic malignant syndrome *disease ( disease* NMS *disease ) is the rarest and most serious of the neuroleptic - induced disease* movement disorders *disease .
We describe a case of neuroleptic malignant syndrome ( NMS ) associated with the use of ziprasidone .	We describe a case of disease* neuroleptic malignant syndrome *disease ( disease* NMS *disease ) associated with the use of ziprasidone .
Although conventional neuroleptics are more frequently associated with NMS , atypical antipsychotic drugs like ziprasidone may also be a cause .	Although conventional neuroleptics are more frequently associated with disease* NMS *disease , atypical antipsychotic drugs like ziprasidone may also be a cause .
The patient is a 24 - year - old male with a history of schizophrenia who developed signs and symptoms of NMS after 2 days of treatment with an 80 - mg / day dose of orally administrated ziprasidone .	The patient is a 24 - year - old male with a history of disease* schizophrenia *disease who developed signs and symptoms of disease* NMS *disease after 2 days of treatment with an 80 - mg / day dose of orally administrated ziprasidone .
This case is the earliest ( second day of treatment ) NMS due to ziprasidone reported in the literature .	This case is the earliest ( second day of treatment ) disease* NMS *disease due to ziprasidone reported in the literature .
Peripheral iron dextran induced degeneration of dopaminergic neurons in rat substantia nigra .	Peripheral iron dextran induced disease* degeneration of dopaminergic neurons *disease in rat substantia nigra .
Iron accumulation is considered to be involved in the pathogenesis of Parkinson ' s disease .	Iron accumulation is considered to be involved in the pathogenesis of disease* Parkinson ' s disease *disease .
To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the degeneration of dopaminergic neurons and increased iron content in the SN of iron dextran overloaded animals .	To demonstrate the relationship between peripheral iron overload and dopaminergic neuron loss in rat substantia nigra ( SN ) , in the present study we used fast cyclic voltammetry , tyrosine hydroxylase ( TH ) immunohistochemistry , Perls ' iron staining , and high performance liquid chromatography - electrochemical detection to study the disease* degeneration of dopaminergic neurons *disease and increased iron content in the SN of iron dextran overloaded animals .
The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH - immunoreactive neurons in the SN .	The findings showed that peripheral iron dextran overload increased the iron staining positive cells and reduced the number of TH - immunoreactive neurons in the SN .
As a result , dopamine release and content , as well as its metabolites contents were decreased in caudate putamen .	As a result , dopamine release and content , as well as its metabolites contents were decreased in caudate putamen .
Even more dramatic changes were found in chronic overload group .	Even more dramatic changes were found in chronic overload group .
These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive iron causes the degeneration of dopaminergic neurons .	These results suggest that peripheral iron dextran can increase the iron level in the SN , where excessive iron causes the disease* degeneration of dopaminergic neurons *disease .
The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload .	The chronic iron overload may be more destructive to dopaminergic neurons than the acute iron overload .
Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats .	Attenuated disruption of prepulse inhibition by dopaminergic stimulation after maternal deprivation and adolescent corticosterone treatment in rats .
The development of schizophrenia may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events , in combination leading to overt disease .	The development of disease* schizophrenia *disease may include an early neurodevelopmental stress component which increases vulnerability to later stressful life events , in combination leading to overt disease .
We investigated the effect of an early stress , in the form of maternal deprivation , combined with a later stress , simulated by chronic periadolescent corticosterone treatment , on behaviour in rats .	We investigated the effect of an early stress , in the form of maternal deprivation , combined with a later stress , simulated by chronic periadolescent corticosterone treatment , on behaviour in rats .
Acute treatment with apomorphine caused disruption of prepulse inhibition ( PPI ) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment , but was surprisingly absent in rats that had undergone the combined early and late stress .	Acute treatment with apomorphine caused disruption of prepulse inhibition ( PPI ) in controls and in rats that had undergone either maternal deprivation or corticosterone treatment , but was surprisingly absent in rats that had undergone the combined early and late stress .
Amphetamine treatment significantly disrupted PPI in both non - deprived groups , but was absent in both maternally deprived groups .	Amphetamine treatment significantly disrupted PPI in both non - deprived groups , but was absent in both maternally deprived groups .
The serotonin - 1A receptor agonist , 8 - OH - DPAT , induced a significant disruption of PPI in all groups .	The serotonin - 1A receptor agonist , 8 - OH - DPAT , induced a significant disruption of PPI in all groups .
Amphetamine - induced locomotor hyperactivity was similar in all groups .	Amphetamine - induced disease* locomotor hyperactivity *disease was similar in all groups .
These results show an inhibitory interaction of early stress , caused by maternal deprivation , combined with ' adolescent ' stress , simulated by corticosterone treatment , on dopaminergic regulation of PPI .	These results show an inhibitory interaction of early stress , caused by maternal deprivation , combined with ' adolescent ' stress , simulated by corticosterone treatment , on dopaminergic regulation of PPI .
The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation , or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus .	The altered effects of apomorphine and amphetamine could indicate differential changes in dopamine receptor signalling leading to functional desensitisation , or altered modulation of sensory gating in the nucleus accumbens by limbic structures such as the hippocampus .
An extremely rare case of delusional parasitosis in a chronic hepatitis C patient during pegylated interferon alpha - 2b and ribavirin treatment .	An extremely rare case of disease* delusional parasitosis *disease in a disease* chronic hepatitis C *disease patient during pegylated interferon alpha - 2b and ribavirin treatment .
During treatment of chronic hepatitis C patients with interferon and ribavirin , a lot of side effects are described .	During treatment of disease* chronic hepatitis C *disease patients with interferon and ribavirin , a lot of side effects are described .
Twenty - three percent to 44 % of patients develop depression .	Twenty - three percent to 44 % of patients develop disease* depression *disease .
A minority of patients evolve to psychosis .	A minority of patients evolve to disease* psychosis *disease .
To the best of our knowledge , no cases of psychogenic parasitosis occurring during interferon therapy have been described in the literature .	To the best of our knowledge , no cases of disease* psychogenic parasitosis *disease occurring during interferon therapy have been described in the literature .
We present a 49 - year - old woman who developed a delusional parasitosis during treatment with pegylated interferon alpha - 2b weekly and ribavirin .	We present a 49 - year - old woman who developed a disease* delusional parasitosis *disease during treatment with pegylated interferon alpha - 2b weekly and ribavirin .
She complained of seeing parasites and the larvae of fleas in her stools .	She complained of seeing parasites and the larvae of fleas in her stools .
This could not be confirmed by any technical examination .	This could not be confirmed by any technical examination .
All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .	All the complaints disappeared after stopping pegylated interferon alpha - 2b and reappeared after restarting it .
She had a complete sustained viral response .	She had a complete sustained viral response .
Hepatonecrosis and cholangitis related to long - term phenobarbital therapy : an autopsy report of two patients .	disease* Hepatonecrosis *disease and disease* cholangitis *disease related to long - term phenobarbital therapy : an autopsy report of two patients .
Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic liver disease .	Phenobarbital ( PB ) has a reputation for safety , and it is commonly believed that PB - related increases in serum aminotransferase levels do not indicate or predict the development of significant chronic disease* liver disease *disease .
Here we report of two adult patients with a long history of epilepsy treated with PB who died suddenly : one as consequence of cardiac arrest , the other of acute bronchopneumonia .	Here we report of two adult patients with a long history of disease* epilepsy *disease treated with PB who died suddenly : one as consequence of disease* cardiac arrest *disease , the other of acute disease* bronchopneumonia *disease .
At autopsy , analysis of liver parenchyma revealed rich portal inflammatory infiltrate , which consisted of mixed eosinophil and monocyte cells , associated with several foci of necrosis surrounded by a hard ring of non - specific granulomatous tissue .	At autopsy , analysis of liver parenchyma revealed rich portal inflammatory infiltrate , which consisted of mixed eosinophil and monocyte cells , associated with several foci of disease* necrosis *disease surrounded by a hard ring of non - specific granulomatous tissue .
Inflammatory reactions of internal and external hepatic biliary ducts were also seen .	Inflammatory reactions of internal and external hepatic biliary ducts were also seen .
Our findings illustrate that PB may be associated with chronic liver damage , which may lead to more serious and deleterious consequences .	Our findings illustrate that PB may be associated with chronic disease* liver damage *disease , which may lead to more serious and deleterious consequences .
For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic chronic hepatic enzyme dysfunction .	For this reason , each clinician should recognize this entity in the differential diagnosis of PB - related asymptomatic disease* chronic hepatic enzyme dysfunction *disease .
Delayed leukoencephalopathy with stroke - like presentation in chemotherapy recipients .	Delayed disease* leukoencephalopathy *disease with disease* stroke *disease - like presentation in chemotherapy recipients .
BACKGROUND : A transient leukoencephalopathy mimicking cerebrovascular accident has been described as a complication of chemotherapy , most commonly in recipients of intrathecal methotrexate for childhood leukaemia .	BACKGROUND : A transient disease* leukoencephalopathy *disease mimicking disease* cerebrovascular accident *disease has been described as a complication of chemotherapy , most commonly in recipients of intrathecal methotrexate for childhood disease* leukaemia *disease .
Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration .	Recently published neuroimaging data suggest a common pathophysiology associated with a variety of chemotherapy agents and modes of administration .
METHODS : We reviewed the medical literature for single reports and case series of patients presenting with stroke - like episodes while receiving systemic or intrathecal chemotherapy .	METHODS : We reviewed the medical literature for single reports and case series of patients presenting with disease* stroke *disease - like episodes while receiving systemic or intrathecal chemotherapy .
We only included studies providing detailed neuroimaging data .	We only included studies providing detailed neuroimaging data .
Patients with cerebrovascular accidents were excluded .	Patients with disease* cerebrovascular accidents *disease were excluded .
RESULTS : We identified 27 reports of toxic leukoencephalopathy in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .	RESULTS : We identified 27 reports of toxic disease* leukoencephalopathy *disease in patients treated with methotrexate ( intrathecal , systemic ) , 5 - fluorouracil and its derivative carmofur , and capecitabine .
Diffusion weighted imaging ( DWI ) of all patients revealed well demarcated hyperintense lesions within the subcortical white matter of the cerebral hemispheres and the corpus callosum , corresponding to areas of decreased proton diffusion on apparent diffusion coefficient ( ADC ) maps ( available in 21 / 27 patients ) .	Diffusion weighted imaging ( DWI ) of all patients revealed well demarcated hyperintense disease* lesions within the subcortical white matter *disease of the cerebral hemispheres and the corpus callosum , corresponding to areas of decreased proton diffusion on apparent diffusion coefficient ( ADC ) maps ( available in 21 / 27 patients ) .
Lesions exceeded the confines of adjacent vascular territories .	Lesions exceeded the confines of adjacent vascular territories .
Complete resolution of symptoms within 1 - 4 days was accompanied by normalisation of ADC abnormalities .	Complete resolution of symptoms within 1 - 4 days was accompanied by normalisation of ADC abnormalities .
However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent white matter abnormalities .	However , fluid attenuated inversion recovery ( FLAIR ) sequences frequently revealed persistent disease* white matter abnormalities *disease .
CONCLUSIONS : Several pathophysiological models of delayed leukoencephalopathy after exposure to intrathecal or systemic chemotherapy have been proposed .	CONCLUSIONS : Several pathophysiological models of delayed disease* leukoencephalopathy *disease after exposure to intrathecal or systemic chemotherapy have been proposed .
DWI findings in this cohort are indicative of cytotoxic oedema within cerebral white matter and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome .	DWI findings in this cohort are indicative of disease* cytotoxic oedema within cerebral white matter *disease and lend support to an at least partially reversible metabolic derangement as the basis for this syndrome .
Prenatal exposure to fluoxetine induces fetal pulmonary hypertension in the rat .	Prenatal exposure to fluoxetine induces disease* fetal pulmonary hypertension *disease in the rat .
RATIONALE : Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women .	RATIONALE : Fluoxetine is a selective serotonin reuptake inhibitor antidepressant widely used by pregnant women .
Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent pulmonary hypertension syndrome of the newborn .	Epidemiological data suggest that fluoxetine exposure prenatally increases the prevalence of persistent disease* pulmonary hypertension syndrome *disease of the newborn .
The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a pulmonary hypertension protective fluoxetine effect in adult rodents .	The mechanism responsible for this effect is unclear and paradoxical , considering the current evidence of a disease* pulmonary hypertension *disease protective fluoxetine effect in adult rodents .
OBJECTIVES : To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate .	OBJECTIVES : To evaluate the fluoxetine effect on fetal rat pulmonary vascular smooth muscle mechanical properties and cell proliferation rate .
METHODS : Pregnant rats were treated with fluoxetine ( 10 mg / kg ) from Day 11 through Day 21 of gestation .	METHODS : Pregnant rats were treated with fluoxetine ( 10 mg / kg ) from Day 11 through Day 21 of gestation .
MEASUREMENTS AND MAIN RESULTS : Fetuses were delivered by cesarean section .	MEASUREMENTS AND MAIN RESULTS : Fetuses were delivered by cesarean section .
As compared with controls , fluoxetine exposure resulted in fetal pulmonary hypertension as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .	As compared with controls , fluoxetine exposure resulted in disease* fetal pulmonary hypertension *disease as evidenced by an increase in the weight ratio of the right ventricle to the left ventricle plus septum ( P = 0 . 02 ) and by an increase in pulmonary arterial medial thickness ( P < 0 . 01 ) .
Postnatal mortality was increased among experimental animals , and arterial oxygen saturation was 96 + / - 1 % in 1 - day - old control animals and significantly lower ( P < 0 . 01 ) in fluoxetine - exposed pups ( 79 + / - 2 % ) .	Postnatal mortality was increased among experimental animals , and arterial oxygen saturation was 96 + / - 1 % in 1 - day - old control animals and significantly lower ( P < 0 . 01 ) in fluoxetine - exposed pups ( 79 + / - 2 % ) .
In vitro , fluoxetine induced pulmonary arterial muscle contraction in fetal , but not adult , animals ( P < 0 . 01 ) and reduced serotonin - induced contraction at both ages ( P < 0 . 01 ) .	In vitro , fluoxetine induced pulmonary arterial muscle contraction in fetal , but not adult , animals ( P < 0 . 01 ) and reduced serotonin - induced contraction at both ages ( P < 0 . 01 ) .
After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal , but not adult , cells ( P < 0 . 01 ) .	After in utero exposure to a low fluoxetine concentration the pulmonary arterial smooth muscle cell proliferation rate was significantly increased in fetal , but not adult , cells ( P < 0 . 01 ) .
CONCLUSIONS : In contrast to the adult , fluoxetine exposure in utero induces pulmonary hypertension in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .	CONCLUSIONS : In contrast to the adult , fluoxetine exposure in utero induces disease* pulmonary hypertension *disease in the fetal rat as a result of a developmentally regulated increase in pulmonary vascular smooth muscle proliferation .
Disulfiram - induced transient optic and peripheral neuropathy : a case report .	Disulfiram - induced transient disease* optic and peripheral neuropathy *disease : a case report .
AIM : To report a case of optic and peripheral neuropathy after chronic use of disulfiram for alcohol dependence management .	AIM : To report a case of disease* optic and peripheral neuropathy *disease after chronic use of disulfiram for disease* alcohol dependence *disease management .
MATERIALS AND METHODS : A case report .	MATERIALS AND METHODS : A case report .
RESULTS : A 57 - year - old male presented with gradual loss of vision in both eyes with intermittent headaches for 2 months .	RESULTS : A 57 - year - old male presented with gradual disease* loss of vision *disease in both eyes with intermittent disease* headaches *disease for 2 months .
He also complained of paraesthesia with numbness in both feet .	He also complained of disease* paraesthesia *disease with disease* numbness *disease in both feet .
His vision was 6 / 15 and 2 / 60 in the right and left eyes , respectively .	His vision was 6 / 15 and 2 / 60 in the right and left eyes , respectively .
Fundoscopy revealed bilaterally swollen optic nerve heads .	Fundoscopy revealed bilaterally swollen optic nerve heads .
Visual field testing confirmed bilateral central - caecal scotomata .	Visual field testing confirmed bilateral central - caecal disease* scotomata *disease .
He had been taking disulfiram for alcohol dependence for the preceding 3 years .	He had been taking disulfiram for disease* alcohol dependence *disease for the preceding 3 years .
Disulfiram discontinuation lead to an immediate symptomatic improvement .	Disulfiram discontinuation lead to an immediate symptomatic improvement .
CONCLUSION : Physicians initiating long - term disulfiram therapy should be aware of these adverse effects .	CONCLUSION : Physicians initiating long - term disulfiram therapy should be aware of these adverse effects .
They should recommend annual ophthalmic reviews with visual field testing .	They should recommend annual ophthalmic reviews with visual field testing .
Patients should be reassured with respect to the reversibility of these adverse effects .	Patients should be reassured with respect to the reversibility of these adverse effects .
Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants .	Intraocular pressure in patients with disease* uveitis *disease treated with fluocinolone acetonide implants .
OBJECTIVE : To report the incidence and management of elevated intraocular pressure ( IOP ) in patients with uveitis treated with the fluocinolone acetonide ( FA ) intravitreal implant .	OBJECTIVE : To report the incidence and management of disease* elevated intraocular pressure *disease ( IOP ) in patients with disease* uveitis *disease treated with the fluocinolone acetonide ( FA ) intravitreal implant .
DESIGN : Pooled data from 3 multicenter , double - masked , randomized , controlled , phase 2b / 3 clinical trials evaluating the safety and efficacy of the 0 . 59 - mg or 2 . 1 - mg FA intravitreal implant or standard therapy were analyzed .	DESIGN : Pooled data from 3 multicenter , double - masked , randomized , controlled , phase 2b / 3 clinical trials evaluating the safety and efficacy of the 0 . 59 - mg or 2 . 1 - mg FA intravitreal implant or standard therapy were analyzed .
RESULTS : During the 3 - year follow - up , 71 . 0 % of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55 . 1 % , 24 . 7 % , and 6 . 2 % of eyes reached an IOP of 30 mm Hg or more , 40 mm Hg or more , and 50 mm Hg or more , respectively .	RESULTS : During the 3 - year follow - up , 71 . 0 % of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55 . 1 % , 24 . 7 % , and 6 . 2 % of eyes reached an IOP of 30 mm Hg or more , 40 mm Hg or more , and 50 mm Hg or more , respectively .
Topical IOP - lowering medication was administered in 74 . 8 % of implanted eyes , and IOP - lowering surgeries , most of which were trabeculectomies ( 76 . 2 % ) , were performed on 36 . 6 % of implanted eyes .	Topical IOP - lowering medication was administered in 74 . 8 % of implanted eyes , and IOP - lowering surgeries , most of which were trabeculectomies ( 76 . 2 % ) , were performed on 36 . 6 % of implanted eyes .
Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .	Intraocular pressure - lowering surgeries were considered a success ( postoperative IOP of 6 - 21 mm Hg with or without additional IOP - lowering medication ) in 85 . 1 % of eyes at 1 year .
The rate of hypotony ( IOP < / = 5 mm Hg ) following IOP - lowering surgery ( 42 . 5 % ) was not different from that of implanted eyes not subjected to surgery ( 35 . 4 % ) ( P = . 09 ) .	The rate of disease* hypotony *disease ( IOP < / = 5 mm Hg ) following IOP - lowering surgery ( 42 . 5 % ) was not different from that of implanted eyes not subjected to surgery ( 35 . 4 % ) ( P = . 09 ) .
CONCLUSION : Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery .	CONCLUSION : Elevated IOP is a significant complication with the FA intravitreal implant but may be controlled with medication and surgery .
Myocardial Fas ligand expression increases susceptibility to AZT - induced cardiomyopathy .	Myocardial Fas ligand expression increases susceptibility to AZT - induced disease* cardiomyopathy *disease .
BACKGROUND : Dilated cardiomyopathy ( DCM ) and myocarditis occur in many HIV - infected individuals , resulting in symptomatic heart failure in up to 5 % of patients .	BACKGROUND : disease* Dilated cardiomyopathy *disease ( disease* DCM *disease ) and disease* myocarditis *disease occur in many disease* HIV - infected *disease individuals , resulting in symptomatic disease* heart failure *disease in up to 5 % of patients .
Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of acquired immunodeficiency syndrome ( AIDS ) , but has resulted in an increase in cardiac and skeletal myopathies .	Highly active antiretroviral therapy ( HAART ) has significantly reduced morbidity and mortality of disease* acquired immunodeficiency syndrome *disease ( disease* AIDS *disease ) , but has resulted in an increase in disease* cardiac and skeletal myopathies *disease .
METHODS AND RESULTS : In order to investigate whether the HAART component zidovudine ( 3 ' - azido - 2 ' , 3 ' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of DCM , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .	METHODS AND RESULTS : In order to investigate whether the HAART component zidovudine ( 3 ' - azido - 2 ' , 3 ' - deoxythymidine ; AZT ) triggers the Fas - dependent cell - death pathway and cause cytoskeletal disruption in a murine model of disease* DCM *disease , 8 - week - old transgenic ( expressing Fas ligand in the myocardium : FasL Tg ) and non - transgenic ( NTg ) mice received water ad libitum containing different concentrations of AZT ( 0 , 0 . 07 , 0 . 2 , and 0 . 7 mg / ml ) .
After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .	After 6 weeks , cardiac function was assessed by echocardiography and morphology was assessed by histopathologic and immunohistochemical methods .
NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function .	NTg and untreated FasL Tg mice showed little or no change in cardiac structure or function .
In contrast , AZT - treated FasL Tg mice developed cardiac dilation and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .	In contrast , AZT - treated FasL Tg mice developed disease* cardiac dilation *disease and depressed cardiac function in a dose - dependent manner , with concomitant inflammatory infiltration of both ventricles .
These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .	These changes were associated with an increased sarcolemmal expression of Fas and FasL , as well as increased activation of caspase 3 , translocation of calpain 1 to the sarcolemma and sarcomere , and increased numbers of cells undergoing apoptosis .
These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .	These were associated with changes in dystrophin and cardiac troponin I localization , as well as loss of sarcolemmal integrity .
CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced cardiomyopathy due to activation of apoptotic pathways , resulting in cardiac dilation and dysfunction .	CONCLUSIONS : The expression of Fas ligand in the myocardium , as identified in HIV - positive patients , might increase the susceptibility to HAART - induced disease* cardiomyopathy *disease due to activation of apoptotic pathways , resulting in disease* cardiac dilation and dysfunction *disease .
Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .	Gastrointestinal tolerability of etoricoxib in disease* rheumatoid arthritis *disease patients : results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial ( EDGE - II ) .
OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and diclofenac in patients with rheumatoid arthritis ( RA ) .	OBJECTIVE : A randomised , double - blind study to compare the gastrointestinal ( GI ) tolerability , safety and efficacy of etoricoxib and diclofenac in patients with disease* rheumatoid arthritis *disease ( disease* RA *disease ) .
PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with RA were enrolled and received etoricoxib 90 mg daily ( n = 2032 ) or diclofenac 75 mg twice daily ( n = 2054 ) .	PATIENTS AND METHODS : A total of 4086 patients ( mean age 60 . 8 years ) diagnosed with disease* RA *disease were enrolled and received etoricoxib 90 mg daily ( n = 2032 ) or diclofenac 75 mg twice daily ( n = 2054 ) .
Use of gastroprotective agents and low - dose aspirin was allowed .	Use of gastroprotective agents and low - dose aspirin was allowed .
The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences ( AEs ) .	The prespecified primary end point consisted of the cumulative rate of patient discontinuations due to clinical and laboratory GI adverse experiences ( AEs ) .
General safety was also assessed , including adjudicated thrombotic cardiovascular event data .	General safety was also assessed , including adjudicated disease* thrombotic cardiovascular *disease event data .
Efficacy was evaluated using the Patient Global Assessment of Disease Status ( PGADS ; 0 - 4 point scale ) .	Efficacy was evaluated using the Patient Global Assessment of Disease Status ( PGADS ; 0 - 4 point scale ) .
RESULTS : Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the etoricoxib and diclofenac groups , respectively .	RESULTS : Mean ( SD ; maximum ) duration of treatment was 19 . 3 ( 10 . 3 ; 32 . 9 ) and 19 . 1 ( 10 . 4 ; 33 . 1 ) months in the etoricoxib and diclofenac groups , respectively .
The cumulative discontinuation rate due to GI AEs was significantly lower with etoricoxib than diclofenac ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .	The cumulative discontinuation rate due to disease* GI AEs *disease was significantly lower with etoricoxib than diclofenac ( 5 . 2 vs 8 . 5 events per 100 patient - years , respectively ; hazard ratio 0 . 62 ( 95 % CI : 0 . 47 , 0 . 81 ; p < or = 0 . 001 ) ) .
The incidence of discontinuations for hypertension - related and oedema - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for hypertension and p < 0 . 01 for oedema ) .	The incidence of discontinuations for disease* hypertension *disease - related and disease* oedema *disease - related AEs were significantly higher with etoricoxib ( 2 . 5 % and 1 . 1 % respectively ) compared with diclofenac ( 1 . 5 % and 0 . 4 % respectively ; p < 0 . 001 for disease* hypertension *disease and p < 0 . 01 for disease* oedema *disease ) .
Etoricoxib and diclofenac treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .	Etoricoxib and diclofenac treatment resulted in similar efficacy ( PGADS mean changes from baseline - 0 . 62 vs - 0 . 58 , respectively ) .
CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to GI AEs compared with diclofenac 150 mg .	CONCLUSIONS : Etoricoxib 90 mg demonstrated a significantly lower risk for discontinuing treatment due to disease* GI AEs *disease compared with diclofenac 150 mg .
Discontinuations from renovascular AEs , although less common than discontinuations from GI AEs , were significantly higher with etoricoxib .	Discontinuations from renovascular AEs , although less common than discontinuations from disease* GI AEs *disease , were significantly higher with etoricoxib .
Anxiogenic potential of ciprofloxacin and norfloxacin in rats .	Anxiogenic potential of ciprofloxacin and norfloxacin in rats .
INTRODUCTION : The possible anxiogenic effects of fluoroquinolones , namely ciprofloxacin and norfloxacin , were investigated in adult Charles Foster albino rats of either sex , weighing 150 - 200 g .	INTRODUCTION : The possible anxiogenic effects of fluoroquinolones , namely ciprofloxacin and norfloxacin , were investigated in adult Charles Foster albino rats of either sex , weighing 150 - 200 g .
METHODS : The drugs were given orally , in doses of 50 mg / kg for five consecutive days and the experiments were performed on the fifth day .	METHODS : The drugs were given orally , in doses of 50 mg / kg for five consecutive days and the experiments were performed on the fifth day .
The tests included open - field exploratory behaviour , elevated plus maze and elevated zero maze , social interaction and novelty - suppressed feeding latency behaviour .	The tests included open - field exploratory behaviour , elevated plus maze and elevated zero maze , social interaction and novelty - suppressed feeding latency behaviour .
RESULTS : The results indicate that ciprofloxacin - and norfloxacin - treated rats showed anxious behaviour in comparison to control rats in all the parameters studied .	RESULTS : The results indicate that ciprofloxacin - and norfloxacin - treated rats showed disease* anxious behaviour *disease in comparison to control rats in all the parameters studied .
However , ciprofloxacin - and norfloxacin - treated rats did not differ significantly from each other in various behavioural parameters .	However , ciprofloxacin - and norfloxacin - treated rats did not differ significantly from each other in various behavioural parameters .
CONCLUSION : The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin .	CONCLUSION : The present experimental findings substantiate the clinically observed anxiogenic potential of ciprofloxacin and norfloxacin .
Reduction of pain during induction with target - controlled propofol and remifentanil .	Reduction of disease* pain *disease during induction with target - controlled propofol and remifentanil .
BACKGROUND : Pain on injection of propofol is unpleasant .	BACKGROUND : disease* Pain *disease on injection of propofol is unpleasant .
We hypothesized that propofol infusion pain might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .	We hypothesized that propofol infusion disease* pain *disease might be prevented by infusing remifentanil before starting the propofol infusion in a clinical setting where target - controlled infusions ( TCI ) of both drugs were used .
A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of remifentanil to prevent the pain without producing complications .	A prospective , randomized , double - blind , placebo - controlled trial was performed to determine the effect - site concentration ( Ce ) of remifentanil to prevent the disease* pain *disease without producing complications .
METHODS : A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline ( control ) or remifentanil to a target Ce of 2 ng ml ( - 1 ) ( R2 ) , 4 ng ml ( - 1 ) ( R4 ) , or 6 ng ml ( - 1 ) ( R6 ) administered via TCI .	METHODS : A total of 128 patients undergoing general surgery were randomly allocated to receive normal saline ( control ) or remifentanil to a target Ce of 2 ng ml ( - 1 ) ( R2 ) , 4 ng ml ( - 1 ) ( R4 ) , or 6 ng ml ( - 1 ) ( R6 ) administered via TCI .
After the target Ce was achieved , the infusion of propofol was started .	After the target Ce was achieved , the infusion of propofol was started .
Remifentanil - related complications were assessed during the remifentanil infusion , and pain caused by propofol was evaluated using a four - point scale during the propofol infusion .	Remifentanil - related complications were assessed during the remifentanil infusion , and disease* pain *disease caused by propofol was evaluated using a four - point scale during the propofol infusion .
RESULTS : The incidence of pain was significantly lower in Groups R4 and R6 than in the control and R2 groups ( 12 / 32 and 6 / 31 vs 26 / 31 and 25 / 32 , respectively , P < 0 . 001 ) .	RESULTS : The incidence of disease* pain *disease was significantly lower in Groups R4 and R6 than in the control and R2 groups ( 12 / 32 and 6 / 31 vs 26 / 31 and 25 / 32 , respectively , P < 0 . 001 ) .
Pain was less severe in Groups R4 and R6 than in the control and R2 groups ( P < 0 . 001 ) .	disease* Pain *disease was less severe in Groups R4 and R6 than in the control and R2 groups ( P < 0 . 001 ) .
However , both incidence and severity of pain were not different between Groups R4 and R6 .	However , both incidence and severity of disease* pain *disease were not different between Groups R4 and R6 .
No significant complications were observed during the study .	No significant complications were observed during the study .
CONCLUSIONS : During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion pain was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .	CONCLUSIONS : During induction of anaesthesia with TCI of propofol and remifentanil , a significant reduction in propofol infusion disease* pain *disease was achieved without significant complications by prior administration of remifentanil at a target Ce of 4 ng ml ( - 1 ) .
Dexmedetomidine and cardiac protection for non - cardiac surgery : a meta - analysis of randomised controlled trials .	Dexmedetomidine and cardiac protection for non - cardiac surgery : a meta - analysis of randomised controlled trials .
We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non - cardiac surgery .	We conducted a systematic review of the effects of dexmedetomidine on cardiac outcomes following non - cardiac surgery .
We included prospective , randomised peri - operative studies of dexmedetomidine that reported mortality , cardiac morbidity or adverse drug events .	We included prospective , randomised peri - operative studies of dexmedetomidine that reported mortality , cardiac morbidity or adverse drug events .
A PubMed Central and EMBASE search was conducted up to July 2007 .	A PubMed Central and EMBASE search was conducted up to July 2007 .
The reference lists of identified papers were examined for further trials .	The reference lists of identified papers were examined for further trials .
Of 425 studies identified , 20 were included in the meta - analysis ( 840 patients ) .	Of 425 studies identified , 20 were included in the meta - analysis ( 840 patients ) .
Dexmedetomidine was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal myocardial infarction ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and myocardial ischaemia ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .	Dexmedetomidine was associated with a trend towards improved cardiac outcomes ; all - cause mortality ( OR 0 . 27 , 95 % CI 0 . 01 - 7 . 13 , p = 0 . 44 ) , non - fatal disease* myocardial infarction *disease ( OR 0 . 26 , 95 % CI 0 . 04 - 1 . 60 , p = 0 . 14 ) , and disease* myocardial ischaemia *disease ( OR 0 . 65 , 95 % CI 0 . 26 - 1 . 63 , p = 0 . 36 ) .
Peri - operative hypotension ( 26 % , OR 3 . 80 , 95 % CI 1 . 91 - 7 . 54 , p = 0 . 0001 ) and bradycardia ( 17 % , OR 5 . 45 , 95 % CI 2 . 98 - 9 . 95 , p < 0 . 00001 ) were significantly increased .	Peri - operative disease* hypotension *disease ( 26 % , OR 3 . 80 , 95 % CI 1 . 91 - 7 . 54 , p = 0 . 0001 ) and disease* bradycardia *disease ( 17 % , OR 5 . 45 , 95 % CI 2 . 98 - 9 . 95 , p < 0 . 00001 ) were significantly increased .
An anticholinergic did not reduce the incidence of bradycardia ( p = 0 . 43 ) .	An anticholinergic did not reduce the incidence of disease* bradycardia *disease ( p = 0 . 43 ) .
A randomised placebo - controlled trial of dexmedetomidine is warranted .	A randomised placebo - controlled trial of dexmedetomidine is warranted .
Myocardial infarction in pregnancy associated with clomiphene citrate for ovulation induction : a case report .	disease* Myocardial infarction *disease in pregnancy associated with clomiphene citrate for ovulation induction : a case report .
BACKGROUND : Clomiphene citrate ( CC ) is commonly prescribed for ovulation induction .	BACKGROUND : Clomiphene citrate ( CC ) is commonly prescribed for ovulation induction .
It is considered safe , with minimal side effects .	It is considered safe , with minimal side effects .
Thromboembolism is a rare but life - threatening complication that has been reported after ovulation induction with CC .	disease* Thromboembolism *disease is a rare but life - threatening complication that has been reported after ovulation induction with CC .
Spontaneous coronary thrombosis or thromboembolism with subsequent clot lysis has been suggested as one of the most common causes of myocardial infarction ( MI ) during pregnancy , with a subsequently normal coronary angiogram .	Spontaneous disease* coronary thrombosis *disease or disease* thromboembolism *disease with subsequent clot lysis has been suggested as one of the most common causes of disease* myocardial infarction *disease ( disease* MI *disease ) during pregnancy , with a subsequently normal coronary angiogram .
CASE : A 33 - year - old woman with a 5 - week gestation had recently received CC for ovulation induction and presented with chest pain .	CASE : A 33 - year - old woman with a 5 - week gestation had recently received CC for ovulation induction and presented with disease* chest pain *disease .
An electrocardiogram showed a lateral and anterior wall myocardial infarction .	An electrocardiogram showed a lateral and anterior wall disease* myocardial infarction *disease .
Cardiac enzymes showed a peak rise in troponin I to 9 . 10 ng / mL .	Cardiac enzymes showed a peak rise in troponin I to 9 . 10 ng / mL .
An initial exercise stress test was normal .	An initial exercise stress test was normal .
At the time of admission , the patient was at high risk of radiation injury to the fetus , so a coronary angiogram was postponed until the second trimester .	At the time of admission , the patient was at high risk of disease* radiation injury *disease to the fetus , so a coronary angiogram was postponed until the second trimester .
It showed normal coronary vessels .	It showed normal coronary vessels .
CONCLUSION : This appears to be the first reported case documenting a possible association between CC and myocardial infarction .	CONCLUSION : This appears to be the first reported case documenting a possible association between CC and disease* myocardial infarction *disease .
Thrombosis might be a rare but hazardous complication of CC .	disease* Thrombosis *disease might be a rare but hazardous complication of CC .
Given this life - threatening complication , appropriate prophylactic measures should be used in high - risk woman undergoing ovarian stimulation .	Given this life - threatening complication , appropriate prophylactic measures should be used in high - risk woman undergoing ovarian stimulation .
Reverse or inverted left ventricular apical ballooning syndrome ( reverse Takotsubo cardiomyopathy ) in a young woman in the setting of amphetamine use .	Reverse or inverted disease* left ventricular apical ballooning syndrome *disease ( reverse disease* Takotsubo cardiomyopathy *disease ) in a young woman in the setting of amphetamine use .
Transient left ventricular apical ballooning syndrome was first described in Japan as " Takotsubo cardiomyopathy . " This syndrome has been identified in many other countries .	Transient disease* left ventricular apical ballooning syndrome *disease was first described in Japan as " disease* Takotsubo cardiomyopathy *disease . " This syndrome has been identified in many other countries .
Many variations of this syndrome have been recently described in the literature .	Many variations of this syndrome have been recently described in the literature .
One of the rarest is the reverse type of this syndrome , with hyperdynamic apex and complete akinesia of the base ( as opposed to the classic apical ballooning ) .	One of the rarest is the reverse type of this syndrome , with hyperdynamic apex and complete disease* akinesia *disease of the base ( as opposed to the classic disease* apical ballooning *disease ) .
In this article , we report an interesting case of a young woman who presented with this rare type of reverse apical ballooning syndrome occurring after amphetamine use .	In this article , we report an interesting case of a young woman who presented with this rare type of reverse disease* apical ballooning syndrome *disease occurring after amphetamine use .
This report is followed by review of the literature .	This report is followed by review of the literature .
Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension .	Results of a comparative , phase III , 12 - week , multicenter , prospective , randomized , double - blind assessment of the efficacy and tolerability of a fixed - dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II disease* hypertension *disease .
OBJECTIVE : The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II hypertension .	OBJECTIVE : The aim of this study was to evaluate the efficacy and tolerability of a new fixed - dose combination ( FDC ) of telmisartan 40 mg + amlodipine 5 mg ( T + A ) compared with amlodipine 5 - mg monotherapy ( A ) in adult Indian patients with stage II disease* hypertension *disease .
METHODS : This comparative , Phase III , 12 - week , multicenter , prospective , randomized , double - blind study was conducted in Indian patients aged 18 to 65 years with established stage II hypertension .	METHODS : This comparative , Phase III , 12 - week , multicenter , prospective , randomized , double - blind study was conducted in Indian patients aged 18 to 65 years with established stage II disease* hypertension *disease .
Patients were treated with oral FDC of T + A or A QD before breakfast for 12 weeks ; blood pressure ( BP ) and heart rate were measured in the sitting position .	Patients were treated with oral FDC of T + A or A QD before breakfast for 12 weeks ; blood pressure ( BP ) and heart rate were measured in the sitting position .
Primary efficacy end points were reduction in clinical systolic BP ( SBP ) / diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 / < 80 mm Hg ) at end of study .	Primary efficacy end points were reduction in clinical systolic BP ( SBP ) / diastolic BP ( DBP ) from baseline to study end and number of responders ( ie , patients who achieved target SBP / DBP < 130 / < 80 mm Hg ) at end of study .
Tolerability was assessed by treatment - emergent adverse events , identified using physical examination , laboratory analysis , and electrocardiography .	Tolerability was assessed by treatment - emergent adverse events , identified using physical examination , laboratory analysis , and electrocardiography .
RESULTS : A total of 210 patients were enrolled in the study ; 203 patients ( 143 men , 60 women ) completed the study while 7 were lost to follow - up ( 4 patients in the T + A group and 3 in the A group ) and considered with - drawn .	RESULTS : A total of 210 patients were enrolled in the study ; 203 patients ( 143 men , 60 women ) completed the study while 7 were lost to follow - up ( 4 patients in the T + A group and 3 in the A group ) and considered with - drawn .
At study end , statistically significant percentage reductions from baseline within groups and between groups were observed in SBP ( T + A [ - 27 . 4 % ] ; A [ - 16 . 6 % ] ) and DBP ( T + A [ - 20 . 1 % ] ; A [ - 13 . 3 % ] ) ( all , P < 0 . 05 ) .	At study end , statistically significant percentage reductions from baseline within groups and between groups were observed in SBP ( T + A [ - 27 . 4 % ] ; A [ - 16 . 6 % ] ) and DBP ( T + A [ - 20 . 1 % ] ; A [ - 13 . 3 % ] ) ( all , P < 0 . 05 ) .
Response rates were 87 . 3 % ( 89 / 102 ) in the T + A group and 69 . 3 % ( 70 / 101 ) in the A group ( P < 0 . 05 ) .	Response rates were 87 . 3 % ( 89 / 102 ) in the T + A group and 69 . 3 % ( 70 / 101 ) in the A group ( P < 0 . 05 ) .
The prevalences of adverse events were not significantly different between the 2 treatment groups ( T + A , 16 . 0 % [ 17 / 106 ] ; A , 15 . 4 % [ 16 / 104 ] ) .	The prevalences of adverse events were not significantly different between the 2 treatment groups ( T + A , 16 . 0 % [ 17 / 106 ] ; A , 15 . 4 % [ 16 / 104 ] ) .
Peripheral edema was reported in 8 . 5 % patients ( 9 / 106 ) in the T + A group compared with 13 . 5 % ( 14 / 104 ) in the A group , and cough was reported in 3 . 8 % patients ( 4 / 106 ) in the T + A group and 1 . 0 % ( 1 / 104 ) patients in the A group ; these differences did not reach statistical significance .	Peripheral disease* edema *disease was reported in 8 . 5 % patients ( 9 / 106 ) in the T + A group compared with 13 . 5 % ( 14 / 104 ) in the A group , and disease* cough *disease was reported in 3 . 8 % patients ( 4 / 106 ) in the T + A group and 1 . 0 % ( 1 / 104 ) patients in the A group ; these differences did not reach statistical significance .
The incidences of headache , dizziness , and diarrhea were similar between the 2 groups .	The incidences of disease* headache *disease , disease* dizziness *disease , and disease* diarrhea *disease were similar between the 2 groups .
CONCLUSIONS : Among these Indian patients with stage II hypertension , the FDC of T + A was found to be significantly more effective , with regard to BP reductions , than A , and both treatments were well tolerated .	CONCLUSIONS : Among these Indian patients with stage II disease* hypertension *disease , the FDC of T + A was found to be significantly more effective , with regard to BP reductions , than A , and both treatments were well tolerated .
Increased mental slowing associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly .	Increased disease* mental slowing *disease associated with the APOE epsilon4 allele after trihexyphenidyl oral anticholinergic challenge in healthy elderly .
OBJECTIVES : The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and confusion and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .	OBJECTIVES : The objectives of this study were to examine the relationship between APOE epsilon4 and subjective effects of trihexyphenidyl on measures reflecting sedation and disease* confusion *disease and to investigate the relationship between trihexyphenidyl - induced subjective effects and objective memory performance .
METHODS : This study comprised 24 cognitively intact , health elderly adults ( 12 APOE epsilon4 carriers ) at an outpatient geriatric psychiatry research clinic .	METHODS : This study comprised 24 cognitively intact , health elderly adults ( 12 APOE epsilon4 carriers ) at an outpatient geriatric psychiatry research clinic .
This was a randomized , double blind , placebo - controlled , three - way , crossover experimental design .	This was a randomized , double blind , placebo - controlled , three - way , crossover experimental design .
All participants received 1 . 0 mg or 2 . 0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks .	All participants received 1 . 0 mg or 2 . 0 mg trihexyphenidyl or placebo administered in counterbalanced sequences over a period of three consecutive weeks .
Bond and Lader ' s visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline , 1 , 2 . 5 , and 5 hours postdrug administration .	Bond and Lader ' s visual analog scales and alternate versions of the Buschke Selective Reminding Test were administered in a repeated measures design at baseline , 1 , 2 . 5 , and 5 hours postdrug administration .
RESULTS : A 2 . 0 - mg oral dose of trihexyphenidyl resulted in increased subjective ratings of mental slowness in carriers of the APOE epsilon4 allele only .	RESULTS : A 2 . 0 - mg oral dose of trihexyphenidyl resulted in increased subjective ratings of disease* mental slowness *disease in carriers of the APOE epsilon4 allele only .
Drug effects as determined by difference scores between 2 . 0 mg trihexyphenidyl and placebo on ratings of mental slowness significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only .	Drug effects as determined by difference scores between 2 . 0 mg trihexyphenidyl and placebo on ratings of disease* mental slowness *disease significantly correlated with total and delayed recall on the Buschke Selective Reminding Test in carriers of the APOE epsilon4 allele only .
However , no significant effects were found with other visual analog scales reflecting subjective sedation and clear - headedness .	However , no significant effects were found with other visual analog scales reflecting subjective sedation and clear - headedness .
CONCLUSION : The epsilon4 allele in healthy elderly was associated with increased subjective mental slowing after trihexyphenidyl anticholinergic challenge .	CONCLUSION : The epsilon4 allele in healthy elderly was associated with increased subjective disease* mental slowing *disease after trihexyphenidyl anticholinergic challenge .
An evaluation of amikacin nephrotoxicity in the hematology / oncology population .	An evaluation of amikacin disease* nephrotoxicity *disease in the hematology / oncology population .
Amikacin is an aminoglycoside commonly used to provide empirical double gram - negative treatment for febrile neutropenia and other suspected infections .	Amikacin is an aminoglycoside commonly used to provide empirical double gram - negative treatment for disease* febrile neutropenia *disease and other suspected disease* infections *disease .
Strategies of extended - interval and conventional dosing have been utilized extensively in the general medical population ; however , data are lacking to support a dosing strategy in the hematology / oncology population .	Strategies of extended - interval and conventional dosing have been utilized extensively in the general medical population ; however , data are lacking to support a dosing strategy in the hematology / oncology population .
To evaluate amikacin - associated nephrotoxicity in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .	To evaluate amikacin - associated disease* nephrotoxicity *disease in an adult hematology / oncology population , a prospective , randomized , open - label trial was conducted at a university - affiliated medical center .
Forty patients with a diagnosis consistent with a hematologic / oncologic disorder that required treatment with an aminoglycoside were randomized to either conventional or extended - interval amikacin .	Forty patients with a diagnosis consistent with a disease* hematologic / oncologic disorder *disease that required treatment with an aminoglycoside were randomized to either conventional or extended - interval amikacin .
The occurrence of nephrotoxicity by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .	The occurrence of disease* nephrotoxicity *disease by means of an increase in serum creatinine and evaluation of efficacy via amikacin serum concentrations with respective pathogens were assessed .
The occurrence of nephrotoxicity was similar between the conventional and extended - interval groups , at 10 % and 5 % , respectively ( P = 1 . 00 ) .	The occurrence of disease* nephrotoxicity *disease was similar between the conventional and extended - interval groups , at 10 % and 5 % , respectively ( P = 1 . 00 ) .
Six patients in the conventional group had a positive culture , compared with none in the extended - interval group ( P = 0 . 002 ) .	Six patients in the conventional group had a positive culture , compared with none in the extended - interval group ( P = 0 . 002 ) .
The occurrence of nephrotoxicity was similar between the two dosing regimens , but the distribution of risk factors was variable between the two groups .	The occurrence of disease* nephrotoxicity *disease was similar between the two dosing regimens , but the distribution of risk factors was variable between the two groups .
Efficacy could not be assessed .	Efficacy could not be assessed .
High dose dexmedetomidine as the sole sedative for pediatric MRI .	High dose dexmedetomidine as the sole sedative for pediatric MRI .
OBJECTIVE : This large - scale retrospective review evaluates the sedation profile of dexmedetomidine .	OBJECTIVE : This large - scale retrospective review evaluates the sedation profile of dexmedetomidine .
AIM : To determine the hemodynamic responses , efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging ( MRI ) studies .	AIM : To determine the hemodynamic responses , efficacy and adverse events associated with the use of high dose dexmedetomidine as the sole sedative for magnetic resonance imaging ( MRI ) studies .
BACKGROUND : Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies .	BACKGROUND : Dexmedetomidine has been used at our institution since 2005 to provide sedation for pediatric radiological imaging studies .
Over time , an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved .	Over time , an effective protocol utilizing high dose dexmedetomidine as the sole sedative agent has evolved .
METHODS / MATERIALS : As part of the ongoing Quality Assurance process , data on all sedations are reviewed monthly and protocols modified as needed .	METHODS / MATERIALS : As part of the ongoing Quality Assurance process , data on all sedations are reviewed monthly and protocols modified as needed .
Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007 .	Data were analyzed from all 747 consecutive patients who received dexmedetomidine for MRI sedation from April 2005 to April 2007 .
RESULTS : Since 2005 , the 10 - min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg . kg ( - 1 ) , and the infusion rate increased from 1 to 1 . 5 to 2 microg . kg ( - 1 ) . h ( - 1 ) .	RESULTS : Since 2005 , the 10 - min loading dose of our dexmedetomidine protocol increased from 2 to 3 microg . kg ( - 1 ) , and the infusion rate increased from 1 to 1 . 5 to 2 microg . kg ( - 1 ) . h ( - 1 ) .
The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .	The current sedation protocol progressively increased the rate of successful sedation ( able to complete the imaging study ) when using dexmedetomidine alone from 91 . 8 % to 97 . 6 % ( P = 0 . 009 ) , reducing the requirement for adjuvant pentobarbital in the event of sedation failure with dexmedetomidine alone and decreased the mean recovery time by 10 min ( P < 0 . 001 ) .
Although dexmedetomidine sedation was associated with a 16 % incidence of bradycardia , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .	Although dexmedetomidine sedation was associated with a 16 % incidence of disease* bradycardia *disease , all concomitant mean arterial blood pressures were within 20 % of age - adjusted normal range and oxygen saturations were 95 % or higher .
CONCLUSION : Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies .	CONCLUSION : Dexmedetomidine in high doses provides adequate sedation for pediatric MRI studies .
While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established ' awake ' norms , this deviation is generally within 20 % of norms , and is not associated with adverse sequelae .	While use of high dose dexmedetomidine is associated with decreases in heart rate and blood pressure outside the established ' awake ' norms , this deviation is generally within 20 % of norms , and is not associated with adverse sequelae .
Dexmedetomidine is useful as the sole sedative for pediatric MRI .	Dexmedetomidine is useful as the sole sedative for pediatric MRI .
Hepatotoxicity associated with sulfasalazine in inflammatory arthritis : A case series from a local surveillance of serious adverse events .	disease* Hepatotoxicity *disease associated with sulfasalazine in inflammatory disease* arthritis *disease : A case series from a local surveillance of serious adverse events .
BACKGROUND : Spontaneous reporting systems for adverse drug reactions ( ADRs ) are handicapped by under - reporting and limited detail on individual cases .	BACKGROUND : Spontaneous reporting systems for adverse drug reactions ( ADRs ) are handicapped by under - reporting and limited detail on individual cases .
We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of liver failure in two of our patients .	We report an investigation from a local surveillance for serious adverse drug reactions associated with disease modifying anti - rheumatic drugs that was triggered by the occurrence of disease* liver failure *disease in two of our patients .
METHODS : Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years .	METHODS : Serious ADR reports have been solicited from local clinicians by regular postcards over the past seven years .
Patients ' , who had hepatotoxicity on sulfasalazine and met a definition of a serious ADR , were identified .	Patients ' , who had disease* hepatotoxicity *disease on sulfasalazine and met a definition of a serious ADR , were identified .
Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument .	Two clinicians reviewed structured case reports and assessed causality by consensus and by using a causality assessment instrument .
The likely frequency of hepatotoxicity with sulfasalazine was estimated by making a series of conservative assumptions .	The likely frequency of disease* hepatotoxicity *disease with sulfasalazine was estimated by making a series of conservative assumptions .
RESULTS : Ten cases were identified : eight occurred during surveillance .	RESULTS : Ten cases were identified : eight occurred during surveillance .
Eight patients were hospitalised , two in hepatic failure - one died after a liver transplant .	Eight patients were hospitalised , two in disease* hepatic failure *disease - one died after a liver transplant .
All but one event occurred within 6 weeks of treatment .	All but one event occurred within 6 weeks of treatment .
Seven patients had a skin rash , three eosinophilia and one interstitial nephritis .	Seven patients had a disease* skin rash *disease , three disease* eosinophilia *disease and one disease* interstitial nephritis *disease .
Five patients were of Black British of African or Caribbean descent .	Five patients were of Black British of African or Caribbean descent .
Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six .	Liver enzymes showed a hepatocellular pattern in four cases and a mixed pattern in six .
Drug - related hepatotoxicity was judged probable or highly probable in 8 patients .	Drug - related disease* hepatotoxicity *disease was judged probable or highly probable in 8 patients .
The likely frequency of serious hepatotoxicity with sulfasalazine was estimated at 0 . 4 % of treated patients .	The likely frequency of serious disease* hepatotoxicity *disease with sulfasalazine was estimated at 0 . 4 % of treated patients .
CONCLUSION : Serious hepatotoxicity associated with sulfasalazine appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .	CONCLUSION : Serious disease* hepatotoxicity *disease associated with sulfasalazine appears to be under - appreciated and intensive monitoring and vigilance in the first 6 weeks of treatment is especially important .
Complete atrioventricular block secondary to lithium therapy .	Complete disease* atrioventricular block *disease secondary to lithium therapy .
Sinus node dysfunction has been reported most frequently among the adverse cardiovascular effects of lithium .	disease* Sinus node dysfunction *disease has been reported most frequently among the adverse cardiovascular effects of lithium .
In the present case , complete atrioventricular ( AV ) block with syncopal attacks developed secondary to lithium therapy , necessitating permanent pacemaker implantation .	In the present case , complete disease* atrioventricular ( AV ) block *disease with disease* syncopal attacks *disease developed secondary to lithium therapy , necessitating permanent pacemaker implantation .
Serum lithium levels remained under or within the therapeutic range during the syncopal attacks .	Serum lithium levels remained under or within the therapeutic range during the disease* syncopal attacks *disease .
Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .	Lithium should be used with extreme caution , especially in patients with mild disturbance of AV conduction .
Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( CYP ) - induced cystitis .	Exaggerated expression of inflammatory mediators in vasoactive intestinal polypeptide knockout ( VIP - / - ) mice with cyclophosphamide ( CYP ) - induced disease* cystitis *disease .
Vasoactive intestinal polypeptide ( VIP ) is an immunomodulatory neuropeptide distributed in micturition pathways .	Vasoactive intestinal polypeptide ( VIP ) is an immunomodulatory neuropeptide distributed in micturition pathways .
VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( CYP ) - induced cystitis .	VIP ( - / - ) mice exhibit altered bladder function and neurochemical properties in micturition pathways after cyclophosphamide ( CYP ) - induced disease* cystitis *disease .
Given VIP ' s role as an anti - inflammatory mediator , we hypothesized that VIP ( - / - ) mice would exhibit enhanced inflammatory mediator expression after cystitis .	Given VIP ' s role as an anti - inflammatory mediator , we hypothesized that VIP ( - / - ) mice would exhibit enhanced inflammatory mediator expression after disease* cystitis *disease .
A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without CYP - induced cystitis ( 150 mg / kg ; i . p . ; 48 h ) .	A mouse inflammatory cytokine and receptor RT2 profiler array was used to determine regulated transcripts in the urinary bladder of wild type ( WT ) and VIP ( - / - ) mice with or without CYP - induced disease* cystitis *disease ( 150 mg / kg ; i . p . ; 48 h ) .
Four binary comparisons were made : WT control versus CYP treatment ( 48 h ) , VIP ( - / - ) control versus CYP treatment ( 48 h ) , WT control versus VIP ( - / - ) control , and WT with CYP treatment ( 48 h ) versus VIP ( - / - ) with CYP treatment ( 48 h ) .	Four binary comparisons were made : WT control versus CYP treatment ( 48 h ) , VIP ( - / - ) control versus CYP treatment ( 48 h ) , WT control versus VIP ( - / - ) control , and WT with CYP treatment ( 48 h ) versus VIP ( - / - ) with CYP treatment ( 48 h ) .
The genes presented represent ( 1 ) greater than 1 . 5 - fold change in either direction and ( 2 ) the p value is less than 0 . 05 for the comparison being made .	The genes presented represent ( 1 ) greater than 1 . 5 - fold change in either direction and ( 2 ) the p value is less than 0 . 05 for the comparison being made .
Several regulated genes were validated using enzyme - linked immunoassays including IL - 1beta and CXCL1 .	Several regulated genes were validated using enzyme - linked immunoassays including IL - 1beta and CXCL1 .
CYP treatment significantly ( p < or = 0 . 001 ) increased expression of CXCL1 and IL - 1beta in the urinary bladder of WT and VIP ( - / - ) mice , but expression in VIP ( - / - ) mice with CYP treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .	CYP treatment significantly ( p < or = 0 . 001 ) increased expression of CXCL1 and IL - 1beta in the urinary bladder of WT and VIP ( - / - ) mice , but expression in VIP ( - / - ) mice with CYP treatment was significantly ( p < or = 0 . 001 ) greater ( 4 . 2 - to 13 - fold increase ) than that observed in WT urinary bladder ( 3 . 6 - to 5 - fold increase ) .
The data suggest that in VIP ( - / - ) mice with bladder inflammation , inflammatory mediators are increased above that observed in WT with CYP .	The data suggest that in VIP ( - / - ) mice with disease* bladder inflammation *disease , inflammatory mediators are increased above that observed in WT with CYP .
This shift in balance may contribute to increased bladder dysfunction in VIP ( - / - ) mice with bladder inflammation and altered neurochemical expression in micturition pathways .	This shift in balance may contribute to increased disease* bladder dysfunction *disease in VIP ( - / - ) mice with disease* bladder inflammation *disease and altered neurochemical expression in micturition pathways .
Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .	Debrisoquine phenotype and the pharmacokinetics and beta - 2 receptor pharmacodynamics of metoprolol and its enantiomers .
The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .	The metabolism of the cardioselective beta - blocker metoprolol is under genetic control of the debrisoquine / sparteine type .
The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .	The two metabolic phenotypes , extensive ( EM ) and poor metabolizers ( PM ) , show different stereoselective metabolism , resulting in apparently higher beta - 1 adrenoceptor antagonistic potency of racemic metoprolol in EMs .
We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .	We investigated if the latter also applies to the beta - 2 adrenoceptor antagonism by metoprolol .
The drug effect studied was the antagonism by metoprolol of terbutaline - induced hypokalemia .	The drug effect studied was the antagonism by metoprolol of terbutaline - induced disease* hypokalemia *disease .
By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .	By using pharmacokinetic pharmacodynamic modeling the pharmacodynamics of racemic metoprolol and the active S - isomer , were quantitated in EMs and PMs in terms of IC50 values , representing metoprolol plasma concentrations resulting in half - maximum receptor occupancy .
Six EMs received 0 . 5 mg of terbutaline s . c . on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .	Six EMs received 0 . 5 mg of terbutaline s . c . on two different occasions : 1 ) 1 hr after administration of a placebo and 2 ) 1 hr after 150 mg of metoprolol p . o .
Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .	Five PMs were studied according to the same protocol , except for a higher terbutaline dose ( 0 . 75 mg ) on day 2 .
Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .	Blood samples for the analysis of plasma potassium , terbutaline , metoprolol ( racemic , R - and S - isomer ) , and alpha - hydroxymetoprolol concentrations were taken at regular time intervals , during 8 hr after metoprolol .
In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .	In PMs , metoprolol increased the terbutaline area under the plasma concentration vs . time curve ( + 67 % ) .
Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .	Higher metoprolol / alpha - hydroxymetoprolol ratios in PMs were predictive for higher R - / S - isomer ratios of unchanged drug .
There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	There was a difference in metoprolol potency with higher racemic metoprolol IC50 values in PMs ( 72 + / - 7 ng . ml - 1 ) than EMs ( 42 + / - 8 ng . ml - 1 , P less than . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery : findings in six cases .	The hemodynamics of oxytocin and other vasoactive agents during neuraxial anesthesia for cesarean delivery : findings in six cases .
Oxytocin is a commonly used uterotonic that can cause significant and even fatal hypotension , particularly when given as a bolus .	Oxytocin is a commonly used uterotonic that can cause significant and even fatal disease* hypotension *disease , particularly when given as a bolus .
The resulting hypotension can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .	The resulting disease* hypotension *disease can be produced by a decrease in systemic vascular resistance or cardiac output through a decrease in venous return .
Parturients with normal volume status , heart valves and pulmonary vasculature most often respond to this hypotension with a compensatory increase in heart rate and stroke volume .	Parturients with normal volume status , heart valves and pulmonary vasculature most often respond to this disease* hypotension *disease with a compensatory increase in heart rate and disease* stroke *disease volume .
Oxytocin - induced hypotension at cesarean delivery may be incorrectly attributed to blood loss .	Oxytocin - induced disease* hypotension *disease at cesarean delivery may be incorrectly attributed to disease* blood loss *disease .
Pulse power analysis ( also called " pulse contour analysis " ) of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time , thereby elucidating the causative factors behind changes in blood pressure .	Pulse power analysis ( also called " pulse contour analysis " ) of an arterial pressure wave form allows continuous evaluation of systemic vascular resistance and cardiac output in real time , thereby elucidating the causative factors behind changes in blood pressure .
Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia .	Pulse power analysis was conducted in six cases of cesarean delivery performed under neuraxial anesthesia .
Hypotension in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in stroke volume , heart rate and cardiac output .	disease* Hypotension *disease in response to oxytocin was associated with a decrease in systemic vascular resistance and a compensatory increase in disease* stroke *disease volume , heart rate and cardiac output .
Pulse power analysis may be helpful in determining the etiology of and treating hypotension during cesarean delivery under neuraxial anesthesia .	Pulse power analysis may be helpful in determining the etiology of and treating disease* hypotension *disease during cesarean delivery under neuraxial anesthesia .
Protective effects of antithrombin on puromycin aminonucleoside nephrosis in rats .	Protective effects of antithrombin on puromycin aminonucleoside disease* nephrosis *disease in rats .
We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with puromycin aminonucleoside - induced nephrosis , which is an experimental model of human nephrotic syndrome .	We investigated the effects of antithrombin , a plasma inhibitor of coagulation factors , in rats with puromycin aminonucleoside - induced disease* nephrosis *disease , which is an experimental model of human disease* nephrotic syndrome *disease .
Antithrombin ( 50 or 500 IU / kg / i . v . ) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside ( 50 mg / kg / i . v . ) .	Antithrombin ( 50 or 500 IU / kg / i . v . ) was administered to rats once a day for 10 days immediately after the injection of puromycin aminonucleoside ( 50 mg / kg / i . v . ) .
Treatment with antithrombin attenuated the puromycin aminonucleoside - induced hematological abnormalities .	Treatment with antithrombin attenuated the puromycin aminonucleoside - induced disease* hematological abnormalities *disease .
Puromycin aminonucleoside - induced renal dysfunction and hyperlipidemia were also suppressed .	Puromycin aminonucleoside - induced disease* renal dysfunction *disease and disease* hyperlipidemia *disease were also suppressed .
Histopathological examination revealed severe renal damage such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .	Histopathological examination revealed severe disease* renal damage *disease such as proteinaceous casts in tubuli and tubular expansion in the kidney of control rats , while an improvement of the damage was seen in antithrombin - treated rats .
In addition , antithrombin treatment markedly suppressed puromycin aminonucleoside - induced apoptosis of renal tubular epithelial cells .	In addition , antithrombin treatment markedly suppressed puromycin aminonucleoside - induced apoptosis of renal tubular epithelial cells .
Furthermore , puromycin aminonucleoside - induced increases in renal cytokine content were also decreased .	Furthermore , puromycin aminonucleoside - induced increases in renal cytokine content were also decreased .
These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside - induced nephrotic syndrome .	These findings suggest that thrombin plays an important role in the pathogenesis of puromycin aminonucleoside - induced disease* nephrotic syndrome *disease .
Treatment with antithrombin may be clinically effective in patients with nephrotic syndrome .	Treatment with antithrombin may be clinically effective in patients with disease* nephrotic syndrome *disease .
Heparin - induced thrombocytopenia after liver transplantation .	Heparin - induced disease* thrombocytopenia *disease after liver transplantation .
BACKGROUND : Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent thrombosis after liver transplantation .	BACKGROUND : Unfractionated heparin sodium ( UFH ) or low - molecular weight heparin ( LMWH ) is used in anticoagulant protocols at several institutions to prevent disease* thrombosis *disease after liver transplantation .
Heparin - induced thrombocytopenia ( HIT ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .	Heparin - induced disease* thrombocytopenia *disease ( disease* HIT *disease ) is an adverse immune - mediated reaction to heparin , resulting in platelet count decreases of more than 50 % .
The frequencies of HIT after liver transplantation and platelet factor 4 / heparin - reactive antibody ( HIT antibody ) positivity in liver transplantation patients , however , are unknown .	The frequencies of disease* HIT *disease after liver transplantation and platelet factor 4 / heparin - reactive antibody ( disease* HIT *disease antibody ) positivity in liver transplantation patients , however , are unknown .
PATIENTS AND METHODS : The 32 men and 20 women underwent living donor liver transplantation .	PATIENTS AND METHODS : The 32 men and 20 women underwent living donor liver transplantation .
We started LMWH ( 25 IU / kg / h ) on postoperative day ( POD ) 1 , switching to UFH ( 5000 U / d ) on POD 2 or 3 .	We started LMWH ( 25 IU / kg / h ) on postoperative day ( POD ) 1 , switching to UFH ( 5000 U / d ) on POD 2 or 3 .
The dose of UFH was changed according to the activated clotting time level .	The dose of UFH was changed according to the activated clotting time level .
HIT antibody levels were measured the day before surgery and on POD 7 and 14 .	disease* HIT *disease antibody levels were measured the day before surgery and on POD 7 and 14 .
Platelet count was measured daily for 3 weeks .	Platelet count was measured daily for 3 weeks .
RESULTS : The average platelet counts preoperatively , and on POD 7 , 14 , and 21 were 65 , 88 , 149 , and 169 x 10 ( 9 ) / L , respectively .	RESULTS : The average platelet counts preoperatively , and on POD 7 , 14 , and 21 were 65 , 88 , 149 , and 169 x 10 ( 9 ) / L , respectively .
Two patients developed hepatic artery thrombosis on POD 11 and 19 , respectively , although they were HIT antibody - negative and their platelet counts were stable .	Two patients developed hepatic artery disease* thrombosis *disease on POD 11 and 19 , respectively , although they were disease* HIT *disease antibody - negative and their platelet counts were stable .
In 2 other patients , the platelet count decreased suddenly from 107 x 10 ( 9 ) / L on POD 4 to 65 x 10 ( 9 ) / L on POD 6 and from 76 x 10 ( 9 ) / L on POD 7 to 33 x 10 ( 9 ) / L on POD 9 , respectively .	In 2 other patients , the platelet count decreased suddenly from 107 x 10 ( 9 ) / L on POD 4 to 65 x 10 ( 9 ) / L on POD 6 and from 76 x 10 ( 9 ) / L on POD 7 to 33 x 10 ( 9 ) / L on POD 9 , respectively .
The heparin - induced platelet aggregation test was negative in these patients .	The heparin - induced disease* platelet aggregation *disease test was negative in these patients .
The percentage of HIT antibody - positive patients was 0 . 5 % preoperatively , 5 . 6 % on POD 7 , and 5 . 6 % on POD 14 .	The percentage of disease* HIT *disease antibody - positive patients was 0 . 5 % preoperatively , 5 . 6 % on POD 7 , and 5 . 6 % on POD 14 .
None of the subjects / patients developed UFH - related HIT .	None of the subjects / patients developed UFH - related disease* HIT *disease .
CONCLUSIONS : In our series , the occurrence of HIT after liver transplantation was uncommon .	CONCLUSIONS : In our series , the occurrence of disease* HIT *disease after liver transplantation was uncommon .
Doxorubicin cardiomyopathy - induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor .	Doxorubicin disease* cardiomyopathy *disease - induced disease* inflammation *disease and apoptosis are attenuated by gene deletion of the kinin B1 receptor .
Clinical use of the anthracycline doxorubicin ( DOX ) is limited by its cardiotoxic effects , which are attributed to the induction of apoptosis .	Clinical use of the anthracycline doxorubicin ( DOX ) is limited by its disease* cardiotoxic *disease effects , which are attributed to the induction of apoptosis .
To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX cardiomyopathy , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac inflammation and apoptosis after induction of DOX - induced cardiomyopathy .	To elucidate the possible role of the kinin B1 receptor ( B1R ) during the development of DOX disease* cardiomyopathy *disease , we studied B1R knockout mice ( B1R ( - / - ) ) by investigating cardiac disease* inflammation *disease and apoptosis after induction of DOX - induced disease* cardiomyopathy *disease .
DOX control mice showed cardiac dysfunction measured by pressure - volume loops in vivo .	DOX control mice showed disease* cardiac dysfunction *disease measured by pressure - volume loops in vivo .
This was associated with a reduced activation state of AKT , as well as an increased bax / bcl2 ratio in Western blots , indicating cardiac apoptosis .	This was associated with a reduced activation state of AKT , as well as an increased bax / bcl2 ratio in Western blots , indicating disease* cardiac apoptosis *disease .
Furthermore , mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue .	Furthermore , mRNA levels of the proinflammatory cytokine interleukin 6 were increased in the cardiac tissue .
In DOX B1R ( - / - ) mice , cardiac dysfunction was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .	In DOX B1R ( - / - ) mice , disease* cardiac dysfunction *disease was improved compared to DOX control mice , which was associated with normalization of the bax / bcl - 2 ratio and interleukin 6 , as well as AKT activation state .
These findings suggest that B1R is detrimental in DOX cardiomyopathy in that it mediates the inflammatory response and apoptosis .	These findings suggest that B1R is detrimental in DOX disease* cardiomyopathy *disease in that it mediates the inflammatory response and apoptosis .
These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX cardiomyopathy .	These insights might have useful implications for future studies utilizing B1R antagonists for treatment of human DOX disease* cardiomyopathy *disease .
Detailed spectral profile analysis of penicillin - induced epileptiform activity in anesthetized rats .	Detailed spectral profile analysis of penicillin - induced disease* epileptiform activity *disease in anesthetized rats .
Penicillin model is a widely used experimental model for epilepsy research .	Penicillin model is a widely used experimental model for disease* epilepsy *disease research .
In the present study we aimed to portray a detailed spectral analysis of penicillin - induced epileptiform activity in comparison with basal brain activity in anesthetized Wistar rats .	In the present study we aimed to portray a detailed spectral analysis of penicillin - induced disease* epileptiform activity *disease in comparison with basal brain activity in anesthetized Wistar rats .
Male Wistar rats were anesthetized with i . p . urethane and connected to an electrocorticogram setup .	Male Wistar rats were anesthetized with i . p . urethane and connected to an electrocorticogram setup .
After a short period of basal activity recording , epileptic focus was induced by injecting 400IU / 2 microl penicillin - G potassium into the left lateral ventricle while the cortical activity was continuously recorded .	After a short period of basal activity recording , disease* epileptic *disease focus was induced by injecting 400IU / 2 microl penicillin - G potassium into the left lateral ventricle while the cortical activity was continuously recorded .
Basal activity , latent period and the penicillin - induced epileptiform activity periods were then analyzed using both conventional methods and spectral analysis .	Basal activity , latent period and the penicillin - induced disease* epileptiform activity *disease periods were then analyzed using both conventional methods and spectral analysis .
Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta , theta ( slow and fast ) , alpha - sigma , beta ( 1 and 2 ) and gamma ( 1 and 2 ) bands .	Spectral analyses were conducted by dividing the whole spectrum into different frequency bands including delta , theta ( slow and fast ) , alpha - sigma , beta ( 1 and 2 ) and gamma ( 1 and 2 ) bands .
Our results show that the most affected frequency bands were delta , theta , beta - 2 and gamma - 2 bands during the epileptiform activity and there were marked differences in terms of spectral densities between three investigated episodes ( basal activity , latent period and epileptiform activity ) .	Our results show that the most affected frequency bands were delta , theta , beta - 2 and gamma - 2 bands during the disease* epileptiform activity *disease and there were marked differences in terms of spectral densities between three investigated episodes ( basal activity , latent period and disease* epileptiform activity *disease ) .
Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental epilepsies .	Our results may help to analyze novel data obtained using similar experimental models and the simple analysis method described here can be used in similar studies to investigate the basic neuronal mechanism of this or other types of experimental disease* epilepsies *disease .
High fat diet - fed obese rats are highly sensitive to doxorubicin - induced cardiotoxicity .	High fat diet - fed disease* obese *disease rats are highly sensitive to doxorubicin - induced disease* cardiotoxicity *disease .
Often , chemotherapy by doxorubicin ( Adriamycin ) is limited due to life threatening cardiotoxicity in patients during and posttherapy .	Often , chemotherapy by doxorubicin ( Adriamycin ) is limited due to life threatening disease* cardiotoxicity *disease in patients during and posttherapy .
Recently , we have shown that moderate diet restriction remarkably protects against doxorubicin - induced cardiotoxicity .	Recently , we have shown that moderate diet restriction remarkably protects against doxorubicin - induced disease* cardiotoxicity *disease .
This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty - acid oxidation , ATP synthesis , and upregulated JAK / STAT3 pathway .	This cardioprotection is accompanied by decreased cardiac oxidative stress and triglycerides and increased cardiac fatty - acid oxidation , ATP synthesis , and upregulated JAK / STAT3 pathway .
In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces obesity in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced cardiotoxicity .	In the current study , we investigated whether a physiological intervention by feeding 40 % high fat diet ( HFD ) , which induces disease* obesity *disease in male Sprague - Dawley rats ( 250 - 275 g ) , sensitizes to doxorubicin - induced disease* cardiotoxicity *disease .
A LD ( 10 ) dose ( 8 mg doxorubicin / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity , cardiac dysfunction , lipid peroxidation , and 80 % mortality in the obese ( OB ) rats in the absence of any significant renal or hepatic toxicity .	A LD ( 10 ) dose ( 8 mg doxorubicin / kg , ip ) administered on day 43 of the HFD feeding regimen led to higher disease* cardiotoxicity *disease , disease* cardiac dysfunction *disease , lipid peroxidation , and 80 % mortality in the disease* obese *disease ( disease* OB *disease ) rats in the absence of any significant disease* renal or hepatic toxicity *disease .
Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and OB hearts .	Doxorubicin toxicokinetics studies revealed no change in accumulation of doxorubicin and doxorubicinol ( toxic metabolite ) in the normal diet - fed ( ND ) and disease* OB *disease hearts .
Mechanistic studies revealed that OB rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in OB ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .	Mechanistic studies revealed that disease* OB *disease rats are sensitized due to : ( 1 ) higher oxyradical stress leading to upregulation of uncoupling proteins 2 and 3 , ( 2 ) downregulation of cardiac peroxisome proliferators activated receptor - alpha , ( 3 ) decreased plasma adiponectin levels , ( 4 ) decreased cardiac fatty - acid oxidation ( 666 . 9 + / - 14 . 0 nmol / min / g heart in ND versus 400 . 2 + / - 11 . 8 nmol / min / g heart in disease* OB *disease ) , ( 5 ) decreased mitochondrial AMP - alpha2 protein kinase , and ( 6 ) 86 % drop in cardiac ATP levels accompanied by decreased ATP / ADP ratio after doxorubicin administration .
Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK / STAT3 pathway .	Decreased cardiac erythropoietin and increased SOCS3 further downregulated the cardioprotective JAK / STAT3 pathway .
In conclusion , HFD - induced obese rats are highly sensitized to doxorubicin - induced cardiotoxicity by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .	In conclusion , HFD - induced disease* obese *disease rats are highly sensitized to doxorubicin - induced disease* cardiotoxicity *disease by substantially downregulating cardiac mitochondrial ATP generation , increasing oxidative stress and downregulating the JAK / STAT3 pathway .
Isoproterenol induces primary loss of dystrophin in rat hearts : correlation with myocardial injury .	Isoproterenol induces primary loss of dystrophin in rat hearts : correlation with disease* myocardial injury *disease .
The mechanism of isoproterenol - induced myocardial damage is unknown , but a mismatch of oxygen supply vs . demand following coronary hypotension and myocardial hyperactivity is the best explanation for the complex morphological alterations observed .	The mechanism of isoproterenol - induced disease* myocardial damage *disease is unknown , but a mismatch of oxygen supply vs . demand following coronary disease* hypotension *disease and disease* myocardial hyperactivity *disease is the best explanation for the complex morphological alterations observed .
Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol .	Severe alterations in the structural integrity of the sarcolemma of cardiomyocytes have been demonstrated to be caused by isoproterenol .
Taking into account that the sarcolemmal integrity is stabilized by the dystrophin - glycoprotein complex ( DGC ) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins .	Taking into account that the sarcolemmal integrity is stabilized by the dystrophin - glycoprotein complex ( DGC ) that connects actin and laminin in contractile machinery and extracellular matrix and by integrins , this study tests the hypothesis that isoproterenol affects sarcolemmal stability through changes in the DGC and integrins .
We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration .	We found different sensitivity of the DGC and integrin to isoproterenol subcutaneous administration .
Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix .	Immunofluorescent staining revealed that dystrophin is the most sensitive among the structures connecting the actin in the cardiomyocyte cytoskeleton and the extracellular matrix .
The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin .	The sarcomeric actin dissolution occurred after the reduction or loss of dystrophin .
Subsequently , after lysis of myofilaments , gamma - sarcoglycan , beta - dystroglycan , beta1 - integrin , and laminin alpha - 2 expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .	Subsequently , after lysis of myofilaments , gamma - sarcoglycan , beta - dystroglycan , beta1 - integrin , and laminin alpha - 2 expressions were reduced followed by their breakdown , as epiphenomena of the myocytolytic process .
In conclusion , administration of isoproterenol to rats results in primary loss of dystrophin , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .	In conclusion , administration of isoproterenol to rats results in primary loss of dystrophin , the most sensitive among the structural proteins that form the DGC that connects the extracellular matrix and the cytoskeleton in cardiomyocyte .
These changes , related to ischaemic injury , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol .	These changes , related to disease* ischaemic injury *disease , explain the severe alterations in the structural integrity of the sarcolemma of cardiomyocytes and hence severe and irreversible injury induced by isoproterenol .
Etiologic factors in the pathogenesis of liver tumors associated with oral contraceptives .	Etiologic factors in the pathogenesis of disease* liver tumors *disease associated with oral contraceptives .
Within the last several years , previously rare liver tumors have been seen in young women using oral contraceptive steroids .	Within the last several years , previously rare disease* liver tumors *disease have been seen in young women using oral contraceptive steroids .
The Registry for Liver Tumors Associated with Oral Contraceptives at the University of California , Irvine , has clearly identified 27 cases .	The Registry for disease* Liver Tumors *disease Associated with Oral Contraceptives at the University of California , Irvine , has clearly identified 27 cases .
The recent literature contains 44 case reports .	The recent literature contains 44 case reports .
Common to these 71 cases has been a histopathologic diagnosis of focal nodular hyperplasia , adenoma , hamartoma , and hepatoma .	Common to these 71 cases has been a histopathologic diagnosis of disease* focal nodular hyperplasia *disease , disease* adenoma *disease , disease* hamartoma *disease , and disease* hepatoma *disease .
Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids .	Significant statistical etiologic factors include prolonged uninterrupted usage of oral contraceptive steroids .
Eight deaths and liver rupture in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon .	Eight deaths and liver disease* rupture *disease in 18 patients attest to the seriousness of this new potentially lethal adverse phenomenon .
Ifosfamide continuous infusion without mesna .	Ifosfamide continuous infusion without mesna .
A phase I trial of a 14 - day cycle .	A phase I trial of a 14 - day cycle .
Twenty patients received 27 courses of ifosfamide administered as a 24 - hour continuous infusion for 14 days without Mesna .	Twenty patients received 27 courses of ifosfamide administered as a 24 - hour continuous infusion for 14 days without Mesna .
The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short - term infusions administered with Mesna .	The goal of the study was to deliver a dose rate and total cumulative dose of ifosfamide that would be comparable to standard bolus or short - term infusions administered with Mesna .
Dose escalations proceeded from 200 to 300 , 400 , 450 , 500 , and 550 mg / m2 / d .	Dose escalations proceeded from 200 to 300 , 400 , 450 , 500 , and 550 mg / m2 / d .
Four patients developed transient microscopic hematuria at 400 , 450 , and 500 mg / m2 / d .	Four patients developed transient microscopic disease* hematuria *disease at 400 , 450 , and 500 mg / m2 / d .
There were no instances of macroscopic hematuria .	There were no instances of macroscopic disease* hematuria *disease .
At 550 mg / m2 / d , three patients experienced nonurologic toxicity ; confusion ( 1 ) , nausea ( 1 ) , and Grade 2 leukopenia ( 1 ) .	At 550 mg / m2 / d , three patients experienced nonurologic disease* toxicity *disease ; disease* confusion *disease ( 1 ) , disease* nausea *disease ( 1 ) , and Grade 2 disease* leukopenia *disease ( 1 ) .
The recommended dose of 500 mg / m2 / d delivers a total dose of 7 g / m2 per cycle , which is comparable to that delivered in clinical practice for bolus or short - term infusion .	The recommended dose of 500 mg / m2 / d delivers a total dose of 7 g / m2 per cycle , which is comparable to that delivered in clinical practice for bolus or short - term infusion .
Because few patients received multiple courses over time , the cumulative effects are indeterminate in the present trial .	Because few patients received multiple courses over time , the cumulative effects are indeterminate in the present trial .
The frequency and predictability of hematuria are not precise , and at least daily monitoring by urine Hematest is essential , adding Mesna to the infusate in patients with persistent hematuria .	The frequency and predictability of disease* hematuria *disease are not precise , and at least daily monitoring by urine Hematest is essential , adding Mesna to the infusate in patients with persistent disease* hematuria *disease .
The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to 890 per cycle .	The protracted infusion schedule for ifosfamide permits convenient outpatient administration without Mesna and reduces the drug cost of clinical usage of this agent by up to 890 per cycle .
Clinical activity was demonstrated in a single patient , but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained .	Clinical activity was demonstrated in a single patient , but a comparative trial of standard bolus schedules with the protracted infusion schedule will be necessary to determine if the clinical effectiveness of the drug is maintained .
A case of ventricular tachycardia related to caffeine pretreatment .	A case of disease* ventricular tachycardia *disease related to caffeine pretreatment .
Suboptimal seizure duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher seizure thresholds .	Suboptimal disease* seizure *disease duration is commonly encountered in electroconvulsive therapy practice , especially in older patients with higher disease* seizure *disease thresholds .
Intravenous caffeine is commonly used to improve seizure duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign ventricular ectopy .	Intravenous caffeine is commonly used to improve disease* seizure *disease duration and quality in such patients and is generally well tolerated aside from occasional reports of relatively benign disease* ventricular ectopy *disease .
We describe a patient with no previous history of cardiac disease or arrhythmia who developed sustained bigeminy and 2 brief runs of ventricular tachycardia after caffeine administration .	We describe a patient with no previous history of disease* cardiac disease *disease or disease* arrhythmia *disease who developed sustained bigeminy and 2 brief runs of disease* ventricular tachycardia *disease after caffeine administration .
Although intravenous caffeine is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious ventricular arrhythmias .	Although intravenous caffeine is generally well tolerated , the clinician should be aware of the potential for unpredictable and serious disease* ventricular arrhythmias *disease .
Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin .	Fatal disease* haemopericardium *disease and disease* gastrointestinal haemorrhage *disease due to possible interaction of cranberry juice with warfarin .
We report a case of fatal internal haemorrhage in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin .	We report a case of fatal internal disease* haemorrhage *disease in an elderly man who consumed only cranberry juice for two weeks while maintaining his usual dosage of warfarin .
We propose that naturally occurring compounds such as flavonoids , which are present in fruit juices , may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin .	We propose that naturally occurring compounds such as flavonoids , which are present in fruit juices , may increase the potency of warfarin by competing for the enzymes that normally inactivate warfarin .
While traditionally regarded as foodstuffs , consumption of fruit juices should be considered when patients develop adverse drug reactions .	While traditionally regarded as foodstuffs , consumption of fruit juices should be considered when patients develop adverse drug reactions .
Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced seizures in mice .	Effect of increasing intraperitoneal infusion rates on bupropion hydrochloride - induced disease* seizures *disease in mice .
BACKGROUND : It is not known if there is a relationship between input rate and incidence of bupropion - induced seizures .	BACKGROUND : It is not known if there is a relationship between input rate and incidence of bupropion - induced disease* seizures *disease .
This is important , since different controlled release formulations of bupropion release the active drug at different rates .	This is important , since different controlled release formulations of bupropion release the active drug at different rates .
METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known convulsive dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced convulsions in the Swiss albino mice .	METHODS : We investigated the effect of varying the intraperitoneal infusion rates of bupropion HCl 120 mg / kg , a known disease* convulsive *disease dose 50 ( CD50 ) , on the incidence and severity of bupropion - induced disease* convulsions *disease in the Swiss albino mice .
A total of 69 mice , approximately 7 weeks of age , and weighing 21 . 0 to 29 . 1 g were randomly assigned to bupropion HCl 120 mg / kg treatment by intraperitoneal ( IP ) administration in 7 groups ( 9 to 10 animals per group ) .	A total of 69 mice , approximately 7 weeks of age , and weighing 21 . 0 to 29 . 1 g were randomly assigned to bupropion HCl 120 mg / kg treatment by intraperitoneal ( IP ) administration in 7 groups ( 9 to 10 animals per group ) .
Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min , 15 min , 30 min , 60 min , 90 min , 120 min , and 240 min .	Bupropion HCl was infused through a surgically implanted IP dosing catheter with infusions in each group of 0 min , 15 min , 30 min , 60 min , 90 min , 120 min , and 240 min .
The number , time of onset , duration and the intensity of the convulsions or absence of convulsions were recorded .	The number , time of onset , duration and the intensity of the disease* convulsions *disease or absence of disease* convulsions *disease were recorded .
RESULTS : The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced convulsions in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .	RESULTS : The results showed that IP administration of bupropion HCl 120 mg / kg by bolus injection induced disease* convulsions *disease in 6 out of 10 mice ( 60 % of convulsing mice ) in group 1 .
Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of convulsions at infusion times of 15 to 90 min compared to bolus injection .	Logistic regression analysis revealed that infusion time was significant ( p = 0 . 0004 ; odds ratio = 0 . 974 ) and increasing the IP infusion time of bupropion HCl 120 mg / kg was associated with a 91 % reduced odds of disease* convulsions *disease at infusion times of 15 to 90 min compared to bolus injection .
Further increase in infusion time resulted in further reduction in the odds of convulsions to 99 . 8 % reduction at 240 min .	Further increase in infusion time resulted in further reduction in the odds of disease* convulsions *disease to 99 . 8 % reduction at 240 min .
CONCLUSION : In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and convulsive dose of bupropion and the risk of convulsions in a prospective study is novel .	CONCLUSION : In conclusion , the demonstration of an inverse relationship between infusion time of a fixed and disease* convulsive *disease dose of bupropion and the risk of disease* convulsions *disease in a prospective study is novel .
Graft - versus - host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy : results of the EVTAC trial .	disease* Graft - versus - host disease *disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of disease* sinusoidal obstruction syndrome *disease and disease* microangiopathy *disease : results of the EVTAC trial .
A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft - versus - host disease ( GVHD ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .	A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for disease* graft - versus - host disease *disease ( disease* GVHD *disease ) after allogeneic hematopoietic stem cell transplantation ( HSCT ) .
Everolimus , a derivative of sirolimus , seems to mediate antileukemia effects .	Everolimus , a derivative of sirolimus , seems to mediate antileukemia effects .
We report on a combination of everolimus and tacrolimus in 24 patients ( median age , 62 years ) with either myelodysplastic syndrome ( MDS ; n = 17 ) or acute myeloid leukemia ( AML ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .	We report on a combination of everolimus and tacrolimus in 24 patients ( median age , 62 years ) with either disease* myelodysplastic syndrome *disease ( disease* MDS *disease ; n = 17 ) or disease* acute myeloid leukemia *disease ( disease* AML *disease ; n = 7 ) undergoing intensive conditioning followed by HSCT from related ( n = 4 ) or unrelated ( n = 20 ) donors .
All patients engrafted , and only 1 patient experienced grade IV mucositis .	All patients engrafted , and only 1 patient experienced grade IV disease* mucositis *disease .
Nine patients ( 37 % ) developed acute grade II - IV GVHD , and 11 of 17 evaluable patients ( 64 % ) developed chronic extensive GVHD .	Nine patients ( 37 % ) developed acute grade II - IV disease* GVHD *disease , and 11 of 17 evaluable patients ( 64 % ) developed chronic extensive disease* GVHD *disease .
Transplantation - associated microangiopathy ( TMA ) occurred in 7 patients ( 29 % ) , with 2 cases of acute renal failure .	disease* Transplantation - associated microangiopathy *disease ( disease* TMA *disease ) occurred in 7 patients ( 29 % ) , with 2 cases of disease* acute renal failure *disease .
The study was terminated prematurely because an additional 6 patients ( 25 % ) developed sinusoidal obstruction syndrome ( SOS ) , which was fatal in 2 cases .	The study was terminated prematurely because an additional 6 patients ( 25 % ) developed disease* sinusoidal obstruction syndrome *disease ( disease* SOS *disease ) , which was fatal in 2 cases .
With a median follow - up of 26 months , the 2 - year overall survival rate was 47 % .	With a median follow - up of 26 months , the 2 - year overall survival rate was 47 % .
Although this new combination appears to be effective as a prophylactic regimen for acute GVHD , the incidence of TMA and SOS is considerably higher than seen with other regimens .	Although this new combination appears to be effective as a prophylactic regimen for acute disease* GVHD *disease , the incidence of disease* TMA *disease and disease* SOS *disease is considerably higher than seen with other regimens .
Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas .	Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic disease* colorectal adenomas *disease .
A phase III clinical trial assessed the recurrence of adenomatous polyps after treatment for 36 months with difluoromethylornithine ( DFMO ) plus sulindac or matched placebos .	A phase III clinical trial assessed the recurrence of disease* adenomatous polyps *disease after treatment for 36 months with difluoromethylornithine ( DFMO ) plus sulindac or matched placebos .
Temporary hearing loss is a known toxicity of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .	Temporary disease* hearing loss *disease is a known disease* toxicity *disease of treatment with DFMO , thus a comprehensive approach was developed to analyze serial air conduction audiograms .
The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within - subject correlation due to repeated measurements at frequencies .	The generalized estimating equation method estimated the mean difference between treatment arms with regard to change in air conduction pure tone thresholds while accounting for within - subject correlation due to repeated measurements at frequencies .
Based on 290 subjects , there was an average difference of 0 . 50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo ( 95 % confidence interval , - 0 . 64 to 1 . 63 dB ; P = 0 . 39 ) , adjusted for baseline values , age , and frequencies .	Based on 290 subjects , there was an average difference of 0 . 50 dB between subjects treated with DFMO plus sulindac compared with those treated with placebo ( 95 % confidence interval , - 0 . 64 to 1 . 63 dB ; P = 0 . 39 ) , adjusted for baseline values , age , and frequencies .
In the normal speech range of 500 to 3 , 000 Hz , an estimated difference of 0 . 99 dB ( - 0 . 17 to 2 . 14 dB ; P = 0 . 09 ) was detected .	In the normal speech range of 500 to 3 , 000 Hz , an estimated difference of 0 . 99 dB ( - 0 . 17 to 2 . 14 dB ; P = 0 . 09 ) was detected .
Dose intensity did not add information to models .	Dose intensity did not add information to models .
There were 14 of 151 ( 9 . 3 % ) in the DFMO plus sulindac group and 4 of 139 ( 2 . 9 % ) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested ( P = 0 . 02 ) .	There were 14 of 151 ( 9 . 3 % ) in the DFMO plus sulindac group and 4 of 139 ( 2 . 9 % ) in the placebo group who experienced at least 15 dB hearing reduction from baseline in 2 or more consecutive frequencies across the entire range tested ( P = 0 . 02 ) .
Follow - up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1 . 08 dB ( - 0 . 81 to 2 . 96 dB ; P = 0 . 26 ) between treatment arms .	Follow - up air conduction done at least 6 months after end of treatment showed an adjusted mean difference in hearing thresholds of 1 . 08 dB ( - 0 . 81 to 2 . 96 dB ; P = 0 . 26 ) between treatment arms .
There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant hearing loss compared with the placebo group .	There was no significant difference in the proportion of subjects in the DFMO plus sulindac group who experienced clinically significant disease* hearing loss *disease compared with the placebo group .
The estimated attributable risk of ototoxicity from exposure to the drug is 8 . 4 % ( 95 % confidence interval , - 2 . 0 % to 18 . 8 % ; P = 0 . 12 ) .	The estimated attributable risk of disease* ototoxicity *disease from exposure to the drug is 8 . 4 % ( 95 % confidence interval , - 2 . 0 % to 18 . 8 % ; P = 0 . 12 ) .
There is a < 2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo .	There is a < 2 dB difference in mean threshold for patients treated with DFMO plus sulindac compared with those treated with placebo .
Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing glomerulonephritis after restarting sulphasalazine treatment .	Proteinase 3 - antineutrophil cytoplasmic antibody - ( PR3 - ANCA ) positive necrotizing disease* glomerulonephritis *disease after restarting sulphasalazine treatment .
A 59 - year - old woman with ulcerative colitis developed red eyes , pleural effusion , eosinophilia and urinary abnormalities after restarting of sulphasalazine treatment .	A 59 - year - old woman with disease* ulcerative colitis *disease developed disease* red eyes *disease , disease* pleural effusion *disease , disease* eosinophilia *disease and disease* urinary abnormalities *disease after restarting of sulphasalazine treatment .
Light microscopy of a kidney biopsy revealed segmental necrotizing glomerulonephritis without deposition of immunoglobulin or complement .	Light microscopy of a kidney biopsy revealed disease* segmental necrotizing glomerulonephritis *disease without deposition of immunoglobulin or complement .
Proteinase 3 - antineutrophil cytoplasmic antibody ( PR3 - ANCA ) titer was elevated at 183 ELISA units ( EU ) in sera ( normal range less than 10 EU ) , myeloperoxidase - ANCA was negative .	Proteinase 3 - antineutrophil cytoplasmic antibody ( PR3 - ANCA ) titer was elevated at 183 ELISA units ( EU ) in sera ( normal range less than 10 EU ) , myeloperoxidase - ANCA was negative .
PR3 - ANCA titer was 250 and 1 , 070 EU in pleural effusions on right and left side , respectively .	PR3 - ANCA titer was 250 and 1 , 070 EU in disease* pleural effusions *disease on right and left side , respectively .
Although cessation of sulphasalazine treatment resulted in improvements in fever , red eyes , chest pain , titer of C - reactive protein and volume of the pleural effusions , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the pleural effusion remained .	Although cessation of sulphasalazine treatment resulted in improvements in disease* fever *disease , disease* red eyes *disease , disease* chest pain *disease , titer of C - reactive protein and volume of the disease* pleural effusions *disease , we initiated steroid therapy , because PR3 - ANCA titer rose to 320 EU , eosinophil count increased to 1 , 100 cells / microl , and the disease* pleural effusion *disease remained .
One month after steroid therapy , the pleural effusion disappeared , and PR3 - ANCA titer normalized 3 months later .	One month after steroid therapy , the disease* pleural effusion *disease disappeared , and PR3 - ANCA titer normalized 3 months later .
This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing glomerulonephritis .	This case suggests that sulphasalazine can induce PR3 - ANCA - positive necrotizing disease* glomerulonephritis *disease .
Comparison of unilateral pallidotomy and subthalamotomy findings in advanced idiopathic Parkinson ' s disease .	Comparison of unilateral pallidotomy and subthalamotomy findings in advanced disease* idiopathic Parkinson ' s disease *disease .
A prospective , randomized , double - blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced idiopathic Parkinson ' s disease ( PD ) refractory to medical treatment was designed .	A prospective , randomized , double - blind pilot study to compare the results of stereotactic unilateral pallidotomy and subthalamotomy in advanced disease* idiopathic Parkinson ' s disease *disease ( disease* PD *disease ) refractory to medical treatment was designed .
Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and levodopa - induced dyskinesias were selected .	Ten consecutive patients ( mean age , 58 . 4 + / - 6 . 8 years ; 7 men , 3 women ) with similar characteristics at the duration of disease ( mean disease time , 8 . 4 + / - 3 . 5 years ) , disabling motor fluctuations ( Hoehn _ Yahr stage 3 - 5 in off - drug phases ) and levodopa - induced disease* dyskinesias *disease were selected .
All patients had bilateral symptoms and their levodopa equivalent dosing were analysed .	All patients had bilateral symptoms and their levodopa equivalent dosing were analysed .
Six patients were operated on in the globus pallidus interna ( GPi ) and four in the subthalamic nucleus ( STN ) .	Six patients were operated on in the globus pallidus interna ( GPi ) and four in the subthalamic nucleus ( STN ) .
Clinical evaluation included the use of the Unified Parkinson ' s Disease Rating Scale ( UPDRS ) , Hoehn _ Yahr score and Schwab England activities of daily living ( ADL ) score in ' on ' - and ' off ' - drug conditions before surgery and 6 months after surgery .	Clinical evaluation included the use of the Unified disease* Parkinson ' s Disease *disease Rating Scale ( UPDRS ) , Hoehn _ Yahr score and Schwab England activities of daily living ( ADL ) score in ' on ' - and ' off ' - drug conditions before surgery and 6 months after surgery .
There was statistically significant improvement in all contralateral major parkinsonian motor signs in all patients followed for 6 months .	There was statistically significant improvement in all contralateral major disease* parkinsonian *disease motor signs in all patients followed for 6 months .
Levodopa equivalent daily intake was significantly reduced in the STN group .	Levodopa equivalent daily intake was significantly reduced in the STN group .
Changes in UPDRS , Hoehn _ Yahr and Schwab England ADL scores were similar in both groups .	Changes in UPDRS , Hoehn _ Yahr and Schwab England ADL scores were similar in both groups .
Cognitive functions were unchanged in both groups .	Cognitive functions were unchanged in both groups .
Complications were observed in two patients : one had a left homonymous hemianopsia after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg / day .	Complications were observed in two patients : one had a left disease* homonymous hemianopsia *disease after pallidotomy and another one developed left hemiballistic movements 3 days after subthalamotomy which partly improved within 1 month with Valproate 1000 mg / day .
The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced PD refractory to medical treatment .	The findings of this study suggest that lesions of the unilateral STN and GPi are equally effective treatment for patients with advanced disease* PD *disease refractory to medical treatment .
DSMM XI study : dose definition for intravenous cyclophosphamide in combination with bortezomib / dexamethasone for remission induction in patients with newly diagnosed myeloma .	DSMM XI study : dose definition for intravenous cyclophosphamide in combination with bortezomib / dexamethasone for remission induction in patients with newly diagnosed disease* myeloma *disease .
A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed multiple myeloma ( MM ) .	A clinical trial was initiated to evaluate the recommended dose of cyclophosphamide in combination with bortezomib and dexamethasone as induction treatment before stem cell transplantation for younger patients with newly diagnosed disease* multiple myeloma *disease ( disease* MM *disease ) .
Thirty patients were treated with three 21 - day cycles of bortezomib 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900 , 1 , 200 , or 1 , 500 mg / m ( 2 ) on day 1 .	Thirty patients were treated with three 21 - day cycles of bortezomib 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 plus dexamethasone 40 mg on the day of bortezomib injection and the day after plus cyclophosphamide at 900 , 1 , 200 , or 1 , 500 mg / m ( 2 ) on day 1 .
The maximum tolerated dose of cyclophosphamide was defined as 900 mg / m ( 2 ) .	The maximum tolerated dose of cyclophosphamide was defined as 900 mg / m ( 2 ) .
At this dose level , 92 % of patients achieved at least a partial response .	At this dose level , 92 % of patients achieved at least a partial response .
The overall response rate [ complete response ( CR ) plus partial response ( PR ) ] across all dose levels was 77 % , with a 10 % CR rate .	The overall response rate [ complete response ( CR ) plus partial response ( PR ) ] across all dose levels was 77 % , with a 10 % CR rate .
No patient experienced progressive disease .	No patient experienced progressive disease .
The most frequent adverse events were hematological and gastrointestinal toxicities as well as neuropathy .	The most frequent adverse events were disease* hematological and gastrointestinal toxicities *disease as well as disease* neuropathy *disease .
The results suggest that bortezomib in combination with cyclophosphamide at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed MM that warrants further investigation .	The results suggest that bortezomib in combination with cyclophosphamide at 900 mg / m ( 2 ) and dexamethasone is an effective induction treatment for patients with newly diagnosed disease* MM *disease that warrants further investigation .
Naloxone reversal of hypotension due to captopril overdose .	Naloxone reversal of disease* hypotension *disease due to captopril disease* overdose *disease .
The hemodynamic effects of captopril and other angiotensin - converting enzyme inhibitors may be mediated by the endogenous opioid system .	The hemodynamic effects of captopril and other angiotensin - converting enzyme inhibitors may be mediated by the endogenous opioid system .
The opioid antagonist naloxone has been shown to block or reverse the hypotensive actions of captopril .	The opioid antagonist naloxone has been shown to block or reverse the disease* hypotensive *disease actions of captopril .
We report a case of an intentional captopril overdose , manifested by marked hypotension , that resolved promptly with the administration of naloxone .	We report a case of an intentional captopril disease* overdose *disease , manifested by marked disease* hypotension *disease , that resolved promptly with the administration of naloxone .
To our knowledge , this is the first reported case of captopril - induced hypotension treated with naloxone .	To our knowledge , this is the first reported case of captopril - induced disease* hypotension *disease treated with naloxone .
Our experience demonstrates a possible role of naloxone in the reversal of hypotension resulting from captopril .	Our experience demonstrates a possible role of naloxone in the reversal of disease* hypotension *disease resulting from captopril .
Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products .	Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products .
Heparin is a commonly implemented anticoagulant used to treat critically ill patients .	Heparin is a commonly implemented anticoagulant used to treat critically ill patients .
Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a hypotensive response in pigs following a single high - dose infusion .	Recently , a number of commercial lots of heparin products were found to be contaminated with an oversulfated chondroitin sulfate ( OSCS ) derivative that could elicit a disease* hypotensive *disease response in pigs following a single high - dose infusion .
Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent hypotension in pigs .	Using both contaminated heparin products and the synthetically produced derivative , we showed that the OSCS produces dose - dependent disease* hypotension *disease in pigs .
The no observed effect level ( NOEL ) for this contaminant appears to be approximately 1mg / kg , corresponding to a contamination level of approximately 3 % .	The no observed effect level ( NOEL ) for this contaminant appears to be approximately 1mg / kg , corresponding to a contamination level of approximately 3 % .
We also demonstrated that OSCS can be identified in heparin products using a simple , inexpensive , commercially available heparin enzyme immunoassay ( EIA ) kit that has a limit of detection of approximately 0 . 1 % , well below the NOEL .	We also demonstrated that OSCS can be identified in heparin products using a simple , inexpensive , commercially available heparin enzyme immunoassay ( EIA ) kit that has a limit of detection of approximately 0 . 1 % , well below the NOEL .
This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives .	This kit may provide a useful method to test heparin products for contamination with oversulfated GAG derivatives .
5 flourouracil - induced apical ballooning syndrome : a case report .	5 flourouracil - induced disease* apical ballooning syndrome *disease : a case report .
The apical ballooning syndrome ( ABS ) is a recently described stress - mediated acute cardiac syndrome characterized by transient wall - motion abnormalities involving the apex and midventricle with hyperkinesis of the basal left ventricular ( LV ) segments without obstructive epicardial coronary disease .	The disease* apical ballooning syndrome *disease ( disease* ABS *disease ) is a recently described stress - mediated disease* acute cardiac syndrome *disease characterized by transient wall - motion abnormalities involving the apex and midventricle with disease* hyperkinesis *disease of the basal left ventricular ( LV ) segments without obstructive disease* epicardial coronary disease *disease .
Cardiotoxicity is not an uncommon adverse effect of chemotherapeutic agents .	disease* Cardiotoxicity *disease is not an uncommon adverse effect of chemotherapeutic agents .
However , there are no reports of ABS secondary to chemotherapeutic agents .	However , there are no reports of disease* ABS *disease secondary to chemotherapeutic agents .
We describe the case of a woman who developed the syndrome after chemotherapy for metastatic cancer .	We describe the case of a woman who developed the syndrome after chemotherapy for metastatic disease* cancer *disease .
A 79 - year - old woman presented with typical ischemic chest pain , elevated cardiac enzymes with significant ST - segment abnormalities on her electrocardiogram .	A 79 - year - old woman presented with typical disease* ischemic disease* chest pain *disease , elevated cardiac enzymes with significant ST - segment abnormalities on her electrocardiogram .
She underwent recent chemotherapy with fluorouracil for metastatic colorectal cancer .	She underwent recent chemotherapy with fluorouracil for metastatic disease* colorectal cancer *disease .
Echocardiography revealed a wall - motion abnormality involving the apical and periapical segments which appeared akinetic .	Echocardiography revealed a wall - motion abnormality involving the apical and periapical segments which appeared disease* akinetic *disease .
Coronary angiography revealed no obstructive coronary lesions .	Coronary angiography revealed no obstructive coronary lesions .
The patient was stabilized with medical therapy .	The patient was stabilized with medical therapy .
Four weeks later she remained completely asymptomatic .	Four weeks later she remained completely asymptomatic .
Echocardiogram revealed a normal ejection fraction and a resolution of the apical akinesis .	Echocardiogram revealed a normal ejection fraction and a resolution of the apical disease* akinesis *disease .
Pathogenetic mechanisms of cardiac complications in cancer patients undergoing chemotherapy include coronary vasospasm , endothelial damage and consequent thrombus formation .	Pathogenetic mechanisms of disease* cardiac complications *disease in disease* cancer *disease patients undergoing chemotherapy include disease* coronary vasospasm *disease , endothelial damage and consequent disease* thrombus *disease formation .
In our patient , both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by cancer diagnosis as well as chemotherapy may have contributed the development of ABS .	In our patient , both supraphysiologic levels of plasma catecholamines and stress related neuropeptides caused by disease* cancer *disease diagnosis as well as chemotherapy may have contributed the development of disease* ABS *disease .
Rapid reversal of anticoagulation reduces hemorrhage volume in a mouse model of warfarin - associated intracerebral hemorrhage .	Rapid reversal of anticoagulation reduces disease* hemorrhage *disease volume in a mouse model of warfarin - associated disease* intracerebral hemorrhage *disease .
Warfarin - associated intracerebral hemorrhage ( W - ICH ) is a severe type of stroke .	Warfarin - associated disease* intracerebral hemorrhage *disease ( W - disease* ICH *disease ) is a severe type of disease* stroke *disease .
There is no consensus on the optimal treatment for W - ICH .	There is no consensus on the optimal treatment for W - disease* ICH *disease .
Using a mouse model , we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate ( PCC ) can reduce hemorrhagic blood volume .	Using a mouse model , we tested whether the rapid reversal of anticoagulation using human prothrombin complex concentrate ( PCC ) can reduce hemorrhagic blood volume .
Male CD - 1 mice were treated with warfarin ( 2 mg / kg over 24 h ) , resulting in a mean ( + / - s . d . ) International Normalized Ratio of 3 . 5 + / - 0 . 9 .	Male CD - 1 mice were treated with warfarin ( 2 mg / kg over 24 h ) , resulting in a mean ( + / - s . d . ) International Normalized Ratio of 3 . 5 + / - 0 . 9 .
First , we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice .	First , we showed that an intravenous administration of human PCC rapidly reversed anticoagulation in mice .
Second , a stereotactic injection of collagenase was administered to induce hemorrhage in the right striatum .	Second , a stereotactic injection of collagenase was administered to induce disease* hemorrhage *disease in the right striatum .
Forty - five minutes later , the animals were randomly treated with PCC ( 100 U / kg ) or saline i . v . ( n = 12 per group ) .	Forty - five minutes later , the animals were randomly treated with PCC ( 100 U / kg ) or saline i . v . ( n = 12 per group ) .
Twenty - four hours after hemorrhage induction , hemorrhagic blood volume was quantified using a photometric hemoglobin assay .	Twenty - four hours after disease* hemorrhage *disease induction , hemorrhagic blood volume was quantified using a photometric hemoglobin assay .
The mean hemorrhagic blood volume was reduced in PCC - treated animals ( 6 . 5 + / - 3 . 1 microL ) compared with saline controls ( 15 . 3 + / - 11 . 2 microL , P = 0 . 015 ) .	The mean hemorrhagic blood volume was reduced in PCC - treated animals ( 6 . 5 + / - 3 . 1 microL ) compared with saline controls ( 15 . 3 + / - 11 . 2 microL , P = 0 . 015 ) .
In the saline group , 45 % of the mice developed large hematomas ( i . e . , > 15 microL ) .	In the saline group , 45 % of the mice developed large disease* hematomas *disease ( i . e . , > 15 microL ) .
In contrast , such extensive lesions were never found in the PCC group .	In contrast , such extensive lesions were never found in the PCC group .
We provide experimental data suggesting PCC to be an effective acute treatment for W - ICH in terms of reducing hemorrhagic blood volume .	We provide experimental data suggesting PCC to be an effective acute treatment for W - disease* ICH *disease in terms of reducing hemorrhagic blood volume .
Future studies are needed to assess the therapeutic potential emerging from our finding for human W - ICH .	Future studies are needed to assess the therapeutic potential emerging from our finding for human W - disease* ICH *disease .
Long term hormone therapy for perimenopausal and postmenopausal women .	Long term hormone therapy for perimenopausal and postmenopausal women .
BACKGROUND : Hormone therapy ( HT ) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women .	BACKGROUND : Hormone therapy ( HT ) is widely used for controlling menopausal symptoms and has also been used for the management and prevention of disease* cardiovascular disease *disease , disease* osteoporosis *disease and disease* dementia *disease in older women .
This is an updated version of the original Cochrane review first published in 2005 .	This is an updated version of the original Cochrane review first published in 2005 .
OBJECTIVES : To assess the effect of long - term HT on mortality , cardiovascular outcomes , cancer , gallbladder disease , cognition , fractures and quality of life .	OBJECTIVES : To assess the effect of long - term HT on mortality , cardiovascular outcomes , disease* cancer *disease , disease* gallbladder disease *disease , cognition , disease* fractures *disease and quality of life .
SEARCH STRATEGY : We searched the following databases to November 2007 : Trials Register of the Cochrane Menstrual Disorders and Subfertility Group , Cochrane Central Register of Controlled Trials , MEDLINE , EMBASE , Biological Abstracts .	SEARCH STRATEGY : We searched the following databases to November 2007 : Trials Register of the Cochrane disease* Menstrual Disorders *disease and Subfertility Group , Cochrane Central Register of Controlled Trials , MEDLINE , EMBASE , Biological Abstracts .
Also relevant non - indexed journals and conference abstracts .	Also relevant non - indexed journals and conference abstracts .
SELECTION CRITERIA : Randomised double - blind trials of HT versus placebo , taken for at least one year by perimenopausal or postmenopausal women .	SELECTION CRITERIA : Randomised double - blind trials of HT versus placebo , taken for at least one year by perimenopausal or postmenopausal women .
HT included oestrogens , with or without progestogens , via oral , transdermal , subcutaneous or transnasal routes .	HT included oestrogens , with or without progestogens , via oral , transdermal , subcutaneous or transnasal routes .
DATA COLLECTION AND ANALYSIS : Two authors independently assessed trial quality and extracted data .	DATA COLLECTION AND ANALYSIS : Two authors independently assessed trial quality and extracted data .
MAIN RESULTS : Nineteen trials involving 41 , 904 women were included .	MAIN RESULTS : Nineteen trials involving 41 , 904 women were included .
In relatively healthy women , combined continuous HT significantly increased the risk of venous thrombo - embolism or coronary event ( after one year ' s use ) , stroke ( after three years ) , breast cancer and gallbladder disease .	In relatively healthy women , combined continuous HT significantly increased the risk of disease* venous thrombo - embolism *disease or coronary event ( after one year ' s use ) , disease* stroke *disease ( after three years ) , disease* breast cancer *disease and disease* gallbladder disease *disease .
Long - term oestrogen - only HT significantly increased the risk of venous thrombo - embolism , stroke and gallbladder disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of breast cancer .	Long - term oestrogen - only HT significantly increased the risk of disease* venous thrombo - embolism *disease , disease* stroke *disease and disease* gallbladder disease *disease ( after one to two years , three years and seven years ' use respectively ) , but did not significantly increase the risk of disease* breast cancer *disease .
The only statistically significant benefits of HT were a decreased incidence of fractures and ( for combined HT ) colon cancer , with long - term use .	The only statistically significant benefits of HT were a decreased incidence of disease* fractures *disease and ( for combined HT ) disease* colon cancer *disease , with long - term use .
Among women aged over 65 who were relatively healthy ( i . e . generally fit , without overt disease ) and taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .	Among women aged over 65 who were relatively healthy ( i . e . generally fit , without overt disease ) and taking continuous combined HT , there was a statistically significant increase in the incidence of disease* dementia *disease .
Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thrombo - embolism . One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .	Among women with disease* cardiovascular disease *disease , long - term use of combined continuous HT significantly increased the risk of disease* venous thrombo - embolism *disease . One trial analysed subgroups of 2839 relatively healthy 50 to 59 year old women taking combined continuous HT and 1637 taking oestrogen - only HT , versus similar - sized placebo groups .
The only significantly increased risk reported was for venous thrombo - embolism in women taking combined continuous HT : their absolute risk remained low , at less than 1 / 500 .	The only significantly increased risk reported was for disease* venous thrombo - embolism *disease in women taking combined continuous HT : their absolute risk remained low , at less than 1 / 500 .
However , this study was not powered to detect differences between groups of younger women .	However , this study was not powered to detect differences between groups of younger women .
AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .	AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .
We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .	We need more evidence on the safety of HT for menopausal symptom control , though short - term use appears to be relatively safe for healthy younger women .
Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis .	disease* Acute renal failure *disease in patients with disease* AIDS *disease on tenofovir while receiving prolonged vancomycin course for disease* osteomyelitis *disease .
Renal failure developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .	disease* Renal failure *disease developed after a prolonged course of vancomycin therapy in 2 patients who were receiving tenofovir disoproxil fumarate as part of an antiretroviral regimen .
Tenofovir has been implicated in the development of Fanconi syndrome and renal insufficiency because of its effects on the proximal renal tubule .	Tenofovir has been implicated in the development of disease* Fanconi syndrome *disease and disease* renal insufficiency *disease because of its effects on the proximal renal tubule .
Vancomycin nephrotoxicity is infrequent but may result from coadministration with a nephrotoxic agent .	Vancomycin disease* nephrotoxicity *disease is infrequent but may result from coadministration with a disease* nephrotoxic *disease agent .
Clinicians should be aware that tenofovir may raise the risk of renal failure during prolonged administration of vancomycin .	Clinicians should be aware that tenofovir may raise the risk of disease* renal failure *disease during prolonged administration of vancomycin .
Recurrent dysosmia induced by pyrazinamide .	Recurrent disease* dysosmia *disease induced by pyrazinamide .
Pyrazinamide can have adverse effects such as hepatic toxicity , hyperuricemia or digestive disorders .	Pyrazinamide can have adverse effects such as disease* hepatic toxicity *disease , disease* hyperuricemia *disease or digestive disorders .
In rare cases , alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs .	In rare cases , alterations in taste and smell function have been reported for pyrazinamide when combined with other drugs .
We report a case of reversible olfactory disorder related to pyrazinamide in a woman , with a positive rechallenge .	We report a case of reversible disease* olfactory disorder *disease related to pyrazinamide in a woman , with a positive rechallenge .
The patient presented every day a sensation of smelling something burning 15 min after drug intake .	The patient presented every day a sensation of smelling something burning 15 min after drug intake .
Dysosmia disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge .	disease* Dysosmia *disease disappeared completely after pyrazinamide withdrawal and recurred after its rechallenge .
The case was reported to the Tunisian Centre of Pharmacovigilance .	The case was reported to the Tunisian Centre of Pharmacovigilance .
Mice lacking mPGES - 1 are resistant to lithium - induced polyuria .	Mice lacking mPGES - 1 are resistant to lithium - induced disease* polyuria *disease .
Cyclooxygenase - 2 activity is required for the development of lithium - induced polyuria .	Cyclooxygenase - 2 activity is required for the development of lithium - induced disease* polyuria *disease .
However , the involvement of a specific , terminal prostaglandin ( PG ) isomerase has not been evaluated .	However , the involvement of a specific , terminal prostaglandin ( PG ) isomerase has not been evaluated .
The present study was undertaken to assess lithium - induced polyuria in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .	The present study was undertaken to assess lithium - induced disease* polyuria *disease in mice deficient in microsomal prostaglandin E synthase - 1 ( mPGES - 1 ) .
A 2 - wk administration of LiCl ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked polyuria with hyposmotic urine .	A 2 - wk administration of LiCl ( 4 mmol . kg ( - 1 ) . day ( - 1 ) ip ) in mPGES - 1 + / + mice led to a marked disease* polyuria *disease with hyposmotic urine .
This was associated with elevated renal mPGES - 1 protein expression and increased urine PGE ( 2 ) excretion .	This was associated with elevated renal mPGES - 1 protein expression and increased urine PGE ( 2 ) excretion .
In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced polyuria and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .	In contrast , mPGES - 1 - / - mice were largely resistant to lithium - induced disease* polyuria *disease and a urine concentrating defect , accompanied by nearly complete blockade of high urine PGE ( 2 ) and cAMP output .
Immunoblotting , immunohistochemistry , and quantitative ( q ) RT - PCR consistently detected a significant decrease in aquaporin - 2 ( AQP2 ) protein expression in both the renal cortex and medulla of lithium - treated + / + mice .	Immunoblotting , immunohistochemistry , and quantitative ( q ) RT - PCR consistently detected a significant decrease in aquaporin - 2 ( AQP2 ) protein expression in both the renal cortex and medulla of lithium - treated + / + mice .
This decrease was significantly attenuated in the - / - mice .	This decrease was significantly attenuated in the - / - mice .
qRT - PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex .	qRT - PCR detected similar patterns of changes in AQP2 mRNA in the medulla but not in the cortex .
Similarly , the total protein abundance of the Na - K - 2Cl cotransporter ( NKCC2 ) in the medulla but not in the cortex of the + / + mice was significantly reduced by lithium treatment .	Similarly , the total protein abundance of the Na - K - 2Cl cotransporter ( NKCC2 ) in the medulla but not in the cortex of the + / + mice was significantly reduced by lithium treatment .
In contrast , the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the - / - mice .	In contrast , the dowregulation of renal medullary NKCC2 expression was significantly attenuated in the - / - mice .
We conclude that mPGES - 1 - derived PGE ( 2 ) mediates lithium - induced polyuria likely via inhibition of AQP2 and NKCC2 expression .	We conclude that mPGES - 1 - derived PGE ( 2 ) mediates lithium - induced disease* polyuria *disease likely via inhibition of AQP2 and NKCC2 expression .
Preservation of renal blood flow during hypotension induced with fenoldopam in dogs .	Preservation of renal blood flow during disease* hypotension *disease induced with fenoldopam in dogs .
The introduction of drugs that could induce hypotension with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .	The introduction of drugs that could induce disease* hypotension *disease with different pharmacological actions would be advantageous because side effects unique to a specific drug could be minimized by selecting appropriate therapy .
Specific dopamine - 1 , ( DA1 ) and dopamine - 2 ( DA2 ) receptor agonists are now under clinical investigation .	Specific dopamine - 1 , ( DA1 ) and dopamine - 2 ( DA2 ) receptor agonists are now under clinical investigation .
Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation .	Fenoldopam mesylate is a specific DA1 receptor agonist that lowers blood pressure by vasodilatation .
The hypothesis that fenoldopam could be used to induce hypotension and preserve blood flow to the kidney was tested .	The hypothesis that fenoldopam could be used to induce disease* hypotension *disease and preserve blood flow to the kidney was tested .
Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively , in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia .	Systemic aortic blood pressure and renal blood flow were measured continuously with a carotid arterial catheter and an electromagnetic flow probe respectively , in order to compare the cardiovascular and renal vascular effects of fenoldopam and sodium nitroprusside in ten dogs under halothane general anaesthesia .
Mean arterial pressure was decreased 30 + / - 8 per cent from control with infusion of fenoldopam ( 3 . 4 + / - 2 . 0 micrograms . kg - 1 . min - 1 ) and 34 + / - 4 per cent with infusion of sodium nitroprusside ( 5 . 9 micrograms . kg - 1 . min - 1 ) ( NS ) .	Mean arterial pressure was decreased 30 + / - 8 per cent from control with infusion of fenoldopam ( 3 . 4 + / - 2 . 0 micrograms . kg - 1 . min - 1 ) and 34 + / - 4 per cent with infusion of sodium nitroprusside ( 5 . 9 micrograms . kg - 1 . min - 1 ) ( NS ) .
Renal blood flow ( RBF ) increased during fenoldopam - induced hypotension 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced hypotension ( P less than 0 . 01 ) .	Renal blood flow ( RBF ) increased during fenoldopam - induced disease* hypotension *disease 11 + / - 7 per cent and decreased 21 + / - 8 per cent during sodium nitroprusside - induced disease* hypotension *disease ( P less than 0 . 01 ) .
Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced hypotension .	Sodium nitroprusside is a non - selective arteriolar and venous vasodilator that can produce redistribution of blood flow away from the kidney during induced disease* hypotension *disease .
Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced hypotension .	Fenoldopam is a selective dopamine - 1 ( DA1 ) receptor agonist that causes vasodilatation to the kidney and other organs with DA1 receptors and preserves blood flow to the kidney during induced disease* hypotension *disease .
Seizures associated with levofloxacin : case presentation and literature review .	disease* Seizures *disease associated with levofloxacin : case presentation and literature review .
PURPOSE : We present a case of a patient who developed seizures shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced seizures .	PURPOSE : We present a case of a patient who developed disease* seizures *disease shortly after initiating treatment with levofloxacin and to discuss the potential drug - drug interactions related to the inhibition of cytochrome P450 ( CYP ) 1A2 in this case , as well as in other cases , of levofloxacin - induced disease* seizures *disease .
METHODS : Several biomedical databases were searched including MEDLINE , Cochrane and Ovid .	METHODS : Several biomedical databases were searched including MEDLINE , Cochrane and Ovid .
The main search terms utilized were case report and levofloxacin .	The main search terms utilized were case report and levofloxacin .
The search was limited to studies published in English .	The search was limited to studies published in English .
RESULTS : Six cases of levofloxacin - induced seizures have been reported in the literature .	RESULTS : Six cases of levofloxacin - induced disease* seizures *disease have been reported in the literature .
Drug - drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases .	Drug - drug interactions related to the inhibition of CYP1A2 by levofloxacin are likely involved in the clinical outcome of these cases .
CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates .	CONCLUSIONS : Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates .
Dextran - etodolac conjugates : synthesis , in vitro and in vivo evaluation .	Dextran - etodolac conjugates : synthesis , in vitro and in vivo evaluation .
Etodolac ( E ) , is a non - narcotic analgesic and antiinflammatory drug .	Etodolac ( E ) , is a non - narcotic analgesic and antiinflammatory drug .
A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac - dextran conjugates ( ED ) to improve its aqueous solubility and reduce gastrointestinal side effects .	A biodegradable polymer dextran has been utilized as a carrier for synthesis of etodolac - dextran conjugates ( ED ) to improve its aqueous solubility and reduce gastrointestinal side effects .
An activated moiety , i . e . N - acylimidazole derivative of etodolac ( EAI ) , was condensed with the polysaccharide polymer dextran of different molecular weights ( 40000 , 60000 , 110000 and 200000 ) .	An activated moiety , i . e . N - acylimidazole derivative of etodolac ( EAI ) , was condensed with the polysaccharide polymer dextran of different molecular weights ( 40000 , 60000 , 110000 and 200000 ) .
IR spectral data confirmed formation of ester bonding in the conjugates .	IR spectral data confirmed formation of ester bonding in the conjugates .
Etodolac contents were evaluated by UV - spectrophotometric analysis .	Etodolac contents were evaluated by UV - spectrophotometric analysis .
The molecular weights were determined by measuring viscosity using the Mark - Howink - Sakurada equation .	The molecular weights were determined by measuring viscosity using the Mark - Howink - Sakurada equation .
In vitro hydrolysis of ED was done in aqueous buffers ( pH 1 . 2 , 7 . 4 , 9 ) and in 80 % ( v / v ) human plasma ( pH 7 . 4 ) .	In vitro hydrolysis of ED was done in aqueous buffers ( pH 1 . 2 , 7 . 4 , 9 ) and in 80 % ( v / v ) human plasma ( pH 7 . 4 ) .
At pH 9 , a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7 . 4 and 80 % human plasma ( pH 7 . 4 ) , following first - order kinetics .	At pH 9 , a higher rate of etodolac release from ED was observed as compared to aqueous buffer of pH 7 . 4 and 80 % human plasma ( pH 7 . 4 ) , following first - order kinetics .
In vivo investigations were performed in animals .	In vivo investigations were performed in animals .
Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced writhing model ( mice ) and carrageenan - induced rat paw edema model , respectively .	Acute analgesic and antiinflammatory activities were ascertained using acetic acid induced disease* writhing *disease model ( mice ) and carrageenan - induced rat paw disease* edema *disease model , respectively .
In comparison to control , E and ED1 - ED4 showed highly significant analgesic and antiinflammatory activities ( p < 0 . 001 ) .	In comparison to control , E and ED1 - ED4 showed highly significant analgesic and antiinflammatory activities ( p < 0 . 001 ) .
Biological evaluation suggested that conjugates ( ED1 - ED4 ) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug - - etodolac .	Biological evaluation suggested that conjugates ( ED1 - ED4 ) retained comparable analgesic and antiinflammatory activities with remarkably reduced ulcerogenicity as compared to their parent drug - - etodolac .
The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models .	The antiarrhythmic effect and possible ionic mechanisms of pilocarpine on animal models .
This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig arrhythmia models .	This study was designed to evaluate the effects of pilocarpine and explore the underlying ionic mechanism , using both aconitine - induced rat and ouabain - induced guinea pig disease* arrhythmia *disease models .
Confocal microscopy was used to measure intracellular free - calcium concentrations ( [ Ca ( 2 + ) ] ( i ) ) in isolated myocytes .	Confocal microscopy was used to measure intracellular free - calcium concentrations ( [ Ca ( 2 + ) ] ( i ) ) in isolated myocytes .
The current data showed that pilocarpine significantly delayed onset of arrhythmias , decreased the time course of ventricular tachycardia and fibrillation , reduced arrhythmia score , and increased the survival time of arrhythmic rats and guinea pigs .	The current data showed that pilocarpine significantly delayed onset of disease* arrhythmias *disease , decreased the time course of disease* ventricular tachycardia and fibrillation *disease , reduced disease* arrhythmia *disease score , and increased the survival time of disease* arrhythmic *disease rats and guinea pigs .
[ Ca ( 2 + ) ] ( i ) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine .	[ Ca ( 2 + ) ] ( i ) overload induced by aconitine or ouabain was reduced in isolated myocytes pretreated with pilocarpine .
Moreover , M ( 3 ) - muscarinic acetylcholine receptor ( mAChR ) antagonist 4 - DAMP ( 4 - diphenylacetoxy - N - methylpiperidine - methiodide ) partially abolished the beneficial effects of pilocarpine .	Moreover , M ( 3 ) - muscarinic acetylcholine receptor ( mAChR ) antagonist 4 - DAMP ( 4 - diphenylacetoxy - N - methylpiperidine - methiodide ) partially abolished the beneficial effects of pilocarpine .
These data suggest that pilocarpine produced antiarrhythmic actions on arrhythmic rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M ( 3 ) - mAChR .	These data suggest that pilocarpine produced antiarrhythmic actions on disease* arrhythmic *disease rat and guinea pig models induced by aconitine or ouabain via stimulating the cardiac M ( 3 ) - mAChR .
The mechanism may be related to the improvement of Ca ( 2 + ) handling .	The mechanism may be related to the improvement of Ca ( 2 + ) handling .
Effect of Hibiscus rosa sinensis on reserpine - induced neurobehavioral and biochemical alterations in rats .	Effect of Hibiscus rosa sinensis on reserpine - induced neurobehavioral and biochemical alterations in rats .
Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial dyskinesia and neurochemical alterations .	Effect of methanolic extract of Hibiscus rosa sinensis ( 100 - 300 mg / kg ) was studied on reserpine - induced orofacial disease* dyskinesia *disease and neurochemical alterations .
The rats were treated with intraperitoneal reserpine ( 1 mg / kg , ip ) for 3 days every other day .	The rats were treated with intraperitoneal reserpine ( 1 mg / kg , ip ) for 3 days every other day .
On day 5 , vacuous chewing movements and tongue protrusions were counted for 5 min .	On day 5 , vacuous chewing movements and tongue protrusions were counted for 5 min .
Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however , coadministration of Hibiscus rosa sinensis roots extract ( 100 , 200 and 300 mg / kg , per orally ) attenuated the effects .	Reserpine treated rats significantly developed vacuous chewing movements and tongue protrusions however , coadministration of Hibiscus rosa sinensis roots extract ( 100 , 200 and 300 mg / kg , per orally ) attenuated the effects .
Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione reductase ( GSH ) , an index of oxidative stress process .	Biochemical analysis of brain revealed that the reserpine treatment significantly increased lipid peroxidation and decreased levels of superoxide dismutase ( SOD ) , catalase ( CAT ) and glutathione reductase ( GSH ) , an index of oxidative stress process .
Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD , CAT and GSH levels .	Coadministration of extract significantly reduced the lipid peroxidation and reversed the decrease in brain SOD , CAT and GSH levels .
The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine - induced orofacial dyskinesia and oxidative stress .	The results of the present study suggested that Hibiscus rosa sinensis had a protective role against reserpine - induced orofacial disease* dyskinesia *disease and oxidative stress .
Dynamic response of blood vessel in acute renal failure .	Dynamic response of blood vessel in disease* acute renal failure *disease .
In this study we postulated that during acute renal failure induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .	In this study we postulated that during disease* acute renal failure *disease induced by gentamicin the transient or dynamic response of blood vessels could be affected , and that antioxidants can prevent the changes in dynamic responses of blood vessels .
The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered , but also dynamics of this response , was used in this paper .	The new approach to ex vivo blood vessel experiments in which not only the end points of vessels response within the time interval is considered , but also dynamics of this response , was used in this paper .
Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals .	Our results confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals .
The beneficial effects of vitamin C administration to gentamicin - treated animals are also confirmed through : lower level of blood urea and creatinine and higher level of potassium .	The beneficial effects of vitamin C administration to gentamicin - treated animals are also confirmed through : lower level of blood urea and creatinine and higher level of potassium .
The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin - treated animals ( 8 . 07 + / - 1 . 7 s vs . 5 . 64 + / - 0 . 18 s ) .	The pressure dynamic responses of isolated blood vessels show a faster pressure change in gentamicin - treated animals ( 8 . 07 + / - 1 . 7 s vs . 5 . 64 + / - 0 . 18 s ) .
Vitamin C administration induced slowdown of pressure change back to the control values .	Vitamin C administration induced slowdown of pressure change back to the control values .
The pressure dynamic properties , quantitatively defined by comparative pressure dynamic and total pressure dynamic , confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals and beneficial effects of vitamin C administration .	The pressure dynamic properties , quantitatively defined by comparative pressure dynamic and total pressure dynamic , confirm the alteration in dynamic response of blood vessels during the change of pressure in gentamicin - treated animals and beneficial effects of vitamin C administration .
Reversible myocardial hypertrophy induced by tacrolimus in a pediatric heart transplant recipient : case report .	Reversible disease* myocardial hypertrophy *disease induced by tacrolimus in a pediatric heart transplant recipient : case report .
Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation .	Tacrolimus is a potent immunosuppressant that is frequently used in organ transplantation .
However , adverse effects include cardiac toxicity .	However , adverse effects include disease* cardiac toxicity *disease .
Herein we describe transient myocardial hypertrophy induced by tacrolimus after heart transplantation .	Herein we describe transient disease* myocardial hypertrophy *disease induced by tacrolimus after heart transplantation .
The hypertrophy caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .	The disease* hypertrophy *disease caused no clinical symptoms but was noted because of elevation of plasma brain natriuretic peptide concentration and confirmed at echocardiography .
Initially , allograft rejection was feared ; however , myocardial biopsy samples revealed only interstitial edema and mild myocardial hypertrophy ; neither cellular nor humoral rejection was detected .	Initially , allograft rejection was feared ; however , myocardial biopsy samples revealed only interstitial disease* edema *disease and mild disease* myocardial hypertrophy *disease ; neither cellular nor humoral rejection was detected .
The blood tacrolimus concentration was higher than usual at that time ; thus , tacrolimus dosage was reduced .	The blood tacrolimus concentration was higher than usual at that time ; thus , tacrolimus dosage was reduced .
Myocardial hypertrophy completely resolved upon reducing the target concentration of tacrolimus and did not recur , as confirmed at echocardiography and myocardial biopsy .	disease* Myocardial hypertrophy *disease completely resolved upon reducing the target concentration of tacrolimus and did not recur , as confirmed at echocardiography and myocardial biopsy .
Thus , we conclude that tacrolimus induces reversible myocardial hypertrophy .	Thus , we conclude that tacrolimus induces reversible disease* myocardial hypertrophy *disease .
In patients receiving tacrolimus therapy , blood concentration should be carefully controlled and extreme attention paid to cardiac involvement .	In patients receiving tacrolimus therapy , blood concentration should be carefully controlled and extreme attention paid to cardiac involvement .
Nimodipine prevents memory impairment caused by nitroglycerin - induced hypotension in adult mice .	Nimodipine prevents disease* memory impairment *disease caused by nitroglycerin - induced disease* hypotension *disease in adult mice .
BACKGROUND : Hypotension and a resultant decrease in cerebral blood flow have been implicated in the development of cognitive dysfunction .	BACKGROUND : disease* Hypotension *disease and a resultant decrease in cerebral blood flow have been implicated in the development of disease* cognitive dysfunction *disease .
We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced hypotension would preserve long - term associative memory .	We tested the hypothesis that nimodipine ( NIMO ) administered at the onset of nitroglycerin ( NTG ) - induced disease* hypotension *disease would preserve long - term associative memory .
METHODS : The passive avoidance ( PA ) paradigm was used to assess memory retention .	METHODS : The passive avoidance ( PA ) paradigm was used to assess memory retention .
For PA training , latencies ( seconds ) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered .	For PA training , latencies ( seconds ) were recorded for entry from a suspended platform into a Plexiglas tube where a shock was automatically delivered .
Latencies were recorded 48 h later for a testing trial .	Latencies were recorded 48 h later for a testing trial .
Ninety - six Swiss - Webster mice ( 30 - 35 g , 6 - 8 wk ) , were randomized into 6 groups 1 ) saline ( control ) , 2 ) NTG immediately after learning , 3 ) NTG 3 h after learning , 4 ) NTG and NIMO , 5 ) vehicle , and 6 ) NIMO alone .	Ninety - six Swiss - Webster mice ( 30 - 35 g , 6 - 8 wk ) , were randomized into 6 groups 1 ) saline ( control ) , 2 ) NTG immediately after learning , 3 ) NTG 3 h after learning , 4 ) NTG and NIMO , 5 ) vehicle , and 6 ) NIMO alone .
The extent of hypotension and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .	The extent of disease* hypotension *disease and changes in brain tissue oxygenation ( PbtO ( 2 ) ) and in cerebral blood flow were studied in a separate group of animals .
RESULTS : All groups exhibited similar training latencies ( 17 . 0 + / - 4 . 6 s ) .	RESULTS : All groups exhibited similar training latencies ( 17 . 0 + / - 4 . 6 s ) .
Mice subjected to hypotensive episodes showed a significant decrease in latency time ( 178 + / - 156 s ) compared with those injected with saline , NTG + NIMO , or delayed NTG ( 580 + / - 81 s , 557 + / - 67 s , and 493 + / - 146 s , respectively ) .	Mice subjected to disease* hypotensive *disease episodes showed a significant decrease in latency time ( 178 + / - 156 s ) compared with those injected with saline , NTG + NIMO , or delayed NTG ( 580 + / - 81 s , 557 + / - 67 s , and 493 + / - 146 s , respectively ) .
A Kruskal - Wallis 1 - way analysis of variance indicated a significant difference among the 4 treatment groups ( H = 15 . 34 ; P < 0 . 001 ) .	A Kruskal - Wallis 1 - way analysis of variance indicated a significant difference among the 4 treatment groups ( H = 15 . 34 ; P < 0 . 001 ) .
In a separate group of mice not subjected to behavioral studies , the same dose of NTG ( n = 3 ) and NTG + NIMO ( n = 3 ) caused mean arterial blood pressure to decrease from 85 . 9 + / - 3 . 8 mm Hg sem to 31 . 6 + / - 0 . 8 mm Hg sem and from 86 . 2 + / - 3 . 7 mm Hg sem to 32 . 6 + / - 0 . 2 mm Hg sem , respectively .	In a separate group of mice not subjected to behavioral studies , the same dose of NTG ( n = 3 ) and NTG + NIMO ( n = 3 ) caused mean arterial blood pressure to decrease from 85 . 9 + / - 3 . 8 mm Hg sem to 31 . 6 + / - 0 . 8 mm Hg sem and from 86 . 2 + / - 3 . 7 mm Hg sem to 32 . 6 + / - 0 . 2 mm Hg sem , respectively .
Mean arterial blood pressure in mice treated with NIMO alone decreased from 88 . 1 + / - 3 . 8 mm Hg to 80 . 0 + / - 2 . 9 mm Hg .	Mean arterial blood pressure in mice treated with NIMO alone decreased from 88 . 1 + / - 3 . 8 mm Hg to 80 . 0 + / - 2 . 9 mm Hg .
The intergroup difference was statistically significant ( P < 0 . 05 ) .	The intergroup difference was statistically significant ( P < 0 . 05 ) .
PbtO ( 2 ) decreased from 51 . 7 + / - 4 . 5 mm Hg sem to 33 . 8 + / - 5 . 2 mm Hg sem in the NTG group and from 38 . 6 + / - 6 . 1 mm Hg sem to 25 . 4 + / - 2 . 0 mm Hg sem in the NTG + NIMO groups , respectively .	PbtO ( 2 ) decreased from 51 . 7 + / - 4 . 5 mm Hg sem to 33 . 8 + / - 5 . 2 mm Hg sem in the NTG group and from 38 . 6 + / - 6 . 1 mm Hg sem to 25 . 4 + / - 2 . 0 mm Hg sem in the NTG + NIMO groups , respectively .
There were no significant differences among groups .	There were no significant differences among groups .
CONCLUSION : In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced hypotension had no effect .	CONCLUSION : In a PA retention paradigm , the injection of NTG immediately after learning produced a significant impairment of long - term associative memory in mice , whereas delayed induced disease* hypotension *disease had no effect .
NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of hypotension .	NIMO attenuated the disruption in consolidation of long - term memory caused by NTG but did not improve latency in the absence of disease* hypotension *disease .
The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during hypotension , because there were no differences in the PbtO ( 2 ) indices among groups .	The observed effect of NIMO may have been attributable to the preservation of calcium homeostasis during disease* hypotension *disease , because there were no differences in the PbtO ( 2 ) indices among groups .
Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson ' s disease .	Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of disease* Parkinson ' s disease *disease .
Metabotropic glutamate ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of Parkinson ' s disease ( PD ) .	Metabotropic glutamate ( mGlu ) receptors modulate synaptic transmission in the central nervous system and represent promising therapeutic targets for symptomatic treatment of disease* Parkinson ' s disease *disease ( disease* PD *disease ) .
Among the eight mGlu receptor subtypes , mGlu7 receptor is prominently expressed in the basal ganglia , but its role in restoring motor function in animal models of PD is not known .	Among the eight mGlu receptor subtypes , mGlu7 receptor is prominently expressed in the basal ganglia , but its role in restoring motor function in animal models of disease* PD *disease is not known .
The effects of N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of PD .	The effects of N , N ' - dibenzhydrylethane - 1 , 2 - diamine dihydrochloride ( AMN082 ) , the first selective allosteric activator of mGlu7 receptors , were thus tested in different rodent models of disease* PD *disease .
Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses haloperidol - induced catalepsy in rats .	Here , we show that oral ( 5 mg / kg ) or intrastriatal administration ( 0 . 1 and 0 . 5 nmol ) of AMN082 reverses haloperidol - induced disease* catalepsy *disease in rats .
AMN082 ( 2 . 5 and 5 mg / kg ) reduces apomorphine - induced rotations in unilateral 6 - hydroxydopamine ( 6 - OHDA ) - lesioned rats .	AMN082 ( 2 . 5 and 5 mg / kg ) reduces apomorphine - induced rotations in unilateral 6 - hydroxydopamine ( 6 - OHDA ) - lesioned rats .
In a more complex task commonly used to evaluate major akinetic symptoms of PD patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .	In a more complex task commonly used to evaluate major disease* akinetic *disease symptoms of disease* PD *disease patients , 5 mg / kg AMN082 reverses the increased reaction time to respond to a cue of bilateral 6 - OHDA - lesioned rats .
In addition , AMN082 reduces the duration of haloperidol - induced catalepsy in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .	In addition , AMN082 reduces the duration of haloperidol - induced disease* catalepsy *disease in a mGlu7 receptor - dependent manner in wild - type but not mGlu7 receptor knockout mice .
Higher doses of AMN082 ( 10 and 20 mg / kg p . o . ) have no effect on the same models of PD .	Higher doses of AMN082 ( 10 and 20 mg / kg p . o . ) have no effect on the same models of disease* PD *disease .
Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity .	Overall these findings suggest that mGlu7 receptor activation can reverse motor dysfunction associated with reduced dopamine activity .
Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies .	Selective ligands of mGlu7 receptor subtypes may thus be considered as promising compounds for the development of antiparkinsonian therapeutic strategies .
Sorafenib - induced acute myocardial infarction due to coronary artery spasm .	Sorafenib - induced acute disease* myocardial infarction *disease due to disease* coronary artery spasm *disease .
A 65 - year - old man with advanced renal cell carcinoma was admitted due to continuing chest pain at rest .	A 65 - year - old man with advanced disease* renal cell carcinoma *disease was admitted due to continuing disease* chest pain *disease at rest .
Two weeks before his admission , sorafenib had been started .	Two weeks before his admission , sorafenib had been started .
He was diagnosed with non - ST - elevation myocardial infarction by laboratory data and electrocardiogram .	He was diagnosed with non - ST - elevation disease* myocardial infarction *disease by laboratory data and electrocardiogram .
Enhanced heart magnetic resonance imaging also showed subendocardial infarction .	Enhanced heart magnetic resonance imaging also showed disease* subendocardial infarction *disease .
However , there was no stenosis in coronary arteries on angiography .	However , there was no stenosis in coronary arteries on angiography .
Coronary artery spasm was induced by a provocative test .	disease* Coronary artery spasm *disease was induced by a provocative test .
Cessation of sorafenib and administration of Ca - channel blocker and nitrates ameliorated his symptoms , but relapse occurred after resumption of sorafenib .	Cessation of sorafenib and administration of Ca - channel blocker and nitrates ameliorated his symptoms , but relapse occurred after resumption of sorafenib .
Addition of oral nicorandil reduced his symptoms and maintained stable angina status .	Addition of oral nicorandil reduced his symptoms and maintained disease* stable angina *disease status .
We report the first case of sorafenib - induced coronary artery spasm .	We report the first case of sorafenib - induced disease* coronary artery spasm *disease .
Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival .	Sorafenib is a multikinase inhibitor that targets signaling pathways necessary for cellular proliferation and survival .
On the other hand , the Rho / ROCK pathway has an important role in the pathogenesis of coronary artery spasm .	On the other hand , the Rho / ROCK pathway has an important role in the pathogenesis of disease* coronary artery spasm *disease .
Our report may show an adverse effect on the Rho / ROCK pathway by sorafenib use .	Our report may show an adverse effect on the Rho / ROCK pathway by sorafenib use .
A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB .	A novel animal model to evaluate the ability of a drug delivery system to promote the passage through the BBB .
The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood - brain barrier ( BBB ) and / or to improve the brain localization of a bioactive compound .	The purpose of this investigation was to explore the potentiality of a novel animal model to be used for the in vivo evaluation of the ability of a drug delivery system to promote the passage through the blood - brain barrier ( BBB ) and / or to improve the brain localization of a bioactive compound .
A Tween 80 - coated poly - L - lactid acid nanoparticles was used as a model of colloidal drug delivery system , able to trespass the BBB .	A Tween 80 - coated poly - L - lactid acid nanoparticles was used as a model of colloidal drug delivery system , able to trespass the BBB .
Tacrine , administered in LiCl pre - treated rats , induces electrocorticographic seizures and delayed hippocampal damage .	Tacrine , administered in LiCl pre - treated rats , induces electrocorticographic disease* seizures *disease and delayed disease* hippocampal damage *disease .
The toxic effects of tacrine - loaded poly - L - lactid acid nanoparticles ( 5mg / kg ) , a saline solution of tacrine ( 5mg / kg ) and an empty colloidal nanoparticle suspension were compared following i . p . administration in LiCl - pre - treated Wistar rats .	The toxic effects of tacrine - loaded poly - L - lactid acid nanoparticles ( 5mg / kg ) , a saline solution of tacrine ( 5mg / kg ) and an empty colloidal nanoparticle suspension were compared following i . p . administration in LiCl - pre - treated Wistar rats .
All the animals treated with tacrine - loaded nanoparticles showed an earlier outcome of CNS adverse symptoms , i . e . epileptic onset , with respect to those animals treated with the free compound ( 10 min vs . 22 min respectively ) .	All the animals treated with tacrine - loaded nanoparticles showed an earlier outcome of CNS adverse symptoms , i . e . disease* epileptic *disease onset , with respect to those animals treated with the free compound ( 10 min vs . 22 min respectively ) .
In addition , tacrine - loaded nanoparticles administration induced damage of neuronal cells in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .	In addition , tacrine - loaded nanoparticles administration induced disease* damage of neuronal cells *disease in CA1 field of the hippocampus in all treated animals , while the saline solution of tacrine only in 60 % of animals .
Empty nanoparticles provided similar results to control ( saline - treated ) group of animals .	Empty nanoparticles provided similar results to control ( saline - treated ) group of animals .
In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of epilepsy in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .	In conclusion , the evaluation of time - to - onset of symptoms and the severity of neurodegenerative processes induced by the tacrine - lithium model of disease* epilepsy *disease in the rat , could be used to evaluate preliminarily the capability of a drug delivery system to trespass ( or not ) the BBB in vivo .
High - dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients .	High - dose tranexamic Acid is associated with nonischemic clinical disease* seizures *disease in cardiac surgical patients .
BACKGROUND : In 2 separate centers , we observed a notable increase in the incidence of postoperative convulsive seizures from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .	BACKGROUND : In 2 separate centers , we observed a notable increase in the incidence of postoperative disease* convulsive disease* seizures *disease from 1 . 3 % to 3 . 8 % in patients having undergone major cardiac surgical procedures .
These events were temporally coincident with the initial use of high - dose tranexamic acid ( TXA ) therapy after withdrawal of aprotinin from general clinical usage .	These events were temporally coincident with the initial use of high - dose tranexamic acid ( TXA ) therapy after withdrawal of aprotinin from general clinical usage .
The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and seizures after cardiac surgery .	The purpose of this review was to perform a retrospective analysis to examine whether there was a relation between TXA usage and disease* seizures *disease after cardiac surgery .
METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative seizures .	METHODS : An in - depth chart review was undertaken in all 24 patients who developed perioperative disease* seizures *disease .
Electroencephalographic activity was recorded in 11 of these patients , and all patients had a formal neurological evaluation and brain imaging studies .	Electroencephalographic activity was recorded in 11 of these patients , and all patients had a formal neurological evaluation and brain imaging studies .
RESULTS : Twenty - one of the 24 patients did not have evidence of new cerebral ischemic injury , but seizures were likely due to ischemic brain injury in 3 patients .	RESULTS : Twenty - one of the 24 patients did not have evidence of new disease* cerebral ischemic injury *disease , but disease* seizures *disease were likely due to disease* ischemic brain injury *disease in 3 patients .
All patients with seizures did not have permanent neurological abnormalities .	All patients with disease* seizures *disease did not have permanent disease* neurological abnormalities *disease .
All 24 patients with seizures received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .	All 24 patients with disease* seizures *disease received high doses of TXA intraoperatively ranging from 61 to 259 mg / kg , had a mean age of 69 . 9 years , and 21 of 24 had undergone open chamber rather than coronary bypass procedures .
All but one patient were managed using cardiopulmonary bypass .	All but one patient were managed using cardiopulmonary bypass .
No evidence of brain ischemic , metabolic , or hyperthermia - induced causes for their seizures was apparent .	No evidence of disease* brain ischemic *disease , metabolic , or disease* hyperthermia *disease - induced causes for their disease* seizures *disease was apparent .
CONCLUSION : Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical seizures in susceptible patients .	CONCLUSION : Our results suggest that use of high - dose TXA in older patients in conjunction with cardiopulmonary bypass and open - chamber cardiac surgery is associated with clinical disease* seizures *disease in susceptible patients .
Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs .	Electrocardiographic changes and disease* cardiac arrhythmias *disease in patients receiving psychotropic drugs .
Eight patients had cardiac manifestations that were life - threatening in five while taking psychotropic drugs , either phenothiazines or tricyclic antidepressants .	Eight patients had cardiac manifestations that were life - threatening in five while taking psychotropic drugs , either phenothiazines or tricyclic antidepressants .
Although most patients were receiving several drugs , Mellaril ( thioridazine ) appeared to be responsible for five cases of ventricular tachycardia , one of which was fatal in a 35 year old woman .	Although most patients were receiving several drugs , Mellaril ( thioridazine ) appeared to be responsible for five cases of disease* ventricular tachycardia *disease , one of which was fatal in a 35 year old woman .
Supraventricular tachycardia developed in one patient receiving Thorazine ( chlorpromazine ) .	disease* Supraventricular tachycardia *disease developed in one patient receiving Thorazine ( chlorpromazine ) .
Aventyl ( nortriptyline ) and Elavil ( amitriptyline ) each produced left bundle branch block in a 73 year old woman .	Aventyl ( nortriptyline ) and Elavil ( amitriptyline ) each produced disease* left bundle branch block *disease in a 73 year old woman .
Electrocardiographic T and U wave abnormalities were present in most patients .	Electrocardiographic T and U wave abnormalities were present in most patients .
The ventricular arrhythmias responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .	The disease* ventricular arrhythmias *disease responded to intravenous administration of lidocaine and to direct current electric shock ; ventricular pacing was required in some instances and intravenous administration of propranolol combined with ventricular pacing in one .
The tachyarrhythmias generally subsided within 48 hours after administration of the drugs was stopped .	The disease* tachyarrhythmias *disease generally subsided within 48 hours after administration of the drugs was stopped .
Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent heart disease .	Five of the eight patients were 50 years of age or younger ; only one clearly had antecedent disease* heart disease *disease .
Major cardiac arrhythmias are a potential hazard in patients without heart disease who are receiving customary therapeutic doses of psychotropic drugs .	Major disease* cardiac arrhythmias *disease are a potential hazard in patients without disease* heart disease *disease who are receiving customary therapeutic doses of psychotropic drugs .
A prospective clinical trial is suggested to quantify the risk of cardiac complications to patients receiving phenothiazines or tricyclic antidepressant drugs .	A prospective clinical trial is suggested to quantify the risk of disease* cardiac complications *disease to patients receiving phenothiazines or tricyclic antidepressant drugs .
Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated immunodeficient mice .	Sensitivity of erythroid progenitor colonies to erythropoietin in azidothymidine treated disease* immunodeficient *disease mice .
The anaemia induced by 3 ' - azido - 3 ' dideoxythymidine ( AZT ) is poorly understood .	The disease* anaemia *disease induced by 3 ' - azido - 3 ' dideoxythymidine ( AZT ) is poorly understood .
We have used a murine model of AIDS , infection of female C57BL / 6 mice with LP - BM5 murine leukaemia ( MuLV ) virus , to determine if AZT - induced anaemia is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .	We have used a murine model of disease* AIDS *disease , disease* infection *disease of female C57BL / 6 mice with LP - BM5 murine disease* leukaemia *disease ( MuLV ) virus , to determine if AZT - induced disease* anaemia *disease is due , in part , to decreased responsiveness of erythropoietic precursors ( BFU - e ) to erythropoietin ( EPO ) .
Mice in the early stage of LP - BM5 MuLV disease were given AZT in their drinking water at 1 . 0 and 2 . 5 mg / ml .	Mice in the early stage of LP - BM5 MuLV disease were given AZT in their drinking water at 1 . 0 and 2 . 5 mg / ml .
AZT produced anaemia in both groups , in a dose - dependent fashion .	AZT produced disease* anaemia *disease in both groups , in a dose - dependent fashion .
Despite the anaemia , the number of splenic and bone marrow BFU - e in AZT treated mice increased up to five - fold over levels observed in infected untreated animals after 15 d of treatment .	Despite the disease* anaemia *disease , the number of splenic and bone marrow BFU - e in AZT treated mice increased up to five - fold over levels observed in infected untreated animals after 15 d of treatment .
Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected , untreated mice .	Colony formation by splenic and bone marrow BFUe was stimulated at lower concentrations of EPO in mice receiving AZT for 15 d than for infected , untreated mice .
By day 30 , sensitivity of both splenic and bone marrow BFU - e of treated animals returned to that observed from cells of infected untreated animals .	By day 30 , sensitivity of both splenic and bone marrow BFU - e of treated animals returned to that observed from cells of infected untreated animals .
The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of anaemia observed when compared with phenylhydrazine ( PHZ ) treated mice .	The mean plasma levels of EPO observed in AZT treated mice were appropriate for the degree of disease* anaemia *disease observed when compared with phenylhydrazine ( PHZ ) treated mice .
The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of anaemia .	The numbers of BFU - e and the percentage of bone marrow erythroblasts observed were comparable in AZT and PHZ treated mice with similar degrees of disease* anaemia *disease .
However , reticulocytosis was inappropriate for the degree of anaemia observed in AZT treated infected mice .	However , disease* reticulocytosis *disease was inappropriate for the degree of disease* anaemia *disease observed in AZT treated infected mice .
AZT - induced peripheral anaemia in the face of increased numbers of BFU - e and increased levels of plasma EPO suggest a lesion in terminal differentiation .	AZT - induced peripheral disease* anaemia *disease in the face of increased numbers of BFU - e and increased levels of plasma EPO suggest a lesion in terminal differentiation .
Sedation depth during spinal anesthesia and the development of postoperative delirium in elderly patients undergoing hip fracture repair .	Sedation depth during spinal anesthesia and the development of disease* postoperative delirium *disease in elderly patients undergoing disease* hip fracture *disease repair .
OBJECTIVE : To determine whether limiting intraoperative sedation depth during spinal anesthesia for hip fracture repair in elderly patients can decrease the prevalence of postoperative delirium .	OBJECTIVE : To determine whether limiting intraoperative sedation depth during spinal anesthesia for disease* hip fracture *disease repair in elderly patients can decrease the prevalence of disease* postoperative delirium *disease .
PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative delirium or severe dementia who underwent hip fracture repair under spinal anesthesia with propofol sedation .	PATIENTS AND METHODS : We performed a double - blind , randomized controlled trial at an academic medical center of elderly patients ( > or = 65 years ) without preoperative disease* delirium *disease or severe disease* dementia *disease who underwent disease* hip fracture *disease repair under spinal anesthesia with propofol sedation .
Sedation depth was titrated using processed electroencephalography with the bispectral index ( BIS ) , and patients were randomized to receive either deep ( BIS , approximately 50 ) or light ( BIS , > or = 80 ) sedation .	Sedation depth was titrated using processed electroencephalography with the bispectral index ( BIS ) , and patients were randomized to receive either deep ( BIS , approximately 50 ) or light ( BIS , > or = 80 ) sedation .
Postoperative delirium was assessed as defined by Diagnostic and Statistical Manual of Mental Disorders ( Third Edition Revised ) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery .	disease* Postoperative delirium *disease was assessed as defined by Diagnostic and Statistical Manual of disease* Mental Disorders *disease ( Third Edition Revised ) criteria using the Confusion Assessment Method beginning at any time from the second day after surgery .
RESULTS : From April 2 , 2005 , through October 30 , 2008 , a total of 114 patients were randomized .	RESULTS : From April 2 , 2005 , through October 30 , 2008 , a total of 114 patients were randomized .
The prevalence of postoperative delirium was significantly lower in the light sedation group ( 11 / 57 [ 19 % ] vs 23 / 57 [ 40 % ] in the deep sedation group ; P = . 02 ) , indicating that 1 incident of delirium will be prevented for every 4 . 7 patients treated with light sedation .	The prevalence of disease* postoperative delirium *disease was significantly lower in the light sedation group ( 11 / 57 [ 19 % ] vs 23 / 57 [ 40 % ] in the deep sedation group ; P = . 02 ) , indicating that 1 incident of disease* delirium *disease will be prevented for every 4 . 7 patients treated with light sedation .
The mean + / - SD number of days of delirium during hospitalization was lower in the light sedation group than in the deep sedation group ( 0 . 5 + / - 1 . 5 days vs 1 . 4 + / - 4 . 0 days ; P = . 01 ) .	The mean + / - SD number of days of disease* delirium *disease during hospitalization was lower in the light sedation group than in the deep sedation group ( 0 . 5 + / - 1 . 5 days vs 1 . 4 + / - 4 . 0 days ; P = . 01 ) .
CONCLUSION : The use of light propofol sedation decreased the prevalence of postoperative delirium by 50 % compared with deep sedation .	CONCLUSION : The use of light propofol sedation decreased the prevalence of disease* postoperative delirium *disease by 50 % compared with deep sedation .
Limiting depth of sedation during spinal anesthesia is a simple , safe , and cost - effective intervention for preventing postoperative delirium in elderly patients that could be widely and readily adopted .	Limiting depth of sedation during spinal anesthesia is a simple , safe , and cost - effective intervention for preventing disease* postoperative delirium *disease in elderly patients that could be widely and readily adopted .
The protective role of Nrf2 in streptozotocin - induced diabetic nephropathy .	The protective role of Nrf2 in streptozotocin - induced disease* diabetic nephropathy *disease .
OBJECTIVE : Diabetic nephropathy is one of the major causes of renal failure , which is accompanied by the production of reactive oxygen species ( ROS ) .	OBJECTIVE : disease* Diabetic nephropathy *disease is one of the major causes of disease* renal failure *disease , which is accompanied by the production of reactive oxygen species ( ROS ) .
Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis .	Nrf2 is the primary transcription factor that controls the antioxidant response essential for maintaining cellular redox homeostasis .
Here , we report our findings demonstrating a protective role of Nrf2 against diabetic nephropathy .	Here , we report our findings demonstrating a protective role of Nrf2 against disease* diabetic nephropathy *disease .
RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against diabetic nephropathy using human kidney biopsy tissues from diabetic nephropathy patients , a streptozotocin - induced diabetic nephropathy model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .	RESEARCH DESIGN AND METHODS : We explore the protective role of Nrf2 against disease* diabetic nephropathy *disease using human kidney biopsy tissues from disease* diabetic nephropathy *disease patients , a streptozotocin - induced disease* diabetic nephropathy *disease model in Nrf2 ( - / - ) mice , and cultured human mesangial cells .
RESULTS : The glomeruli of human diabetic nephropathy patients were under oxidative stress and had elevated Nrf2 levels .	RESULTS : The glomeruli of human disease* diabetic nephropathy *disease patients were under oxidative stress and had elevated Nrf2 levels .
In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced renal damage .	In the animal study , Nrf2 was demonstrated to be crucial in ameliorating streptozotocin - induced disease* renal damage *disease .
This is evident by Nrf2 ( - / - ) mice having higher ROS production and suffering from greater oxidative DNA damage and renal injury compared with Nrf2 ( + / + ) mice .	This is evident by Nrf2 ( - / - ) mice having higher ROS production and suffering from greater oxidative DNA damage and disease* renal injury *disease compared with Nrf2 ( + / + ) mice .
Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2 - mediated protection against diabetic nephropathy is , at least , partially through inhibition of transforming growth factor - beta1 ( TGF - beta1 ) and reduction of extracellular matrix production .	Mechanistic studies in both in vivo and in vitro systems showed that the Nrf2 - mediated protection against disease* diabetic nephropathy *disease is , at least , partially through inhibition of transforming growth factor - beta1 ( TGF - beta1 ) and reduction of extracellular matrix production .
In human renal mesangial cells , high glucose induced ROS production and activated expression of Nrf2 and its downstream genes .	In human renal mesangial cells , high glucose induced ROS production and activated expression of Nrf2 and its downstream genes .
Furthermore , activation or overexpression of Nrf2 inhibited the promoter activity of TGF - beta1 in a dose - dependent manner , whereas knockdown of Nrf2 by siRNA enhanced TGF - beta1 transcription and fibronectin production .	Furthermore , activation or overexpression of Nrf2 inhibited the promoter activity of TGF - beta1 in a dose - dependent manner , whereas knockdown of Nrf2 by siRNA enhanced TGF - beta1 transcription and fibronectin production .
CONCLUSIONS : This work clearly indicates a protective role of Nrf2 in diabetic nephropathy , suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of diabetic nephropathy .	CONCLUSIONS : This work clearly indicates a protective role of Nrf2 in disease* diabetic nephropathy *disease , suggesting that dietary or therapeutic activation of Nrf2 could be used as a strategy to prevent or slow down the progression of disease* diabetic nephropathy *disease .
Metformin prevents experimental gentamicin - induced nephropathy by a mitochondria - dependent pathway .	Metformin prevents experimental gentamicin - induced disease* nephropathy *disease by a mitochondria - dependent pathway .
The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent vascular dysfunction even in nondiabetic patients .	The antidiabetic drug metformin can diminish apoptosis induced by oxidative stress in endothelial cells and prevent disease* vascular dysfunction *disease even in nondiabetic patients .
Here we tested whether it has a beneficial effect in a rat model of gentamicin toxicity .	Here we tested whether it has a beneficial effect in a rat model of gentamicin disease* toxicity *disease .
Mitochondrial analysis , respiration intensity , levels of reactive oxygen species , permeability transition , and cytochrome c release were assessed 3 and 6 days after gentamicin administration .	Mitochondrial analysis , respiration intensity , levels of reactive oxygen species , permeability transition , and cytochrome c release were assessed 3 and 6 days after gentamicin administration .
Metformin treatment fully blocked gentamicin - mediated acute renal failure .	Metformin treatment fully blocked gentamicin - mediated disease* acute renal failure *disease .
This was accompanied by a lower activity of N - acetyl - beta - D - glucosaminidase , together with a decrease of lipid peroxidation and increase of antioxidant systems .	This was accompanied by a lower activity of N - acetyl - beta - D - glucosaminidase , together with a decrease of lipid peroxidation and increase of antioxidant systems .
Metformin also protected the kidney from histological damage 6 days after gentamicin administration .	Metformin also protected the kidney from histological damage 6 days after gentamicin administration .
These in vivo markers of kidney dysfunction and their correction by metformin were complemented by in vitro studies of mitochondrial function .	These in vivo markers of disease* kidney dysfunction *disease and their correction by metformin were complemented by in vitro studies of mitochondrial function .
We found that gentamicin treatment depleted respiratory components ( cytochrome c , NADH ) , probably due to the opening of mitochondrial transition pores .	We found that gentamicin treatment depleted respiratory components ( cytochrome c , NADH ) , probably due to the opening of mitochondrial transition pores .
These injuries , partly mediated by a rise in reactive oxygen species from the electron transfer chain , were significantly decreased by metformin .	These injuries , partly mediated by a rise in reactive oxygen species from the electron transfer chain , were significantly decreased by metformin .
Thus , our study suggests that pleiotropic effects of metformin can lessen gentamicin nephrotoxicity and improve mitochondrial homeostasis .	Thus , our study suggests that pleiotropic effects of metformin can lessen gentamicin disease* nephrotoxicity *disease and improve mitochondrial homeostasis .
Risk of nephropathy after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .	Risk of disease* nephropathy *disease after consumption of nonionic contrast media by children undergoing cardiac angiography : a prospective study .
Despite increasing reports on nonionic contrast media - induced nephropathy ( CIN ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .	Despite increasing reports on nonionic contrast media - induced disease* nephropathy *disease ( disease* CIN *disease ) in hospitalized adult patients during cardiac procedures , the studies in pediatrics are limited , with even less focus on possible predisposing factors and preventive measures for patients undergoing cardiac angiography .
This prospective study determined the incidence of CIN for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of cyanosis .	This prospective study determined the incidence of disease* CIN *disease for two nonionic contrast media ( CM ) , iopromide and iohexol , among 80 patients younger than 18 years and compared the rates for this complication in relation to the type and dosage of CM and the presence of disease* cyanosis *disease .
The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .	The 80 patients in the study consecutively received either iopromide ( group A , n = 40 ) or iohexol ( group B , n = 40 ) .
Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .	Serum sodium ( Na ) , potassium ( K ) , and creatinine ( Cr ) were measured 24 h before angiography as baseline values , then measured again at 12 - , 24 - , and 48 - h intervals after CM use .
Urine samples for Na and Cr also were checked at the same intervals .	Urine samples for Na and Cr also were checked at the same intervals .
Risk of renal failure , Injury to the kidney , Failure of kidney function , Loss of kidney function , and End - stage renal damage ( RIFLE criteria ) were used to define CIN and its incidence in the study population .	Risk of disease* renal failure *disease , disease* Injury to the kidney *disease , disease* Failure of kidney function *disease , disease* Loss of kidney function *disease , and End - stage disease* renal damage *disease ( RIFLE criteria ) were used to define disease* CIN *disease and its incidence in the study population .
Accordingly , among the 15 CIN patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had renal injury , whereas 5 % of group B had increased risk and 2 . 5 % had renal injury .	Accordingly , among the 15 disease* CIN *disease patients ( 18 . 75 % ) , 7 . 5 % of the patients in group A had increased risk and 3 . 75 % had disease* renal injury *disease , whereas 5 % of group B had increased risk and 2 . 5 % had disease* renal injury *disease .
Whereas 33 . 3 % of the patients with CIN were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of CIN related to the different dosages of CM ( p = 0 . 014 ) .	Whereas 33 . 3 % of the patients with disease* CIN *disease were among those who received the proper dosage of CM , the percentage increased to 66 . 6 % among those who received larger doses , with a significant difference in the incidence of disease* CIN *disease related to the different dosages of CM ( p = 0 . 014 ) .
Among the 15 patients with CIN , 6 had cyanotic congenital heart diseases , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .	Among the 15 patients with disease* CIN *disease , 6 had cyanotic disease* congenital heart diseases *disease , but the incidence did not differ significantly from that for the noncyanotic patients ( p = 0 . 243 ) .
Although clinically silent , CIN is not rare in pediatrics .	Although clinically silent , disease* CIN *disease is not rare in pediatrics .
The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of cyanosis , and although CIN usually is reversible , more concern is needed for the prevention of such a complication in children .	The incidence depends on dosage but not on the type of consumed nonionic CM , nor on the presence of disease* cyanosis *disease , and although disease* CIN *disease usually is reversible , more concern is needed for the prevention of such a complication in children .
Renal function and hemodynamics during prolonged isoflurane - induced hypotension in humans .	Renal function and hemodynamics during prolonged isoflurane - induced disease* hypotension *disease in humans .
The effect of isoflurane - induced hypotension on glomerular function and renal blood flow was investigated in 20 human subjects .	The effect of isoflurane - induced disease* hypotension *disease on glomerular function and renal blood flow was investigated in 20 human subjects .
Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were measured by inulin and para - aminohippurate ( PAH ) clearance , respectively .	Glomerular filtration rate ( GFR ) and effective renal plasma flow ( ERPF ) were measured by inulin and para - aminohippurate ( PAH ) clearance , respectively .
Anesthesia was maintained with fentanyl , nitrous oxide , oxygen , and isoflurane .	Anesthesia was maintained with fentanyl , nitrous oxide , oxygen , and isoflurane .
Hypotension was induced for 236 . 9 + / - 15 . 1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .	disease* Hypotension *disease was induced for 236 . 9 + / - 15 . 1 min by increasing the isoflurane inspired concentration to maintain a mean arterial pressure of 59 . 8 + / - 0 . 4 mmHg .
GFR and ERPF decreased with the induction of anesthesia but not significantly more during hypotension .	GFR and ERPF decreased with the induction of anesthesia but not significantly more during disease* hypotension *disease .
Postoperatively , ERPF returned to preoperative values , whereas GFR was higher than preoperative values .	Postoperatively , ERPF returned to preoperative values , whereas GFR was higher than preoperative values .
Renal vascular resistance increased during anesthesia but decreased when hypotension was induced , allowing the maintenance of renal blood flow .	Renal vascular resistance increased during anesthesia but decreased when disease* hypotension *disease was induced , allowing the maintenance of renal blood flow .
We conclude that renal compensatory mechanisms are preserved during isoflurane - induced hypotension and that renal function and hemodynamics quickly return to normal when normotension is resumed .	We conclude that renal compensatory mechanisms are preserved during isoflurane - induced disease* hypotension *disease and that renal function and hemodynamics quickly return to normal when normotension is resumed .
Brainstem dysgenesis in an infant prenatally exposed to cocaine .	disease* Brainstem dysgenesis *disease in an infant prenatally exposed to cocaine .
Many authors described the effects on the fetus of maternal cocaine abuse during pregnancy .	Many authors described the effects on the fetus of maternal disease* cocaine abuse *disease during pregnancy .
Vasoconstriction appears to be the common mechanism of action leading to a wide range of fetal anomalies .	Vasoconstriction appears to be the common mechanism of action leading to a wide range of disease* fetal anomalies *disease .
We report on an infant with multiple cranial - nerve involvement attributable to brainstem dysgenesis , born to a cocaine - addicted mother .	We report on an infant with disease* multiple cranial - nerve involvement *disease attributable to disease* brainstem dysgenesis *disease , born to a disease* cocaine - addicted *disease mother .
A cross - sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys .	A cross - sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys .
OBJECTIVE : The aim of the present study was to investigate the effect of risperidone - induced hyperprolactinemia on trabecular bone mineral density ( BMD ) in children and adolescents .	OBJECTIVE : The aim of the present study was to investigate the effect of risperidone - induced disease* hyperprolactinemia *disease on trabecular bone mineral density ( BMD ) in children and adolescents .
METHOD : Medically healthy 7 - to 17 - year - old males chronically treated , in a naturalistic setting , with risperidone were recruited for this cross - sectional study through child psychiatry outpatient clinics between November 2005 and June 2007 .	METHOD : Medically healthy 7 - to 17 - year - old males chronically treated , in a naturalistic setting , with risperidone were recruited for this cross - sectional study through child psychiatry outpatient clinics between November 2005 and June 2007 .
Anthropometric measurements and laboratory testing were conducted .	Anthropometric measurements and laboratory testing were conducted .
The clinical diagnoses were based on chart review , and developmental and treatment history was obtained from the medical record .	The clinical diagnoses were based on chart review , and developmental and treatment history was obtained from the medical record .
Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography , and areal BMD of the lumbar spine was estimated using dual - energy x - ray absorptiometry .	Volumetric BMD of the ultradistal radius was measured using peripheral quantitative computed tomography , and areal BMD of the lumbar spine was estimated using dual - energy x - ray absorptiometry .
RESULTS : Hyperprolactinemia was present in 49 % of 83 boys ( n = 41 ) treated with risperidone for a mean of 2 . 9 years .	RESULTS : disease* Hyperprolactinemia *disease was present in 49 % of 83 boys ( n = 41 ) treated with risperidone for a mean of 2 . 9 years .
Serum testosterone concentration increased with pubertal status but was not affected by hyperprolactinemia .	Serum testosterone concentration increased with pubertal status but was not affected by disease* hyperprolactinemia *disease .
As expected , bone mineral content and BMD increased with sexual maturity .	As expected , bone mineral content and BMD increased with sexual maturity .
After adjusting for the stage of sexual development and height and BMI z scores , serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius ( P < . 03 ) .	After adjusting for the stage of sexual development and height and BMI z scores , serum prolactin was negatively associated with trabecular volumetric BMD at the ultradistal radius ( P < . 03 ) .
Controlling for relevant covariates , we also found treatment with selective serotonin reuptake inhibitors ( SSRIs ) to be associated with lower trabecular BMD at the radius ( P = . 03 ) and BMD z score at the lumbar spine ( P < . 05 ) .	Controlling for relevant covariates , we also found treatment with selective serotonin reuptake inhibitors ( SSRIs ) to be associated with lower trabecular BMD at the radius ( P = . 03 ) and BMD z score at the lumbar spine ( P < . 05 ) .
These findings became more marked when the analysis was restricted to non - Hispanic white patients .	These findings became more marked when the analysis was restricted to non - Hispanic white patients .
Of 13 documented fractures , 3 occurred after risperidone and SSRIs were started , and none occurred in patients with hyperprolactinemia .	Of 13 documented disease* fractures *disease , 3 occurred after risperidone and SSRIs were started , and none occurred in patients with disease* hyperprolactinemia *disease .
CONCLUSIONS : This is the first study to link risperidone - induced hyperprolactinemia and SSRI treatment to lower BMD in children and adolescents .	CONCLUSIONS : This is the first study to link risperidone - induced disease* hyperprolactinemia *disease and SSRI treatment to lower BMD in children and adolescents .
Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues .	Future research should evaluate the longitudinal course of this adverse event to determine its temporal stability and whether a higher fracture rate ensues .
Fear - potentiated startle , but not light - enhanced startle , is enhanced by anxiogenic drugs .	Fear - potentiated disease* startle *disease , but not light - enhanced disease* startle *disease , is enhanced by anxiogenic drugs .
RATIONALE AND OBJECTIVES : The light - enhanced startle paradigm ( LES ) is suggested to model anxiety , because of the non - specific cue and the long - term effect .	RATIONALE AND OBJECTIVES : The light - enhanced disease* startle *disease paradigm ( LES ) is suggested to model disease* anxiety *disease , because of the non - specific cue and the long - term effect .
In contrast , the fear - potentiated startle ( FPS ) is suggested to model conditioned fear .	In contrast , the fear - potentiated disease* startle *disease ( FPS ) is suggested to model conditioned fear .
However , the pharmacological profiles of these two paradigms are very similar .	However , the pharmacological profiles of these two paradigms are very similar .
The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms .	The present study investigated the effects of putative anxiogenic drugs on LES and FPS and aimed at determining the sensitivity of LES for anxiogenic drugs and to potentially showing a pharmacological differentiation between these two paradigms .
METHODS : Male Wistar rats received each dose of the alpha ( 2 ) - adrenoceptor antagonist yohimbine ( 0 . 25 - 1 . 0mg / kg ) , the 5 - HT ( 2C ) receptor agonist m - chlorophenylpiperazine ( mCPP , 0 . 5 - 2 . 0mg / kg ) or the GABA ( A ) inverse receptor agonist pentylenetetrazole ( PTZ , 3 - 30mg / kg ) and were subsequently tested in either LES or FPS .	METHODS : Male Wistar rats received each dose of the alpha ( 2 ) - adrenoceptor antagonist yohimbine ( 0 . 25 - 1 . 0mg / kg ) , the 5 - HT ( 2C ) receptor agonist m - chlorophenylpiperazine ( mCPP , 0 . 5 - 2 . 0mg / kg ) or the GABA ( A ) inverse receptor agonist pentylenetetrazole ( PTZ , 3 - 30mg / kg ) and were subsequently tested in either LES or FPS .
RESULTS : None of the drugs enhanced LES , whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values .	RESULTS : None of the drugs enhanced LES , whereas mCPP increased percentage FPS and yohimbine increased absolute FPS values .
Furthermore , yohimbine increased baseline startle amplitude in the LES , while mCPP suppressed baseline startle in both the LES and FPS and PTZ suppressed baseline startle in the FPS .	Furthermore , yohimbine increased baseline disease* startle *disease amplitude in the LES , while mCPP suppressed baseline disease* startle *disease in both the LES and FPS and PTZ suppressed baseline disease* startle *disease in the FPS .
CONCLUSIONS : In contrast to findings in the FPS paradigm , none of the drugs were able to exacerbate the LES response .	CONCLUSIONS : In contrast to findings in the FPS paradigm , none of the drugs were able to exacerbate the LES response .
Thus , a clear pharmacological differentiation was found between LES and FPS .	Thus , a clear pharmacological differentiation was found between LES and FPS .
Rosaceiform dermatitis associated with topical tacrolimus treatment .	Rosaceiform disease* dermatitis *disease associated with topical tacrolimus treatment .
We describe herein 3 patients who developed rosacea - like dermatitis eruptions while using 0 . 03 % or 0 . 1 % tacrolimus ointment for facial dermatitis .	We describe herein 3 patients who developed disease* rosacea *disease - like disease* dermatitis disease* eruptions *disease while using 0 . 03 % or 0 . 1 % tacrolimus ointment for disease* facial dermatitis *disease .
Skin biopsy specimens showed telangiectasia and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis .	Skin biopsy specimens showed disease* telangiectasia *disease and noncaseating epithelioid granulomatous tissue formation in the papillary to mid dermis .
Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform dermatitis , although many cases have not been reported .	Continuous topical use of immunomodulators such as tacrolimus or pimecrolimus should be regarded as a potential cause of rosaceiform disease* dermatitis *disease , although many cases have not been reported .
Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice .	Coenzyme Q10 treatment ameliorates acute cisplatin disease* nephrotoxicity *disease in mice .
The nephroprotective effect of coenzyme Q10 was investigated in mice with acute renal injury induced by a single i . p . injection of cisplatin ( 5 mg / kg ) .	The nephroprotective effect of coenzyme Q10 was investigated in mice with disease* acute renal injury *disease induced by a single i . p . injection of cisplatin ( 5 mg / kg ) .
Coenzyme Q10 treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before cisplatin administration .	Coenzyme Q10 treatment ( 10 mg / kg / day , i . p . ) was applied for 6 consecutive days , starting 1 day before cisplatin administration .
Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin .	Coenzyme Q10 significantly reduced blood urea nitrogen and serum creatinine levels which were increased by cisplatin .
Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of tumor necrosis factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .	Coenzyme Q10 significantly compensated deficits in the antioxidant defense mechanisms ( reduced glutathione level and superoxide dismutase activity ) , suppressed lipid peroxidation , decreased the elevations of disease* tumor disease* necrosis *disease factor - alpha , nitric oxide and platinum ion concentration , and attenuated the reductions of selenium and zinc ions in renal tissue resulted from cisplatin administration .
Also , histopathological renal tissue damage mediated by cisplatin was ameliorated by coenzyme Q10 treatment .	Also , histopathological disease* renal tissue damage *disease mediated by cisplatin was ameliorated by coenzyme Q10 treatment .
Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin - induced overexpression of inducible nitric oxide synthase , nuclear factor - kappaB , caspase - 3 and p53 in renal tissue .	Immunohistochemical analysis revealed that coenzyme Q10 significantly decreased the cisplatin - induced overexpression of inducible nitric oxide synthase , nuclear factor - kappaB , caspase - 3 and p53 in renal tissue .
It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin nephrotoxicity commonly encountered in clinical practice .	It was concluded that coenzyme Q10 represents a potential therapeutic option to protect against acute cisplatin disease* nephrotoxicity *disease commonly encountered in clinical practice .
Reversible cholestasis with bile duct injury following azathioprine therapy .	Reversible disease* cholestasis *disease with disease* bile duct injury *disease following azathioprine therapy .
A case report .	A case report .
A 67 - year - old patient , with primary polymyositis and without previous evidence of liver disease , developed clinical and biochemical features of severe cholestasis 3 months after initiation of azathioprine therapy .	A 67 - year - old patient , with primary disease* polymyositis *disease and without previous evidence of disease* liver disease *disease , developed clinical and biochemical features of severe disease* cholestasis *disease 3 months after initiation of azathioprine therapy .
Liver biopsy showed cholestasis with both cytological and architectural alterations of interlobular bile ducts .	Liver biopsy showed disease* cholestasis *disease with both cytological and architectural alterations of interlobular bile ducts .
Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities .	Azathioprine withdrawal resulted after 7 weeks in the resolution of clinical and biochemical abnormalities .
It is believed that this is the first reported case of reversible azathioprine - induced cholestasis associated with histological evidence of bile duct injury .	It is believed that this is the first reported case of reversible azathioprine - induced disease* cholestasis *disease associated with histological evidence of disease* bile duct injury *disease .
Dopamine is not essential for the development of methamphetamine - induced neurotoxicity .	Dopamine is not essential for the development of methamphetamine - induced disease* neurotoxicity *disease .
It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced toxicity to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease toxicity , whereas drugs that increase DA neurotransmission enhance toxicity .	It is widely believed that dopamine ( DA ) mediates methamphetamine ( METH ) - induced disease* toxicity *disease to brain dopaminergic neurons , because drugs that interfere with DA neurotransmission decrease disease* toxicity *disease , whereas drugs that increase DA neurotransmission enhance disease* toxicity *disease .
However , temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data .	However , temperature effects of drugs that have been used to manipulate brain DA neurotransmission confound interpretation of the data .
Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA neurotoxicity is also confounded by drug effects on body temperature .	Here we show that the recently reported ability of L - dihydroxyphenylalanine to reverse the protective effect of alpha - methyl - para - tyrosine on METH - induced DA disease* neurotoxicity *disease is also confounded by drug effects on body temperature .
Further , we show that mice genetically engineered to be deficient in brain DA develop METH neurotoxicity , as long as the thermic effects of METH are preserved .	Further , we show that mice genetically engineered to be deficient in brain DA develop METH disease* neurotoxicity *disease , as long as the thermic effects of METH are preserved .
In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH - induced dopaminergic deficits that are of comparable magnitude on both sides of the brain .	In addition , we demonstrate that mice genetically engineered to have unilateral brain DA deficits develop METH - induced disease* dopaminergic deficits *disease that are of comparable magnitude on both sides of the brain .
Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic neurotoxicity and suggest that mechanisms independent of DA warrant more intense investigation .	Taken together , these findings demonstrate that DA is not essential for the development of METH - induced dopaminergic disease* neurotoxicity *disease and suggest that mechanisms independent of DA warrant more intense investigation .
Swallowing - induced atrial tachyarrhythmia triggered by salbutamol : case report and review of the literature .	Swallowing - induced disease* atrial tachyarrhythmia *disease triggered by salbutamol : case report and review of the literature .
CASE : A 49 - year - old patient experienced chest discomfort while swallowing .	CASE : A 49 - year - old patient experienced chest discomfort while swallowing .
On electrocardiogram , episodes of atrial tachyarrhythmia were recorded immediately after swallowing ; 24 - hour Holter monitoring recorded several events .	On electrocardiogram , episodes of disease* atrial tachyarrhythmia *disease were recorded immediately after swallowing ; 24 - hour Holter monitoring recorded several events .
The arrhythmia resolved after therapy with atenolol , but recurred a year later .	The disease* arrhythmia *disease resolved after therapy with atenolol , but recurred a year later .
The patient noticed that before these episodes he had been using an inhalator of salbutamol .	The patient noticed that before these episodes he had been using an inhalator of salbutamol .
After stopping the beta - agonist , and after a week with the atenolol , the arrhythmia disappeared .	After stopping the beta - agonist , and after a week with the atenolol , the disease* arrhythmia *disease disappeared .
DISCUSSION : Swallowing - induced atrial tachyarrhythmia ( SIAT ) is a rare phenomenon .	DISCUSSION : Swallowing - induced disease* atrial tachyarrhythmia *disease ( disease* SIAT *disease ) is a rare phenomenon .
Fewer than 50 cases of SIAT have been described in the literature .	Fewer than 50 cases of disease* SIAT *disease have been described in the literature .
This article summarizes all the cases published , creating a comprehensive review of the current knowledge and approach to SIAT .	This article summarizes all the cases published , creating a comprehensive review of the current knowledge and approach to disease* SIAT *disease .
It discusses demographics , clinical characteristics and types of arrhythmia , postulated mechanisms of SIAT , and different treatment possibilities such as medications , surgery , and radiofrequency catheter ablation ( RFCA ) .	It discusses demographics , clinical characteristics and types of disease* arrhythmia *disease , postulated mechanisms of disease* SIAT *disease , and different treatment possibilities such as medications , surgery , and radiofrequency catheter ablation ( RFCA ) .
CONCLUSION : Salbutamol is presented here as a possible trigger for SIAT .	CONCLUSION : Salbutamol is presented here as a possible trigger for disease* SIAT *disease .
Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce tachycardia ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .	Although it is difficult to define causality in a case report , it is logical to think that a beta - agonist like salbutamol ( known to induce disease* tachycardia *disease ) may be the trigger of adrenergic reflexes originating in the esophagus while swallowing and that a beta - blocker such as atenolol ( that blocks the adrenergic activity ) may relieve it .
The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced diabetes mellitus .	The ability of insulin treatment to reverse or prevent the changes in urinary bladder function caused by streptozotocin - induced disease* diabetes mellitus *disease .
1 .	1 .
The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin - diabetic rats were investigated .	The effects of insulin treatment on in vivo and in vitro urinary bladder function in streptozotocin - disease* diabetic *disease rats were investigated .
2 .	2 .
Diabetes of 2 months duration resulted in decreases in body weight and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition ; effects which were prevented by insulin treatment .	disease* Diabetes *disease of 2 months duration resulted in decreases in body weight and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition ; effects which were prevented by insulin treatment .
3 .	3 .
Insulin treatment also prevented the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .	Insulin treatment also prevented the increases in contractile responses of bladder body strips from disease* diabetic *disease rats to nerve stimulation , ATP , and bethanechol .
4 .	4 .
Diabetes of 4 months duration also resulted in decreases in body weight , and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition , effects which were reversed by insulin treatment for the final 2 months of the study .	disease* Diabetes *disease of 4 months duration also resulted in decreases in body weight , and increases in fluid consumption , urine volume , frequency of micturition , and average volume per micturition , effects which were reversed by insulin treatment for the final 2 months of the study .
5 .	5 .
Insulin treatment reversed the increases in contractile responses of bladder body strips from diabetic rats to nerve stimulation , ATP , and bethanechol .	Insulin treatment reversed the increases in contractile responses of bladder body strips from disease* diabetic *disease rats to nerve stimulation , ATP , and bethanechol .
6 .	6 .
The data indicate that the effects of streptozotocin - induced diabetes on urinary bladder function are both prevented and reversed by insulin treatment .	The data indicate that the effects of streptozotocin - induced disease* diabetes *disease on urinary bladder function are both prevented and reversed by insulin treatment .
Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol - induced catalepsy .	Glutamatergic neurotransmission mediated by NMDA receptors in the inferior colliculus can modulate haloperidol - induced disease* catalepsy *disease .
The inferior colliculus ( IC ) is primarily involved in the processing of auditory information , but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system .	The inferior colliculus ( IC ) is primarily involved in the processing of auditory information , but it is distinguished from other auditory nuclei in the brainstem by its connections with structures of the motor system .
Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing , escape - like behavior , and immobility .	Functional evidence relating the IC to motor behavior derives from experiments showing that activation of the IC by electrical stimulation or excitatory amino acid microinjection causes freezing , escape - like behavior , and immobility .
However , the nature of this immobility is still unclear .	However , the nature of this immobility is still unclear .
The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the catalepsy induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .	The present study examined the influence of excitatory amino acid - mediated mechanisms in the IC on the disease* catalepsy *disease induced by the dopamine receptor blocker haloperidol administered systemically ( 1 or 0 . 5 mg / kg ) in rats .
Haloperidol - induced catalepsy was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .	Haloperidol - induced disease* catalepsy *disease was challenged with prior intracollicular microinjections of glutamate NMDA receptor antagonists , MK - 801 ( 15 or 30 mmol / 0 . 5 microl ) and AP7 ( 10 or 20 nmol / 0 . 5 microl ) , or of the NMDA receptor agonist N - methyl - d - aspartate ( NMDA , 20 or 30 nmol / 0 . 5 microl ) .
The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of haloperidol significantly attenuated the catalepsy , as indicated by a reduced latency to step down from a horizontal bar .	The results showed that intracollicular microinjection of MK - 801 and AP7 previous to systemic injections of haloperidol significantly attenuated the disease* catalepsy *disease , as indicated by a reduced latency to step down from a horizontal bar .
Accordingly , intracollicular microinjection of NMDA increased the latency to step down the bar .	Accordingly , intracollicular microinjection of NMDA increased the latency to step down the bar .
These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced catalepsy and participate in the regulation of motor activity .	These findings suggest that glutamate - mediated mechanisms in the neural circuits at the IC level influence haloperidol - induced disease* catalepsy *disease and participate in the regulation of motor activity .
Severe congestive heart failure patient on amiodarone presenting with myxedemic coma : a case report .	Severe disease* congestive heart failure *disease patient on amiodarone presenting with disease* myxedemic coma *disease : a case report .
This is a case report of myxedema coma secondary to amiodarone - induced hypothyroidism in a patient with severe congestive heart failure ( CHF ) .	This is a case report of disease* myxedema coma *disease secondary to amiodarone - induced disease* hypothyroidism *disease in a patient with severe disease* congestive heart failure *disease ( disease* CHF *disease ) .
To our knowledge and after reviewing the literature there is one case report of myxedema coma during long term amiodarone therapy .	To our knowledge and after reviewing the literature there is one case report of disease* myxedema coma *disease during long term amiodarone therapy .
Myxedema coma is a life threatening condition that carries a mortality reaching as high as 20 % with treatment .	disease* Myxedema coma *disease is a life threatening condition that carries a mortality reaching as high as 20 % with treatment .
The condition is treated with intravenous thyroxine ( T4 ) or intravenous tri - iodo - thyronine ( T3 ) .	The condition is treated with intravenous thyroxine ( T4 ) or intravenous tri - iodo - thyronine ( T3 ) .
Patients with CHF on amiodarone may suffer serious morbidity and mortality from hypothyroidism , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .	Patients with disease* CHF *disease on amiodarone may suffer serious morbidity and mortality from disease* hypothyroidism *disease , and thus may deserve closer follow up for thyroid stimulating hormone ( TSH ) levels .
This case report carries an important clinical application given the frequent usage of amiodarone among CHF patients .	This case report carries an important clinical application given the frequent usage of amiodarone among disease* CHF *disease patients .
The myriad clinical presentation of myxedema coma and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among CHF patients presenting with hypotension , weakness or other unexplained symptoms .	The myriad clinical presentation of disease* myxedema coma *disease and its serious morbidity and mortality stresses the need to suspect this clinical syndrome among disease* CHF *disease patients presenting with disease* hypotension *disease , disease* weakness *disease or other unexplained symptoms .
Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic Alzheimer ' s disease in male rats .	Effects of active constituents of Crocus sativus L . , crocin on streptozocin - induced model of sporadic disease* Alzheimer ' s disease *disease in male rats .
BACKGROUND : The involvement of water - soluble carotenoids , crocins , as the main and active components of Crocus sativus L . extract in learning and memory processes has been proposed .	BACKGROUND : The involvement of water - soluble carotenoids , crocins , as the main and active components of Crocus sativus L . extract in learning and memory processes has been proposed .
In the present study , the effect of crocins on sporadic Alzheimer ' s disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .	In the present study , the effect of crocins on sporadic disease* Alzheimer ' s disease *disease induced by intracerebroventricular ( icv ) streptozocin ( STZ ) in male rats was investigated .
METHODS : Male adult Wistar rats ( n = 90 and 260 - 290 g ) were divided into 1 , control ; 2 and 3 , crocins ( 15 and 30 mg / kg ) ; 4 , STZ ; 5 and 6 , STZ + crocins ( 15 and 30 mg / kg ) groups .	METHODS : Male adult Wistar rats ( n = 90 and 260 - 290 g ) were divided into 1 , control ; 2 and 3 , crocins ( 15 and 30 mg / kg ) ; 4 , STZ ; 5 and 6 , STZ + crocins ( 15 and 30 mg / kg ) groups .
In Alzheimer ' s disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .	In disease* Alzheimer ' s disease *disease groups , rats were injected with STZ - icv bilaterally ( 3 mg / kg ) in first day and 3 days later , a similar STZ - icv application was repeated .
In STZ + crocin animal groups , crocin was applied in doses of 15 and 30 mg / kg , i . p . , one day pre - surgery and continued for three weeks .	In STZ + crocin animal groups , crocin was applied in doses of 15 and 30 mg / kg , i . p . , one day pre - surgery and continued for three weeks .
Prescription of crocin in each dose was repeated once for two days .	Prescription of crocin in each dose was repeated once for two days .
However , the learning and memory performance was assessed using passive avoidance paradigm , and for spatial cognition evaluation , Y - maze task was used .	However , the learning and memory performance was assessed using passive avoidance paradigm , and for spatial cognition evaluation , Y - maze task was used .
RESULTS : It was found out that crocin ( 30 mg / kg ) - treated STZ - injected rats show higher correct choices and lower errors in Y - maze than vehicle - treated STZ - injected rats .	RESULTS : It was found out that crocin ( 30 mg / kg ) - treated STZ - injected rats show higher correct choices and lower errors in Y - maze than vehicle - treated STZ - injected rats .
In addition , crocin in the mentioned dose could significantly attenuated learning and memory impairment in treated STZ - injected group in passive avoidance test .	In addition , crocin in the mentioned dose could significantly attenuated disease* learning and memory impairment *disease in treated STZ - injected group in passive avoidance test .
CONCLUSION : Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the cognitive deficits caused by STZ - icv in rats and its potential in the treatment of neurodegenerative diseases such as Alzheimer ' s disease .	CONCLUSION : Therefore , these results demonstrate the effectiveness of crocin ( 30 mg / kg ) in antagonizing the disease* cognitive deficits *disease caused by STZ - icv in rats and its potential in the treatment of disease* neurodegenerative diseases *disease such as disease* Alzheimer ' s disease *disease .
Serotonin 6 receptor gene is associated with methamphetamine - induced psychosis in a Japanese population .	Serotonin 6 receptor gene is associated with methamphetamine - induced disease* psychosis *disease in a Japanese population .
BACKGROUND : Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia .	BACKGROUND : Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for disease* psychotic disorders *disease such as disease* schizophrenia *disease .
The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced hyperactivity in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .	The serotonin 6 ( 5 - HT6 ) receptor is therapeutically targeted by several second generation antipsychotics , such as clozapine and olanzapine , and d - amphetamine - induced disease* hyperactivity *disease in rats is corrected with the use of a selective 5 - HT6 receptor antagonist .
In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .	In addition , the disrupted prepulse inhibition induced by d - amphetamine or phencyclidine was restored by 5 - HT6 receptor antagonist in an animal study using rats .
These animal models were considered to reflect the positive symptoms of schizophrenia , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of psychotic disorders .	These animal models were considered to reflect the positive symptoms of disease* schizophrenia *disease , and the above evidence suggests that altered 5 - HT6 receptors are involved in the pathophysiology of disease* psychotic disorders *disease .
The symptoms of methamphetamine ( METH ) - induced psychosis are similar to those of paranoid type schizophrenia .	The symptoms of methamphetamine ( METH ) - induced disease* psychosis *disease are similar to those of disease* paranoid type schizophrenia *disease .
Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced psychosis .	Therefore , we conducted an analysis of the association of the 5 - HT6 gene ( HTR6 ) with METH - induced disease* psychosis *disease .
METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced psychosis patients and 337 controls ) in the Japanese population .	METHOD : Using five tagging SNPs ( rs6693503 , rs1805054 , rs4912138 , rs3790757 and rs9659997 ) , we conducted a genetic association analysis of case - control samples ( 197 METH - induced disease* psychosis *disease patients and 337 controls ) in the Japanese population .
The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .	The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients .
RESULTS : rs6693503 was associated with METH - induced psychosis patients in the allele / genotype - wise analysis .	RESULTS : rs6693503 was associated with METH - induced disease* psychosis *disease patients in the allele / genotype - wise analysis .
Moreover , this association remained significant after Bonferroni correction .	Moreover , this association remained significant after Bonferroni correction .
In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced psychosis patients , respectively .	In the haplotype - wise analysis , we detected an association between two markers ( rs6693503 and rs1805054 ) and three markers ( rs6693503 , rs1805054 and rs4912138 ) in HTR6 and METH - induced disease* psychosis *disease patients , respectively .
CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced psychosis in the Japanese population .	CONCLUSION : HTR6 may play an important role in the pathophysiology of METH - induced disease* psychosis *disease in the Japanese population .
Neural correlates of S - ketamine induced psychosis during overt continuous verbal fluency .	Neural correlates of S - ketamine induced disease* psychosis *disease during overt continuous verbal fluency .
The glutamatergic N - methyl - D - aspartate ( NMDA ) receptor has been implicated in the pathophysiology of schizophrenia .	The glutamatergic N - methyl - D - aspartate ( NMDA ) receptor has been implicated in the pathophysiology of disease* schizophrenia *disease .
Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in schizophrenia .	Administered to healthy volunteers , a subanesthetic dose of the non - competitive NMDA receptor antagonist ketamine leads to psychopathological symptoms similar to those observed in disease* schizophrenia *disease .
In patients with schizophrenia , ketamine exacerbates the core symptoms of illness , supporting the hypothesis of a glutamatergic dysfunction .	In patients with disease* schizophrenia *disease , ketamine exacerbates the core symptoms of illness , supporting the hypothesis of a disease* glutamatergic dysfunction *disease .
In a counterbalanced , placebo - controlled , double - blind study design , healthy subjects were administered a continuous subanesthetic S - ketamine infusion while differences in BOLD responses measured with fMRI were detected .	In a counterbalanced , placebo - controlled , double - blind study design , healthy subjects were administered a continuous subanesthetic S - ketamine infusion while differences in BOLD responses measured with fMRI were detected .
During the scanning period , subjects performed continuous overt verbal fluency tasks ( phonological , lexical and semantic ) .	During the scanning period , subjects performed continuous overt verbal fluency tasks ( phonological , lexical and semantic ) .
Ketamine - induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale ( PANSS ) .	Ketamine - induced psychopathological symptoms were assessed with the Positive and Negative Syndrome Scale ( PANSS ) .
Ketamine elicited psychosis like psychopathology .	Ketamine elicited disease* psychosis *disease like psychopathology .
Post - hoc t - tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency , while the phonological domain remained unaffected .	Post - hoc t - tests revealed significant differences between placebo and ketamine for the amounts of words generated during lexical and semantic verbal fluency , while the phonological domain remained unaffected .
Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency , but not for semantic verbal fluency .	Ketamine led to enhanced cortical activations in supramarginal and frontal brain regions for phonological and lexical verbal fluency , but not for semantic verbal fluency .
Ketamine induces activation changes in healthy subjects similar to those observed in patients with schizophrenia , particularly in frontal and temporal brain regions .	Ketamine induces activation changes in healthy subjects similar to those observed in patients with disease* schizophrenia *disease , particularly in frontal and temporal brain regions .
Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of schizophrenia .	Our results provide further support for the hypothesis of an NMDA receptor dysfunction in the pathophysiology of disease* schizophrenia *disease .
Long - term prognosis for transplant - free survivors of paracetamol - induced acute liver failure .	Long - term prognosis for transplant - free survivors of paracetamol - induced disease* acute liver failure *disease .
BACKGROUND : The prognosis for transplant - free survivors of paracetamol - induced acute liver failure remains unknown .	BACKGROUND : The prognosis for transplant - free survivors of paracetamol - induced disease* acute liver failure *disease remains unknown .
AIM : To examine whether paracetamol - induced acute liver failure increases long - term mortality .	AIM : To examine whether paracetamol - induced disease* acute liver failure *disease increases long - term mortality .
METHODS : We followed up all transplant - free survivors of paracetamol - induced acute liver injury , hospitalized in a Danish national referral centre during 1984 - 2004 .	METHODS : We followed up all transplant - free survivors of paracetamol - induced disease* acute liver injury *disease , hospitalized in a Danish national referral centre during 1984 - 2004 .
We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the liver injury led to an acute liver failure and those in whom it did not .	We compared age - specific mortality rates from 1 year post - discharge through 2008 between those in whom the disease* liver injury *disease led to an disease* acute liver failure *disease and those in whom it did not .
RESULTS : We included 641 patients .	RESULTS : We included 641 patients .
On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced liver injury had caused an acute liver failure ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of acute liver failure died of liver disease , whereas suicides were frequent in both groups .	On average , age - specific mortality rates were slightly higher for the 101 patients whose paracetamol - induced disease* liver injury *disease had caused an disease* acute liver failure *disease ( adjusted mortality rate ratio = 1 . 70 , 95 % CI 1 . 02 - 2 . 85 ) , but the association was age - dependent , and no survivors of disease* acute liver failure *disease died of disease* liver disease *disease , whereas suicides were frequent in both groups .
These observations speak against long - term effects of acute liver failure .	These observations speak against long - term effects of disease* acute liver failure *disease .
More likely , the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of substance abuse among survivors of acute liver failure .	More likely , the elevated mortality rate ratio resulted from incomplete adjustment for the greater prevalence of disease* substance abuse *disease among survivors of disease* acute liver failure *disease .
CONCLUSIONS : Paracetamol - induced acute liver failure did not affect long - term mortality .	CONCLUSIONS : Paracetamol - induced disease* acute liver failure *disease did not affect long - term mortality .
Clinical follow - up may be justified by the cause of the liver failure , but not by the liver failure itself .	Clinical follow - up may be justified by the cause of the disease* liver failure *disease , but not by the disease* liver failure *disease itself .
In vivo characterization of a dual adenosine A2A / A1 receptor antagonist in animal models of Parkinson ' s disease .	In vivo characterization of a dual adenosine A2A / A1 receptor antagonist in animal models of disease* Parkinson ' s disease *disease .
The in vivo characterization of a dual adenosine A ( 2A ) / A ( 1 ) receptor antagonist in several animal models of Parkinson ' s disease is described .	The in vivo characterization of a dual adenosine A ( 2A ) / A ( 1 ) receptor antagonist in several animal models of disease* Parkinson ' s disease *disease is described .
Discovery and scale - up syntheses of compound 1 are described in detail , highlighting optimization steps that increased the overall yield of 1 from 10 . 0 % to 30 . 5 % .	Discovery and scale - up syntheses of compound 1 are described in detail , highlighting optimization steps that increased the overall yield of 1 from 10 . 0 % to 30 . 5 % .
Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of Parkinson ' s disease including mouse and rat models of haloperidol - induced catalepsy , mouse model of reserpine - induced akinesia , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .	Compound 1 is a potent A ( 2A ) / A ( 1 ) receptor antagonist in vitro ( A ( 2A ) K ( i ) = 4 . 1 nM ; A ( 1 ) K ( i ) = 17 . 0 nM ) that has excellent activity , after oral administration , across a number of animal models of disease* Parkinson ' s disease *disease including mouse and rat models of haloperidol - induced disease* catalepsy *disease , mouse model of reserpine - induced disease* akinesia *disease , rat 6 - hydroxydopamine ( 6 - OHDA ) lesion model of drug - induced rotation , and MPTP - treated non - human primate model .
Effects of the hippocampal deep brain stimulation on cortical epileptic discharges in penicillin - induced epilepsy model in rats .	Effects of the hippocampal deep brain stimulation on cortical disease* epileptic *disease discharges in penicillin - induced disease* epilepsy *disease model in rats .
AIM : Experimental and clinical studies have revealed that hippocampal DBS can control epileptic activity , but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined .	AIM : Experimental and clinical studies have revealed that hippocampal DBS can control disease* epileptic *disease activity , but the mechanism of action is obscure and optimal stimulation parameters are not clearly defined .
The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical epileptic activity in penicillin - induced epilepsy model .	The aim was to evaluate the effects of high frequency hippocampal stimulation on cortical disease* epileptic *disease activity in penicillin - induced disease* epilepsy *disease model .
MATERIAL AND METHODS : Twenty - five Sprague - Dawley rats were implanted DBS electrodes .	MATERIAL AND METHODS : Twenty - five Sprague - Dawley rats were implanted DBS electrodes .
In group - 1 ( n = 10 ) hippocampal DBS was off and in the group - 2 ( n = 10 ) hippocampal DBS was on ( 185 Hz , 0 . 5V , 1V , 2V , and 5V for 60 sec ) following penicillin G injection intracortically .	In group - 1 ( n = 10 ) hippocampal DBS was off and in the group - 2 ( n = 10 ) hippocampal DBS was on ( 185 Hz , 0 . 5V , 1V , 2V , and 5V for 60 sec ) following penicillin G injection intracortically .
In the control group hippocampal DBS was on following 8 l saline injection intracortically .	In the control group hippocampal DBS was on following 8 l saline injection intracortically .
EEG recordings were obtained before and 15 minutes following penicillin - G injection , and at 10th minutes following each stimulus for analysis in terms of frequency , amplitude , and power spectrum .	EEG recordings were obtained before and 15 minutes following penicillin - G injection , and at 10th minutes following each stimulus for analysis in terms of frequency , amplitude , and power spectrum .
RESULTS : High frequency hippocampal DBS suppressed the acute penicillin - induced cortical epileptic activity independent from stimulus intensity .	RESULTS : High frequency hippocampal DBS suppressed the acute penicillin - induced cortical disease* epileptic *disease activity independent from stimulus intensity .
In the control group , hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation .	In the control group , hippocampal stimulation alone lead only to diffuse slowing of cerebral bioelectrical activity at 5V stimulation .
CONCLUSION : Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical epileptic activity effectively without causing secondary epileptic discharges .	CONCLUSION : Our results revealed that continuous high frequency stimulation of the hippocampus suppressed acute cortical disease* epileptic *disease activity effectively without causing secondary disease* epileptic *disease discharges .
These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with epilepsy .	These results are important in terms of defining the optimal parameters of hippocampal DBS in patients with disease* epilepsy *disease .
CCNU ( lomustine ) toxicity in dogs : a retrospective study ( 2002 - 07 ) .	CCNU ( lomustine ) disease* toxicity *disease in dogs : a retrospective study ( 2002 - 07 ) .
OBJECTIVE : To describe the incidence of haematological , renal , hepatic and gastrointestinal toxicities in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( CCNU ) .	OBJECTIVE : To describe the incidence of disease* haematological , renal , hepatic and gastrointestinal toxicities *disease in tumour - bearing dogs receiving 1 - ( 2 - chloroethyl ) - 3 - cyclohexyl - 1 - nitrosourea ( CCNU ) .
DESIGN : The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated .	DESIGN : The medical records of 206 dogs that were treated with CCNU at the Melbourne Veterinary Specialist Centre between February 2002 and December 2007 were retrospectively evaluated .
RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of toxicity .	RESULTS : Of the 206 dogs treated with CCNU , 185 met the inclusion criteria for at least one class of disease* toxicity *disease .
CCNU was used most commonly in the treatment of lymphoma , mast cell tumour , brain tumour , histiocytic tumours and epitheliotropic lymphoma .	CCNU was used most commonly in the treatment of disease* lymphoma *disease , disease* mast cell tumour *disease , disease* brain tumour *disease , disease* histiocytic tumours *disease and disease* epitheliotropic lymphoma *disease .
Throughout treatment , 56 . 9 % of dogs experienced neutropenia , 34 . 2 % experienced anaemia and 14 . 2 % experienced thrombocytopenia .	Throughout treatment , 56 . 9 % of dogs experienced disease* neutropenia *disease , 34 . 2 % experienced disease* anaemia *disease and 14 . 2 % experienced disease* thrombocytopenia *disease .
Gastrointestinal toxicosis was detected in 37 . 8 % of dogs , the most common sign of which was vomiting ( 24 . 3 % ) .	disease* Gastrointestinal toxicosis *disease was detected in 37 . 8 % of dogs , the most common sign of which was disease* vomiting *disease ( 24 . 3 % ) .
Potential renal toxicity and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .	Potential renal disease* toxicity *disease and elevated alanine transaminase ( ALT ) concentration were reported in 12 . 2 % and 48 . 8 % of dogs , respectively .
The incidence of hepatic failure was 1 . 2 % .	The incidence of disease* hepatic failure *disease was 1 . 2 % .
CONCLUSIONS : CCNU - associated toxicity in dogs is common , but is usually not life threatening .	CONCLUSIONS : CCNU - associated disease* toxicity *disease in dogs is common , but is usually not life threatening .
Central vein thrombosis and topical dipivalyl epinephrine .	Central disease* vein thrombosis *disease and topical dipivalyl epinephrine .
A report is given on an 83 - year - old female who acquired central vein thrombosis in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced glaucoma discovered in the other eye .	A report is given on an 83 - year - old female who acquired central disease* vein thrombosis *disease in her seeing eye one day after having started topical medication with dipivalyl epinephrine for advanced disease* glaucoma *disease discovered in the other eye .
From present knowledge about the effects of adrenergic eye drops on ocular blood circulation , it is difficult to suggest an association between the two events , which may be coincidental only .	From present knowledge about the effects of adrenergic eye drops on ocular blood circulation , it is difficult to suggest an association between the two events , which may be coincidental only .
Benzylacyclouridine reverses azidothymidine - induced marrow suppression without impairment of anti - human immunodeficiency virus activity .	Benzylacyclouridine reverses azidothymidine - induced disease* marrow suppression *disease without impairment of anti - human disease* immunodeficiency *disease virus activity .
Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman immunodeficiency virus ( HIV ) activity .	Increased extracellular concentrations of uridine ( Urd ) have been reported to reduce , in vitro , azidothymidine ( AZT ) - induced inhibition of human granulocyte - macrophage progenitor cells without impairment of its antihuman disease* immunodeficiency *disease virus ( HIV ) activity .
Because of the clinical toxicities associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced anemia and leukopenia was assessed .	Because of the clinical disease* toxicities *disease associated with chronic Urd administration , the ability of benzylacyclouridine ( BAU ) to effect , in vivo , AZT - induced disease* anemia *disease and disease* leukopenia *disease was assessed .
This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related toxicity .	This agent inhibits Urd catabolism and , in vivo , increases the plasma concentration of Urd in a dose - dependent manner , without Urd - related disease* toxicity *disease .
In mice rendered anemic and leukopenic by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced anemia and leukopenia ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved megaloblastosis .	In mice rendered disease* anemic *disease and disease* leukopenic *disease by the administration of AZT for 28 days in drinking water ( 1 . 5 mg / mL ) , the continued administration of AZT plus daily BAU ( 300 mg / kg , orally ) partially reversed AZT - induced disease* anemia *disease and disease* leukopenia *disease ( P less than . 05 ) , increased peripheral reticulocytes ( to 4 . 9 % , P less than . 01 ) , increased cellularity in the marrow , and improved disease* megaloblastosis *disease .
When coadministered with AZT from the onset of drug administration , BAU reduced AZT - induced marrow toxicity .	When coadministered with AZT from the onset of drug administration , BAU reduced AZT - induced disease* marrow toxicity *disease .
In vitro , at a concentration of 100 mumol / L , BAU possesses minimal anti - HIV activity and has no effect on the ability of AZT to reverse the HIV - induced cytopathic effect in MT4 cells .	In vitro , at a concentration of 100 mumol / L , BAU possesses minimal anti - HIV activity and has no effect on the ability of AZT to reverse the HIV - induced cytopathic effect in MT4 cells .
The clinical and biochemical implications of these findings are discussed .	The clinical and biochemical implications of these findings are discussed .
Lethal anuria complicating high dose ifosfamide chemotherapy in a breast cancer patient with an impaired renal function .	Lethal disease* anuria *disease complicating high dose ifosfamide chemotherapy in a disease* breast cancer *disease patient with an disease* impaired renal function *disease .
A sixty - year - old woman with advanced breast cancer , previously treated with cisplatin , developed an irreversible lethal renal failure with anuria , the day after 5 g / m2 bolus ifosfamide .	A sixty - year - old woman with advanced disease* breast cancer *disease , previously treated with cisplatin , developed an irreversible lethal disease* renal failure *disease with disease* anuria *disease , the day after 5 g / m2 bolus ifosfamide .
Postrenal failure was excluded by echography .	disease* Postrenal failure *disease was excluded by echography .
A prerenal component could have contributed to renal failure because of a transient hypotension , due to an increasing ascitis , occurring just before anuria .	A prerenal component could have contributed to disease* renal failure *disease because of a transient disease* hypotension *disease , due to an increasing ascitis , occurring just before disease* anuria *disease .
However , correction of the hemodynamic parameters did not improve renal function .	However , correction of the hemodynamic parameters did not improve renal function .
Ifosfamide is a known nephrotoxic drug with demonstrated tubulopathies .	Ifosfamide is a known disease* nephrotoxic *disease drug with demonstrated disease* tubulopathies *disease .
We strongly suspect that this lethal anuria was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient hypotension .	We strongly suspect that this lethal disease* anuria *disease was mainly due to ifosfamide , occurring in a patient having received previous cisplatin chemotherapy and with poor kidney perfusion due to transient disease* hypotension *disease .
We recommend careful use of ifosfamide in patients pretreated with nephrotoxic chemotherapy and inadequate renal perfusion .	We recommend careful use of ifosfamide in patients pretreated with disease* nephrotoxic *disease chemotherapy and inadequate renal perfusion .
Nociceptive effects induced by intrathecal administration of prostaglandin D2 , E2 , or F2 alpha to conscious mice .	Nociceptive effects induced by intrathecal administration of prostaglandin D2 , E2 , or F2 alpha to conscious mice .
The effects of intrathecal administration of prostaglandins on pain responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .	The effects of intrathecal administration of prostaglandins on disease* pain *disease responses in conscious mice were evaluated by using hot plate and acetic acid writhing tests .
Prostaglandin D2 ( 0 . 5 - 3 ng / mouse ) had a hyperalgesic action on the response to a hot plate during a 3 - 60 min period after injection .	Prostaglandin D2 ( 0 . 5 - 3 ng / mouse ) had a disease* hyperalgesic *disease action on the response to a hot plate during a 3 - 60 min period after injection .
Prostaglandin E2 showed a hyperalgesic effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .	Prostaglandin E2 showed a disease* hyperalgesic *disease effect at doses of 1 pg to 10 ng / mouse , but the effect lasted shorter ( 3 - 30 min ) than that of prostaglandin D2 .
Similar results were obtained by acetic acid writhing tests .	Similar results were obtained by acetic acid writhing tests .
The hyperalgesic effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by AH6809 , a prostanoid EP1 - receptor antagonist .	The disease* hyperalgesic *disease effect of prostaglandin D2 was blocked by simultaneous injection of a substance P antagonist ( greater than or equal to 100 ng ) but not by AH6809 , a prostanoid EP1 - receptor antagonist .
Conversely , prostaglandin E2 - induced hyperalgesia was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .	Conversely , prostaglandin E2 - induced disease* hyperalgesia *disease was blocked by AH6809 ( greater than or equal to 500 ng ) but not by the substance P antagonist .
Prostaglandin F2 alpha had little effect on pain responses .	Prostaglandin F2 alpha had little effect on disease* pain *disease responses .
These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert hyperalgesia in the spinal cord , but in different ways .	These results demonstrate that both prostaglandin D2 and prostaglandin E2 exert disease* hyperalgesia *disease in the spinal cord , but in different ways .
D - penicillamine in the treatment of localized scleroderma .	D - penicillamine in the treatment of disease* localized scleroderma *disease .
Localized scleroderma has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children .	disease* Localized scleroderma *disease has no recognized internal organ involvement but may be disfiguring and disabling when the cutaneous lesions are extensive or affect children .
There is no accepted or proven treatment for localized scleroderma .	There is no accepted or proven treatment for disease* localized scleroderma *disease .
Case reports of 11 patients with severe , extensive localized scleroderma who were treated with D - penicillamine are summarized in this article .	Case reports of 11 patients with severe , extensive disease* localized scleroderma *disease who were treated with D - penicillamine are summarized in this article .
This drug was judged to have a favorable effect on the disease course in 7 ( 64 % ) of 11 patients .	This drug was judged to have a favorable effect on the disease course in 7 ( 64 % ) of 11 patients .
Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients , skin softening in 5 , and more normal growth of the affected limb in 2 of 3 children .	Improvement began within 3 to 6 months and consisted of cessation of active cutaneous lesions in all 7 patients , skin softening in 5 , and more normal growth of the affected limb in 2 of 3 children .
Joint stiffness and contractures also improved .	Joint stiffness and disease* contractures *disease also improved .
The dose of D - penicillamine associated with a favorable response was as low as 2 to 5 mg / kg per day given over a period ranging from 15 to 53 months .	The dose of D - penicillamine associated with a favorable response was as low as 2 to 5 mg / kg per day given over a period ranging from 15 to 53 months .
D - Penicillamine caused nephrotic syndrome in 1 patient and milder reversible proteinuria in 3 other patients ; none developed renal insufficiency .	D - Penicillamine caused disease* nephrotic syndrome *disease in 1 patient and milder reversible disease* proteinuria *disease in 3 other patients ; none developed disease* renal insufficiency *disease .
These data suggest that D - penicillamine may be effective in severe cases of localized scleroderma .	These data suggest that D - penicillamine may be effective in severe cases of disease* localized scleroderma *disease .
Cerebral sinus thrombosis as a potential hazard of antifibrinolytic treatment in menorrhagia .	disease* Cerebral sinus thrombosis *disease as a potential hazard of antifibrinolytic treatment in disease* menorrhagia *disease .
We describe a 42 - year - old woman who developed superior sagittal and left transverse sinus thrombosis associated with prolonged epsilon - aminocaproic acid therapy for menorrhagia .	We describe a 42 - year - old woman who developed superior disease* sagittal and left transverse sinus thrombosis *disease associated with prolonged epsilon - aminocaproic acid therapy for disease* menorrhagia *disease .
This antifibrinolytic agent has been used in women with menorrhagia to promote clotting and reduce blood loss .	This antifibrinolytic agent has been used in women with disease* menorrhagia *disease to promote clotting and reduce disease* blood loss *disease .
Although increased risk of thromboembolic disease has been reported during treatment with epsilon - aminocaproic acid , cerebral sinus thrombosis has not been previously described .	Although increased risk of disease* thromboembolic disease *disease has been reported during treatment with epsilon - aminocaproic acid , disease* cerebral sinus thrombosis *disease has not been previously described .
Careful use of epsilon - aminocaproic acid therapy is recommended .	Careful use of epsilon - aminocaproic acid therapy is recommended .
Seizure activity with imipenem therapy : incidence and risk factors .	disease* Seizure *disease activity with imipenem therapy : incidence and risk factors .
Two elderly patients with a history of either cerebral vascular accident ( CVA ) or head trauma and no evidence of renal disease developed seizures while receiving maximum doses of imipenem / cilastatin .	Two elderly patients with a history of either disease* cerebral vascular accident *disease ( disease* CVA *disease ) or disease* head trauma *disease and no evidence of disease* renal disease *disease developed disease* seizures *disease while receiving maximum doses of imipenem / cilastatin .
Neither patient had reported previous seizures or seizure - like activity nor was receiving anticonvulsant agents .	Neither patient had reported previous disease* seizures *disease or disease* seizure *disease - like activity nor was receiving anticonvulsant agents .
All seizures were controlled with therapeutic doses of phenytoin .	All disease* seizures *disease were controlled with therapeutic doses of phenytoin .
Both patients had received maximum doses of other beta - lactam antibiotics without evidence of seizure activity .	Both patients had received maximum doses of other beta - lactam antibiotics without evidence of disease* seizure *disease activity .
Midline B3 serotonin nerves in rat medulla are involved in hypotensive effect of methyldopa .	Midline B3 serotonin nerves in rat medulla are involved in disease* hypotensive *disease effect of methyldopa .
Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a hypotensive response mediated by a projection descending into the spinal cord .	Previous experiments in this laboratory have shown that microinjection of methyldopa onto the ventrolateral cells of the B3 serotonin neurons in the medulla elicits a disease* hypotensive *disease response mediated by a projection descending into the spinal cord .
The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla , coinciding with the raphe magnus .	The present experiments were designed to investigate the role of the midline cells of the B3 serotonin neurons in the medulla , coinciding with the raphe magnus .
In spontaneously hypertensive , stroke - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent hypotension of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .	In spontaneously disease* hypertensive *disease , disease* stroke *disease - prone rats , microinjection of methyldopa into the area of the midline B3 serotonin cell group in the ventral medulla caused a potent disease* hypotension *disease of 30 - 40 mm Hg , which was maximal 2 - 3 h after administration and was abolished by the serotonin neurotoxin 5 , 7 - dihydroxytryptamine ( 5 , 7 - DHT ) injected intracerebroventricularly .
However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this hypotension .	However , intraspinal injection of 5 , 7 - DHT to produce a more selective lesion of only descending serotonin projections in the spinal cord did not affect this disease* hypotension *disease .
Further , 5 , 7 - DHT lesion of serotonin nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 serotonin cells , did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection .	Further , 5 , 7 - DHT lesion of serotonin nerves travelling in the median forebrain bundle , one of the main ascending pathways from the B3 serotonin cells , did not affect the fall in blood pressure associated with a midline B3 serotonin methyldopa injection .
It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced hypotension via descending projections , the midline serotonin B3 cells in the medulla contribute to the hypotensive action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .	It is concluded therefore that , unlike the ventrolateral B3 cells which mediate a methyldopa - induced disease* hypotension *disease via descending projections , the midline serotonin B3 cells in the medulla contribute to the disease* hypotensive *disease action of methyldopa , either by way of an ascending projection which does not pass through the median forebrain bundle , or through a projection restricted to the caudal brainstem .
Antiarrhythmic plasma concentrations of cibenzoline on canine ventricular arrhythmias .	Antiarrhythmic plasma concentrations of cibenzoline on canine disease* ventricular arrhythmias *disease .
Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine ventricular arrhythmias , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each arrhythmia model was determined .	Using two - stage coronary ligation - , digitalis - , and adrenaline - induced canine disease* ventricular arrhythmias *disease , antiarrhythmic effects of cibenzoline were examined and the minimum effective plasma concentration for each disease* arrhythmia *disease model was determined .
Cibenzoline suppressed all the arrhythmias , and the minimum effective plasma concentrations for arrhythmias induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .	Cibenzoline suppressed all the disease* arrhythmias *disease , and the minimum effective plasma concentrations for disease* arrhythmias *disease induced by 24 - h coronary ligation , 48 - h coronary ligation , digitalis , and adrenaline were 1 . 9 + / - 0 . 9 ( by 8 mg / kg i . v . ) , 1 . 6 + / - 0 . 5 ( by 8 mg / kg i . v . ) , 0 . 6 + / - 0 . 2 ( by 2 mg / kg i . v . ) , and 3 . 5 + / - 1 . 3 ( by 5 mg / kg i . v . ) micrograms / ml , respectively ( mean + / - SDM , n = 6 - 7 ) .
The concentration for adrenaline - induced arrhythmia was significantly higher than those for the other types of arrhythmias .	The concentration for adrenaline - induced disease* arrhythmia *disease was significantly higher than those for the other types of disease* arrhythmias *disease .
This pharmacological profile is similar to those of mexiletine and tocainide , and all three drugs have central nervous system ( CNS ) stimulant action .	This pharmacological profile is similar to those of mexiletine and tocainide , and all three drugs have central nervous system ( CNS ) stimulant action .
Because cibenzoline had only weak hypotensive and sinus node depressive effects and was found to be orally active when given to coronary ligation arrhythmia dogs , its clinical usefulness is expected .	Because cibenzoline had only weak disease* hypotensive *disease and sinus node disease* depressive *disease effects and was found to be orally active when given to coronary ligation disease* arrhythmia *disease dogs , its clinical usefulness is expected .
Continuous ambulatory ECG monitoring during fluorouracil therapy : a prospective study .	Continuous ambulatory ECG monitoring during fluorouracil therapy : a prospective study .
Although there have been anecdotal reports of cardiac toxicity associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .	Although there have been anecdotal reports of disease* cardiac toxicity *disease associated with fluorouracil ( 5 - FU ) therapy , this phenomenon has not been studied in a systematic fashion .
We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid tumors in order to assess the incidence of ischemic ST changes .	We prospectively performed continuous ambulatory ECG monitoring on 25 patients undergoing 5 - FU infusion for treatment of solid disease* tumors *disease in order to assess the incidence of disease* ischemic *disease ST changes .
Patients were monitored for 23 + / - 4 hours before 5 - FU infusion , and 98 + / - 9 hours during 5 - FU infusion .	Patients were monitored for 23 + / - 4 hours before 5 - FU infusion , and 98 + / - 9 hours during 5 - FU infusion .
Anginal episodes were rare : only one patient had angina ( during 5 - FU infusion ) .	disease* Anginal *disease episodes were rare : only one patient had disease* angina *disease ( during 5 - FU infusion ) .
However , asymptomatic ST changes ( greater than or equal to 1 mm ST deviation ) were common : six of 25 patients ( 24 % ) had ST changes before 5 - FU infusion v 17 ( 68 % ) during 5 - FU infusion ( P less than . 002 ) .	However , asymptomatic ST changes ( greater than or equal to 1 mm ST deviation ) were common : six of 25 patients ( 24 % ) had ST changes before 5 - FU infusion v 17 ( 68 % ) during 5 - FU infusion ( P less than . 002 ) .
The incidence of ischemic episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .	The incidence of disease* ischemic *disease episodes per patient per hour was 0 . 05 + / - 0 . 02 prior to 5 - FU infusion v 0 . 13 + / - 0 . 03 during 5 - FU infusion ( P less than . 001 ) ; the duration of ECG changes was 0 . 6 + / - 0 . 3 minutes per patient per hour before 5 - FU v 1 . 9 + / - 0 . 5 minutes per patient per hour during 5 - FU ( P less than . 01 ) .
ECG changes were more common among patients with known coronary artery disease .	ECG changes were more common among patients with known disease* coronary artery disease *disease .
There were two cases of sudden death , both of which occurred at the end of the chemotherapy course .	There were two cases of disease* sudden death *disease , both of which occurred at the end of the chemotherapy course .
We conclude that 5 - FU infusion is associated with a significant increase in silent ST segment deviation suggestive of ischemia , particularly among patients with coronary artery disease .	We conclude that 5 - FU infusion is associated with a significant increase in silent ST segment deviation suggestive of disease* ischemia *disease , particularly among patients with disease* coronary artery disease *disease .
The mechanism and clinical significance of these ECG changes remain to be determined .	The mechanism and clinical significance of these ECG changes remain to be determined .
Nature , time course and dose dependence of zidovudine - related side effects : results from the Multicenter Canadian Azidothymidine Trial .	Nature , time course and dose dependence of zidovudine - related side effects : results from the Multicenter Canadian Azidothymidine Trial .
To characterize the nature , time course and dose dependency of zidovudine - related side effects , we undertook a multicenter , prospective , dose - range finding study .	To characterize the nature , time course and dose dependency of zidovudine - related side effects , we undertook a multicenter , prospective , dose - range finding study .
Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of HIV disease .	Our study group consisted of 74 HIV - positive homosexual men belonging to groups II B , III and IV C2 from the Centers for Disease Control ( CDC ) classification of disease* HIV disease *disease .
Following a 3 - week observation period , volunteers were treated with zidovudine 600 mg / day for 18 weeks , 900 mg / day for 9 weeks and 1200 mg / day for 9 weeks , followed by a washout period of 6 weeks after which they were re - started on 1200 mg / day or the highest tolerated dose at 8 - hourly intervals .	Following a 3 - week observation period , volunteers were treated with zidovudine 600 mg / day for 18 weeks , 900 mg / day for 9 weeks and 1200 mg / day for 9 weeks , followed by a washout period of 6 weeks after which they were re - started on 1200 mg / day or the highest tolerated dose at 8 - hourly intervals .
Subjects were randomly assigned to 4 - hourly or 8 - hourly regimens within CDC groups while taking 600 and 1200 mg / day .	Subjects were randomly assigned to 4 - hourly or 8 - hourly regimens within CDC groups while taking 600 and 1200 mg / day .
Clinical and laboratory evaluations were performed at 3 - week intervals .	Clinical and laboratory evaluations were performed at 3 - week intervals .
Symptomatic adverse effects were present in 96 % of subjects , most commonly nausea ( 64 % ) , fatigue ( 55 % ) and headache ( 49 % ) .	Symptomatic adverse effects were present in 96 % of subjects , most commonly disease* nausea *disease ( 64 % ) , disease* fatigue *disease ( 55 % ) and disease* headache *disease ( 49 % ) .
These were generally self - limited , reappearing briefly at each dose increment .	These were generally self - limited , reappearing briefly at each dose increment .
A decrease in hemoglobin occurred shortly after initiation of therapy .	A decrease in hemoglobin occurred shortly after initiation of therapy .
This was not dose dependent and reversed rapidly upon discontinuation of treatment .	This was not dose dependent and reversed rapidly upon discontinuation of treatment .
A red blood cell count decrease , a mean cell volume increase and a granulocyte count decrease developed early in a dose - independent fashion , reverting at least partially during the washout phase .	A red blood cell count decrease , a mean cell volume increase and a granulocyte count decrease developed early in a dose - independent fashion , reverting at least partially during the washout phase .
The decrease in reticulocyte count was dose related between 600 and 900 mg / day with no further change when the dose was escalated to 1200 mg / day .	The decrease in reticulocyte count was dose related between 600 and 900 mg / day with no further change when the dose was escalated to 1200 mg / day .
Bone marrow changes occurred rapidly as demonstrated by megaloblastosis in 95 % of 65 specimens at week 18 . ( ABSTRACT TRUNCATED AT 250 WORDS )	Bone marrow changes occurred rapidly as demonstrated by disease* megaloblastosis *disease in 95 % of 65 specimens at week 18 . ( ABSTRACT TRUNCATED AT 250 WORDS )
National project on the prevention of mother - to - infant infection by hepatitis B virus in Japan .	National project on the prevention of mother - to - infant disease* infection by hepatitis B virus *disease in Japan .
In Japan , a nationwide prevention program against mother - to - infant infection by hepatitis B virus ( HBV ) started in 1985 .	In Japan , a nationwide prevention program against mother - to - infant disease* infection by hepatitis B virus *disease ( HBV ) started in 1985 .
This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( HBsAg ) and hepatitis B e antigen ( HBeAg ) positive mothers .	This program consists of double screenings of pregnant women and prophylactic treatment to the infants born to both hepatitis B surface antigen ( HBsAg ) and hepatitis B e antigen ( HBeAg ) positive mothers .
These infants are treated with two injections of hepatitis B immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .	These infants are treated with two injections of disease* hepatitis B *disease immune globulin ( HBIG ) and at least three injections of plasma derived hepatitis B vaccine .
We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987 .	We sent questionnaires about the numbers of each procedure or examination during nine months of investigation period to each local government in 1986 and 1987 .
93 . 4 % pregnant women had the chance to be examined for HBsAg , and the positive rate was 1 . 4 to 1 . 5 % .	93 . 4 % pregnant women had the chance to be examined for HBsAg , and the positive rate was 1 . 4 to 1 . 5 % .
The HBeAg positive rate in HBsAg positive was 23 to 26 % .	The HBeAg positive rate in HBsAg positive was 23 to 26 % .
The HBsAg positive rate in neonates and in infants before two months were 3 % and 2 % respectively .	The HBsAg positive rate in neonates and in infants before two months were 3 % and 2 % respectively .
Some problems may arise , because 27 to 30 % of infants need the fourth vaccination in some restricted areas .	Some problems may arise , because 27 to 30 % of infants need the fourth vaccination in some restricted areas .
Involvement of the mu - opiate receptor in peripheral analgesia .	Involvement of the mu - opiate receptor in peripheral disease* analgesia *disease .
The intradermal injection of mu ( morphine , Tyr - D - Ala - Gly - NMe - Phe - Gly - ol and morphiceptin ) , kappa ( trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide ) and delta ( [ D - Pen2 . 5 ] - enkephalin and [ D - Ser2 ] - [ Leu ] enkephalin - Thr ) selective opioid - agonists , by themselves , did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat .	The intradermal injection of mu ( morphine , Tyr - D - Ala - Gly - NMe - Phe - Gly - ol and morphiceptin ) , kappa ( trans - 3 , 4 - dichloro - N - methyl - N [ 2 - ( 1 - pyrrolidinyl ) cyclohexyl ] benzeneactemide ) and delta ( [ D - Pen2 . 5 ] - enkephalin and [ D - Ser2 ] - [ Leu ] enkephalin - Thr ) selective opioid - agonists , by themselves , did not significantly affect the mechanical nociceptive threshold in the hindpaw of the rat .
Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of prostaglandin E2 - induced hyperalgesia .	Intradermal injection of mu , but not delta or kappa opioid - agonists , however , produced dose - dependent inhibition of prostaglandin E2 - induced disease* hyperalgesia *disease .
The analgesic effect of the mu - agonist morphine was dose - dependently antagonized by naloxone and prevented by co - injection of pertussis toxin .	The analgesic effect of the mu - agonist morphine was dose - dependently antagonized by naloxone and prevented by co - injection of pertussis toxin .
Morphine did not , however , alter the hyperalgesia induced by 8 - bromo cyclic adenosine monophosphate .	Morphine did not , however , alter the disease* hyperalgesia *disease induced by 8 - bromo cyclic adenosine monophosphate .
We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu - opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system .	We conclude that the analgesic action of opioids on the peripheral terminals of primary afferents is via a binding site with characteristics of the mu - opioid receptor and that this action is mediated by inhibition of the cyclic adenosine monophosphate second messenger system .
Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl - induced muscular rigidity in the rat .	Involvement of locus coeruleus and noradrenergic neurotransmission in fentanyl - induced disease* muscular rigidity *disease in the rat .
Whereas muscular rigidity is a well - known side effect that is associated with high - dose fentanyl anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .	Whereas disease* muscular rigidity *disease is a well - known side effect that is associated with high - dose fentanyl anesthesia , a paucity of information exists with regard to its underlying mechanism ( s ) .
We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon , using male Sprague - Dawley rats anesthetized with ketamine .	We investigated in this study the possible engagement of locus coeruleus of the pons in this phenomenon , using male Sprague - Dawley rats anesthetized with ketamine .
Under proper control of respiration , body temperature and end - tidal CO2 , intravenous administration of fentanyl ( 50 or 100 micrograms / kg ) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles .	Under proper control of respiration , body temperature and end - tidal CO2 , intravenous administration of fentanyl ( 50 or 100 micrograms / kg ) consistently promoted an increase in electromyographic activity recorded from the gastrocnemius and abdominal rectus muscles .
Such an induced muscular rigidity by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , prazosin .	Such an induced disease* muscular rigidity *disease by the narcotic agent was significantly antagonized or even reduced by prior electrolytic lesions of the locus coeruleus or pretreatment with the alpha - adrenoceptor blocker , prazosin .
Microinjection of fentanyl ( 2 . 5 micrograms / 50 nl ) directly into this pontine nucleus , on the other hand , elicited discernible electromyographic excitation .	Microinjection of fentanyl ( 2 . 5 micrograms / 50 nl ) directly into this pontine nucleus , on the other hand , elicited discernible electromyographic excitation .
It is speculated that the induction of muscular rigidity by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .	It is speculated that the induction of disease* muscular rigidity *disease by fentanyl may involve the coerulospinal noradrenergic fibers to the spinal motoneurons .
Dexmedetomidine , acting through central alpha - 2 adrenoceptors , prevents opiate - induced muscle rigidity in the rat .	Dexmedetomidine , acting through central alpha - 2 adrenoceptors , prevents opiate - induced disease* muscle rigidity *disease in the rat .
The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( D - MED ) is capable of inducing muscle flaccidity and anesthesia in rats and dogs .	The highly - selective alpha - 2 adrenergic agonist dexmedetomidine ( D - MED ) is capable of inducing disease* muscle flaccidity *disease and anesthesia in rats and dogs .
Intense generalized muscle rigidity is an undesirable side effect of potent opiate agonists .	Intense generalized disease* muscle rigidity *disease is an undesirable side effect of potent opiate agonists .
Although the neurochemistry of opiate - induced rigidity has yet to be fully elucidated , recent work suggests a role for a central adrenergic mechanism .	Although the neurochemistry of opiate - induced disease* rigidity *disease has yet to be fully elucidated , recent work suggests a role for a central adrenergic mechanism .
In the present study , the authors determined if treatment with D - MED prevents the muscle rigidity caused by high - dose alfentanil anesthesia in the rat .	In the present study , the authors determined if treatment with D - MED prevents the disease* muscle rigidity *disease caused by high - dose alfentanil anesthesia in the rat .
Animals ( n = 42 ) were treated intraperitoneally with one of the following six regimens : 1 ) L - MED ( the inactive L - isomer of medetomidine ) , 30 micrograms / kg ; 2 ) D - MED , 10 micrograms / kg ; 3 ) D - MED , 30 micrograms / kg ; 4 ) D - MED [ 30 micrograms / kg ] and the central - acting alpha - 2 antagonist , idazoxan [ 10 mg / kg ] ; 5 ) D - MED [ 30 micrograms / kg ] and the peripheral - acting alpha - 2 antagonist DG - 5128 [ 10 mg / kg ] , or ; 6 ) saline .	Animals ( n = 42 ) were treated intraperitoneally with one of the following six regimens : 1 ) L - MED ( the inactive L - isomer of medetomidine ) , 30 micrograms / kg ; 2 ) D - MED , 10 micrograms / kg ; 3 ) D - MED , 30 micrograms / kg ; 4 ) D - MED [ 30 micrograms / kg ] and the central - acting alpha - 2 antagonist , idazoxan [ 10 mg / kg ] ; 5 ) D - MED [ 30 micrograms / kg ] and the peripheral - acting alpha - 2 antagonist DG - 5128 [ 10 mg / kg ] , or ; 6 ) saline .
Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment .	Baseline electromyographic activity was recorded from the gastrocnemius muscle before and after drug treatment .
Each rat was then injected with alfentanil ( ALF , 0 . 5 mg / kg sc ) .	Each rat was then injected with alfentanil ( ALF , 0 . 5 mg / kg sc ) .
ALF injection resulted in a marked increase in hindlimb EMG activity in the L - MED treatment group which was indistinguishable from that seen in animals treated with saline .	ALF injection resulted in a marked increase in hindlimb EMG activity in the L - MED treatment group which was indistinguishable from that seen in animals treated with saline .
In contrast , D - MED prevented alfentanil - induced muscle rigidity in a dose - dependent fashion .	In contrast , D - MED prevented alfentanil - induced disease* muscle rigidity *disease in a dose - dependent fashion .
The small EMG values obtained in the high - dose D - MED group were comparable with those recorded in earlier studies from control animals not given any opiate .	The small EMG values obtained in the high - dose D - MED group were comparable with those recorded in earlier studies from control animals not given any opiate .
The high - dose D - MED animals were flaccid , akinetic , and lacked a startle response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )	The high - dose D - MED animals were flaccid , disease* akinetic *disease , and lacked a disease* startle *disease response during the entire experimental period . ( ABSTRACT TRUNCATED AT 250 WORDS )
Some central effects of repeated treatment with fluvoxamine .	Some central effects of repeated treatment with fluvoxamine .
We investigated the effect of repeated treatment with fluvoxamine , a selective serotonin uptake inhibitor , on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the " behavioral despair " test .	We investigated the effect of repeated treatment with fluvoxamine , a selective serotonin uptake inhibitor , on behavioral effects of dopaminomimetics and methoxamine and on the animal behavior in the " behavioral despair " test .
A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced hyperactivity .	A repeated treatment with fluvoxamine ( twice daily for 14 days ) potentiated in mice and in rats ( weaker ) the amphetamine - induced disease* hyperactivity *disease .
The hyperactivity induced by nomifensine in mice remained unaffected by fluvoxamine .	The disease* hyperactivity *disease induced by nomifensine in mice remained unaffected by fluvoxamine .
The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine .	The stimulation of locomotor activity by intracerebroventricularly administered methoxamine was not affected by repeated treatment with fluvoxamine .
Given three times fluvoxamine had no effect on the immobilization time in the " behavioral despair " test in rats .	Given three times fluvoxamine had no effect on the immobilization time in the " behavioral despair " test in rats .
The results indicate that fluvoxamine given repeatedly acts differently than citalopram , another selective serotonin uptake inhibitor , and differs also from other antidepressant drugs .	The results indicate that fluvoxamine given repeatedly acts differently than citalopram , another selective serotonin uptake inhibitor , and differs also from other antidepressant drugs .
Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on bupivacaine - induced cardiovascular impairments in rats .	Protective effect of a specific platelet - activating factor antagonist , BN 52021 , on bupivacaine - induced disease* cardiovascular impairments *disease in rats .
Administration of the local anaesthetic bupivacaine ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) leading to death ( in 67 % or 90 % of animals respectively ) .	Administration of the local anaesthetic bupivacaine ( 1 . 5 or 2 mg / kg , i . v . ) to rats elicited a marked disease* decrease of mean arterial blood pressure ( MBP ) and heart rate ( HR ) *disease leading to death ( in 67 % or 90 % of animals respectively ) .
Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . ) suppressed both the decrease of MBP and HR .	Intravenous injection of the specific platelet - activating factor ( PAF ) antagonist BN 52021 ( 10 mg / kg ) , 30 min before bupivacaine administration ( 2 mg / kg i . v . ) suppressed both the disease* decrease of MBP and HR *disease .
In contrast , doses of 1 mg / kg BN 52021 given 30 min before or 10 mg / kg administered 5 min before i . v . injection of bupivacaine were ineffective .	In contrast , doses of 1 mg / kg BN 52021 given 30 min before or 10 mg / kg administered 5 min before i . v . injection of bupivacaine were ineffective .
When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the decrease of MBP and HR was observed , whereas the dose of 10 mg / kg was ineffective .	When BN 52021 ( 20 mg / kg i . v . ) was injected immediately after bupivacaine ( 2 mg / kg ) , a partial reversion of the disease* decrease of MBP and HR *disease was observed , whereas the dose of 10 mg / kg was ineffective .
A partial recovery of bupivacaine - induced ECG alterations was observed after pretreatment of the rats with BN 52021 .	A partial recovery of bupivacaine - induced ECG alterations was observed after pretreatment of the rats with BN 52021 .
Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced cardiovascular toxicity .	Since the administration of BN 52021 , at all doses studied , did not alter MBP and HR at the doses used , the bulk of these results clearly demonstrate a protective action of BN 52021 , a specific antagonist of PAF , against bupivacaine - induced disease* cardiovascular toxicity *disease .
Thus , consistent with its direct effect on heart , PAF appears to be implicated in bupivacaine - induced cardiovascular alterations .	Thus , consistent with its direct effect on heart , PAF appears to be implicated in bupivacaine - induced disease* cardiovascular alterations *disease .
The epidemiology of the acute flank pain syndrome from suprofen .	The epidemiology of the acute disease* flank pain *disease syndrome from suprofen .
Suprofen , a new nonsteroidal anti - inflammatory drug , was marketed in early 1986 as an analgesic agent .	Suprofen , a new nonsteroidal anti - inflammatory drug , was marketed in early 1986 as an analgesic agent .
Until physicians began reporting an unusual acute flank pain syndrome to the spontaneous reporting system , 700 , 000 persons used the drug in the United States .	Until physicians began reporting an unusual acute disease* flank pain *disease syndrome to the spontaneous reporting system , 700 , 000 persons used the drug in the United States .
Through August 1986 , a total of 163 cases of this syndrome were reported .	Through August 1986 , a total of 163 cases of this syndrome were reported .
To elucidate the epidemiology of the syndrome , a case - control study was performed , comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen - exposed control subjects who did not have the syndrome .	To elucidate the epidemiology of the syndrome , a case - control study was performed , comparing 62 of the case patients who had been reported to the spontaneous reporting system to 185 suprofen - exposed control subjects who did not have the syndrome .
Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from hay fever and asthma ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use alcohol ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .	Case patients were more likely to be men ( odds ratio , 3 . 8 ; 95 % confidence interval , 1 . 2 - 12 . 1 ) , suffer from disease* hay fever *disease and disease* asthma *disease ( odds ratio , 3 . 4 ; 95 % confidence interval , 1 . 0 - 11 . 9 ) ; to participate in regular exercise ( odds ratio , 5 . 9 ; 95 % confidence interval , 1 . 1 - 30 . 7 ) , especially in the use of Nautilus equipment ( p = 0 . 02 ) ; and to use alcohol ( odds ratio , 4 . 4 ; 95 % confidence interval , 1 . 1 - 17 . 5 ) .
Possible risk factors included young age , concurrent use of other analgesic agents ( especially ibuprofen ) , preexisting renal disease , a history of kidney stones , a history of gout , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .	Possible risk factors included young age , concurrent use of other analgesic agents ( especially ibuprofen ) , preexisting disease* renal disease *disease , a history of disease* kidney stones *disease , a history of disease* gout *disease , a recent increase in activity , a recent increase in sun exposure , and residence in the Sunbelt .
These were findings that were suggestive but did not reach conventional statistical significance .	These were findings that were suggestive but did not reach conventional statistical significance .
These findings are consistent with the postulated mechanism for this unusual syndrome : acute diffuse crystallization of uric acid in renal tubules .	These findings are consistent with the postulated mechanism for this unusual syndrome : acute diffuse crystallization of uric acid in renal tubules .
Phlorizin - induced glycosuria does not prevent gentamicin nephrotoxicity in rats .	Phlorizin - induced disease* glycosuria *disease does not prevent gentamicin disease* nephrotoxicity *disease in rats .
Because rats with streptozotocin - induced diabetes mellitus ( DM ) have a high solute diuresis ( glycosuria of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced acute renal failure ( ARF ) .	Because rats with streptozotocin - induced disease* diabetes mellitus *disease ( disease* DM *disease ) have a high solute diuresis ( disease* glycosuria *disease of 10 to 12 g / day ) , we have suggested that this may in part be responsible for their resistance to gentamicin - induced disease* acute renal failure *disease ( disease* ARF *disease ) .
The protection from gentamicin nephrotoxicity was studied in non - diabetic rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .	The protection from gentamicin disease* nephrotoxicity *disease was studied in non - disease* diabetic *disease rats with chronic solute diuresis induced by blockage of tubular glucose reabsorption with phlorizin ( P ) .
DM rats with mild glycosuria ( similar in degree to that of the P treated animals ) were also studied .	disease* DM *disease rats with mild disease* glycosuria *disease ( similar in degree to that of the P treated animals ) were also studied .
Unanesthetized adult female , Sprague - Dawley rats were divided in four groups and studied for 15 days .	Unanesthetized adult female , Sprague - Dawley rats were divided in four groups and studied for 15 days .
Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild DM + gentamicin ) .	Group 1 ( P alone ) received P , 360 mg / day , for 15 days ; Group II ( P + gentamicin ) ; Group III ( gentamicin alone ) and Group IV ( mild disease* DM *disease + gentamicin ) .
Nephrotoxic doses ( 40 mg / kg body wt / day ) of gentamicin were injected during the last nine days of study to the animals of groups II to IV .	disease* Nephrotoxic *disease doses ( 40 mg / kg body wt / day ) of gentamicin were injected during the last nine days of study to the animals of groups II to IV .
In Group I , P induced a moderate and stable glycosuria ( 3 . 9 + / - 0 . 1 g / day , SE ) , and no functional or morphologic evidence of renal dysfunction ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( tubular necrosis score [ maximum 4 ] , zero ) .	In Group I , P induced a moderate and stable disease* glycosuria *disease ( 3 . 9 + / - 0 . 1 g / day , SE ) , and no functional or morphologic evidence of disease* renal dysfunction *disease ( baseline CCr 2 . 1 + / - 0 . 1 ml / min , undetectable lysozymuria ) or damage ( disease* tubular necrosis *disease score [ maximum 4 ] , zero ) .
In Group II , P did not prevent gentamicin - ARF ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and tubular necrosis score , 3 . 9 + / - 0 . 1 ) .	In Group II , P did not prevent gentamicin - disease* ARF *disease ( maximal decrease in CCr at day 9 . 89 % , P less than 0 . 001 ; peak lysozymuria , 1863 + / - 321 micrograms / day ; and disease* tubular necrosis *disease score , 3 . 9 + / - 0 . 1 ) .
These values were not different from those of Group III : maximal decrease in CCr 73 % ( P less than 0 . 001 ) ; lysozymuria , 2147 + / - 701 micrograms / day ; tubular necrosis score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )	These values were not different from those of Group III : maximal decrease in CCr 73 % ( P less than 0 . 001 ) ; lysozymuria , 2147 + / - 701 micrograms / day ; disease* tubular necrosis *disease score , 3 . 8 + / - 0 . 1 . ( ABSTRACT TRUNCATED AT 250 WORDS )
Catalepsy induced by combinations of ketamine and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .	disease* Catalepsy *disease induced by combinations of ketamine and morphine : potentiation , antagonism , tolerance and cross - tolerance in the rat .
Previous studies demonstrated that both ketamine and morphine induced analgesia and catalepsy in the rat .	Previous studies demonstrated that both ketamine and morphine induced disease* analgesia *disease and disease* catalepsy *disease in the rat .
Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the cataleptic response ; this augmentation was attributed to residual morphine in the brain .	Pre - treatment with ketamine produced cross - tolerance to morphine , whereas pretreatment with morphine did not induce cross - tolerance to ketamine but rather augmented the disease* cataleptic *disease response ; this augmentation was attributed to residual morphine in the brain .
The present studies explored the duration of the loss of righting reflex induced by sub - effective doses of ketamine and morphine , administered simultaneously .	The present studies explored the duration of the loss of righting reflex induced by sub - effective doses of ketamine and morphine , administered simultaneously .
There was mutual potentiation between sub - effective doses of ketamine and morphine , but sub - effective doses of ketamine partly antagonized fully - effective doses of morphine .	There was mutual potentiation between sub - effective doses of ketamine and morphine , but sub - effective doses of ketamine partly antagonized fully - effective doses of morphine .
Latency to the loss of righting reflex , rigidity and behavior on recovery , reflected the relative predominance of ketamine or morphine in each combination .	Latency to the loss of righting reflex , disease* rigidity *disease and behavior on recovery , reflected the relative predominance of ketamine or morphine in each combination .
Naloxone inhibited the induced cataleptic effects .	Naloxone inhibited the induced disease* cataleptic *disease effects .
The degree and time course of development of tolerance to daily administration of sub - effective dose combinations of ketamine and morphine were similar .	The degree and time course of development of tolerance to daily administration of sub - effective dose combinations of ketamine and morphine were similar .
Rats , tolerant to ketamine - dominant combinations , were cross - tolerant to both drugs , while those tolerant to morphine - dominant combinations were cross - tolerant to morphine but showed either no cross - tolerance or an augmented response to ketamine .	Rats , tolerant to ketamine - dominant combinations , were cross - tolerant to both drugs , while those tolerant to morphine - dominant combinations were cross - tolerant to morphine but showed either no cross - tolerance or an augmented response to ketamine .
While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced catalepsy , differences in latency , rigidity and behavior , asymmetry of cross - tolerance and a widely - different ID50 for naloxone would argue against an action at a single opioid site .	While the mutual potentiation , antagonism and tolerance suggest common mechanisms for the induced disease* catalepsy *disease , differences in latency , disease* rigidity *disease and behavior , asymmetry of cross - tolerance and a widely - different ID50 for naloxone would argue against an action at a single opioid site .
Hydrocortisone - induced hypertension in humans : pressor responsiveness and sympathetic function .	Hydrocortisone - induced disease* hypertension *disease in humans : pressor responsiveness and sympathetic function .
Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects .	Oral hydrocortisone increases blood pressure and enhances pressor responsiveness in normal human subjects .
We studied the effects of 1 week of oral hydrocortisone ( 200 mg / day ) on blood pressure , cardiac output , total peripheral resistance , forearm vascular resistance , and norepinephrine spillover to plasma in eight healthy male volunteers .	We studied the effects of 1 week of oral hydrocortisone ( 200 mg / day ) on blood pressure , cardiac output , total peripheral resistance , forearm vascular resistance , and norepinephrine spillover to plasma in eight healthy male volunteers .
Although diastolic blood pressure remained unchanged , systolic blood pressure increased from 119 to 135 mm Hg ( SED + / - 3 . 4 , p less than 0 . 01 ) , associated with an increased cardiac output ( 5 . 85 - 7 . 73 l / min , SED + / - 0 . 46 , p less than 0 . 01 ) .	Although diastolic blood pressure remained unchanged , systolic blood pressure increased from 119 to 135 mm Hg ( SED + / - 3 . 4 , p less than 0 . 01 ) , associated with an disease* increased cardiac output *disease ( 5 . 85 - 7 . 73 l / min , SED + / - 0 . 46 , p less than 0 . 01 ) .
Total peripheral vascular resistance fell from 15 . 1 to 12 . 2 mm Hg / l / min ( SED + / - 1 . 03 , p less than 0 . 05 ) .	Total peripheral vascular resistance fell from 15 . 1 to 12 . 2 mm Hg / l / min ( SED + / - 1 . 03 , p less than 0 . 05 ) .
Resting forearm vascular resistance remained unchanged , but the reflex response to the cold pressor test was accentuated , the rise in resistance increasing from 10 . 5 mm Hg / ml / 100 ml / min ( R units ) before treatment to 32 . 6 R units after treatment ( SED + / - 6 . 4 , p less than 0 . 025 ) .	Resting forearm vascular resistance remained unchanged , but the reflex response to the cold pressor test was accentuated , the rise in resistance increasing from 10 . 5 mm Hg / ml / 100 ml / min ( R units ) before treatment to 32 . 6 R units after treatment ( SED + / - 6 . 4 , p less than 0 . 025 ) .
The rise in forearm vascular resistance accompanying intra - arterial norepinephrine ( 25 , 50 , and 100 ng / min ) was also significantly greater after hydrocortisone , increasing from an average of 14 . 9 + / - 2 . 4 R units before treatment to 35 . 1 + / - 5 . 5 R units after hydrocortisone ( SED + / - 6 . 0 , p less than 0 . 05 ) .	The rise in forearm vascular resistance accompanying intra - arterial norepinephrine ( 25 , 50 , and 100 ng / min ) was also significantly greater after hydrocortisone , increasing from an average of 14 . 9 + / - 2 . 4 R units before treatment to 35 . 1 + / - 5 . 5 R units after hydrocortisone ( SED + / - 6 . 0 , p less than 0 . 05 ) .
A shift to the left in the dose - response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment .	A shift to the left in the dose - response relation and fall in threshold suggested increased sensitivity to norepinephrine after treatment .
Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased .	Measurement of resting norepinephrine spillover rate to plasma and norepinephrine uptake indicated that overall resting sympathetic nervous system activity was not increased .
The rise in resting blood pressure with hydrocortisone is associated with an increased cardiac output ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )	The disease* rise in resting blood pressure *disease with hydrocortisone is associated with an disease* increased cardiac output *disease ( presumably due to increased blood volume ) . ( ABSTRACT TRUNCATED AT 250 WORDS )
Neuromuscular blockade with magnesium sulfate and nifedipine .	disease* Neuromuscular blockade *disease with magnesium sulfate and nifedipine .
A patient who received tocolysis with nifedipine developed neuromuscular blockade after 500 mg of magnesium sulfate was administered .	A patient who received tocolysis with nifedipine developed disease* neuromuscular blockade *disease after 500 mg of magnesium sulfate was administered .
This reaction demonstrates that nifedipine can seriously potentiate the toxicity of magnesium .	This reaction demonstrates that nifedipine can seriously potentiate the disease* toxicity *disease of magnesium .
Caution should be exercised when these two tocolytics are combined .	Caution should be exercised when these two tocolytics are combined .
Chronic carbamazepine inhibits the development of local anesthetic seizures kindled by cocaine and lidocaine .	Chronic carbamazepine inhibits the development of local anesthetic disease* seizures *disease kindled by cocaine and lidocaine .
The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled seizures and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .	The effects of carbamazepine ( CBZ ) treatment on local anesthetic - kindled disease* seizures *disease and lethality were evaluated in different stages of the kindling process and under different methods of CBZ administration .
Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced seizures , but had little effect on the fully developed local anesthetic seizures .	Chronic oral CBZ inhibited the development of both lidocaine - and cocaine - induced disease* seizures *disease , but had little effect on the fully developed local anesthetic disease* seizures *disease .
Chronic CBZ also decreased the incidence of seizure - related mortality in the cocaine - injected rats .	Chronic CBZ also decreased the incidence of disease* seizure *disease - related mortality in the cocaine - injected rats .
Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced seizures .	Acute CBZ over a range of doses ( 15 - 50 mg / kg ) had no effect on completed lidocaine - kindled or acute cocaine - induced disease* seizures *disease .
Repeated i . p . injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled seizures .	Repeated i . p . injection of CBZ ( 15 mg / kg ) also was without effect on the development of lidocaine - or cocaine - kindled disease* seizures *disease .
The differential effects of CBZ depending upon stage of seizure development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled seizures .	The differential effects of CBZ depending upon stage of disease* seizure *disease development suggest that distinct mechanisms underlie the development versus maintenance of local anesthetic - kindled disease* seizures *disease .
The effectiveness of chronic but not repeated , intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens .	The effectiveness of chronic but not repeated , intermittent injections of CBZ suggests that different biochemical consequences result from the different treatment regimens .
The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data , but remains to be directly evaluated .	The possible utility of chronic CBZ in preventing the development of toxic side effects in human cocaine users is suggested by these data , but remains to be directly evaluated .
Magnetic resonance imaging of cerebral venous thrombosis secondary to " low - dose " birth control pills .	Magnetic resonance imaging of cerebral disease* venous thrombosis *disease secondary to " low - dose " birth control pills .
The clinical and radiographic features of cerebral deep venous thrombosis in a 21 - year - old white woman are presented .	The clinical and radiographic features of cerebral disease* deep venous thrombosis *disease in a 21 - year - old white woman are presented .
This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes .	This nulliparous patient presented with relatively mild clinical symptoms and progressing mental status changes .
The only known risk factor was " low - dose " oral contraceptive pills .	The only known risk factor was " low - dose " oral contraceptive pills .
The magnetic resonance image ( MRI ) showed increased signal intensity from the internal cerebral veins , vein of Galen , and straight sinus .	The magnetic resonance image ( MRI ) showed increased signal intensity from the internal cerebral veins , vein of Galen , and straight sinus .
The diagnosis was confirmed by arterial angiography .	The diagnosis was confirmed by arterial angiography .
Beta - 2 - adrenoceptor - mediated hypokalemia and its abolishment by oxprenolol .	Beta - 2 - adrenoceptor - mediated disease* hypokalemia *disease and its abolishment by oxprenolol .
The time course and concentration - effect relationship of terbutaline - induced hypokalemia was studied , using computer - aided pharmacokinetic - dynamic modeling .	The time course and concentration - effect relationship of terbutaline - induced disease* hypokalemia *disease was studied , using computer - aided pharmacokinetic - dynamic modeling .
Subsequently we investigated the efficacy of oxprenolol in antagonizing such hypokalemia , together with the pharmacokinetic interaction between both drugs .	Subsequently we investigated the efficacy of oxprenolol in antagonizing such disease* hypokalemia *disease , together with the pharmacokinetic interaction between both drugs .
Six healthy subjects were given a 0 . 5 mg subcutaneous dose of terbutaline on two occasions : 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally .	Six healthy subjects were given a 0 . 5 mg subcutaneous dose of terbutaline on two occasions : 1 hour after oral administration of a placebo and 1 hour after 80 mg oxprenolol orally .
In the 7 - hour period after terbutaline administration , plasma samples were taken for determination of plasma potassium levels and drug concentrations .	In the 7 - hour period after terbutaline administration , plasma samples were taken for determination of plasma potassium levels and drug concentrations .
The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects .	The sigmoid Emax model offered a good description of the relation between terbutaline concentrations and potassium effects .
Oxprenolol caused decreases of 65 % and 56 % of terbutaline volume of distribution and clearance , respectively , and an increase of 130 % of its AUC .	Oxprenolol caused decreases of 65 % and 56 % of terbutaline volume of distribution and clearance , respectively , and an increase of 130 % of its AUC .
In spite of higher terbutaline concentrations after oxprenolol pretreatment , the hypokalemia was almost completely antagonized by the beta 2 - blocking action .	In spite of higher terbutaline concentrations after oxprenolol pretreatment , the disease* hypokalemia *disease was almost completely antagonized by the beta 2 - blocking action .
A dystonia - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .	A disease* dystonia *disease - like syndrome after neuropeptide ( MSH / ACTH ) stimulation of the rat locus ceruleus .
The movement disorder investigated in these studies has some features in common with human idiopathic dystonia , and information obtained in these studies may be of potential clinical benefit .	The disease* movement disorder *disease investigated in these studies has some features in common with human idiopathic disease* dystonia *disease , and information obtained in these studies may be of potential clinical benefit .
The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE - mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo - cerebellar pathway .	The present experimental results indicated that peptidergic stimulation of the LC resulted in a NE - mediated inhibition of cerebellar Purkinje cells located at terminals of the ceruleo - cerebellar pathway .
However , it is not certain as to the following : ( a ) what receptors were stimulated by the ACTH N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term depression at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the movement disorder ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .	However , it is not certain as to the following : ( a ) what receptors were stimulated by the ACTH N - terminal fragments at the LC that resulted in this disorder ; ( b ) whether NE , released onto Purkinje cell synapses located at terminals of the ceruleo - cerebellar pathway , did indeed cause the long - term disease* depression *disease at Purkinje cell synapses ( previously described by others ) that resulted in the long duration of the disease* movement disorder *disease ; ( c ) whether the inhibition of inhibitory Purkinje cells resulted in disinhibition or increased excitability of the unilateral cerebellar fastigial or interpositus nuclei , the output targets of the Purkinje cell axons , that may have been an important contributing factor to this disorder .
These questions are currently being investigated .	These questions are currently being investigated .
Enhanced stimulus - induced neurotransmitter overflow in epinephrine - induced hypertensive rats is not mediated by prejunctional beta - adrenoceptor activation .	Enhanced stimulus - induced neurotransmitter overflow in epinephrine - induced disease* hypertensive *disease rats is not mediated by prejunctional beta - adrenoceptor activation .
The present study examines the effect of 6 - day epinephrine treatment ( 100 micrograms / kg per h , s . c . ) on stimulus - induced ( 1 Hz ) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle - and epinephrine - treated rats .	The present study examines the effect of 6 - day epinephrine treatment ( 100 micrograms / kg per h , s . c . ) on stimulus - induced ( 1 Hz ) endogenous neurotransmitter overflow from the isolated perfused kidney of vehicle - and epinephrine - treated rats .
Renal catecholamine stores and stimulus - induced overflow in the vehicle - treated group consisted of norepinephrine only .	Renal catecholamine stores and stimulus - induced overflow in the vehicle - treated group consisted of norepinephrine only .
However , epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40 % of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree .	However , epinephrine treatment resulted in the incorporation of epinephrine into renal catecholamine stores such that approximately 40 % of the catecholamine present was epinephrine while the norepinephrine content was reduced by a similar degree .
Total tissue catecholamine content of the kidney on a molar basis was unchanged .	Total tissue catecholamine content of the kidney on a molar basis was unchanged .
Stimulus - induced fractional overflow of neurotransmitter from the epinephrine - treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney .	Stimulus - induced fractional overflow of neurotransmitter from the epinephrine - treated kidneys was approximately twice normal and consisted of both norepinephrine and epinephrine in proportions similar to those found in the kidney .
This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade .	This difference in fractional overflow between groups was not affected by neuronal and extraneuronal uptake blockade .
Propranolol had no effect on stimulus - induced overflow in either group .	Propranolol had no effect on stimulus - induced overflow in either group .
Phentolamine increased stimulus - induced overflow in both groups although the increment in overflow was greater in the epinephrine - treated group .	Phentolamine increased stimulus - induced overflow in both groups although the increment in overflow was greater in the epinephrine - treated group .
In conclusion , chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow .	In conclusion , chronic epinephrine treatment results in enhanced fractional neurotransmitter overflow .
However , neither alterations in prejunctional beta - adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration .	However , neither alterations in prejunctional beta - adrenoceptor influences nor alterations in neuronal and extraneuronal uptake mechanisms appear to be responsible for this alteration .
Furthermore , data obtained with phentolamine alone do not suggest alpha - adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment .	Furthermore , data obtained with phentolamine alone do not suggest alpha - adrenoceptor desensitization as the cause of the enhanced neurotransmitter overflow after epinephrine treatment .
GABA involvement in naloxone induced reversal of respiratory paralysis produced by thiopental .	GABA involvement in naloxone induced reversal of disease* respiratory paralysis *disease produced by thiopental .
No agent is yet available to reverse respiratory paralysis produced by CNS depressants , such as general anesthetics .	No agent is yet available to reverse disease* respiratory paralysis *disease produced by CNS depressants , such as general anesthetics .
In this study naloxone reversed respiratory paralysis induced by thiopental in rats .	In this study naloxone reversed disease* respiratory paralysis *disease induced by thiopental in rats .
25 mg / kg , i . v . thiopental produced anesthesia without altering respiratory rate , increased GABA , decreased glutamate , and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem .	25 mg / kg , i . v . thiopental produced anesthesia without altering respiratory rate , increased GABA , decreased glutamate , and had no effect on aspartate or glycine levels compared to controls in rat cortex and brain stem .
Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental .	Pretreatment of rats with thiosemicarbazide for 30 minutes abolished the anesthetic action as well as the respiratory depressant action of thiopental .
50 mg / kg , i . v . thiopental produced respiratory arrest with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .	50 mg / kg , i . v . thiopental produced disease* respiratory arrest *disease with further increase in GABA and decrease in glutamate again in cortex and brain stem without affecting any of the amino acids studied in four regions of rat brain .
Naloxone ( 2 . 5 mg / kg , i . v . ) reversed respiratory paralysis , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .	Naloxone ( 2 . 5 mg / kg , i . v . ) reversed disease* respiratory paralysis *disease , glutamate and GABA levels to control values in brain stem and cortex with no changes in caudate or cerebellum .
These data suggest naloxone reverses respiratory paralysis produced by thiopental and involves GABA in its action .	These data suggest naloxone reverses disease* respiratory paralysis *disease produced by thiopental and involves GABA in its action .
Diazepam facilitates reflex bradycardia in conscious rats .	Diazepam facilitates reflex disease* bradycardia *disease in conscious rats .
The effects of diazepam on cardiovascular function were assessed in conscious rats .	The effects of diazepam on cardiovascular function were assessed in conscious rats .
Intravenous administration of diazepam ( 1 - 30 mg kg - 1 ) produced a dose - dependent decrease in both the mean arterial pressure and the heart rate .	Intravenous administration of diazepam ( 1 - 30 mg kg - 1 ) produced a dose - dependent decrease in both the mean arterial pressure and the heart rate .
Also , reflex bradycardia was produced in rats by intravenous infusion of adrenaline ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .	Also , reflex disease* bradycardia *disease was produced in rats by intravenous infusion of adrenaline ( 1 . 25 - 2 . 5 micrograms kg - 1 ) .
Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex bradycardia .	Intravenous pretreatment of the rats with diazepam , although causing no change in the adrenaline - induced pressor effect , did enhance the adrenaline - induced reflex disease* bradycardia *disease .
However , the diazepam enhancement of adrenaline - induced reflex bradycardia was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .	However , the diazepam enhancement of adrenaline - induced reflex disease* bradycardia *disease was antagonized by pretreatment of rats with an intravenous dose of picrotoxin ( an agent blocks chloride channels by binding to sites associated with the benzodiazepine - GABA - chloride channel macromolecular complex ) .
The data indicate that diazepam acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex bradycardia mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .	The data indicate that diazepam acts through the benzodiazepine - GABA - chloride channel macromolecular complex within the central nervous system to facilitate reflex disease* bradycardia *disease mediated through baroreceptor reflexes in response to an acute increase in arterial pressure .
Initial potassium loss and hypokalaemia during chlorthalidone administration in patients with essential hypertension : the influence of dietary sodium restriction .	Initial potassium loss and disease* hypokalaemia *disease during chlorthalidone administration in patients with essential disease* hypertension *disease : the influence of dietary sodium restriction .
To investigate the initial potassium loss and development of hypokalaemia during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential hypertension who had shown hypokalaemia under prior oral diuretic treatment .	To investigate the initial potassium loss and development of disease* hypokalaemia *disease during the administration of an oral diuretic , metabolic balance studies were performed in ten patients with essential disease* hypertension *disease who had shown disease* hypokalaemia *disease under prior oral diuretic treatment .
Chlorthalidone ( 50 mg daily ) was given for 14 days .	Chlorthalidone ( 50 mg daily ) was given for 14 days .
Six patients received a normal - sodium diet and four a low - sodium ( 17 mmol / day ) diet .	Six patients received a normal - sodium diet and four a low - sodium ( 17 mmol / day ) diet .
All patients had a normal initial total body potassium ( 40K ) .	All patients had a normal initial total body potassium ( 40K ) .
The electrolyte balances , weight , bromide space , plasma renin activity , and aldosterone secretion rate were measured .	The electrolyte balances , weight , bromide space , plasma renin activity , and aldosterone secretion rate were measured .
In both groups a potassium deficit developed , with proportionally larger losses from the extracellular than from the intracellular compartment .	In both groups a potassium deficit developed , with proportionally larger losses from the extracellular than from the intracellular compartment .
In the normal - sodium group the highest mean potassium deficit was 176 mmol on day 9 , after which some potassium was regained ; in the low - sodium group the highest deficit was 276 mmol on day 13 .	In the normal - sodium group the highest mean potassium deficit was 176 mmol on day 9 , after which some potassium was regained ; in the low - sodium group the highest deficit was 276 mmol on day 13 .
The normal - sodium group showed an immediate but temporary rise of the renin and aldosterone levels ; in the low - sodium group renin and aldosterone increased more slowly but remained elevated .	The normal - sodium group showed an immediate but temporary rise of the renin and aldosterone levels ; in the low - sodium group renin and aldosterone increased more slowly but remained elevated .
It is concluded that dietary sodium restriction increases diuretic - induced potassium loss , presumably by an increased activity of the renin - angiotensin - aldosterone system , while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion .	It is concluded that dietary sodium restriction increases diuretic - induced potassium loss , presumably by an increased activity of the renin - angiotensin - aldosterone system , while sodium delivery to the distal renal tubules remains sufficiently high to allow increased potassium secretion .
Reversal of neuroleptic - induced catalepsy by novel aryl - piperazine anxiolytic drugs .	Reversal of neuroleptic - induced disease* catalepsy *disease by novel aryl - piperazine anxiolytic drugs .
The novel anxiolytic drug , buspirone , reverses catalepsy induced by haloperidol .	The novel anxiolytic drug , buspirone , reverses disease* catalepsy *disease induced by haloperidol .
A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced catalepsy .	A series of aryl - piperazine analogues of buspirone and other 5 - hydroxytryptaminergic agonists were tested for their ability to reverse haloperidol induced disease* catalepsy *disease .
Those drugs with strong affinity for 5 - hydroxytryptamine1a receptors were able to reverse catalepsy .	Those drugs with strong affinity for 5 - hydroxytryptamine1a receptors were able to reverse disease* catalepsy *disease .
Drugs with affinity for other 5 - HT receptors or weak affinity were ineffective .	Drugs with affinity for other 5 - HT receptors or weak affinity were ineffective .
However , inhibition of postsynaptic 5 - HT receptors neither inhibited nor potentiated reversal of catalepsy and leaves open the question as to the site or mechanism for this effect .	However , inhibition of postsynaptic 5 - HT receptors neither inhibited nor potentiated reversal of disease* catalepsy *disease and leaves open the question as to the site or mechanism for this effect .
Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium .	Glycopyrronium requirements for antagonism of the muscarinic side effects of edrophonium .
We have compared , in 60 adult patients , the cardiovascular effects of glycopyrronium 5 micrograms kg - 1 and 10 micrograms kg - 1 given either simultaneously or 1 min before edrophonium 1 mg kg - 1 .	We have compared , in 60 adult patients , the cardiovascular effects of glycopyrronium 5 micrograms kg - 1 and 10 micrograms kg - 1 given either simultaneously or 1 min before edrophonium 1 mg kg - 1 .
Significant differences between the four groups were detected ( P less than 0 . 001 ) .	Significant differences between the four groups were detected ( P less than 0 . 001 ) .
Both groups receiving 10 micrograms kg - 1 showed increases in heart rate of up to 30 beat min - 1 ( 95 % confidence limits 28 - 32 beat min - 1 ) .	Both groups receiving 10 micrograms kg - 1 showed increases in heart rate of up to 30 beat min - 1 ( 95 % confidence limits 28 - 32 beat min - 1 ) .
Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , edrophonium - induced bradycardias .	Use of glycopyrronium 5 micrograms kg - 1 provided greater cardiovascular stability and , given 1 min before the edrophonium , was sufficient to minimize early , edrophonium - induced disease* bradycardias *disease .
This low dose of glycopyrronium provided good control of oropharyngeal secretions .	This low dose of glycopyrronium provided good control of oropharyngeal secretions .
Selective injection of iopentol , iohexol and metrizoate into the left coronary artery of the dog .	Selective injection of iopentol , iohexol and metrizoate into the left coronary artery of the dog .
Induction of ventricular fibrillation and decrease of aortic pressure .	Induction of disease* ventricular fibrillation *disease and decrease of aortic pressure .
In twenty beagle dogs selective injections were made into the left coronary artery with iopentol , iohexol and metrizoate in doses of 4 ml , 8 ml and 16 ml .	In twenty beagle dogs selective injections were made into the left coronary artery with iopentol , iohexol and metrizoate in doses of 4 ml , 8 ml and 16 ml .
Thirty - six iopentol injections , 35 iohexol injections and 37 metrizoate injections were made .	Thirty - six iopentol injections , 35 iohexol injections and 37 metrizoate injections were made .
Frequencies of ventricular fibrillation were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .	Frequencies of disease* ventricular fibrillation *disease were significantly lower ( p less than 0 . 05 ) after iopentol ( 0 % ) and iohexol ( 3 % ) than after metrizoate ( 22 % ) .
Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses .	Iopentol and iohexol also produced significantly less decrease in aortic blood pressure than metrizoate at the different doses .
Thyroid function and urine - concentrating ability during lithium treatment .	Thyroid function and urine - concentrating ability during lithium treatment .
It has been suggested that adenylate cyclase inhibition may be important in the development of both nephrogenic diabetes insipidus and hypothyroidism during lithium treatment .	It has been suggested that adenylate cyclase inhibition may be important in the development of both disease* nephrogenic diabetes insipidus *disease and disease* hypothyroidism *disease during lithium treatment .
We measured serum thyroxine and urine - concentrating ability ( Umax ) in response to desmopressin ( DDAVP ) in 85 patients receiving lithium .	We measured serum thyroxine and urine - concentrating ability ( Umax ) in response to desmopressin ( DDAVP ) in 85 patients receiving lithium .
Hypothyroidism developed in eight patients while they were taking lithium .	disease* Hypothyroidism *disease developed in eight patients while they were taking lithium .
Impaired Umax was found in both euthyroid and hypothyroid patients while some hypothyroid patients concentrated their urine well .	Impaired Umax was found in both euthyroid and disease* hypothyroid *disease patients while some disease* hypothyroid *disease patients concentrated their urine well .
It is concluded that the dominant mechanisms by which lithium exerts these two effects are different .	It is concluded that the dominant mechanisms by which lithium exerts these two effects are different .
Remodelling of nerve structure in experimental isoniazid neuropathy in the rat .	Remodelling of nerve structure in experimental isoniazid disease* neuropathy *disease in the rat .
The neuropathy caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .	The disease* neuropathy *disease caused by a single dose of isoniazid in rats was studied with a computer - assisted morphometric method .
Scatter diagrams of the g ratio ( quotient fibre diameter / axon diameter ) define regenerating fibres as a distinct population , distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre .	Scatter diagrams of the g ratio ( quotient fibre diameter / axon diameter ) define regenerating fibres as a distinct population , distinguishable from the surviving fibres by reduced sheath thickness and reduced axon calibre .
There was also evidence of a subtle direct toxic effect on the entire fibre population , causing axon shrinkage masked by readjustment of the myelin sheath .	There was also evidence of a subtle direct toxic effect on the entire fibre population , causing axon shrinkage masked by readjustment of the myelin sheath .
Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , chlorpheniramine , and placebo in the treatment of spring allergic rhinitis .	Multicenter , double - blind , multiple - dose , parallel - groups efficacy and safety trial of azelastine , chlorpheniramine , and placebo in the treatment of disease* spring allergic rhinitis *disease .
Azelastine , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of spring allergic rhinitis in a multicenter , double - blind , multiple - dose , parallel - groups study .	Azelastine , a novel antiallergic medication , was compared with chlorpheniramine maleate and placebo for efficacy and safety in the treatment of disease* spring allergic rhinitis *disease in a multicenter , double - blind , multiple - dose , parallel - groups study .
One hundred fifty - five subjects participated .	One hundred fifty - five subjects participated .
Subjects ranged in age from 18 to 60 years of age and had at least a 2 - year history of spring allergic rhinitis , confirmed by positive skin test to spring aeroallergens .	Subjects ranged in age from 18 to 60 years of age and had at least a 2 - year history of disease* spring allergic rhinitis *disease , confirmed by positive skin test to spring aeroallergens .
Medications were given four times daily ; the azelastine groups received 0 . 5 , 1 . 0 , or 2 . 0 mg in the morning and evening with placebo in the early and late afternoon ; the chlorpheniramine group received 4 . 0 mg four times daily .	Medications were given four times daily ; the azelastine groups received 0 . 5 , 1 . 0 , or 2 . 0 mg in the morning and evening with placebo in the early and late afternoon ; the chlorpheniramine group received 4 . 0 mg four times daily .
Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4 - week treatment period while subjects received study medications .	Daily subject symptom cards were completed during a screening period to assess pretreatment symptoms and during a 4 - week treatment period while subjects received study medications .
Individual symptoms , total symptoms , and major symptoms were compared to determine efficacy of medication .	Individual symptoms , total symptoms , and major symptoms were compared to determine efficacy of medication .
Elicited , volunteered , and observed adverse experiences were recorded for each subject and compared among groups .	Elicited , volunteered , and observed adverse experiences were recorded for each subject and compared among groups .
Vital signs , body weights , serum chemistry values , complete blood cell counts , urine studies , and electrocardiograms were obtained for each subject and compared among groups .	Vital signs , body weights , serum chemistry values , complete blood cell counts , urine studies , and electrocardiograms were obtained for each subject and compared among groups .
Symptoms relief in the group receiving the highest concentration of azelastine ( 2 . 0 mg twice daily ) was statistically greater than in the placebo group during all weeks of the study .	Symptoms relief in the group receiving the highest concentration of azelastine ( 2 . 0 mg twice daily ) was statistically greater than in the placebo group during all weeks of the study .
Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study .	Lower doses of azelastine were statistically more effective than placebo only during portions of the first 3 weeks of the study .
In contrast , although the chlorpheniramine group did have fewer symptoms than the placebo group during the study , the difference never reached statistical significance during any week of the study .	In contrast , although the chlorpheniramine group did have fewer symptoms than the placebo group during the study , the difference never reached statistical significance during any week of the study .
There were no serious side effects in any of the treatment groups .	There were no serious side effects in any of the treatment groups .
Drowsiness and altered taste perception were increased significantly over placebo only in the high - dose azelastine group .	disease* Drowsiness *disease and disease* altered taste perception *disease were increased significantly over placebo only in the high - dose azelastine group .
Azelastine appears to be a safe , efficacious medication for seasonal allergic rhinitis .	Azelastine appears to be a safe , efficacious medication for disease* seasonal allergic rhinitis *disease .
Toxicity due to remission inducing drugs in rheumatoid arthritis .	disease* Toxicity *disease due to remission inducing drugs in disease* rheumatoid arthritis *disease .
Association with HLA - B35 and Cw4 antigens .	Association with HLA - B35 and Cw4 antigens .
Twenty - five patients with rheumatoid arthritis ( RA ) who developed toxicity while taking remission inducing drugs and 30 without toxicity were studied for possible associations with class I and II HLA antigens .	Twenty - five patients with disease* rheumatoid arthritis *disease ( disease* RA *disease ) who developed disease* toxicity *disease while taking remission inducing drugs and 30 without disease* toxicity *disease were studied for possible associations with class I and II HLA antigens .
A strong association has been found between nephritis and dermatitis due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between dermatitis due to gold thiosulphate and B35 .	A strong association has been found between disease* nephritis *disease and disease* dermatitis *disease due to Tiopronin ( a D - Penicillamine like compound ) and class I antigens B35 - Cw4 , and between disease* dermatitis *disease due to gold thiosulphate and B35 .
Compared to healthy controls a lower DR5 frequency was observed in patients with RA except for the Tiopronin related nephritis group .	Compared to healthy controls a lower DR5 frequency was observed in patients with disease* RA *disease except for the Tiopronin related disease* nephritis *disease group .
Transient contralateral rotation following unilateral substantia nigra lesion reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine .	Transient disease* contralateral rotation *disease following unilateral disease* substantia nigra lesion *disease reflects susceptibility of the nigrostriatal system to exhaustion by amphetamine .
Following unilateral 6 - OHDA induced SN lesion , a transient period of contralateral rotation has been reported to precede the predominant ipsilateral circling .	Following unilateral 6 - OHDA induced disease* SN lesion *disease , a transient period of disease* contralateral rotation *disease has been reported to precede the predominant disease* ipsilateral circling *disease .
In order to clarify the nature of this initial contralateral rotation we examined the effect of the duration of recovery period after the lesion , on amphetamine - induced rotational behavior .	In order to clarify the nature of this initial disease* contralateral rotation *disease we examined the effect of the duration of recovery period after the lesion , on amphetamine - induced disease* rotational behavior *disease .
Three days post lesion , most rats circled predominantly contralaterally to the lesion .	Three days post lesion , most rats circled predominantly contralaterally to the lesion .
Such contralateral rotation may result from either degeneration - induced breakdown of the DA pool , or lesion - induced increase of DA turnover in the spared neurons .	Such disease* contralateral rotation *disease may result from either degeneration - induced breakdown of the DA pool , or lesion - induced increase of DA turnover in the spared neurons .
A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning , indicating involvement of spared cells in the contralateral rotation .	A substantial degree of contralateral preference was still evident when amphetamine was administered for the first time 24 days after lesioning , indicating involvement of spared cells in the disease* contralateral rotation *disease .
However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , amphetamine - induced rotation tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .	However , regardless of the duration of recovery ( and irrespective of either lesion volume , amphetamine dose , or post - lesion motor exercise ) , amphetamine - induced disease* rotation *disease tended to become gradually more ipsilateral as the observation session progressed , and all rats circled ipsilaterally to the lesion in response to further amphetamine injections .
These findings suggest that amphetamine has an irreversible effect on the post - lesion DA pool contributing to contralateral rotation .	These findings suggest that amphetamine has an irreversible effect on the post - lesion DA pool contributing to disease* contralateral rotation *disease .
Mitomycin C associated hemolytic uremic syndrome .	Mitomycin C associated disease* hemolytic uremic syndrome *disease .
Mitomycin C associated Hemolytic Uremic Syndrome ( HUS ) is a potentially fatal but uncommon condition that is not yet widely recognised .	Mitomycin C associated disease* Hemolytic Uremic Syndrome *disease ( disease* HUS *disease ) is a potentially fatal but uncommon condition that is not yet widely recognised .
It consists of microangiopathic hemolytic anemia , thrombocytopenia and progressive renal failure associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .	It consists of microangiopathic disease* hemolytic anemia *disease , disease* thrombocytopenia *disease and progressive disease* renal failure *disease associated with mitomycin C treatment and affects about 10 % of patients treated with this agent .
The renal failure usually develops about 8 - 10 mth after start of mitomycin C treatment and the mortality is approximately 60 % from renal failure or pulmonary edema .	The disease* renal failure *disease usually develops about 8 - 10 mth after start of mitomycin C treatment and the mortality is approximately 60 % from disease* renal failure *disease or disease* pulmonary edema *disease .
Renal lesions are similar to those seen in idiopathic HUS and include arteriolar fibrin thrombi , expanded subendothelial zones in glomerular capillary walls , ischemic wrinkling of glomerular basement membranes and mesangiolysis .	disease* Renal lesions *disease are similar to those seen in idiopathic disease* HUS *disease and include arteriolar fibrin disease* thrombi *disease , expanded subendothelial zones in glomerular capillary walls , disease* ischemic *disease wrinkling of glomerular basement membranes and mesangiolysis .
The mechanism of action is postulated as mitomycin C - induced endothelial cell damage .	The mechanism of action is postulated as mitomycin C - induced endothelial cell damage .
We describe the clinical course and pathological findings in a 65 yr - old man with gastric adenocarcinoma who developed renal failure and thrombocytopenia while on treatment with mitomycin C and died in pulmonary edema .	We describe the clinical course and pathological findings in a 65 yr - old man with disease* gastric adenocarcinoma *disease who developed disease* renal failure *disease and disease* thrombocytopenia *disease while on treatment with mitomycin C and died in disease* pulmonary edema *disease .
Ketanserin pretreatment reverses alfentanil - induced muscle rigidity .	Ketanserin pretreatment reverses alfentanil - induced disease* muscle rigidity *disease .
Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the muscle rigidity produced in rats by the potent short - acting opiate agonist alfentanil .	Systemic pretreatment with ketanserin , a relatively specific type - 2 serotonin receptor antagonist , significantly attenuated the disease* muscle rigidity *disease produced in rats by the potent short - acting opiate agonist alfentanil .
Following placement of subcutaneous electrodes in each animal ' s left gastrocnemius muscle , rigidity was assessed by analyzing root - mean - square electromyographic activity .	Following placement of subcutaneous electrodes in each animal ' s left gastrocnemius muscle , disease* rigidity *disease was assessed by analyzing root - mean - square electromyographic activity .
Intraperitoneal ketanserin administration at doses of 0 . 63 and 2 . 5 mg / kg prevented the alfentanil - induced increase in electromyographic activity compared with animals pretreated with saline .	Intraperitoneal ketanserin administration at doses of 0 . 63 and 2 . 5 mg / kg prevented the alfentanil - induced increase in electromyographic activity compared with animals pretreated with saline .
Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the rigidity produced by alfentanil .	Chlordiazepoxide at doses up to 10 mg / kg failed to significantly influence the disease* rigidity *disease produced by alfentanil .
Despite the absence of rigidity , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .	Despite the absence of disease* rigidity *disease , animals that received ketanserin ( greater than 0 . 31 mg / kg i . p . ) followed by alfentanil were motionless , flaccid , and less responsive to external stimuli than were animals receiving alfentanil alone .
Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60 - min recording period than did animals that received ketanserin alone .	Rats that received ketanserin and alfentanil exhibited less rearing and exploratory behavior at the end of the 60 - min recording period than did animals that received ketanserin alone .
These results , in combination with previous work , suggest that muscle rigidity , a clinically relevant side - effect of parenteral narcotic administration , may be partly mediated via serotonergic pathways .	These results , in combination with previous work , suggest that disease* muscle rigidity *disease , a clinically relevant side - effect of parenteral narcotic administration , may be partly mediated via serotonergic pathways .
Pretreatment with type - 2 serotonin antagonists may be clinically useful in attenuating opiate - induced rigidity , although further studies will be necessary to assess the interaction of possibly enhanced CNS , cardiovascular , and respiratory depression .	Pretreatment with type - 2 serotonin antagonists may be clinically useful in attenuating opiate - induced disease* rigidity *disease , although further studies will be necessary to assess the interaction of possibly enhanced CNS , disease* cardiovascular , and respiratory depression *disease .
Antagonism of diazepam - induced sedative effects by Ro15 - 1788 in patients after surgery under lumbar epidural block .	Antagonism of diazepam - induced sedative effects by Ro15 - 1788 in patients after surgery under lumbar epidural block .
A double - blind placebo - controlled investigation of efficacy and safety .	A double - blind placebo - controlled investigation of efficacy and safety .
The aim of this study was to assess the efficacy of Ro15 - 1788 and a placebo in reversing diazepam - induced effects after surgery under epidural block , and to evaluate the local tolerance and general safety of Ro15 - 1788 .	The aim of this study was to assess the efficacy of Ro15 - 1788 and a placebo in reversing diazepam - induced effects after surgery under epidural block , and to evaluate the local tolerance and general safety of Ro15 - 1788 .
Fifty - seven patients were sedated with diazepam for surgery under epidural anaesthesia .	Fifty - seven patients were sedated with diazepam for surgery under epidural anaesthesia .
Antagonism of diazepam - induced effects by Ro15 - 1788 was investigated postoperatively in a double - blind placebo - controlled trial .	Antagonism of diazepam - induced effects by Ro15 - 1788 was investigated postoperatively in a double - blind placebo - controlled trial .
The patient ' s subjective assessment of mood rating , an objective test of performance , a test for amnesia , and vital signs were recorded for up to 300 min after administration of the trial drug .	The patient ' s subjective assessment of mood rating , an objective test of performance , a test for disease* amnesia *disease , and vital signs were recorded for up to 300 min after administration of the trial drug .
No significant differences between the two groups were observed for mood rating , amnesia , or vital signs .	No significant differences between the two groups were observed for mood rating , disease* amnesia *disease , or vital signs .
The Ro15 - 1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug .	The Ro15 - 1788 group showed a significant improvement in the performance test up to 120 min after administration of the drug .
There was no evidence of reaction at the injection site .	There was no evidence of reaction at the injection site .
Chorea associated with oral contraception .	disease* Chorea *disease associated with oral contraception .
Three patients developed chorea while receiving oral contraceptives .	Three patients developed disease* chorea *disease while receiving oral contraceptives .
Two were young patients whose chorea developed long after treatment had been started and disappeared soon after it had been discontinued .	Two were young patients whose disease* chorea *disease developed long after treatment had been started and disappeared soon after it had been discontinued .
The third patient had acute amphetamine - induced chorea after prolonged oral contraception .	The third patient had acute amphetamine - induced disease* chorea *disease after prolonged oral contraception .
Prolonged administration of female sex hormones is a possible cause of chorea in women who have not previously had chorea or rheumatic fever .	Prolonged administration of female sex hormones is a possible cause of disease* chorea *disease in women who have not previously had disease* chorea *disease or disease* rheumatic fever *disease .
Co - carcinogenic effect of retinyl acetate on forestomach carcinogenesis of male F344 rats induced with butylated hydroxyanisole .	Co - disease* carcinogenic *disease effect of retinyl acetate on disease* forestomach carcinogenesis *disease of male F344 rats induced with butylated hydroxyanisole .
The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole ( BHA ) - induced rat forestomach tumorigenesis was examined .	The potential modifying effect of retinyl acetate ( RA ) on butylated hydroxyanisole ( BHA ) - induced rat disease* forestomach tumorigenesis *disease was examined .
Male F344 rats , 5 weeks of age , were maintained on diet containing 1 % or 2 % BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations ( w / v ) for 52 weeks .	Male F344 rats , 5 weeks of age , were maintained on diet containing 1 % or 2 % BHA by weight and simultaneously on drinking water supplemented with RA at various concentrations ( w / v ) for 52 weeks .
In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of forestomach tumors ( squamous cell papilloma and carcinoma ) to 60 % ( 9 / 15 , 2 rats with carcinoma ) from 15 % ( 3 / 20 , one rat with carcinoma ) in the group given RA - free water .	In groups given 2 % BHA , although marked hyperplastic changes of the forestomach epithelium were observed in all animals , co - administration of 0 . 25 % RA significantly ( P less than 0 . 05 ) increased the incidence of disease* forestomach tumors *disease ( disease* squamous cell papilloma *disease and disease* carcinoma *disease ) to 60 % ( 9 / 15 , 2 rats with disease* carcinoma *disease ) from 15 % ( 3 / 20 , one rat with disease* carcinoma *disease ) in the group given RA - free water .
In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced epithelial hyperplasia .	In rats given 1 % BHA , RA co - administered at a dose of 0 . 05 , 0 . 1 , 0 . 2 or 0 . 25 % showed a dose - dependent enhancing effect on the development of the BHA - induced disease* epithelial hyperplasia *disease .
Tumors , all papillomas , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % RA co - administration .	disease* Tumors *disease , all disease* papillomas *disease , were induced in 3 rats ( 17 % ) with 0 . 25 % RA and in one rat ( 10 % ) with 0 . 05 % RA co - administration .
RA alone did not induce hyperplastic changes in the forestomach .	RA alone did not induce hyperplastic changes in the forestomach .
These findings indicate that RA acted as a co - carcinogen in the BHA forestomach carcinogenesis of the rat .	These findings indicate that RA acted as a co - carcinogen in the BHA disease* forestomach carcinogenesis *disease of the rat .
A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C .	A prospective study on the dose dependency of disease* cardiotoxicity *disease induced by mitomycin C .
Since 1975 mitomycin C ( MMC ) has been suggested to be cardiotoxic , especially when combined with or given following doxorubicin .	Since 1975 mitomycin C ( MMC ) has been suggested to be disease* cardiotoxic *disease , especially when combined with or given following doxorubicin .
Data on dose dependency or incidence concerning this side effect were not known .	Data on dose dependency or incidence concerning this side effect were not known .
We have initiated a prospective study to obtain some more data on these subjects .	We have initiated a prospective study to obtain some more data on these subjects .
Forty - four MMC - treated patients were studied , 37 of them could be evaluated .	Forty - four MMC - treated patients were studied , 37 of them could be evaluated .
All patients were studied by repeated physical examinations , chest X - rays , electro - and echocardiography and radionuclide left ventricular ejection fraction ( EF ) determinations .	All patients were studied by repeated physical examinations , chest X - rays , electro - and echocardiography and radionuclide left ventricular ejection fraction ( EF ) determinations .
The results were evaluated per cumulative dose level .	The results were evaluated per cumulative dose level .
One of the patients developed cardiac failure after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .	One of the patients developed disease* cardiac failure *disease after 30 mg m - 2 MMC and only 150 mg m - 2 doxorubicin .
The cardiac failure was predicted by a drop in EF determined during a cold pressor test .	The disease* cardiac failure *disease was predicted by a drop in EF determined during a cold pressor test .
None of the other patients developed clinical cardiotoxicity , nor did the studied parameters change .	None of the other patients developed clinical disease* cardiotoxicity *disease , nor did the studied parameters change .
The literature on this subject was also reviewed .	The literature on this subject was also reviewed .
Based on the combined data from the present study and the literature , we suggest that MMC - related cardiotoxicity is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .	Based on the combined data from the present study and the literature , we suggest that MMC - related disease* cardiotoxicity *disease is dose dependent , occurring at cumulative dose levels of 30 mg m - 2 or more , mainly in patients also ( previously or simultaneously ) treated with doxorubicin .
The incidence is likely to be less than 10 % even for this risk group .	The incidence is likely to be less than 10 % even for this risk group .
Reversible cerebral lesions associated with tiazofurin usage : MR demonstration .	Reversible disease* cerebral lesions *disease associated with tiazofurin usage : MR demonstration .
Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation .	Tiazofurin is an experimental chemotherapeutic agent currently undergoing clinical evaluation .
We report our results with magnetic resonance ( MR ) in demonstrating reversible cerebral abnormalities concurrent with the use of this drug .	We report our results with magnetic resonance ( MR ) in demonstrating reversible disease* cerebral abnormalities *disease concurrent with the use of this drug .
The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography .	The abnormalities on MR were correlated with findings on CT as well as with cerebral angiography .
The utility of MR in the evaluation of patients receiving this new agent is illustrated .	The utility of MR in the evaluation of patients receiving this new agent is illustrated .
Receptor mechanisms of nicotine - induced locomotor hyperactivity in chronic nicotine - treated rats .	Receptor mechanisms of nicotine - induced disease* locomotor hyperactivity *disease in chronic nicotine - treated rats .
Rats were pretreated with saline or nicotine ( 1 . 5 mg / kg per day ) by subcutaneously implanting each animal with an Alzet osmotic mini - pump which continuously released saline or nicotine for 1 , 5 and 14 days .	Rats were pretreated with saline or nicotine ( 1 . 5 mg / kg per day ) by subcutaneously implanting each animal with an Alzet osmotic mini - pump which continuously released saline or nicotine for 1 , 5 and 14 days .
At the end of each pretreatment period , animals were used for ( i ) determining their locomotor response to acutely injected nicotine ( 0 . 2 mg / kg , s . c . ) and ( ii ) measuring the density of L - [ 3H ] nicotine and [ 3H ] spiperone binding sites in the striatum .	At the end of each pretreatment period , animals were used for ( i ) determining their locomotor response to acutely injected nicotine ( 0 . 2 mg / kg , s . c . ) and ( ii ) measuring the density of L - [ 3H ] nicotine and [ 3H ] spiperone binding sites in the striatum .
We observed no changes in nicotine - induced locomotor response , striatal L - [ 3H ] nicotine and [ 3H ] spiperone binding in the animals pretreated with nicotine for 1 day .	We observed no changes in nicotine - induced locomotor response , striatal L - [ 3H ] nicotine and [ 3H ] spiperone binding in the animals pretreated with nicotine for 1 day .
In rats which were pretreated with nicotine for 5 days , there was a significant increase in the nicotine - stimulated locomotor response which was associated with an increase in the number of L - [ 3H ] nicotine binding sites and also with an elevated dopamine ( DA ) level in the striatum .	In rats which were pretreated with nicotine for 5 days , there was a significant increase in the nicotine - stimulated locomotor response which was associated with an increase in the number of L - [ 3H ] nicotine binding sites and also with an elevated dopamine ( DA ) level in the striatum .
The number of striatal [ 3H ] spiperone binding sites was not affected .	The number of striatal [ 3H ] spiperone binding sites was not affected .
In animals pretreated with nicotine for 14 days , the nicotine - induced locomotor response remained to be potentiated .	In animals pretreated with nicotine for 14 days , the nicotine - induced locomotor response remained to be potentiated .
However , this response was correlated with an elevated number of striatal [ 3H ] spiperone binding sites , whereas the number of striatal L - [ 3H ] nicotine binding sites and the striatal DA level were normal .	However , this response was correlated with an elevated number of striatal [ 3H ] spiperone binding sites , whereas the number of striatal L - [ 3H ] nicotine binding sites and the striatal DA level were normal .
These results suggest that chronic nicotine - treated rats develop locomotor hyperactivity in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .	These results suggest that chronic nicotine - treated rats develop disease* locomotor hyperactivity *disease in response to nicotine initially due to increases of both the density of nicotinic receptors and DA concentration , followed by inducing DA receptor supersensitivity in the striatum .
Amelioration of bendrofluazide - induced hypokalemia by timolol .	Amelioration of bendrofluazide - induced disease* hypokalemia *disease by timolol .
The beta adrenergic blocking drug , timolol , tended to correct the hypokalemia of short - term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant .	The beta adrenergic blocking drug , timolol , tended to correct the disease* hypokalemia *disease of short - term bendrofluazide treatment in 6 healthy male subjects and although the effect was small it was significant .
Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium / potassium ratio .	Timolol also reduced the rise in plasma aldosterone and urine potassium excretion following bendrofluazide and increased the urine sodium / potassium ratio .
There was no evidence of a shift of potassium from the intracellular to the extracellular space .	There was no evidence of a shift of potassium from the intracellular to the extracellular space .
St .	disease* St .
Anthony ' s fire , then and now : a case report and historical review .	disease* Anthony ' s fire *disease , then and now : a case report and historical review .
A rare case of morbid vasospasm , together with striking angiographic findings , is described secondary to the ingestion of methysergide by a 48 - year - old woman .	A rare case of morbid disease* vasospasm *disease , together with striking angiographic findings , is described secondary to the ingestion of methysergide by a 48 - year - old woman .
A brief review of the literature on similar cases is presented .	A brief review of the literature on similar cases is presented .
A discussion of the history of ergot includes its original discovery , the epidemics of gangrene that it has caused through the ages and its past and present role in the management of migraine headache .	A discussion of the history of ergot includes its original discovery , the epidemics of disease* gangrene *disease that it has caused through the ages and its past and present role in the management of disease* migraine headache *disease .
Despite the advent of calcium channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in migraine therapy , so that the danger of St .	Despite the advent of calcium channel blockers and beta - adrenergic antagonists , ergot preparations continue to play a major role in disease* migraine *disease therapy , so that the danger of disease* St .
Anthony ' s fire persists .	disease* Anthony ' s fire *disease persists .
Cardiac transplantation : improved quality of survival with a modified immunosuppressive protocol .	Cardiac transplantation : improved quality of survival with a modified immunosuppressive protocol .
The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients .	The effects on renal function on two different immunosuppressive protocols were evaluated retrospectively in two subsequent groups of heart transplant recipients .
In group I , cyclosporine was given before the procedure at a loading dose of 17 . 5 mg / kg and then continued after the procedure to keep a whole blood level about 1000 ng / ml .	In group I , cyclosporine was given before the procedure at a loading dose of 17 . 5 mg / kg and then continued after the procedure to keep a whole blood level about 1000 ng / ml .
In group II , cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine , which was used for the first postoperative week .	In group II , cyclosporine was started only after the procedure at a lower dosage and was complemented by azathioprine , which was used for the first postoperative week .
Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels .	Group II showed a better perioperative renal function as determined by serum blood urea nitrogen and serum creatinine levels .
Group II also showed a significant decrease of chronic nephrotoxicity secondary to long - term therapy with cyclosporine .	Group II also showed a significant decrease of chronic disease* nephrotoxicity *disease secondary to long - term therapy with cyclosporine .
Despite this improvement in late renal function , group II still shows a slow rise in serum creatinine .	Despite this improvement in late renal function , group II still shows a slow rise in serum creatinine .
We think that even these lower dosages of cyclosporine can cause chronic nephrotoxicity and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .	We think that even these lower dosages of cyclosporine can cause chronic disease* nephrotoxicity *disease and that further modification of the immunosuppressive regimen is required to completely abolish this toxic side effect .
Ethopropazine and benztropine in neuroleptic - induced parkinsonism .	Ethopropazine and benztropine in neuroleptic - induced disease* parkinsonism *disease .
In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients .	In a 12 - week controlled study ethopropazine was compared to benztropine in the treatment of disease* parkinsonism *disease induced by fluphenazine enanthate in 60 disease* schizophrenic *disease outpatients .
Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine , their previous antiparkinsonian drug .	Ethopropazine and benztropine were found to be equally effective in controlling disease* parkinsonian symptoms *disease and were as efficacious as procyclidine , their previous antiparkinsonian drug .
However , benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment , and significantly more anxiety and depression than ethopropazine treated patients .	However , benztropine treated patients had a significant increase in disease* tardive dyskinesia *disease compared to their condition during procyclindine treatment , and significantly more disease* anxiety *disease and disease* depression *disease than ethopropazine treated patients .
This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic - induced parkinsonian symptoms , because of its more toxic central and peripheral atropinic effect .	This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic - induced disease* parkinsonian symptoms *disease , because of its more toxic central and peripheral atropinic effect .
Quinidine phenylethylbarbiturate - induced fulminant hepatitis in a pregnant woman .	Quinidine phenylethylbarbiturate - induced fulminant disease* hepatitis *disease in a pregnant woman .
A case report .	A case report .
We report the case of a 19 - year - old Laotian patient affected by fulminant hepatitis during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .	We report the case of a 19 - year - old Laotian patient affected by fulminant disease* hepatitis *disease during the third trimester of her pregnancy after a 1 - month administration of quinidine phenylethylbarbiturate .
After delivery , the patient underwent orthotopic liver transplantation .	After delivery , the patient underwent orthotopic liver transplantation .
The patient was in good condition 16 months after liver transplantation .	The patient was in good condition 16 months after liver transplantation .
Quinidine itself or phenylethylbarbiturate may be responsible for fulminant hepatitis in this patient .	Quinidine itself or phenylethylbarbiturate may be responsible for fulminant disease* hepatitis *disease in this patient .
Mechanisms of myocardial ischemia induced by epinephrine : comparison with exercise - induced ischemia .	Mechanisms of disease* myocardial ischemia *disease induced by epinephrine : comparison with exercise - induced disease* ischemia *disease .
The role of epinephrine in eliciting myocardial ischemia was examined in patients with coronary artery disease .	The role of epinephrine in eliciting disease* myocardial ischemia *disease was examined in patients with disease* coronary artery disease *disease .
Objective signs of ischemia and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise .	Objective signs of disease* ischemia *disease and factors increasing myocardial oxygen consumption were compared during epinephrine infusion and supine bicycle exercise .
Both epinephrine and exercise produced myocardial ischemia as evidenced by ST segment depression and angina .	Both epinephrine and exercise produced disease* myocardial ischemia *disease as evidenced by ST segment disease* depression *disease and disease* angina *disease .
However , the mechanisms of myocardial ischemia induced by epinephrine were significantly different from those of exercise .	However , the mechanisms of disease* myocardial ischemia *disease induced by epinephrine were significantly different from those of exercise .
Exercise - induced myocardial ischemia was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while epinephrine - induced ischemia was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .	Exercise - induced disease* myocardial ischemia *disease was marked predominantly by increased heart rate and rate - pressure product with a minor contribution of end - diastolic volume , while epinephrine - induced disease* ischemia *disease was characterized by a marked increase in contractility and a less pronounced increase in heart rate and rate - pressure product .
These findings indicate that ischemia produced by epinephrine , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .	These findings indicate that disease* ischemia *disease produced by epinephrine , as may occur during states of emotional distress , has a mechanism distinct from that due to physical exertion .
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10 - propargyl - 5 , 8 - dideazafolic acid ( CB 3717 ) .	Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10 - propargyl - 5 , 8 - dideazafolic acid ( CB 3717 ) .
CB 3717 , N10 - propargyl - 5 , 8 - dideazafolic acid , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose cytotoxicity is mediated solely through the inhibition of this enzyme .	CB 3717 , N10 - propargyl - 5 , 8 - dideazafolic acid , is a tight - binding inhibitor of thymidylate synthase ( TS ) whose disease* cytotoxicity *disease is mediated solely through the inhibition of this enzyme .
Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates .	Recent preclinical studies have focused on the intracellular formation of CB 3717 polyglutamates .
Following a 12 - hour exposure of L1210 cells to 50 microM [ 3H ] CB 3717 , 30 % of the extractable radioactivity could be accounted for as CB 3717 tetra - and pentaglutamate , as determined by high - pressure liquid chromatography ( HPLC ) analyses .	Following a 12 - hour exposure of L1210 cells to 50 microM [ 3H ] CB 3717 , 30 % of the extractable radioactivity could be accounted for as CB 3717 tetra - and pentaglutamate , as determined by high - pressure liquid chromatography ( HPLC ) analyses .
As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than CB 3717 , respectively , and their formation may , therefore , be an important determinant of CB 3717 cytotoxicity .	As inhibitors of isolated L1210 TS , CB 3717 di - , tri - , tetra - and pentaglutamate are 26 - , 87 - , 119 - and 114 - fold more potent than CB 3717 , respectively , and their formation may , therefore , be an important determinant of CB 3717 disease* cytotoxicity *disease .
In early clinical studies with CB 3717 , activity has been seen in breast cancer , ovarian cancer , hepatoma , and mesothelioma .	In early clinical studies with CB 3717 , activity has been seen in disease* breast cancer *disease , disease* ovarian cancer *disease , disease* hepatoma *disease , and disease* mesothelioma *disease .
Toxicities included hepatotoxicity , malaise , and dose - limiting nephrotoxicity .	disease* Toxicities *disease included disease* hepatotoxicity *disease , disease* malaise *disease , and dose - limiting disease* nephrotoxicity *disease .
This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions .	This latter effect is thought to be due to drug precipitation within the renal tubule as a result of the poor solubility of CB 3717 under acidic conditions .
In an attempt to overcome this problem , a clinical trial of CB 3717 administered with alkaline diuresis is under way .	In an attempt to overcome this problem , a clinical trial of CB 3717 administered with alkaline diuresis is under way .
Preliminary results at 400 and 500 mg / m2 suggest that a reduction in nephrotoxicity may have been achieved with only 1 instance of renal toxicity in 10 patients .	Preliminary results at 400 and 500 mg / m2 suggest that a reduction in disease* nephrotoxicity *disease may have been achieved with only 1 instance of disease* renal toxicity *disease in 10 patients .
Hepatotoxicity and malaise are again the most frequent side effects .	disease* Hepatotoxicity *disease and disease* malaise *disease are again the most frequent side effects .
Evidence of antitumor activity has been seen in 3 patients .	Evidence of antitumor activity has been seen in 3 patients .
Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved .	Pharmacokinetic investigations have shown that alkaline diuresis does not alter CB 3717 plasma levels or urinary excretion and that satisfactory urinary alkalinization can be readily achieved .
Type B hepatitis after needle - stick exposure : prevention with hepatitis B immune globulin .	disease* Type B hepatitis *disease after needle - stick exposure : prevention with disease* hepatitis B *disease immune globulin .
Final report of the Veterans Administration Cooperative Study .	Final report of the Veterans Administration Cooperative Study .
Hepatitis B immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing type B hepatitis after needle - stick exposure to hepatitis B surface antigen ( HBsAG ) - positive donors .	disease* Hepatitis B *disease immune globulin ( HBIG ) and immune serum globulin ( ISG ) were examined in a randomized , double - blind trial to assess their relative efficacies in preventing disease* type B hepatitis *disease after needle - stick exposure to hepatitis B surface antigen ( HBsAG ) - positive donors .
Clinical hepatitis developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .	Clinical disease* hepatitis *disease developed in 1 . 4 % of HBIG and in 5 . 9 % of ISG recipients ( P = 0 . 016 ) , and seroconversion ( anti - HBs ) occurred in 5 . 6 % and 20 . 7 % of them respectively ( P less than 0 . 001 ) .
Mild and transient side - effects were noted in 3 . 0 % of ISG and in 3 . 2 % of HBIG recipients .	Mild and transient side - effects were noted in 3 . 0 % of ISG and in 3 . 2 % of HBIG recipients .
Available donor sera were examined for DNA polymerase ( DNAP ) and e antigen and antibody ( HBeAg ; anti - HBE ) .	Available donor sera were examined for DNA polymerase ( DNAP ) and e antigen and antibody ( HBeAg ; anti - HBE ) .
Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg - positive donors .	Both DNAP and HBeAg showed a highly statistically significant correlation with the infectivity of HBsAg - positive donors .
Hepatitis B immune globulin remained significantly superior to ISG in preventing type B hepatitis even when the analysis was confined to these two high - risk subgroups .	disease* Hepatitis B *disease immune globulin remained significantly superior to ISG in preventing disease* type B hepatitis *disease even when the analysis was confined to these two high - risk subgroups .
The efficacy of ISG in preventing type B hepatitis cannot be ascertained because a true placebo group was not included .	The efficacy of ISG in preventing disease* type B hepatitis *disease cannot be ascertained because a true placebo group was not included .
Production of autochthonous prostate cancer in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .	Production of autochthonous disease* prostate cancer *disease in Lobund - Wistar rats by treatments with N - nitroso - N - methylurea and testosterone .
More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable prostate adenocarcinomas ( PAs ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the tumor - bearing rats manifested metastatic lesions .	More than 50 % of Lobund - Wistar ( L - W ) strain rats developed large , palpable disease* prostate adenocarcinomas *disease ( disease* PAs *disease ) following treatments with N - nitroso - N - methylurea ( CAS : 684 - 93 - 5 ) and testosterone propionate [ ( TP ) CAS : 57 - 85 - 2 ] , and most of the disease* tumor *disease - bearing rats manifested metastatic lesions .
The incubation periods averaged 10 . 6 months .	The incubation periods averaged 10 . 6 months .
Within the same timeframe , no L - W rat developed a similar palpable PA when treated only with TP .	Within the same timeframe , no L - W rat developed a similar palpable disease* PA *disease when treated only with TP .
In L - W rats , TP acted as a tumor enhancement agent , with primary emphasis on the development of prostate cancer .	In L - W rats , TP acted as a disease* tumor *disease enhancement agent , with primary emphasis on the development of disease* prostate cancer *disease .
Relative efficacy and toxicity of netilmicin and tobramycin in oncology patients .	Relative efficacy and disease* toxicity *disease of netilmicin and tobramycin in oncology patients .
We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe infections .	We prospectively compared the efficacy and safety of netilmicin sulfate or tobramycin sulfate in conjunction with piperacillin sodium in 118 immunocompromised patients with presumed severe disease* infections *disease .
The two treatment regimens were equally efficacious .	The two treatment regimens were equally efficacious .
Nephrotoxicity occurred in a similar proportion in patients treated with netilmicin and tobramycin ( 17 % vs 11 % ) .	disease* Nephrotoxicity *disease occurred in a similar proportion in patients treated with netilmicin and tobramycin ( 17 % vs 11 % ) .
Ototoxicity occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .	disease* Ototoxicity *disease occurred in four ( 9 . 5 % ) of 42 netilmicin and piperacillin and in 12 ( 22 % ) of 54 tobramycin and piperacillin - treated patients .
Of those evaluated with posttherapy audiograms , three of four netilmicin and piperacillin - treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin - treated patients .	Of those evaluated with posttherapy audiograms , three of four netilmicin and piperacillin - treated patients had auditory thresholds return to baseline compared with one of nine tobramycin and piperacillin - treated patients .
The number of greater than or equal to 15 - dB increases in auditory threshold as a proportion of total greater than or equal to 15 - dB changes ( increases and decreases ) was significantly lower in netilmicin and piperacillin - vs tobramycin and piperacillin - treated patients ( 18 of 78 vs 67 of 115 ) .	The number of greater than or equal to 15 - dB increases in auditory threshold as a proportion of total greater than or equal to 15 - dB changes ( increases and decreases ) was significantly lower in netilmicin and piperacillin - vs tobramycin and piperacillin - treated patients ( 18 of 78 vs 67 of 115 ) .
We conclude that aminoglycoside - associated ototoxicity was less severe and more often reversible with netilmicin than with tobramycin .	We conclude that aminoglycoside - associated disease* ototoxicity *disease was less severe and more often reversible with netilmicin than with tobramycin .
Urinary enzymes and protein patterns as indicators of injury to different regions of the kidney .	Urinary enzymes and protein patterns as indicators of disease* injury to different regions of the kidney *disease .
Acute experimental models of renal damage to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .	disease* Acute experimental models of renal damage *disease to the proximal tubular , glomerular , and papillary regions of the rat were produced by administration of hexachloro - 1 : 3 - butadiene ( HCBD ) , puromycin aminonucleoside ( PAN ) , and 2 - bromoethylamine ( BEA ) , respectively .
Several routine indicators of nephrotoxicity , the enzymes alkaline phosphatase and N - acetyl - beta - glucosaminidase , and the molecular weight of protein excretion were determined on urine samples .	Several routine indicators of disease* nephrotoxicity *disease , the enzymes alkaline phosphatase and N - acetyl - beta - glucosaminidase , and the molecular weight of disease* protein excretion *disease were determined on urine samples .
Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from glomerular damage produced by PAN .	Tubular damage produced by HCBD or BEA was discriminated both quantitatively and qualitatively from disease* glomerular damage *disease produced by PAN .
The latter was characterized by a pronounced increase in protein excretion , especially proteins with molecular weight greater than 40 , 000 Da .	The latter was characterized by a pronounced increase in disease* protein excretion *disease , especially proteins with molecular weight greater than 40 , 000 Da .
In contrast , protein excretion in tubular damage was raised only slightly and characterized by excretion of proteins of a wide range of molecular weights .	In contrast , disease* protein excretion *disease in tubular damage was raised only slightly and characterized by disease* excretion of proteins *disease of a wide range of molecular weights .
Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis ( volume and specific gravity ) and by measurement of the two urinary enzymes .	Proximal tubular damage caused by HCBD and papillary damage caused by BEA were distinguished both by conventional urinalysis ( volume and specific gravity ) and by measurement of the two urinary enzymes .
Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N - acetyl - beta - glucosaminidase showed a sustained elevation in papillary damage .	Alkaline phosphatase and glucose were markedly and transiently elevated in proximal tubular damage and N - acetyl - beta - glucosaminidase showed a sustained elevation in papillary damage .
It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of renal damage .	It is concluded that both selective urinary enzymes and the molecular weight pattern of urinary proteins can be used to provide diagnostic information about the possible site of disease* renal damage *disease .
A catch in the Reye .	A catch in the disease* Reye *disease .
Twenty - six cases of Reye syndrome from The Children ' s Hospital , Camperdown , Australia , occurring between 1973 and 1982 were reviewed .	Twenty - six cases of disease* Reye syndrome *disease from The Children ' s Hospital , Camperdown , Australia , occurring between 1973 and 1982 were reviewed .
Of these , 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of Reye syndrome .	Of these , 20 cases met the US Public Health Service Centers for Disease Control criteria for the diagnosis of disease* Reye syndrome *disease .
Aspirin or salicylate ingestion had occurred in only one of the 20 cases ( 5 % ) , and paracetamol ( acetaminophen ) had been administered in only six of the cases ( 30 % ) .	Aspirin or salicylate ingestion had occurred in only one of the 20 cases ( 5 % ) , and paracetamol ( acetaminophen ) had been administered in only six of the cases ( 30 % ) .
Pathologic confirmation of the diagnosis of Reye syndrome was accomplished in 90 % of the cases .	Pathologic confirmation of the diagnosis of disease* Reye syndrome *disease was accomplished in 90 % of the cases .
The incidence of Reye syndrome in New South Wales , Australia , is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain .	The incidence of disease* Reye syndrome *disease in New South Wales , Australia , is estimated from this study to be approximately nine cases per 1 million children compared with recent US data of ten to 20 cases per 1 million children and three to seven cases per 1 million children in Great Britain .
The mortality for these Reye syndrome cases in Australia was 45 % as compared with a 32 % case - fatality rate in the United States .	The mortality for these disease* Reye syndrome *disease cases in Australia was 45 % as compared with a 32 % case - fatality rate in the United States .
In Australia , the pediatric usage of aspirin has been extremely low for the past 25 years ( less than 1 % of total dosage units sold ) , with paracetamol ( acetaminophen ) dominating the pediatric analgesic and antipyretic market .	In Australia , the pediatric usage of aspirin has been extremely low for the past 25 years ( less than 1 % of total dosage units sold ) , with paracetamol ( acetaminophen ) dominating the pediatric analgesic and antipyretic market .
Reye syndrome may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion , since there were no cases found at The Children ' s Hospital in 1983 , 1984 , or 1985 .	disease* Reye syndrome *disease may be disappearing from Australia despite a total lack of association with salicylates or aspirin ingestion , since there were no cases found at The Children ' s Hospital in 1983 , 1984 , or 1985 .
Postpartum psychosis induced by bromocriptine .	Postpartum disease* psychosis *disease induced by bromocriptine .
Two multigravida patients with no prior psychiatric history were seen with postpartum psychosis , having received bromocriptine for inhibition of lactation .	Two multigravida patients with no prior disease* psychiatric *disease history were seen with postpartum disease* psychosis *disease , having received bromocriptine for disease* inhibition of lactation *disease .
Bromocriptine given in high doses has been associated with psychosis in patients receiving the drug for Parkinson ' s disease .	Bromocriptine given in high doses has been associated with disease* psychosis *disease in patients receiving the drug for disease* Parkinson ' s disease *disease .
These cases demonstrate that bromocriptine may cause psychosis even when given in low doses .	These cases demonstrate that bromocriptine may cause disease* psychosis *disease even when given in low doses .
Hyperglycemic acidotic coma and death in Kearns - Sayre syndrome .	disease* Hyperglycemic acidotic coma *disease and death in disease* Kearns - Sayre syndrome *disease .
This paper presents the clinical and metabolic findings in two young boys with long - standing Kearns - Sayre syndrome .	This paper presents the clinical and metabolic findings in two young boys with long - standing disease* Kearns - Sayre syndrome *disease .
Following short exposure to oral prednisone , both boys developed lethargy , increasing somnolence , polydipsia , polyphagia , and polyuria .	Following short exposure to oral prednisone , both boys developed disease* lethargy *disease , increasing disease* somnolence *disease , disease* polydipsia *disease , disease* polyphagia *disease , and disease* polyuria *disease .
Both presented in the emergency room with profound coma , hypotension , severe hyperglycemia , and acidosis .	Both presented in the emergency room with profound disease* coma *disease , disease* hypotension *disease , severe disease* hyperglycemia *disease , and disease* acidosis *disease .
Nonketotic lactic acidosis was present in one and ketosis without a known serum lactate level was present in the other .	Nonketotic disease* lactic acidosis *disease was present in one and disease* ketosis *disease without a known serum lactate level was present in the other .
Respiratory failure rapidly ensued and both patients expired in spite of efforts at resuscitation .	disease* Respiratory failure *disease rapidly ensued and both patients expired in spite of efforts at resuscitation .
We believe these two cases represent a newly described and catastrophic metabolic - endocrine failure in the Kearns - Sayre syndrome .	We believe these two cases represent a newly described and catastrophic disease* metabolic - endocrine failure *disease in the disease* Kearns - Sayre syndrome *disease .
Experimental cyclosporine nephrotoxicity : risk of concomitant chemotherapy .	Experimental cyclosporine disease* nephrotoxicity *disease : risk of concomitant chemotherapy .
The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of renal toxicity was evaluated in rats .	The role of cyclosporine ( CSA ) alone or in combination with various chemotherapeutics in the development of disease* renal toxicity *disease was evaluated in rats .
Administration of 20 mg / kg / day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man .	Administration of 20 mg / kg / day CSA for 4 weeks caused renal functional and structural changes similar to those reported in man .
The combined administration of CSA and various chemotherapeutic drugs with a nephrotoxic potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced toxicity in the rat model .	The combined administration of CSA and various chemotherapeutic drugs with a disease* nephrotoxic *disease potential , such as gentamicin ( at therapeutic doses ) , amphothericin B and ketoconazole , which are frequently used in immunosuppressed patients , did not aggravate the CSA induced disease* toxicity *disease in the rat model .
Gentamicin at toxic doses , however , increased CSA nephrotoxicity .	Gentamicin at toxic doses , however , increased CSA disease* nephrotoxicity *disease .
Thus , the nephrotoxicity induced by CSA has a different pathogenetic mechanism .	Thus , the disease* nephrotoxicity *disease induced by CSA has a different pathogenetic mechanism .
Diuretics , potassium and arrhythmias in hypertensive coronary disease .	Diuretics , potassium and disease* arrhythmias *disease in disease* hypertensive disease* coronary disease *disease .
It has been proposed that modest changes in plasma potassium can alter the tendency towards cardiac arrhythmias .	It has been proposed that modest changes in plasma potassium can alter the tendency towards disease* cardiac arrhythmias *disease .
If this were so , patients with coronary artery disease might be especially susceptible .	If this were so , patients with disease* coronary artery disease *disease might be especially susceptible .
Thus , myocardial electrical excitability was measured in patients with mild essential hypertension and known coronary artery disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .	Thus , myocardial electrical excitability was measured in patients with mild essential disease* hypertension *disease and known disease* coronary artery disease *disease after 8 weeks of treatment with a potassium - conserving diuretic ( amiloride ) and a similar period on a potassium - losing diuretic ( chlorthalidone ) in a randomised study .
Plasma potassium concentrations were on average 1 mmol / L lower during the chlorthalidone phase compared to amiloride therapy .	Plasma potassium concentrations were on average 1 mmol / L lower during the chlorthalidone phase compared to amiloride therapy .
Blood pressure and volume states as assessed by bodyweight , plasma renin and noradrenaline ( norepinephrine ) concentrations were similar on the 2 regimens .	Blood pressure and volume states as assessed by bodyweight , plasma renin and noradrenaline ( norepinephrine ) concentrations were similar on the 2 regimens .
Compared to amiloride treatment , the chlorthalidone phase was associated with an increased frequency of ventricular ectopic beats ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .	Compared to amiloride treatment , the chlorthalidone phase was associated with an increased frequency of disease* ventricular ectopic beats *disease ( 24 - hour Holter monitoring ) and a higher Lown grading , increased upslope and duration of the monophasic action potential , prolonged ventricular effective refractory period , and increased electrical instability during programmed ventricular stimulation .
The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with ischaemic heart disease , even minor falls in plasma potassium concentrations are probably best avoided in such patients .	The above results indicate that because potassium - losing diuretic therapy can increase myocardial electrical excitability in patients with disease* ischaemic heart disease *disease , even minor falls in plasma potassium concentrations are probably best avoided in such patients .
Transketolase abnormality in tolazamide - induced Wernicke ' s encephalopathy .	Transketolase abnormality in tolazamide - induced disease* Wernicke ' s encephalopathy *disease .
We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a diabetic patient who developed Wernicke ' s encephalopathy when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic Wernicke - Korsakoff syndrome .	We studied a thiamine - dependent enzyme , transketolase , from fibroblasts of a disease* diabetic *disease patient who developed disease* Wernicke ' s encephalopathy *disease when treated with tolazamide , in order to delineate if this patient also had transketolase abnormality [ high Km for thiamine pyrophosphate ( TPP ) ] , as previously reported in postalcoholic disease* Wernicke - Korsakoff syndrome *disease .
In addition to this patient , we also studied this enzyme from three diabetic kindreds without any history of Wernicke ' s encephalopathy and from four normal controls .	In addition to this patient , we also studied this enzyme from three disease* diabetic *disease kindreds without any history of disease* Wernicke ' s encephalopathy *disease and from four normal controls .
We found that the above - mentioned patient and one of the diabetic kindreds with no history of Wernicke ' s encephalopathy had abnormal transketolase as determined by its Km for TPP .	We found that the above - mentioned patient and one of the disease* diabetic *disease kindreds with no history of disease* Wernicke ' s encephalopathy *disease had abnormal transketolase as determined by its Km for TPP .
These data suggest a similarity between postalcoholic Wernicke - Korsakoff syndrome and the patient with tolazamide - induced Wernicke ' s encephalopathy from the standpoint of transketolase abnormality .	These data suggest a similarity between postalcoholic disease* Wernicke - Korsakoff syndrome *disease and the patient with tolazamide - induced disease* Wernicke ' s encephalopathy *disease from the standpoint of transketolase abnormality .
Bradycardia due to trihexyphenidyl hydrochloride .	disease* Bradycardia *disease due to trihexyphenidyl hydrochloride .
A chronic schizophrenic patient was treated with an anticholinergic drug , trihexyphenidyl hydrochloride .	A chronic disease* schizophrenic *disease patient was treated with an anticholinergic drug , trihexyphenidyl hydrochloride .
The patient developed , paradoxically , sinus bradycardia .	The patient developed , paradoxically , sinus disease* bradycardia *disease .
The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs .	The reaction was specific to trihexyphenidyl and not to other anticholinergic drugs .
This antidyskinetic drug is widely used in clinical psychiatric practice and physicians should be aware of this side effect .	This antidyskinetic drug is widely used in clinical disease* psychiatric *disease practice and physicians should be aware of this side effect .
Post - operative rigidity after fentanyl administration .	Post - operative disease* rigidity *disease after fentanyl administration .
A case of thoraco - abdominal rigidity leading to respiratory failure is described in the post - operative period in an elderly patient who received a moderate dose of fentanyl .	A case of thoraco - abdominal disease* rigidity *disease leading to disease* respiratory failure *disease is described in the post - operative period in an elderly patient who received a moderate dose of fentanyl .
This was successfully reversed by naloxone .	This was successfully reversed by naloxone .
The mechanisms possibly implicated in this accident are discussed .	The mechanisms possibly implicated in this accident are discussed .
Anti - carcinogenic action of phenobarbital given simultaneously with diethylnitrosamine in the rat .	Anti - disease* carcinogenic *disease action of phenobarbital given simultaneously with diethylnitrosamine in the rat .
The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on carcinogenesis when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .	The present work has been planned in order to elucidate the effect of phenobarbital ( PB : 15 mg per rat of ingested dose ) on disease* carcinogenesis *disease when it is administered simultaneously with diethylnitrosamine ( DEN : 10 mg / kg / day ) .
Wistar rats ( 180 g ) were treated by DEN alone or by DEN + PB during 2 , 4 and 6 weeks according to our schedule for hepatocarcinogenesis .	Wistar rats ( 180 g ) were treated by DEN alone or by DEN + PB during 2 , 4 and 6 weeks according to our schedule for disease* hepatocarcinogenesis *disease .
After the end of the treatment , the number and the size of induced PAS positive preneoplastic foci was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks .	After the end of the treatment , the number and the size of induced PAS positive disease* preneoplastic foci *disease was significantly reduced when PB was given simultaneously with DEN for 4 and 6 weeks .
The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats .	The mitotic inhibition and the production of micronuclei normally observed after partial hepatectomy in DEN treated rats were also significantly decreased in DEN + PB treated rats .
When the treatment last only 2 weeks , the presence of PB did not change significantly the last parameters .	When the treatment last only 2 weeks , the presence of PB did not change significantly the last parameters .
In DEN + PB treated rats , the survival was prolonged and the tumor incidence decreased as compared with the results obtained by DEN alone .	In DEN + PB treated rats , the survival was prolonged and the disease* tumor *disease incidence decreased as compared with the results obtained by DEN alone .
It is concluded that PB , which promotes carcinogenesis when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .	It is concluded that PB , which promotes disease* carcinogenesis *disease when administered after the DEN treatment , reduces the carcinogen effect when given simultaneously with DEN .
This ' anti - carcinogen ' effect acts on the initiation as well as on the promotion of the precancerous lesions .	This ' anti - carcinogen ' effect acts on the initiation as well as on the promotion of the disease* precancerous lesions *disease .
Biochemical investigations are in progress to obtain more information about this ' paradoxical ' PB effect .	Biochemical investigations are in progress to obtain more information about this ' paradoxical ' PB effect .
Bilateral optic neuropathy due to combined ethambutol and isoniazid treatment .	disease* Bilateral optic neuropathy *disease due to combined ethambutol and isoniazid treatment .
The case of a 40 - year - old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported .	The case of a 40 - year - old patient who underwent an unsuccessful cadaver kidney transplantation and was treated with ethambutol and isoniazid is reported .
A bilateral retrobulbar neuropathy with an unusual central bitemporal hemianopic scotoma was found .	A disease* bilateral retrobulbar neuropathy *disease with an unusual central bitemporal hemianopic disease* scotoma *disease was found .
Ethambutol was stopped and only small improvement of the visual acuity followed .	Ethambutol was stopped and only small improvement of the visual acuity followed .
Isoniazid was discontinued later , followed by a dramatic improvement in the visual acuity .	Isoniazid was discontinued later , followed by a dramatic improvement in the visual acuity .
The hazards of optic nerve toxicity due to ethambutol are known .	The hazards of optic nerve disease* toxicity *disease due to ethambutol are known .
We emphasize the potential danger in the use of ethambutol and isoniazid .	We emphasize the potential danger in the use of ethambutol and isoniazid .
A prospective study of adverse reactions associated with vancomycin therapy .	A prospective study of adverse reactions associated with vancomycin therapy .
A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16 - month period .	A prospective evaluation of the efficacy and safety of vancomycin was conducted in 54 consecutive patients over a 16 - month period .
Vancomycin was curative in 95 % of 43 patients with proven infection .	Vancomycin was curative in 95 % of 43 patients with proven disease* infection *disease .
Drugs were ceased in six patients because of adverse reactions ; in three of these vancomycin was considered the likely cause .	Drugs were ceased in six patients because of adverse reactions ; in three of these vancomycin was considered the likely cause .
Reactions included thrombophlebitis ( 20 of 54 patients ) , rash ( 4 of 54 ) , nephrotoxicity ( 4 of 50 ) , proteinuria ( 1 of 50 ) and ototoxicity ( 1 of 11 patients tested by audiometry ) .	Reactions included disease* thrombophlebitis *disease ( 20 of 54 patients ) , disease* rash *disease ( 4 of 54 ) , disease* nephrotoxicity *disease ( 4 of 50 ) , disease* proteinuria *disease ( 1 of 50 ) and disease* ototoxicity *disease ( 1 of 11 patients tested by audiometry ) .
Thrombophlebitis occurred only with infusion through peripheral cannulae ; nephrotoxicity and ototoxicity were confined to patients receiving an aminoglycoside plus vancomycin .	disease* Thrombophlebitis *disease occurred only with infusion through peripheral cannulae ; disease* nephrotoxicity *disease and disease* ototoxicity *disease were confined to patients receiving an aminoglycoside plus vancomycin .
We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for infections caused by susceptible bacteria .	We conclude that vancomycin , administered appropriately , constitutes safe , effective therapy for disease* infections *disease caused by susceptible bacteria .
Factors associated with nephrotoxicity and clinical outcome in patients receiving amikacin .	Factors associated with disease* nephrotoxicity *disease and clinical outcome in patients receiving amikacin .
Data from 60 patients treated with amikacin were analyzed for factors associated with nephrotoxicity .	Data from 60 patients treated with amikacin were analyzed for factors associated with disease* nephrotoxicity *disease .
In 42 of these patients , data were examined for factors associated with clinical outcome .	In 42 of these patients , data were examined for factors associated with clinical outcome .
Variables evaluated included patient weight , age , sex , serum creatinine level , creatinine clearance , duration of therapy , total dose , mean daily dose , organism minimum inhibitory concentration ( MIC ) , mean peak levels , mean trough levels , mean area under the serum concentration - time curve ( AUC ) , total AUC , mean AUC greater than MIC , total AUC greater than MIC , mean Schumacher ' s intensity factor ( IF ) , total IF , In ( mean maximum concentration [ Cmax ] / MIC ) .	Variables evaluated included patient weight , age , sex , serum creatinine level , creatinine clearance , duration of therapy , total dose , mean daily dose , organism minimum inhibitory concentration ( MIC ) , mean peak levels , mean trough levels , mean area under the serum concentration - time curve ( AUC ) , total AUC , mean AUC greater than MIC , total AUC greater than MIC , mean Schumacher ' s intensity factor ( IF ) , total IF , In ( mean maximum concentration [ Cmax ] / MIC ) .
Model - dependent pharmacokinetic parameters were calculated by computer based on a one - compartment model .	Model - dependent pharmacokinetic parameters were calculated by computer based on a one - compartment model .
When the parameters were examined individually , duration of therapy and total AUC correlated significantly ( P less than . 05 ) with nephrotoxicity .	When the parameters were examined individually , duration of therapy and total AUC correlated significantly ( P less than . 05 ) with disease* nephrotoxicity *disease .
In contrast , a stepwise discriminant function analysis identified only duration of therapy ( P less than . 001 ) as an important factor .	In contrast , a stepwise discriminant function analysis identified only duration of therapy ( P less than . 001 ) as an important factor .
Based on this model and on Bayes ' theorem , the predictive accuracy of identifying " nephrotoxic " patients increased from 0 . 17 to 0 . 39 .	Based on this model and on Bayes ' theorem , the predictive accuracy of identifying " disease* nephrotoxic *disease " patients increased from 0 . 17 to 0 . 39 .
When examined individually , mean IF , MIC , total dose , mean daily dose , and ln ( mean Cmax / MIC ) correlated significantly ( P less than . 05 ) with cure .	When examined individually , mean IF , MIC , total dose , mean daily dose , and ln ( mean Cmax / MIC ) correlated significantly ( P less than . 05 ) with cure .
In contrast , a simultaneous multivariable analysis identified IF , MIC , and total dose according to one model and ln ( mean Cmax / MIC ) according to a second statistical model of parameters selected to have the greatest prospective value .	In contrast , a simultaneous multivariable analysis identified IF , MIC , and total dose according to one model and ln ( mean Cmax / MIC ) according to a second statistical model of parameters selected to have the greatest prospective value .
Based on Bayes ' theorem and the first model , the predictive accuracy of identifying patients not cured increased from 0 . 19 to 0 . 83 .	Based on Bayes ' theorem and the first model , the predictive accuracy of identifying patients not cured increased from 0 . 19 to 0 . 83 .
For the second model , the predictive accuracy increased from 0 . 19 to 0 . 50 . ( ABSTRACT TRUNCATED AT 250 WORDS )	For the second model , the predictive accuracy increased from 0 . 19 to 0 . 50 . ( ABSTRACT TRUNCATED AT 250 WORDS )
Cardiac toxicity of 5 - fluorouracil .	disease* Cardiac toxicity *disease of 5 - fluorouracil .
Report of a case of spontaneous angina .	Report of a case of spontaneous disease* angina *disease .
We report a case of a patient with colon carcinoma and liver metastasis who presented chest pain after 5 - fluorouracil ( 5 - FU ) administration .	We report a case of a patient with disease* colon carcinoma *disease and liver disease* metastasis *disease who presented disease* chest pain *disease after 5 - fluorouracil ( 5 - FU ) administration .
Clinical electrocardiographic evolution was similar to that observed in Prinzmetal ' s angina , and chest pain promptly resolved with nifedipine .	Clinical electrocardiographic evolution was similar to that observed in disease* Prinzmetal ' s angina *disease , and disease* chest pain *disease promptly resolved with nifedipine .
These data suggest that coronary spasm may be the cause of cardiotoxicity due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU cardiotoxicity .	These data suggest that disease* coronary spasm *disease may be the cause of disease* cardiotoxicity *disease due to 5 - FU , and that calcium antagonists may probably be used in the prevention or treatment of 5 - FU disease* cardiotoxicity *disease .
Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed neuropathy in chickens .	Dose - related beneficial and adverse effects of dietary corticosterone on organophosphorus - induced delayed disease* neuropathy *disease in chickens .
Tri - ortho - tolyl phosphate ( TOTP ) , 360 mg / kg , po , and 0 , 0 ' - diisopropyl phosphorofluoridate ( DFP ) , 1 mg / kg sc , were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone .	Tri - ortho - tolyl phosphate ( TOTP ) , 360 mg / kg , po , and 0 , 0 ' - diisopropyl phosphorofluoridate ( DFP ) , 1 mg / kg sc , were administered to adult White Leghorn chickens 24 hr after they were placed on diets containing 0 to 300 ppm corticosterone .
Supplemented diets were continued until clinical signs and lesions of delayed neuropathy appeared .	Supplemented diets were continued until clinical signs and lesions of delayed disease* neuropathy *disease appeared .
Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced neuropathy , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .	Although low concentrations ( less than or equal to 50 ppm ) of corticosterone had beneficial effects on TOTP - induced disease* neuropathy *disease , greater than or equal to 200 ppm exacerbated clinical signs in chickens given either TOTP or DFP .
Neurotoxic esterase activities 24 hr after TOTP or DFP were less than 20 % of values measured in chickens not given organophosphorous compounds .	disease* Neurotoxic *disease esterase activities 24 hr after TOTP or DFP were less than 20 % of values measured in chickens not given organophosphorous compounds .
Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase .	Chickens given 200 ppm corticosterone without TOTP or DFP had significantly elevated activity of plasma cholinesterase and significantly inhibited activity of liver carboxylesterase .
Degenerating myelinated fibers were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP .	disease* Degenerating myelinated fibers *disease were also evident in distal levels of the peripheral nerves of chickens given TOTP or DFP .
Hepatotoxicity of amiodarone .	disease* Hepatotoxicity *disease of amiodarone .
Amiodarone has proved very effective in the treatment of otherwise resistant cardiac tachyarrhythmias .	Amiodarone has proved very effective in the treatment of otherwise resistant cardiac disease* tachyarrhythmias *disease .
The use of amiodarone has , however , been limited due to its serious side - effects .	The use of amiodarone has , however , been limited due to its serious side - effects .
A patient with cholestatic hepatitis due to amiodarone treatment is presented below and a review of the hepatotoxicity of amiodarone is given .	A patient with disease* cholestatic hepatitis *disease due to amiodarone treatment is presented below and a review of the disease* hepatotoxicity *disease of amiodarone is given .
It is concluded that solid evidence exists of hepatic injury due to amiodarone treatment , including steatosis , alterations resembling alcoholic hepatitis , cholestatic hepatitis and micronodular cirrhosis of the liver .	It is concluded that solid evidence exists of disease* hepatic injury *disease due to amiodarone treatment , including disease* steatosis *disease , alterations resembling disease* alcoholic hepatitis *disease , disease* cholestatic hepatitis *disease and micronodular disease* cirrhosis of the liver *disease .
Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels .	Patients receiving amiodarone should be regularly screened with respect to hepatic enzyme levels .
Therapy should be discontinued on the suspicion of cholestatic injury or hepatomegaly .	Therapy should be discontinued on the suspicion of disease* cholestatic injury *disease or disease* hepatomegaly *disease .
Promotional effects of testosterone and dietary fat on prostate carcinogenesis in genetically susceptible rats .	Promotional effects of testosterone and dietary fat on prostate disease* carcinogenesis *disease in genetically susceptible rats .
Germfree ( GF ) Lobund strain Wistar ( LW ) rats , fed vegetable diet L - 485 , have developed prostate adenocarcinomas spontaneously ( 10 % incidence ) at average age 34 months .	Germfree ( GF ) Lobund strain Wistar ( LW ) rats , fed vegetable diet L - 485 , have developed disease* prostate adenocarcinomas *disease spontaneously ( 10 % incidence ) at average age 34 months .
Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of prostate cancer after an average interval of 14 months : 24 % had developed gross tumors , and 40 % when it included microscopic tumors .	Conventional LW rats , implanted with testosterone at age 4 months , developed a higher incidence of disease* prostate cancer *disease after an average interval of 14 months : 24 % had developed gross disease* tumors *disease , and 40 % when it included microscopic disease* tumors *disease .
Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed prostate cancer after intervals of 6 - 12 months .	Preliminary results indicate that testosterone - treated LW rats that were fed the same diet , which was supplemented with corn oil up to 20 % fat , developed disease* prostate cancer *disease after intervals of 6 - 12 months .
Aged GF Sprague - Dawley ( SD ) rats have not developed prostate cancer spontaneously .	Aged GF Sprague - Dawley ( SD ) rats have not developed disease* prostate cancer *disease spontaneously .
Conventional SD rats fed diet L - 485 and treated with testosterone developed only prostatitis .	Conventional SD rats fed diet L - 485 and treated with testosterone developed only disease* prostatitis *disease .
Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental prostate cancer .	Experimental designs should consider genetic susceptibility as a basic prerequisite for studies on experimental disease* prostate cancer *disease .
Time course alterations of QTC interval due to hypaque 76 .	Time course alterations of QTC interval due to hypaque 76 .
Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one , three , five and ten minutes after injection of hypaque 76 .	Sequential measurement of QT interval during left ventricular angiography was made 30 seconds and one , three , five and ten minutes after injection of hypaque 76 .
The subjects were ten patients found to have normal left ventricles and coronary arteries .	The subjects were ten patients found to have normal left ventricles and coronary arteries .
Significant QTC prolongation occurred in 30 seconds to one minute in association with marked hypotension and elevation of cardiac output .	Significant disease* QTC prolongation *disease occurred in 30 seconds to one minute in association with marked disease* hypotension *disease and elevation of cardiac output .
Rat extraocular muscle regeneration .	Rat extraocular muscle regeneration .
Repair of local anesthetic - induced damage .	Repair of local anesthetic - induced damage .
Local anesthetics that are commonly used in ophthalmic surgery ( 0 . 75 % bupivacaine hydrochloride , 2 . 0 % mepivacaine hydrochloride , and 2 . 0 % lidocaine hydrochloride plus 1 : 100 , 000 epinephrine ) were injected into the retrobulbar area of rat eyes .	Local anesthetics that are commonly used in ophthalmic surgery ( 0 . 75 % bupivacaine hydrochloride , 2 . 0 % mepivacaine hydrochloride , and 2 . 0 % lidocaine hydrochloride plus 1 : 100 , 000 epinephrine ) were injected into the retrobulbar area of rat eyes .
Controls were injected with physiological saline .	Controls were injected with physiological saline .
All three anesthetics produced massive degeneration of the extraocular muscles .	All three anesthetics produced massive degeneration of the extraocular muscles .
Muscle degeneration is followed by regeneration of the damaged muscle fibers .	disease* Muscle degeneration *disease is followed by regeneration of the damaged muscle fibers .
In addition to muscle damage , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .	In addition to disease* muscle damage *disease , severe damage was also seen in harderian glands , especially after exposure to mepivacaine and lidocaine plus epinephrine .
With these findings in rats , it is hypothesized that the temporary diplopia sometimes seen in patients after ophthalmic surgery might be due to anesthetic - induced damage to the extraocular muscles .	With these findings in rats , it is hypothesized that the temporary disease* diplopia *disease sometimes seen in patients after ophthalmic surgery might be due to anesthetic - induced damage to the extraocular muscles .
Gentamicin nephropathy in a neonate .	Gentamicin disease* nephropathy *disease in a neonate .
The clinical and autopsy findings in a premature baby who died of acute renal failure after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .	The clinical and autopsy findings in a premature baby who died of disease* acute renal failure *disease after therapy with gentamicin ( 5 mg / kg / day ) and penicillin are presented .
The serum gentamicin concentration had reached toxic levels when anuria developed .	The serum gentamicin concentration had reached toxic levels when disease* anuria *disease developed .
Numerous periodic acid Schiff ( PAS ) positive , diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules .	Numerous periodic acid Schiff ( PAS ) positive , diastase resistant cytoplasmic inclusion bodies which appeared as myelin figures in cytosegresomes under the electron microscope were identified in the proximal convoluted tubules .
The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported .	The pathological changes induced by gentamicin in the human neonatal kidneys have not been previously reported .
Induction by paracetamol of bladder and liver tumours in the rat .	Induction by paracetamol of disease* bladder and liver tumours *disease in the rat .
Effects on hepatocyte fine structure .	Effects on hepatocyte fine structure .
Groups of male and female inbred Leeds strain rats were fed diets containing either 0 . 5 % or 1 . 0 % paracetamol by weight for up to 18 months .	Groups of male and female inbred Leeds strain rats were fed diets containing either 0 . 5 % or 1 . 0 % paracetamol by weight for up to 18 months .
At the 1 . 0 % dosage level , 20 % of rats of both sexes developed neoplastic nodules of the liver , a statistically significant incidence .	At the 1 . 0 % dosage level , 20 % of rats of both sexes developed neoplastic nodules of the liver , a statistically significant incidence .
These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration , the latter also being observed in the low dosage male rats .	These rats also showed gross enlargement of their livers and an increase in foci of cellular alteration , the latter also being observed in the low dosage male rats .
Papillomas of the transitional epithelium of the bladder developed in all paracetamol - treated groups , and three rats bore bladder carcinomas .	disease* Papillomas *disease of the transitional epithelium of the bladder developed in all paracetamol - treated groups , and three rats bore disease* bladder carcinomas *disease .
However , significant yields of bladder tumours were only obtained from low dosage females and high dosage males .	However , significant yields of disease* bladder tumours *disease were only obtained from low dosage females and high dosage males .
Additionally , 20 to 25 % of paracetamol - treated rats developed hyperplasia of the bladder epithelium , which was not coincident with the presence of bladder calculi .	Additionally , 20 to 25 % of paracetamol - treated rats developed disease* hyperplasia *disease of the bladder epithelium , which was not coincident with the presence of disease* bladder calculi *disease .
A low yield of tumours at various other sites also arose following paracetamol feeding .	A low yield of disease* tumours *disease at various other sites also arose following paracetamol feeding .
An electron microscope study of the livers of paracetamol - treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known hepatocarcinogens .	An electron microscope study of the livers of paracetamol - treated rats revealed ultrastructural changes in the hepatocytes that resemble those that result from exposure to a variety of known disease* hepatocarcinogens *disease .
Transient hemiparesis : a rare manifestation of diphenylhydantoin toxicity .	Transient disease* hemiparesis *disease : a rare manifestation of diphenylhydantoin disease* toxicity *disease .
Report of two cases .	Report of two cases .
Among the common side effects of diphenylhydantoin ( DPH ) overdose , the most frequently encountered neurological signs are those of cerebellar dysfunction .	Among the common side effects of diphenylhydantoin ( DPH ) disease* overdose *disease , the most frequently encountered neurological signs are those of disease* cerebellar dysfunction *disease .
Very rarely , the toxic neurological manifestations of this drug are of cerebral origin .	Very rarely , the toxic neurological manifestations of this drug are of cerebral origin .
Two patients are presented who suffered progressive hemiparesis due to DPH overdose .	Two patients are presented who suffered progressive disease* hemiparesis *disease due to DPH disease* overdose *disease .
Both had brain surgery before DPH treatment .	Both had brain surgery before DPH treatment .
It is assumed that patients with some cerebral damage are liable to manifest DPH toxicity as focal neurological signs .	It is assumed that patients with some disease* cerebral damage *disease are liable to manifest DPH disease* toxicity *disease as focal neurological signs .
Tiapride in levodopa - induced involuntary movements .	Tiapride in levodopa - induced disease* involuntary movements *disease .
Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose involuntary movements in 16 patients with idiopathic Parkinson ' s disease .	Tiapride , a substituted benzamide derivative closely related to metoclopramide , reduced levodopa - induced peak dose disease* involuntary movements *disease in 16 patients with disease* idiopathic Parkinson ' s disease *disease .
However , an unacceptable increase in disability from Parkinsonism with aggravation of end - of - dose akinesia led to its cessation in 14 patients .	However , an unacceptable increase in disability from disease* Parkinsonism *disease with aggravation of end - of - dose disease* akinesia *disease led to its cessation in 14 patients .
Tiapride had no effect on levodopa - induced early morning of " off - period " segmental dystonia .	Tiapride had no effect on levodopa - induced early morning of " off - period " segmental disease* dystonia *disease .
These results fail to support the notion that levodopa - induced dyskinesias are caused by overstimulation of a separate group of dopamine receptors .	These results fail to support the notion that levodopa - induced disease* dyskinesias *disease are caused by overstimulation of a separate group of dopamine receptors .
Quinidine hepatitis .	Quinidine disease* hepatitis *disease .
Long - term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT , lactic acid dehydrogenase , and alkaline phosphatase .	Long - term administration of quinidine was associated with persistent elevation of serum concentrations of SGOT , lactic acid dehydrogenase , and alkaline phosphatase .
Liver biopsy showed active hepatitis .	Liver biopsy showed active disease* hepatitis *disease .
Discontinuance of quinidine therapy led to normalization of liver function tests .	Discontinuance of quinidine therapy led to normalization of liver function tests .
A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT , alkaline phosphatase , and lactic acid dehydrogenase values .	A challenge dose of quinidine caused clinical symptoms and abrupt elevation of SGOT , alkaline phosphatase , and lactic acid dehydrogenase values .
We concluded that this patient had quinidine hepatotoxicity and believe that this is the first case reported with liver biopsy documentation .	We concluded that this patient had quinidine disease* hepatotoxicity *disease and believe that this is the first case reported with liver biopsy documentation .
This report also suggests that , even after long - term administration , the hepatic toxicity is reversible .	This report also suggests that , even after long - term administration , the disease* hepatic toxicity *disease is reversible .
Arterial thromboembolism in patients receiving systemic heparin therapy : a complication associated with heparin - induced thrombocytopenia .	Arterial disease* thromboembolism *disease in patients receiving systemic heparin therapy : a complication associated with heparin - induced disease* thrombocytopenia *disease .
Arterial thromboembolism is a recognized complication of systemic heparin therapy .	Arterial disease* thromboembolism *disease is a recognized complication of systemic heparin therapy .
Characteristic of the entity is arterial occlusion by platelet - fibrin thrombi with distal ischemia occurring four to twenty days after the initiation of heparin therapy , preceded by profound thrombocytopenia with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .	Characteristic of the entity is disease* arterial occlusion *disease by platelet - fibrin disease* thrombi *disease with distal disease* ischemia *disease occurring four to twenty days after the initiation of heparin therapy , preceded by profound disease* thrombocytopenia *disease with platelet counts in the range of 30 , 000 to 40 , 000 per cubic millimeter .
The clinically apparent occlusion may be preceded by gastrointestinal and musculoskeletal symptoms that appear to be ischemic in origin , and might serve to warn the clinician of these complications .	The clinically apparent occlusion may be preceded by disease* gastrointestinal and musculoskeletal symptoms *disease that appear to be disease* ischemic *disease in origin , and might serve to warn the clinician of these complications .
Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed .	Previous reports of these phenomena as well as recent studies of the effect of heparin are reviewed .
The common factor relating thromboembolism and thrombocytopenia is heparin - induced platelet aggregation .	The common factor relating disease* thromboembolism *disease and disease* thrombocytopenia *disease is heparin - induced disease* platelet aggregation *disease .
Appropriate treatment consists of discontinuation of heparin , and anticoagulation with sodium warfarin if necessary .	Appropriate treatment consists of discontinuation of heparin , and anticoagulation with sodium warfarin if necessary .
Vascular procedures are performed as indicated .	Vascular procedures are performed as indicated .
Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .	Pharmacology of GYKI - 41 099 ( chlorpropanol , Tobanum ) a new potent beta - adrenergic antagonist .
The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .	The compound GYKI - 41 099 , as a beta - adrenergic antagonist , is 3 - 8 times more potent than propranolol in vitro and in vivo .
Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain arrhythmia in dogs and cats .	Its antiarrhythmic effectiveness surpasses that of propranolol and pindolol inhibiting the ouabain disease* arrhythmia *disease in dogs and cats .
GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .	GYKI - 41 900 has a negligible cardiodepressant activity ; it is not cardioselective .
The compound shows a rapid and long lasting effect .	The compound shows a rapid and long lasting effect .
There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .	There was a prolonged elimination of the radioactivity after the injection of 14C - 41 099 to rats and dogs .
The half life of the unlabeled substance in humans was more than 10 hours .	The half life of the unlabeled substance in humans was more than 10 hours .
Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension .	Adverse reactions to bendrofluazide and propranolol for the treatment of mild disease* hypertension *disease .
Report of Medical Research Council Working Party on Mild to Moderate Hypertension .	Report of Medical Research Council Working Party on Mild to Moderate disease* Hypertension *disease .
Participants in the Medical Research Council treatment trial for mild hypertension are randomly allocated to one of four treatment groups : bendrofluazide , propranolol , or a placebo for either of these drugs .	Participants in the Medical Research Council treatment trial for mild disease* hypertension *disease are randomly allocated to one of four treatment groups : bendrofluazide , propranolol , or a placebo for either of these drugs .
The trial is single - blind .	The trial is single - blind .
23 582 patient - years of observation have been completed so far , 10 684 on active drugs and 12 898 on placebos .	23 582 patient - years of observation have been completed so far , 10 684 on active drugs and 12 898 on placebos .
The results show an association between bendrofluazide treatment and impotence , and impotence also occurred more frequently in patients taking propranolol than in those taking placebos .	The results show an association between bendrofluazide treatment and disease* impotence *disease , and disease* impotence *disease also occurred more frequently in patients taking propranolol than in those taking placebos .
Other adverse reactions significantly linked with active drugs include impaired glucose tolerance in men and women and gout in men , associated with bendrofluazide treatment , and Raynaud ' s phenomenon and dyspnoea in men and women taking propranolol .	Other adverse reactions significantly linked with active drugs include disease* impaired glucose tolerance *disease in men and women and disease* gout *disease in men , associated with bendrofluazide treatment , and disease* Raynaud ' s phenomenon *disease and disease* dyspnoea *disease in men and women taking propranolol .
No corneal disease is known to have occurred in the propranolol group .	No disease* corneal disease *disease is known to have occurred in the propranolol group .
Mean serum potassium level fell , and urea and uric acid levels rose , in men and women taking bendrofluazide .	Mean serum potassium level fell , and urea and uric acid levels rose , in men and women taking bendrofluazide .
In the propranolol group , serum potassium and uric acid levels rose in both sexes , but the urea level rose significantly in women only .	In the propranolol group , serum potassium and uric acid levels rose in both sexes , but the urea level rose significantly in women only .
Serotonergic drugs , benzodiazepines and baclofen block muscimol - induced myoclonic jerks in a strain of mice .	Serotonergic drugs , benzodiazepines and baclofen block muscimol - induced disease* myoclonic jerks *disease in a strain of mice .
In male Swiss mice , muscimol produced myoclonic jerks .	In male Swiss mice , muscimol produced disease* myoclonic jerks *disease .
A 3 mg / kg ( i . p . ) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min .	A 3 mg / kg ( i . p . ) dose induced this response in all of the mice tested and the peak response of 73 jerks per min was observed between 27 and 45 min .
Increasing the brain serotonin levels by the administration of 5 - hydroxytryptophan ( 80 - 160 mg / kg ) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect .	Increasing the brain serotonin levels by the administration of 5 - hydroxytryptophan ( 80 - 160 mg / kg ) in combination with a peripheral decarboxylase inhibitor resulted in an inhibition of the muscimol effect .
However , in a similar experiment l - dopa ( 80 - 160 mg / kg ) was without effect .	However , in a similar experiment l - dopa ( 80 - 160 mg / kg ) was without effect .
In doses of 3 - 10 mg / kg , the serotonin receptor agonist MK - 212 caused a dose - dependent blockade of the response of muscimol .	In doses of 3 - 10 mg / kg , the serotonin receptor agonist MK - 212 caused a dose - dependent blockade of the response of muscimol .
Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the myoclonic jerks .	Of the benzodiazepines , clonazepam ( 0 . 1 - 0 . 3 mg / kg ) was found to be several fold more potent than diazepam ( 0 . 3 - 3 mg / kg ) in blocking the disease* myoclonic jerks *disease .
While ( - ) - baclofen ( 1 - 3 mg / kg ) proved to be an effective antagonist of muscimol , its ( + ) - isomer ( 5 - 20 mg / kg ) lacked this property .	While ( - ) - baclofen ( 1 - 3 mg / kg ) proved to be an effective antagonist of muscimol , its ( + ) - isomer ( 5 - 20 mg / kg ) lacked this property .
Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical myoclonus , the muscimol - induced myoclonus seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .	Considering the fact that 5 - HTP and the benzodiazepines have been found to be beneficial in the management of clinical disease* myoclonus *disease , the muscimol - induced disease* myoclonus *disease seems to be a satisfactory animal model that may prove useful for the development of new drug treatments for this condition .
Our present study indicated the possible value of MK - 212 and ( - ) - baclofen in the management of clinical myoclonus .	Our present study indicated the possible value of MK - 212 and ( - ) - baclofen in the management of clinical disease* myoclonus *disease .
Adverse interaction between beta - adrenergic blocking drugs and verapamil - - report of three cases .	Adverse interaction between beta - adrenergic blocking drugs and verapamil - - report of three cases .
Three patients with ischaemic heart disease developed profound cardiac failure , hypotension and bradycardia during combined therapy with verapamil and beta - adrenergic blocking drugs .	Three patients with disease* ischaemic heart disease *disease developed profound disease* cardiac failure *disease , disease* hypotension *disease and disease* bradycardia *disease during combined therapy with verapamil and beta - adrenergic blocking drugs .
This clinical picture resolved completely with cessation of the combined therapy .	This clinical picture resolved completely with cessation of the combined therapy .
Baseline left ventricular function , assessed by cardiac catheterisation or nuclear angiography , was normal in two patients and only mildly reduced in the other .	Baseline left ventricular function , assessed by cardiac catheterisation or nuclear angiography , was normal in two patients and only mildly reduced in the other .
Simultaneously administration of beta - adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution .	Simultaneously administration of beta - adrenergic blocking drugs and verapamil may result in profound adverse interactions and should only be administered with great caution .
Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states .	Comparison of the effectiveness of ranitidine and cimetidine in inhibiting acid secretion in patients with gastric hypersecretory states .
The H2 - histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short - and long - term basis in 22 patients with gastric acid hypersecretory states .	The H2 - histamine receptor antagonists ranitidine and cimetidine were compared for their abilities to control gastric acid hypersecretion on a short - and long - term basis in 22 patients with gastric acid hypersecretory states .
Nineteen patients had Zollinger - Ellison syndrome , one patient had systemic mastocytosis , and two patients had idiopathic hypersecretion .	Nineteen patients had disease* Zollinger - Ellison syndrome *disease , one patient had disease* systemic mastocytosis *disease , and two patients had idiopathic hypersecretion .
The rates of onset of the action of cimetidine and ranitidine were the same .	The rates of onset of the action of cimetidine and ranitidine were the same .
The actions of both drugs were increased by anticholinergic agents , and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion .	The actions of both drugs were increased by anticholinergic agents , and there was a close correlation between the daily maintenance dose of each drug needed to control acid secretion .
However , ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed ( 1 . 2 g per day for ranitidine and 3 . 6 g per day for cimetidine ) .	However , ranitidine was threefold more potent than cimetidine both in acute inhibition studies and in the median maintenance dose needed ( 1 . 2 g per day for ranitidine and 3 . 6 g per day for cimetidine ) .
Sixty percent of the males developed breast changes or impotence while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine .	Sixty percent of the males developed breast changes or disease* impotence *disease while taking cimetidine and in all cases these changes disappeared when cimetidine was replaced by ranitidine .
Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with hepatic or hematologic toxicity or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .	Treatment with high doses of cimetidine ( one to 60 months ; median , 11 months ) or ranitidine ( two to 31 months ; median , 14 months ) was not associated with disease* hepatic or hematologic toxicity *disease or alterations of serum gastrin concentrations , but ranitidine therapy was associated with a significantly lower serum creatinine level than seen with cimetidine therapy .
The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states .	The results show that both drugs can adequately inhibit acid secretion in patients with gastric hypersecretory states .
Both are safe at high doses , but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine .	Both are safe at high doses , but ranitidine is threefold more potent and does not cause the antiandrogen side effects frequently seen with high doses of cimetidine .
Epileptogenic properties of enflurane and their clinical interpretation .	Epileptogenic properties of enflurane and their clinical interpretation .
Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported .	Three cases of EEG changes induced by single exposure to enflurane anesthesia are reported .
In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor seizures .	In one patient , enflurane administered during a donor nephrectomy resulted in unexpected partial motor disease* seizures *disease .
Until the cause of the seizures was correctly identified , the patient was inappropriately treated with anticonvulsants .	Until the cause of the disease* seizures *disease was correctly identified , the patient was inappropriately treated with anticonvulsants .
Two other patients suffered from partial , complex and generalized seizures uncontrolled by medication .	Two other patients suffered from partial , complex and generalized disease* seizures *disease uncontrolled by medication .
Epileptic foci delineated and activated by enflurane were surgically ablated and the patients are now seizure - free .	disease* Epileptic *disease foci delineated and activated by enflurane were surgically ablated and the patients are now disease* seizure *disease - free .
Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG .	Previous exposures to enflurane have to be disclosed to avoid mistakes in clinical interpretation of the EEG .
On the other hand , enflurane may prove to be a safe fast acting activator of epileptic foci during corticography or depth electrode intraoperative recordings .	On the other hand , enflurane may prove to be a safe fast acting activator of disease* epileptic *disease foci during corticography or depth electrode intraoperative recordings .
Development of isoproterenol - induced cardiac hypertrophy .	Development of isoproterenol - induced disease* cardiac hypertrophy *disease .
The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .	The development of disease* cardiac hypertrophy *disease was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol ( ISO ) ( 0 . 3 mg / kg body weight ) .
A time course was established for the change in tissue mass , RNA and DNA content , as well as hydroxyproline content .	A time course was established for the change in tissue mass , RNA and DNA content , as well as hydroxyproline content .
Heart weight increased 44 % after 8 days of treatment with a half time of 3 . 4 days .	Heart weight increased 44 % after 8 days of treatment with a half time of 3 . 4 days .
Ventricular RNA content was elevated 26 % after 24 h of a single injection and reached a maximal level following 8 days of therapy .	Ventricular RNA content was elevated 26 % after 24 h of a single injection and reached a maximal level following 8 days of therapy .
The half time for RNA accumulation was 2 . 0 days .	The half time for RNA accumulation was 2 . 0 days .
The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46 % after 4 days of therapy .	The total content of hydroxyproline remained stable during the first 2 days of treatment but increased 46 % after 4 days of therapy .
Ventricular DNA content was unchanged during the early stage ( 1 - 4 days ) of hypertrophic growth but increased to a new steady - state level 19 % above the controls after 8 days of treatment .	Ventricular DNA content was unchanged during the early stage ( 1 - 4 days ) of disease* hypertrophic *disease growth but increased to a new steady - state level 19 % above the controls after 8 days of treatment .
Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed hypertrophy .	Intraventricular pressures and coronary flow measures were similar for control and experimental animals following 4 days of developed disease* hypertrophy *disease .
However , dP / dt in the ISO - treated hearts was slightly but significantly ( P less than 0 . 05 ) elevated .	However , dP / dt in the ISO - treated hearts was slightly but significantly ( P less than 0 . 05 ) elevated .
These data indicate that the adaptive response to ISO shows an early hypertrophic phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .	These data indicate that the adaptive response to ISO shows an early disease* hypertrophic *disease phase ( 1 - 4 days ) characterized by a substantial increase in RNA content and cardiac mass in the absence of changes in DNA .
However , prolonged stimulation ( 8 - 12 days ) appears to represent a complex integration of both cellular hypertrophy and hyperplasia within the heart .	However , prolonged stimulation ( 8 - 12 days ) appears to represent a complex integration of both cellular disease* hypertrophy *disease and disease* hyperplasia *disease within the heart .
Multiple side effects of penicillamine therapy in one patient with rheumatoid arthritis .	Multiple side effects of penicillamine therapy in one patient with disease* rheumatoid arthritis *disease .
Skin rashes , proteinuria , systemic lupus erythematosus , polymyositis and myasthenia gravis have all been recorded as complications of penicillamine therapy in patients with rheumatoid arthritis .	disease* Skin rashes *disease , disease* proteinuria *disease , disease* systemic lupus erythematosus *disease , disease* polymyositis *disease and disease* myasthenia gravis *disease have all been recorded as complications of penicillamine therapy in patients with disease* rheumatoid arthritis *disease .
A patient who had developed all 5 is now described .	A patient who had developed all 5 is now described .
The skin lesion resembled elastosis perforans serpiginosa , which has been reported as a rare side effect in patients with Wilson ' s disease but not in patients with rheumatoid arthritis treated with penicillamine .	The disease* skin lesion *disease resembled disease* elastosis perforans serpiginosa *disease , which has been reported as a rare side effect in patients with disease* Wilson ' s disease *disease but not in patients with disease* rheumatoid arthritis *disease treated with penicillamine .
Obsolete but dangerous antacid preparations .	Obsolete but dangerous antacid preparations .
One case of acute hypercalcaemia and two of recurrent nephrolithiasis are reported in patients who had regularly consumed large amounts of calcium carbon - ate - sodium bicarbonate powders for more than 20 years .	One case of acute disease* hypercalcaemia *disease and two of recurrent disease* nephrolithiasis *disease are reported in patients who had regularly consumed large amounts of calcium carbon - ate - sodium bicarbonate powders for more than 20 years .
The powders had been obtained from pharmacists unknown to the patients ' medical practitioners .	The powders had been obtained from pharmacists unknown to the patients ' medical practitioners .
It is suggested that these preparations were responsible for the patient ' s problems , and that such powders should no longer be freely obtainable .	It is suggested that these preparations were responsible for the patient ' s problems , and that such powders should no longer be freely obtainable .
Doxorubicin cardiomyopathy in children with left - sided Wilms tumor .	Doxorubicin disease* cardiomyopathy *disease in children with left - sided disease* Wilms tumor *disease .
Two children with Wilms tumor of the left kidney experienced severe anthracycline cardiomyopathy after irradiation to the tumor bed and conventional dosage of doxorubicin .	Two children with disease* Wilms tumor *disease of the left kidney experienced severe anthracycline disease* cardiomyopathy *disease after irradiation to the disease* tumor *disease bed and conventional dosage of doxorubicin .
The cardiomyopathy is attributed 1 ) to the fact that radiation fields for left Wilms tumor include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .	The disease* cardiomyopathy *disease is attributed 1 ) to the fact that radiation fields for left disease* Wilms tumor *disease include the lower portion of the heart and 2 ) to the interaction of doxorubicin and irradiation on cardiac muscle .
It is recommended that doxorubicin dosage be sharply restricted in children with Wilms tumor of the left kidney who receive postoperative irradiation .	It is recommended that doxorubicin dosage be sharply restricted in children with disease* Wilms tumor *disease of the left kidney who receive postoperative irradiation .
Effects of calcitonin on rat extrapyramidal motor system : behavioral and biochemical data .	Effects of calcitonin on rat extrapyramidal motor system : behavioral and biochemical data .
The effects of i . v . c . injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system , were investigated in male rats .	The effects of i . v . c . injection of human and salmon calcitonin on biochemical and behavioral parameters related to the extrapyramidal motor system , were investigated in male rats .
Calcitonin injection resulted in a potentiation of haloperidol - induced catalepsy and a partial prevention of apomorphine - induced hyperactivity .	Calcitonin injection resulted in a potentiation of haloperidol - induced disease* catalepsy *disease and a partial prevention of apomorphine - induced disease* hyperactivity *disease .
Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity .	Moreover calcitonin induced a significant decrease in nigral GAD activity but no change in striatal DA and DOPAC concentration or GAD activity .
The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA - related behavioral messages of striatal origin .	The results are discussed in view of a primary action of calcitonin on the striatonigral GABAergic pathway mediating the DA - related behavioral messages of striatal origin .
Naloxazone pretreatment modifies cardiorespiratory , temperature , and behavioral effects of morphine .	Naloxazone pretreatment modifies cardiorespiratory , temperature , and behavioral effects of morphine .
Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone , an antagonist of high - affinity mu 1 opioid receptors .	Behavioral and cardiorespiratory responses to a lethal dose of morphine were evaluated in rats pretreated with saline or naloxazone , an antagonist of high - affinity mu 1 opioid receptors .
Pretreatment with naloxazone significantly blocked morphine analgesia , catalepsy and hypothermia at a dose which completely eliminated high - affinity binding in brain membranes .	Pretreatment with naloxazone significantly blocked morphine disease* analgesia *disease , disease* catalepsy *disease and disease* hypothermia *disease at a dose which completely eliminated high - affinity binding in brain membranes .
Moreover , naloxazone significantly attenuated the morphine - induced hypotension and respiratory depression , whereas morphine - induced bradycardia was less affected .	Moreover , naloxazone significantly attenuated the morphine - induced disease* hypotension *disease and disease* respiratory depression *disease , whereas morphine - induced disease* bradycardia *disease was less affected .
Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine .	Results indicate that subpopulations of mu receptors may mediate selective behavioral and cardiorespiratory responses to morphine .
Modification of drug action by hyperammonemia .	Modification of drug action by disease* hyperammonemia *disease .
Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular incoordination by diazepam , but NH4Ac treatment alone had no effect .	Pretreatment with ammonium acetate ( NH4Ac ) ( 6 mmol / kg s . c . ) approximately doubled the time morphine - treated mice remained on a hot surface and similarly increased muscular disease* incoordination *disease by diazepam , but NH4Ac treatment alone had no effect .
Thus , hyperammonemia is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with liver disease .	Thus , disease* hyperammonemia *disease is capable of altering drug action and must be considered along with impaired drug metabolism in enhanced drug responses associated with disease* liver disease *disease .
Experiments in vitro showed that acetylcholine - induced catecholamine release from bovine adrenal medulla is depressed as much as 50 % by 0 . 3 mM NH4Ac and KCl - induced contractions of guinea - pig ileum were inhibited 20 % by 5 mM NH4Ac .	Experiments in vitro showed that acetylcholine - induced catecholamine release from bovine adrenal medulla is depressed as much as 50 % by 0 . 3 mM NH4Ac and KCl - induced contractions of guinea - pig ileum were inhibited 20 % by 5 mM NH4Ac .
Addition of excess calcium reversed the depression in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .	Addition of excess calcium reversed the disease* depression *disease in both tissues , but calcium - independent catecholamine release by acetaldehyde was not blocked by NH4Ac .
These results suggested that ammonia blocks calcium channels .	These results suggested that ammonia blocks calcium channels .
Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept .	Parallels in the actions of NH4Ac and the calcium channel blocker verapamil support this concept .
Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine analgesia - and diazepam - induced muscular incoordination and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .	Both verapamil ( 10 mg / kg i . p . ) and NH4Ac pretreatment enhanced morphine disease* analgesia *disease - and diazepam - induced muscular disease* incoordination *disease and antagonized amphetamine - induced motor activity , and neither verapamil nor NH4Ac affected the convulsant action of metrazol .
The data suggest that hyperammonemia exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .	The data suggest that disease* hyperammonemia *disease exerts a calcium channel blocking action which enhances the effects of central nervous system depressants and certain opioid analgesics .
Levodopa - induced dyskinesia and thalamotomy .	Levodopa - induced disease* dyskinesia *disease and thalamotomy .
Levodopa - induced dyskinesia of the limbs in thirteen cases of Parkinsonism , which was choreic , ballistic or dystonic in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .	Levodopa - induced disease* dyskinesia *disease of the limbs in thirteen cases of disease* Parkinsonism *disease , which was choreic , ballistic or disease* dystonic *disease in type , was alleviated almost completely by stereotaxic surgery using a microelectrode technique for the ventralis oralis anterior and posterior nuclei of the thalamus , but much less by the ventralis intermedius nucleus .
Control of levodopa - induced dyskinesias by thalamic lesions in the course of routine treatment of Parkinsonism is discussed .	Control of levodopa - induced disease* dyskinesias *disease by disease* thalamic lesions *disease in the course of routine treatment of disease* Parkinsonism *disease is discussed .
Treatment of ifosfamide - induced urothelial toxicity by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable lung cancer .	Treatment of ifosfamide - induced disease* urothelial toxicity *disease by oral administration of sodium 2 - mercaptoethane sulphonate ( MESNA ) to patients with inoperable disease* lung cancer *disease .
The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against urothelial toxicity induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable lung cancer under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .	The protective effect of oral administration of the thiol compound sodium 2 - mercaptoethane sulphonate ( MESNA ) against disease* urothelial toxicity *disease induced by ifosfamide ( IF ) was tested in a group of 45 patients with inoperable disease* lung cancer *disease under treatment with IF ( 2250 mg / m2 on days 2 - 5 ) as part of a polychemotherapy regimen repeated in a 4 - week cycle .
MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg / m2 , each administered at 0 hr ( = injection of IF ) , 4 hr and 8 hr p . i .	MESNA was given orally on the days of treatment with IF in 3 doses of 840 mg / m2 , each administered at 0 hr ( = injection of IF ) , 4 hr and 8 hr p . i .
Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic haematuria and no episodes of gross haematuria .	Out of a total of 88 courses of this treatment we observed 10 episodes of asymptomatic microscopic disease* haematuria *disease and no episodes of gross disease* haematuria *disease .
In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions ( total 31 % ) .	In this group of 45 patients under protection with MESNA there were 5 complete remissions and 9 partial remissions ( total 31 % ) .
A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures ( raised fluid intake and forced diuresis ) .	A further group of 25 patients under polychemotherapy with IF were treated by conventional prophylactic measures ( raised fluid intake and forced diuresis ) .
In this group there were 1 complete and 5 partial remissions ( total 24 % ) , but nearly all patients developed either gross haematuria and / or symptoms of bladder irritation ( cystitis and pollakisuria ) .	In this group there were 1 complete and 5 partial remissions ( total 24 % ) , but nearly all patients developed either gross disease* haematuria *disease and / or symptoms of disease* bladder irritation *disease ( disease* cystitis *disease and disease* pollakisuria *disease ) .
There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic toxicity of the cytostatic treatment .	There were no appreciable differences between the MESNA series and the conventional prophylaxis series with respect to either haematological or systemic disease* toxicity *disease of the cytostatic treatment .
Our results support the view that MESNA , given orally in conjunction with combined cytostatic regimens which include IF , simplifies the treatment and provides optimum protection for the urinary epithelium .	Our results support the view that MESNA , given orally in conjunction with combined cytostatic regimens which include IF , simplifies the treatment and provides optimum protection for the urinary epithelium .
Protection with oral MESNA is particularly suitable for outpatients .	Protection with oral MESNA is particularly suitable for outpatients .
Myoclonic , atonic , and absence seizures following institution of carbamazepine therapy in children .	disease* Myoclonic , atonic , and absence seizures *disease following institution of carbamazepine therapy in children .
Five children , aged 3 to 11 years , treated with carbamazepine for epilepsy , had an acute aberrant reaction characterized by the onset of myoclonic , atypical absence and / or atonic ( minor motor ) seizures within a few days .	Five children , aged 3 to 11 years , treated with carbamazepine for disease* epilepsy *disease , had an acute aberrant reaction characterized by the onset of disease* myoclonic , atypical absence and / or atonic ( minor motor ) seizures *disease within a few days .
When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor seizures resolve in 3 and 6 months , and one had the seizures persist .	When the carbamazepine was discontinued , two of the children returned to their former state very quickly , two had the minor motor disease* seizures *disease resolve in 3 and 6 months , and one had the disease* seizures *disease persist .
The child in whom the seizures persisted was later found to have ceroid lipofuscinosis .	The child in whom the disease* seizures *disease persisted was later found to have disease* ceroid lipofuscinosis *disease .
The other children are doing well on other anticonvulsants .	The other children are doing well on other anticonvulsants .
Effect of prostaglandin synthetase inhibitors on experimentally induced convulsions in rats .	Effect of prostaglandin synthetase inhibitors on experimentally induced disease* convulsions *disease in rats .
To investigate the relationship of prostaglandins ( PGs ) to seizure induction , the effects of six PG synthetase inhibitors on convulsions induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .	To investigate the relationship of prostaglandins ( PGs ) to disease* seizure *disease induction , the effects of six PG synthetase inhibitors on disease* convulsions *disease induced by flurothyl , picrotoxin , pentetrazol ( PTZ ) , electroshock or bicuculline were evaluated .
Ibuprofen , sulindac , mefenamic acid , and low dose meclofenamic acid increased the latency - to - onset in the flurothyl and / or PTZ models ; the electroshock , picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents .	Ibuprofen , sulindac , mefenamic acid , and low dose meclofenamic acid increased the latency - to - onset in the flurothyl and / or PTZ models ; the electroshock , picrotoxin and bicuculline models were not significantly affected by any of the pretreatment agents .
These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced convulsions , but not picrotoxin - , electroshock - , or bicuculline - induced convulsions .	These results suggest that PGs are involved in the mechanism ( s ) underlying fluorthyl - and PTZ - induced disease* convulsions *disease , but not picrotoxin - , electroshock - , or bicuculline - induced disease* convulsions *disease .
Acute changes of blood ammonia may predict short - term adverse effects of valproic acid .	Acute changes of blood ammonia may predict short - term adverse effects of valproic acid .
Valproic acid ( VPA ) was given to 24 epileptic patients who were already being treated with other antiepileptic drugs .	Valproic acid ( VPA ) was given to 24 disease* epileptic *disease patients who were already being treated with other antiepileptic drugs .
A standardized loading dose of VPA was administered , and venous blood was sampled at 0 , 1 , 2 , 3 , and 4 hours .	A standardized loading dose of VPA was administered , and venous blood was sampled at 0 , 1 , 2 , 3 , and 4 hours .
Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of drowsiness ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .	Ammonia ( NH3 ) was higher in patients who , during continuous therapy , complained of disease* drowsiness *disease ( 7 patients ) than in those who were symptom - free ( 17 patients ) , although VPA plasma levels were similar in both groups .
By measuring VPA - induced changes of blood NH3 content , it may be possible to identify patients at higher risk of obtundation when VPA is given chronically .	By measuring VPA - induced changes of blood NH3 content , it may be possible to identify patients at higher risk of obtundation when VPA is given chronically .
Effect of captopril on pre - existing and aminonucleoside - induced proteinuria in spontaneously hypertensive rats .	Effect of captopril on pre - existing and aminonucleoside - induced disease* proteinuria *disease in spontaneously disease* hypertensive *disease rats .
Proteinuria is a side effect of captopril treatment in hypertensive patients .	disease* Proteinuria *disease is a side effect of captopril treatment in disease* hypertensive *disease patients .
The possibility of reproducing the same renal abnormality with captopril was examined in SHR .	The possibility of reproducing the same disease* renal abnormality *disease with captopril was examined in SHR .
Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate proteinuria pre - existing in SHR .	Oral administration of captopril at 100 mg / kg for 14 days failed to aggravate disease* proteinuria *disease pre - existing in SHR .
Also , captopril treatment failed to potentiate or facilitate development of massive proteinuria invoked by puromycin aminonucleoside in SHR .	Also , captopril treatment failed to potentiate or facilitate development of massive disease* proteinuria *disease invoked by puromycin aminonucleoside in SHR .
Captopril had little or no demonstrable effects on serum electrolyte concentrations , excretion of urine , sodium and potassium , endogenous creatinine clearance , body weight , and food and water consumption .	Captopril had little or no demonstrable effects on serum electrolyte concentrations , excretion of urine , sodium and potassium , endogenous creatinine clearance , body weight , and food and water consumption .
However , ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR .	However , ketone bodies were consistently present in urine and several lethalities occurred during multiple dosing of captopril in SHR .
Complete heart block following a single dose of trazodone .	Complete disease* heart block *disease following a single dose of trazodone .
Forty minutes after receiving a single starting dose of trazodone , a patient developed complete heart block .	Forty minutes after receiving a single starting dose of trazodone , a patient developed complete disease* heart block *disease .
The case illustrates that , despite the results of earlier studies , trazodone ' s effect on cardiac conduction may be severe in individuals at risk for conduction delay .	The case illustrates that , despite the results of earlier studies , trazodone ' s effect on cardiac conduction may be severe in individuals at risk for conduction delay .
Phenobarbital - induced dyskinesia in a neurologically - impaired child .	Phenobarbital - induced disease* dyskinesia *disease in a disease* neurologically - impaired *disease child .
A 2 - year - old child with known neurologic impairment developed a dyskinesia soon after starting phenobarbital therapy for seizures .	A 2 - year - old child with known disease* neurologic impairment *disease developed a disease* dyskinesia *disease soon after starting phenobarbital therapy for disease* seizures *disease .
Known causes of movement disorders were eliminated after evaluation .	Known causes of disease* movement disorders *disease were eliminated after evaluation .
On repeat challenge with phenobarbital , the dyskinesia recurred .	On repeat challenge with phenobarbital , the disease* dyskinesia *disease recurred .
Phenobarbital should be added to the list of anticonvulsant drugs that can cause movement disorders .	Phenobarbital should be added to the list of anticonvulsant drugs that can cause disease* movement disorders *disease .
Effects of amine pretreatment on ketamine catatonia in pinealectomized or hypophysectomized animals .	Effects of amine pretreatment on ketamine disease* catatonia *disease in pinealectomized or hypophysectomized animals .
The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine - induced catatonia in the intact , pinealectomized or hypophysectomized chick and rat .	The present studies were designed to clarify the role of catecholamines and pineal idolamines on ketamine - induced disease* catatonia *disease in the intact , pinealectomized or hypophysectomized chick and rat .
In the pinealectomized chick , pretreatment with dopamine increased the duration of catatonia ( DOC ) after ketamine , but pretreatment with norepinephrine did not .	In the pinealectomized chick , pretreatment with dopamine increased the duration of disease* catatonia *disease ( DOC ) after ketamine , but pretreatment with norepinephrine did not .
The pineal indolamines exhibited mixed actions .	The pineal indolamines exhibited mixed actions .
Serotonin and N - acetyl serotonin which augmented ketamine DOC , did not do so in the absence of the pineal gland , whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick .	Serotonin and N - acetyl serotonin which augmented ketamine DOC , did not do so in the absence of the pineal gland , whereas melatonin potentiated the ketamine DOC in both the intact and pinealectomized chick .
Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent ; furthermore , melatonin did not augment the ketamine DOC whereas dopamine continued to do so .	Ketamine was more potent in the hypophysectomized chick and the circadian rhythm noted in the intact chick was absent ; furthermore , melatonin did not augment the ketamine DOC whereas dopamine continued to do so .
This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood - brain barrier in the young chick and the intact barrier in the rat .	This study did not demonstrate a species difference regarding the role of the amines on the pineal in spite of the immature blood - brain barrier in the young chick and the intact barrier in the rat .
In addition , these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin .	In addition , these data indicate a direct role of the pituitary in the augmentation of ketamine DOC induced by melatonin .
Furthermore , dopamine appeared to act on systems more closely involved with the induction of ketamine catatonia rather than directly on the pituitary .	Furthermore , dopamine appeared to act on systems more closely involved with the induction of ketamine disease* catatonia *disease rather than directly on the pituitary .
Heparin - induced thrombocytopenia , thrombosis , and hemorrhage .	Heparin - induced disease* thrombocytopenia *disease , disease* thrombosis *disease , and disease* hemorrhage *disease .
Sixty - two patients with a heparin - induced thrombocytopenia are reported .	Sixty - two patients with a heparin - induced disease* thrombocytopenia *disease are reported .
Clinical manifestations of this disorder include hemorrhage or , more frequently , thromboembolic events in patients receiving heparin .	Clinical manifestations of this disorder include disease* hemorrhage *disease or , more frequently , disease* thromboembolic *disease events in patients receiving heparin .
Laboratory testing has revealed a falling platelet count , increased resistance to heparin , and aggregation of platelets by the patient ' s plasma when heparin is added .	Laboratory testing has revealed disease* a falling platelet count *disease , increased resistance to heparin , and aggregation of platelets by the patient ' s plasma when heparin is added .
Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .	Immunologic testing has demonstrated the presence of a heparin - dependent platelet membrane antibody .
The 20 deaths , 52 hemorrhagic and thromboembolic complications , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .	The 20 deaths , 52 disease* hemorrhagic and thromboembolic complications *disease , and 21 surgical procedures to manage the complications confirm the seriousness of the disorder .
Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .	Specific risk factors have not been identified ; therefore , all patients receiving heparin should be monitored .
If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , platelet aggregation testing , using the patient ' s plasma , is indicated .	If the platelet count falls to less than 100 , 000 / mm3 , while the patient is receiving heparin , disease* platelet aggregation *disease testing , using the patient ' s plasma , is indicated .
Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .	Management consists of cessation of heparin , platelet anti - aggregating agents , and alternate forms of anticoagulation when indicated .
Ventricular fibrillation from diatrizoate with and without chelating agents .	disease* Ventricular fibrillation *disease from diatrizoate with and without chelating agents .
The toxicity of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .	The disease* toxicity *disease of Renografin 76 % was compared with that of Hypaque 76 % by selective injection of each into the right coronary artery of dogs .
Renografin contains the chelating agents sodium citrate and disodium edetate , while Hypaque contains calcium disodium edetate and no sodium citrate .	Renografin contains the chelating agents sodium citrate and disodium edetate , while Hypaque contains calcium disodium edetate and no sodium citrate .
Ventricular fibrillation occurred significantly more often with Renografin , suggesting that chelating agents contribute to toxicity in coronary angiography .	disease* Ventricular fibrillation *disease occurred significantly more often with Renografin , suggesting that chelating agents contribute to disease* toxicity *disease in coronary angiography .
Long - term efficacy and toxicity of high - dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation .	Long - term efficacy and disease* toxicity *disease of high - dose amiodarone therapy for disease* ventricular tachycardia *disease or disease* ventricular fibrillation *disease .
Amiodarone was administered to 154 patients who had sustained , symptomatic ventricular tachycardia ( VT ) ( n = 118 ) or a cardiac arrest ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .	Amiodarone was administered to 154 patients who had sustained , symptomatic disease* ventricular tachycardia *disease ( disease* VT *disease ) ( n = 118 ) or a disease* cardiac arrest *disease ( n = 36 ) and who were refractory to conventional antiarrhythmic drugs .
The loading dose was 800 mg / day for 6 weeks and the maintenance dose was 600 mg / day .	The loading dose was 800 mg / day for 6 weeks and the maintenance dose was 600 mg / day .
Sixty - nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic VT or ventricular fibrillation ( VF ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .	Sixty - nine percent of patients continued treatment with amiodarone and had no recurrence of symptomatic disease* VT *disease or disease* ventricular fibrillation *disease ( disease* VF *disease ) over a follow - up of 6 to 52 months ( mean + / - standard deviation 14 . 2 + / - 8 . 2 ) .
Six percent of the patients had a nonfatal recurrence of VT and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug .	Six percent of the patients had a nonfatal recurrence of disease* VT *disease and were successfully managed by continuing amiodarone at a higher dose or by the addition of a conventional antiarrhythmic drug .
One or more adverse drug reactions occurred in 51 % of patients .	One or more adverse drug reactions occurred in 51 % of patients .
Adverse effects forced a reduction in the dose of amiodarone in 41 % and discontinuation of amiodarone in 10 % of patients .	Adverse effects forced a reduction in the dose of amiodarone in 41 % and discontinuation of amiodarone in 10 % of patients .
The most common symptomatic adverse reactions were tremor or ataxia ( 35 % ) , nausea and anorexia ( 8 % ) , visual halos or blurring ( 6 % ) , thyroid function abnormalities ( 6 % ) and pulmonary interstitial infiltrates ( 5 % ) .	The most common symptomatic adverse reactions were disease* tremor *disease or disease* ataxia *disease ( 35 % ) , disease* nausea *disease and disease* anorexia *disease ( 8 % ) , disease* visual halos or blurring *disease ( 6 % ) , disease* thyroid function abnormalities *disease ( 6 % ) and disease* pulmonary interstitial infiltrates *disease ( 5 % ) .
Although large - dose amiodarone is highly effective in the long - term treatment of VT or VF refractory to conventional antiarrhythmic drugs , it causes significant toxicity in approximately 50 % of patients .	Although large - dose amiodarone is highly effective in the long - term treatment of disease* VT *disease or disease* VF *disease refractory to conventional antiarrhythmic drugs , it causes significant disease* toxicity *disease in approximately 50 % of patients .
However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with VT or VF can be successfully managed with amiodarone .	However , when the dose is adjusted based on clinical response or the development of adverse effects , 75 % of patients with disease* VT *disease or disease* VF *disease can be successfully managed with amiodarone .
Why may epsilon - aminocaproic acid ( EACA ) induce myopathy in man ?	Why may epsilon - aminocaproic acid ( EACA ) induce disease* myopathy *disease in man ?
Report of a case and literature review .	Report of a case and literature review .
A case of necrotizing myopathy due to a short epsilon - aminocaproic acid ( EACA ) treatment in a 72 year - old patient with subarachnoid haemorrhage ( SAH ) is described .	A case of disease* necrotizing myopathy *disease due to a short epsilon - aminocaproic acid ( EACA ) treatment in a 72 year - old patient with disease* subarachnoid haemorrhage *disease ( disease* SAH *disease ) is described .
Pathogenetic hypotheses are discussed .	Pathogenetic hypotheses are discussed .
Cerebral hemorrhage associated with phenylpropanolamine in combination with caffeine .	disease* Cerebral hemorrhage *disease associated with phenylpropanolamine in combination with caffeine .
Phenylpropanolamine ( PPA ) is a drug that has been associated with serious side effects including stroke .	Phenylpropanolamine ( PPA ) is a drug that has been associated with serious side effects including disease* stroke *disease .
It is often combined with caffeine in diet preparations and " look - alike " pills .	It is often combined with caffeine in diet preparations and " look - alike " pills .
In order to determine if PPA / caffeine can lead to stroke in normotensive and / or hypertensive rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .	In order to determine if PPA / caffeine can lead to disease* stroke *disease in normotensive and / or disease* hypertensive *disease rats , we administered the combination in six times the allowed human dose calculated on a per weight basis for the rats two times per day for five days .
Subarachnoid and cerebral hemorrhage was noted in 18 % of the hypertensive rats .	disease* Subarachnoid and cerebral hemorrhage *disease was noted in 18 % of the disease* hypertensive *disease rats .
A single PPA / caffeine administration ( same dose ) lead to acute hypertension in both the normotensive and hypertensive animals .	A single PPA / caffeine administration ( same dose ) lead to acute disease* hypertension *disease in both the normotensive and disease* hypertensive *disease animals .
These results suggest that PPA / caffeine can lead to cerebral hemorrhage in previously hypertensive animals when administered in greater than the allowed dosage .	These results suggest that PPA / caffeine can lead to disease* cerebral hemorrhage *disease in previously disease* hypertensive *disease animals when administered in greater than the allowed dosage .
An acute elevation in blood pressure may be a contributing factor .	An acute elevation in blood pressure may be a contributing factor .
Renal papillary necrosis due to naproxen .	disease* Renal papillary necrosis *disease due to naproxen .
A 31 - year - old man with rheumatoid arthritis , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed renal papillary necrosis ( RPN ) 4 months after institution of naproxen therapy .	A 31 - year - old man with disease* rheumatoid arthritis *disease , who had previously been treated with sulindac , fenoprofen calcium , high dose salicylates and gold salts , developed disease* renal papillary necrosis *disease ( disease* RPN *disease ) 4 months after institution of naproxen therapy .
No other factor predisposing to RPN could be discovered .	No other factor predisposing to disease* RPN *disease could be discovered .
Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months .	Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months .
We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents .	We review previous reports linking disease* RPN *disease to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced disease* renal toxicity *disease from other antiinflammatory agents .
Nephrotoxic effects of aminoglycoside treatment on renal protein reabsorption and accumulation .	disease* Nephrotoxic *disease effects of aminoglycoside treatment on renal protein reabsorption and accumulation .
To quantify the effects of gentamicin , kanamycin and netilmicin on renal protein reabsorption and accumulation , these drugs were administered to rats intraperitoneally ( 30 mg / kg / day ) for 7 , 14 or 21 days .	To quantify the effects of gentamicin , kanamycin and netilmicin on renal protein reabsorption and accumulation , these drugs were administered to rats intraperitoneally ( 30 mg / kg / day ) for 7 , 14 or 21 days .
Scanning electron microscopy of the glomerular endothelia , urinary measurements of sodium , potassium , endogenous lysozyme , N - acetyl - beta - D - glucosaminidase ( NAG ) as well as clearance and accumulation experiments after i . v . administration of egg - white lysozyme and measurements of inulin clearance ( GFR ) were done in each treatment group .	Scanning electron microscopy of the glomerular endothelia , urinary measurements of sodium , potassium , endogenous lysozyme , N - acetyl - beta - D - glucosaminidase ( NAG ) as well as clearance and accumulation experiments after i . v . administration of egg - white lysozyme and measurements of inulin clearance ( GFR ) were done in each treatment group .
Gentamicin administration decreased diameter , density and shape of endothelial fenestrae .	Gentamicin administration decreased diameter , density and shape of endothelial fenestrae .
Kanamycin and netilmicin appeared to have no effect at the dose used .	Kanamycin and netilmicin appeared to have no effect at the dose used .
All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium .	All three aminoglycosides decreased GFR and increased urinary excretion of sodium and potassium .
While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i . v . administration of egg - white lysozyme netilmicin had no effect .	While gentamicin and kanamycin decreased the percentage reabsorption and accumulation of lysozyme after i . v . administration of egg - white lysozyme netilmicin had no effect .
Daily excretion of total protein , endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin .	Daily excretion of total protein , endogenous lysozyme and NAG increased only after treatment with kanamycin and gentamicin .
Thus , aminoglycosides may act as nephrotoxicants at glomerular and / or tubular level inducing impairment of renal reabsorption and accumulation of proteins .	Thus , aminoglycosides may act as nephrotoxicants at glomerular and / or tubular level inducing disease* impairment of renal reabsorption *disease and accumulation of proteins .
Induction of the obstructive sleep apnea syndrome in a woman by exogenous androgen administration .	Induction of the disease* obstructive sleep apnea syndrome *disease in a woman by exogenous androgen administration .
We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the syndrome of obstructive sleep apnea while being administered exogenous androgens .	We documented airway occlusion during sleep and an abnormally high supraglottic resistance while awake in a 54 - yr - old woman who had developed physical changes and the disease* syndrome of obstructive sleep apnea *disease while being administered exogenous androgens .
When the androgens were withdrawn , the patient ' s physical changes , symptoms , sleep study , and supraglottic resistance all returned to normal .	When the androgens were withdrawn , the patient ' s physical changes , symptoms , sleep study , and supraglottic resistance all returned to normal .
A rechallenge with androgen produced symptoms of obstructive sleep apnea that abated upon withdrawal of the hormone .	A rechallenge with androgen produced symptoms of disease* obstructive sleep apnea *disease that abated upon withdrawal of the hormone .
Previous reports have favored a role of androgens in the pathogenesis of sleep apnea .	Previous reports have favored a role of androgens in the pathogenesis of disease* sleep apnea *disease .
Our report provides direct evidence for this role .	Our report provides direct evidence for this role .
Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep .	Structural and functional measurements indicate that androgens exert a permissive or necessary action on the structural configuration of the oropharynx that predisposes to obstruction during sleep .
Development of the obstructive sleep apnea syndrome must be considered a possible side effect of androgen therapy .	Development of the disease* obstructive sleep apnea syndrome *disease must be considered a possible side effect of androgen therapy .
Cardiotoxic and possible leukemogenic effects of adriamycin in nonhuman primates .	disease* Cardiotoxic *disease and possible leukemogenic effects of adriamycin in nonhuman primates .
10 monkeys ( macaques ) received adriamycin by monthly intravenous injections at 12 mg / m2 ( 1 mg / kg ) .	10 monkeys ( macaques ) received adriamycin by monthly intravenous injections at 12 mg / m2 ( 1 mg / kg ) .
8 of the 10 monkeys developed congestive heart failure at an average cumulative adriamycin dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .	8 of the 10 monkeys developed disease* congestive heart failure *disease at an average cumulative adriamycin dose ( 310 mg / m2 ) well below that considered the safe upper limit ( 550 mg / m2 ) in man .
Histologically , the myocardial lesions resembled those found in human anthracycline - induced cardiomyopathy .	Histologically , the disease* myocardial lesions *disease resembled those found in human anthracycline - induced disease* cardiomyopathy *disease .
1 of the 10 monkeys developed acute myeloblastic leukemia after receiving 324 mg / m2 of adriamycin ; the 10th monkey is alive and well 26 months after the last dose of drug .	1 of the 10 monkeys developed disease* acute myeloblastic leukemia *disease after receiving 324 mg / m2 of adriamycin ; the 10th monkey is alive and well 26 months after the last dose of drug .
Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that leukemia may be a consequence of prolonged treatment with this drug .	Our results suggest that adriamycin is a more potent cardiotoxin in monkeys than in man , and that disease* leukemia *disease may be a consequence of prolonged treatment with this drug .
Tricuspid valve regurgitation and lithium carbonate toxicity in a newborn infant .	disease* Tricuspid valve regurgitation *disease and lithium carbonate disease* toxicity *disease in a newborn infant .
A newborn with massive tricuspid regurgitation , atrial flutter , congestive heart failure , and a high serum lithium level is described .	A newborn with massive disease* tricuspid regurgitation *disease , disease* atrial flutter *disease , disease* congestive heart failure *disease , and a high serum lithium level is described .
This is the first patient to initially manifest tricuspid regurgitation and atrial flutter , and the 11th described patient with cardiac disease among infants exposed to lithium compounds in the first trimester of pregnancy .	This is the first patient to initially manifest disease* tricuspid regurgitation *disease and disease* atrial flutter *disease , and the 11th described patient with disease* cardiac disease *disease among infants exposed to lithium compounds in the first trimester of pregnancy .
Sixty - three percent of these infants had tricuspid valve involvement .	Sixty - three percent of these infants had tricuspid valve involvement .
Lithium carbonate may be a factor in the increasing incidence of congenital heart disease when taken during early pregnancy .	Lithium carbonate may be a factor in the increasing incidence of disease* congenital heart disease *disease when taken during early pregnancy .
It also causes neurologic depression , cyanosis , and cardiac arrhythmia when consumed prior to delivery .	It also causes disease* neurologic depression *disease , disease* cyanosis *disease , and disease* cardiac arrhythmia *disease when consumed prior to delivery .
Effects of the novel compound aniracetam ( Ro 13 - 5057 ) upon impaired learning and memory in rodents .	Effects of the novel compound aniracetam ( Ro 13 - 5057 ) upon disease* impaired learning and memory *disease in rodents .
The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally impaired cognitive functions ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal hypercapnia immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term amnesia for a passive avoidance task ; ( 3 ) complete protection against amnesia for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or hypercapnia applied immediately before retrieval testing ( 24 h after acquisition ) .	The effect of aniracetam ( Ro 13 - 5057 , 1 - anisoyl - 2 - pyrrolidinone ) was studied on various forms of experimentally disease* impaired cognitive functions *disease ( learning and memory ) in rodents and produced the following effects : ( 1 ) almost complete prevention of the incapacity to learn a discrete escape response in rats exposed to sublethal disease* hypercapnia *disease immediately before the acquisition session ; ( 2 ) partial ( rats ) or complete ( mice ) prevention of the scopolamine - induced short - term disease* amnesia *disease for a passive avoidance task ; ( 3 ) complete protection against disease* amnesia *disease for a passive avoidance task in rats submitted to electroconvulsive shock immediately after avoidance acquisition ; ( 4 ) prevention of the long - term retention - or retrieval - deficit for a passive avoidance task induced in rats and mice by chloramphenicol or cycloheximide administered immediately after acquisition ; ( 5 ) reversal , when administered as late as 1 h before the retention test , of the deficit in retention or retrieval of a passive avoidance task induced by cycloheximide injected 2 days previously ; ( 6 ) prevention of the deficit in the retrieval of an active avoidance task induced in mice by subconvulsant electroshock or disease* hypercapnia *disease applied immediately before retrieval testing ( 24 h after acquisition ) .
These improvements or normalizations of impaired cognitive functions were seen at oral aniracetam doses of 10 - 100 mg / kg .	These improvements or normalizations of disease* impaired cognitive functions *disease were seen at oral aniracetam doses of 10 - 100 mg / kg .
Generally , the dose - response curves were bell - shaped .	Generally , the dose - response curves were bell - shaped .
The mechanisms underlying the activity of aniracetam and its ' therapeutic window ' are unknown .	The mechanisms underlying the activity of aniracetam and its ' therapeutic window ' are unknown .
Piracetam , another pyrrolidinone derivative was used for comparison .	Piracetam , another pyrrolidinone derivative was used for comparison .
It was active only in six of nine tests and had about one - tenth the potency of aniracetam .	It was active only in six of nine tests and had about one - tenth the potency of aniracetam .
The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process .	The results indicate that aniracetam improves cognitive functions which are impaired by different procedure and in different phases of the learning and memory process .
Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats .	Effect of calcium chloride on gross behavioural changes produced by carbachol and eserine in cats .
The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , mydriasis , tremor and clonic - tonic convulsions produced by carbachol and eserine injected similarly was investigated .	The effect of calcium chloride injected into the cerebral ventricles of group - housed unanaesthetized cats upon vocalization ( rage , hissing and snarling ) , fighting ( attack with paws and claws , defense with paws and claws and biting ) , disease* mydriasis *disease , disease* tremor *disease and disease* clonic - tonic convulsions *disease produced by carbachol and eserine injected similarly was investigated .
Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine .	Calcium chloride depressed or almost completely abolished the vocalization and fighting due to carbachol and eserine .
On the other hand , mydriasis , tremor and clonic - tonic convulsions evoked by carbachol and eserine were not significantly changed by calcium chloride .	On the other hand , disease* mydriasis *disease , disease* tremor *disease and disease* clonic - tonic convulsions *disease evoked by carbachol and eserine were not significantly changed by calcium chloride .
It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as mydriasis , tremor and clonic - tonic convulsions caused by carbachol and eserine .	It is apparent that calcium chloride can " dissociate " vocalization and fighting from autonomic and motor phenomena such as disease* mydriasis *disease , disease* tremor *disease and disease* clonic - tonic convulsions *disease caused by carbachol and eserine .
Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites .	Calcium chloride inhibited the vocalization and fighting produced by carbachol and eserine most probably by a nonspecific stabilizing action on central muscarinic cholinoceptive sites .
These results further support the view that calcium ions in excess have an atropine - like action also in the central nervous system .	These results further support the view that calcium ions in excess have an atropine - like action also in the central nervous system .
Thiazide diuretics , hypokalemia and cardiac arrhythmias .	Thiazide diuretics , disease* hypokalemia *disease and disease* cardiac arrhythmias *disease .
Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs .	Thiazide diuretics are widely accepted as the cornerstone of antihypertensive treatment programs .
Hypokalemia is a commonly encountered metabolic consequence of chronic thiazide therapy .	disease* Hypokalemia *disease is a commonly encountered metabolic consequence of chronic thiazide therapy .
We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate diastolic hypertension with hydrochlorothiazide ( HCTC ) administered on a twice daily schedule .	We treated 38 patients ( 22 low renin , 16 normal renin ) with moderate disease* diastolic hypertension *disease with hydrochlorothiazide ( HCTC ) administered on a twice daily schedule .
Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg , 150 mg and 200 mg daily until blood pressure normalized .	Initial dose was 50 mg and the dose was increased at monthly intervals to 100 mg , 150 mg and 200 mg daily until blood pressure normalized .
The serum K during the control period was 4 . 5 + / - 0 . 2 mEq / l an on 50 , 100 , 150 and 200 mg HCTZ daily 3 . 9 + / - 0 . 3 , 3 . 4 + / - 0 . 2 , 2 . 9 + / - 0 . 2 , and 2 . 4 + / - 0 . 3 mEq / l , respectively .	The serum K during the control period was 4 . 5 + / - 0 . 2 mEq / l an on 50 , 100 , 150 and 200 mg HCTZ daily 3 . 9 + / - 0 . 3 , 3 . 4 + / - 0 . 2 , 2 . 9 + / - 0 . 2 , and 2 . 4 + / - 0 . 3 mEq / l , respectively .
Corresponding figures for whole body K were 4107 + / - 208 , 3722 + / - 319 , 3628 + / - 257 , 3551 + / - 336 , and 3269 + / - 380 mEq , respectively .	Corresponding figures for whole body K were 4107 + / - 208 , 3722 + / - 319 , 3628 + / - 257 , 3551 + / - 336 , and 3269 + / - 380 mEq , respectively .
In 13 patients we observed the effects of HCTZ therapy ( 100 mg daily ) on the occurrence of PVC ' s during rest as well as during static and dynamic exercise .	In 13 patients we observed the effects of HCTZ therapy ( 100 mg daily ) on the occurrence of PVC ' s during rest as well as during static and dynamic exercise .
During rest we observed 0 . 6 + / - 0 . 08 PVC beats / min + / - SEM and during static and dynamic exercise 0 . 6 + / - 0 . 06 and 0 . 8 + / - 0 . 15 , respectively .	During rest we observed 0 . 6 + / - 0 . 08 PVC beats / min + / - SEM and during static and dynamic exercise 0 . 6 + / - 0 . 06 and 0 . 8 + / - 0 . 15 , respectively .
Corresponding figures during HCTZ therapy 100 mg daily were 1 . 4 + / - 0 . 1 , 3 . 6 + / - 0 . 7 and 5 . 7 4 / - 0 . 8 , respectively .	Corresponding figures during HCTZ therapy 100 mg daily were 1 . 4 + / - 0 . 1 , 3 . 6 + / - 0 . 7 and 5 . 7 4 / - 0 . 8 , respectively .
The occurrence of PVC ' s correlated significantly with the fall in serum K + observed r = 0 . 72 , p less than 0 . 001 .	The occurrence of PVC ' s correlated significantly with the fall in serum K + observed r = 0 . 72 , p less than 0 . 001 .
In conclusion we found that thiazide diuretics cause hypokalemia and depletion of body potassium .	In conclusion we found that thiazide diuretics cause disease* hypokalemia *disease and depletion of body potassium .
The more profound hypokalemia , the greater the propensity for the occurrence of PVC ' s .	The more profound disease* hypokalemia *disease , the greater the propensity for the occurrence of PVC ' s .
Circulating lysosomal enzymes and acute hepatic necrosis .	Circulating lysosomal enzymes and disease* acute hepatic necrosis *disease .
The activities of the lysosomal enzymes acid and neutral protease , N - acetylglucosaminidase , and acid phosphatase were measured in the serum of patients with fulminant hepatic failure .	The activities of the lysosomal enzymes acid and neutral protease , N - acetylglucosaminidase , and acid phosphatase were measured in the serum of patients with disease* fulminant hepatic failure *disease .
Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived fulminant hepatic failure after paracetamol overdose , whereas activities were increased equally in patients with fulminant hepatic failure due to viral hepatitis whether or not they survived .	Acid protease ( cathepsin D ) activity was increased about tenfold in patients who died and nearly fourfold in those who survived disease* fulminant hepatic failure *disease after paracetamol disease* overdose *disease , whereas activities were increased equally in patients with disease* fulminant hepatic failure *disease due to disease* viral hepatitis *disease whether or not they survived .
A correlation was found between serum acid protease activity and prothrombin time , and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase , which showed a sharp early peak and then a fall .	A correlation was found between serum acid protease activity and prothrombin time , and the increase in cathepsin D activity was sustained over several days compared with aspartate aminotransferase , which showed a sharp early peak and then a fall .
Circulating lysosomal proteases can damage other organs , and measurement of their activity may therefore be of added value in assessing prognosis in this condition .	Circulating lysosomal proteases can damage other organs , and measurement of their activity may therefore be of added value in assessing prognosis in this condition .
Hepatic veno - occlusive disease caused by 6 - thioguanine .	disease* Hepatic veno - occlusive disease *disease caused by 6 - thioguanine .
Clinically reversible veno - occlusive disease of the liver developed in a 23 - year - old man with acute lymphocytic leukemia after 10 months of maintenance therapy with 6 - thioguanine .	Clinically reversible disease* veno - occlusive disease of the liver *disease developed in a 23 - year - old man with disease* acute lymphocytic leukemia *disease after 10 months of maintenance therapy with 6 - thioguanine .
Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement .	Serial liver biopsies showed the development and resolution of intense sinusoidal engorgement .
Although this disease was clinically reversible , some subintimal fibrosis about the terminal hepatic veins persisted .	Although this disease was clinically reversible , some subintimal disease* fibrosis *disease about the terminal hepatic veins persisted .
This case presented a unique opportunity to observe the histologic features of clinically reversible hepatic veno - occlusive disease over time , and may be the first case of veno - occlusive related solely to 6 - thioguanine .	This case presented a unique opportunity to observe the histologic features of clinically reversible disease* hepatic veno - occlusive disease *disease over time , and may be the first case of veno - occlusive related solely to 6 - thioguanine .
Chlorpropamide - induced optic neuropathy .	Chlorpropamide - induced disease* optic neuropathy *disease .
A 65 - year - old woman with adult - onset diabetes treated with chlorpropamide ( Diabenese ) had a toxic optic neuropathy that resolved with discontinuation of chlorpropamide therapy .	A 65 - year - old woman with disease* adult - onset diabetes *disease treated with chlorpropamide ( Diabenese ) had a disease* toxic optic neuropathy *disease that resolved with discontinuation of chlorpropamide therapy .
Visual loss occurs in diabetics for a variety of reasons , and accurate diagnosis is necessary to institute appropriate therapy .	disease* Visual loss *disease occurs in disease* diabetics *disease for a variety of reasons , and accurate diagnosis is necessary to institute appropriate therapy .
The possibility of a drug - induced optic neuropathy should be considered in the differential diagnosis of visual loss in diabetics .	The possibility of a drug - induced disease* optic neuropathy *disease should be considered in the differential diagnosis of disease* visual loss *disease in disease* diabetics *disease .
Plasma and urinary lipids and lipoproteins during the development of nephrotic syndrome induced in the rat by puromycin aminonucleoside .	Plasma and urinary lipids and lipoproteins during the development of disease* nephrotic syndrome *disease induced in the rat by puromycin aminonucleoside .
This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in nephrotic syndrome induced by puromycin aminonucleoside were due to nephrotic syndrome per se , or , at least in part , to the aminonucleoside .	This study was undertaken to ascertain whether the alterations of plasma lipoproteins found in disease* nephrotic syndrome *disease induced by puromycin aminonucleoside were due to disease* nephrotic syndrome *disease per se , or , at least in part , to the aminonucleoside .
The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside ( 20 mg / kg for 7 days ) and the subsequent development of nephrotic syndrome .	The purpose of the present study was to investigate the changes in plasma and urinary lipoproteins during the administration of puromycin aminonucleoside ( 20 mg / kg for 7 days ) and the subsequent development of disease* nephrotic syndrome *disease .
Since massive albuminuria occurred after 6 days of treatment , the time - course study was divided into two stages : pre - nephrotic stage ( day 1 - 5 ) and nephrotic stage ( day 6 - 11 ) .	Since massive disease* albuminuria *disease occurred after 6 days of treatment , the time - course study was divided into two stages : pre - disease* nephrotic *disease stage ( day 1 - 5 ) and disease* nephrotic *disease stage ( day 6 - 11 ) .
In pre - nephrotic stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .	In pre - disease* nephrotic *disease stage the plasma level of fatty acids , triacylglycerol and VLDL decreased while that of phospholipid , cholesteryl esters and HDL remained constant .
Plasma apolipoprotein A - I tended to increase ( 40 % increase at day 5 ) .	Plasma apolipoprotein A - I tended to increase ( 40 % increase at day 5 ) .
At the beginning of nephrotic stage ( day 6 ) the concentration of plasma albumin dropped to a very low level , while that of apolipoprotein A - I increased abruptly ( 4 - fold increase ) and continued to rise , although less steeply , in the following days .	At the beginning of disease* nephrotic *disease stage ( day 6 ) the concentration of plasma albumin dropped to a very low level , while that of apolipoprotein A - I increased abruptly ( 4 - fold increase ) and continued to rise , although less steeply , in the following days .
The plasma concentration of HDL followed the same pattern .	The plasma concentration of HDL followed the same pattern .
Plasma VLDL and LDL increased at a later stage ( day 9 ) .	Plasma VLDL and LDL increased at a later stage ( day 9 ) .
Plasma apolipoprotein A - I was found not only in HDL ( 1 . 063 - 1 . 210 g / ml ) but also in the LDL density class ( 1 . 025 - 1 . 050 g / ml ) .	Plasma apolipoprotein A - I was found not only in HDL ( 1 . 063 - 1 . 210 g / ml ) but also in the LDL density class ( 1 . 025 - 1 . 050 g / ml ) .
In the pre - nephrotic stage lipoproteinuria was negligible , while in the early nephrotic stage the urinary loss of plasma lipoproteins consisted mainly of HDL .	In the pre - disease* nephrotic *disease stage lipoproteinuria was negligible , while in the early disease* nephrotic *disease stage the urinary loss of plasma lipoproteins consisted mainly of HDL .
These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL .	These observations indicate that puromycin aminonucleoside alters plasma lipoproteins by lowering VLDL and increasing HDL .
It is likely that the early and striking increase of plasma HDL found in nephrotic rats is related to a direct effect of the drug on HDL metabolism .	It is likely that the early and striking increase of plasma HDL found in disease* nephrotic *disease rats is related to a direct effect of the drug on HDL metabolism .
Fatal aplastic anemia following topical administration of ophthalmic chloramphenicol .	Fatal disease* aplastic anemia *disease following topical administration of ophthalmic chloramphenicol .
A 73 - year - old woman died of aplastic anemia less than two months after undergoing cataract extraction and beginning topical therapy with chloramphenicol .	A 73 - year - old woman died of disease* aplastic anemia *disease less than two months after undergoing disease* cataract *disease extraction and beginning topical therapy with chloramphenicol .
The first signs of pancytopenia began within one month of the surgery .	The first signs of disease* pancytopenia *disease began within one month of the surgery .
The pattern of the aplastic anemia was associated with an idiosyncratic response to chloramphenicol .	The pattern of the disease* aplastic anemia *disease was associated with an idiosyncratic response to chloramphenicol .
This was the second report of fatal aplastic anemia after topical treatment with chloramphenicol for ocular conditions , although two cases of reversible bone marrow hypoplasia have also been reported .	This was the second report of fatal disease* aplastic anemia *disease after topical treatment with chloramphenicol for ocular conditions , although two cases of reversible disease* bone marrow hypoplasia *disease have also been reported .
Any other suspected cases of ocular toxicity associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .	Any other suspected cases of disease* ocular toxicity *disease associated with topically applied chloramphenicol should be reported to the National Registry of Drug - Induced Ocular Side Effects , Oregon Health Sciences University , Portland , OR 97201 .
Midazolam compared with thiopentone as an induction agent .	Midazolam compared with thiopentone as an induction agent .
In patients premedicated with scopolamine + morphine ( + 5 mg nitrazepam the evening before surgery ) , the sleep - inducing effect of midazolam 0 . 15 mg / kg i . v . was clearly slower in onset than that of thiopentone 4 . 67 mg / kg i . v . Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although apnoea occurred less often in the midazolam group it lasted longer .	In patients premedicated with scopolamine + morphine ( + 5 mg nitrazepam the evening before surgery ) , the sleep - inducing effect of midazolam 0 . 15 mg / kg i . v . was clearly slower in onset than that of thiopentone 4 . 67 mg / kg i . v . Somewhat fewer cardiovascular and local sequelae were found in the midazolam group , but , although disease* apnoea *disease occurred less often in the midazolam group it lasted longer .
On the whole , the differences between midazolam and thiopentone had no apparent clinical consequences .	On the whole , the differences between midazolam and thiopentone had no apparent clinical consequences .
Midazolam is a new alternative agent for induction in combination anaesthesia .	Midazolam is a new alternative agent for induction in combination anaesthesia .
Extrapyramidal side effects and oral haloperidol : an analysis of explanatory patient and treatment characteristics .	Extrapyramidal side effects and oral haloperidol : an analysis of explanatory patient and treatment characteristics .
The incidence of extrapyramidal side effects ( EPS ) was evaluated in 98 patients treated with haloperidol .	The incidence of extrapyramidal side effects ( EPS ) was evaluated in 98 patients treated with haloperidol .
The incidence of parkinsonism was higher at higher doses of haloperidol and in younger patients .	The incidence of disease* parkinsonism *disease was higher at higher doses of haloperidol and in younger patients .
Prophylactic antiparkinsonian medication was effective in younger but not in older patients .	Prophylactic antiparkinsonian medication was effective in younger but not in older patients .
However , these medications were more effective in both young and old patients when given after parkinsonism developed .	However , these medications were more effective in both young and old patients when given after disease* parkinsonism *disease developed .
Akathisia was controlled by the benzodiazepine lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .	disease* Akathisia *disease was controlled by the benzodiazepine lorazepam in 14 out of 16 patients , while prophylactic antiparkinsonians were ineffective .
The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol .	The present study points to patient characteristics that may be of significance in the development of EPS due to haloperidol .
Deaths from local anesthetic - induced convulsions in mice .	Deaths from local anesthetic - induced disease* convulsions *disease in mice .
Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced convulsions .	Median convulsant ( CD50 ) and median lethal ( LD50 ) doses of three representative local anesthetics were determined in adult mice to evaluate the threat to life of local anesthetic - induced disease* convulsions *disease .
The CD50 and LD50 , respectively , were 57 . 7 and 58 . 7 mg / kg for bupivacaine , 111 . 0 and 133 . 1 mg / kg for lidocaine , and 243 . 4 and 266 . 5 mg / kg for chloroprocaine .	The CD50 and LD50 , respectively , were 57 . 7 and 58 . 7 mg / kg for bupivacaine , 111 . 0 and 133 . 1 mg / kg for lidocaine , and 243 . 4 and 266 . 5 mg / kg for chloroprocaine .
When given intraperitoneally , bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine .	When given intraperitoneally , bupivacaine thus was only about twice as toxic as lidocaine and four times as toxic as chloroprocaine .
Convulsions always preceded death , except after precipitous cardiopulmonary arrest from extreme doses .	disease* Convulsions *disease always preceded death , except after precipitous disease* cardiopulmonary arrest *disease from extreme doses .
A CD50 dose of local anesthetic ( causing convulsions in 50 % of mice ) was fatal in 90 % of bupivacaine - induced seizures , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .	A CD50 dose of local anesthetic ( causing disease* convulsions *disease in 50 % of mice ) was fatal in 90 % of bupivacaine - induced disease* seizures *disease , in 57 % of the chloroprocaine group , and in 6 % of the lidocaine group .
The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated convulsions present much more of a threat to life than heretofore appreciated .	The narrow gap between convulsant and lethal doses of local anesthetics indicates that untreated disease* convulsions *disease present much more of a threat to life than heretofore appreciated .
REM sleep deprivation changes behavioral response to catecholaminergic and serotonergic receptor activation in rats .	disease* REM sleep deprivation *disease changes behavioral response to catecholaminergic and serotonergic receptor activation in rats .
The effects of REM sleep deprivation ( REMD ) on apomorphine - induced aggressiveness and quipazine - induced head twitches in rats were determined .	The effects of disease* REM sleep deprivation *disease ( disease* REMD *disease ) on apomorphine - induced disease* aggressiveness *disease and quipazine - induced disease* head twitches *disease in rats were determined .
Forty - eight hr of REMD increased apomorphine - induced aggressiveness , and reduced ( immediately after completing of REMD ) or increased ( 96 hr after completing of REMD ) quipazine - induced head twitches .	Forty - eight hr of disease* REMD *disease increased apomorphine - induced disease* aggressiveness *disease , and reduced ( immediately after completing of disease* REMD *disease ) or increased ( 96 hr after completing of disease* REMD *disease ) quipazine - induced disease* head twitches *disease .
Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments .	Results are discussed in terms of similarity to pharmacological effects of other antidepressive treatments .
Fatal aplastic anemia due to indomethacin - - lymphocyte transformation tests in vitro .	Fatal disease* aplastic anemia *disease due to indomethacin - - lymphocyte transformation tests in vitro .
Although indomethacin has been implicated as a possible cause of aplastic anemia on the basis of a few clinical observations , its role has not been definitely established .	Although indomethacin has been implicated as a possible cause of disease* aplastic anemia *disease on the basis of a few clinical observations , its role has not been definitely established .
A case of fatal aplastic anemia is described in which no drugs other than allopurinol and indomethacin were given .	A case of fatal disease* aplastic anemia *disease is described in which no drugs other than allopurinol and indomethacin were given .
Indomethacin was first given four weeks prior to the onset of symptoms .	Indomethacin was first given four weeks prior to the onset of symptoms .
A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing aplastic anemia in a susceptible patient .	A positive lymphocyte transformation test with indomethacin in vitro further substantiates the potential role of this drug in causing disease* aplastic anemia *disease in a susceptible patient .
Fortunately , this seems to be a very rare complication .	Fortunately , this seems to be a very rare complication .
Dose - effect and structure - function relationships in doxorubicin cardiomyopathy .	Dose - effect and structure - function relationships in doxorubicin disease* cardiomyopathy *disease .
The cardiomyopathy ( CM ) produced by the anticancer drug doxorubicin ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of myocardial disease .	The disease* cardiomyopathy *disease ( disease* CM *disease ) produced by the anticancer drug doxorubicin ( DXR ) ( Adriamycin ) provides a unique opportunity to analyze dose - effect and structure - function relationships during development of disease* myocardial disease *disease .
We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR .	We measured the degree of morphologic damage by ultrastructural examination of endomyocardial biopsy and the degree of performance abnormally by right heart catheterization in patients receiving DXR .
Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg / m2 .	Morphologic damage was variable but was proportional to the total cumulative DXR dose between 100 and 600 mg / m2 .
Performance abnormalities correlated weakly with dose , exhibited a curvilinear relationship , and had a " threshold " for expression .	Performance abnormalities correlated weakly with dose , exhibited a curvilinear relationship , and had a " threshold " for expression .
Catheterization abnormalities correlated well with morphologic damage ( r = 0 . 57 to 0 . 78 ) in a subgroup of patients in whom exercise hemodynamics were measured , and this relationship also exhibited a curvilinear , threshold configuration .	Catheterization abnormalities correlated well with morphologic damage ( r = 0 . 57 to 0 . 78 ) in a subgroup of patients in whom exercise hemodynamics were measured , and this relationship also exhibited a curvilinear , threshold configuration .
In DXR - CM myocardial damage is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .	In DXR - disease* CM disease* myocardial damage *disease is proportional to the degree of cytotoxic insult ( DXR dose ) while myocardial function is preserved until a critical dose or degree of damage is reached , after which myocardial performance deteriorates rapidly .
Massive cerebral edema associated with fulminant hepatic failure in acetaminophen overdose : possible role of cranial decompression .	Massive disease* cerebral edema *disease associated with fulminant disease* hepatic failure *disease in acetaminophen disease* overdose *disease : possible role of cranial decompression .
Cerebral edema may complicate the course of fulminant hepatic failure .	disease* Cerebral edema *disease may complicate the course of disease* fulminant hepatic failure *disease .
Response to conventional therapy has been disappointing .	Response to conventional therapy has been disappointing .
We present a patient with fatal acetaminophen - induced fulminant hepatic failure , with signs and symptoms of cerebral edema , unresponsive to conventional medical therapy .	We present a patient with fatal acetaminophen - induced disease* fulminant hepatic failure *disease , with signs and symptoms of disease* cerebral edema *disease , unresponsive to conventional medical therapy .
Cranial decompression was carried out .	Cranial decompression was carried out .
A justification of the need for further evaluation of cranial decompression in such patients is presented .	A justification of the need for further evaluation of cranial decompression in such patients is presented .
Subjective assessment of sexual dysfunction of patients on long - term administration of digoxin .	Subjective assessment of disease* sexual dysfunction *disease of patients on long - term administration of digoxin .
Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone ( LH ) .	Various data suggest that male patients who have received digoxin on a longterm basis have increased levels of serum estrogen and decreased levels of plasma testosterone and luteinizing hormone ( LH ) .
This study was undertaken to investigate the links between the long - term administration of digoxin therapy and sexual behavior , and the effect of digoxin on plasma levels of estradiol , testosterone , and LH .	This study was undertaken to investigate the links between the long - term administration of digoxin therapy and sexual behavior , and the effect of digoxin on plasma levels of estradiol , testosterone , and LH .
The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the rheumatic heart disease patients .	The patients of the study and control group ( without digoxin ) were of similar cardiac functional capacity and age ( 25 - 40 years ) and were randomly selected from the disease* rheumatic heart disease *disease patients .
A subjective assessment of sexual behavior in the study and control groups was carried out , using parameters such as sexual desire , sexual excitement , and frequency of sexual relations .	A subjective assessment of sexual behavior in the study and control groups was carried out , using parameters such as sexual desire , sexual excitement , and frequency of sexual relations .
Personal interviews and a questionnaire were also used for the evaluation of sexual behavior .	Personal interviews and a questionnaire were also used for the evaluation of sexual behavior .
The findings support the reports concerning digoxin effect on plasma estradiol , testosterone , and LH .	The findings support the reports concerning digoxin effect on plasma estradiol , testosterone , and LH .
The differences in the means were significant .	The differences in the means were significant .
Tests used to evaluate the changes in sexual behavior showed a significant decrease in sexual desire , sexual excitement phase ( erection ) , and frequency of sexual relations in the study group .	Tests used to evaluate the changes in sexual behavior showed a significant disease* decrease in sexual desire *disease , sexual excitement phase ( erection ) , and frequency of sexual relations in the study group .
Endometrial carcinoma after Hodgkin disease in childhood .	disease* Endometrial carcinoma *disease after disease* Hodgkin disease *disease in childhood .
A 34 - year - old patient developed metastic endometrial carcinoma after Hodgkin disease in childhood .	A 34 - year - old patient developed metastic disease* endometrial carcinoma *disease after disease* Hodgkin disease *disease in childhood .
She had ovarian failure after abdominal irradiation and chemotherapy for Hodgkin disease , and received exogenous estrogens , a treatment implicated in the development of endometrial cancer in menopausal women .	She had disease* ovarian failure *disease after abdominal irradiation and chemotherapy for disease* Hodgkin disease *disease , and received exogenous estrogens , a treatment implicated in the development of disease* endometrial cancer *disease in menopausal women .
Young women on replacement estrogens for ovarian failure after cancer therapy may also have increased risk of endometrial carcinoma and should be examined periodically .	Young women on replacement estrogens for disease* ovarian failure *disease after disease* cancer *disease therapy may also have increased risk of disease* endometrial carcinoma *disease and should be examined periodically .
Long - term lithium treatment and the kidney .	Long - term lithium treatment and the kidney .
Interim report on fifty patients .	Interim report on fifty patients .
This is a report on the first part of our study of the effects of long - term lithium treatment on the kidney .	This is a report on the first part of our study of the effects of long - term lithium treatment on the kidney .
Creatinine clearance , maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long - term lithium for more than one year .	Creatinine clearance , maximum urinary osmolality and 24 hour urine volume have been tested in 50 affectively ill patients who have been on long - term lithium for more than one year .
These findings have been compared with norms and with values of the same tests from screening prior to lithium , available for most of our patients .	These findings have been compared with norms and with values of the same tests from screening prior to lithium , available for most of our patients .
No evidence was found for any reduction of glomerular filtration during lithium treatment .	No evidence was found for any reduction of glomerular filtration during lithium treatment .
Low clearance values found in several patients could be accounted for by their age and their pre - lithium values .	Low clearance values found in several patients could be accounted for by their age and their pre - lithium values .
Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients .	Urinary concentration defect appeared frequent but the extent of the impairment is difficult to assess because of the uncertainty about the norms applicable to this group of patients .
The concentration defect appeared reversible , at least in part .	The concentration defect appeared reversible , at least in part .
Polyuria above 3 litres / 24 hours was found in 10 % of patients .	disease* Polyuria *disease above 3 litres / 24 hours was found in 10 % of patients .
An attempt is made to draw practical conclusions from the preliminary findings .	An attempt is made to draw practical conclusions from the preliminary findings .
Nephrotoxicity of cyclosporin A and FK506 : inhibition of calcineurin phosphatase .	disease* Nephrotoxicity *disease of cyclosporin A and FK506 : inhibition of calcineurin phosphatase .
Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and hypertrophy of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .	Cyclosporin A ( CsA ; 50 mg / kg ) and Fujimycine ( FK506 ; 5 mg / kg ) , but not the related macrolide immunosuppressant rapamycin ( 5 mg / kg ) , caused a reduction of glomerular filtration rate , degenerative changes of proximal tubular epithelium , and disease* hypertrophy *disease of the juxtaglomerular apparatus in male Wistar rats when given for 10 days .
The molecular mechanisms of CsA and FK506 toxicity were investigated .	The molecular mechanisms of CsA and FK506 disease* toxicity *disease were investigated .
Cyclophilin A and FK506 - binding protein , the main intracytoplasmic receptors for CsA and FK506 , respectively , were each detected in renal tissue extract .	Cyclophilin A and FK506 - binding protein , the main intracytoplasmic receptors for CsA and FK506 , respectively , were each detected in renal tissue extract .
In the kidney , high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506 , but not by rapamycin .	In the kidney , high levels of immunoreactive and enzymatically active calcineurin were found which were inhibited by the immunosuppressants CsA and FK506 , but not by rapamycin .
Finally , specific immunophilin - drug - calcineurin complexes formed only in the presence of CsA and FK506 , but not rapamycin .	Finally , specific immunophilin - drug - calcineurin complexes formed only in the presence of CsA and FK506 , but not rapamycin .
These results suggest that the nephrotoxic effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .	These results suggest that the disease* nephrotoxic *disease effects of CsA and FK506 is likely mediated through binding to renal immunophilin and inhibiting calcineurin phosphatase .
Acute renal failure in high dose carboplatin chemotherapy .	disease* Acute renal failure *disease in high dose carboplatin chemotherapy .
Carboplatin has been reported to cause acute renal failure when administered in high doses to adult patients .	Carboplatin has been reported to cause disease* acute renal failure *disease when administered in high doses to adult patients .
We report a 4 1 / 2 - year - old girl who was treated with high - dose carboplatin for metastatic parameningeal embryonal rhabdomyosarcoma .	We report a 4 1 / 2 - year - old girl who was treated with high - dose carboplatin for metastatic parameningeal disease* embryonal rhabdomyosarcoma *disease .
Acute renal failure developed followed by a slow partial recovery of renal function .	disease* Acute renal failure *disease developed followed by a slow partial recovery of renal function .
Possible contributing factors are discussed .	Possible contributing factors are discussed .
Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol .	Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol .
Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3 ' , 5 ' - monophosphate ) .	Among various oral antiplatelets , a combination of a novel prostacyclin analogue beraprost ( BPT ) and a potent phosphodiesterase inhibitor cilostazol ( CLZ ) may result in untoward clinical effects due to possible synergistic elevation of intracellular cAMP ( cyclic adenosine 3 ' , 5 ' - monophosphate ) .
Thereby , a clinical study of the combined administration of the two agents was attempted .	Thereby , a clinical study of the combined administration of the two agents was attempted .
Twelve healthy volunteers were assigned to take BPT / CLZ in the following schedule ; BPT : 40 micrograms at day 1 and 120 micrograms t . i . d . from day 7 to 14 , CLZ : 200 mg t . i . d . from day 3 to 14 .	Twelve healthy volunteers were assigned to take BPT / CLZ in the following schedule ; BPT : 40 micrograms at day 1 and 120 micrograms t . i . d . from day 7 to 14 , CLZ : 200 mg t . i . d . from day 3 to 14 .
At various time intervals , physical examination and blood collection for ex vivo platelet aggregation and determination of intraplatelet cAMP were performed .	At various time intervals , physical examination and blood collection for ex vivo disease* platelet aggregation *disease and determination of intraplatelet cAMP were performed .
Throughout the observation period , no significant alteration in vital signs was observed .	Throughout the observation period , no significant alteration in vital signs was observed .
Seven out of 12 subjects experienced headache of a short duration accompanying facial flush in one and nausea in one , especially after ingestion of CLZ .	Seven out of 12 subjects experienced disease* headache *disease of a short duration accompanying disease* facial flush *disease in one and disease* nausea *disease in one , especially after ingestion of CLZ .
All of these symptoms , probably caused by the vasodilating effect of the two agents , were of mild degree and no special treatment was required .	All of these symptoms , probably caused by the vasodilating effect of the two agents , were of mild degree and no special treatment was required .
Intraplatelet cAMP content was gradually but significantly increased to 9 . 84 + / - 4 . 59 pmol per 10 ( 9 ) platelets at day 14 in comparison with the initial value ( 6 . 87 + / - 2 . 25 pmol ) .	Intraplatelet cAMP content was gradually but significantly increased to 9 . 84 + / - 4 . 59 pmol per 10 ( 9 ) platelets at day 14 in comparison with the initial value ( 6 . 87 + / - 2 . 25 pmol ) .
The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted .	The platelet aggregability was significantly suppressed at various time intervals but no additive or synergistic inhibitory effect by the combined administration was noted .
In conclusion , the combined administration of BPT / CLZ is safe at doses used in the study , though the beneficial clinical effect of the combined administration has yet to be elucidated .	In conclusion , the combined administration of BPT / CLZ is safe at doses used in the study , though the beneficial clinical effect of the combined administration has yet to be elucidated .
Pravastatin - associated myopathy .	Pravastatin - associated disease* myopathy *disease .
Report of a case .	Report of a case .
A case of acute inflammatory myopathy associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .	A case of acute disease* inflammatory myopathy *disease associated with the use of pravastatin , a new hydrophilic 3 - hydroxy - 3 methylglutaril coenzyme A reductase inhibitor , is reported .
The patient , a 69 - year - old man was affected by non - insulin - dependent diabetes mellitus and hypertension .	The patient , a 69 - year - old man was affected by disease* non - insulin - dependent diabetes mellitus *disease and disease* hypertension *disease .
He assumed pravastatin ( 20 mg / day ) because of hypercholesterolemia .	He assumed pravastatin ( 20 mg / day ) because of disease* hypercholesterolemia *disease .
He was admitted with acute myopathy of the lower limbs which resolved in a few days after pravastatin discontinuation .	He was admitted with acute disease* myopathy *disease of the lower limbs which resolved in a few days after pravastatin discontinuation .
A previously unknown hypothyroidism , probably due to chronic autoimmune thyroiditis , was evidenced .	A previously unknown disease* hypothyroidism *disease , probably due to chronic disease* autoimmune thyroiditis *disease , was evidenced .
Muscle biopsy ( left gastrocnemius ) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4 + lymphocytes .	Muscle biopsy ( left gastrocnemius ) revealed a perimysial and endomysial inflammatory infiltrate with a prevalence of CD4 + lymphocytes .
While lovastatin and simvastatin have been associated with toxic myopathy , pravastatin - associated myopathy could represent a distinct , inflammatory entity .	While lovastatin and simvastatin have been associated with toxic disease* myopathy *disease , pravastatin - associated disease* myopathy *disease could represent a distinct , inflammatory entity .
Reversal of ammonia coma in rats by L - dopa : a peripheral effect .	Reversal of ammonia disease* coma *disease in rats by L - dopa : a peripheral effect .
Ammonia coma was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .	Ammonia disease* coma *disease was produced in rats within 10 to 15 minutes of an intraperitonealinjection of 1 . 7 mmol NH4CL .
This coma was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the ammonium salt injection .	This disease* coma *disease was prevented with 1 . 68 mmol L - dopa given by gastric intubation 15 minutes before the ammonium salt injection .
The effect of L - dopa was correlated with a decrease in blood and brain ammonia , an increase in brain dopamine , and an increase in renal excretion of ammonia and urea .	The effect of L - dopa was correlated with a decrease in blood and brain ammonia , an increase in brain dopamine , and an increase in renal excretion of ammonia and urea .
Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia coma nor affect the blood and brain ammonia concentrations .	Intraventricular infusion of dopamine sufficient to raise the brain dopamine to the same extent did not prevent the ammonia disease* coma *disease nor affect the blood and brain ammonia concentrations .
Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the ammonia coma was not prevented .	Bilateral nephrectomy eliminated the beneficial effect of L - dopa on blood and brain ammonia and the ammonia disease* coma *disease was not prevented .
Thus , the reduction in blood and brain ammonia and the prevention of ammonia coma after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .	Thus , the reduction in blood and brain ammonia and the prevention of ammonia disease* coma *disease after L - dopa , can be accounted for by the peripheral effect of dopamine on renal function rather than its central action .
These results provide a reasonable explanation for the beneficial effects observed in some encephalopathic patients receiving L - dopa .	These results provide a reasonable explanation for the beneficial effects observed in some disease* encephalopathic *disease patients receiving L - dopa .
Etoposide - related myocardial infarction .	Etoposide - related disease* myocardial infarction *disease .
The occurrence of a myocardial infarction is reported after chemotherapy containing etoposide , in a man with no risk factors for coronary heart disease .	The occurrence of a disease* myocardial infarction *disease is reported after chemotherapy containing etoposide , in a man with no risk factors for disease* coronary heart disease *disease .
Possible causal mechanisms are discussed .	Possible causal mechanisms are discussed .
Halogenated anesthetics form liver adducts and antigens that cross - react with halothane - induced antibodies .	Halogenated anesthetics form liver adducts and antigens that cross - react with halothane - induced antibodies .
Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type hepatic injury both alone and following previous exposure to halothane .	Two halogenated anesthetics , enflurane and isoflurane , have been associated with an allergic - type disease* hepatic injury *disease both alone and following previous exposure to halothane .
Halothane hepatitis appears to involve an aberrant immune response .	Halothane disease* hepatitis *disease appears to involve an aberrant immune response .
An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane hepatitis patients .	An antibody response to a protein - bound biotransformation product ( trifluoroacetyl adduct ) has been detected on halothane disease* hepatitis *disease patients .
This study was performed to determine cross - reactivity between enflurane and isoflurane with the hypersensitivity induced by halothane .	This study was performed to determine cross - reactivity between enflurane and isoflurane with the disease* hypersensitivity *disease induced by halothane .
The subcellular and lobular production of hepatic neoantigens recognized by halothane - induced antibodies following enflurane and isoflurane , and the biochemical nature of these neoantigens was investigated in two animal models .	The subcellular and lobular production of hepatic neoantigens recognized by halothane - induced antibodies following enflurane and isoflurane , and the biochemical nature of these neoantigens was investigated in two animal models .
Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver .	Enflurane administration resulted in neoantigens detected in both the microsomal and cytosolic fraction of liver homogenates and in the centrilobular region of the liver .
In the same liver , biochemical analysis detected fluorinated liver adducts that were up to 20 - fold greater in guinea pigs than in rats .	In the same liver , biochemical analysis detected fluorinated liver adducts that were up to 20 - fold greater in guinea pigs than in rats .
This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a hypersensitivity condition similar to that of halothane hepatitis either alone or subsequent to halothane administration .	This supports and extends previous evidence for a mechanism by which enflurane and / or isoflurane could produce a disease* hypersensitivity *disease condition similar to that of halothane disease* hepatitis *disease either alone or subsequent to halothane administration .
The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens .	The guinea pig would appear to be a useful model for further investigations of the immunological response to these antigens .
Cholinergic toxicity resulting from ocular instillation of echothiophate iodide eye drops .	Cholinergic disease* toxicity *disease resulting from ocular instillation of echothiophate iodide eye drops .
A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound muscle weakness and was initially given the diagnosis of myasthenia gravis .	A patient developed a severe cholinergic syndrome from the use of echothiophate iodide ophthalmic drops , presented with profound disease* muscle weakness *disease and was initially given the diagnosis of disease* myasthenia gravis *disease .
Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops .	Red blood cell and serum cholinesterase levels were severely depressed and symptoms resolved spontaneously following discontinuation of the eye drops .
Seizure after flumazenil administration in a pediatric patient .	disease* Seizure *disease after flumazenil administration in a pediatric patient .
Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and respiratory depression induced by benzodiazepines .	Flumazenil is a benzodiazepine receptor antagonist used to reverse sedation and disease* respiratory depression *disease induced by benzodiazepines .
Seizures and cardiac arrhythmias have complicated its use in adult patients .	disease* Seizures *disease and disease* cardiac arrhythmias *disease have complicated its use in adult patients .
Overdose patients who have coingested tricyclic antidepressants have a higher risk of these complications .	disease* Overdose *disease patients who have coingested tricyclic antidepressants have a higher risk of these complications .
Little information exists concerning adverse effects of flumazenil in children .	Little information exists concerning adverse effects of flumazenil in children .
We report the occurrence of a generalized tonic - clonic seizure in a pediatric patient following the administration of flumazenil .	We report the occurrence of a generalized disease* tonic - clonic seizure *disease in a pediatric patient following the administration of flumazenil .
Phase I trial of 13 - cis - retinoic acid in children with neuroblastoma following bone marrow transplantation .	Phase I trial of 13 - cis - retinoic acid in children with disease* neuroblastoma *disease following bone marrow transplantation .
PURPOSE : Treatment of neuroblastoma cell lines with 13 - cis - retinoic acid ( cis - RA ) can cause sustained inhibition of proliferation .	PURPOSE : Treatment of disease* neuroblastoma *disease cell lines with 13 - cis - retinoic acid ( cis - RA ) can cause sustained inhibition of proliferation .
Since cis - RA has demonstrated clinical responses in neuroblastoma patients , it may be effective in preventing relapse after cytotoxic therapy .	Since cis - RA has demonstrated clinical responses in disease* neuroblastoma *disease patients , it may be effective in preventing relapse after cytotoxic therapy .
This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , toxicities , and pharmacokinetics of cis - RA administered on an intermittent schedule in children with neuroblastoma following bone marrow transplantation ( BMT ) .	This phase I trial was designed to determine the maximal - tolerated dosage ( MTD ) , disease* toxicities *disease , and pharmacokinetics of cis - RA administered on an intermittent schedule in children with disease* neuroblastoma *disease following bone marrow transplantation ( BMT ) .
PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis - RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .	PATIENTS AND METHODS : Fifty - one assessable patients , 2 to 12 years of age , were treated with oral cis - RA administered in two equally divided doses daily for 2 weeks , followed by a 2 - week rest period , for up to 12 courses .
The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting toxicity ( DLT ) was observed .	The dose was escalated from 100 to 200 mg / m2 / d until dose - limiting disease* toxicity *disease ( DLT ) was observed .
A single intrapatient dose escalation was permitted .	A single intrapatient dose escalation was permitted .
RESULTS : The MTD of cis - RA was 160 mg / m2 / d .	RESULTS : The MTD of cis - RA was 160 mg / m2 / d .
Dose - limiting toxicities in six of nine patients at 200 mg / m2 / d included hypercalcemia ( n = 3 ) , rash ( n = 2 ) , and anemia / thrombocytopenia / emesis / rash ( n = 1 ) .	Dose - limiting disease* toxicities *disease in six of nine patients at 200 mg / m2 / d included disease* hypercalcemia *disease ( n = 3 ) , disease* rash *disease ( n = 2 ) , and disease* anemia *disease / disease* thrombocytopenia *disease / disease* emesis *disease / disease* rash *disease ( n = 1 ) .
All toxicities resolved after cis - RA was discontinued .	All disease* toxicities *disease resolved after cis - RA was discontinued .
Three complete responses were observed in marrow metastases .	Three complete responses were observed in marrow disease* metastases *disease .
Serum levels of 7 . 4 + / - 3 . 0 mumol / L ( peak ) and 4 . 0 + / - 2 . 8 mumol / L ( trough ) at the MTD were maintained during 14 days of therapy .	Serum levels of 7 . 4 + / - 3 . 0 mumol / L ( peak ) and 4 . 0 + / - 2 . 8 mumol / L ( trough ) at the MTD were maintained during 14 days of therapy .
The DLT correlated with serum levels > or = 10 mumol / L .	The DLT correlated with serum levels > or = 10 mumol / L .
CONCLUSION : The MTD of cis - RA given on this intermittent schedule was 160 mg / m2 / d .	CONCLUSION : The MTD of cis - RA given on this intermittent schedule was 160 mg / m2 / d .
Serum levels known to be effective against neuroblastoma in vitro were achieved at this dose .	Serum levels known to be effective against disease* neuroblastoma *disease in vitro were achieved at this dose .
The DLT included hypercalcemia , and may be predicted by serum cis - RA levels .	The DLT included disease* hypercalcemia *disease , and may be predicted by serum cis - RA levels .
Monitoring of serum calcium and cis - RA levels is indicated in future trials .	Monitoring of serum calcium and cis - RA levels is indicated in future trials .
Time dependence of plasma malondialdehyde , oxypurines , and nucleosides during incomplete cerebral ischemia in the rat .	Time dependence of plasma malondialdehyde , oxypurines , and nucleosides during incomplete disease* cerebral ischemia *disease in the rat .
Incomplete cerebral ischemia ( 30 min ) was induced in the rat by bilaterally clamping the common carotid arteries .	Incomplete disease* cerebral ischemia *disease ( 30 min ) was induced in the rat by bilaterally clamping the common carotid arteries .
Peripheral venous blood samples were withdrawn from the femoral vein four times ( once every 5 min ) before ischemia ( 0 time ) and 5 , 15 , and 30 min after ischemia .	Peripheral venous blood samples were withdrawn from the femoral vein four times ( once every 5 min ) before disease* ischemia *disease ( 0 time ) and 5 , 15 , and 30 min after disease* ischemia *disease .
Plasma extracts were analyzed by a highly sensitive high - performance liquid chromatographic method for the direct determination of malondialdehyde , oxypurines , and nucleosides .	Plasma extracts were analyzed by a highly sensitive high - performance liquid chromatographic method for the direct determination of malondialdehyde , oxypurines , and nucleosides .
During ischemia , a time - dependent increase of plasma oxypurines and nucleosides was observed .	During disease* ischemia *disease , a time - dependent increase of plasma oxypurines and nucleosides was observed .
Plasma malondialdehyde , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of ischemia , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .	Plasma malondialdehyde , which was present in minimal amount at zero time ( 0 . 058 mumol / liter plasma ; SD 0 . 015 ) , increased after 5 min of disease* ischemia *disease , resulting in a fivefold increase after 30 min of carotid occlusion ( 0 . 298 mumol / liter plasma ; SD 0 . 078 ) .
Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model , one receiving 20 mg / kg b . w . of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before ischemia , the other receiving 650 micrograms / kg b . w . of the hypotensive drug nitroprusside at a flow rate of 103 microliters / min intravenously during ischemia , although in this latter group malondialdehyde was significantly higher .	Increased plasma malondialdehyde was also recorded in two other groups of animals subjected to the same experimental model , one receiving 20 mg / kg b . w . of the cyclooxygenase inhibitor acetylsalicylate intravenously immediately before disease* ischemia *disease , the other receiving 650 micrograms / kg b . w . of the disease* hypotensive *disease drug nitroprusside at a flow rate of 103 microliters / min intravenously during disease* ischemia *disease , although in this latter group malondialdehyde was significantly higher .
The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during ischemic phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )	The present data indicate that the determination of malondialdehyde , oxypurines , and nucleosides in peripheral blood , may be used to monitor the metabolic alterations of tissues occurring during disease* ischemic *disease phenomena . ( ABSTRACT TRUNCATED AT 250 WORDS )
Acute renal toxicity of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .	Acute disease* renal toxicity *disease of doxorubicin ( adriamycin ) - loaded cyanoacrylate nanoparticles .
Acute doxorubicin - loaded nanoparticle ( DXNP ) renal toxicity was explored in both normal rats and rats with experimental glomerulonephritis .	Acute doxorubicin - loaded nanoparticle ( DXNP ) disease* renal toxicity *disease was explored in both normal rats and rats with experimental disease* glomerulonephritis *disease .
In normal rats , 2 / 6 rats given free doxorubicin ( DX ) ( 5 mg / kg ) died within one week , whereas all control animals and all rats having received free NP or DXNP survived .	In normal rats , 2 / 6 rats given free doxorubicin ( DX ) ( 5 mg / kg ) died within one week , whereas all control animals and all rats having received free NP or DXNP survived .
A 3 times higher proteinuria appeared in animals treated with DXNP than in those treated with DX .	A 3 times higher disease* proteinuria *disease appeared in animals treated with DXNP than in those treated with DX .
Free NP did not provoke any proteinuria .	Free NP did not provoke any disease* proteinuria *disease .
Two hr post - injection , DXNP was 2 . 7 times more concentrated in kidneys than free DX ( p < 0 . 025 ) .	Two hr post - injection , DXNP was 2 . 7 times more concentrated in kidneys than free DX ( p < 0 . 025 ) .
In rats with immune experimental glomerulonephritis , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .	In rats with immune experimental disease* glomerulonephritis *disease , 5 / 6 rats given DX died within 7 days , in contrast to animals treated by DXNP , NP , or untreated , which all survived .
Proteinuria appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .	disease* Proteinuria *disease appeared in all series , but was 2 - 5 times more intense ( p > 0 . 001 ) and prolonged after doxorubicin treatment ( 400 - 700 mg / day ) , without significant difference between DXNP and DX .
Rats treated by unloaded NP behaved as controls .	Rats treated by unloaded NP behaved as controls .
These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced renal toxicity of the former .	These results demonstrate that , in these experimental conditions , DXNP killed less animals than free DX , despite of an enhanced disease* renal toxicity *disease of the former .
Both effects ( better survival and nephrosis ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system , including mesangial cells .	Both effects ( better survival and disease* nephrosis *disease ) are most probably related to an enhanced capture of DXNP by cells of the mononuclear phagocyte system , including mesangial cells .
Prostaglandin E2 - induced bladder hyperactivity in normal , conscious rats : involvement of tachykinins ?	Prostaglandin E2 - induced disease* bladder hyperactivity *disease in normal , conscious rats : involvement of tachykinins ?
In normal conscious rats investigated by continuous cystometry , intravesically instilled prostaglandin ( PG ) E2 facilitated micturition and increased basal intravesical pressure .	In normal conscious rats investigated by continuous cystometry , intravesically instilled prostaglandin ( PG ) E2 facilitated micturition and increased basal intravesical pressure .
The effect was attenuated by both the NK1 receptor selective antagonist RP 67 , 580 and the NK2 receptor selective antagonist SR 48 , 968 , given intra - arterially , suggesting that it was mediated by stimulation of both NK1 and NK2 receptors .	The effect was attenuated by both the NK1 receptor selective antagonist RP 67 , 580 and the NK2 receptor selective antagonist SR 48 , 968 , given intra - arterially , suggesting that it was mediated by stimulation of both NK1 and NK2 receptors .
Intra - arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex , indicating that the PG had a direct contractant effect on the detrusor smooth muscle .	Intra - arterially given PGE2 produced a distinct increase in bladder pressure before initiating a micturition reflex , indicating that the PG had a direct contractant effect on the detrusor smooth muscle .
The effect of intra - arterial PGE2 could not be blocked by intra - arterial RP 67 , 580 or SR 48 , 968 , which opens the possibility that the micturition reflex elicited by intra - arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically .	The effect of intra - arterial PGE2 could not be blocked by intra - arterial RP 67 , 580 or SR 48 , 968 , which opens the possibility that the micturition reflex elicited by intra - arterial PGE2 was mediated by pathways other than the reflex initiated when the PG was given intravesically .
The present results thus suggest that intra - arterial PGE2 , given near the bladder , may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor .	The present results thus suggest that intra - arterial PGE2 , given near the bladder , may initiate micturition in the normal rat chiefly by directly contracting the smooth muscle of the detrusor .
However , when given intravesically , PGE2 may stimulate micturition by releasing tachykinins from nerves in and / or immediately below the urothelium .	However , when given intravesically , PGE2 may stimulate micturition by releasing tachykinins from nerves in and / or immediately below the urothelium .
These tachykinins , in turn , initiate a micturition reflex by stimulating NK1 and NK2 receptors .	These tachykinins , in turn , initiate a micturition reflex by stimulating NK1 and NK2 receptors .
Prostanoids may , via release of tachykinins , contribute to both urge and bladder hyperactivity seen in inflammatory conditions of the lower urinary tract .	Prostanoids may , via release of tachykinins , contribute to both urge and disease* bladder hyperactivity *disease seen in inflammatory conditions of the lower urinary tract .
Refractory cardiogenic shock and complete heart block after verapamil SR and metoprolol treatment .	Refractory disease* cardiogenic shock *disease and complete disease* heart block *disease after verapamil SR and metoprolol treatment .
A case report .	A case report .
A seventy - eight - year - old woman presented with complete heart block and refractory hypotension two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .	A seventy - eight - year - old woman presented with complete disease* heart block *disease and refractory disease* hypotension *disease two days after a therapeutic dose of sustained - release verapamil with concomitant use of metoprolol .
The patient continued to remain hypotensive with complete heart block , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine .	The patient continued to remain disease* hypotensive *disease with complete disease* heart block *disease , even with multiple uses of intravenous atropine as well as high doses of pressor agents such as dopamine and dobutamine .
However , shortly after the use of intravenous calcium chloride , the refractory hypotension and complete heart block resolved .	However , shortly after the use of intravenous calcium chloride , the refractory disease* hypotension *disease and complete disease* heart block *disease resolved .
Protective effect of misoprostol on indomethacin induced renal dysfunction in elderly patients .	Protective effect of misoprostol on indomethacin induced disease* renal dysfunction *disease in elderly patients .
OBJECTIVE : To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin .	OBJECTIVE : To evaluate the possible protective effects of misoprostol on renal function in hospitalized elderly patients treated with indomethacin .
METHODS : Forty - five hospitalized elderly patients ( > 65 years old ) who required therapy with nonsteroidal antiinflammatory drugs ( NSAID ) were randomly assigned to receive either indomethacin , 150 mg / day ( Group A ) , or indomethacin 150 mg / day plus misoprostol at 0 . 6 mg / day ( Group B ) .	METHODS : Forty - five hospitalized elderly patients ( > 65 years old ) who required therapy with nonsteroidal antiinflammatory drugs ( NSAID ) were randomly assigned to receive either indomethacin , 150 mg / day ( Group A ) , or indomethacin 150 mg / day plus misoprostol at 0 . 6 mg / day ( Group B ) .
Laboratory variables of renal function [ serum creatinine , blood urea nitrogen ( BUN ) and electrolytes ] were evaluated before initiation of therapy and every 2 days , until termination of the study ( a period of at least 6 days ) .	Laboratory variables of renal function [ serum creatinine , blood urea nitrogen ( BUN ) and electrolytes ] were evaluated before initiation of therapy and every 2 days , until termination of the study ( a period of at least 6 days ) .
Response to treatment was estimated by the visual analog scale for severity of pain .	Response to treatment was estimated by the visual analog scale for severity of disease* pain *disease .
RESULTS : Forty - two patients completed the study , 22 in Group A and 20 in Group B .	RESULTS : Forty - two patients completed the study , 22 in Group A and 20 in Group B .
BUN and creatinine increased by > 50 % of baseline levels in 54 and 45 % of Group A patients , respectively , compared to only 20 and 10 % of Group B patients ( p < 0 . 05 ) .	BUN and creatinine increased by > 50 % of baseline levels in 54 and 45 % of Group A patients , respectively , compared to only 20 and 10 % of Group B patients ( p < 0 . 05 ) .
Potassium ( K ) increment of 0 . 6 mEq / l or more was observed in 50 % of Group A , but in only 15 % of Group B patients ( p < 0 . 05 ) .	Potassium ( K ) increment of 0 . 6 mEq / l or more was observed in 50 % of Group A , but in only 15 % of Group B patients ( p < 0 . 05 ) .
The mean increments in BUN , creatinine , and K were reduced by 63 , 80 , and 42 % , respectively , in Group B patients compared to Group A . Response to treatment did not differ significantly between the 2 groups .	The mean increments in BUN , creatinine , and K were reduced by 63 , 80 , and 42 % , respectively , in Group B patients compared to Group A . Response to treatment did not differ significantly between the 2 groups .
CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related renal dysfunction .	CONCLUSION : Hospitalized elderly patients are at risk for developing indomethacin related disease* renal dysfunction *disease .
Addition of misoprostol can minimize this renal impairment without affecting pain control .	Addition of misoprostol can minimize this disease* renal impairment *disease without affecting disease* pain *disease control .
Cognitive deterioration from long - term abuse of dextromethorphan : a case report .	disease* Cognitive deterioration *disease from long - term abuse of dextromethorphan : a case report .
Dextromethorphan ( DM ) , the dextrorotatory isomer of 3 - hydroxy - N - methylmorphinan , is the main ingredient in a number of widely available , over - the - counter antitussives .	Dextromethorphan ( DM ) , the dextrorotatory isomer of 3 - hydroxy - N - methylmorphinan , is the main ingredient in a number of widely available , over - the - counter antitussives .
Initial studies ( Bornstein 1968 ) showed that it possessed no respiratory suppressant effects and no addiction liability .	Initial studies ( Bornstein 1968 ) showed that it possessed no respiratory suppressant effects and no addiction liability .
Subsequently , however , several articles reporting abuse of this drug have appeared in the literature .	Subsequently , however , several articles reporting abuse of this drug have appeared in the literature .
The drug is known to cause a variety of acute toxic effects , ranging from nausea , restlessness , insomnia , ataxia , slurred speech and nystagmus to mood changes , perceptual alterations , inattention , disorientation and aggressive behavior ( Rammer et al 1988 ; Katona and Watson 1986 ; Isbell and Fraser 1953 ; Devlin et al 1985 ; McCarthy 1971 ; Dodds and Revai 1967 ; Degkwitz 1964 ; Hildebrand et al 1989 ) .	The drug is known to cause a variety of acute toxic effects , ranging from disease* nausea *disease , disease* restlessness *disease , disease* insomnia *disease , disease* ataxia *disease , slurred speech and disease* nystagmus *disease to mood changes , perceptual alterations , inattention , disorientation and disease* aggressive behavior *disease ( Rammer et al 1988 ; Katona and Watson 1986 ; Isbell and Fraser 1953 ; Devlin et al 1985 ; McCarthy 1971 ; Dodds and Revai 1967 ; Degkwitz 1964 ; Hildebrand et al 1989 ) .
There have also been two reported fatalities from DM overdoses ( Fleming 1986 ) .	There have also been two reported fatalities from DM overdoses ( Fleming 1986 ) .
However , there are no reports describing the effects of chronic abuse .	However , there are no reports describing the effects of chronic abuse .
This report describes a case of cognitive deterioration resulting from prolonged use of DM .	This report describes a case of disease* cognitive deterioration *disease resulting from prolonged use of DM .
Effects of ouabain on myocardial oxygen supply and demand in patients with chronic coronary artery disease .	Effects of ouabain on myocardial oxygen supply and demand in patients with chronic disease* coronary artery disease *disease .
A hemodynamic , volumetric , and metabolic study in patients without heart failure .	A hemodynamic , volumetric , and metabolic study in patients without disease* heart failure *disease .
The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive coronary artery disease , but have not been measured previously in man .	The effects of digitalis glycosides on myocardial oxygen supply and demand are of particular interest in the presence of obstructive disease* coronary artery disease *disease , but have not been measured previously in man .
We assessed the effects of ouabain ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic coronary artery disease without clinical congestive heart failure .	We assessed the effects of ouabain ( 0 . 015 mg / kg body weight ) on hemodynamic , volumetric , and metabolic parameters in 11 patients with severe chronic disease* coronary artery disease *disease without clinical disease* congestive heart failure *disease .
Because the protocol was long and involved interventions which might affect the determinations , we also studied in nine patients using an identical protocol except that ouabain administration was omitted .	Because the protocol was long and involved interventions which might affect the determinations , we also studied in nine patients using an identical protocol except that ouabain administration was omitted .
Left ventricular end - diastolic pressure and left ventricular end - diastolic volume fell in each patient given ouabain , even though they were initially elevated in only two patients .	Left ventricular end - diastolic pressure and left ventricular end - diastolic volume fell in each patient given ouabain , even though they were initially elevated in only two patients .
Left ventricular end - diastolic pressure fell from 11 . 5 + / - 1 . 4 ( mean + / - SE ) to 5 . 6 + / - 0 . 9 mm Hg ( P less than 0 . 001 ) and left ventricular end - diastolic volume fell from 100 + / - 17 to 82 + / - 12 ml / m2 ( P less than 0 . 01 ) 1 h after ouabain infusion was completed .	Left ventricular end - diastolic pressure fell from 11 . 5 + / - 1 . 4 ( mean + / - SE ) to 5 . 6 + / - 0 . 9 mm Hg ( P less than 0 . 001 ) and left ventricular end - diastolic volume fell from 100 + / - 17 to 82 + / - 12 ml / m2 ( P less than 0 . 01 ) 1 h after ouabain infusion was completed .
The maximum velocity of contractile element shortening increased from 1 . 68 + / - 0 . 11 ml / s to 2 . 18 + / - 0 . 21 muscle - lengths / s ( P less than 0 . 05 ) and is consistent with an increase in contractility .	The maximum velocity of contractile element shortening increased from 1 . 68 + / - 0 . 11 ml / s to 2 . 18 + / - 0 . 21 muscle - lengths / s ( P less than 0 . 05 ) and is consistent with an increase in contractility .
No significant change in these parameters occurred in the control patients .	No significant change in these parameters occurred in the control patients .
No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients .	No significant change in myocardial oxygen consumption occurred after ouabain administration but this may be related to a greater decrease in mean arterial pressure in the ouabain patients than in the control patients .
We conclude that in patients with chronic coronary artery disease who are not in clinical congestive heart failure left ventricular end - diastolic volume falls after ouabain administration even when it is initially normal .	We conclude that in patients with chronic disease* coronary artery disease *disease who are not in clinical disease* congestive heart failure disease* left ventricular end - diastolic volume falls *disease after ouabain administration even when it is initially normal .
Though this fall would be associated with a decrease in wall tension , and , therefore , of myocardial oxygen consumption , it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption .	Though this fall would be associated with a decrease in wall tension , and , therefore , of myocardial oxygen consumption , it may not be of sufficient magnitude to prevent a net increase in myocardial oxygen consumption .
Nevertheless , compensatory mechanisms prevent a deterioration of resting myocardial metabolism .	Nevertheless , compensatory mechanisms prevent a deterioration of resting myocardial metabolism .
Dexamethasone - induced ocular hypertension in perfusion - cultured human eyes .	Dexamethasone - induced disease* ocular hypertension *disease in perfusion - cultured human eyes .
PURPOSE : Glucocorticoid administration can lead to the development of ocular hypertension and corticosteroid glaucoma in a subset of the population through a decrease in the aqueous humor outflow facility .	PURPOSE : Glucocorticoid administration can lead to the development of disease* ocular hypertension *disease and disease* corticosteroid glaucoma *disease in a subset of the population through a decrease in the aqueous humor outflow facility .
The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated , perfusion - cultured human eyes .	The purpose of this study was to determine whether glucocorticoid treatment can directly affect the outflow facility of isolated , perfusion - cultured human eyes .
METHODS : The anterior segments of human donor eyes from regional eye banks were placed in a constant flow , variable pressure perfusion culture system .	METHODS : The anterior segments of human donor eyes from regional eye banks were placed in a constant flow , variable pressure perfusion culture system .
Paired eyes were perfused in serum - free media with or without 10 ( - 7 ) M dexamethasone for 12 days .	Paired eyes were perfused in serum - free media with or without 10 ( - 7 ) M dexamethasone for 12 days .
Intraocular pressure was monitored daily .	Intraocular pressure was monitored daily .
After incubation , the eyes were morphologically characterized by light microscopy , transmission and scanning electron microscopy , and scanning laser confocal microscopy .	After incubation , the eyes were morphologically characterized by light microscopy , transmission and scanning electron microscopy , and scanning laser confocal microscopy .
RESULTS : A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17 . 5 + / - 3 . 8 mm Hg after 12 days of dexamethasone exposure .	RESULTS : A significant increase in intraocular pressure developed in 13 of the 44 pairs of eyes perfused with dexamethasone with an average pressure rise of 17 . 5 + / - 3 . 8 mm Hg after 12 days of dexamethasone exposure .
The contralateral control eyes , which did not receive dexamethasone , maintained a stable intraocular pressure during the same period .	The contralateral control eyes , which did not receive dexamethasone , maintained a stable intraocular pressure during the same period .
The outflow pathway of the untreated eyes appeared morphologically normal .	The outflow pathway of the untreated eyes appeared morphologically normal .
In contrast , the dexamethasone - treated hypertensive eyes had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .	In contrast , the dexamethasone - treated disease* hypertensive eyes *disease had thickened trabecular beams , decreased intertrabecular spaces , thickened juxtacanalicular tissue , activated trabecular meshwork cells , and increased amounts of amorphogranular extracellular material , especially in the juxtacanalicular tissue and beneath the endothelial lining of the canal of Schlemm .
The dexamethasone - treated nonresponder eyes appeared to be morphologically similar to the untreated eyes , although several subtle dexamethasone - induced morphologic changes were evident .	The dexamethasone - treated nonresponder eyes appeared to be morphologically similar to the untreated eyes , although several subtle dexamethasone - induced morphologic changes were evident .
CONCLUSION : Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of ocular hypertension in approximately 30 % of the dexamethasone - treated eyes .	CONCLUSION : Dexamethasone treatment of isolated , perfusion - cultured human eyes led to the generation of disease* ocular hypertension *disease in approximately 30 % of the dexamethasone - treated eyes .
Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for corticosteroid glaucoma and open angle glaucoma .	Steroid treatment resulted in morphologic changes in the trabecular meshwork similar to those reported for disease* corticosteroid glaucoma *disease and disease* open angle glaucoma *disease .
This system may provide an acute model in which to study the pathogenic mechanisms involved in steroid glaucoma and primary open angle glaucoma .	This system may provide an acute model in which to study the pathogenic mechanisms involved in disease* steroid glaucoma *disease and disease* primary open angle glaucoma *disease .
Auditory disturbance associated with interscalene brachial plexus block .	Auditory disturbance associated with interscalene brachial plexus block .
We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block ( IBPB ) .	We performed an audiometric study in 20 patients who underwent surgery of the shoulder region under an interscalene brachial plexus block ( IBPB ) .
Bupivacaine 0 . 75 % with adrenaline was given followed by a 24 - hr continuous infusion of 0 . 25 % bupivacaine .	Bupivacaine 0 . 75 % with adrenaline was given followed by a 24 - hr continuous infusion of 0 . 25 % bupivacaine .
Three audiometric threshold measurements ( 0 . 25 - 18 kHz ) were made : the first before IBPB , the second 2 - 6 h after surgery and the third on the first day after operation .	Three audiometric threshold measurements ( 0 . 25 - 18 kHz ) were made : the first before IBPB , the second 2 - 6 h after surgery and the third on the first day after operation .
In four patients hearing impairment on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .	In four patients disease* hearing impairment *disease on the side of the block was demonstrated after operation , in three measurements on the day of surgery and in one on the following day .
The frequencies at which the impairment occurred varied between patients ; in one only low frequencies ( 0 . 25 - 0 . 5 kHz ) were involved .	The frequencies at which the impairment occurred varied between patients ; in one only low frequencies ( 0 . 25 - 0 . 5 kHz ) were involved .
The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine .	The maximum change in threshold was 35 dB at 6 kHz measured at the end of the continuous infusion of bupivacaine .
This patient had hearing threshold changes ( 15 - 20 dB ) at 6 - 10 kHz on the opposite side also .	This patient had hearing threshold changes ( 15 - 20 dB ) at 6 - 10 kHz on the opposite side also .
IBPB may cause transient auditory dysfunction in the ipsilateral ear , possibly via an effect on sympathetic innervation .	IBPB may cause transient disease* auditory dysfunction *disease in the ipsilateral ear , possibly via an effect on sympathetic innervation .
The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with HIV - 1 infection and 200 - 500 CD4 cells / mm3 .	The safety and efficacy of combination N - butyl - deoxynojirimycin ( SC - 48334 ) and zidovudine in patients with disease* HIV - 1 infection *disease and 200 - 500 CD4 cells / mm3 .
We conducted a double - blind , randomized phase II study to evaluate the safety and activity of combination therapy with N - butyl - deoxynojirimycin ( SC - 48334 ) ( an alpha - glucosidase I inhibitor ) and zidovudine versus zidovudine alone .	We conducted a double - blind , randomized phase II study to evaluate the safety and activity of combination therapy with N - butyl - deoxynojirimycin ( SC - 48334 ) ( an alpha - glucosidase I inhibitor ) and zidovudine versus zidovudine alone .
Patients with 200 to 500 CD4 cells / mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC - 48334 ( 1000 mg every 8 h ) and zidovudine ( 100 mg every 8 h ) or zidovudine and placebo .	Patients with 200 to 500 CD4 cells / mm3 who tolerated < or = 12 weeks of prior zidovudine therapy received SC - 48334 ( 1000 mg every 8 h ) and zidovudine ( 100 mg every 8 h ) or zidovudine and placebo .
Sixty patients received combination therapy and 58 , zidovudine and placebo .	Sixty patients received combination therapy and 58 , zidovudine and placebo .
Twenty - three patients ( 38 % ) and 15 ( 26 % ) , in the combination and zidovudine groups , respectively , discontinued therapy ( p = 0 . 15 ) .	Twenty - three patients ( 38 % ) and 15 ( 26 % ) , in the combination and zidovudine groups , respectively , discontinued therapy ( p = 0 . 15 ) .
The mean SC - 48334 steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human immunodeficiency virus ( HIV ) .	The mean SC - 48334 steady - state trough level ( 4 . 04 + / - 0 . 99 micrograms / ml ) was below the in vitro inhibitory concentration for human disease* immunodeficiency *disease virus ( HIV ) .
The mean increase in CD4 cells at week 4 was 73 . 8 cells / mm3 and 52 . 4 cells / mm3 for the combination and zidovudine groups , respectively ( p > 0 . 36 ) .	The mean increase in CD4 cells at week 4 was 73 . 8 cells / mm3 and 52 . 4 cells / mm3 for the combination and zidovudine groups , respectively ( p > 0 . 36 ) .
For patients with prior zidovudine therapy , the mean change in CD4 cells in the combination and zidovudine groups was 63 . 7 cells / mm3 and 4 . 9 cells / mm3 at week 8 and 6 . 8 cells / mm3 and - 45 . 1 cells / mm3 at week 16 , respectively .	For patients with prior zidovudine therapy , the mean change in CD4 cells in the combination and zidovudine groups was 63 . 7 cells / mm3 and 4 . 9 cells / mm3 at week 8 and 6 . 8 cells / mm3 and - 45 . 1 cells / mm3 at week 16 , respectively .
The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six ( 40 % ) and two ( 11 % ) at week 4 ( p = 0 . 10 ) and five ( 45 % ) and two ( 14 % ) at week 24 ( p = 0 . 08 ) , respectively .	The number of patients with suppression of HIV p24 antigenemia in the combination and zidovudine groups was six ( 40 % ) and two ( 11 % ) at week 4 ( p = 0 . 10 ) and five ( 45 % ) and two ( 14 % ) at week 24 ( p = 0 . 08 ) , respectively .
Diarrhea , flatulence , abdominal pain , and weight loss were common for combination recipients . ( ABSTRACT TRUNCATED AT 250 WORDS )	disease* Diarrhea *disease , disease* flatulence *disease , disease* abdominal pain *disease , and disease* weight loss *disease were common for combination recipients . ( ABSTRACT TRUNCATED AT 250 WORDS )
Prolonged paralysis due to nondepolarizing neuromuscular blocking agents and corticosteroids .	Prolonged disease* paralysis *disease due to nondepolarizing neuromuscular blocking agents and corticosteroids .
The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged muscle weakness , although the site of the lesion and the predisposing factors have been unclear .	The long - term use of nondepolarizing neuromuscular blocking agents ( ND - NMBA ) has recently been implicated as a cause of prolonged disease* muscle weakness *disease , although the site of the lesion and the predisposing factors have been unclear .
We report 3 patients ( age 37 - 52 years ) with acute respiratory insufficiency who developed prolonged weakness following the discontinuation of ND - NMBAs .	We report 3 patients ( age 37 - 52 years ) with acute disease* respiratory insufficiency *disease who developed prolonged disease* weakness *disease following the discontinuation of ND - NMBAs .
Two patients also received intravenous corticosteroids .	Two patients also received intravenous corticosteroids .
Renal function was normal but hepatic function was impaired in all patients , and all had acidosis .	Renal function was normal but hepatic function was impaired in all patients , and all had disease* acidosis *disease .
Electrophysiologic studies revealed low amplitude compound motor action potentials , normal sensory studies , and fibrillations .	Electrophysiologic studies revealed low amplitude compound motor action potentials , normal sensory studies , and fibrillations .
Repetitive stimulation at 2 Hz showed a decremental response in 2 patients .	Repetitive stimulation at 2 Hz showed a decremental response in 2 patients .
The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng / mL .	The serum vecuronium level measured in 1 patient 14 days after the drug had been discontinued was 172 ng / mL .
A muscle biopsy in this patient showed loss of thick , myosin filaments .	A muscle biopsy in this patient showed disease* loss of thick , myosin filaments *disease .
The weakness in these patients is due to pathology at both the neuromuscular junction ( most likely due to ND - NMBA ) and muscle ( most likely due to corticosteroids ) .	The disease* weakness *disease in these patients is due to disease* pathology at both the neuromuscular junction *disease ( most likely due to ND - NMBA ) and muscle ( most likely due to corticosteroids ) .
Hepatic dysfunction and acidosis are contributing risk factors .	disease* Hepatic dysfunction *disease and disease* acidosis *disease are contributing risk factors .
Failure of ancrod in the treatment of heparin - induced arterial thrombosis .	Failure of ancrod in the treatment of heparin - induced arterial disease* thrombosis *disease .
The morbidity and mortality associated with heparin - induced thrombosis remain high despite numerous empirical therapies .	The morbidity and mortality associated with heparin - induced disease* thrombosis *disease remain high despite numerous empirical therapies .
Ancrod has been used successfully for prophylaxis against development of thrombosis in patients with heparin induced platelet aggregation who require brief reexposure to heparin , but its success in patients who have developed the thrombosis syndrome is not well defined .	Ancrod has been used successfully for prophylaxis against development of disease* thrombosis *disease in patients with heparin induced disease* platelet aggregation *disease who require brief reexposure to heparin , but its success in patients who have developed the disease* thrombosis *disease syndrome is not well defined .
The authors present a case of failure of ancrod treatment in a patient with heparin - induced thrombosis .	The authors present a case of failure of ancrod treatment in a patient with heparin - induced disease* thrombosis *disease .
Water intoxication associated with oxytocin administration during saline - induced abortion .	disease* Water intoxication *disease associated with oxytocin administration during saline - induced disease* abortion *disease .
Four cases of water intoxication in connection with oxytocin administration during saline - induced abortions are described .	Four cases of disease* water intoxication *disease in connection with oxytocin administration during saline - induced disease* abortions *disease are described .
The mechanism of water intoxication is discussed in regard to these cases .	The mechanism of disease* water intoxication *disease is discussed in regard to these cases .
Oxytocin administration during midtrimester - induced abortions is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of water intoxication and instructed to watch the diuresis and report such early signs of the syndrome as asthenia , muscular irritability , or headaches .	Oxytocin administration during midtrimester - induced disease* abortions *disease is advocated only if it can be carried out under careful observations of an alert nursing staff , aware of the symptoms of disease* water intoxication *disease and instructed to watch the diuresis and report such early signs of the syndrome as disease* asthenia *disease , muscular disease* irritability *disease , or disease* headaches *disease .
The oxytocin should be given only in Ringers lactate or , alternately , in Ringers lactate and a 5 per cent dextrose and water solutions .	The oxytocin should be given only in Ringers lactate or , alternately , in Ringers lactate and a 5 per cent dextrose and water solutions .
The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases .	The urinary output should be monitored and the oxytocin administration discontinued and the serum electrolytes checked if the urinary output decreases .
The oxytocin should not be administered in excess of 36 hours .	The oxytocin should not be administered in excess of 36 hours .
If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance .	If the patient has not aborted by then the oxytocin should be discontinued for 10 to 12 hours in order to perform electrolyte determinations and correct any electrolyte imbalance .
Light chain proteinuria and cellular mediated immunity in rifampin treated patients with tuberculosis .	Light chain disease* proteinuria *disease and cellular mediated immunity in rifampin treated patients with disease* tuberculosis *disease .
Light chain proteinuria was found in 9 of 17 tuberculosis patients treated with rifampin .	Light chain disease* proteinuria *disease was found in 9 of 17 disease* tuberculosis *disease patients treated with rifampin .
Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different .	Concomitant assay of cellular mediated immunity in these patients using skin test antigen and a lymphokine in vitro test provided results that were different .
Response to Varidase skin test antigen was negative for all eight tuberculosis patients tested , but there occurred a hyper - responsiveness of the lymphocytes of these eight patients to phytomitogen ( PHA - P ) . as well as of those of seven other tuberculous patients .	Response to Varidase skin test antigen was negative for all eight disease* tuberculosis *disease patients tested , but there occurred a hyper - responsiveness of the lymphocytes of these eight patients to phytomitogen ( PHA - P ) . as well as of those of seven other disease* tuberculous *disease patients .
This last finding may be related to time of testing and / or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte .	This last finding may be related to time of testing and / or endogenous serum binding of rifampin which could have inhibited mitogen activity for the lymphocyte .
KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity .	KF17837 : a novel selective adenosine A2A receptor antagonist with anticataleptic activity .
KF17837 is a novel selective adenosine A2A receptor antagonist .	KF17837 is a novel selective adenosine A2A receptor antagonist .
Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the cataleptic responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner .	Oral administration of KF17837 ( 2 . 5 , 10 . 0 and 30 . 0 mg / kg ) significantly ameliorated the disease* cataleptic *disease responses induced by intracerebroventricular administration of an adenosine A2A receptor agonist , CGS 21680 ( 10 micrograms ) , in a dose - dependent manner .
KF17837 also reduced the catalepsy induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .	KF17837 also reduced the disease* catalepsy *disease induced by haloperidol ( 1 mg / kg i . p . ) and by reserpine ( 5 mg / kg i . p . ) .
These anticataleptic effects were exhibited dose dependently at doses from 0 . 625 and 2 . 5 mg / kg p . o . , respectively .	These anticataleptic effects were exhibited dose dependently at doses from 0 . 625 and 2 . 5 mg / kg p . o . , respectively .
Moreover , KF17837 ( 0 . 625 mg / kg p . o . ) potentiated the anticataleptic effects of a subthreshold dose of L - 3 , 4 - dihydroxyphenylalanine ( L - DOPA ; 25 mg / kg i . p . ) plus benserazide ( 6 . 25 mg / kg i . p . ) .	Moreover , KF17837 ( 0 . 625 mg / kg p . o . ) potentiated the anticataleptic effects of a subthreshold dose of L - 3 , 4 - dihydroxyphenylalanine ( L - DOPA ; 25 mg / kg i . p . ) plus benserazide ( 6 . 25 mg / kg i . p . ) .
These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists .	These results suggested that KF17837 is a centrally active adenosine A2A receptor antagonist and that the dopaminergic function of the nigrostriatal pathway is potentiated by adenosine A2A receptor antagonists .
Furthermore , KF17837 may be a useful drug in the treatment of parkinsonism .	Furthermore , KF17837 may be a useful drug in the treatment of disease* parkinsonism *disease .
Effect of nondopaminergic drugs on L - dopa - induced dyskinesias in MPTP - treated monkeys .	Effect of nondopaminergic drugs on L - dopa - induced disease* dyskinesias *disease in MPTP - treated monkeys .
A group of four monkeys was rendered parkinsonian with the toxin MPTP .	A group of four monkeys was rendered disease* parkinsonian *disease with the toxin MPTP .
They were then treated chronically with L - DOPA / benserazide 50 / 12 . 5 mg / kg given orally daily for 2 months .	They were then treated chronically with L - DOPA / benserazide 50 / 12 . 5 mg / kg given orally daily for 2 months .
This dose produced a striking antiparkinsonian effect , but all animals manifested dyskinesia .	This dose produced a striking antiparkinsonian effect , but all animals manifested disease* dyskinesia *disease .
A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L - DOPA to see if the dyskinetic movements would be modified .	A series of agents acting primarily on neurotransmitters other than dopamine were then tested in combination with L - DOPA to see if the disease* dyskinetic *disease movements would be modified .
Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the dyskinetic movements but at the cost of a return of parkinsonian symptomatology .	Several drugs , including clonidine , physostigmine , methysergide , 5 - MDOT , propranolol , and MK - 801 , markedly reduced the disease* dyskinetic *disease movements but at the cost of a return of disease* parkinsonian *disease symptomatology .
However , yohimbine and meperidine reduced predominantly the dyskinetic movements .	However , yohimbine and meperidine reduced predominantly the disease* dyskinetic *disease movements .
Baclofen was also useful in one monkey against a more dystonic form of dyskinesia .	Baclofen was also useful in one monkey against a more disease* dystonic *disease form of disease* dyskinesia *disease .
Atropine converted the dystonic movements into chorea .	Atropine converted the disease* dystonic *disease movements into disease* chorea *disease .
Hallucinations and ifosfamide - induced neurotoxicity .	disease* Hallucinations *disease and ifosfamide - induced disease* neurotoxicity *disease .
BACKGROUND : Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide .	BACKGROUND : disease* Hallucinations *disease as a symptom of central disease* neurotoxicity *disease are a known but poorly described side effect of ifosfamide .
Most cases of ifosfamide - induced hallucinations have been reported with other mental status changes .	Most cases of ifosfamide - induced disease* hallucinations *disease have been reported with other mental status changes .
METHODS : The authors interviewed six persons with ifosfamide - induced hallucinations in the presence of a clear sensorium .	METHODS : The authors interviewed six persons with ifosfamide - induced disease* hallucinations *disease in the presence of a clear sensorium .
All patients were receiving high - dose ifosfamide as part of their bone marrow transplant procedure .	All patients were receiving high - dose ifosfamide as part of their bone marrow transplant procedure .
RESULTS : Hallucinations occurred only when the patient ' s eyes were closed and , in all but one case , were reported as disturbing or frightening .	RESULTS : disease* Hallucinations *disease occurred only when the patient ' s eyes were closed and , in all but one case , were reported as disturbing or frightening .
Underreporting of these hallucinations by patients is likely .	Underreporting of these disease* hallucinations *disease by patients is likely .
CONCLUSIONS : Hallucinations may be the sole or first manifestation of neurotoxicity .	CONCLUSIONS : disease* Hallucinations *disease may be the sole or first manifestation of disease* neurotoxicity *disease .
The incidence may be dose and infusion - time related .	The incidence may be dose and infusion - time related .
The clinician should be alerted for possible ifosfamide - induced hallucinations , which may occur without other signs of neurotoxicity .	The clinician should be alerted for possible ifosfamide - induced disease* hallucinations *disease , which may occur without other signs of disease* neurotoxicity *disease .
" Eyes - closed " hallucinatory experiences appear to be an unusual feature of this presentation .	" Eyes - closed " disease* hallucinatory *disease experiences appear to be an unusual feature of this presentation .
Patients anxious about this experience respond well to support and education about this occurrence .	Patients anxious about this experience respond well to support and education about this occurrence .
Optimal pharmacologic management of disturbed patients is unclear .	Optimal pharmacologic management of disturbed patients is unclear .
If agitation becomes marked , high - potency neuroleptics ( i . e . , haloperidol ) may be effective .	If disease* agitation *disease becomes marked , high - potency neuroleptics ( i . e . , haloperidol ) may be effective .
Photodistributed nifedipine - induced facial telangiectasia .	Photodistributed nifedipine - induced facial disease* telangiectasia *disease .
Five months after starting nifedipine ( Adalat ) , two patients developed photodistributed facial telangiectasia , which became more noticeable with time .	Five months after starting nifedipine ( Adalat ) , two patients developed photodistributed facial disease* telangiectasia *disease , which became more noticeable with time .
Neither patient complained of photosensitivity or flushing .	Neither patient complained of photosensitivity or disease* flushing *disease .
Both patients reported a significant cosmetic improvement after discontinuing the drug .	Both patients reported a significant cosmetic improvement after discontinuing the drug .
One commenced the closely related drug amlodipine 3 years later , with recurrence of telangiectasia .	One commenced the closely related drug amlodipine 3 years later , with recurrence of disease* telangiectasia *disease .
The photodistribution of the telangiectasia suggests a significant drug / light interaction .	The photodistribution of the disease* telangiectasia *disease suggests a significant drug / light interaction .
Penicillamine - induced rapidly progressive glomerulonephritis in a patient with rheumatoid arthritis .	Penicillamine - induced rapidly progressive disease* glomerulonephritis *disease in a patient with disease* rheumatoid arthritis *disease .
A 67 - year - old woman with rheumatoid arthritis presented rapidly progressive glomerulonephritis ( RPGN ) after 5 months of D - penicillamine ( 250 mg / day ) treatment .	A 67 - year - old woman with disease* rheumatoid arthritis *disease presented rapidly progressive disease* glomerulonephritis *disease ( disease* RPGN *disease ) after 5 months of D - penicillamine ( 250 mg / day ) treatment .
Light microscopy study showed severe glomerulonephritis with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .	Light microscopy study showed severe disease* glomerulonephritis *disease with crescent formation in 60 % of the glomeruli and infiltration of inflammatory cells in the wall of an arteriole .
Immunofluorescence revealed scanty granular IgG , IgA and C3 deposits along the capillary walls and mesangium .	Immunofluorescence revealed scanty granular IgG , IgA and C3 deposits along the capillary walls and mesangium .
The patient was treated with steroid pulse , plasmapheresis , cyclophosphamide and antiplatelet agents .	The patient was treated with steroid pulse , plasmapheresis , cyclophosphamide and antiplatelet agents .
A complete recovery of renal function was achieved in a few weeks .	A complete recovery of renal function was achieved in a few weeks .
This new case of RPGN in the course of D - penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and proteinuria in these patients .	This new case of disease* RPGN *disease in the course of D - penicillamine treatment emphasizes the need for frequent monitoring of renal function and evaluation of urinary sediment and disease* proteinuria *disease in these patients .
The prompt discontinuation of D - penicillamine and vigorous treatment measures could allow for a good prognosis as in this case .	The prompt discontinuation of D - penicillamine and vigorous treatment measures could allow for a good prognosis as in this case .
A case of polymyositis in a patient with primary biliary cirrhosis treated with D - penicillamine .	A case of disease* polymyositis *disease in a patient with disease* primary biliary cirrhosis *disease treated with D - penicillamine .
Although D - penicillamine has been used for many rheumatologic diseases , toxicity limits its usefulness in many patients .	Although D - penicillamine has been used for many disease* rheumatologic diseases *disease , disease* toxicity *disease limits its usefulness in many patients .
Polymyositis / dermatomyositis can develop as one of the autoimmune complications of D - penicillamine treatment , but its exact pathogenesis remains unclear .	disease* Polymyositis *disease / disease* dermatomyositis *disease can develop as one of the autoimmune complications of D - penicillamine treatment , but its exact pathogenesis remains unclear .
We report a patient with primary biliary cirrhosis , who developed polymyositis while receiving D - penicillamine therapy .	We report a patient with disease* primary biliary cirrhosis *disease , who developed disease* polymyositis *disease while receiving D - penicillamine therapy .
We described the special clinical course of the patient .	We described the special clinical course of the patient .
Patients receiving D - penicillamine therapy should be followed carefully for the development of autoimmune complications like polymyositis / dermatomyositis .	Patients receiving D - penicillamine therapy should be followed carefully for the development of autoimmune complications like disease* polymyositis *disease / disease* dermatomyositis *disease .
Hyperalgesia and myoclonus in terminal cancer patients treated with continuous intravenous morphine .	disease* Hyperalgesia *disease and disease* myoclonus *disease in terminal disease* cancer *disease patients treated with continuous intravenous morphine .
Eight cancer patients in the terminal stages of the disease treated with high doses of intravenous morphine developed hyperalgesia .	Eight disease* cancer *disease patients in the terminal stages of the disease treated with high doses of intravenous morphine developed disease* hyperalgesia *disease .
All cases were retrospectively sampled from three different hospitals in Copenhagen .	All cases were retrospectively sampled from three different hospitals in Copenhagen .
Five patients developed universal hyperalgesia and hyperesthesia which in 2 cases were accompanied by myoclonus .	Five patients developed universal disease* hyperalgesia *disease and disease* hyperesthesia *disease which in 2 cases were accompanied by disease* myoclonus *disease .
In 3 patients a pre - existing neuralgia increased to excruciating intensity and in 2 of these cases myoclonus occurred simultaneously .	In 3 patients a pre - existing disease* neuralgia *disease increased to excruciating intensity and in 2 of these cases disease* myoclonus *disease occurred simultaneously .
Although only few clinical descriptions of the relationship between hyperalgesia / myoclonus and high doses of morphine are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .	Although only few clinical descriptions of the relationship between disease* hyperalgesia *disease / disease* myoclonus *disease and high doses of morphine are available , experimental support from animal studies indicates that morphine , or its metabolites , plays a causative role for the observed behavioural syndrome .
The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations .	The possible mechanisms are discussed and treatment proposals given suggesting the use of more efficacious opioids with less excitatory potency in these situations .
Liposomal daunorubicin in advanced Kaposi ' s sarcoma : a phase II study .	Liposomal daunorubicin in advanced disease* Kaposi ' s sarcoma *disease : a phase II study .
We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin ( DaunoXome ) in the treatment of AIDS related Kaposi ' s sarcoma .	We report a non - randomized Phase II clinical trial to assess the efficacy and safety of liposomal daunorubicin ( DaunoXome ) in the treatment of disease* AIDS *disease related disease* Kaposi ' s sarcoma *disease .
Eleven homosexual men with advanced Kaposi ' s sarcoma were entered in the trial .	Eleven homosexual men with advanced disease* Kaposi ' s sarcoma *disease were entered in the trial .
Changes in size , colour and associated oedema of selected ' target ' lesions were measured .	Changes in size , colour and associated disease* oedema *disease of selected ' target ' lesions were measured .
Clinical , biochemical and haematological toxicities were assessed .	Clinical , biochemical and haematological disease* toxicities *disease were assessed .
Ten subjects were evaluated .	Ten subjects were evaluated .
A partial response was achieved in four , of whom two subsequently relapsed .	A partial response was achieved in four , of whom two subsequently relapsed .
Stabilization of Kaposi ' s sarcoma occurred in the remaining six , maintained until the end of the trial period in four .	Stabilization of disease* Kaposi ' s sarcoma *disease occurred in the remaining six , maintained until the end of the trial period in four .
The drug was generally well tolerated , with few mild symptoms of toxicity .	The drug was generally well tolerated , with few mild symptoms of disease* toxicity *disease .
The main problem encountered was haematological toxicity , with three subjects experiencing severe neutropenia ( neutrophil count < 0 . 5 x 10 ( 9 ) / l ) .	The main problem encountered was haematological disease* toxicity *disease , with three subjects experiencing severe disease* neutropenia *disease ( neutrophil count < 0 . 5 x 10 ( 9 ) / l ) .
There was no evidence of cardiotoxicity .	There was no evidence of disease* cardiotoxicity *disease .
In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of Kaposi ' s sarcoma .	In this small patient sample , liposomal daunorubicin was an effective and well tolerated agent in the treatment of disease* Kaposi ' s sarcoma *disease .
Long - term effects of vincristine on the peripheral nervous system .	Long - term effects of vincristine on the peripheral nervous system .
Forty patients with Non - Hodgkin ' s Lymphoma treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .	Forty patients with disease* Non - Hodgkin ' s Lymphoma *disease treated with vincristine between 1984 and 1990 ( cumulative dose 12 mg in 18 - 24 weeks ) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system .
The patients were interviewed with emphasis on neuropathic symptoms .	The patients were interviewed with emphasis on disease* neuropathic symptoms *disease .
Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed , four to 77 months ( median 34 months ) after vincristine treatment .	Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed , four to 77 months ( median 34 months ) after vincristine treatment .
Twenty - seven patients reported neuropathic symptoms .	Twenty - seven patients reported disease* neuropathic symptoms *disease .
In 13 of these 27 patients symptoms were still present at the time of examination .	In 13 of these 27 patients symptoms were still present at the time of examination .
In these patients sensory signs and symptoms predominated .	In these patients sensory signs and symptoms predominated .
In the other 14 patients symptoms had been present in the past .	In the other 14 patients symptoms had been present in the past .
Symptoms persisted maximally 40 months since cessation of therapy .	Symptoms persisted maximally 40 months since cessation of therapy .
There was no age difference between patients with and without complaints at the time of examination .	There was no age difference between patients with and without complaints at the time of examination .
Normal reflexes were found in two third of patients .	Normal reflexes were found in two third of patients .
Neuropathic complaints were not very troublesome on the long term .	Neuropathic complaints were not very troublesome on the long term .
It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good .	It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine disease* neuropathy *disease are reversible for a great deal and prognosis is fairly good .
Hepatic adenomas and focal nodular hyperplasia of the liver in young women on oral contraceptives : case reports .	Hepatic disease* adenomas *disease and disease* focal nodular hyperplasia *disease of the liver in young women on oral contraceptives : case reports .
Two cases of hepatic adenoma and one of focal nodular hyperplasia presumably associated with the use of oral contraceptives , are reported .	Two cases of hepatic disease* adenoma *disease and one of disease* focal nodular hyperplasia *disease presumably associated with the use of oral contraceptives , are reported .
Special reference is made to their clinical presentation , which may be totally asymptomatic .	Special reference is made to their clinical presentation , which may be totally asymptomatic .
Liver - function tests are of little diagnostic value , but valuable information may be obtained from both liver scanning and hepatic angiography .	Liver - function tests are of little diagnostic value , but valuable information may be obtained from both liver scanning and hepatic angiography .
Histologic differences and clinical similarities between hepatic adenoma and focal nodular hyperplasia of the liver are discussed .	Histologic differences and clinical similarities between hepatic disease* adenoma *disease and disease* focal nodular hyperplasia *disease of the liver are discussed .
Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced seizures .	Loss of glutamate decarboxylase mRNA - containing neurons in the rat dentate gyrus following pilocarpine - induced disease* seizures *disease .
In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to seizure - induced damage in a model of chronic seizures .	In situ hybridization methods were used to determine if glutamic acid decarboxylase ( GAD ) mRNA - containing neurons within the hilus of the dentate gyrus are vulnerable to disease* seizure *disease - induced damage in a model of chronic disease* seizures *disease .
Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced seizures .	Sprague - Dawley rats were injected intraperitoneally with pilocarpine , and the hippocampal formation was studied histologically at 1 , 2 , 4 , and 8 week intervals after pilocarpine - induced disease* seizures *disease .
In situ hybridization histochemistry , using a digoxigenin - labeled GAD cRNA probe , demonstrated a substantial decrease in the number of GAD mRNA - containing neurons in the hilus of the dentate gyrus in the pilocarpine - treated rats as compared to controls at all time intervals .	In situ hybridization histochemistry , using a digoxigenin - labeled GAD cRNA probe , demonstrated a substantial decrease in the number of GAD mRNA - containing neurons in the hilus of the dentate gyrus in the pilocarpine - treated rats as compared to controls at all time intervals .
Additional neuronanatomical studies , including cresyl violet staining , neuronal degeneration methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to neuronal loss rather than to a decrease in GAD mRNA levels .	Additional neuronanatomical studies , including cresyl violet staining , disease* neuronal degeneration *disease methods , and histochemical localization of glial fibrillary acidic protein , suggested that the decrease in the number of GAD mRNA - containing neurons was related to disease* neuronal loss *disease rather than to a decrease in GAD mRNA levels .
The loss of GAD mRNA - containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer .	The loss of GAD mRNA - containing neurons in the hilus contrasted with the relative preservation of labeled putative basket cells along the inner margin of the granule cell layer .
Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA - containing neurons in the hilus of both groups of experimental animals .	Quantitative analyses of labeled neurons in three regions of the dentate gyrus in the 1 and 2 week groups showed statistically significant decreases in the mean number of GAD mRNA - containing neurons in the hilus of both groups of experimental animals .
No significant differences were found in the molecular layer or the granule cell layer , which included labeled neurons along the lower margin of the granule cell layer .	No significant differences were found in the molecular layer or the granule cell layer , which included labeled neurons along the lower margin of the granule cell layer .
The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to seizure - induced damage .	The results indicate that , in this model , a subpopulation of GAD mRNA - containing neurons within the dentate gyrus is selectively vulnerable to disease* seizure *disease - induced damage .
Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons .	Such differential vulnerability appears to be another indication of the heterogeneity of GABA neurons .
Effects of deliberate hypotension induced by labetalol with isoflurane on neuropsychological function .	Effects of deliberate disease* hypotension *disease induced by labetalol with isoflurane on neuropsychological function .
The effect of deliberate hypotension on brain function measured by neuropsychological tests was studied in 41 adult patients .	The effect of deliberate disease* hypotension *disease on brain function measured by neuropsychological tests was studied in 41 adult patients .
Twenty - four patients were anaesthetized for middle - ear surgery with deliberate hypotension induced by labetalol with isoflurane ( hypotensive group ) .	Twenty - four patients were anaesthetized for middle - ear surgery with deliberate disease* hypotension *disease induced by labetalol with isoflurane ( disease* hypotensive *disease group ) .
Seventeen patients without hypotension served as a control group .	Seventeen patients without disease* hypotension *disease served as a control group .
The mean arterial pressure was 77 + / - 2 mmHg ( 10 . 3 + / - 0 . 3 kPa ) before hypotension and 50 + / - 0 mmHg ( 6 . 7 + / - 0 . 0 kPa ) during hypotension in the hypotensive group , and 86 + / - 2 mmHg ( 11 . 5 + / - 0 . 3 kPa ) during anaesthesia in the control group .	The mean arterial pressure was 77 + / - 2 mmHg ( 10 . 3 + / - 0 . 3 kPa ) before disease* hypotension *disease and 50 + / - 0 mmHg ( 6 . 7 + / - 0 . 0 kPa ) during disease* hypotension *disease in the disease* hypotensive *disease group , and 86 + / - 2 mmHg ( 11 . 5 + / - 0 . 3 kPa ) during anaesthesia in the control group .
The following psychological tests were performed : four subtests of the Wechsler Adult Intelligence Scale ( similarities , digit span , vocabulary and digit symbol ) , Trail - Making tests A and B , Zung tests ( self - rating anxiety scale and self - rating depression scale ) and two - part memory test battery with immediate and delayed recall .	The following psychological tests were performed : four subtests of the Wechsler Adult Intelligence Scale ( similarities , digit span , vocabulary and digit symbol ) , Trail - Making tests A and B , Zung tests ( self - rating disease* anxiety *disease scale and self - rating disease* depression *disease scale ) and two - part memory test battery with immediate and delayed recall .
The tests were performed preoperatively and 2 days postoperatively .	The tests were performed preoperatively and 2 days postoperatively .
There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value .	There were no statistically significant differences between the groups in any of the tests in the changes from preoperative value to postoperative value .
The results indicate that hypotension induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .	The results indicate that disease* hypotension *disease induced by labetalol with isoflurane has no significant harmful effects on mental functions compared to normotensive anaesthesia .
Apparent cure of rheumatoid arthritis by bone marrow transplantation .	Apparent cure of disease* rheumatoid arthritis *disease by bone marrow transplantation .
We describe the induction of sustained remissions and possible cure of severe erosive rheumatoid arthritis ( RA ) by bone marrow transplantation ( BMT ) in 2 patients .	We describe the induction of sustained remissions and possible cure of severe erosive disease* rheumatoid arthritis *disease ( disease* RA *disease ) by bone marrow transplantation ( BMT ) in 2 patients .
BMT was used to treat severe aplastic anemia which was caused by gold in one case and D - penicillamine in the other .	BMT was used to treat severe disease* aplastic anemia *disease which was caused by gold in one case and D - penicillamine in the other .
In the 8 and 6 years since the transplants ( representing 8 and 4 years since cessation of all immunosuppressive therapy , respectively ) , the RA in each case has been completely quiescent .	In the 8 and 6 years since the transplants ( representing 8 and 4 years since cessation of all immunosuppressive therapy , respectively ) , the disease* RA *disease in each case has been completely quiescent .
Although short term remission of severe RA following BMT has been reported , these are the first cases for which prolonged followup has been available .	Although short term remission of severe disease* RA *disease following BMT has been reported , these are the first cases for which prolonged followup has been available .
This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive synovitis .	This experience raises the question of the role of BMT itself as a therapeutic option for patients with uncontrolled destructive disease* synovitis *disease .
Seizures induced by combined levomepromazine - fluvoxamine treatment .	disease* Seizures *disease induced by combined levomepromazine - fluvoxamine treatment .
We report a case of combined levomepromazine - fluvoxamine treatment - induced seizures .	We report a case of combined levomepromazine - fluvoxamine treatment - induced disease* seizures *disease .
It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity .	It seems that combined treatment of fluvoxamine with phenothiazines may possess proconvulsive activity .
Case report : pentamidine and polymorphic ventricular tachycardia revisited .	Case report : pentamidine and polymorphic disease* ventricular tachycardia *disease revisited .
Pentamidine isethionate has been associated with ventricular tachyarrhythmias , including torsade de pointes .	Pentamidine isethionate has been associated with disease* ventricular tachyarrhythmias *disease , including disease* torsade de pointes *disease .
This article reports two cases of this complication and reviews all reported cases to date .	This article reports two cases of this complication and reviews all reported cases to date .
Pentamidine - induced torsade de pointes may be related to serum magnesium levels and hypomagnesemia may synergistically induce torsade .	Pentamidine - induced disease* torsade de pointes *disease may be related to serum magnesium levels and disease* hypomagnesemia *disease may synergistically induce torsade .
Torsade de pointes occurred after an average of 10 days of treatment with pentamidine .	disease* Torsade de pointes *disease occurred after an average of 10 days of treatment with pentamidine .
In these patients , no other acute side effects of pentamidine were observed .	In these patients , no other acute side effects of pentamidine were observed .
Torsade de pointes can be treated when recognized early , possibly without discontinuation of pentamidine .	disease* Torsade de pointes *disease can be treated when recognized early , possibly without discontinuation of pentamidine .
When QTc interval prolongation is observed , early magnesium supplementation is advocated .	When disease* QTc interval prolongation *disease is observed , early magnesium supplementation is advocated .
Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia .	Efficacy and tolerability of lovastatin in 3390 women with moderate disease* hypercholesterolemia *disease .
OBJECTIVE : To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia .	OBJECTIVE : To evaluate the efficacy and safety of lovastatin in women with moderate disease* hypercholesterolemia *disease .
DESIGN : The Expanded Clinical Evaluation of Lovastatin ( EXCEL ) Study , a multicenter , double - blind , diet - and placebo - controlled trial , in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily , or 20 or 40 mg twice daily for 48 weeks .	DESIGN : The Expanded Clinical Evaluation of Lovastatin ( EXCEL ) Study , a multicenter , double - blind , diet - and placebo - controlled trial , in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily , or 20 or 40 mg twice daily for 48 weeks .
SETTING : Ambulatory patients recruited by 362 participating centers throughout the United States .	SETTING : Ambulatory patients recruited by 362 participating centers throughout the United States .
PATIENTS : Women ( n = 3390 ) from the total cohort of 8245 volunteers .	PATIENTS : Women ( n = 3390 ) from the total cohort of 8245 volunteers .
MEASUREMENTS : Plasma total , low - density lipoprotein ( LDL ) , and high - density lipoprotein ( HDL ) cholesterol , and triglycerides ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study .	MEASUREMENTS : Plasma total , low - density lipoprotein ( LDL ) , and high - density lipoprotein ( HDL ) cholesterol , and triglycerides ; and laboratory and clinical evidence of adverse events monitored periodically throughout the study .
RESULTS : Among women , lovastatin ( 20 to 80 mg / d ) produced sustained ( 12 - to 48 - week ) , dose - related changes ( P < 0 . 001 ) : decreases in LDL cholesterol ( 24 % to 40 % ) and triglycerides ( 9 % to 18 % ) , and increases in HDL cholesterol ( 6 . 7 % to 8 . 6 % ) .	RESULTS : Among women , lovastatin ( 20 to 80 mg / d ) produced sustained ( 12 - to 48 - week ) , dose - related changes ( P < 0 . 001 ) : decreases in LDL cholesterol ( 24 % to 40 % ) and triglycerides ( 9 % to 18 % ) , and increases in HDL cholesterol ( 6 . 7 % to 8 . 6 % ) .
Depending on the dose , from 82 % to 95 % of lovastatin - treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4 . 14 mmol / L ( 160 mg / dL ) , and 40 % to 87 % achieved the goal of 3 . 36 mmol / L ( 130 mg / dL ) .	Depending on the dose , from 82 % to 95 % of lovastatin - treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4 . 14 mmol / L ( 160 mg / dL ) , and 40 % to 87 % achieved the goal of 3 . 36 mmol / L ( 130 mg / dL ) .
Successive transaminase elevations greater than three times the upper limit of normal occurred in 0 . 1 % of women and were dose dependent above the 20 - mg dose .	Successive transaminase elevations greater than three times the upper limit of normal occurred in 0 . 1 % of women and were dose dependent above the 20 - mg dose .
Myopathy , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .	disease* Myopathy *disease , defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal , was rare and associated with the highest recommended daily dose of lovastatin ( 80 mg ) .
Estrogen - replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin .	Estrogen - replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin .
CONCLUSION : Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women .	CONCLUSION : Lovastatin is highly effective and generally well tolerated as therapy for primary disease* hypercholesterolemia *disease in women .
Tetany and rhabdomyolysis due to surreptitious furosemide - - importance of magnesium supplementation .	disease* Tetany *disease and disease* rhabdomyolysis *disease due to surreptitious furosemide - - importance of magnesium supplementation .
Diuretics may induce hypokalemia , hypocalcemia and hypomagnesemia .	Diuretics may induce disease* hypokalemia *disease , disease* hypocalcemia *disease and disease* hypomagnesemia *disease .
While severe hypokalemia may cause muscle weakness , severe hypomagnesemia is associated with muscle spasms and tetany which cannot be corrected by potassium and calcium supplementation alone ( 1 , 2 ) .	While severe disease* hypokalemia *disease may cause disease* muscle weakness *disease , severe disease* hypomagnesemia *disease is associated with disease* muscle spasms *disease and disease* tetany *disease which cannot be corrected by potassium and calcium supplementation alone ( 1 , 2 ) .
Surreptitious diuretic ingestion has been described , mainly in women who are concerned that they are obese or edematous .	Surreptitious diuretic ingestion has been described , mainly in women who are concerned that they are disease* obese *disease or disease* edematous *disease .
Symptomatic hypokalemia has been reported in such patients ( 3 - 7 ) and in one case hypocalcemia was observed ( 8 ) , but the effects of magnesium depletion were not noted in these patients .	Symptomatic disease* hypokalemia *disease has been reported in such patients ( 3 - 7 ) and in one case disease* hypocalcemia *disease was observed ( 8 ) , but the effects of magnesium depletion were not noted in these patients .
Ciprofloxacin - induced nephrotoxicity in patients with cancer .	Ciprofloxacin - induced disease* nephrotoxicity *disease in patients with disease* cancer *disease .
Nephrotoxicity associated with ciprofloxacin is uncommon .	disease* Nephrotoxicity *disease associated with ciprofloxacin is uncommon .
Five patients with cancer who developed acute renal failure that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .	Five patients with disease* cancer *disease who developed disease* acute renal failure *disease that followed treatment with ciprofloxacin are described and an additional 15 cases reported in the literature are reviewed .
Other than elevation of serum creatinine levels , characteristic clinical manifestations and abnormal laboratory findings are not frequently present .	Other than elevation of serum creatinine levels , characteristic clinical manifestations and abnormal laboratory findings are not frequently present .
Allergic interstitial nephritis is believed to be the underlying pathological - process .	Allergic disease* interstitial nephritis *disease is believed to be the underlying pathological - process .
Definitive diagnosis requires performance of renal biopsy , although this is not always feasible .	Definitive diagnosis requires performance of renal biopsy , although this is not always feasible .
An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced acute renal failure .	An improvement in renal function that followed the discontinuation of the offending antibiotic supports the presumptive diagnosis of ciprofloxacin - induced disease* acute renal failure *disease .
Venous complications of midazolam versus diazepam .	disease* Venous complications *disease of midazolam versus diazepam .
Although some studies have suggested fewer venous complications are associated with midazolam than with diazepam for endoscopic procedures , this variable has not been well documented .	Although some studies have suggested fewer disease* venous complications *disease are associated with midazolam than with diazepam for endoscopic procedures , this variable has not been well documented .
We prospectively evaluated the incidence of venous complications after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .	We prospectively evaluated the incidence of disease* venous complications *disease after intravenous injection of diazepam or midazolam in 122 consecutive patients undergoing colonoscopy and esophagogastroduodenoscopy .
Overall , venous complications were more frequent with diazepam ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .	Overall , disease* venous complications *disease were more frequent with diazepam ( 22 of 62 patients ) than with midazolam ( 4 of 60 patients ) ( p < 0 . 001 ) .
A palpable venous cord was present in 23 % ( 14 of 62 ) of patients in the diazepam group , compared with 2 % ( 1 of 60 patients ) in the midazolam group ( p < 0 . 002 ) .	A palpable venous cord was present in 23 % ( 14 of 62 ) of patients in the diazepam group , compared with 2 % ( 1 of 60 patients ) in the midazolam group ( p < 0 . 002 ) .
Pain at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .	disease* Pain *disease at the injection site occurred in 35 % ( 22 of 62 ) of patients in the diazepam group compared with 7 % ( 4 of 60 patients ) in the midazolam group ( p < 0 . 001 ) .
Swelling and warmth at the injection site were not significantly different between the two groups .	disease* Swelling *disease and warmth at the injection site were not significantly different between the two groups .
Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , alcohol use , and pain during the injection had no effect on the incidence of venous complications .	Smoking , nonsteroidal anti - inflammatory drug use , intravenous catheter site , dwell time of the needle , alcohol use , and disease* pain *disease during the injection had no effect on the incidence of disease* venous complications *disease .
Clarithromycin - associated visual hallucinations in a patient with chronic renal failure on continuous ambulatory peritoneal dialysis .	Clarithromycin - associated disease* visual hallucinations *disease in a patient with disease* chronic renal failure *disease on continuous ambulatory peritoneal dialysis .
Visual hallucinations are a rare event in chronic renal failure and not related to uremia per se .	disease* Visual hallucinations *disease are a rare event in disease* chronic renal failure *disease and not related to disease* uremia *disease per se .
Unreported in the literature is visual hallucinations occurring in association with the new macrolide antibiotic , clarithromycin .	Unreported in the literature is disease* visual hallucinations *disease occurring in association with the new macrolide antibiotic , clarithromycin .
We describe such a case in a patient with end - stage renal disease ( ESRD ) maintained on continuous ambulatory peritoneal dialysis ( CAPD ) .	We describe such a case in a patient with disease* end - stage renal disease *disease ( disease* ESRD *disease ) maintained on continuous ambulatory peritoneal dialysis ( CAPD ) .
The combination of a relatively high dose of clarithromycin in face of chronic renal failure in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this neurotoxic side effect .	The combination of a relatively high dose of clarithromycin in face of disease* chronic renal failure *disease in a functionally anephric patient , with underlying aluminum intoxication , may have facilitated the appearance of this disease* neurotoxic *disease side effect .
It is important to understand the pharmacokinetics of medications in face of chronic renal failure , the possibility of drug interactions , and how these factors should help guide medication therapy in the ESRD patient .	It is important to understand the pharmacokinetics of medications in face of disease* chronic renal failure *disease , the possibility of drug interactions , and how these factors should help guide medication therapy in the disease* ESRD *disease patient .
Changes in peroxisomes in preneoplastic liver and hepatoma of mice induced by alpha - benzene hexachloride .	Changes in peroxisomes in preneoplastic liver and disease* hepatoma *disease of mice induced by alpha - benzene hexachloride .
Peroxisomes in hepatomas and hyperplastic preneoplastic liver lesions induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .	Peroxisomes in disease* hepatomas *disease and hyperplastic preneoplastic disease* liver lesions *disease induced in mice by 500 ppm alpha - benzene hexachloride were examined histochemically and electron microscopically .
Although most of the hepatomas were well - differentiated tumors and contained a considerable number of peroxisomes , the tumor cells did not respond to ethyl - alpha - p - chlorophenoxyisobutyrate with proliferation of peroxisomes .	Although most of the disease* hepatomas *disease were well - differentiated disease* tumors *disease and contained a considerable number of peroxisomes , the disease* tumor *disease cells did not respond to ethyl - alpha - p - chlorophenoxyisobutyrate with proliferation of peroxisomes .
At the 16th week of carcinogen feeding , hyperplastic nodules appeared and advanced to further stages .	At the 16th week of carcinogen feeding , hyperplastic nodules appeared and advanced to further stages .
A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes .	A majority of the nodules showed a considerable number of peroxisomes and the inductive proliferation of peroxisomes .
Within the nodules , foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared .	Within the nodules , foci of proliferation of the cells that showed no inducibility of proliferation of peroxisomes appeared .
These cells proliferated further , replacing the most part of the nodules , and with this process hepatomas appeared to have been formed .	These cells proliferated further , replacing the most part of the nodules , and with this process disease* hepatomas *disease appeared to have been formed .
No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl - alpha - p - chlorophenoxyisobutyrate unlike in the case of rats .	No abnormal matrical inclusions of peroxisomes were formed in the cells of hyperplastic nodules by ethyl - alpha - p - chlorophenoxyisobutyrate unlike in the case of rats .
Contribution of the sympathetic nervous system to salt - sensitivity in lifetime captopril - treated spontaneously hypertensive rats .	Contribution of the sympathetic nervous system to salt - sensitivity in lifetime captopril - treated spontaneously disease* hypertensive *disease rats .
OBJECTIVE : To test the hypothesis that , in lifetime captopril - treated spontaneously hypertensive rats ( SHR ) , the sympathetic nervous system contributes importantly to the hypertensive effect of dietary sodium chloride supplementation .	OBJECTIVE : To test the hypothesis that , in lifetime captopril - treated spontaneously disease* hypertensive *disease rats ( SHR ) , the sympathetic nervous system contributes importantly to the disease* hypertensive *disease effect of dietary sodium chloride supplementation .
METHODS : Male SHR ( aged 6 weeks ) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet .	METHODS : Male SHR ( aged 6 weeks ) that had been treated from conception onward with either captopril or vehicle remained on a basal sodium chloride diet or were fed a high sodium chloride diet .
After 2 weeks , the rats were subjected to ganglionic blockade and 2 days later , an infusion of clonidine .	After 2 weeks , the rats were subjected to ganglionic blockade and 2 days later , an infusion of clonidine .
RESULTS : Lifetime captopril treatment significantly lowered mean arterial pressure in both groups .	RESULTS : Lifetime captopril treatment significantly lowered mean arterial pressure in both groups .
Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced increase in MAP in both groups .	Intravenous infusion of the ganglionic blocker hexamethonium resulted in a rapid decline in MAP that eliminated the dietary sodium chloride - induced disease* increase in MAP *disease in both groups .
Infusion of the central nervous system alpha2 - adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high ( compared with the basal ) sodium chloride diet .	Infusion of the central nervous system alpha2 - adrenergic receptor agonist clonidine also resulted in a greater reduction in MAP in both groups of SHR that were fed the high ( compared with the basal ) sodium chloride diet .
CONCLUSIONS : In both lifetime captopril - treated and control SHR , the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet .	CONCLUSIONS : In both lifetime captopril - treated and control SHR , the sympathetic nervous system contributes to the pressor effects of a high sodium chloride diet .
Angioedema associated with droperidol administration .	disease* Angioedema *disease associated with droperidol administration .
Angioedema , also known as angioneurotic edema or Quincke ' s disease , is a well - demarcated , localized edema involving the subcutaneous tissues that may cause upper - airway obstruction .	disease* Angioedema *disease , also known as disease* angioneurotic edema *disease or disease* Quincke ' s disease *disease , is a well - demarcated , localized disease* edema *disease involving the subcutaneous tissues that may cause disease* upper - airway obstruction *disease .
We report the case of a previously healthy 19 - year - old man with no known drug allergies in whom angioedema with significant tongue swelling and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol .	We report the case of a previously healthy 19 - year - old man with no known disease* drug allergies *disease in whom disease* angioedema *disease with significant disease* tongue swelling *disease and protrusion developed within 10 minutes of the administration of a single IV dose of droperidol .
Late cardiotoxicity after treatment for a malignant bone tumor .	Late disease* cardiotoxicity *disease after treatment for a malignant disease* bone tumor *disease .
Cardiac function was assessed in long - term survivors of malignant bone tumors who were treated according to Rosen ' s T5 or T10 protocol , both including doxorubicin .	Cardiac function was assessed in long - term survivors of malignant disease* bone tumors *disease who were treated according to Rosen ' s T5 or T10 protocol , both including doxorubicin .
Thirty - one patients , age 10 - 45 years ( median age 17 . 8 years ) were evaluated 2 . 3 - 14 . 1 years ( median 8 . 9 years ) following completion of treatment .	Thirty - one patients , age 10 - 45 years ( median age 17 . 8 years ) were evaluated 2 . 3 - 14 . 1 years ( median 8 . 9 years ) following completion of treatment .
Cumulative doses of doxorubicin were 225 - 550 mg / m2 ( median dose 360 ) .	Cumulative doses of doxorubicin were 225 - 550 mg / m2 ( median dose 360 ) .
The evaluation consisted of a history , physical examination , electrocardiogram ( ECG ) , signal averaged ECG , 24 - hour ambulatory ECG , echocardiography and radionuclide angiography .	The evaluation consisted of a history , physical examination , electrocardiogram ( ECG ) , signal averaged ECG , 24 - hour ambulatory ECG , echocardiography and radionuclide angiography .
Eighteen of 31 ( 58 % ) patients showed cardiac toxicity , defined as having one or more of the following abnormalities : late potentials , complex ventricular arrhythmias , left ventricular dilation , decreased shortening fraction , or decreased ejection fraction .	Eighteen of 31 ( 58 % ) patients showed disease* cardiac toxicity *disease , defined as having one or more of the following abnormalities : late potentials , complex disease* ventricular arrhythmias *disease , left disease* ventricular dilation *disease , decreased shortening fraction , or decreased ejection fraction .
The incidence of cardiac abnormalities increased with length of follow - up ( P < or = . 05 ) .	The incidence of disease* cardiac abnormalities *disease increased with length of follow - up ( P < or = . 05 ) .
No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status , except for heart rate variability .	No correlation could be demonstrated between cumulative dose of doxorubicin and cardiac status , except for heart rate variability .
When adjusted to body surface area , the left ventricular posterior wall thickness ( LVPW index ) was decreased in all patients .	When adjusted to body surface area , the left ventricular posterior wall thickness ( LVPW index ) was decreased in all patients .
The incidence of doxorubicin - induced cardiotoxicity is high and increases with follow - up , irrespective of cumulative dose .	The incidence of doxorubicin - induced disease* cardiotoxicity *disease is high and increases with follow - up , irrespective of cumulative dose .
Life - long cardiac follow - up in these patients is warranted .	Life - long cardiac follow - up in these patients is warranted .
The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for cardiotoxicity .	The results of our study suggest that heart rate variability and LVPW index could be sensitive indicators for disease* cardiotoxicity *disease .
Acute blood pressure elevations with caffeine in men with borderline systemic hypertension .	Acute blood pressure elevations with caffeine in men with borderline systemic disease* hypertension *disease .
Whether the vasoconstrictive actions of caffeine are enhanced in hypertensive persons has not been demonstrated .	Whether the vasoconstrictive actions of caffeine are enhanced in disease* hypertensive *disease persons has not been demonstrated .
Thus , caffeine ( 3 . 3 mg / kg ) versus placebo was tested in 48 healthy men ( aged 20 to 35 years ) selected after screening on 2 separate occasions .	Thus , caffeine ( 3 . 3 mg / kg ) versus placebo was tested in 48 healthy men ( aged 20 to 35 years ) selected after screening on 2 separate occasions .
Borderline hypertensive men ( n = 24 ) were selected with screening systolic blood pressure ( BP ) of 140 to 160 mm Hg and / or diastolic BP 90 to 99 mm Hg .	Borderline disease* hypertensive *disease men ( n = 24 ) were selected with screening systolic blood pressure ( BP ) of 140 to 160 mm Hg and / or diastolic BP 90 to 99 mm Hg .
Low - risk controls ( n = 24 ) reported no parental history of hypertension and had screening BP < 130 / 85 mm Hg .	Low - risk controls ( n = 24 ) reported no parental history of disease* hypertension *disease and had screening BP < 130 / 85 mm Hg .
Participants were then tested on 2 occasions after 12 - hour abstinence from caffeine in each of 2 protocols ; this required a total of 4 laboratory visits .	Participants were then tested on 2 occasions after 12 - hour abstinence from caffeine in each of 2 protocols ; this required a total of 4 laboratory visits .
Caffeine - induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls ( + 8 . 4 vs + 3 . 8 mm Hg , p < 0 . 0001 ) , and were attributable to larger changes in impedance - derived measures of systemic vascular resistance ( + 135 vs + 45 dynes . s . cm - 5 , p < 0 . 004 ) .	Caffeine - induced changes in diastolic BP were 2 to 3 times larger in borderline subjects than in controls ( + 8 . 4 vs + 3 . 8 mm Hg , p < 0 . 0001 ) , and were attributable to larger changes in impedance - derived measures of systemic vascular resistance ( + 135 vs + 45 dynes . s . cm - 5 , p < 0 . 004 ) .
These findings were consistent and reached significance in both protocols .	These findings were consistent and reached significance in both protocols .
The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96 % .	The percentage of borderline subjects in whom diastolic BP changes exceeded the median control response was 96 % .
Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved hypertensive BP levels after caffeine ingestion .	Consequently , whereas all participants exhibited normotensive levels during the resting predrug baseline , 33 % of borderline subjects achieved disease* hypertensive *disease BP levels after caffeine ingestion .
Thus , in borderline hypertensive men , exaggerated responses to caffeine were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline hypertensives .	Thus , in borderline disease* hypertensive *disease men , exaggerated responses to caffeine were : selective for diastolic BP , consistent with greater vasoconstriction , replicated in 2 protocols , and representative of nearly all borderline disease* hypertensives *disease .
We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression , as well as hinder accurate diagnosis and treatment .	We suspect that the potential for caffeine to stabilize high resistance states in susceptible persons suggests that its use may facilitate their disease progression , as well as hinder accurate diagnosis and treatment .
Absence of effect of sertraline on time - based sensitization of cognitive impairment with haloperidol .	Absence of effect of sertraline on time - based sensitization of disease* cognitive impairment *disease with haloperidol .
This double - blind , randomized , placebo - controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects .	This double - blind , randomized , placebo - controlled study evaluated the effects of haloperidol alone and haloperidol plus sertraline on cognitive and psychomotor function in 24 healthy male subjects .
METHOD : All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25 .	METHOD : All subjects received placebo on Day 1 and haloperidol 2 mg on Days 2 and 25 .
From Days 9 to 25 , subjects were randomly assigned to either sertraline ( 12 subjects ) or placebo ( 12 subjects ) ; the sertraline dose was titrated from 50 to 200 mg / day from Days 9 to 16 , and remained at 200 mg / day for the final 10 days of the drug administration period .	From Days 9 to 25 , subjects were randomly assigned to either sertraline ( 12 subjects ) or placebo ( 12 subjects ) ; the sertraline dose was titrated from 50 to 200 mg / day from Days 9 to 16 , and remained at 200 mg / day for the final 10 days of the drug administration period .
Cognitive function testing was performed before dosing and over a 24 - hour period after dosing on Days 1 , 2 , and 25 .	Cognitive function testing was performed before dosing and over a 24 - hour period after dosing on Days 1 , 2 , and 25 .
RESULTS : Impairment of cognitive function was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing .	RESULTS : disease* Impairment of cognitive function *disease was observed 6 to 8 hours after administration of haloperidol on Day 2 but was not evident 23 hours after dosing .
When single - dose haloperidol was given again 25 days later , greater impairment with earlier onset was noted in several tests in both treatment groups , suggesting enhancement of this effect .	When single - dose haloperidol was given again 25 days later , greater impairment with earlier onset was noted in several tests in both treatment groups , suggesting enhancement of this effect .
There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group .	There was no indication that sertraline exacerbated the impairment produced by haloperidol since an equivalent effect also occurred in the placebo group .
Three subjects ( 2 on sertraline and 1 on placebo ) withdrew from the study because of side effects .	Three subjects ( 2 on sertraline and 1 on placebo ) withdrew from the study because of side effects .
Ten subjects in each group reported side effects related to treatment .	Ten subjects in each group reported side effects related to treatment .
The side effect profiles of sertraline and of placebo were similar .	The side effect profiles of sertraline and of placebo were similar .
CONCLUSION : Haloperidol produced a clear profile of cognitive impairment that was not worsened by concomitant sertraline administration .	CONCLUSION : Haloperidol produced a clear profile of disease* cognitive impairment *disease that was not worsened by concomitant sertraline administration .
Coexistence of cerebral venous sinus and internal carotid artery thrombosis associated with exogenous sex hormones .	Coexistence of disease* cerebral venous sinus and internal carotid artery thrombosis *disease associated with exogenous sex hormones .
A case report .	A case report .
A forty - six year - old premenopausal woman developed headache , nausea and vomiting , left hemiparesis and seizure two days after parenteral use of progesterone and estradiol .	A forty - six year - old premenopausal woman developed disease* headache *disease , disease* nausea *disease and disease* vomiting *disease , left disease* hemiparesis *disease and disease* seizure *disease two days after parenteral use of progesterone and estradiol .
Diabetes mellitus ( DM ) was found during admission .	disease* Diabetes mellitus *disease ( disease* DM *disease ) was found during admission .
Computed tomography showed a hemorrhagic infarct in the right frontal lobe and increased density in the superior sagittal sinus ( SSS ) .	Computed tomography showed a disease* hemorrhagic infarct *disease in the right frontal lobe and increased density in the superior sagittal sinus ( SSS ) .
Left carotid angiography found occlusion of the left internal carotid artery ( ICA ) .	Left carotid angiography found disease* occlusion of the left internal carotid artery *disease ( ICA ) .
Right carotid angiograms failed to show the SSS and inferior sagittal sinus , suggestive of venous sinus thrombosis .	Right carotid angiograms failed to show the SSS and inferior sagittal sinus , suggestive of disease* venous sinus thrombosis *disease .
Coexistence of the cerebral artery and the venous sinus occlusion has been described infrequently .	Coexistence of the disease* cerebral artery and the venous sinus occlusion *disease has been described infrequently .
In this case , the authors postulate that the use of estradiol and progesterone and the underlying DM increased vascular thrombogenicity , which provided a common denominator for thrombosis of both the ICA and the venous sinus .	In this case , the authors postulate that the use of estradiol and progesterone and the underlying disease* DM *disease increased vascular thrombogenicity , which provided a common denominator for disease* thrombosis of both the ICA and the venous sinus *disease .
Chemotherapy of advanced inoperable non - small cell lung cancer with paclitaxel : a phase II trial .	Chemotherapy of advanced inoperable disease* non - small cell lung cancer *disease with paclitaxel : a phase II trial .
Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different tumor types , notably ovarian and breast carcinoma .	Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) has demonstrated significant antineoplastic activity against different disease* tumor *disease types , notably disease* ovarian and breast carcinoma *disease .
Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV non - small cell lung cancer ( NSCLC ) reported response rates of 21 % and 24 % .	Two phase II trials of 24 - hour paclitaxel infusions in chemotherapy - naive patients with stage IIIB or IV disease* non - small cell lung cancer *disease ( disease* NSCLC *disease ) reported response rates of 21 % and 24 % .
Leukopenia was dose limiting : as many as 62 . 5 % of patients experienced grade 4 leukopenia .	disease* Leukopenia *disease was dose limiting : as many as 62 . 5 % of patients experienced grade 4 disease* leukopenia *disease .
We investigated the efficacy and toxicity of a 3 - hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV NSCLC .	We investigated the efficacy and disease* toxicity *disease of a 3 - hour paclitaxel infusion in a phase II trial in patients with inoperable stage IIIB or IV disease* NSCLC *disease .
The 58 patients treated ( 41 men and 17 women ) had a median age of 59 years ( age range , 25 to 75 ) and a performance status of 0 through 2 .	The 58 patients treated ( 41 men and 17 women ) had a median age of 59 years ( age range , 25 to 75 ) and a performance status of 0 through 2 .
Most patients ( 72 . 4 % ) had stage IV NSCLC .	Most patients ( 72 . 4 % ) had stage IV disease* NSCLC *disease .
Paclitaxel 225 mg / m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication .	Paclitaxel 225 mg / m2 was infused over 3 hours every 3 weeks with standard prophylactic premedication .
Of 50 patients evaluable for response , 12 ( 24 % ) had partial remission , 26 ( 52 % ) had no change , and 12 had disease progression ( 24 % ) .	Of 50 patients evaluable for response , 12 ( 24 % ) had partial remission , 26 ( 52 % ) had no change , and 12 had disease progression ( 24 % ) .
Hematologic toxicities were mild : only one patient ( 2 % ) developed grade 3 or 4 neutropenia , while 29 % had grade 1 or 2 .	Hematologic disease* toxicities *disease were mild : only one patient ( 2 % ) developed grade 3 or 4 disease* neutropenia *disease , while 29 % had grade 1 or 2 .
Grade 1 or 2 polyneuropathy affected 56 % of patients while only one ( 2 % ) experienced severe polyneuropathy .	Grade 1 or 2 disease* polyneuropathy *disease affected 56 % of patients while only one ( 2 % ) experienced severe disease* polyneuropathy *disease .
Similarly , grade 1 or 2 myalgia / arthralgia was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .	Similarly , grade 1 or 2 disease* myalgia *disease / disease* arthralgia *disease was observed in 63 . 2 % of patients , but only 14 . 3 % experienced grade 3 or 4 .
Nausea and vomiting were infrequent , with 14 % of patients experiencing grade 1 or 2 and only 2 % experiencing grade 3 or 4 .	disease* Nausea *disease and disease* vomiting *disease were infrequent , with 14 % of patients experiencing grade 1 or 2 and only 2 % experiencing grade 3 or 4 .
Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic toxicity .	Paclitaxel is thus an active single agent in this patient population , with a 3 - hour infusion proving comparably effective to a 24 - hour infusion and superior in terms of the incidence of hematologic and nonhematologic disease* toxicity *disease .
Further phase II studies with paclitaxel combined with other drugs active against NSCLC are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .	Further phase II studies with paclitaxel combined with other drugs active against disease* NSCLC *disease are indicated , and phase III studies comparing paclitaxel with standard chemotherapy remain to be completed .
Paclitaxel combined with carboplatin in the first - line treatment of advanced ovarian cancer .	Paclitaxel combined with carboplatin in the first - line treatment of advanced disease* ovarian cancer *disease .
In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced ovarian cancer , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .	In a phase I study to determine the maximum tolerated dose of paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) given as a 3 - hour infusion in combination with carboplatin administered every 21 days to women with advanced disease* ovarian cancer *disease , paclitaxel doses were escalated as follows : level 1 , 135 mg / m2 ; level 2 , 160 mg / m2 ; level 3 , 185 mg / m2 ; and level 4 , 210 mg / m2 .
The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration - time curve ( AUC ) of 5 using the Calvert formula .	The fixed dose of carboplatin at levels 1 through 4 was given to achieve an area under the concentration - time curve ( AUC ) of 5 using the Calvert formula .
In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7 . 5 , respectively , combined with a fixed paclitaxel dose of 185 mg / m2 .	In levels 5 and 6 the carboplatin dose was targeted at AUCs of 6 and 7 . 5 , respectively , combined with a fixed paclitaxel dose of 185 mg / m2 .
To date , 30 previously untreated patients , all with a good performance status ( Eastern Cooperative Oncology Group 0 to 2 ) have been entered into this ongoing study .	To date , 30 previously untreated patients , all with a good performance status ( Eastern Cooperative Oncology Group 0 to 2 ) have been entered into this ongoing study .
The dose - limiting toxicity of the combination was myelosuppression ( leukopenia , granulocytopenia , and thrombocytopenia ) .	The dose - limiting disease* toxicity *disease of the combination was disease* myelosuppression *disease ( disease* leukopenia *disease , disease* granulocytopenia *disease , and disease* thrombocytopenia *disease ) .
Neurotoxicity was largely moderate .	disease* Neurotoxicity *disease was largely moderate .
So far , 14 patients are evaluable for response ; of these , eight ( 57 % ) showed objective ( complete or partial ) response and disease stabilized in six patients .	So far , 14 patients are evaluable for response ; of these , eight ( 57 % ) showed objective ( complete or partial ) response and disease stabilized in six patients .
No patient had disease progression .	No patient had disease progression .
We conclude that the combination of paclitaxel 185 mg / m2 administered as a 3 - hour infusion followed immediately by a 1 - hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21 - day schedule in the outpatient setting .	We conclude that the combination of paclitaxel 185 mg / m2 administered as a 3 - hour infusion followed immediately by a 1 - hour infusion of carboplatin at an AUC of 6 can be administered safely in a 21 - day schedule in the outpatient setting .
The recommended dose for phase III studies is paclitaxel 185 mg / m2 and carboplatin AUC 6 .	The recommended dose for phase III studies is paclitaxel 185 mg / m2 and carboplatin AUC 6 .
Effects of acute steroid administration on ventilatory and peripheral muscles in rats .	Effects of acute steroid administration on ventilatory and peripheral muscles in rats .
Occasional case reports have shown that acute myopathy may occur in patients treated with massive doses of corticosteroids .	Occasional case reports have shown that acute disease* myopathy *disease may occur in patients treated with massive doses of corticosteroids .
The mechanism of this myopathy is poorly understood .	The mechanism of this disease* myopathy *disease is poorly understood .
Therefore , 60 male rats were randomly assigned to receive daily injection of saline ( C ) , methylprednisolone ( M ) , or triamcinolone ( T ) 80 mg / kg / d for 5 d .	Therefore , 60 male rats were randomly assigned to receive daily injection of saline ( C ) , methylprednisolone ( M ) , or triamcinolone ( T ) 80 mg / kg / d for 5 d .
Nutritional intake , measured daily in 15 animals , showed a significant reduction of food intake in the steroid - treated groups ( - 50 and - 79 % in M and T , respectively ) .	Nutritional intake , measured daily in 15 animals , showed a significant disease* reduction of food intake *disease in the steroid - treated groups ( - 50 and - 79 % in M and T , respectively ) .
This was associated with a similar loss in body weight .	This was associated with a similar disease* loss in body weight *disease .
In the 45 remaining animals , diaphragm contractility and histopathologic features of several muscles were studied .	In the 45 remaining animals , diaphragm contractility and histopathologic features of several muscles were studied .
Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment .	Weights of respiratory and peripheral muscles were similarly decreased after steroid treatment .
Maximal twitches of the diaphragm were lower in the C group ( 653 + / - 174 g / cm ( 2 ) ) than in the M group ( 837 + / - 171 g / cm ( 2 ) ; p < 0 . 05 ) and the T group ( 765 + / - 145 g / cm ( 2 ) , NS ) .	Maximal twitches of the diaphragm were lower in the C group ( 653 + / - 174 g / cm ( 2 ) ) than in the M group ( 837 + / - 171 g / cm ( 2 ) ; p < 0 . 05 ) and the T group ( 765 + / - 145 g / cm ( 2 ) , NS ) .
Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with M , whereas tetanic tensions were similar .	Half - relaxation time was prolonged in both steroid groups , and time to peak tension was longer with M , whereas disease* tetanic *disease tensions were similar .
Steroid treatment also induced a leftward shift of the force - frequency curve at 25 and 50 Hz when compared with saline treatment ( p < 0 . 05 ) .	Steroid treatment also induced a leftward shift of the force - frequency curve at 25 and 50 Hz when compared with saline treatment ( p < 0 . 05 ) .
ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber atrophy in the steroid groups and also diaphragmatic type IIa atrophy with T , whereas histologic examinations revealed a normal muscular pattern with absence of necrosis .	ATPase staining of the diaphragm , scalenus medius , and gastrocnemius showed type IIb fiber disease* atrophy *disease in the steroid groups and also diaphragmatic type IIa disease* atrophy *disease with T , whereas histologic examinations revealed a normal muscular pattern with absence of disease* necrosis *disease .
Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that muscle atrophy was considerably less pronounced in PF animals than in T - treated animals .	Finally , a pair - fed ( PF ) study , performed in 18 rats ( C , T , and PF ) , showed that disease* muscle atrophy *disease was considerably less pronounced in PF animals than in T - treated animals .
We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb atrophy , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle necrosis ; ( 4 ) type IIb atrophy was not caused by acute nutritional deprivation alone .	We conclude that ( 1 ) short - term treatment with massive doses of steroids induced severe respiratory and limb muscle wasting ; ( 2 ) both types of steroids induced predominantly type IIb disease* atrophy *disease , resulting in the expected alterations in diaphragm contractile properties ; ( 3 ) neither steroid caused muscle disease* necrosis *disease ; ( 4 ) type IIb disease* atrophy *disease was not caused by acute nutritional deprivation alone .
Continuous subcutaneous administration of mesna to prevent ifosfamide - induced hemorrhagic cystitis .	Continuous subcutaneous administration of mesna to prevent ifosfamide - induced disease* hemorrhagic cystitis *disease .
Hemorrhagic cystitis is a major potential toxicity of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent .	disease* Hemorrhagic cystitis *disease is a major potential disease* toxicity *disease of ifosfamide that can be prevented by administering mesna along with the cytotoxic agent .
Mesna is generally administered by the intravenous route , although experience with oral delivery of the drug has increased .	Mesna is generally administered by the intravenous route , although experience with oral delivery of the drug has increased .
The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access .	The continuous subcutaneous administration of mesna has the advantage of not requiring intravenous access .
In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced emesis and is unable to absorb the drug .	In addition , subcutaneous delivery of the neutralizing agent will not be associated with the risk of inadequate urinary mesna concentrations , such as in a patient taking oral mesna who experiences severe ifosfamide - induced disease* emesis *disease and is unable to absorb the drug .
Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe , practical , and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting .	Limited clinical experience with continuous subcutaneous mesna administration suggests it is a safe , practical , and economic method of drug delivery that permits ifosfamide to be administered successfully in the outpatient setting .
Leg and back pain after spinal anaesthesia involving hyperbaric 5 % lignocaine .	disease* Leg and back pain *disease after spinal anaesthesia involving hyperbaric 5 % lignocaine .
Fifty - four patients , aged 27 - 90 years , who were given lignocaine 5 % in 6 . 8 % glucose solution for spinal anaesthesia were studied .	Fifty - four patients , aged 27 - 90 years , who were given lignocaine 5 % in 6 . 8 % glucose solution for spinal anaesthesia were studied .
Thirteen of these patients experienced pain in the legs and / or back after recovery from anaesthesia .	Thirteen of these patients experienced disease* pain in the legs and / or back *disease after recovery from anaesthesia .
The patients affected were younger ( p < 0 . 05 ) and the site of the dural puncture was higher ( p < 0 . 01 ) than those individuals without pain .	The patients affected were younger ( p < 0 . 05 ) and the site of the dural puncture was higher ( p < 0 . 01 ) than those individuals without disease* pain *disease .
Five of the 13 patients ( 38 % ) with pain and seven of the 41 patients ( 17 % ) without pain admitted to a high alcohol intake , which might be a contributing factor .	Five of the 13 patients ( 38 % ) with disease* pain *disease and seven of the 41 patients ( 17 % ) without disease* pain *disease admitted to a high alcohol intake , which might be a contributing factor .
Leg and / or back pain is associated with the intrathecal use of hyperbaric 5 % lignocaine .	disease* Leg and / or back pain *disease is associated with the intrathecal use of hyperbaric 5 % lignocaine .
The use of serum cholinesterase in succinylcholine apnoea .	The use of serum cholinesterase in succinylcholine disease* apnoea *disease .
Fifteen patients demonstrating unexpected prolonged apnoea lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase .	Fifteen patients demonstrating unexpected prolonged disease* apnoea *disease lasting several hours after succinylcholine have been treated by a new preparation of human serum cholinesterase .
Adequate spontaneous respiration was re - established in an average period of ten minutes after the injection .	Adequate spontaneous respiration was re - established in an average period of ten minutes after the injection .
In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase .	In 12 patients biochemical genetic examinations confirmed the presence of an atypical serum cholinesterase .
In three patients none of the usual variants were found .	In three patients none of the usual variants were found .
It is therefore supposed that other unknown variants of serum cholinesterase exist which cannot hydrolyze succinylcholine .	It is therefore supposed that other unknown variants of serum cholinesterase exist which cannot hydrolyze succinylcholine .
The use of serum cholinesterase in succinylcholine apnoea provided considerable relief to both patient and anaesthetist .	The use of serum cholinesterase in succinylcholine disease* apnoea *disease provided considerable relief to both patient and anaesthetist .
Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in ethinyl estradiol - induced cholestasis in rats .	Increased sulfation and decreased 7alpha - hydroxylation of deoxycholic acid in ethinyl estradiol - induced disease* cholestasis *disease in rats .
Deoxycholic acid conjugation , transport capacity , and metabolism were compared in control and ethinyl estradiol - treated rats .	Deoxycholic acid conjugation , transport capacity , and metabolism were compared in control and ethinyl estradiol - treated rats .
Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid , and both were decreased by ethinyl estradiol treatment .	Control rats were found to have a lower capacity to transport deoxycholic acid than taurodeoxycholic acid , and both were decreased by ethinyl estradiol treatment .
During [ 24 - 14C ] sodium deoxycholate infusion , [ 14C ] biliary bile acid secretion increased , but bile flow did not change significantly in either control or ethinyl estradiol - treated rats .	During [ 24 - 14C ] sodium deoxycholate infusion , [ 14C ] biliary bile acid secretion increased , but bile flow did not change significantly in either control or ethinyl estradiol - treated rats .
Ethinyl estradiol - treated animals excreted significantly less 14C as taurocholic acid than did control animals , consistent with an impairment of 7alpha - hydroxylation of taurodeoxycholic acid .	Ethinyl estradiol - treated animals excreted significantly less 14C as taurocholic acid than did control animals , consistent with an impairment of 7alpha - hydroxylation of taurodeoxycholic acid .
Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid , but did result in an increase in sulfation of taurodeoxycholic acid from 1 . 5 % in controls to nearly 4 . 0 % ( P less than 0 . 01 ) .	Ethinyl estradiol treatment did not impair conjugation of deoxycholic acid , but did result in an increase in sulfation of taurodeoxycholic acid from 1 . 5 % in controls to nearly 4 . 0 % ( P less than 0 . 01 ) .
These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species .	These results are consistent with the hypothesis that the rat has a poorer tolerance for deoxycholic acid than do certain other species .
Furthermore , the rat converts deoxycholic acid , a poor choleretic , to taurocholic acid , a good choleretic .	Furthermore , the rat converts deoxycholic acid , a poor choleretic , to taurocholic acid , a good choleretic .
When this conversion is impaired with ethinyl estradiol treatment , sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid .	When this conversion is impaired with ethinyl estradiol treatment , sulfation may be an important alternate pathway for excretion of this potentially harmful bile acid .
Influence of diet free of NAD - precursors on acetaminophen hepatotoxicity in mice .	Influence of diet free of NAD - precursors on acetaminophen disease* hepatotoxicity *disease in mice .
Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - hepatitis , suggesting that the AAP - induced liver injury involves a step which depends on adenoribosylation .	Recently , we demonstrated the hepatoprotective effects of nicotinic acid amide , a selective inhibitor of poly ( ADP - ribose ) polymerase ( PARP ; EC 2 . 4 . 2 . 30 ) on mice suffering from acetaminophen ( AAP ) - disease* hepatitis *disease , suggesting that the AAP - induced disease* liver injury *disease involves a step which depends on adenoribosylation .
The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP hepatitis and evaluates the influence of simultaneous ethanol consumption in these animals .	The present study investigates the effects of a diet free of precursors of NAD , the substrate on which PARP acts , in female NMRI mice with AAP disease* hepatitis *disease and evaluates the influence of simultaneous ethanol consumption in these animals .
Liver injuries were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .	disease* Liver injuries *disease were quantified as serum activities of glutamate - oxaloacetate transaminase ( GOT ) and glutamate - pyruvate transaminase ( GPT ) .
While AAP caused a 117 - fold elevation of serum transaminase activities in mice kept on a standard laboratory diet , which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide ( NAA ) , adverse effects were noted in animals fed a diet free of precursors of NAD .	While AAP caused a 117 - fold elevation of serum transaminase activities in mice kept on a standard laboratory diet , which was significantly exacerbated by ethanol and inhibited by nicotinic acid amide ( NAA ) , adverse effects were noted in animals fed a diet free of precursors of NAD .
In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the liver damage was inhibited by 50 % by ethanol .	In these animals , only minor increases of serum transaminase activities were measured in the presence of AAP , and unlike the exacerbation caused by ethanol in mice on a standard diet , the disease* liver damage *disease was inhibited by 50 % by ethanol .
A further 64 % reduction of hepatitis was observed , when NAA was given to ethanol / AAP - mice .	A further 64 % reduction of disease* hepatitis *disease was observed , when NAA was given to ethanol / AAP - mice .
Our results provide evidence that the AAP - induced hepatitis and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme ' s substrate NAD .	Our results provide evidence that the AAP - induced disease* hepatitis *disease and its exacerbation by ethanol can either be reduced by end - product inhibition of PARP by NAA or by dietary depletion of the enzyme ' s substrate NAD .
We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid hepatic damage in patients treated with this widely used analgesic .	We see the main application of NAA as for the combinational use in pharmaceutical preparations of acetaminophen in order to avoid disease* hepatic damage *disease in patients treated with this widely used analgesic .
Nightmares and hallucinations after long - term intake of tramadol combined with antidepressants .	Nightmares and disease* hallucinations *disease after long - term intake of tramadol combined with antidepressants .
Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat cancer pain and chronic non malignant pain .	Tramadol is a weak opioid with effects on adrenergic and serotonergic neurotransmission that is used to treat disease* cancer disease* pain *disease and chronic non malignant disease* pain *disease .
This drug was initiated in association with paroxetine and dosulepine hydrochloride in a tetraparetic patient with chronic pain .	This drug was initiated in association with paroxetine and dosulepine hydrochloride in a disease* tetraparetic *disease patient with disease* chronic pain *disease .
Fifty - six days after initiation of the treatment the patient presented hallucinations that only stopped after the withdrawal of psycho - active drugs and tramadol .	Fifty - six days after initiation of the treatment the patient presented disease* hallucinations *disease that only stopped after the withdrawal of psycho - active drugs and tramadol .
The case report questions the long term use of pain killers combined with psycho - active drugs in chronic non malignant pain , especially if pain is under control .	The case report questions the long term use of disease* pain *disease killers combined with psycho - active drugs in chronic non malignant disease* pain *disease , especially if disease* pain *disease is under control .
Effect of calcium chloride and 4 - aminopyridine therapy on desipramine toxicity in rats .	Effect of calcium chloride and 4 - aminopyridine therapy on desipramine disease* toxicity *disease in rats .
BACKGROUND : Hypotension is a major contributor to mortality in tricyclic antidepressant overdose .	BACKGROUND : disease* Hypotension *disease is a major contributor to mortality in tricyclic antidepressant disease* overdose *disease .
Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues .	Recent data suggest that tricyclic antidepressants inhibit calcium influx in some tissues .
This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced hypotension .	This study addressed the potential role of calcium channel blockade in tricyclic antidepressant - induced disease* hypotension *disease .
METHODS : Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker overdose .	METHODS : Two interventions were studied that have been shown previously to improve blood pressure with calcium channel blocker disease* overdose *disease .
CaCl2 and 4 - aminopyridine .	CaCl2 and 4 - aminopyridine .
Anesthetized rats received the tricyclic antidepressant desipramine IP to produce hypotension , QRS prolongation , and bradycardia .	Anesthetized rats received the tricyclic antidepressant desipramine IP to produce disease* hypotension *disease , QRS prolongation , and disease* bradycardia *disease .
Fifteen min later , animals received CaCl2 , NaHCO3 , or saline .	Fifteen min later , animals received CaCl2 , NaHCO3 , or saline .
In a second experiment , rats received tricyclic antidepressant desipramine IP followed in 15 min by 4 - aminopyridine or saline .	In a second experiment , rats received tricyclic antidepressant desipramine IP followed in 15 min by 4 - aminopyridine or saline .
RESULTS : NaHCO3 briefly ( 5 min ) reversed hypotension and QRS prolongation .	RESULTS : NaHCO3 briefly ( 5 min ) reversed disease* hypotension *disease and QRS prolongation .
CaCl2 and 4 - aminopyridine failed to improve blood pressure .	CaCl2 and 4 - aminopyridine failed to improve blood pressure .
The incidence of ventricular arrhythmias ( p = 0 . 004 ) and seizures ( p = 0 . 03 ) in the CaCl2 group was higher than the other groups .	The incidence of disease* ventricular arrhythmias *disease ( p = 0 . 004 ) and disease* seizures *disease ( p = 0 . 03 ) in the CaCl2 group was higher than the other groups .
CONCLUSION : The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced hypotension in rats .	CONCLUSION : The administration of CaCl2 or 4 - aminopyridine did not reverse tricyclic antidepressant - induced disease* hypotension *disease in rats .
CaCl2 therapy may possibly worsen both cardiovascular and central nervous system toxicity .	CaCl2 therapy may possibly worsen both disease* cardiovascular and central nervous system toxicity *disease .
These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced hypotension .	These findings do not support a role for calcium channel inhibition in the pathogenesis of tricyclic antidepressant - induced disease* hypotension *disease .
Valsartan , a new angiotensin II antagonist for the treatment of essential hypertension : a comparative study of the efficacy and safety against amlodipine .	Valsartan , a new angiotensin II antagonist for the treatment of essential disease* hypertension *disease : a comparative study of the efficacy and safety against amlodipine .
OBJECTIVE : To compare the antihypertensive efficacy of a new angiotensin II antagonist , valsartan , with a reference therapy , amlodipine .	OBJECTIVE : To compare the antihypertensive efficacy of a new angiotensin II antagonist , valsartan , with a reference therapy , amlodipine .
METHODS : One hundred sixty - eight adult outpatients with mild to moderate hypertension were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks .	METHODS : One hundred sixty - eight adult outpatients with mild to moderate disease* hypertension *disease were randomly allocated in double - blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks .
After 8 weeks of therapy , in patients whose blood pressure remained uncontrolled , 5 mg amlodipine was added to the initial therapy .	After 8 weeks of therapy , in patients whose blood pressure remained uncontrolled , 5 mg amlodipine was added to the initial therapy .
Patients were assessed at 4 , 8 , and 12 weeks .	Patients were assessed at 4 , 8 , and 12 weeks .
The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks .	The primary efficacy variable was change from baseline in mean sitting diastolic blood pressure at 8 weeks .
Secondary variables included change in sitting systolic blood pressure and responder rates .	Secondary variables included change in sitting systolic blood pressure and responder rates .
RESULTS : Both valsartan and amlodipine were effective at lowering blood pressure at 4 , 8 , and 12 weeks .	RESULTS : Both valsartan and amlodipine were effective at lowering blood pressure at 4 , 8 , and 12 weeks .
Similar decreases were observed in both groups , with no statistically significant differences between the groups for any variable analyzed .	Similar decreases were observed in both groups , with no statistically significant differences between the groups for any variable analyzed .
For the primary variable the difference was 0 . 5 mm Hg in favor of valsartan ( p = 0 . 68 ; 95 % confidence interval , - 2 . 7 to 1 . 7 ) .	For the primary variable the difference was 0 . 5 mm Hg in favor of valsartan ( p = 0 . 68 ; 95 % confidence interval , - 2 . 7 to 1 . 7 ) .
Responder rates at 8 weeks were 66 . 7 % for valsartan and 60 . 2 % for amlodipine ( p = 0 . 39 ) .	Responder rates at 8 weeks were 66 . 7 % for valsartan and 60 . 2 % for amlodipine ( p = 0 . 39 ) .
Both treatments were well tolerated .	Both treatments were well tolerated .
The incidence of drug - related dependent edema was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .	The incidence of drug - related dependent disease* edema *disease was somewhat higher in the amlodipine group , particularly at a dose of 10 mg per day ( 2 . 4 % for 80 mg valsartan ; 3 . 6 % for 5 mg amlodipine ; 0 % for valsartan plus 5 mg amlodipine ; 14 . 3 % for 10 mg amlodipine ) .
CONCLUSIONS : The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate hypertension .	CONCLUSIONS : The data show that valsartan is at least as effective as amlodipine in the treatment of mild to moderate disease* hypertension *disease .
The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class , dihydropyridine calcium antagonists .	The results also show valsartan to be well tolerated and suggest that it is not associated with side effects characteristic of this comparator class , dihydropyridine calcium antagonists .
A measure of pupillary oscillation as a marker of cocaine - induced paranoia .	A measure of disease* pupillary oscillation *disease as a marker of cocaine - induced disease* paranoia *disease .
Cocaine - induced paranoia ( CIP ) remains an important drug - induced model of idiopathic paranoia for which no psychophysiologic marker has yet emerged .	Cocaine - induced disease* paranoia *disease ( disease* CIP *disease ) remains an important drug - induced model of idiopathic disease* paranoia *disease for which no psychophysiologic marker has yet emerged .
Measures of pupillary oscillation were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past CIP ( n = 32 ) from another group of crack addicts who denied past CIP ( n = 29 ) .	Measures of disease* pupillary oscillation *disease were able to significantly distinguish a group of abstinent crack cocaine abusers endorsing past disease* CIP *disease ( n = 32 ) from another group of crack addicts who denied past disease* CIP *disease ( n = 29 ) .
Serotonin syndrome from venlafaxine - tranylcypromine interaction .	disease* Serotonin syndrome *disease from venlafaxine - tranylcypromine interaction .
Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , muscle rigidity , salivation , confusion , agitation and hyperthermia .	Excessive stimulation of serotonin 5HT1A receptors causes a syndrome of serotonin excess that consists of shivering , disease* muscle rigidity *disease , disease* salivation *disease , disease* confusion *disease , disease* agitation *disease and disease* hyperthermia *disease .
The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor ( MAOI ) and a specific serotonin reuptake inhibitor .	The most common cause of this syndrome is an interaction between a monoamine oxidase inhibitor ( MAOI ) and a specific serotonin reuptake inhibitor .
Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine .	Venlafaxine is a new antidepressant agent that inhibits the reuptake of serotonin and norepinephrine .
We report a venlafaxine - MAOI interaction that resulted in the serotonin syndrome in a 23 - y - old male who was taking tranylcypromine for depression .	We report a venlafaxine - MAOI interaction that resulted in the disease* serotonin syndrome *disease in a 23 - y - old male who was taking tranylcypromine for disease* depression *disease .
He had been well until the morning of presentation when he took 1 / 2 tab of venlafaxine .	He had been well until the morning of presentation when he took 1 / 2 tab of venlafaxine .
Within 2 h he became confused with jerking movements of his extremities , tremors and rigidity .	Within 2 h he became confused with jerking movements of his extremities , disease* tremors *disease and disease* rigidity *disease .
He was brought directly to a hospital where he was found to be agitated and confused with shivering , myoclonic jerks , rigidity , salivation and diaphoresis .	He was brought directly to a hospital where he was found to be agitated and confused with shivering , disease* myoclonic jerks *disease , disease* rigidity *disease , disease* salivation *disease and diaphoresis .
His pupils were 7 mm and sluggishly reactive to light .	His pupils were 7 mm and sluggishly reactive to light .
Vital signs were : blood pressure 120 / 67 mm Hg , heart rate 127 / min , respiratory rate 28 / min , and temperature 97 F .	Vital signs were : blood pressure 120 / 67 mm Hg , heart rate 127 / min , respiratory rate 28 / min , and temperature 97 F .
After 180 mg of diazepam i . v . he remained tremulous with muscle rigidity and clenched jaws .	After 180 mg of diazepam i . v . he remained tremulous with disease* muscle rigidity *disease and clenched jaws .
He was intubated for airway protection and because of hypoventilation , and was paralyzed to control muscle rigidity .	He was intubated for airway protection and because of disease* hypoventilation *disease , and was disease* paralyzed *disease to control disease* muscle rigidity *disease .
His subsequent course was remarkable for non - immune thrombocytopenia which resolved .	His subsequent course was remarkable for non - immune disease* thrombocytopenia *disease which resolved .
The patient ' s maximal temperature was 101 . 2 F and his CPK remained < 500 units / L with no other evidence of rhabdomyolysis .	The patient ' s maximal temperature was 101 . 2 F and his CPK remained < 500 units / L with no other evidence of disease* rhabdomyolysis *disease .
His mental status normalized and he was transferred to a psychiatry ward .	His mental status normalized and he was transferred to a psychiatry ward .
This patient survived without sequelae due to the aggressive sedation and neuromuscular paralysis .	This patient survived without sequelae due to the aggressive sedation and neuromuscular disease* paralysis *disease .
Cyclophosphamide associated bladder cancer - - a highly aggressive disease : analysis of 12 cases .	Cyclophosphamide associated disease* bladder cancer *disease - - a highly aggressive disease : analysis of 12 cases .
PURPOSE : We gained knowledge of the etiology , treatment and prevention of cyclophosphamide associated urothelial cancer .	PURPOSE : We gained knowledge of the etiology , treatment and prevention of cyclophosphamide associated disease* urothelial cancer *disease .
MATERIALS AND METHODS : The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated bladder cancer were reviewed .	MATERIALS AND METHODS : The medical records of 6 men and 6 women ( mean age 55 years ) with cyclophosphamide associated disease* bladder cancer *disease were reviewed .
RESULTS : All tumors were grade 3 or 4 transitional cell carcinoma .	RESULTS : All disease* tumors *disease were grade 3 or 4 transitional cell disease* carcinoma *disease .
Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease .	Of the 5 patients initially treated with endoscopic resection alone only 1 is alive without disease .
Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months .	Of the 6 patients who underwent early cystectomy 4 were alive at 24 to 111 months .
The remaining patient with extensive cancer underwent partial cystectomy for palliation and died 3 months later .	The remaining patient with extensive disease* cancer *disease underwent partial cystectomy for palliation and died 3 months later .
CONCLUSIONS : Cyclophosphamide associated bladder tumor is an aggressive disease .	CONCLUSIONS : Cyclophosphamide associated disease* bladder tumor *disease is an aggressive disease .
However , long - term survival is possible when radical cystectomy is performed for bladder tumors with any sign of invasion and for recurrent high grade disease , even when noninvasive .	However , long - term survival is possible when radical cystectomy is performed for disease* bladder tumors *disease with any sign of invasion and for recurrent high grade disease , even when noninvasive .
A phase I clinical study of the antipurine antifolate lometrexol ( DDATHF ) given with oral folic acid .	A phase I clinical study of the antipurine antifolate lometrexol ( DDATHF ) given with oral folic acid .
Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase ( GARFT ) , an enzyme essential for de novo purine synthesis .	Lometrexol is an antifolate which inhibits glycinamide ribonucleotide formyltransferase ( GARFT ) , an enzyme essential for de novo purine synthesis .
Extensive experimental and limited clinical data have shown that lometrexol has activity against tumours which are refractory to other drugs , notably methotrexate .	Extensive experimental and limited clinical data have shown that lometrexol has activity against disease* tumours *disease which are refractory to other drugs , notably methotrexate .
However , the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative toxicities .	However , the initial clinical development of lometrexol was curtailed because of severe and cumulative antiproliferative disease* toxicities *disease .
Preclinical murine studies demonstrated that the toxicity of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .	Preclinical murine studies demonstrated that the disease* toxicity *disease of lometrexol can be prevented by low dose folic acid administration , i . e . for 7 days prior to and 7 days following a single bolus dose .
This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the toxicity of lometrexol can be markedly reduced by folic acid supplementation .	This observation prompted a Phase I clinical study of lometrexol given with folic acid supplementation which has confirmed that the disease* toxicity *disease of lometrexol can be markedly reduced by folic acid supplementation .
Thrombocytopenia and mucositis were the major toxicities .	disease* Thrombocytopenia *disease and disease* mucositis *disease were the major disease* toxicities *disease .
There was no clear relationship between clinical toxicity and the extent of plasma folate elevation .	There was no clear relationship between clinical disease* toxicity *disease and the extent of plasma folate elevation .
Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce toxicity by enhancing lometrexol plasma clearance .	Associated studies demonstrated that lometrexol plasma pharmacokinetics were not altered by folic acid administration indicating that supplementation is unlikely to reduce disease* toxicity *disease by enhancing lometrexol plasma clearance .
The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor .	The work described in this report has identified for the first time a clinically acceptable schedule for the administration of a GARFT inhibitor .
This information will facilitate the future evaluation of this class of compounds in cancer therapy .	This information will facilitate the future evaluation of this class of compounds in disease* cancer *disease therapy .
Fatal excited delirium following cocaine use : epidemiologic findings provide new evidence for mechanisms of cocaine toxicity .	Fatal excited disease* delirium *disease following cocaine use : epidemiologic findings provide new evidence for mechanisms of cocaine disease* toxicity *disease .
We describe an outbreak of deaths from cocaine - induced excited delirium ( EDDs ) in Dade County , Florida between 1979 and 1990 .	We describe an outbreak of deaths from cocaine - induced excited disease* delirium *disease ( disease* EDDs *disease ) in Dade County , Florida between 1979 and 1990 .
From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 EDDs were compared with 125 victims of accidental cocaine overdose without excited delirium .	From a registry of all cocaine - related deaths in Dade County , Florida , from 1969 - 1990 , 58 disease* EDDs *disease were compared with 125 victims of accidental cocaine disease* overdose *disease without excited disease* delirium *disease .
Compared with controls , EDDs were more frequently black , male , and younger .	Compared with controls , disease* EDDs *disease were more frequently black , male , and younger .
They were less likely to have a low body mass index , and more likely to have died in police custody , to have received medical treatment immediately before death , to have survived for a longer period , to have developed hyperthermia , and to have died in summer months .	They were less likely to have a low body mass index , and more likely to have died in police custody , to have received medical treatment immediately before death , to have survived for a longer period , to have developed disease* hyperthermia *disease , and to have died in summer months .
EDDs had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls .	disease* EDDs *disease had concentrations of cocaine and benzoylecgonine in autopsy blood that were similar to those for controls .
The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate agitation , delirium , aberrant thermoregulation , rhabdomyolysis , and sudden death .	The epidemiologic findings are most consistent with the hypothesis that chronic cocaine use disrupts dopaminergic function and , when coupled with recent cocaine use , may precipitate disease* agitation *disease , disease* delirium *disease , aberrant thermoregulation , disease* rhabdomyolysis *disease , and disease* sudden death *disease .
Pemoline induced acute choreoathetosis : case report and review of the literature .	Pemoline induced acute disease* choreoathetosis *disease : case report and review of the literature .
BACKGROUND : Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of attention deficit disorder .	BACKGROUND : Pemoline is an oxazolidine derivative that is structurally different from amphetamines and used in the treatment of disease* attention deficit disorder *disease .
Pemoline has not been commonly associated in the literature as a cause of acute movement disorders .	Pemoline has not been commonly associated in the literature as a cause of acute disease* movement disorders *disease .
The following case describes two children acutely poisoned with pemoline who experienced profound choreoathetosis .	The following case describes two children acutely poisoned with pemoline who experienced profound disease* choreoathetosis *disease .
CASE REPORT : Two , 3 - year - old male , identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets .	CASE REPORT : Two , 3 - year - old male , identical twin siblings presented to the emergency department after found playing with a an empty bottle of pemoline originally containing 59 tablets .
The children had a medical history significant for attention deficit disorder previously treated with methylphenidate without success .	The children had a medical history significant for disease* attention deficit disorder *disease previously treated with methylphenidate without success .
This was their first day of pemoline therapy .	This was their first day of pemoline therapy .
The choreoathetoid movements began 45 min to 1 h after ingestion .	The disease* choreoathetoid *disease movements began 45 min to 1 h after ingestion .
The children gave no history of prior movement disorders and there was no family history of movement disorders .	The children gave no history of prior disease* movement disorders *disease and there was no family history of disease* movement disorders *disease .
The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the choreoathetoid movements .	The children received gastrointestinal decontamination and high doses of intravenous benzodiazepines in an attempt to control the disease* choreoathetoid *disease movements .
Despite treatment , the children continued to have choreoathetosis for approximately 24 hours .	Despite treatment , the children continued to have disease* choreoathetosis *disease for approximately 24 hours .
Forty - eight hours after admission , the children appeared to be at their baseline and were discharged home .	Forty - eight hours after admission , the children appeared to be at their baseline and were discharged home .
CONCLUSION : Pemoline associated movement disorder has been rarely reported in the acute toxicology literature .	CONCLUSION : Pemoline associated disease* movement disorder *disease has been rarely reported in the acute toxicology literature .
The possibility of choreoathetoid movements should be considered in patients presenting after pemoline overdose .	The possibility of disease* choreoathetoid *disease movements should be considered in patients presenting after pemoline disease* overdose *disease .
Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve .	Effect of myopic excimer laser photorefractive keratectomy on the electrophysiologic function of the retina and optic nerve .
PURPOSE : To assess by electrophysiologic testing the effect of photorefractive keratectomy ( PRK ) on the retina and optic nerve .	PURPOSE : To assess by electrophysiologic testing the effect of photorefractive keratectomy ( PRK ) on the retina and optic nerve .
SETTING : Eye Clinic , S .	SETTING : Eye Clinic , S .
Salvatore Hospital , L ' Aquila University , Italy .	Salvatore Hospital , L ' Aquila University , Italy .
METHODS : Standard pattern electroretinograms ( P - ERGs ) and standard pattern visual evoked potentials ( P - VEPs ) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5 . 00 and 15 . 00 diopters ( D ) ( mean 8 . 00 D ) .	METHODS : Standard pattern electroretinograms ( P - ERGs ) and standard pattern visual evoked potentials ( P - VEPs ) were done in 25 eyes of 25 patients who had myopic PRK for an attempted correction between 5 . 00 and 15 . 00 diopters ( D ) ( mean 8 . 00 D ) .
Testing was done preoperatively and 3 , 6 , 12 , and 18 months postoperatively .	Testing was done preoperatively and 3 , 6 , 12 , and 18 months postoperatively .
The contralateral eyes served as controls .	The contralateral eyes served as controls .
During the follow - up , 3 patients ( 12 % ) developed steroid - induced elevated intraocular pressure ( IOP ) that resolved after corticosteroid therapy was discontinued .	During the follow - up , 3 patients ( 12 % ) developed steroid - induced disease* elevated intraocular pressure *disease ( IOP ) that resolved after corticosteroid therapy was discontinued .
RESULTS : No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively .	RESULTS : No statistically significant differences were seen between treated and control eyes nor between treated eyes preoperatively and postoperatively .
CONCLUSION : Myopic excimer laser PRK did not seem to affect the posterior segment .	CONCLUSION : Myopic excimer laser PRK did not seem to affect the posterior segment .
The transient steroid - induced IOP rise did not seem to cause functional impairment .	The transient steroid - induced disease* IOP rise *disease did not seem to cause functional impairment .
Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure .	Neutrophil superoxide and hydrogen peroxide production in patients with disease* acute liver failure *disease .
Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of bacterial infections in patients with acute liver failure ( ALF ) .	Defects in superoxide and hydrogen peroxide production may be implicated in the high incidence of disease* bacterial infections *disease in patients with disease* acute liver failure *disease ( disease* ALF *disease ) .
In the present study , oxygen radical production in patients with ALF due to paracetamol overdose was compared with that of healthy volunteers .	In the present study , oxygen radical production in patients with disease* ALF *disease due to paracetamol disease* overdose *disease was compared with that of healthy volunteers .
Neutrophils from 14 ALF patients were stimulated via the complement receptors using zymosan opsonized with ALF or control serum .	Neutrophils from 14 disease* ALF *disease patients were stimulated via the complement receptors using zymosan opsonized with disease* ALF *disease or control serum .
Superoxide and hydrogen peroxide production by ALF neutrophils stimulated with zymosan opsonized with ALF serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .	Superoxide and hydrogen peroxide production by disease* ALF *disease neutrophils stimulated with zymosan opsonized with disease* ALF *disease serum was significantly reduced compared with the control subjects ( P < 0 . 01 ) .
This defect persisted when zymosan opsonized by control serum was used ( P < 0 . 05 ) .	This defect persisted when zymosan opsonized by control serum was used ( P < 0 . 05 ) .
Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 ALF patients was unaffected compared with control neutrophils .	Superoxide and hydrogen peroxide production in neutrophils stimulated with formyl - methionyl - leucyl - phenylalanine ( fMLP ) from a further 18 disease* ALF *disease patients was unaffected compared with control neutrophils .
Serum C3 complement levels were significantly reduced in ALF patients compared with control subjects ( P < 0 . 0005 ) .	Serum C3 complement levels were significantly reduced in disease* ALF *disease patients compared with control subjects ( P < 0 . 0005 ) .
These results demonstrate a neutrophil defect in ALF due to paracetamol overdose , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .	These results demonstrate a neutrophil defect in disease* ALF *disease due to paracetamol disease* overdose *disease , that is complement dependent but independent of serum complement , possibly connected to the complement receptor .
Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen , adriamycin , carbon tetrachloride , chloroform and galactosamine .	Cholesteryl hemisuccinate treatment protects rodents from the toxic effects of acetaminophen , adriamycin , carbon tetrachloride , chloroform and galactosamine .
In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the hepatotoxic effects of carbon tetrachloride ( CCl4 ) .	In addition to its use as a stabilizer / rigidifier of membranes , cholesteryl hemisuccinate , tris salt ( CS ) administration has also been shown to protect rats from the disease* hepatotoxic *disease effects of carbon tetrachloride ( CCl4 ) .
To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced toxicity .	To further our understanding of the mechanism of CS cytoprotection , we examined in rats and mice the protective abilities of CS and the non - hydrolyzable ether form of CS , gamma - cholesteryloxybutyric acid , tris salt ( CSE ) against acetaminophen - , adriamycin - , carbon tetrachloride - , chloroform - and galactosamine - induced disease* toxicity *disease .
The results of these studies demonstrated that CS - mediated protection is not selective for a particular species , organ system or toxic chemical .	The results of these studies demonstrated that CS - mediated protection is not selective for a particular species , organ system or toxic chemical .
A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the hepatotoxic effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably cardiotoxic ) effect of adriamycin administration .	A 24 - h pretreatment of both rats and mice with a single dose of CS ( 100mg / kg , i . p . ) , resulted in significant protection against the disease* hepatotoxic *disease effects of CCl4 , CHCl3 , acetaminophen and galactosamine and against the lethal ( and presumably disease* cardiotoxic *disease ) effect of adriamycin administration .
Maximal CS - mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult .	Maximal CS - mediated protection was observed in experimental animals pretreated 24 h prior to the toxic insult .
These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death .	These data suggest that CS intervenes in a critical cellular event that is an important common pathway to toxic cell death .
The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine hepatotoxicity ) .	The mechanism of CS protection does not appear to be dependent on the inhibition of chemical bioactivation to a toxic reactive intermediate ( in light of the protection observed against galactosamine disease* hepatotoxicity *disease ) .
However , based on the data presented , we can not exclude the possibility that CS administration inhibits chemical bioactivation .	However , based on the data presented , we can not exclude the possibility that CS administration inhibits chemical bioactivation .
Our findings do suggest that CS - mediated protection is dependent on the action of the intact anionic CS molecule ( non - hydrolyzable CSE was as protective as CS ) , whose mechanism has yet to be defined .	Our findings do suggest that CS - mediated protection is dependent on the action of the intact anionic CS molecule ( non - hydrolyzable CSE was as protective as CS ) , whose mechanism has yet to be defined .
A murine model of adenomyosis : the effects of hyperprolactinemia induced by fluoxetine hydrochloride , a selective serotonin reuptake inhibitor , on adenomyosis induction in Wistar albino rats .	A murine model of disease* adenomyosis *disease : the effects of disease* hyperprolactinemia *disease induced by fluoxetine hydrochloride , a selective serotonin reuptake inhibitor , on disease* adenomyosis *disease induction in Wistar albino rats .
OBJECTIVE : The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused hyperprolactinemia and its effects with respect to adenomyosis .	OBJECTIVE : The aim of this study was to investigate whether fluoxetine given to castrated and noncastrated rats caused disease* hyperprolactinemia *disease and its effects with respect to disease* adenomyosis *disease .
DESIGN : Fluoxetine , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce hyperprolactinemia .	DESIGN : Fluoxetine , a serotonin reuptake inhibitor , was given to Wistar Albino rats for 98 days to produce disease* hyperprolactinemia *disease .
The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls .	The drug was given to two groups consisting of castrated and noncastrated rats and compared to two groups of castrated and noncastrated controls .
Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days .	Prolactin levels were measured and the uteri of the rats were removed for histopathological analysis at the end of 98 days .
SETTING : Marmara University School of Medicine , Department of Histology and Embryology , Zeynep Kamil Women and Children ' s Hospital .	SETTING : Marmara University School of Medicine , Department of Histology and Embryology , Zeynep Kamil Women and Children ' s Hospital .
MAIN OUTCOME MEASURES : Serum prolactin levels , uterine histopathology .	MAIN OUTCOME MEASURES : Serum prolactin levels , uterine histopathology .
RESULTS : The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups .	RESULTS : The prolactin levels of castrated and noncastrated groups treated with fluoxetine were statistically significantly higher when compared to their respective control groups .
Histological studies revealed 11 cases of adenomyosis , all within the noncastrated group receiving fluoxetine .	Histological studies revealed 11 cases of disease* adenomyosis *disease , all within the noncastrated group receiving fluoxetine .
CONCLUSION : It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma .	CONCLUSION : It was suggested that high serum prolactin levels cause degeneration of myometrial cells in the presence of ovarian steroids that results in a myometrial invasion by endometrial stroma .
This invasion eventually progresses to adenomyosis .	This invasion eventually progresses to disease* adenomyosis *disease .
Postinfarction ventricular septal defect associated with long - term steroid therapy .	Postinfarction disease* ventricular septal defect *disease associated with long - term steroid therapy .
Two cases of postinfarction ventricular septal rupture in patients on long - term steroid therapy are presented and the favourable outcome in both cases described .	Two cases of postinfarction disease* ventricular septal rupture *disease in patients on long - term steroid therapy are presented and the favourable outcome in both cases described .
A possible association between steroid therapy and subsequent postinfarction septal rupture is discussed .	A possible association between steroid therapy and subsequent postinfarction disease* septal rupture *disease is discussed .
Neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic seizures and status epilepticus in mice .	Neuroactive steroids protect against pilocarpine - and kainic acid - induced limbic disease* seizures *disease and disease* status epilepticus *disease in mice .
Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced seizures in mice .	Several structurally related metabolites of progesterone ( 3 alpha - hydroxy pregnane - 20 - ones ) and deoxycorticosterone ( 3 alpha - hydroxy pregnane - 21 - diol - 20 - ones ) and their 3 beta - epimers were evaluated for protective activity against pilocarpine - , kainic acid - and N - methyl - D - aspartate ( NMDA ) - induced disease* seizures *disease in mice .
Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor seizures and status epilepticus ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .	Steroids with the 3 - hydroxy group in the alpha - position and 5 - H in the alpha - or beta - configurations were highly effective in protecting against pilocarpine ( 416 mg / kg , s . c . ) - induced limbic motor disease* seizures *disease and disease* status epilepticus *disease ( ED50 values , 7 . 0 - 18 . 7 mg / kg , i . p . ) .
The corresponding epimers with the 3 - hydroxy group in the beta - position were also effective but less potent ( ED50 values , 33 . 8 - 63 . 5 , i . p . ) .	The corresponding epimers with the 3 - hydroxy group in the beta - position were also effective but less potent ( ED50 values , 33 . 8 - 63 . 5 , i . p . ) .
Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine seizures , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for seizure protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative toxicity .	Although the neuroactive steroids were considerably less potent than the benzodiazepine clonazepam in protecting against pilocarpine disease* seizures *disease , steroids with the 5 alpha , 3 alpha - configuration had comparable or higher protective index values ( TD50 for motor impairment divided by ED50 for disease* seizure *disease protection ) than clonazepam , indicating that some neuroactive steroids may have lower relative disease* toxicity *disease .
Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic seizures induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the seizures .	Steroids with the 5 alpha , 3 alpha - or 5 beta , 3 alpha - configurations also produced a dose - dependent delay in the onset of limbic disease* seizures *disease induced by kainic acid ( 32 mg / kg , s . c . ) , but did not completely protect against the disease* seizures *disease .
However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic seizures and status epilepticus was obtained .	However , when a second dose of the steroid was administered 1 hr after the first dose , complete protection from the kainic acid - induced limbic disease* seizures *disease and disease* status epilepticus *disease was obtained .
The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA seizures or lethality .	The steroids also caused a dose - dependent delay in NMDA ( 257 mg / kg , s . c . ) - induced lethality , but did not completely protect against NMDA disease* seizures *disease or lethality .
We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced seizures and status epilepticus in mice , and may be of utility in the treatment of some forms of status epilepticus in humans .	We conclude that neuroactive steroids are highly effective in protecting against pilocarpine - and kainic acid - induced disease* seizures *disease and disease* status epilepticus *disease in mice , and may be of utility in the treatment of some forms of disease* status epilepticus *disease in humans .
Hepatic and extrahepatic angiotensinogen gene expression in rats with acute nephrotic syndrome .	Hepatic and extrahepatic angiotensinogen gene expression in rats with acute disease* nephrotic syndrome *disease .
Plasma concentration and urine excretion of the renin - angiotensin system proteins are altered in rats with nephrotic syndrome ( NS ) .	Plasma concentration and urine excretion of the renin - angiotensin system proteins are altered in rats with disease* nephrotic syndrome *disease ( disease* NS *disease ) .
In this work the messenger ribonucleic acid ( mRNA ) levels of angiotensinogen ( Ao ) were analyzed with the slot - blot hybridization technique in liver and other extrahepatic tissues : kidney , heart , brain , and adrenal gland from control , nephrotic , and pair - fed ( PF ) rats .	In this work the messenger ribonucleic acid ( mRNA ) levels of angiotensinogen ( Ao ) were analyzed with the slot - blot hybridization technique in liver and other extrahepatic tissues : kidney , heart , brain , and adrenal gland from control , disease* nephrotic *disease , and pair - fed ( PF ) rats .
NS was induced by a single injection of puromycin amino - nucleoside ( PAN ) .	disease* NS *disease was induced by a single injection of puromycin amino - nucleoside ( PAN ) .
Although a great urinary excretion and half - normal plasma levels of Ao were observed on day 6 after PAN injection , when NS was clearly established , hepatic Ao mRNA levels did not change .	Although a great urinary excretion and half - normal plasma levels of Ao were observed on day 6 after PAN injection , when disease* NS *disease was clearly established , hepatic Ao mRNA levels did not change .
Furthermore , the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6 , nor did its hepatic levels at days 1 , 3 , 5 , or 7 after PAN injection .	Furthermore , the Ao mRNA levels did not change in any of the extrahepatic tissues studied on day 6 , nor did its hepatic levels at days 1 , 3 , 5 , or 7 after PAN injection .
These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute NS induced by PAN .	These data suggest that the hepatic and extrahepatic Ao mRNA levels are unaltered during the development of the acute disease* NS *disease induced by PAN .
Neuroleptic malignant syndrome with risperidone .	disease* Neuroleptic malignant syndrome *disease with risperidone .
Neuroleptic malignant syndrome is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia .	disease* Neuroleptic malignant syndrome *disease is thought to be a result of dopamine D2 receptor blockade in the striatum of the basal ganglia .
Risperidone , a benzisoxazole derivative antipsychotic , has high serotonin 5 - HT2 receptor blockade and dose - related D2 receptor blockade .	Risperidone , a benzisoxazole derivative antipsychotic , has high serotonin 5 - HT2 receptor blockade and dose - related D2 receptor blockade .
The high ratio is believed to impart the low frequency of extrapyramidal symptoms with risperidone at low dosages .	The high ratio is believed to impart the low frequency of disease* extrapyramidal symptoms *disease with risperidone at low dosages .
With this low frequency of extrapyramidal symptoms , it was thought the frequency of neuroleptic malignant syndrome might also be lowered .	With this low frequency of disease* extrapyramidal symptoms *disease , it was thought the frequency of disease* neuroleptic malignant syndrome *disease might also be lowered .
A 73 - year - old woman developed neuroleptic malignant syndrome after monotherapy with risperidone .	A 73 - year - old woman developed disease* neuroleptic malignant syndrome *disease after monotherapy with risperidone .
The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine .	The syndrome reversed after discontinuing risperidone and starting treatment with dantrolene and bromocriptine .
It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from neuroleptic malignant syndrome .	It appears that the protection from extrapyramidal side effects observed with risperidone does not ensure protection from disease* neuroleptic malignant syndrome *disease .
The attenuating effect of carteolol hydrochloride , a beta - adrenoceptor antagonist , on neuroleptic - induced catalepsy in rats .	The attenuating effect of carteolol hydrochloride , a beta - adrenoceptor antagonist , on neuroleptic - induced disease* catalepsy *disease in rats .
It is known that beta - adrenoceptor antagonists are effective in the treatment of akathisia , one of the extrapyramidal side effects that occur during neuroleptic treatment .	It is known that beta - adrenoceptor antagonists are effective in the treatment of disease* akathisia *disease , one of the extrapyramidal side effects that occur during neuroleptic treatment .
Neuroleptic - induced catalepsy , a model of neuroleptic - induced extrapyramidal side effects , was considered suitable as a model for predicting neuroleptic - induced akathisia in humans , although neuroleptic - induced catalepsy was not considered a specific test for neuroleptic - induced akathisia .	Neuroleptic - induced disease* catalepsy *disease , a model of neuroleptic - induced extrapyramidal side effects , was considered suitable as a model for predicting neuroleptic - induced disease* akathisia *disease in humans , although neuroleptic - induced disease* catalepsy *disease was not considered a specific test for neuroleptic - induced disease* akathisia *disease .
Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced catalepsy in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .	Therefore , the effects of carteolol , a beta - adrenoceptor antagonist , on haloperidol - induced disease* catalepsy *disease in rats were behaviorally studied and compared with those of propranolol and biperiden , a muscarinic receptor antagonist .
Carteolol , as well as propranolol and biperiden , inhibited the haloperidol - induced catalepsy .	Carteolol , as well as propranolol and biperiden , inhibited the haloperidol - induced disease* catalepsy *disease .
The inhibitory effect of carteolol was almost comparable to that of propranolol , but was weaker than that of biperiden .	The inhibitory effect of carteolol was almost comparable to that of propranolol , but was weaker than that of biperiden .
Carteolol did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and hyperlocomotion in rats .	Carteolol did not evoke postsynaptic dopamine receptor - stimulating behavioral signs such as stereotypy and disease* hyperlocomotion *disease in rats .
Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine - induced stereotypy and locomotor activity in rats .	Carteolol did not antagonize the inhibitory effects of haloperidol on apomorphine - induced stereotypy and locomotor activity in rats .
In addition , carteolol did not evoke 5 - HT1A receptor - stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5 - hydroxytryptophan - induced head twitch in rats .	In addition , carteolol did not evoke 5 - HT1A receptor - stimulating behavioral signs such as flat body posture and forepaw treading and did not inhibit 5 - hydroxytryptophan - induced head twitch in rats .
Finally , carteolol did not inhibit physostigmine - induced lethality in rats .	Finally , carteolol did not inhibit physostigmine - induced lethality in rats .
These results strongly suggest that carteolol improves haloperidol - induced catalepsy via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of akathisia without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .	These results strongly suggest that carteolol improves haloperidol - induced disease* catalepsy *disease via its beta - adrenoceptor antagonistic activity and is expected to be effective in the treatment of disease* akathisia *disease without attenuating neuroleptic - induced antipsychotic effects due to its postsynaptic dopamine receptor antagonistic activity .
Granulosa cell tumor of the ovary associated with antecedent tamoxifen use .	disease* Granulosa cell tumor of the ovary *disease associated with antecedent tamoxifen use .
BACKGROUND : Increased attention has been focused recently on the estrogenic effects of tamoxifen .	BACKGROUND : Increased attention has been focused recently on the estrogenic effects of tamoxifen .
Review of the literature reveals an association between tamoxifen use and gynecologic tumors .	Review of the literature reveals an association between tamoxifen use and gynecologic disease* tumors *disease .
CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive breast carcinoma .	CASE : A 52 - year - old postmenopausal woman was treated with tamoxifen for stage II estrogen receptor - positive disease* breast carcinoma *disease .
Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use .	Her aspartate transaminase and alanine transaminase levels increase markedly after 6 months of tamoxifen use .
After an additional 17 months of elevated serum transaminases , the patient was found to have a stage Ic granulosa cell tumor of the ovary .	After an additional 17 months of elevated serum transaminases , the patient was found to have a stage Ic disease* granulosa cell tumor of the ovary *disease .
CONCLUSION : Patients with tamoxifen - induced liver dysfunction may be at increased risk for granulosa cell tumors because of alterations in tamoxifen metabolism .	CONCLUSION : Patients with tamoxifen - induced disease* liver dysfunction *disease may be at increased risk for disease* granulosa cell tumors *disease because of alterations in tamoxifen metabolism .
Lifetime treatment of mice with azidothymidine ( AZT ) produces myelodysplasia .	Lifetime treatment of mice with azidothymidine ( AZT ) produces disease* myelodysplasia *disease .
AZT has induced a macrocytic anemia in AIDS patients on long term AZT therapy .	AZT has induced a disease* macrocytic anemia *disease in disease* AIDS *disease patients on long term AZT therapy .
It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation .	It is generally assumed that DNA elongation is stopped by the insertion of AZT into the chain in place of thymidine thus preventing the phosphate hydroxyl linkages and therefore suppresses hemopoietic progenitor cell proliferation in an early stage of differentiation .
CBA / Ca male mice started on AZT 0 . 75 mg / ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0 . 5 mg / ml H2O for a group , another group removed from AZT to see recovery , and third group remained on 0 . 75 mg .	CBA / Ca male mice started on AZT 0 . 75 mg / ml H2O at 84 days of age and kept on it for 687 days when dosage reduced to 0 . 5 mg / ml H2O for a group , another group removed from AZT to see recovery , and third group remained on 0 . 75 mg .
At 687 days mice that had been on 0 . 75 mg had average platelet counts of 2 . 5 x 10 ( 6 ) .	At 687 days mice that had been on 0 . 75 mg had average platelet counts of 2 . 5 x 10 ( 6 ) .
Histological examination on 9 of 10 mice with such thrombocytopenia showed changes compatible with myelodysplastic syndrome ( MDS ) .	Histological examination on 9 of 10 mice with such disease* thrombocytopenia *disease showed changes compatible with disease* myelodysplastic syndrome *disease ( disease* MDS *disease ) .
A variety of histological patterns was observed .	A variety of histological patterns was observed .
There were two cases of hypocellular myelodysplasia , two cases of hypersegmented myelodysplastic granulocytosis , two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei , one case of megakaryocytic myelosis associated with a hyperplastic marrow , dysmyelopoiesis and a hypocellular marrow and two cases of myelodysplasia with dyserythropoiesis , hemosiderosis and a hypocellular marrow .	There were two cases of hypocellular disease* myelodysplasia *disease , two cases of hypersegmented disease* myelodysplastic *disease granulocytosis , two cases of hypercellular marrow with abnormal megakaryocytes with bizarre nuclei , one case of megakaryocytic myelosis associated with a disease* hyperplastic marrow *disease , disease* dysmyelopoiesis *disease and a disease* hypocellular marrow *disease and two cases of disease* myelodysplasia *disease with disease* dyserythropoiesis *disease , disease* hemosiderosis *disease and a disease* hypocellular marrow *disease .
Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the myelodysplastic syndrome .	Above mentioned AZT incorporation may have induced an ineffective hemopoiesis in the primitive hemopoietic progenitor cells , which is known to be seen commonly in the disease* myelodysplastic syndrome *disease .
Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine .	Biphasic response of the SA node of the dog heart in vivo to selective administration of ketamine .
Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery .	Effect of ketamine on the SA node of the dog heart was studied in vivo using a selective perfusion technique of the SA node artery .
Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a depression of the SA nodal activity by a direct action .	Injections of ketamine in doses from 100 microgram to 3 mg into the artery produced a disease* depression *disease of the SA nodal activity by a direct action .
This depression was followed by the sudden appearance of a stimulatory phase .	This disease* depression *disease was followed by the sudden appearance of a stimulatory phase .
Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine - induced tachycardia , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .	Bilateral vagotomy and sympathectomy or prior administration of a ganglion blocker failed to inhibit the occurrence of the ketamine - induced disease* tachycardia *disease , while it was completely abolished in the reserpinized dogs or by a prior injection of a beta - blocking agent into the SA node artery .
This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery .	This may indicate that an activation of the peripheral adrenergic mechanism plays an important role in the induction of the excitatory effect of ketamine injected in the SA node artery .
Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat pituitary tumors may mediate estrogen - initiated tumor angiogenesis .	Over expression of vascular endothelial growth factor and its receptor during the development of estrogen - induced rat disease* pituitary tumors *disease may mediate estrogen - initiated disease* tumor *disease angiogenesis .
Estrogens , which have been associated with several types of human and animal cancers , can induce tumor angiogenesis in the pituitary of Fischer 344 rats .	Estrogens , which have been associated with several types of human and animal disease* cancers *disease , can induce disease* tumor *disease angiogenesis in the pituitary of Fischer 344 rats .
The mechanistic details of tumor angiogenesis induction , during estrogen carcinogenesis , are still unknown .	The mechanistic details of disease* tumor *disease angiogenesis induction , during estrogen disease* carcinogenesis *disease , are still unknown .
To elucidate the role of estrogen in the regulation of tumor angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .	To elucidate the role of estrogen in the regulation of disease* tumor *disease angiogenesis in the pituitary of female rats , the density of blood vessels was analysed using factor VIII related antigen ( FVIIIRAg ) immunohistochemistry and the expression of vascular endothelial growth factor / vascular permeability factor ( VEGF / VPF ) was examined by Western blot and immunohistochemical analysis .
The expression of VEGF receptor ( VEGFR - 2 / Flk - 1 / KDR ) was also examined by immunohistochemistry .	The expression of VEGF receptor ( VEGFR - 2 / Flk - 1 / KDR ) was also examined by immunohistochemistry .
The results demonstrated that 17beta - estradiol ( E2 ) induces neovascularization , as well as the growth and enlargement of blood vessels after 7 days of exposure .	The results demonstrated that 17beta - estradiol ( E2 ) induces neovascularization , as well as the growth and enlargement of blood vessels after 7 days of exposure .
The high tumor angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .	The high disease* tumor *disease angiogenic potential was associated with an elevated VEGF / VPF protein expression in the E2 exposed pituitary of ovariectomized ( OVEX ) rats .
VEGF / VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin ( UEA1 ) binding studies , indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non - endothelial cells .	VEGF / VPF and FVIIIRAg immunohistochemistry and endothelial specific lectin ( UEA1 ) binding studies , indicate that the elevation of VEGF protein expression initially occurred in both blood vessels and non - endothelial cells .
After 15 days of E2 exposure , VEGF / VPF protein expression , in the non - endothelial cell population , sharply declined and was restricted to the blood vessels .	After 15 days of E2 exposure , VEGF / VPF protein expression , in the non - endothelial cell population , sharply declined and was restricted to the blood vessels .
The function of non - endothelial - derived VEGF is not clear .	The function of non - endothelial - derived VEGF is not clear .
Furthermore , immunohistochemical studies demonstrated that VEGFR - 2 ( flk - 1 / KDR ) , expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure .	Furthermore , immunohistochemical studies demonstrated that VEGFR - 2 ( flk - 1 / KDR ) , expression was elevated significantly in the endothelial cells of microblood vessels after 7 days of E2 exposure .
These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced tumor angiogenesis in the rat pituitary .	These findings suggest that over expression of VEGF and its receptor ( VEGFR - 2 ) may play an important role in the initial step of the regulation of estrogen induced disease* tumor *disease angiogenesis in the rat pituitary .
Persistent nephrogenic diabetes insipidus following lithium therapy .	Persistent disease* nephrogenic diabetes insipidus *disease following lithium therapy .
We report the case of a patient who developed severe hypernatraemic dehydration following a head injury .	We report the case of a patient who developed severe hypernatraemic disease* dehydration *disease following a disease* head injury *disease .
Ten years previously he had been diagnosed to have lithium - induced nephrogenic diabetes insipidus , and lithium therapy had been discontinued .	Ten years previously he had been diagnosed to have lithium - induced disease* nephrogenic diabetes insipidus *disease , and lithium therapy had been discontinued .
He remained thirsty and polyuric despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of nephrogenic diabetes insipidus .	He remained thirsty and disease* polyuric *disease despite cessation of lithium and investigations on admission showed him to have normal osmoregulated thirst and vasopressin secretion , with clear evidence of disease* nephrogenic diabetes insipidus *disease .
Lithium induced nephrogenic diabetes insipidus is considered to be reversible on cessation of therapy but polyuria persisted in this patient for ten years after lithium was stopped .	Lithium induced disease* nephrogenic diabetes insipidus *disease is considered to be reversible on cessation of therapy but disease* polyuria *disease persisted in this patient for ten years after lithium was stopped .
We discuss the possible renal mechanisms and the implications for management of patients with lithium - induced nephrogenic diabetes insipidus .	We discuss the possible renal mechanisms and the implications for management of patients with lithium - induced disease* nephrogenic diabetes insipidus *disease .
Effects of NIK - 247 on cholinesterase and scopolamine - induced amnesia .	Effects of NIK - 247 on cholinesterase and scopolamine - induced disease* amnesia *disease .
The effects of NIK - 247 on cholinesterase , scopolamine - induced amnesia and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .	The effects of NIK - 247 on cholinesterase , scopolamine - induced disease* amnesia *disease and spontaneous movement were examined and compared with those of the well - known cholinesterase inhibitors tacrine and E - 2020 .
NIK - 247 , tacrine and E - 2020 all strongly inhibited acetylcholinesterase ( AChE ) in human red blood cells ( IC50s = 1 . 0 x 10 ( - 6 ) , 2 . 9 x 10 ( - 7 ) and 3 . 7 x 10 ( - 8 ) M , respectively ) .	NIK - 247 , tacrine and E - 2020 all strongly inhibited acetylcholinesterase ( AChE ) in human red blood cells ( IC50s = 1 . 0 x 10 ( - 6 ) , 2 . 9 x 10 ( - 7 ) and 3 . 7 x 10 ( - 8 ) M , respectively ) .
In addition , NIK - 247 and tacrine , but not E - 2020 , strongly inhibited butyrylcholinestrase ( BuChE ) in human serum .	In addition , NIK - 247 and tacrine , but not E - 2020 , strongly inhibited butyrylcholinestrase ( BuChE ) in human serum .
All three drugs produced mixed inhibition of AChE activity .	All three drugs produced mixed inhibition of AChE activity .
Moreover , the inhibitory effect of NIK - 247 on AChE was reversible .	Moreover , the inhibitory effect of NIK - 247 on AChE was reversible .
All compounds at 0 . 1 - 1 mg / kg p . o . significantly improved the amnesia induced by scopolamine ( 0 . 5 mg / kg s . c . ) in rats performing a passive avoidance task .	All compounds at 0 . 1 - 1 mg / kg p . o . significantly improved the disease* amnesia *disease induced by scopolamine ( 0 . 5 mg / kg s . c . ) in rats performing a passive avoidance task .
The three compounds at 1 and 3 mg / kg p . o . did not significantly decrease spontaneous movement by rats .	The three compounds at 1 and 3 mg / kg p . o . did not significantly decrease spontaneous movement by rats .
These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced amnesia but does not affect spontaneous movement .	These findings suggest that NIK - 247 at a low dose ( 0 . 1 - 1 mg / kg p . o . ) improves scopolamine - induced disease* amnesia *disease but does not affect spontaneous movement .
The findings suggest that NIK - 247 may be a useful drug for the treatment of Alzheimer ' s disease .	The findings suggest that NIK - 247 may be a useful drug for the treatment of disease* Alzheimer ' s disease *disease .
Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in parkinsonian levodopa - primed monkeys .	Potential therapeutic use of the selective dopamine D1 receptor agonist , A - 86929 : an acute study in disease* parkinsonian *disease levodopa - primed monkeys .
The clinical utility of dopamine ( DA ) D1 receptor agonists in the treatment of Parkinson ' s disease ( PD ) is still unclear .	The clinical utility of dopamine ( DA ) D1 receptor agonists in the treatment of disease* Parkinson ' s disease *disease ( disease* PD *disease ) is still unclear .
The therapeutic use of selective DA D1 receptor agonists such as SKF - 82958 ( 6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide ) and A - 77636 ( [ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride ) seems limited because of their duration of action , which is too short for SKF - 82958 ( < 1 hr ) and too long for A - 77636 ( > 20 hr , leading to behavioral tolerance ) .	The therapeutic use of selective DA D1 receptor agonists such as SKF - 82958 ( 6 - chloro - 7 , 8 - dihydroxy - 3 - allyl - 1 - phenyl - 2 , 3 , 4 , 5 - tetrahydro - 1H - 3 - benzaze pine hydrobromide ) and A - 77636 ( [ 1R , 3S ] 3 - [ 1 ' - admantyl ] - 1 - aminomethyl - 3 , 4 - dihydro - 5 , 6 - dihydroxy - 1H - 2 - benzo pyran hydrochloride ) seems limited because of their duration of action , which is too short for SKF - 82958 ( < 1 hr ) and too long for A - 77636 ( > 20 hr , leading to behavioral tolerance ) .
We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced dyskinesias to evaluate the locomotor and dyskinetic effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .	We therefore conducted the present acute dose - response study in four 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( MPTP ) - exposed cynomolgus monkeys primed to exhibit levodopa - induced disease* dyskinesias *disease to evaluate the locomotor and disease* dyskinetic *disease effects on challenge with four doses ( from 0 . 03 to 1 . 0 mg / kg ) of A - 86929 ( [ - ] - [ 5aR , 11bS ] - 4 , 5 , 5a , 6 , 7 , 11b - hexahydro - 2 - propyl - 3 - thia - 5 - + + + azacyclopent - 1 - ena [ c ] phenathrene - 9 - 10 - diol ) , a selective and full DA D1 - like receptor agonist with an intermediate duration of action .
Levodopa and the DA D2 - like receptor agonist , LY - 171555 ( [ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride ) were also used for comparison .	Levodopa and the DA D2 - like receptor agonist , LY - 171555 ( [ 4aR - trans ] - 4 , 4a , 5 , 6 , 7 , 8 , 8a , 9 - o - dihydro - 5n - propyl - 2H - pyrazo lo - 3 - 4 - quinoline hydrochloride ) were also used for comparison .
Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced parkinsonism as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced dyskinesias in these animals than with either LY - 171555 or subsequent challenge of levodopa .	Acute administration of A - 86929 was as efficacious in alleviating MPTP - induced disease* parkinsonism *disease as levodopa and LY - 171555 , but was less likely to reproduce the levodopa - induced disease* dyskinesias *disease in these animals than with either LY - 171555 or subsequent challenge of levodopa .
Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus ( referred to as the basal ganglia output ) compared with levodopa and selective DA D2 receptor agonist .	Selective stimulation of the DA D1 receptor may provide better integration of neural inputs transmitted to the internal segment of the globus pallidus ( referred to as the basal ganglia output ) compared with levodopa and selective DA D2 receptor agonist .
Potent DA D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in PD and merit further attention .	Potent DA D1 receptor agents with an intermediate duration of efficacy such as A - 86929 ( approximately 4 hr at higher doses tested ) are potential therapeutic tools in disease* PD *disease and merit further attention .
Neuropeptide - Y immunoreactivity in the pilocarpine model of temporal lobe epilepsy .	Neuropeptide - Y immunoreactivity in the pilocarpine model of disease* temporal lobe epilepsy *disease .
Neuropeptide - Y ( NPY ) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental temporal lobe epilepsy ( TLE ) .	Neuropeptide - Y ( NPY ) is expressed by granule cells and mossy fibres of the hippocampal dentate gyrus during experimental disease* temporal lobe epilepsy *disease ( disease* TLE *disease ) .
This expression may represent an endogenous damping mechanism since NPY has been shown to block seizure - like events following high - frequency stimulation in hippocampal slices .	This expression may represent an endogenous damping mechanism since NPY has been shown to block disease* seizure *disease - like events following high - frequency stimulation in hippocampal slices .
The pilocarpine ( PILO ) model of epilepsy is characterized by an acute period of status epilepticus followed by spontaneous recurrent seizures and related brain damage .	The pilocarpine ( PILO ) model of disease* epilepsy *disease is characterized by an acute period of disease* status epilepticus *disease followed by spontaneous recurrent disease* seizures *disease and related disease* brain damage *disease .
We report peroxidase - antiperoxidase immunostaining for NPY in several brain regions in this model .	We report peroxidase - antiperoxidase immunostaining for NPY in several brain regions in this model .
PILO - injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals , in the dentate gyrus inner molecular layer and , in a few cases , within presumed granule cells .	PILO - injected animals exhibited NPY immunoreactivity in the region of the mossy fibre terminals , in the dentate gyrus inner molecular layer and , in a few cases , within presumed granule cells .
NPY immunoreactivity was also dramatically changed in the entorhinal cortex , amygdala and sensorimotor areas .	NPY immunoreactivity was also dramatically changed in the entorhinal cortex , amygdala and sensorimotor areas .
In addition , PILO injected animals exhibited a reduction in the number of NPY - immunoreactive interneurons compared with controls .	In addition , PILO injected animals exhibited a reduction in the number of NPY - immunoreactive interneurons compared with controls .
The results demonstrate that changes in NPY expression , including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons , are present in the PILO model of TLE .	The results demonstrate that changes in NPY expression , including expression in the granule cells and mossy fibres and the loss of vulnerable NPY neurons , are present in the PILO model of disease* TLE *disease .
However , the significance of this changed synthesis of NPY remains to be determined .	However , the significance of this changed synthesis of NPY remains to be determined .
Posteroventral medial pallidotomy in advanced Parkinson ' s disease .	Posteroventral medial pallidotomy in advanced disease* Parkinson ' s disease *disease .
BACKGROUND : Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced Parkinson ' s disease , but the studies to date have involved small numbers of patients and short - term follow - up .	BACKGROUND : Posteroventral medial pallidotomy sometimes produces striking improvement in patients with advanced disease* Parkinson ' s disease *disease , but the studies to date have involved small numbers of patients and short - term follow - up .
METHODS : Forty patients with Parkinson ' s disease underwent serial , detailed assessments both after drug withdrawal ( " off " period ) and while taking their optimal medical regimens ( " on " period ) .	METHODS : Forty patients with disease* Parkinson ' s disease *disease underwent serial , detailed assessments both after drug withdrawal ( " off " period ) and while taking their optimal medical regimens ( " on " period ) .
All patients were examined preoperatively and 39 were examined at six months ; 27 of the patients were also examined at one year , and 11 at two years .	All patients were examined preoperatively and 39 were examined at six months ; 27 of the patients were also examined at one year , and 11 at two years .
RESULTS : The percent improvements at six months were as follows : off - period score for overall motor function , 28 percent ( 95 percent confidence interval , 19 to 38 percent ) , with most of the improvement in the contralateral limbs ; off - period score for activities of daily living , 29 percent ( 95 percent confidence interval , 19 to 39 percent ) ; on - period score for contralateral dyskinesias , 82 percent ( 95 percent confidence interval , 72 to 91 percent ) ; and on - period score for ipsilateral dyskinesias , 44 percent ( 95 percent confidence interval , 29 to 59 percent ) .	RESULTS : The percent improvements at six months were as follows : off - period score for overall motor function , 28 percent ( 95 percent confidence interval , 19 to 38 percent ) , with most of the improvement in the contralateral limbs ; off - period score for activities of daily living , 29 percent ( 95 percent confidence interval , 19 to 39 percent ) ; on - period score for contralateral disease* dyskinesias *disease , 82 percent ( 95 percent confidence interval , 72 to 91 percent ) ; and on - period score for ipsilateral disease* dyskinesias *disease , 44 percent ( 95 percent confidence interval , 29 to 59 percent ) .
The improvements in dyskinesias and the total scores for off - period parkinsonism , contralateral bradykinesia , and rigidity were sustained in the 11 patients examined at two years .	The improvements in disease* dyskinesias *disease and the total scores for off - period disease* parkinsonism *disease , contralateral disease* bradykinesia *disease , and disease* rigidity *disease were sustained in the 11 patients examined at two years .
The improvement in ipsilateral dyskinesias was lost after one year , and the improvements in postural stability and gait lasted only three to six months .	The improvement in ipsilateral disease* dyskinesias *disease was lost after one year , and the improvements in postural stability and gait lasted only three to six months .
Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery .	Approximately half the patients who had been dependent on assistance in activities of daily living in the off period before surgery became independent after surgery .
The complications of surgery were generally well tolerated , and there were no significant changes in the use of medication .	The complications of surgery were generally well tolerated , and there were no significant changes in the use of medication .
CONCLUSIONS : In late - stage Parkinson ' s disease , pallidotomy significantly reduces levodopa - induced dyskinesias and off - period disability .	CONCLUSIONS : In late - stage disease* Parkinson ' s disease *disease , pallidotomy significantly reduces levodopa - induced disease* dyskinesias *disease and off - period disability .
Much of the benefit is sustained at two years , although some improvements , such as those on the ipsilateral side and in axial symptoms , wane within the first year .	Much of the benefit is sustained at two years , although some improvements , such as those on the ipsilateral side and in axial symptoms , wane within the first year .
The on - period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy .	The on - period symptoms that are resistant to dopaminergic therapy do not respond to pallidotomy .
Clarithromycin - induced ventricular tachycardia .	Clarithromycin - induced disease* ventricular tachycardia *disease .
Clarithromycin is a relatively new macrolide antibiotic that offers twice - daily dosing .	Clarithromycin is a relatively new macrolide antibiotic that offers twice - daily dosing .
It differs from erythromycin only in the methylation of the hydroxyl group at position 6 .	It differs from erythromycin only in the methylation of the hydroxyl group at position 6 .
Although the side - effect profile of erythromycin is established , including gastroenteritis and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer macrolides is still being recorded .	Although the side - effect profile of erythromycin is established , including disease* gastroenteritis *disease and interactions with other drugs subject to hepatic mixed - function oxidase metabolism , experience with the newer macrolides is still being recorded .
Cardiotoxicity has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides .	disease* Cardiotoxicity *disease has been demonstrated after both intravenous and oral administration of erythromycin but has never been reported with the newer macrolides .
We report a case of ventricular dysrhythmias that occurred after six therapeutic doses of clarithromycin .	We report a case of disease* ventricular dysrhythmias *disease that occurred after six therapeutic doses of clarithromycin .
The dysrhythmias resolved after discontinuation of the drug .	The disease* dysrhythmias *disease resolved after discontinuation of the drug .
Effect of glyceryl trinitrate on the sphincter of Oddi spasm evoked by prostigmine - morphine administration .	Effect of glyceryl trinitrate on the disease* sphincter of Oddi spasm *disease evoked by prostigmine - morphine administration .
OBJECTIVE : In this study the effect of glyceryl trinitrate on the prostigmine - morphine - induced sphincter of Oddi spasm was evaluated in nine female patients with sphincter of Oddi dyskinesia .	OBJECTIVE : In this study the effect of glyceryl trinitrate on the prostigmine - morphine - induced disease* sphincter of Oddi spasm *disease was evaluated in nine female patients with disease* sphincter of Oddi dyskinesia *disease .
METHOD : Sphincter of Oddi spasm was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .	METHOD : disease* Sphincter of Oddi spasm *disease was induced by prostigmine - morphine administration ( 0 . 5 mg prostigmine intramuscularly and 10 mg morphine subcutaneously ) and visualized by quantitative hepatobiliary scintigraphy .
The entire procedure was repeated during glyceryl trinitrate infusion ( Nitrolingual 1 microg / kg / min for 120 min ) .	The entire procedure was repeated during glyceryl trinitrate infusion ( Nitrolingual 1 microg / kg / min for 120 min ) .
RESULTS : Prostigmine - morphine provocation caused significant increases in the time to peak activity ( Tmax ) over the hepatic hilum ( HH : 34 . 33 + / - 5 . 05 vs . 22 . 77 + / - 3 . 26 ) and the common bile duct ( CBD : 60 . 44 + / - 5 . 99 vs . 40 . 0 + / - 2 . 88 ) and in the half - time of excretion ( T1 / 2 ) over the liver parenchyma ( LP : 120 . 04 + / - 16 . 01 vs . 27 . 37 + / - 2 . 19 ) , HH ( 117 . 61 + / - 14 . 71 vs . 31 . 85 + / - 3 . 99 ) and CBD ( 158 . 11 + / - 9 . 18 vs . 40 . 1 + / - 6 . 24 ) , indicating a complete spasm at the level of the sphincter of Oddi .	RESULTS : Prostigmine - morphine provocation caused significant increases in the time to peak activity ( Tmax ) over the hepatic hilum ( HH : 34 . 33 + / - 5 . 05 vs . 22 . 77 + / - 3 . 26 ) and the common bile duct ( CBD : 60 . 44 + / - 5 . 99 vs . 40 . 0 + / - 2 . 88 ) and in the half - time of excretion ( T1 / 2 ) over the liver parenchyma ( LP : 120 . 04 + / - 16 . 01 vs . 27 . 37 + / - 2 . 19 ) , HH ( 117 . 61 + / - 14 . 71 vs . 31 . 85 + / - 3 . 99 ) and CBD ( 158 . 11 + / - 9 . 18 vs . 40 . 1 + / - 6 . 24 ) , indicating a complete disease* spasm *disease at the level of the sphincter of Oddi .
Glyceryl trinitrate infusion completely normalized the prostigmine - morphine - induced alterations in these quantitative parameters ( TmaX over the LP : 11 . 33 + / - 1 . 13 ; over the HH : 18 . 88 + / - 1 . 48 ; and over the CBD : 36 . 22 + / - 1 . 92 ; and T1 / 2 over the LP : 28 . 21 + / - 1 . 83 ; over the HH : 33 . 42 + / - 3 . 10 ; and over the CBD : 41 . 66 + / - 6 . 33 ) , suggesting an effective sphincter - relaxing effect of glyceryl trinitrate .	Glyceryl trinitrate infusion completely normalized the prostigmine - morphine - induced alterations in these quantitative parameters ( TmaX over the LP : 11 . 33 + / - 1 . 13 ; over the HH : 18 . 88 + / - 1 . 48 ; and over the CBD : 36 . 22 + / - 1 . 92 ; and T1 / 2 over the LP : 28 . 21 + / - 1 . 83 ; over the HH : 33 . 42 + / - 3 . 10 ; and over the CBD : 41 . 66 + / - 6 . 33 ) , suggesting an effective sphincter - relaxing effect of glyceryl trinitrate .
CONCLUSION : These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine - induced sphincter of Oddi spasm in humans .	CONCLUSION : These results provide the first evidence of the effectiveness of glyceryl trinitrate on the morphine - induced disease* sphincter of Oddi spasm *disease in humans .
Since glyceryl trinitrate is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of sphincter of Oddi dyskinesia .	Since glyceryl trinitrate is able to overcome even the drastic effect of morphine , it might be of relevance in the treatment of disease* sphincter of Oddi dyskinesia *disease .
Immunopathology of penicillamine - induced glomerular disease .	Immunopathology of penicillamine - induced disease* glomerular disease *disease .
Four patients with rheumatoid arthritis developed heavy proteinuria after five to 12 months of treatment with D - penicillamine .	Four patients with disease* rheumatoid arthritis *disease developed heavy disease* proteinuria *disease after five to 12 months of treatment with D - penicillamine .
Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase , or no departure from normal .	Light microscopy of renal biopsy samples showed minimal glomerular capillary wall thickening and mesangial matrix increase , or no departure from normal .
Electron microscopy , however , revealed subepithelial electron - dense deposits , fusion of epithelial cell foot processes , and evidence of mesangial cell hyperactivity .	Electron microscopy , however , revealed subepithelial electron - dense deposits , fusion of epithelial cell foot processes , and evidence of mesangial cell hyperactivity .
Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3 .	Immunofluorescence microscopy demonstrated granular capillary wall deposits of IgG and C3 .
The findings were similar to those in early membranous glomerulonephritis , differences being observed however in the results of staining for the early - acting complement components C1q and C4 .	The findings were similar to those in early disease* membranous glomerulonephritis *disease , differences being observed however in the results of staining for the early - acting complement components C1q and C4 .
It is tentatively concluded that complement was activated by the classical pathway .	It is tentatively concluded that complement was activated by the classical pathway .
Experimental cranial pain elicited by capsaicin : a PET study .	Experimental cranial disease* pain *disease elicited by capsaicin : a PET study .
Using a positron emission tomography ( PET ) study it was shown recently that in migraine without aura certain areas in the brain stem were activated during the headache state , but not in the headache free interval .	Using a positron emission tomography ( PET ) study it was shown recently that in disease* migraine *disease without aura certain areas in the brain stem were activated during the disease* headache *disease state , but not in the disease* headache *disease free interval .
It was suggested that this brain stem activation is inherent to the migraine attack itself and represents the so called ' migraine generator ' .	It was suggested that this brain stem activation is inherent to the disease* migraine *disease attack itself and represents the so called ' disease* migraine *disease generator ' .
To test this hypothesis we performed an experimental pain study in seven healthy volunteers , using the same positioning in the PET scanner as in the migraine patients .	To test this hypothesis we performed an experimental disease* pain *disease study in seven healthy volunteers , using the same positioning in the PET scanner as in the disease* migraine *disease patients .
A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning painful sensation in the first division of the trigeminal nerve .	A small amount of capsaicin was administered subcutaneously in the right forehead to evoke a burning disease* painful *disease sensation in the first division of the trigeminal nerve .
Increases of regional cerebral blood flow ( rCBF ) were found bilaterally in the insula , in the anterior cingulate cortex , the cavernous sinus and the cerebellum .	Increases of regional cerebral blood flow ( rCBF ) were found bilaterally in the insula , in the anterior cingulate cortex , the cavernous sinus and the cerebellum .
Using the same stereotactic space limits as in the above mentioned migraine study no brain stem activation was found in the acute pain state compared to the pain free state .	Using the same stereotactic space limits as in the above mentioned disease* migraine *disease study no brain stem activation was found in the acute disease* pain *disease state compared to the disease* pain *disease free state .
The increase of activation in the region of the cavernous sinus however , suggests that this structure is more likely to be involved in trigeminal transmitted pain as such , rather than in a specific type of headache as was suggested for cluster headache .	The increase of activation in the region of the cavernous sinus however , suggests that this structure is more likely to be involved in trigeminal transmitted disease* pain *disease as such , rather than in a specific type of disease* headache *disease as was suggested for disease* cluster headache *disease .
Value of methylprednisolone in prevention of the arthralgia - myalgia syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .	Value of methylprednisolone in prevention of the disease* arthralgia *disease - disease* myalgia *disease syndrome associated with the total dose infusion of iron dextran : a double blind randomized trial .
The safety and efficacy of total dose infusion ( TDI ) of iron dextran has been well documented .	The safety and efficacy of total dose infusion ( TDI ) of iron dextran has been well documented .
In 40 % of treated patients , an arthralgia - myalgia syndrome develops .	In 40 % of treated patients , an disease* arthralgia *disease - disease* myalgia *disease syndrome develops .
The purpose of this randomized , double - blind , prospective study was to investigate whether intravenous ( i . v . ) administration of methylprednisolone ( MP ) prevents this complication .	The purpose of this randomized , double - blind , prospective study was to investigate whether intravenous ( i . v . ) administration of methylprednisolone ( MP ) prevents this complication .
Sixty - five patients , 34 women and 31 men , ages 36 to 80 years , received either normal saline before and after TDI ( group 1 ) , 125 mg i . v . MP before and saline after TDI ( group 2 ) , or 125 mg i . v . MP before and after TDI ( group 3 ) .	Sixty - five patients , 34 women and 31 men , ages 36 to 80 years , received either normal saline before and after TDI ( group 1 ) , 125 mg i . v . MP before and saline after TDI ( group 2 ) , or 125 mg i . v . MP before and after TDI ( group 3 ) .
Patients were observed for 72 hours and reactions were recorded and graded according to severity .	Patients were observed for 72 hours and reactions were recorded and graded according to severity .
Fifty - eight percent of group 1 patients , 33 % of group 2 , and 26 % of group 3 had reactions to TDI .	Fifty - eight percent of group 1 patients , 33 % of group 2 , and 26 % of group 3 had reactions to TDI .
The severity of reactions ( minimal , mild , and moderate , respectively ) was as follows : group 1 - - 6 , 6 , and 2 ; group 2 - - 1 , 5 , and 0 ; group 3 - - 5 , 1 , and 0 .	The severity of reactions ( minimal , mild , and moderate , respectively ) was as follows : group 1 - - 6 , 6 , and 2 ; group 2 - - 1 , 5 , and 0 ; group 3 - - 5 , 1 , and 0 .
Data were analyzed by the two - sided Fisher ' s exact test using 95 % confidence intervals with the approximation of Woolf .	Data were analyzed by the two - sided Fisher ' s exact test using 95 % confidence intervals with the approximation of Woolf .
These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the arthralgia - myalgia syndrome .	These data demonstrate that administration of MP before and after TDI reduces the frequency and severity of the disease* arthralgia *disease - disease* myalgia *disease syndrome .
We conclude that 125 mg i . v . MP should be given routinely before and after TDI of iron dextran .	We conclude that 125 mg i . v . MP should be given routinely before and after TDI of iron dextran .
Prolongation of the QT interval related to cisapride - diltiazem interaction .	disease* Prolongation of the QT interval *disease related to cisapride - diltiazem interaction .
Cisapride , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of gastrointestinal motility disorders .	Cisapride , a cytochrome P450 3A4 ( CYP3A4 ) substrate , is widely prescribed for the treatment of disease* gastrointestinal motility disorders *disease .
Prolongation of QT interval , torsades de pointes , and sudden cardiac death have been reported after concomitant administration with erythromycin or azole antifungal agents , but not with other CYP3A4 inhibitors .	disease* Prolongation of QT interval *disease , disease* torsades de pointes *disease , and disease* sudden cardiac death *disease have been reported after concomitant administration with erythromycin or azole antifungal agents , but not with other CYP3A4 inhibitors .
A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for gastroesophageal reflux disorder and diltiazem , an agent that has inhibitory effect on CYP3A4 , for hypertension .	A possible drug interaction occurred in a 45 - year - old woman who was taking cisapride for disease* gastroesophageal reflux disorder *disease and diltiazem , an agent that has inhibitory effect on CYP3A4 , for disease* hypertension *disease .
The patient was in near syncope and had QT - interval prolongation .	The patient was in near disease* syncope *disease and had disease* QT - interval prolongation *disease .
After discontinuing cisapride , the QT interval returned to normal and symptoms did not recur .	After discontinuing cisapride , the QT interval returned to normal and symptoms did not recur .
We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4 , including diltiazem .	We suggest that caution be taken when cisapride is prescribed with any potent inhibitor of CYP3A4 , including diltiazem .
Cortical motor overactivation in parkinsonian patients with L - dopa - induced peak - dose dyskinesia .	Cortical motor overactivation in disease* parkinsonian *disease patients with L - dopa - induced peak - dose disease* dyskinesia *disease .
We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of parkinsonian patients on L - dopa medication , the first one without L - dopa induced dyskinesia ( n = 23 ) and the other with moderate peak - dose dyskinesia ( n = 15 ) , and of a group of 14 normal subjects .	We have studied the regional cerebral blood flow ( rCBF ) changes induced by the execution of a finger - to - thumb opposition motor task in the supplementary and primary motor cortex of two groups of disease* parkinsonian *disease patients on L - dopa medication , the first one without L - dopa induced disease* dyskinesia *disease ( n = 23 ) and the other with moderate peak - dose disease* dyskinesia *disease ( n = 15 ) , and of a group of 14 normal subjects .
Single photon emission tomography with i . v . 133Xe was used to measure the rCBF changes .	Single photon emission tomography with i . v . 133Xe was used to measure the rCBF changes .
The dyskinetic parkinsonian patients exhibited a pattern of response which was markedly different from those of the normal subjects and non - dyskinetic parkinsonian patients , with a significant overactivation in the supplementary motor area and the ipsi - and contralateral primary motor areas .	The disease* dyskinetic disease* parkinsonian *disease patients exhibited a pattern of response which was markedly different from those of the normal subjects and non - disease* dyskinetic disease* parkinsonian *disease patients , with a significant overactivation in the supplementary motor area and the ipsi - and contralateral primary motor areas .
These results are compatible with the hypothesis that an hyperkinetic abnormal involuntary movement , like L - dopa - induced peak dose dyskinesia , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .	These results are compatible with the hypothesis that an disease* hyperkinetic disease* abnormal involuntary movement *disease , like L - dopa - induced peak dose disease* dyskinesia *disease , is due to a disinhibition of the primary and associated motor cortex secondary to an excessive outflow of the pallidothalamocortical motor loop .
Open - label assessment of levofloxacin for the treatment of acute bacterial sinusitis in adults .	Open - label assessment of levofloxacin for the treatment of acute bacterial disease* sinusitis *disease in adults .
PURPOSE : To evaluate the efficacy and safety of levofloxacin ( 500 mg orally once daily for 10 to 14 days ) in treating adult outpatients with acute bacterial sinusitis .	PURPOSE : To evaluate the efficacy and safety of levofloxacin ( 500 mg orally once daily for 10 to 14 days ) in treating adult outpatients with acute bacterial disease* sinusitis *disease .
PATIENTS AND METHODS : A total of 329 patients enrolled in the study at 24 centers .	PATIENTS AND METHODS : A total of 329 patients enrolled in the study at 24 centers .
All patients had a pre - therapy Gram ' s stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy .	All patients had a pre - therapy Gram ' s stain and culture of sinus exudate obtained by antral puncture or nasal endoscopy .
Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results .	Clinical response was assessed on the basis of signs and symptoms and sinus radiograph or computed tomography results .
Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre - therapy pathogen ( s ) .	Microbiologic cure rates were determined on the basis of presumed plus documented eradication of the pre - therapy pathogen ( s ) .
RESULTS : The most common pathogens were Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus , and Moraxella catarrhalis .	RESULTS : The most common pathogens were Haemophilus influenzae , Streptococcus pneumoniae , Staphylococcus aureus , and Moraxella catarrhalis .
Of 300 clinically evaluable patients , 175 ( 58 % ) were cured and 90 ( 30 % ) were improved at the post - therapy evaluation , resulting in a clinical success rate of 88 % .	Of 300 clinically evaluable patients , 175 ( 58 % ) were cured and 90 ( 30 % ) were improved at the post - therapy evaluation , resulting in a clinical success rate of 88 % .
Thirty - five patients ( 12 % ) clinically failed treatment .	Thirty - five patients ( 12 % ) clinically failed treatment .
The microbiologic eradication rate ( presumed plus documented ) among 138 microbiologically evaluable patients was 92 % .	The microbiologic eradication rate ( presumed plus documented ) among 138 microbiologically evaluable patients was 92 % .
Microbiologic eradication rates ( presumed plus documented ) of the most common pathogens ranged from 93 % ( M . catarrhalis ) to 100 % ( S . pneumoniae ) at the post - therapy visit .	Microbiologic eradication rates ( presumed plus documented ) of the most common pathogens ranged from 93 % ( M . catarrhalis ) to 100 % ( S . pneumoniae ) at the post - therapy visit .
All but one of the 265 patients who were cured or improved at post - therapy returned for a long - term follow - up visit ; 243 ( 92 % ) remained well 4 to 6 weeks after therapy ; and 21 ( 8 % ) had a relapse of symptoms .	All but one of the 265 patients who were cured or improved at post - therapy returned for a long - term follow - up visit ; 243 ( 92 % ) remained well 4 to 6 weeks after therapy ; and 21 ( 8 % ) had a relapse of symptoms .
Adverse events considered to be related to levofloxacin administration were reported by 29 patients ( 9 % ) .	Adverse events considered to be related to levofloxacin administration were reported by 29 patients ( 9 % ) .
The most common drug - related adverse events were diarrhea , flatulence , and nausea ; most adverse events were mild to moderate in severity .	The most common drug - related adverse events were disease* diarrhea *disease , disease* flatulence *disease , and disease* nausea *disease ; most adverse events were mild to moderate in severity .
CONCLUSION : The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial sinusitis .	CONCLUSION : The results of this study indicate that levofloxacin 500 mg once daily is an effective and safe treatment for acute bacterial disease* sinusitis *disease .
Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case - control study .	Iatrogenic risks of disease* endometrial carcinoma *disease after treatment for disease* breast cancer *disease in a large French case - control study .
F d ration Nationale des Centres de Lutte Contre le Cancer ( FNCLCC ) .	F d ration Nationale des Centres de Lutte Contre le Cancer ( FNCLCC ) .
Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer , its endometrial iatrogenic effects must be carefully examined .	Since tamoxifen is widely used in disease* breast cancer *disease treatment and has been proposed for the prevention of disease* breast cancer *disease , its endometrial iatrogenic effects must be carefully examined .
We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case - control study .	We have investigated the association between disease* endometrial cancer *disease and tamoxifen use or other treatments in women treated for disease* breast cancer *disease in a case - control study .
Cases of endometrial cancer diagnosed after breast cancer ( n = 135 ) and 467 controls matched for age , year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included .	Cases of disease* endometrial cancer *disease diagnosed after disease* breast cancer *disease ( n = 135 ) and 467 controls matched for age , year of diagnosis of disease* breast cancer *disease and hospital and survival time with an intact uterus were included .
Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .	Women who had received tamoxifen were significantly more likely to have disease* endometrial cancer *disease diagnosed than those who had not ( crude relative risk = 4 . 9 , p = 0 . 0001 ) .
Univariate and adjusted analyses showed that the risk increased with the length of treatment ( p = 0 . 0001 ) or the cumulative dose of tamoxifen received ( p = 0 . 0001 ) , irrespective of the daily dose .	Univariate and adjusted analyses showed that the risk increased with the length of treatment ( p = 0 . 0001 ) or the cumulative dose of tamoxifen received ( p = 0 . 0001 ) , irrespective of the daily dose .
Women who had undergone pelvic radiotherapy also had a higher risk ( crude relative risk = 7 . 8 , p = 0 . 0001 ) .	Women who had undergone pelvic radiotherapy also had a higher risk ( crude relative risk = 7 . 8 , p = 0 . 0001 ) .
After adjusting for confounding factors , the risk was higher for tamoxifen users ( p = 0 . 0012 ) , treatment for more than 3 years ( all p < 0 . 03 ) and pelvic radiotherapy ( p = 0 . 012 ) .	After adjusting for confounding factors , the risk was higher for tamoxifen users ( p = 0 . 0012 ) , treatment for more than 3 years ( all p < 0 . 03 ) and pelvic radiotherapy ( p = 0 . 012 ) .
Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment .	Women who had disease* endometrial cancer *disease and had received tamoxifen had more disease* advanced disease *disease and poorer prognosis than those with disease* endometrial cancer *disease who had not received this treatment .
Our results suggest a causal role of tamoxifen in endometrial cancer , particularly when used as currently proposed for breast cancer prevention .	Our results suggest a causal role of tamoxifen in disease* endometrial cancer *disease , particularly when used as currently proposed for disease* breast cancer *disease prevention .
Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer .	Pelvic radiotherapy may be an additional iatrogenic factor for women with disease* breast cancer *disease .
Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis .	disease* Endometrial cancers *disease diagnosed in women treated with tamoxifen have poorer prognosis .
Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment .	Women who receive tamoxifen for disease* breast cancer *disease should be offered gynaecological surveillance during and after treatment .
A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted .	A long - term evaluation of the risk - benefit ratio of tamoxifen as a preventive treatment for disease* breast cancer *disease is clearly warranted .
Contribution of the glycine site of NMDA receptors in rostral and intermediate - caudal parts of the striatum to the regulation of muscle tone in rats .	Contribution of the glycine site of NMDA receptors in rostral and intermediate - caudal parts of the striatum to the regulation of muscle tone in rats .
The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone .	The aim of the present study was to assess the contribution of the glycine site of NMDA receptors in the striatum to the regulation of muscle tone .
Muscle tone was examined using a combined mechanoand electromyographic method , which measured simultaneously the muscle resistance ( MMG ) of the rat ' s hind foot to passive extension and flexion in the ankle joint and the electromyographic activity ( EMG ) of the antagonistic muscles of that joint : gastrocnemius and tibialis anterior .	Muscle tone was examined using a combined mechanoand electromyographic method , which measured simultaneously the muscle resistance ( MMG ) of the rat ' s hind foot to passive extension and flexion in the ankle joint and the electromyographic activity ( EMG ) of the antagonistic muscles of that joint : gastrocnemius and tibialis anterior .
Muscle rigidity was induced by haloperidol ( 2 . 5 mg / kg i . p . ) .	disease* Muscle rigidity *disease was induced by haloperidol ( 2 . 5 mg / kg i . p . ) .
5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced muscle rigidity ( MMG ) and the enhanced electromyographic activity ( EMG ) .	5 , 7 - dichlorokynurenic acid ( 5 , 7 - DCKA ) , a selective glycine site antagonist , injected in doses of 2 . 5 and 4 . 5 microg / 0 . 5 microl bilaterally , into the rostral region of the striatum , decreased both the haloperidol - induced disease* muscle rigidity *disease ( MMG ) and the enhanced electromyographic activity ( EMG ) .
5 , 7 - DCKA injected bilaterally in a dose of 4 . 5 microg / 0 . 5 microl into the intermediate - caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone .	5 , 7 - DCKA injected bilaterally in a dose of 4 . 5 microg / 0 . 5 microl into the intermediate - caudal region of the striatum of rats not pretreated with haloperidol had no effect on the muscle tone .
The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug .	The present results suggest that blockade of the glycine site of NMDA receptors in the rostral part of the striatum may be mainly responsible for the antiparkinsonian action of this drug .
Carboplatin toxic effects on the peripheral nervous system of the rat .	Carboplatin toxic effects on the peripheral nervous system of the rat .
BACKGROUND : The most striking of carboplatin ' s advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of neurotoxic effects .	BACKGROUND : The most striking of carboplatin ' s advantages ( CBDCA ) over cisplatin ( CDDP ) is its markedly reduced rate of disease* neurotoxic *disease effects .
However , the use of CBDCA higher - intensity schedules and the association with other neurotoxic drugs in polychemotherapy may cause some concern about its safety with respect to peripheral nervous system damage .	However , the use of CBDCA higher - intensity schedules and the association with other disease* neurotoxic *disease drugs in polychemotherapy may cause some concern about its safety with respect to disease* peripheral nervous system damage *disease .
MATERIALS AND METHODS : Two different schedules of CBDCA administration ( 10 mg / kg and 15 mg / kg i . p . twice a week for nine times ) were evaluated in Wistar rats .	MATERIALS AND METHODS : Two different schedules of CBDCA administration ( 10 mg / kg and 15 mg / kg i . p . twice a week for nine times ) were evaluated in Wistar rats .
Neurotoxicity was assessed for behavioral ( tail - flick test ) , neurophysiological ( nerve conduction velocity in the tail nerve ) , morphological , morphometrical and analytical effects .	disease* Neurotoxicity *disease was assessed for behavioral ( tail - flick test ) , neurophysiological ( nerve conduction velocity in the tail nerve ) , morphological , morphometrical and analytical effects .
RESULTS : CBDCA administration induced dose - dependent peripheral neurotoxicity .	RESULTS : CBDCA administration induced dose - dependent disease* peripheral neurotoxicity *disease .
Pain perception and nerve conduction velocity in the tail were significantly impaired , particularly after the high - dose treatment .	disease* Pain *disease perception and nerve conduction velocity in the tail were significantly impaired , particularly after the high - dose treatment .
The dorsal root ganglia sensory neurons and , to a lesser extent , satellite cells showed the same changes as those induced by CDDP , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons .	The dorsal root ganglia sensory neurons and , to a lesser extent , satellite cells showed the same changes as those induced by CDDP , mainly affecting the nucleus and nucleolus of ganglionic sensory neurons .
Moreover , significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment .	Moreover , significant amounts of platinum were detected in the dorsal root ganglia and kidney after CBDCA treatment .
CONCLUSIONS : CBDCA is neurotoxic in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that neurotoxicity is induced in the two drugs by the same mechanism .	CONCLUSIONS : CBDCA is disease* neurotoxic *disease in our model , and the type of pathological changes it induces are so closely similar to those caused by CDDP that it is probable that disease* neurotoxicity *disease is induced in the two drugs by the same mechanism .
This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system .	This model can be used alone or in combination with other drugs to explore the effect of CBDCA on the peripheral nervous system .
Effects of cisapride on symptoms and postcibal small - bowel motor function in patients with irritable bowel syndrome .	Effects of cisapride on symptoms and postcibal small - bowel motor function in patients with disease* irritable bowel syndrome *disease .
BACKGROUND : Irritable bowel syndrome is a common cause of abdominal pain and discomfort and may be related to disordered gastrointestinal motility .	BACKGROUND : disease* Irritable bowel syndrome *disease is a common cause of disease* abdominal pain *disease and discomfort and may be related to disease* disordered gastrointestinal motility *disease .
Our aim was to assess the effects of long - term treatment with a prokinetic agent , cisapride , on postprandial jejunal motility and symptoms in the irritable bowel syndrome ( IBS ) .	Our aim was to assess the effects of long - term treatment with a prokinetic agent , cisapride , on postprandial jejunal motility and symptoms in the disease* irritable bowel syndrome *disease ( disease* IBS *disease ) .
METHODS : Thirty - eight patients with IBS ( constipation - predominant , n = 17 ; diarrhoea - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week ' s treatment [ cisapride , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .	METHODS : Thirty - eight patients with disease* IBS *disease ( disease* constipation *disease - predominant , n = 17 ; disease* diarrhoea *disease - predominant , n = 21 ) underwent 24 - h ambulatory jejunal manometry before and after 12 week ' s treatment [ cisapride , 5 mg three times daily ( n = 19 ) or placebo ( n = 19 ) ] .
RESULTS : In diarrhoea - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .	RESULTS : In disease* diarrhoea *disease - predominant patients significant differences in contraction characteristics were observed between the cisapride and placebo groups .
In cisapride - treated diarrhoea - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .	In cisapride - treated disease* diarrhoea *disease - predominant patients the mean contraction amplitude was higher ( 29 . 3 + / - 3 . 2 versus 24 . 9 + / - 2 . 6 mm Hg , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 25 . 7 + / - 6 . 0 mm Hg ) , the mean contraction duration longer ( 3 . 4 + / - 0 . 2 versus 3 . 0 + / - 0 . 2 sec , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 3 . 1 + / - 0 . 5 sec ) , and the mean contraction frequency lower ( 2 . 0 + / - 0 . 2 versus 2 . 5 + / - 0 . 4 cont . / min , cisapride versus placebo ( P < 0 . 001 ) ; pretreatment , 2 . 5 + / - 1 . 1 cont . / min ] than patients treated with placebo .
No significant differences in jejunal motility were found in the constipation - predominant IBS group .	No significant differences in jejunal motility were found in the disease* constipation *disease - predominant disease* IBS *disease group .
Symptoms were assessed by using a visual analogue scale before and after treatment .	Symptoms were assessed by using a visual analogue scale before and after treatment .
Symptom scores relating to the severity of constipation were lower in cisapride - treated constipation - predominant IBS patients [ score , 54 + / - 5 versus 67 + / - 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .	Symptom scores relating to the severity of disease* constipation *disease were lower in cisapride - treated disease* constipation *disease - predominant disease* IBS *disease patients [ score , 54 + / - 5 versus 67 + / - 14 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 62 + / - 19 mm ] .
Diarrhoea - predominant IBS patients had a higher pain score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .	disease* Diarrhoea *disease - predominant disease* IBS *disease patients had a higher disease* pain *disease score after cisapride therapy [ score , 55 + / - 15 versus 34 + / - 12 mm , cisapride versus placebo ( P < 0 . 05 ) ; pretreatment , 67 + / - 19 mm ] .
CONCLUSION : Cisapride affects jejunal contraction characteristics and some symptoms in IBS .	CONCLUSION : Cisapride affects jejunal contraction characteristics and some symptoms in disease* IBS *disease .
Prevention of breast cancer with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .	Prevention of disease* breast cancer *disease with tamoxifen : preliminary findings from the Italian randomised trial among hysterectomised women .
Italian Tamoxifen Prevention Study .	Italian Tamoxifen Prevention Study .
BACKGROUND : Tamoxifen is a candidate chemopreventive agent in breast cancer , although the drug may be associated with the development of endometrial cancer .	BACKGROUND : Tamoxifen is a candidate chemopreventive agent in disease* breast cancer *disease , although the drug may be associated with the development of disease* endometrial cancer *disease .
Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive .	Therefore we did a trial in hysterectomised women of tamoxifen as a chemopreventive .
METHODS : In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have breast cancer and who had had a hysterectomy .	METHODS : In October , 1992 , we started a double - blind placebo - controlled , randomised trial of tamoxifen in women ( mainly in Italy ) who did not have disease* breast cancer *disease and who had had a hysterectomy .
Women were randomised to receive tamoxifen 20 mg per day or placebo , both orally for 5 years .	Women were randomised to receive tamoxifen 20 mg per day or placebo , both orally for 5 years .
The original plan was to follow the intervention phase by 5 years ' follow - up .	The original plan was to follow the intervention phase by 5 years ' follow - up .
In June , 1997 , the trialists and the data - monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study .	In June , 1997 , the trialists and the data - monitoring committee decided to end recruitment primarily because of the number of women dropping out of the study .
Recruitment ended on July 11 , 1997 , and the study will continue as planned .	Recruitment ended on July 11 , 1997 , and the study will continue as planned .
The primary endpoints are the occurrence of and deaths from breast cancer .	The primary endpoints are the occurrence of and deaths from disease* breast cancer *disease .
This preliminary interim analysis is based on intention - to - treat .	This preliminary interim analysis is based on intention - to - treat .
FINDINGS : 5408 women were randomised ; participating women have a median follow - up of 46 months for major endpoints .	FINDINGS : 5408 women were randomised ; participating women have a median follow - up of 46 months for major endpoints .
41 cases of breast cancer occurred so far ; there have been no deaths from breast cancer .	41 cases of disease* breast cancer *disease occurred so far ; there have been no deaths from disease* breast cancer *disease .
There is no difference in breast - cancer frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .	There is no difference in disease* breast - cancer *disease frequency between the placebo ( 22 cases ) and tamoxifen ( 19 ) arms .
There is a statistically significant reduction of breast cancer among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of breast cancer compared with one case among 362 women allocated to tamoxifen .	There is a statistically significant reduction of disease* breast cancer *disease among women receiving tamoxifen who also used hormone - replacement therapy during the trial : among 390 women on such therapy and allocated to placebo , we found eight cases of disease* breast cancer *disease compared with one case among 362 women allocated to tamoxifen .
Compared with the placebo group , there was a significantly increased risk of vascular events and hypertriglyceridaemia among women on tamoxifen .	Compared with the placebo group , there was a significantly increased risk of disease* vascular events *disease and disease* hypertriglyceridaemia *disease among women on tamoxifen .
INTERPRETATION : Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of breast cancer , the postulated protective effects of tamoxifen are not yet apparent .	INTERPRETATION : Although this preliminary analysis has low power , in this cohort of women at low - to - normal risk of disease* breast cancer *disease , the postulated protective effects of tamoxifen are not yet apparent .
Women using hormone - replacement therapy appear to have benefited from use of tamoxifen .	Women using hormone - replacement therapy appear to have benefited from use of tamoxifen .
There were no deaths from breast cancer recorded in women in the study .	There were no deaths from disease* breast cancer *disease recorded in women in the study .
It is essential to continue follow - up to quantify the long - term risks and benefits of tamoxifen therapy .	It is essential to continue follow - up to quantify the long - term risks and benefits of tamoxifen therapy .
Epileptogenic activity of folic acid after drug induces SLE ( folic acid and epilepsy )	Epileptogenic activity of folic acid after drug induces disease* SLE *disease ( folic acid and disease* epilepsy *disease )
OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in epileptic women before and during pregnancy in order to determine the rate of structural birth defects and epilepsy - related side effects .	OBJECTIVE : To study the effect of folic acid - containing multivitamin supplementation in disease* epileptic *disease women before and during pregnancy in order to determine the rate of structural disease* birth defects *disease and disease* epilepsy *disease - related side effects .
STUDY DESIGN : First a randomised trial , later periconception care including in total 12225 females .	STUDY DESIGN : First a randomised trial , later periconception care including in total 12225 females .
RESULTS : Of 60 epileptic women with periconceptional folic acid ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed epilepsy - related side effects during the periconception period .	RESULTS : Of 60 disease* epileptic *disease women with periconceptional folic acid ( 0 . 8 mg ) - containing multivitamin supplementation , no one developed disease* epilepsy *disease - related side effects during the periconception period .
One epileptic woman delivered a newborn with cleft lip and palate .	One disease* epileptic *disease woman delivered a newborn with disease* cleft lip and palate *disease .
Another patient exhibited with a cluster of seizures after the periconception period using another multivitamin .	Another patient exhibited with a cluster of disease* seizures *disease after the periconception period using another multivitamin .
This 22 - year - old epileptic woman was treated continuously by carbamazepine and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .	This 22 - year - old disease* epileptic *disease woman was treated continuously by carbamazepine and a folic acid ( 1 mg ) - containing multivitamin from the 20th week of gestation .
She developed status epilepticus and later symptoms of systemic lupus erythematodes .	She developed disease* status epilepticus *disease and later symptoms of disease* systemic lupus erythematodes *disease .
Her pregnancy ended with stillbirth .	Her pregnancy ended with disease* stillbirth *disease .
CONCLUSIONS : The epileptic pregnant patient ' s autoimmune disease ( probably drug - induced lupus ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of folic acid triggered a cluster of seizures .	CONCLUSIONS : The disease* epileptic *disease pregnant patient ' s disease* autoimmune disease *disease ( probably drug - induced disease* lupus *disease ) could damage the blood - brain barrier , therefore the therapeutic dose ( > or = 1 mg ) of folic acid triggered a cluster of disease* seizures *disease .
Physiological dose ( < 1 mg ) of folic acid both in healthy and 60 epileptic women , all without any autoimmune disease , did not increase the risk for epileptic seizures .	Physiological dose ( < 1 mg ) of folic acid both in healthy and 60 disease* epileptic *disease women , all without any disease* autoimmune disease *disease , did not increase the risk for disease* epileptic seizures *disease .
Stroke and cocaine or amphetamine use .	disease* Stroke *disease and cocaine or amphetamine use .
The association of cocaine and amphetamine use with hemorrhagic and ischemic stroke is based almost solely on data from case series .	The association of cocaine and amphetamine use with hemorrhagic and disease* ischemic disease* stroke *disease is based almost solely on data from case series .
The limited number of epidemiologic studies of stroke and use of cocaine and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .	The limited number of epidemiologic studies of disease* stroke *disease and use of cocaine and / or amphetamine have been done in settings that serve mostly the poor and / or minorities .
This case - control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California .	This case - control study was conducted in the defined population comprising members of Kaiser Permanente of Northern and Southern California .
We attempted to identify all incident strokes in women ages 15 - 44 years during a 3 - year period using hospital admission and discharge records , emergency department logs , and payment requests for out - of - plan hospitalizations .	We attempted to identify all incident disease* strokes *disease in women ages 15 - 44 years during a 3 - year period using hospital admission and discharge records , emergency department logs , and payment requests for out - of - plan hospitalizations .
We selected controls , matched on age and facility of usual care , at random from healthy members of the health plan .	We selected controls , matched on age and facility of usual care , at random from healthy members of the health plan .
We obtained information in face - to - face interviews .	We obtained information in face - to - face interviews .
There were 347 confirmed stroke cases and 1 , 021 controls .	There were 347 confirmed disease* stroke *disease cases and 1 , 021 controls .
The univariate matched odds ratio for stroke in women who admitted to using cocaine and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .	The univariate matched odds ratio for disease* stroke *disease in women who admitted to using cocaine and / or amphetamine was 8 . 5 ( 95 % confidence interval = 3 . 6 - 20 . 0 ) .
After further adjustment for potential confounders , the odds ratio in women who reported using cocaine and / or amphetamine was 7 . 0 ( 95 % confidence interval = 2 . 8 - 17 . 9 ) .	After further adjustment for potential confounders , the odds ratio in women who reported using cocaine and / or amphetamine was 7 . 0 ( 95 % confidence interval = 2 . 8 - 17 . 9 ) .
The use of cocaine and / or amphetamine is a strong risk factor for stroke in this socioeconomically heterogeneous , insured urban population .	The use of cocaine and / or amphetamine is a strong risk factor for disease* stroke *disease in this socioeconomically heterogeneous , insured urban population .
Acute renal failure subsequent to the administration of rifampicin .	disease* Acute renal failure *disease subsequent to the administration of rifampicin .
A follow - up study of cases reported earlier .	A follow - up study of cases reported earlier .
A clinical presentation is made of a 2 - 3 year follow - up of six cases of acute renal failure that have been reported earlier .	A clinical presentation is made of a 2 - 3 year follow - up of six cases of disease* acute renal failure *disease that have been reported earlier .
The patients had developed transient renal failure after the intermittent administration of rifampicin .	The patients had developed transient disease* renal failure *disease after the intermittent administration of rifampicin .
The stage of olig - anuria lasted for 1 - 3 weeks , and five of the patients were treated by hemodialysis .	The stage of olig - disease* anuria *disease lasted for 1 - 3 weeks , and five of the patients were treated by hemodialysis .
Two of the patients died due to unrelated causes during the follow - up period .	Two of the patients died due to unrelated causes during the follow - up period .
The four patients re - examined were clinically cured .	The four patients re - examined were clinically cured .
Pathologic findings by light microscopy and immunofluorescence at biopsy were scarce .	Pathologic findings by light microscopy and immunofluorescence at biopsy were scarce .
Nothing abnormal was seen by electron microscopy in two of the cases studied .	Nothing abnormal was seen by electron microscopy in two of the cases studied .
Renal function was normal .	Renal function was normal .
In three cases the excretion at 131I - hippuran renography was slightly slowed .	In three cases the excretion at 131I - hippuran renography was slightly slowed .
Although in the acute stage the renal lesions histologically appeared toxic , evidence suggestive of an immunological mechanism cannot be excluded .	Although in the acute stage the disease* renal lesions *disease histologically appeared toxic , evidence suggestive of an immunological mechanism cannot be excluded .
Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced cardiomyopathy in beagle dogs .	Chronic effects of a novel synthetic anthracycline derivative ( SM - 5887 ) on normal heart and doxorubicin - induced disease* cardiomyopathy *disease in beagle dogs .
This study was designed to investigate the chronic cardiotoxic potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade cardiotoxicity pre - induced by doxorubicin in beagle dogs .	This study was designed to investigate the chronic disease* cardiotoxic *disease potential of SM - 5887 and a possible deteriorating effect of SM - 5887 on low - grade disease* cardiotoxicity *disease pre - induced by doxorubicin in beagle dogs .
In the chronic treatment , beagle dogs of each sex were given intravenously once every 3 weeks , either a sublethal dose of doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) .	In the chronic treatment , beagle dogs of each sex were given intravenously once every 3 weeks , either a sublethal dose of doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) .
The experiment was terminated 3 weeks after the ninth dosing .	The experiment was terminated 3 weeks after the ninth dosing .
Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological cardiomyopathy , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .	Animals which received over six courses of doxorubicin demonstrated the electrocardiogram ( ECG ) changes , decrease of blood pressure and high - grade histopathological disease* cardiomyopathy *disease , while animals which were terminally sacrificed after the SM - 5887 administration did not show any changes in ECG , blood pressure and histopathological examinations .
To examine a possibly deteriorating cardiotoxic effect of SM - 5887 , low - grade cardiomyopathy was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .	To examine a possibly deteriorating disease* cardiotoxic *disease effect of SM - 5887 , low - grade disease* cardiomyopathy *disease was induced in dogs by four courses of doxorubicin ( 1 . 5 mg / kg ) .
Nine weeks after pre - treatment , dogs were given four courses of either doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) once every 3 weeks .	Nine weeks after pre - treatment , dogs were given four courses of either doxorubicin ( 1 . 5 mg / kg ) or SM - 5887 ( 2 . 5 mg / kg ) once every 3 weeks .
The low - grade cardiotoxic changes were enhanced by the additional doxorubicin treatment .	The low - grade disease* cardiotoxic *disease changes were enhanced by the additional doxorubicin treatment .
On the contrary , the SM - 5887 treatment did not progress the grade of cardiomyopathy .	On the contrary , the SM - 5887 treatment did not progress the grade of disease* cardiomyopathy *disease .
In conclusion , SM - 5887 does not have any potential of chronic cardiotoxicity and deteriorating effect on doxorubicin - induced cardiotoxicity in dogs .	In conclusion , SM - 5887 does not have any potential of chronic disease* cardiotoxicity *disease and deteriorating effect on doxorubicin - induced disease* cardiotoxicity *disease in dogs .
Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication .	Risk for disease* valvular heart disease *disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication .
BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and dexfenfluramine had valvular disease , these drugs were withdrawn from the market .	BACKGROUND : Because uncontrolled echocardiographic surveys suggested that up to 30 % to 38 % of users of fenfluramine and dexfenfluramine had disease* valvular disease *disease , these drugs were withdrawn from the market .
OBJECTIVE : To determine the risk for new or worsening valvular abnormalities among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications .	OBJECTIVE : To determine the risk for new or worsening disease* valvular abnormalities *disease among users of fenfluramine or dexfenfluramine who underwent echocardiography before they began to take these medications .
DESIGN : Cohort study .	DESIGN : Cohort study .
SETTING : Academic primary care practices .	SETTING : Academic primary care practices .
PATIENTS : 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy .	PATIENTS : 46 patients who used fenfluramine or dexfenfluramine for 14 days or more and had echocardiograms obtained before therapy .
MEASUREMENTS : Follow - up echocardiography .	MEASUREMENTS : Follow - up echocardiography .
The primary outcome was new or worsening valvulopathy , defined as progression of either aortic or mitral regurgitation by at least one degree of severity and disease that met U . S .	The primary outcome was new or worsening disease* valvulopathy *disease , defined as progression of either disease* aortic or mitral regurgitation *disease by at least one degree of severity and disease that met U . S .
Food and Drug Administration criteria ( at least mild aortic regurgitation or moderate mitral regurgitation ) .	Food and Drug Administration criteria ( at least mild disease* aortic regurgitation *disease or moderate disease* mitral regurgitation *disease ) .
RESULTS : Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - phentermine developed valvular heart disease .	RESULTS : Two patients ( 4 . 3 % [ 95 % CI , 0 . 6 % to 14 . 8 % ] ) receiving fenfluramine - phentermine developed disease* valvular heart disease *disease .
One had baseline bicuspid aortic valve and mild aortic regurgitation that progressed to moderate regurgitation .	One had baseline disease* bicuspid aortic valve *disease and mild disease* aortic regurgitation *disease that progressed to moderate regurgitation .
The second patient developed new moderate aortic insufficiency .	The second patient developed new moderate disease* aortic insufficiency *disease .
CONCLUSION : Users of diet medications are at risk for valvular heart disease .	CONCLUSION : Users of diet medications are at risk for disease* valvular heart disease *disease .
However , the incidence may be lower than that reported previously .	However , the incidence may be lower than that reported previously .
Therapeutic drug monitoring of tobramycin : once - daily versus twice - daily dosage schedules .	Therapeutic drug monitoring of tobramycin : once - daily versus twice - daily dosage schedules .
OBJECTIVE : To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and toxicity .	OBJECTIVE : To evaluate the effect of dosage regimen ( once - daily vs . twice - daily ) of tobramicyn on steady - state serum concentrations and disease* toxicity *disease .
MATERIALS AND METHODS : Patients undergoing treatment with i . v . tobramycin ( 4 mg / kg / day ) were randomised to two groups .	MATERIALS AND METHODS : Patients undergoing treatment with i . v . tobramycin ( 4 mg / kg / day ) were randomised to two groups .
Group OD ( n = 22 ) received a once - daily dose of tobramycin and group TD ( n = 21 ) received the same dose divided into two doses daily .	Group OD ( n = 22 ) received a once - daily dose of tobramycin and group TD ( n = 21 ) received the same dose divided into two doses daily .
Tobramycin serum concentrations ( peak and trough ) were measured by enzyme multiplied immunoassay .	Tobramycin serum concentrations ( peak and trough ) were measured by enzyme multiplied immunoassay .
The renal and auditory functions of the patients were monitored before , during and immediately after treatment .	The renal and auditory functions of the patients were monitored before , during and immediately after treatment .
RESULTS : The two groups were comparable with respect to sex , age , body weight and renal function .	RESULTS : The two groups were comparable with respect to sex , age , body weight and renal function .
No statistically significant differences were found in mean daily dose , duration of treatment , or cumulative dose .	No statistically significant differences were found in mean daily dose , duration of treatment , or cumulative dose .
Trough concentrations were < 2 g / ml in the two groups ( 100 % ) .	Trough concentrations were < 2 g / ml in the two groups ( 100 % ) .
Peak concentrations were > 6 microg / ml in 100 % of the OD group and in 67 % of the TD group ( P < 0 . 01 ) .	Peak concentrations were > 6 microg / ml in 100 % of the OD group and in 67 % of the TD group ( P < 0 . 01 ) .
Mean peak concentrations were markedly different : 11 . 00 + / - 2 . 89 microg / ml in OD vs . 6 . 53 + / - 1 . 45 microg / ml in TD ( P < 0 . 01 ) .	Mean peak concentrations were markedly different : 11 . 00 + / - 2 . 89 microg / ml in OD vs . 6 . 53 + / - 1 . 45 microg / ml in TD ( P < 0 . 01 ) .
The pharmacokinetics parameters were : Ke , ( 0 . 15 + / - 0 . 03 / h in OD vs . 0 . 24 + / - 0 . 06 / h in TD ) , t1 / 2 , ( 4 . 95 + / - 1 . 41 h in OD vs . 3 . 07 + / - 0 . 71 h in TD ) , Vd ( 0 . 35 + / - 0 . 11 l / kg in OD vs . 0 . 33 + / - 0 . 09 l / kg in TD ) , Cl ( 0 . 86 + / - 0 . 29 ml / min / kg in OD vs . 1 . 28 + / - 0 . 33 ml / min / kg in TD ) .	The pharmacokinetics parameters were : Ke , ( 0 . 15 + / - 0 . 03 / h in OD vs . 0 . 24 + / - 0 . 06 / h in TD ) , t1 / 2 , ( 4 . 95 + / - 1 . 41 h in OD vs . 3 . 07 + / - 0 . 71 h in TD ) , Vd ( 0 . 35 + / - 0 . 11 l / kg in OD vs . 0 . 33 + / - 0 . 09 l / kg in TD ) , Cl ( 0 . 86 + / - 0 . 29 ml / min / kg in OD vs . 1 . 28 + / - 0 . 33 ml / min / kg in TD ) .
Increased serum creatinine was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of nephrotoxicity .	Increased serum creatinine was observed in 73 % of patients in OD versus 57 % of patients in TD , without evidence of disease* nephrotoxicity *disease .
In TD group , three patients developed decreased auditory function , of which one presented with an auditory loss of - 30 dB , whereas in the OD group only one patient presented decreased auditory function .	In TD group , three patients developed disease* decreased auditory function *disease , of which one presented with an disease* auditory loss *disease of - 30 dB , whereas in the OD group only one patient presented disease* decreased auditory function *disease .
CONCLUSION : This small study suggests that a once - daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice - daily regimen .	CONCLUSION : This small study suggests that a once - daily dosing regimen of tobramycin is at least as effective as and is no more and possibly less toxic than the twice - daily regimen .
Using a single - dose therapy , peak concentration determination is not necessary , only trough samples should be monitored to ensure levels below 2 microg / ml .	Using a single - dose therapy , peak concentration determination is not necessary , only trough samples should be monitored to ensure levels below 2 microg / ml .
Enhanced bradycardia induced by beta - adrenoceptor antagonists in rats pretreated with isoniazid .	Enhanced disease* bradycardia *disease induced by beta - adrenoceptor antagonists in rats pretreated with isoniazid .
High doses of isoniazid increase hypotension induced by vasodilators and change the accompanying reflex tachycardia to bradycardia , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .	High doses of isoniazid increase disease* hypotension *disease induced by vasodilators and change the accompanying reflex disease* tachycardia *disease to disease* bradycardia *disease , an interaction attributed to decreased synthesis of brain gamma - aminobutyric acid ( GABA ) .
In the present study , the possible enhancement by isoniazid of bradycardia induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .	In the present study , the possible enhancement by isoniazid of disease* bradycardia *disease induced by beta - adrenoceptor antagonists was determined in rats anaesthetised with chloralose - urethane .
Isoniazid significantly increased bradycardia after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .	Isoniazid significantly increased disease* bradycardia *disease after propranolol , pindolol , labetalol and atenolol , as well as after clonidine , but not after hexamethonium or carbachol .
Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised .	Enhancement was not observed in rats pretreated with methylatropine or previously vagotomised .
These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone .	These results are compatible with interference by isoniazid with GABAergic inhibition of cardiac parasympathetic tone .
Such interference could be exerted centrally , possibly at the nucleus ambiguus , or peripherally at the sinus node .	Such interference could be exerted centrally , possibly at the nucleus ambiguus , or peripherally at the sinus node .
Structural and functional impairment of mitochondria in adriamycin - induced cardiomyopathy in mice : suppression of cytochrome c oxidase II gene expression .	disease* Structural and functional impairment of mitochondria *disease in adriamycin - induced disease* cardiomyopathy *disease in mice : suppression of cytochrome c oxidase II gene expression .
The use of adriamycin ( ADR ) in cancer chemotherapy has been limited due to its cumulative cardiovascular toxicity .	The use of adriamycin ( ADR ) in disease* cancer *disease chemotherapy has been limited due to its cumulative disease* cardiovascular toxicity *disease .
Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase ( COX ) and suppresses its enzyme activity led us to investigate ADR ' s action on the cardiovascular functions and heart mitochondrial morphology in Balb - c mice i . p . treated with ADR for several weeks .	Earlier observations that ADR interacts with mitochondrial cytochrome c oxidase ( COX ) and suppresses its enzyme activity led us to investigate ADR ' s action on the cardiovascular functions and heart mitochondrial morphology in Balb - c mice i . p . treated with ADR for several weeks .
At various times during treatment , the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy .	At various times during treatment , the animals were assessed for cardiovascular functions by electrocardiography and for heart tissue damage by electron microscopy .
In parallel , total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady - state level of three RNA transcripts encoded by the COXII , COXIII , and COXIV genes .	In parallel , total RNA was extracted from samples of dissected heart and analyzed by Northern blot hybridization to determine the steady - state level of three RNA transcripts encoded by the COXII , COXIII , and COXIV genes .
Similarly , samples obtained from the liver of the same animals were analyzed for comparative studies .	Similarly , samples obtained from the liver of the same animals were analyzed for comparative studies .
Our results indicated that 1 ) treatment of mice with ADR caused cardiovascular arrhythmias characterized by bradycardia , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent swelling , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .	Our results indicated that 1 ) treatment of mice with ADR caused disease* cardiovascular arrhythmias *disease characterized by disease* bradycardia *disease , extension of ventricular depolarization time ( tQRS ) , and failure of QRS at high concentrations ( 10 - 14 mg / kg body weight cumulative dose ) ; 2 ) the heart mitochondria underwent disease* swelling *disease , fusion , dissolution , and / or disruption of mitochondrial cristae after several weeks of treatment .
Such abnormalities were not observed in the mitochondria of liver tissue ; and 3 ) among the three genes of COX enzyme examined , only COXII gene expression was suppressed by ADR treatment , mainly after 8 weeks in both heart and liver .	Such abnormalities were not observed in the mitochondria of liver tissue ; and 3 ) among the three genes of COX enzyme examined , only COXII gene expression was suppressed by ADR treatment , mainly after 8 weeks in both heart and liver .
Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of ADR on cardiovascular function involve mitochondrial structural and functional impairment .	Knowing that heart mitochondria represent almost 40 % of heart muscle by weight , we conclude that the deteriorating effects of ADR on cardiovascular function involve disease* mitochondrial structural and functional impairment *disease .
